{
  ADE : 
    {
      1 : 
        {
          1 : " NN compound NN"
          2 : 788
          3 : 
            {
              1 : " *drug0* compound drug0"
              2 : " *drug0* compound drug0"
              3 : " *drug0* compound drug0"
              4 : " *drug0* compound drug0"
              5 : " *drug0* compound drug0"
              6 : " *drug0* compound drug0"
              7 : " *drug0* compound drug0"
              8 : " *drug0* compound drug0"
              9 : " *drug0* compound drug0"
              10 : " *drug0* compound drug0"
            }
          4 : 
            {
              1 : "The literature of drug1 drug2 is reviewed . "
              2 : "CASE : We report a case of a woman with severe drug1 drug2 who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM . "
              3 : "drug1 drug2 revisited . "
              4 : "Three distinct types of drug1 drug2 have been described . "
              5 : "Although drug1 drug2 occurred in one patient , the other five reported no side effects at the doses used . "
              6 : "We present a case of drug1 drug2 reversed by glucagon . "
              7 : "drug1 drug2 is a rare and serious complication of anticoagulation therapy . "
              8 : "Even though only a few cases of this adverse event have been reported in the literature , severe drug1 drug2 needs to be considered in the differential diagnosis when such patients present with respiratory symptoms . "
              9 : "They continued to rise for five more days before drug1 drug2 was suspected . "
              10 : "Spectral-domain optical coherence tomography and adaptive optics may detect drug1 drug2 before symptomatic vision loss . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      2 : 
        {
          1 : "NN nmod VBN acl NN"
          2 : 200
          3 : 
            {
              1 : "drug0 nmod attributed acl *drug0*"
              2 : "drug0 nmod induced acl *drug0*"
              3 : "drug0 nmod treated acl *drug0*"
              4 : "drug0 nmod associated acl *drug0*"
              5 : "drug0 nmod caused acl *drug0*"
              6 : "drug0 nmod associated acl *drug0*"
              7 : "drug0 nmod caused acl *drug0*"
              8 : "drug0 nmod associated acl *drug0*"
              9 : "drug0 nmod induced acl *drug0*"
              10 : "drug0 nmod induced acl *drug0*"
            }
          4 : 
            {
              1 : "Three of these patients had drug1 attributed to drug2 ; 3.6 % of the patients had seizure , or 2 % of imipenem/cilastatin administrations was followed by a seizure attack . "
              2 : "We report a case of drug1 induced by drug2 . "
              3 : "drug1 complicating Crohn 's disease , treated with drug2 . "
              4 : "It remains to be seen whether the drug1 associated with drug2 is a drug-class effect or specific to troglitazone . "
              5 : "A unique case of a transient , nonpigmenting drug1 caused by the radiopaque contrast medium drug2 is reported . "
              6 : "drug1 associated with drug2 . "
              7 : "It has been suggested that drug1 caused by drug2 does not recur with subsequent cytarabine re-challenge . "
              8 : "Exacerbation of drug1 associated with drug2 . "
              9 : "drug1 induced by drug2 . "
              10 : "drug1 induced by drug2 in a non-alcoholic . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      3 : 
        {
          1 : "NN compound NN nmod NN"
          2 : 194
          3 : 
            {
              1 : "drug0 compound tuberculosis nmod *drug0*"
              2 : "drug0 compound testing nmod *drug0*"
              3 : "drug0 compound chemotherapy nmod *drug0*"
              4 : "drug0 compound therapy nmod *drug0*"
              5 : "drug0 compound therapy nmod *drug0*"
              6 : "drug0 nmod *pneumonitis* compound drug0"
              7 : "drug0 compound therapy nmod *drug0*"
              8 : "drug0 compound cream nmod *drug0*"
              9 : "drug0 compound toxicity nmod *drug0*"
              10 : "drug0 compound therapy nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in drug2 renal tuberculosis . "
              2 : "drug1 during drug2 stress testing . "
              3 : "drug1 following drug2 chemotherapy . "
              4 : "drug1 during high-dose drug2 therapy for Graves ' ophthalmopathy . "
              5 : "drug1 to drug2 pulsed therapy for multiple sclerosis . "
              6 : "drug1 pneumonitis with drug2 in a patient with the LEOPARD syndrome . "
              7 : "Recurrent drug1 with lethal outcome during and after drug2 therapy in severe ulcerative colitis . "
              8 : "drug1 from drug2 cream . "
              9 : "drug1 in drug2 toxicity : case report . "
              10 : "Ophthalmologists should be aware of the drug1 of drug2 therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      4 : 
        {
          1 : "NN nmod NN"
          2 : 187
          3 : 
            {
              1 : "drug0 nmod *drug0*"
              2 : "drug0 nmod *drug0*"
              3 : "drug0 nmod *drug0*"
              4 : "drug0 nmod *drug0*"
              5 : "drug0 nmod *drug0*"
              6 : "drug0 nmod *drug0*"
              7 : "drug0 nmod *drug0*"
              8 : "drug0 nmod *drug0*"
              9 : "drug0 nmod *drug0*"
              10 : "drug0 nmod *drug0*"
            }
          4 : 
            {
              1 : "The drug1 of drug2 can accurately be studied with ultrahigh frequency audiometry ( up to 20 kHz ) . "
              2 : "drug1 after high-dose drug2 and melphalan chemotherapy and radiotherapy for Ewing 's sarcoma : a review of the literature and implications for practice . "
              3 : "During clarithromycin coadministration , four out of the seven patients developed moderate-to-severe drug1 of drug2 , such as drowsiness , dizziness , and ataxia , which resolved within 5 days after clarithromycin discontinuation . "
              4 : "drug1 to intravenous drug2 and tolerance to oral cyclosporine : case report and review . "
              5 : "drug1 following intravitreal drug2 . "
              6 : "Primary cutaneous coccidioidomycosis and subsequent drug1 to drug2 in a dog . "
              7 : "Unusual drug1 to drug2 in a critically ill patient . "
              8 : "Controversy concerning the drug1 of drug2 is discussed , and recommendations for the evaluation of renal failure during lithium therapy are provided . "
              9 : "drug1 and transient blindness following intravenous pulse drug2 in children with primary glomerulonephritis . "
              10 : "drug1 from drug2 is a possible side effect to this commonly prescribed antibiotic . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      5 : 
        {
          1 : "NN compound NN nmod VBN acl NN"
          2 : 135
          3 : 
            {
              1 : "drug0 compound neurotoxicity nmod complicated acl *drug0*"
              2 : "drug0 compound treatment nmod associated acl *drug0*"
              3 : "drug0 compound infusion nmod associated acl *drug0*"
              4 : "drug0 compound therapy nmod associated acl *drug0*"
              5 : "drug0 compound withdrawal nmod induced acl *drug0*"
              6 : "drug0 compound treatment nmod associated acl *drug0*"
              7 : "drug0 compound therapy nmod associated acl *drug0*"
              8 : "drug0 compound use nmod associated acl *drug0*"
              9 : "drug0 compound therapy nmod caused acl *drug0*"
              10 : "drug0 compound ingestion nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 complicated by drug2 neurotoxicity : case report . "
              2 : "drug1 probably associated with drug2 treatment : An alert of an adverse event . "
              3 : "Transient drug1 and thrombocytopenia associated with drug2 infusion . "
              4 : "Marked drug1 associated with drug2 therapy . "
              5 : "drug1 induced by drug2 withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept . "
              6 : "drug1 associated with transient free protein S deficiency after drug2 treatment : case report and review of the literature . "
              7 : "The authors describe a case of the drug1 associated with drug2 therapy . "
              8 : "We believe that this is the first report of drug1 associated with drug2 use . "
              9 : "drug1 caused by drug2 therapy for staphylococcal septicemia . "
              10 : "drug1 associated with drug2 ingestion occurred in four patients . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      6 : 
        {
          1 : "NN nmod NN nmod NN"
          2 : 124
          3 : 
            {
              1 : "drug0 nmod administration nmod *drug0*"
              2 : "drug0 nmod treatment nmod *drug0*"
              3 : "drug0 nmod infusion nmod *drug0*"
              4 : "drug0 nmod treatment nmod *drug0*"
              5 : "drug0 nmod ingestion nmod *drug0*"
              6 : "drug0 nmod intake nmod *drug0*"
              7 : "drug0 nmod use nmod *drug0*"
              8 : "drug0 nmod treatment nmod *drug0*"
              9 : "drug0 nmod administration nmod *drug0*"
              10 : "drug0 nmod drop nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in an infant from methemoglobinemia after administration of `` drug2 '' . "
              2 : "In the present paper , we discuss the first Japanese vivax malaria patient whose drug1 after treatment with drug2 . "
              3 : "drug1 following the infusion of drug2 : case report . "
              4 : "Rapidly developing drug1 during treatment with drug2 . "
              5 : "This is the first report of an drug1 by maternal ingestion of drug2 . "
              6 : "We report a case of a drug1 due to the intake of drug2 . "
              7 : "Apparent drug1 in infants after the use of topical drug2 . "
              8 : "drug1 during treatment with drug2 . "
              9 : "drug1 with ductopenia ( vanishing bile duct syndrome ) after administration of drug2 and trimethoprim-sulfamethoxazole . "
              10 : "An 11-day-old infant became lethargic and drug1 after a single drop of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      7 : 
        {
          1 : "NN nmod NN nmod VBD dobj NN"
          2 : 86
          3 : 
            {
              1 : "drug0 nmod treatment nmod *developed* dobj drug0"
              2 : "drug0 nmod initiation nmod *experienced* dobj drug0"
              3 : "drug0 nmod treatment nmod *observed* dobj drug0"
              4 : "drug0 nmod treatment nmod *developed* dobj drug0"
              5 : "drug0 nmod treatment nmod *suffered* dobj drug0"
              6 : "drug0 nmod administration nmod *developed* dobj drug0"
              7 : "drug0 nmod treatment nmod *developed* dobj drug0"
              8 : "drug0 nmod administration nmod *developed* dobj drug0"
              9 : "drug0 nmod infusion nmod *developed* dobj drug0"
              10 : "drug0 nmod dose nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report the case of a patient with multiple myeloma who developed acute drug1 following treatment with oral drug2 and low dose intravenous cyclophosphamide . "
              2 : "We describe a patient who experienced a drug1 after the initiation of drug2 for relief of arthritic pain . "
              3 : "We observed transient drug1 in a patient with neuropsychiatric SLE after treatment with drug2 and cyclophosphamide . "
              4 : "We describe six patients who developed drug1 after treatment with drug2 for depression or gastrointestinal symptoms . "
              5 : "Two elderly women suffered an drug1 after treatment with drug2 . "
              6 : "We report an 82-year-old man who developed drug1 and Torsades de Pointes ( TdP ) after oral administration of drug2 , a novel quinolone antibiotic agent that differs from the third-generation quinolones , for pneumonia . "
              7 : "We now report the first known cancer patient who developed drug1 after treatment with topical drug2 and was shown subsequently to have profound DPD deficiency . "
              8 : "A boy with chronic neutropenia and recurrent inflammatory skin lesions developed drug1 following administration of drug2 . "
              9 : "In this case report , we have described a patient with Crohn 's disease who developed drug1 after the fourth infusion of drug2 due to an unrecognized HBs-antigen carrier state . "
              10 : "In this case report , we present clinical and laboratory findings of a case with chronic hepatitis B that developed drug1 soon after the first dose of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      8 : 
        {
          1 : "NN compound NN nmod NN nmod NN"
          2 : 76
          3 : 
            {
              1 : "drug0 compound therapy nmod association nmod *drug0*"
              2 : "drug0 compound therapy nmod *effluvium* nmod drug0"
              3 : "drug0 compound therapy nmod patient nmod *drug0*"
              4 : "drug0 compound therapy nmod complication nmod *drug0*"
              5 : "drug0 compound administration nmod *series* nmod drug0"
              6 : "drug0 compound therapy nmod *report* nmod drug0"
              7 : "drug0 compound treatment nmod *development* nmod drug0"
              8 : "drug0 compound therapy nmod termination nmod *drug0*"
              9 : "drug0 compound therapy nmod *appearance* nmod drug0"
              10 : "drug0 compound therapy nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "drug1 in association with drug2 therapy . "
              2 : "Such anagen effluvium with drug1 following drug2 therapy has not been observed previously . "
              3 : "This is the first report of drug1 in an adult patient during drug2 therapy . "
              4 : "Severe drug1 as a complication of continuous drug2 therapy . "
              5 : "This review presents the first case series of drug1 associated with acute hemoglobinemia or hemoglobinuria following drug2 administration for ITP . "
              6 : "Although there is one case report of drug1 following drug2 therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t-PA therapy . "
              7 : "Development of drug1 during long-term drug2 treatment . "
              8 : "The former patient had complained once that his drug1 after the termination of drug2 therapy , and the latter patient complained twice during IFN therapy that his visual acuity had decreased . "
              9 : "CONCLUSIONS : This case report showed that the clinical appearance of drug1 after drug2 therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition ( DR5 ) for this pathology . "
              10 : "OBJECTIVE : The aim of this paper is to describe a case of drug1 during drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      9 : 
        {
          1 : "NN nmod NN nmod NN nmod NN"
          2 : 66
          3 : 
            {
              1 : "drug0 nmod treatment nmod *development* nmod drug0"
              2 : "drug0 nmod therapy nmod month nmod *drug0*"
              3 : "drug0 nmod treatment nmod *case* nmod drug0"
              4 : "drug0 nmod association nmod *spectrum* nmod drug0"
              5 : "drug0 nmod treatment nmod beginning nmod *drug0*"
              6 : "drug0 nmod administration nmod *observation* nmod drug0"
              7 : "drug0 nmod concentration nmod girl nmod *drug0*"
              8 : "drug0 nmod administration nmod *report* nmod drug0"
              9 : "drug0 nmod use nmod *syndrome* nmod drug0"
              10 : "drug0 nmod intake nmod *patient* nmod drug0"
            }
          4 : 
            {
              1 : "Development of drug1 following treatment with drug2 . "
              2 : "A 35-year-old nephrotic man developed drug1 with serum creatinine to 1543 micromol/l after a month of therapy with drug2 . "
              3 : "We report the first histopathologically documented case of drug1 after OLP treatment with topical drug2 . "
              4 : "The spectrum of drug1 occurring during antituberculous therapy , particularly in association with drug2 , may be wider than previously suspected . "
              5 : "drug1 at beginning of primary treatment with topical drug2 in a case of conjunctiva-cornea intraepithelial neoplasia . "
              6 : "The observation of drug1 during administration of drug2 suggested that clinical awareness of this complication should be of considerable importance . "
              7 : "drug1 in a 12-year-old HIV-positive girl with an increased serum concentration of drug2 . "
              8 : "CONCLUSION : This is , to our knowledge , the first report of drug1 following accidental intrathecal administration of drug2 . "
              9 : "To our knowledge , the syndrome of drug1 , pulmonary infiltrates , and pleural effusion following use of drug2 has not been previously reported . "
              10 : "We present the first case of a patient with drug1 after oral intake of the phenothiazine drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      10 : 
        {
          1 : "NN nmod NN nmod VBN acl NN"
          2 : 47
          3 : 
            {
              1 : "drug0 nmod use nmod associated acl *drug0*"
              2 : "drug0 nmod administration nmod associated acl *drug0*"
              3 : "drug0 nmod hai nmod associated acl *drug0*"
              4 : "drug0 nmod administration nmod caused acl *drug0*"
              5 : "drug0 nmod reaction nmod caused acl *drug0*"
              6 : "drug0 nmod administration nmod induced acl *drug0*"
              7 : "drug0 nmod combination nmod induced acl *drug0*"
              8 : "drug0 nmod infusion nmod associated acl *drug0*"
              9 : "drug0 nmod withdrawal nmod resolved acl *drug0*"
              10 : "drug0 nmod ingestion nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 associated with the use of drug2 . "
              2 : "We report a premature infant who developed drug1 associated with intraventricular administration of drug2 and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics . "
              3 : "drug1 associated with hepatic artery infusion HAI of drug2 . "
              4 : "drug1 caused by administration of drug2 . "
              5 : "We believe that this is the first description of drug1 caused by an idiosyncratic adverse reaction to drug2 or to one of its metabolites . "
              6 : "Two cases of drug1 induced by the administration of drug2 against paroxysmal supraventricular tachycardia . "
              7 : "drug1 induced by a combination of drug2 and disopyramide and other cytochrome P450 , family 3 , subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice . "
              8 : "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced drug1 associated with their initial infusion of drug2 . "
              9 : "In two of these cases drug1 resolved after withdrawal of drug2 and substitution by a classical or an atypical neuroleptic agent , respectively . "
              10 : "Four cases of drug1 associated with ingestion of the urinary anti-spasmodic agent drug2 are described . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      11 : 
        {
          1 : "NN conj NN compound NN"
          2 : 46
          3 : 
            {
              1 : "drug0 conj *thrombocytopenia* compound drug0"
              2 : "drug0 conj *coma* compound drug0"
              3 : "drug0 conj *crystalluria* compound drug0"
              4 : "drug0 conj *thrombocytopenia* compound drug0"
              5 : "drug0 conj *treatment* compound drug0"
              6 : "drug0 conj *myositis* compound drug0"
              7 : "drug0 compound therapy conj *drug0*"
              8 : "drug0 conj *use* compound drug0"
              9 : "drug0 conj *nephrolithiasis* compound drug0"
              10 : "drug0 conj *injury* compound drug0"
            }
          4 : 
            {
              1 : "Usefulness of antiplatelet drugs in the management of drug1 thrombocytopenia and drug2 . "
              2 : "drug1 hyperglycaemic coma and drug2 : case report and review of literature . "
              3 : "We describe two cases of drug1 crystalluria and drug2 in patients with acquired immunodeficiency syndrome , review the pertinent literature , and discuss the pathogenesis . "
              4 : "This experience supports the hypothesis that heparin can be readministered early to patients with drug1 thrombocytopenia and drug2 , provided antiplatelet therapy is given . "
              5 : "The relationship between drug1 treatment and drug2 in Crohn 's disease . "
              6 : "drug1 focal myositis , drug2 , and mononeuritis . "
              7 : "The Naranjo probability scale suggests a highly probable relationship between drug1 and drug2 therapy in this patient . "
              8 : "Use of the Naranjo probability scale determined the association between drug1 use and drug2 to be probable . "
              9 : "drug1 nephrolithiasis and chronic drug2 were the only possible causes identified in this patient . "
              10 : "drug1 hepatic injury and drug2 have been demonstrated after treatment of leukemia , gestational disease and during treatment of psoriasis and rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      12 : 
        {
          1 : "NN nmod VBN nsubjpass NN"
          2 : 41
          3 : 
            {
              1 : "drug0 nmod *reported* nsubjpass drug0"
              2 : "drug0 nmod *associated* nsubjpass drug0"
              3 : "drug0 nmod *caused* nsubjpass drug0"
              4 : "drug0 nmod *reinitiated* nsubjpass drug0"
              5 : "drug0 nmod *caused* nsubjpass drug0"
              6 : "drug0 nmod *associated* nsubjpass drug0"
              7 : "drug0 nmod *associated* nsubjpass drug0"
              8 : "drug0 nmod *associated* nsubjpass drug0"
              9 : "drug0 nmod *associated* nsubjpass drug0"
              10 : "drug0 nmod *related* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Several such drug1 were reported after combined drug2 and multiagent chemotherapy for B-cell lymphomas . "
              2 : "drug1 is associated with drug2 in animals . "
              3 : "Therefore , we concluded that this patient 's drug1 was caused by drug2 , an additive for an antihistaminic drug . "
              4 : "Escape atrial complexes , which occurred following junctional premature complexes , failed to initiate tachycardia in the control state but drug1 was always reinitiated by an identical escape sequence after drug2 . "
              5 : "Evidence obtained indicated that the drug1 might be caused by drug2 possibly due to the induction of pantothenic acid deficiency . "
              6 : "It was highly suspected that drug1 was associated with the drug2 , and the patient therefore discontinued use of finasteride . "
              7 : "RESULTS : drug1 was associated with drug2 in two patients and clinically apparent agranulocytosis in one patient . "
              8 : "CONCLUSIONS : drug1 may be associated with drug2 with forward displacement of the lens-iris diaphragm and anterior chamber shallowing , resulting in acute myopia and angle-closure glaucoma . "
              9 : "Although drug1 has been associated with drug2 , there are no reports of fulminant liver failure with this agent , and our patient had been treated for > 2 years without signs of toxicity . "
              10 : "In our patient , drug1 possibly was related to drug2 , but the patient did not experience associated allergic symptoms . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      13 : 
        {
          1 : "NN dobj VBD nsubj NN"
          2 : 40
          3 : 
            {
              1 : "drug0 dobj *induced* nsubj drug0"
              2 : "drug0 dobj *induced* nsubj drug0"
              3 : "drug0 dobj *induced* nsubj drug0"
              4 : "drug0 dobj *induced* nsubj drug0"
              5 : "drug0 dobj *exacerbated* nsubj drug0"
              6 : "drug0 dobj *induced* nsubj drug0"
              7 : "drug0 dobj *induced* nsubj drug0"
              8 : "drug0 dobj *induced* nsubj drug0"
              9 : "drug0 dobj *increased* nsubj drug0"
              10 : "drug0 dobj *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 induced drug2 and associated lichenoid eruption . "
              2 : "drug1 induced drug2 . "
              3 : "Transient drug1 induced drug2 and permanent IgE increase . "
              4 : "drug1 induced drug2 -- a near fatal experience . "
              5 : "Intravenous drug1 exacerbated the drug2 . "
              6 : "drug1 induced drug2 : a case report . "
              7 : "A 44-year-old woman is described in whom amiodarone , disopyramide , and drug1 , administered alone separately , induced drug2 ( AVT , torsade de pointes ) . "
              8 : "drug1 induced drug2 with yolk sac tumor . "
              9 : "drug1 increased drug2 : case report and review of literature . "
              10 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) drug1 developed drug2 , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl . "
            }
          5 : 
            {
              1 : 1
              2 : 3
              3 : 1
              4 : 1
              5 : 1
              6 : 2
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      14 : 
        {
          1 : "NN dobj VB nsubj NN"
          2 : 40
          3 : 
            {
              1 : "drug0 dobj *provoke* nsubj drug0"
              2 : "drug0 dobj *aggravate* nsubj drug0"
              3 : "drug0 dobj *precipitate* nsubj drug0"
              4 : "drug0 dobj *induce* nsubj drug0"
              5 : "drug0 dobj *cause* nsubj drug0"
              6 : "drug0 dobj *induce* nsubj drug0"
              7 : "drug0 dobj *induce* nsubj drug0"
              8 : "drug0 dobj *cause* nsubj drug0"
              9 : "drug0 dobj *induce* nsubj drug0"
              10 : "drug0 dobj *cause* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 may rarely provoke drug2 , even with low doses and after just a few weeks of therapy . "
              2 : "drug1 may aggravate clinical and experimental drug2 . "
              3 : "This finding suggests that drug1 can precipitate drug2 in some susceptible patients . "
              4 : "In rare cases drug1 ( MMC ) may induce cancer-associated drug2 , which is characterized by hemolytic anemia , thrombocytopenia and progressive renal failure . "
              5 : "CONCLUSIONS : drug1 may cause reversible drug2 . "
              6 : "This case is remarkable since 1 ) ECM developed after subcutaneous and not after intramuscular injection , 2 ) the injection was given by the patient himself , and 3 ) drug1 can induce drug2 as a side effect . "
              7 : "Oncologists supervising future clinical trials for lung cancer should be alert to the fact that drug1 can potentially induce serious drug2 , although this might depend on racial differences . "
              8 : "DISCUSSION : drug1 , like other atypical antipsychotic drugs , may cause drug2 of muscle origin . "
              9 : "In conclusion , this case strongly suggests that drug1 can induce drug2 which may be misdiagnosed clinically as acute viral hepatitis . "
              10 : "Based on our findings , it is thus concluded that drug1 may cause drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      15 : 
        {
          1 : "NN nmod NN conj NN"
          2 : 32
          3 : 
            {
              1 : "drug0 nmod ingestion conj *drug0*"
              2 : "drug0 nmod development conj *drug0*"
              3 : "drug0 nmod *hypotension* conj drug0"
              4 : "drug0 nmod *panniculitis* conj drug0"
              5 : "drug0 conj excision nmod *drug0*"
              6 : "drug0 nmod *shock* conj drug0"
              7 : "drug0 conj bleomycin nmod *drug0*"
              8 : "drug0 nmod *ratio* conj drug0"
              9 : "drug0 nmod *pneumonitis* conj drug0"
              10 : "drug0 nmod clearance conj *drug0*"
            }
          4 : 
            {
              1 : "The patient 's previous drug1 and the temporal relation of this event and the ingestion of drug2 , as well as the similarity of this case to other reports , point to phenolphthalein as the cause of TEN in this patient . "
              2 : "The reported case represents an unusual association between medication with the proton pump inhibitor drug1 and the development of drug2 suggesting the importance of evaluation of drug use in patients with microscopic colitis . "
              3 : "Hypotension and drug1 with drug2 in pulmonary hypertension . "
              4 : "Localized panniculitis and subsequent drug1 with subcutaneous drug2 ( Copaxone ) injection for the treatment of multiple sclerosis . "
              5 : "drug1 after pterygium excision and intraoperative drug2 . "
              6 : "To our knowledge , our report is one of the first on shock and drug1 from drug2 . "
              7 : "drug1 of the fingertips after bleomycin and drug2 . "
              8 : "PURPOSE : We evaluated the in vitro hemodialysis ratio and subsequent drug1 and pharmacokinetics of drug2 in an anephric patient with Wilms ' tumor . "
              9 : "Interstitial pneumonitis and drug1 complicating use of drug2 : case report and review of the literature . "
              10 : "drug1 , pharmacokinetics , and in vitro hemodialysis clearance of drug2 and metabolites in an anephric pediatric patient with Wilms ' tumor . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      16 : 
        {
          1 : "NN nmod VBN acl NN nmod NN"
          2 : 29
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *drug0*"
              2 : "drug0 nmod treated acl patient nmod *drug0*"
              3 : "drug0 nmod treated acl patient nmod *drug0*"
              4 : "drug0 nmod described acl *toxicity* nmod drug0"
              5 : "drug0 nmod treated acl patient nmod *drug0*"
              6 : "drug0 nmod treated acl patient nmod *drug0*"
              7 : "drug0 nmod associated acl child nmod *drug0*"
              8 : "drug0 nmod treated acl asthmaticus nmod *drug0*"
              9 : "drug0 nmod caused acl child nmod *drug0*"
              10 : "drug0 nmod treated acl farmer nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a patient treated with drug2 for chronic lymphocytic leukemia . "
              2 : "drug1 in a breast cancer patient treated with drug2 with normal transvaginal ultrasonography . "
              3 : "drug1 in a renal transplant patient treated with drug2 : a case report . "
              4 : "The ocular toxicity of drug1 , previously described as drug2 , appears to be a keratitis of moderate severity which requires further study . "
              5 : "drug1 in a multiple sclerosis patient treated with drug2 . "
              6 : "drug1 , hemolytic anemia , hepatitis , and orthostatic hypotension in a patient treated with drug2 . "
              7 : "drug1 in a child associated with drug2 . "
              8 : "drug1 with selective degeneration of myosin filaments following status asthmaticus treated with drug2 and vecuronium . "
              9 : "drug1 in a child caused by drug2 . "
              10 : "CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated drug1 in a farmer treated with drug2 for asthma , a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis , and a visceral involvement after cutaneous leishmaniasis in a man receiving CS . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      17 : 
        {
          1 : "NN dobj VBG advcl VBD dobj NN"
          2 : 27
          3 : 
            {
              1 : "drug0 dobj receiving advcl *developed* dobj drug0"
              2 : "drug0 dobj receiving advcl *had* dobj drug0"
              3 : "drug0 dobj starting advcl *developed* dobj drug0"
              4 : "drug0 dobj *developed* advcl having dobj drug0"
              5 : "drug0 dobj starting advcl *developed* dobj drug0"
              6 : "drug0 dobj using advcl *developed* dobj drug0"
              7 : "drug0 dobj taking advcl *developed* dobj drug0"
              8 : "drug0 dobj receiving advcl *presented* dobj drug0"
              9 : "drug0 dobj receiving advcl *developed* dobj drug0"
              10 : "drug0 dobj taking advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Three senile patients developed drug1 while receiving drug2 . "
              2 : "We describe four patients who had drug1 while receiving drug2 ; no other causes were evident . "
              3 : "METHODS : In an institutional practice setting , two women , aged 25 and 45 , developed drug1 after starting drug2 for epilepsy . "
              4 : "We describe a premenopausal woman who , while having drug1 due to a diagnosis of in situ ductal carcinoma , developed drug2 requiring surgery . "
              5 : "A 61 year-old male patient developed drug1 after starting drug2 . "
              6 : "CONCLUSION : A 37-year-old African - American man with G6PD deficiency developed drug1 , hepatitis , orthostatic hypotension , and aseptic meningitis simultaneously after using drug2 . "
              7 : "We report the cases of two patients who developed acute drug1 after taking drug2 at the recommended dose ( 100 mg daily ) for 7 and 4 weeks , respectively . "
              8 : "We report the case of a young healthy woman who presented an early drug1 when receiving drug2 for a first thromboembolic episode . "
              9 : "We report a case of a young woman with SLE and thrombocytopenia , who developed drug1 , headache , and seizure after receiving drug2 . "
              10 : "Three patients with no history of asthma or allergy developed drug1 while taking drug2 for hypertension . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      18 : 
        {
          1 : "NN compound NN nmod VBD dobj NN"
          2 : 27
          3 : 
            {
              1 : "drug0 compound infusion nmod *developed* dobj drug0"
              2 : "drug0 compound therapy nmod *developed* dobj drug0"
              3 : "drug0 compound therapy nmod *developed* dobj drug0"
              4 : "drug0 compound injection nmod *developed* dobj drug0"
              5 : "drug0 compound administration nmod *developed* dobj drug0"
              6 : "drug0 compound administration nmod *developed* dobj drug0"
              7 : "drug0 compound treatment nmod *developed* dobj drug0"
              8 : "drug0 compound therapy nmod *developed* dobj drug0"
              9 : "drug0 compound treatment nmod *developed* dobj drug0"
              10 : "drug0 compound treatment nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "I saw two patients with kala-azar resistant to sodium stibogluconate who developed drug1 after drug2 infusion ( in spite of tolerating a test dose ) . "
              2 : "We report two cases that developed drug1 ( AML ) during drug2 therapy for breast cancer . "
              3 : "We report a patient who developed drug1 during drug2 therapy . "
              4 : "RESULTS : Two patients with ocular inflammation of unknown origin developed drug1 after drug2 injection . "
              5 : "Reported are three children who developed drug1 after intrathecal drug2 administration followed by complete or partial recovery . "
              6 : "The patient , a 28-year-old man suffering from panic disorder , developed several drug1 during drug2 administration . "
              7 : "We report the case of a patient with chronic lymphocytic leukemia ( CLL ) who developed drug1 ( AIHA ) after drug2 treatment . "
              8 : "Two children with rheumatic fever developed drug1 while on high-dose drug2 therapy . "
              9 : "An infant who developed drug1 during drug2 treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported . "
              10 : "We report three cases of patients who developed drug1 during drug2 treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      19 : 
        {
          1 : " NN nsubj NN nmod NN"
          2 : 26
          3 : 
            {
              1 : " *drug0* nsubj effect nmod drug0"
              2 : "drug0 nmod *effect* nsubj drug0"
              3 : "drug0 nmod *cause* nsubj drug0"
              4 : "drug0 nmod *cause* nsubj drug0"
              5 : " *drug0* nsubj effect nmod drug0"
              6 : " *drug0* nsubj cause nmod drug0"
              7 : "drug0 nmod *cause* nsubj drug0"
              8 : " *drug0* nsubj toxicity nmod drug0"
              9 : "drug0 nmod *cause* nsubj drug0"
              10 : "drug0 nmod *cause* nsubj drug0"
            }
          4 : 
            {
              1 : "The most commonly recognized toxic effect of drug1 is drug2 , which generally is considered uncommon and reversible in medical literature . "
              2 : "Drug-induced drug1 is a non-dose-dependent side effect of drug2 . "
              3 : "The time course of events suggested that drug1 was the cause of the drug2 in this AIDS patient . "
              4 : "INTRODUCTION : Although drug1 used for the treatment of non-small-cell lung cancer is a well-known cause of drug2 ( ILD ) , few case reports on erlotinib-induced ILD have been issued . "
              5 : "The major side effect of drug1 is drug2 . "
              6 : "The most likely cause of such drug1 is drug2 . "
              7 : "CONCLUSION : drug1 is well a known cause of drug2 and thus should be used with caution in the initiation of antiretroviral therapy . "
              8 : "The dose-limiting toxicity of drug1 is drug2 . "
              9 : "drug1 is a rare cause of drug-induced drug2 . "
              10 : "According to the Naranjo et al. adverse-reaction probability scale , drug1 was the probable cause of drug2 in this patient . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      20 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN"
          2 : 26
          3 : 
            {
              1 : "drug0 nmod pathogenesis nmod *involved* nsubjpass drug0"
              2 : "drug0 nmod cause nmod *implicated* nsubjpass drug0"
              3 : "drug0 nmod intake nmod *caused* nsubjpass drug0"
              4 : "drug0 nmod discontinuation nmod *noted* nsubjpass drug0"
              5 : "drug0 nmod ttkg nmod *found* nsubjpass drug0"
              6 : "drug0 nmod injection nmod *associated* nsubjpass drug0"
              7 : "drug0 nmod worsening nmod *associated* nsubjpass drug0"
              8 : "drug0 nmod effect nmod *considered* nsubjpass drug0"
              9 : "drug0 nmod use nmod *linked* nsubjpass drug0"
              10 : "drug0 nmod discontinuation nmod *relieved* nsubjpass drug0"
            }
          4 : 
            {
              1 : "It is tempting to speculate that drug1 may be involved in the pathogenesis of drug2 . "
              2 : "drug1 ( PPA ) recently has been publicly implicated as a cause of drug2 and other neurologic events . "
              3 : "drug1 in this patient was caused by the erroneous intake of 1 g drug2 . "
              4 : "drug1 was noted after discontinuation of drug2 . "
              5 : "drug1 and an inverse correlation was found between TTKG and doses of drug2 ( r = -0.37 ; p < 0.02 ; N = 38 ) . "
              6 : "drug1 may be associated with intravitreal injection of drug2 in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery . "
              7 : "Evidence is shown in this report that drug1 was associated with dangerous worsening of drug2 in patients with atrial flutter . "
              8 : "Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of SLE can not be excluded , drug1 could be considered as an adverse effect of drug2 . "
              9 : "After ruling out a hydrotelluric source of fluorine , the patient 's drug1 was linked to chronic use of drug2 , following the publication in 1978 of the 2 previously reported cases affected by this drug . "
              10 : "Since the drug1 was relieved with discontinuation of drug2 and supportive bronchodilator therapy , the bronchospasm was believed to be caused by propranolol . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      21 : 
        {
          1 : "NN nmod JJ amod NN"
          2 : 25
          3 : 
            {
              1 : "drug0 nmod secondary amod *drug0*"
              2 : "drug0 nmod related amod *drug0*"
              3 : "drug0 nmod secondary amod *drug0*"
              4 : "drug0 nmod secondary amod *drug0*"
              5 : "drug0 nmod related amod *drug0*"
              6 : "drug0 nmod related amod *drug0*"
              7 : "drug0 nmod secondary amod *drug0*"
              8 : "drug0 nmod secondary amod *drug0*"
              9 : "drug0 nmod related amod *drug0*"
              10 : "drug0 nmod related amod *drug0*"
            }
          4 : 
            {
              1 : "We attribute the clinical and radiographic findings to drug1 secondary to intrathecal drug2 . "
              2 : "drug1 related to drug2 : a report of three cases with two fatalities . "
              3 : "We report a case of Stevens-Johnson drug1 ( SJS/TEN ) secondary to drug2 ( TMP-Sx ) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus ( CA-MRSA ) infection . "
              4 : "drug1 secondary to drug2 . "
              5 : "drug1 related to drug2 has been reported in lung and breast cancer . "
              6 : "drug1 related to drug2 : report of three cases . "
              7 : "Drug induced drug1 secondary to drug2 ( IFN-beta ) in multiple sclerosis . "
              8 : "Abdominal wall ulceration and drug1 secondary to drug2 . "
              9 : "drug1 related to drug2 has not been described well . "
              10 : "In addition , there is a report on drug1 related to drug2 , which has an epileptogenic property with a similar action to beta-lactam antibiotics . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 4
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      22 : 
        {
          1 : "NN conj NN nmod NN nmod NN"
          2 : 25
          3 : 
            {
              1 : "drug0 conj nedaplatin nmod chemotherapy nmod *drug0*"
              2 : "drug0 nmod diagnosis nmod time conj *drug0*"
              3 : "drug0 conj ethambutol nmod treatment nmod *drug0*"
              4 : "drug0 conj methotrexate nmod *case* nmod drug0"
              5 : "drug0 conj methotrexate nmod therapy nmod *drug0*"
              6 : "drug0 nmod re-treatment nmod *goiter* conj drug0"
              7 : "drug0 conj alpha-0a nmod treatment nmod *drug0*"
              8 : "drug0 conj methylphenidate nmod injection nmod *drug0*"
              9 : "drug0 nmod dose nmod *aplasia* conj drug0"
              10 : "drug0 conj cisplatin nmod chemotherapy nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 during standard dose combination chemotherapy with nedaplatin and drug2 for testicular cancer . "
              2 : "The male patient was treated with 225-mg/day drug1 and the time to the diagnosis of drug2 was 6 weeks . "
              3 : "drug1 , hepatitis and anti-native DNA antibodies after treatment with ethambutol and drug2 . "
              4 : "The authors report a case of drug1 with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and drug2 . "
              5 : "drug1 due to combination therapy with methotrexate and drug2 in psoriasis . "
              6 : "Goiter and drug1 during re-treatment with drug2 in a patient who previously experienced amiodarone-induced thyrotoxicosis . "
              7 : "drug1 after treatment with pegylated interferon alpha-2a and drug2 . "
              8 : "drug1 following selfadministered intra-arterial injection of methylphenidate and drug2 . "
              9 : "Bone marrow aplasia and drug1 after a single low dose of drug2 . "
              10 : "We report a patient with pulmonary adenocarcinoma complicated by the drug1 ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and drug2 ( VDS ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      23 : 
        {
          1 : "NN conj NN"
          2 : 25
          3 : 
            {
              1 : "drug0 conj *drug0*"
              2 : "drug0 conj *drug0*"
              3 : "drug0 conj *drug0*"
              4 : "drug0 conj *drug0*"
              5 : "drug0 conj *drug0*"
              6 : "drug0 conj *drug0*"
              7 : "drug0 conj *drug0*"
              8 : "drug0 conj *drug0*"
              9 : "drug0 conj *drug0*"
              10 : "drug0 conj *drug0*"
            }
          4 : 
            {
              1 : "Since 1979 , over 30 published case reports have documented the relationship between drug1 and drug2 . "
              2 : "This is the first report of a possible association between an drug1 and drug2 . "
              3 : "Our series of 3 patients supports a causal connection between drug1 and drug2 . "
              4 : "The clinical picture was identical to that of drug1 and hydroxychloroquine drug2 . "
              5 : "Autopsy findings were consistent with drug1 and oxygen-induced drug2 . "
              6 : "drug1 and drug2 : case report and review of the literature . "
              7 : "This is a case report of possible association of drug1 and drug2 in an 11-year-old boy with attention deficit hyperactivity disorder . "
              8 : "On the next day , after a total dose of only 600 mg of drug1 , drug2 and purpura occurred . "
              9 : "A case report of a patient with probable drug1 and bleomycin-induced drug2 is presented . "
              10 : "drug1 and drug2 ( OCS ) : case report and review of atypical antipsychotic-induced OCS . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      24 : 
        {
          1 : "NN compound NN nmod JJ amod NN"
          2 : 23
          3 : 
            {
              1 : "drug0 compound therapy nmod related amod *drug0*"
              2 : "drug0 compound toxicity nmod related amod *drug0*"
              3 : "drug0 compound treatment nmod coincident amod *drug0*"
              4 : "drug0 compound neurotoxicity nmod typical amod *drug0*"
              5 : "drug0 compound interaction nmod secondary amod *drug0*"
              6 : "drug0 compound neurotoxicity nmod compatible amod *drug0*"
              7 : "drug0 compound poisoning nmod secondary amod *drug0*"
              8 : "drug0 compound therapy nmod related amod *drug0*"
              9 : "drug0 compound therapy nmod secondary amod *drug0*"
              10 : "drug0 compound therapy nmod consistent amod *drug0*"
            }
          4 : 
            {
              1 : "We present a case of drug1 related to drug2 therapy . "
              2 : "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed drug1 related to drug2 toxicity . "
              3 : "The second had acute cystitis and was treated by sulphonamide and the third developed drug1 coincident with drug2 treatment for trichomonas vaginalis . "
              4 : "Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed drug1 typical of drug2 neurotoxicity . "
              5 : "drug1 secondary to a drug2 drug interaction . "
              6 : "One patient had drug1 compatible with drug2 neurotoxicity . "
              7 : "CONCLUSION : We report a case of the use of pamidronate for significant drug1 secondary to acute drug2 poisoning . "
              8 : "Liver transplantation for drug1 related to drug2 therapy . "
              9 : "drug1 secondary to drug2 therapy . "
              10 : "Despite the underlying hepatitis C , this case represents drug1 consistent with drug2 therapy for CML . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      25 : 
        {
          1 : " NN nsubj NN nmod NN compound NN"
          2 : 21
          3 : 
            {
              1 : " *drug0* nsubj complication nmod use compound drug0"
              2 : "drug0 compound therapy nmod *complication* nsubj drug0"
              3 : "drug0 compound therapy nmod *complication* nsubj drug0"
              4 : "drug0 compound addiction nmod *complication* nsubj drug0"
              5 : "drug0 compound therapy nmod *complication* nsubj drug0"
              6 : "drug0 compound injection nmod *complication* nsubj drug0"
              7 : "drug0 compound therapy nmod *effect* nsubj drug0"
              8 : "drug0 compound toxicity nmod *complication* nsubj drug0"
              9 : "drug0 compound treatment nmod *complication* nsubj drug0"
              10 : " *drug0* nsubj complication nmod use compound drug0"
            }
          4 : 
            {
              1 : "The most common complication of drug1 use is adverse drug2 . "
              2 : "drug1 is a complication of drug2 therapy that may occur despite treatments with corticosteroids . "
              3 : "BACKGROUND : drug1 , a common mucocutaneous disorder , is a well accepted complication of drug2 therapy . "
              4 : "drug1 is an infrequent but recognized complication of drug2 addiction . "
              5 : "drug1 is a rare complication of drug2 therapy and may be connected with some diagnostic and/or therapeutic problems . "
              6 : "CONCLUSIONS : drug1 is a potential complication of intravitreal drug2 injection . "
              7 : "drug1 is a significant side effect of drug2 therapy , which may limit its clinical use . "
              8 : "After reviewing the literature we suggest the drug1 was a complication of drug2 toxicity which affected the lateral geniculate nucleus which produced blindness . "
              9 : "drug1 is a rare complication of drug2 treatment for alcoholism . "
              10 : "A well-recognized complication of drug1 use is drug2 , but the potential ocular toxicity of isoniazid is often overlooked . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      26 : 
        {
          1 : "NN compound NN nmod NN nmod VBD dobj NN"
          2 : 21
          3 : 
            {
              1 : "drug0 compound infusion nmod initiation nmod *had* dobj drug0"
              2 : "drug0 compound ointment nmod administration nmod *experienced* dobj drug0"
              3 : "drug0 compound therapy nmod course nmod *developed* dobj drug0"
              4 : "drug0 compound therapy nmod institution nmod *developed* dobj drug0"
              5 : "drug0 compound solution nmod use nmod *developed* dobj drug0"
              6 : "drug0 compound regimen nmod treatment nmod *developed* dobj drug0"
              7 : "drug0 compound mg/day nmod treatment nmod *developed* dobj drug0"
              8 : "drug0 dobj *developed* nmod day nmod treatment compound drug0"
              9 : "drug0 compound therapy nmod cessation nmod *developed* dobj drug0"
              10 : "drug0 compound therapy nmod complication nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "He had an immediate drug1 during the initiation of the drug2 infusion with diffuse urticaria , facial swelling , cough , and chest tightness . "
              2 : "We report a case of an 11-year-old boy who experienced an drug1 after administration of drug2 ointment . "
              3 : "Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed drug1 in the course of drug2 therapy . "
              4 : "The patient described in this paper was a 78-year-old diabetic man who developed drug1 following institution of drug2 therapy . "
              5 : "A patient with a large hydatid cyst of the left lobe of the liver developed drug1 following rather liberal use of drug2 solution as a scolicidal agent . "
              6 : "We describe a patient with extranodal non-Hodgkin lymphoma who developed drug1 after treatment with a drug2 chemotherapy regimen . "
              7 : "A 56-year-old white woman with a diagnosis of reactive depression developed severe drug1 after a 30 days ' treatment with drug2 75 mg/day . "
              8 : "On day 7 of drug1 treatment , the patient developed drug2 , macular rash , facial edema , eosinophilia , marked increase in serum creatinine level , and mild hepatitis . "
              9 : "Two infants developed drug1 shortly after cessation of prolonged drug2 therapy for infantile spasms . "
              10 : "One patient developed drug1 as a complication of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 2
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      27 : 
        {
          1 : "NN compound NN nmod VBN nsubjpass NN"
          2 : 20
          3 : 
            {
              1 : "drug0 compound therapy nmod *induced* nsubjpass drug0"
              2 : "drug0 compound infusion nmod *associated* nsubjpass drug0"
              3 : "drug0 compound therapy nmod *observed* nsubjpass drug0"
              4 : "drug0 compound therapy nmod *described* nsubjpass drug0"
              5 : "drug0 compound administration nmod *reported* nsubjpass drug0"
              6 : "drug0 compound patch nmod *related* nsubjpass drug0"
              7 : "drug0 compound therapy nmod *seen* nsubjpass drug0"
              8 : "drug0 compound withdrawal nmod *reduced* nsubjpass drug0"
              9 : "drug0 compound treatment nmod *associated* nsubjpass drug0"
              10 : "drug0 compound therapy nmod *induced* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Because drug1 may be induced by drug2 therapy , the IFN was stopped . "
              2 : "drug1 is rarely associated with drug2 infusion for lympho-proliferative disorders , but it should be considered by those administering rituximab , especially when a patient develops severe pulmonary symptoms soon after infusion . "
              3 : "drug1 were observed in two of the nine children during drug2 therapy . "
              4 : "Recently , drug1 have been described after drug2 therapy . "
              5 : "drug1 and cardiac arrest have been reported during drug2 administration but no effective technique has been described to prevent them . "
              6 : "After extensive neurological ` work up ' , we realized that the drug1 was related to the transdermal drug2 patch that we had prescribed for weaning off the opioid . "
              7 : "drug1 was seen in a patient with pulmonary tuberculosis during drug2 therapy . "
              8 : "The drug1 and tinnitus were gradually reduced after drug2 withdrawal and corticosteroid and azathioprine treatment . "
              9 : "A few recent individual case reports have suggested that a drug1 may be associated with drug2 treatment , but this association is not well described . "
              10 : "CONCLUSIONS : This patient 's drug1 was probably induced by drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      28 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN"
          2 : 19
          3 : 
            {
              1 : "drug0 nmod administration nmod *resulted* nsubj drug0"
              2 : "drug0 nmod treatment nmod *developed* nsubj drug0"
              3 : "drug0 nmod withdrawal nmod *receded* nsubj drug0"
              4 : "drug0 nmod use nmod *resulted* nsubj drug0"
              5 : "drug0 nsubj *reappeared* nmod rechallenge nmod drug0"
              6 : "drug0 nmod withdrawal nmod *regressed* nsubj drug0"
              7 : "drug0 nmod treatment nmod *occurred* nsubj drug0"
              8 : "drug0 nmod development nmod *contributed* nsubj drug0"
              9 : "drug0 nmod therapy nmod *developed* nsubj drug0"
              10 : "drug0 nmod discontinuation nmod *responded* nsubj drug0"
            }
          4 : 
            {
              1 : "Drug-induced drug1 resulted from the administration of drug2 at a dosage of 100 mg twice daily for the treatment of discoid lupus . "
              2 : "drug1 developed in two children with acute lymphoblastic leukemia during induction treatment with drug2 , prednisone , and asparaginase . "
              3 : "drug1 receded after withdrawal of drug2 and treatment with anti-inflammatory drugs . "
              4 : "A case is reported in which drug1 , with a low plasma parathyroid hormone ( PTH ) concentration , resulted from the therapeutic use of drug2 for toxemia of pregnancy . "
              5 : "After rechallenge with monotherapy drug1 , however , the drug2 reappeared within a few weeks , indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis . "
              6 : "Primary drug1 regressed on withdrawal of drug2 . "
              7 : "drug1 occurred in eight women following long-term treatment with drug2 ( = dihydroxybusulfan ) for ovarian carcinoma . "
              8 : "It is very likely that the drug1 used in the antiemetic drug regimen contributed to the development of drug2 in these patients . "
              9 : "drug1 developed in a patient during adjuvant therapy with drug2 for malignant melanoma . "
              10 : "The drug1 responded to discontinuation of drug2 and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      29 : 
        {
          1 : "NN nmod NN nmod VBD dobj NN conj NN"
          2 : 19
          3 : 
            {
              1 : "drug0 nmod treatment nmod *developed* dobj meningitis conj drug0"
              2 : "drug0 nmod addition nmod *experienced* dobj delirium conj drug0"
              3 : "drug0 nmod exposure nmod *developed* dobj dysfunction conj drug0"
              4 : "drug0 nmod dose nmod *developed* dobj pain conj drug0"
              5 : "drug0 nmod treatment nmod *developed* dobj meningitis conj drug0"
              6 : "drug0 nmod treatment nmod *developed* dobj meningitis conj drug0"
              7 : "drug0 conj interval dobj *developed* nmod treatment nmod drug0"
              8 : "drug0 nmod dose nmod *developed* dobj pain conj drug0"
              9 : "drug0 nmod treatment nmod *developed* dobj hyponatremia conj drug0"
              10 : "drug0 nmod administration nmod *developed* dobj eosinophilia conj drug0"
            }
          4 : 
            {
              1 : "PURPOSE : The case of a patient who developed aseptic meningitis , hemolytic anemia , hepatitis , and drug1 simultaneously during treatment with drug2 is described . "
              2 : "The authors describe a woman with chronic schizophrenia who experienced delirium , drug1 , and photosensitivity after the addition of drug2 to her neuroleptic regimen . "
              3 : "The case of an adult who developed both hepatic dysfunction and an drug1 after exposure to drug2 is discussed . "
              4 : "We report the case of a 17-year-old male who developed chest pain , drug1 , and acute left ventricular dysfunction following a single dose of drug2 . "
              5 : "PURPOSE : The case of a patient who developed aseptic meningitis , drug1 , hepatitis , and orthostatic hypotension simultaneously during treatment with drug2 is described . "
              6 : "PURPOSE : The case of a patient who developed aseptic meningitis , hemolytic anemia , drug1 , and orthostatic hypotension simultaneously during treatment with drug2 is described . "
              7 : "During intravenous treatment with drug1 for recurrent gastrointestinal ( GI ) bleeding , a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and drug2 . "
              8 : "We report the case of a 17-year-old male who developed chest pain , elevated cardiac biomarkers , and drug1 following a single dose of drug2 . "
              9 : "Sixteen of 33 patients developed significant hyponatremia and drug1 during oral treatment with drug2 . "
              10 : "CASE PRESENTATION : We report a patient with CF who developed recurrent eosinophilia and drug1 following repeated administration of preservative-free drug2 by inhalation , beginning at 16 months of age . "
            }
          5 : 
            {
              1 : 2
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 2
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      30 : 
        {
          1 : "VB xcomp JJ amod NN"
          2 : 18
          3 : 
            {
              1 : "drug0 xcomp secondary amod *drug0*"
              2 : "drug0 xcomp due amod *drug0*"
              3 : "drug0 xcomp secondary amod *drug0*"
              4 : "drug0 xcomp secondary amod *drug0*"
              5 : "drug0 xcomp secondary amod *drug0*"
              6 : "drug0 xcomp secondary amod *drug0*"
              7 : "drug0 xcomp secondary amod *drug0*"
              8 : "drug0 xcomp related amod *drug0*"
              9 : "drug0 xcomp secondary amod *drug0*"
              10 : "drug0 xcomp secondary amod *drug0*"
            }
          4 : 
            {
              1 : "We present a neonate with a seizure disorder who acutely developed drug1 secondary to drug2 overdose . "
              2 : "drug1 due to drug2 bone marrow toxicity . "
              3 : "drug1 secondary to drug2 in living donor liver transplantation : a case report . "
              4 : "Although gabapentin withdrawal has been previously reported and usually consists of anxiety , diaphoresis , and palpitations , this is the first reported patient with drug1 and status epilepticus secondary to drug2 withdrawal . "
              5 : "drug1 secondary to drug2 in a patient with antiphospholipid antibody syndrome . "
              6 : "We report the case of a 27-year-old Indian woman who developed drug1 and angioedema secondary to drug2 administration . "
              7 : "drug1 secondary to drug2 in the treatment of acute promyelocytic leukemia in first relapse . "
              8 : "drug1 related to drug2 in two patients with HIV infection . "
              9 : "Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of drug1 secondary to drug2 administration at another hospital . "
              10 : "However , drug1 and pericarditis secondary to drug2 use has been rarely reported . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      31 : 
        {
          1 : "NN nmod VBN acl NN compound NN"
          2 : 17
          3 : 
            {
              1 : "drug0 nmod associated acl *syndrome* compound drug0"
              2 : "drug0 nmod associated acl *hemorrhage* compound drug0"
              3 : "drug0 nmod associated acl *phenomenon* compound drug0"
              4 : "drug0 nmod associated acl *use* compound drug0"
              5 : "drug0 nmod presented acl *abuse* compound drug0"
              6 : "drug0 nmod associated acl *thyrotoxicosis* compound drug0"
              7 : "drug0 nmod presented acl *therapy* compound drug0"
              8 : "drug0 nmod associated acl *pigmentation* compound drug0"
              9 : "drug0 nmod induced acl *reaction* compound drug0"
              10 : "drug0 nmod triggered acl *reaction* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and Stevens-Johnson syndrome associated with drug2 treated with tacrolimus . "
              2 : "drug1 hemorrhage associated with a drug2 . "
              3 : "drug1 first-dose phenomenon possibly associated with drug2 : a report of three cases . "
              4 : "Chronic drug1 use associated with drug2 and refractory ventricular arrhythmia . "
              5 : "A 33-year-old man with a history of recreational drug1 abuse presented to the emergency department with drug2 , abdominal pain , and distention . "
              6 : "drug1 thyrotoxicosis associated with drug2 . "
              7 : "CASE REPORT : A woman of 80 years , on long-term drug1 therapy presented with an drug2 ; on investigation the only precipitating factor found was an international normalised ratio of 4.8 . "
              8 : "drug1 and skin pigmentation associated with drug2 . "
              9 : "However , dermatologists should be cautious about a drug1 reaction induced by drug2 or other phenothiazine-derivative drugs . "
              10 : "The clinical findings and laboratory studies suggested an drug1 reaction triggered by drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      32 : 
        {
          1 : "NN dobj VBG acl NN nmod NN"
          2 : 17
          3 : 
            {
              1 : "drug0 dobj taking acl patient nmod *drug0*"
              2 : "drug0 dobj taking acl woman nmod *drug0*"
              3 : "drug0 dobj inducing acl *role* nmod drug0"
              4 : "drug0 dobj taking acl *case* nmod drug0"
              5 : "drug0 dobj using acl patient nmod *drug0*"
              6 : "drug0 dobj receiving acl patient nmod *drug0*"
              7 : "drug0 dobj taking acl patient nmod *drug0*"
              8 : "drug0 dobj receiving acl patient nmod *drug0*"
              9 : "drug0 dobj receiving acl *patient* nmod drug0"
              10 : "drug0 dobj taking acl patient nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a patient taking drug2 . "
              2 : "drug1 due to endometriosis in a premenopausal woman taking drug2 . "
              3 : "The potential role of drug1 in inducing drug2 is emphasized , and the literature on the subject is reviewed . "
              4 : "We report one case of drug1 in a patient , with a 30-year history of rheumatoid arthritis , taking low dose drug2 weekly over a 10-month period . "
              5 : "drug1 due to parvovirus B19 in a Crohn 's disease patient using drug2 . "
              6 : "drug1 in a patient receiving drug2 for ankylosing spondylitis . "
              7 : "drug1 in a patient with diabetes taking drug2 for the treatment of psoriasis . "
              8 : "The drug1 in a patient receiving drug2 can pose a significant management challenge . "
              9 : "A 68-year-old female patient with advanced ovarian carcinoma drug1 whilst receiving a drug2 and cyclophosphamide infusion . "
              10 : "This case describes drug1 in a patient taking drug2 with no previous liver disease and report of being compliant with alcohol abstinence . "
            }
          5 : 
            {
              1 : 3
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      33 : 
        {
          1 : "NN conj NN nmod NN compound NN"
          2 : 16
          3 : 
            {
              1 : "drug0 conj fever nmod *syndrome* compound drug0"
              2 : "drug0 compound treatment nmod *anemia* conj drug0"
              3 : "drug0 conj fluoxetine nmod *rash* compound drug0"
              4 : "drug0 compound therapy nmod *fever* conj drug0"
              5 : "drug0 conj cisplatinum nmod *treatment* compound drug0"
              6 : "drug0 compound therapy nmod *fever* conj drug0"
              7 : "drug0 compound treatment nmod *asthma* conj drug0"
              8 : "drug0 conj cisplatinum nmod *treatment* compound drug0"
              9 : "drug0 compound intoxication nmod failure conj *drug0*"
              10 : "drug0 compound treatment nmod *leukopenia* conj drug0"
            }
          4 : 
            {
              1 : "A patient is described with the characteristic features of drug1 hypersensitivity syndrome ( PHS ) including fever , erythroderma , drug2 , pinhead-sized facial pustules and abnormal liver function tests . "
              2 : "A 66-year-old Japanese woman with severe scleroderma developed anemia and drug1 due to drug2 ( D-Pen ) treatment , although the leukopenia was not markedly severe . "
              3 : "drug1 and skin rash from chocolate during fluoxetine and drug2 treatment : case report . "
              4 : "Fever , drug1 , and pleural effusion following drug2 therapy for herpes zoster ophthalmicus . "
              5 : "drug1 and encephalopathy following treatment of testicular carcinoma with cisplatinum , drug2 , and bleomycin . "
              6 : "Fever , pulmonary infiltrates , and drug1 following drug2 therapy for herpes zoster ophthalmicus . "
              7 : "Asthma and drug1 during drug2 treatment . "
              8 : "drug1 and encephalopathy following treatment of testicular carcinoma with cisplatinum , vinblastine , and drug2 . "
              9 : "We cared for a patient with progressive renal impairment who presented with drug1 , QRS broadening and cardiac failure due to chronic drug2 intoxication . "
              10 : "These cases suggest the possibility that , in some patients , leukopenia or drug1 during drug2 treatment might be dose-related . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      34 : 
        {
          1 : "NN nmod VBN acl NN nmod NN nmod NN"
          2 : 16
          3 : 
            {
              1 : "drug0 nmod associated acl osteomalacia nmod treatment nmod *drug0*"
              2 : "drug0 nmod caused acl cataract nmod removal nmod *drug0*"
              3 : "drug0 nmod treated acl erythematosus nmod child nmod *drug0*"
              4 : "drug0 nmod treated acl patient nmod *case* nmod drug0"
              5 : "drug0 nmod application nmod *male* acl presented nmod drug0"
              6 : "drug0 nmod treated acl lymphoma nmod progression nmod *drug0*"
              7 : "drug0 nmod treated acl sclerosis nmod patient nmod *drug0*"
              8 : "drug0 nmod treated acl asthmaticus nmod *myopathy* nmod drug0"
              9 : "drug0 nmod treated acl patient nmod *development* nmod drug0"
              10 : "drug0 nmod administration nmod *myeloma* acl complicated nmod drug0"
            }
          4 : 
            {
              1 : "Oral drug1 in treatment of osteomalacia associated with drug2 and cholestyramine therapy . "
              2 : "drug1 after removal of cataract caused by intravitreal drug2 in combination with photodynamic therapy for exudative age-related macular degeneration . "
              3 : "This is a case report of fatal drug1 in a child with systemic lupus erythematosus being treated with drug2 and azathioprine . "
              4 : "We describe the first case of drug1 in a patient treated with drug2 . "
              5 : "A 33-year-old male presented with drug1 following the application of drug2 and 0.1 % tretinoin cream to the face intermittently for 9 months . "
              6 : "drug1 as a progression of a nodular lymphocyte-predominant Hodgkin 's lymphoma treated with drug2 : a molecular analysis using laser capture microdissection . "
              7 : "In vitro drug1 in a patient with systemic sclerosis treated with drug2 . "
              8 : "Acute myopathy with selective drug1 following status asthmaticus treated with drug2 and vecuronium . "
              9 : "Development of essential drug1 in a patient treated with drug2 and pentostatin for hairy cell leukemia . "
              10 : "Multiple myeloma complicated by drug1 following first administration of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      35 : 
        {
          1 : "NN nmod NN nmod JJ amod NN"
          2 : 16
          3 : 
            {
              1 : "drug0 nmod therapy nmod secondary amod *drug0*"
              2 : "drug0 nmod initiation nmod secondary amod *drug0*"
              3 : "drug0 nmod injection nmod secondary amod *drug0*"
              4 : "drug0 nmod therapy nmod refractory amod *drug0*"
              5 : "drug0 nmod administration nmod secondary amod *drug0*"
              6 : "drug0 nmod administration nmod concurrent amod *drug0*"
              7 : "drug0 nmod treatment nmod secondary amod *drug0*"
              8 : "drug0 nmod infusion nmod subsequent amod *drug0*"
              9 : "drug0 nmod administration nmod secondary amod *drug0*"
              10 : "drug0 nmod use nmod related amod *drug0*"
            }
          4 : 
            {
              1 : "We discuss a patient who developed drug1 secondary to short-term therapy with drug2 , resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria . "
              2 : "drug1 secondary to initiation of drug2 : a case report and review involving ocular management in cardiac polypharmacy . "
              3 : "drug1 secondary to bolus injection of drug2 . "
              4 : "We report an allogeneic bone marrow transplant recipient who developed drug1 refractory to sequential therapy with drug2 , foscarnet , and cidofovir . "
              5 : "We report two cases of drug1 ( CSFE ) secondary to the intraventricular administration of drug2 . "
              6 : "A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed drug1 concurrent with the administration of drug2 . "
              7 : "A case of drug1 secondary to treatment with drug2 for multiple myeloma . "
              8 : "We present a case report of a patient with typhoid fever who experienced a drug1 subsequent to the infusion of drug2 . "
              9 : "We report a case of acute drug1 secondary to rectal administration of drug2 and sodium biphosphate ( Fleet enema ) . "
              10 : "This article describes two cases of aplastic anemia , at least one of which was almost certainly induced by the use of methazolamide , and one case of drug1 related to the use of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      36 : 
        {
          1 : "NN nmod NNS nmod NN"
          2 : 15
          3 : 
            {
              1 : "drug0 nmod instillations nmod *drug0*"
              2 : "drug0 nmod patients nmod *drug0*"
              3 : "drug0 nmod courses nmod *drug0*"
              4 : "drug0 nmod *reports* nmod drug0"
              5 : "drug0 nmod doses nmod *drug0*"
              6 : "drug0 nmod weeks nmod *drug0*"
              7 : "drug0 nmod doses nmod *drug0*"
              8 : "drug0 nmod *cases* nmod drug0"
              9 : "drug0 nmod *cases* nmod drug0"
              10 : "drug0 nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "MATERIALS AND METHODS : We present two cases of significant morbidity related to drug1 following two instillations of drug2 . "
              2 : "drug1 in patients on infusional drug2 . "
              3 : "drug1 after widely separated courses of drug2 exacerbated by actinomycin-D and mithramycin . "
              4 : "There have been numerous case reports of drug1 with drug2 in the literature , but none reported hyperglycemia within days of initiation of the medication . "
              5 : "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a drug1 following high doses of drug2 for treatment of an acute depression . "
              6 : "A 54-year-old man developed drug1 4 weeks after beginning drug2 for complex partial seizures related to a glioblastoma multiforme brain tumor . "
              7 : "drug1 after normal doses of neubulized drug2 ( salbutamol ) . "
              8 : "CASE PRESENTATION : Three cases of drug1 in drug2 ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma , a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis , and a visceral involvement after cutaneous leishmaniasis in a man receiving CS . "
              9 : "The literature search revealed 22 cases of drug1 to drug2 . "
              10 : "The hospital course of the acute renal failure is presented with a review of the literature on cases of drug1 after drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      37 : 
        {
          1 : "NN compound NN nmod NN dep NN"
          2 : 15
          3 : 
            {
              1 : "drug0 compound therapy nmod side-effect dep *drug0*"
              2 : "drug0 compound therapy nmod complication dep *drug0*"
              3 : "drug0 compound treatment nmod complication dep *drug0*"
              4 : "drug0 compound therapy nmod *block* dep drug0"
              5 : "drug0 compound therapy nmod relation dep *drug0*"
              6 : "drug0 compound production nmod hazard dep *drug0*"
              7 : "drug0 compound toxicity nmod complication dep *drug0*"
              8 : "drug0 compound therapy nmod relationship dep *drug0*"
              9 : "drug0 compound injection nmod complication dep *drug0*"
              10 : "drug0 compound therapy nmod event dep *drug0*"
            }
          4 : 
            {
              1 : "drug1 and pneumonitis : a severe side-effect of low-dose drug2 therapy during rheumatoid arthritis . "
              2 : "drug1 : a complication of drug2 therapy . "
              3 : "drug1 : a complication of drug2 treatment . "
              4 : "Type I second-degree AV block ( drug1 , Wenckebach AV block ) during drug2 therapy for preterm labor . "
              5 : "drug1 among tuberculous patients : its relation to drug2 therapy . "
              6 : "drug1 : an occupational hazard of drug2 production . "
              7 : "drug1 manifested by temporary blindness : a possible complication of drug2 toxicity . "
              8 : "drug1 and diabetic coma : possible relationship to drug2 therapy . "
              9 : "drug1 -- a complication of cervical intrathecal drug2 injection . "
              10 : "drug1 : a newly described adverse event with long-term drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      38 : 
        {
          1 : "NN nmod NN nmod NN nmod NN conj NN"
          2 : 15
          3 : 
            {
              1 : "drug0 nmod use nmod *blindness* nmod response conj drug0"
              2 : "drug0 nmod use nmod *syndrome* nmod fever conj drug0"
              3 : "drug0 conj methotrexate nmod *case* nmod syndrome nmod drug0"
              4 : "drug0 nmod treatment nmod *suffering* nmod thrombocytopenia conj drug0"
              5 : "drug0 conj clindamycin nmod administration nmod *disease* nmod drug0"
              6 : "drug0 conj lovastatin nmod interaction nmod *risk* nmod drug0"
              7 : "drug0 conj rifabutin nmod combination nmod treatment nmod *drug0*"
              8 : "drug0 nmod patient nmod *development* nmod gammopathy conj drug0"
              9 : "drug0 conj rifabutin nmod combination nmod treatment nmod *drug0*"
              10 : "drug0 nmod use nmod *syndrome* nmod fever conj drug0"
            }
          4 : 
            {
              1 : "Total blindness with a transient tonic pupillary response , drug1 , and abnormal visual-evoked potentials developed in a 54-year-old man after the use of drug2 for leg cramps . "
              2 : "To our knowledge , the syndrome of fever , drug1 , and pleural effusion following use of drug2 has not been previously reported . "
              3 : "The authors report a case of Balint syndrome with irreversible drug1 on MRI following intrathecal methotrexate and drug2 . "
              4 : "A patient suffering from heparin-associated thrombocytopenia ( HAT ) , drug1 , and acute renal failure after treatment with standard drug2 is described . "
              5 : "Cholestatic liver disease with drug1 ( vanishing bile duct syndrome ) after administration of clindamycin and drug2 . "
              6 : "CONCLUSIONS : The risk of drug-induced drug1 due to the potential interaction between lovastatin and drug2 or clarithromycin should be considered before the concomitant use of these agents . "
              7 : "drug1 during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin , drug2 and ethambutol . "
              8 : "The development of an IgG lambda-type monoclonal gammopathy and subsequent drug1 in an epilepsy patient on drug2 ( DILANTIN ) therapy for 20 years is reported . "
              9 : "drug1 during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin , clarithromycin and drug2 . "
              10 : "To our knowledge , the syndrome of fever , pulmonary infiltrates , and drug1 following use of drug2 has not been previously reported . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      39 : 
        {
          1 : "NN dep NN"
          2 : 15
          3 : 
            {
              1 : "drug0 dep *drug0*"
              2 : "drug0 dep *drug0*"
              3 : "drug0 dep *drug0*"
              4 : "drug0 dep *drug0*"
              5 : "drug0 dep *drug0*"
              6 : "drug0 dep *drug0*"
              7 : "drug0 dep *drug0*"
              8 : "drug0 dep *drug0*"
              9 : "drug0 dep *drug0*"
              10 : "drug0 dep *drug0*"
            }
          4 : 
            {
              1 : "We report on 7 patients ( 2 women , 5 men ) with chronic renal failure , who developed under a high dosage of the new diuretic drug1 ( range 240 to 1440 mg per day ) drug2 . "
              2 : "drug1 with newer cephalosporins : drug2 . "
              3 : "Severe drug1 associated drug2 is a rare complication of heparin therapy . "
              4 : "The first reported case , in an adult , of drug1 induced drug2 is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria . "
              5 : "We report five cases of drug1 ( CBDCA ) drug2 after weekly low-dose paclitaxel ( 60 mg/m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy . "
              6 : "The incidence of drug1 ( 5-FU ) - related drug2 seems to be dosage and schedule dependent . "
              7 : "drug1 ( Ritalin ) - associated drug2 and glaucoma . "
              8 : "BACKGROUND : drug1 ( IFN ) - associated drug2 is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus , but visual function is usually maintained . "
              9 : "drug1 ( FK506 ) - induced drug2 after liver transplant . "
              10 : "drug1 and cyclophosphamide toxicity simulating drug2 to the lungs in childhood cancer . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      40 : 
        {
          1 : "NN nmod VBN acl NN conj NN"
          2 : 14
          3 : 
            {
              1 : "drug0 nmod associated acl *bradycardia* conj drug0"
              2 : "drug0 nmod caused acl *syndrome* conj drug0"
              3 : "drug0 nmod induced acl *hypoxemia* conj drug0"
              4 : "drug0 nmod associated acl *cardiomyopathy* conj drug0"
              5 : "drug0 nmod caused acl *paraesthesia* conj drug0"
              6 : "drug0 nmod induced acl *rhythm* conj drug0"
              7 : "drug0 nmod associated acl *syndrome* conj drug0"
              8 : "drug0 nmod induced acl *papilloedema* conj drug0"
              9 : "drug0 nmod provoked acl *planus* conj drug0"
              10 : "drug0 nmod treated acl sclerosis conj *drug0*"
            }
          4 : 
            {
              1 : "Bradycardia and drug1 associated with ocular drug2 . "
              2 : "Horner 's syndrome and drug1 caused by high-dose drug2 . "
              3 : "Easily reversible hypoxemia and drug1 induced by drug2 . "
              4 : "A case of acute cardiomyopathy and drug1 associated with drug2 . "
              5 : "The fifth patient exhibited paraesthesia and drug1 caused by drug2 that was misdiagnosed as psychotic agitation . "
              6 : "Alternating sinus rhythm and drug1 induced by drug2 . "
              7 : "Restless legs syndrome and drug1 probably associated with drug2 . "
              8 : "Papilloedema and drug1 apparently induced by drug2 ( Pexid ) . "
              9 : "Lichen planus and drug1 provoked by drug2 . "
              10 : "drug1 and extrapyramidal symptoms in a patient with Tourette 's syndrome , Asperger 's syndrome , and multiple sclerosis treated with drug2 and clomipramine . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      41 : 
        {
          1 : "NN compound NN nmod NNS nmod NN"
          2 : 14
          3 : 
            {
              1 : "drug0 compound therapy nmod patients nmod *drug0*"
              2 : "drug0 compound therapy nmod effects nmod *drug0*"
              3 : "drug0 compound therapy nmod patients nmod *drug0*"
              4 : "drug0 compound use nmod *cases* nmod drug0"
              5 : "drug0 compound nephrotoxicity nmod patients nmod *drug0*"
              6 : "drug0 compound treatment nmod months nmod *drug0*"
              7 : "drug0 compound overdose nmod seizures nmod *drug0*"
              8 : "drug0 compound use nmod *cases* nmod drug0"
              9 : "drug0 compound therapy nmod patients nmod *drug0*"
              10 : "drug0 compound transplantation nmod *patients* nmod drug0"
            }
          4 : 
            {
              1 : "A possible mechanism for drug1 in brain-damaged patients on drug2 therapy is discussed . "
              2 : "drug1 as side effects of drug2 therapy . "
              3 : "drug1 in patients with Wilson 's disease with initial drug2 therapy . "
              4 : "We report two cases of drug1 following drug2 use in cardiac patients with trisomy 21 . "
              5 : "drug1 in certain patients with drug2 nephrotoxicity is also possible . "
              6 : "A female patient with HER2 positive , metastatic breast cancer presented with pulmonary infiltrates , and a drug1 after several months of drug2 treatment . "
              7 : "drug1 immediately after seizures in drug2 overdose . "
              8 : "Infliximab and its serious adverse effects are discussed , and other cases of drug1 with drug2 use are also reviewed . "
              9 : "drug1 with severe lactate acidosis in HIV-infected patients on drug2 therapy . "
              10 : "We describe two patients with drug1 following drug2 non-myeloablative stem cell transplantation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      42 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN"
          2 : 14
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod *drug0*"
              2 : "drug0 nmod caused acl *cases* nmod drug0"
              3 : "drug0 nmod treated acl patients nmod *drug0*"
              4 : "drug0 nmod treated acl patients nmod *drug0*"
              5 : "drug0 nmod treated acl patients nmod *drug0*"
              6 : "drug0 nmod caused acl hands nmod *drug0*"
              7 : "drug0 nmod treated acl patients nmod *drug0*"
              8 : "drug0 nmod treated acl sites nmod *drug0*"
              9 : "drug0 nmod treated acl patients nmod *drug0*"
              10 : "drug0 nmod induced acl *patients* nmod drug0"
            }
          4 : 
            {
              1 : "drug1 and bursitis in multiple sclerosis patients treated with drug2 . "
              2 : "So far , few cases of drug1 caused by drug2 have been reported . "
              3 : "drug1 in 2 patients treated with drug2 . "
              4 : "drug1 in patients treated with drug2 . "
              5 : "This case demonstrates the value of DWI in evaluation and diagnosis of drug1 in patients being treated with drug2 . "
              6 : "Fixed drug drug1 in hands caused by drug2 . "
              7 : "drug1 in patients with prostate cancer treated with drug2 and radiotherapy . "
              8 : "He developed a late drug1 in some sites treated with drug2 . "
              9 : "We conclude that neurosurgeons and neurologists should be aware of calcium antagonist -- related drug1 in patients treated with drug2 . "
              10 : "We report two patients with drug1 induced by drug2 ( SASP ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      43 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD dobj NN"
          2 : 13
          3 : 
            {
              1 : "drug0 nmod treatment nmod course nmod *developed* dobj drug0"
              2 : "drug0 nmod treatment nmod week nmod *developed* dobj drug0"
              3 : "drug0 nmod hyperthyroidism nmod treatment nmod *developed* dobj drug0"
              4 : "drug0 nmod treatment nmod course nmod *developed* dobj drug0"
              5 : "drug0 nmod combination nmod administration nmod *developed* dobj drug0"
              6 : "drug0 nmod treatment nmod course nmod *developed* dobj drug0"
              7 : "drug0 dobj *developed* nmod institution nmod therapy nmod drug0"
              8 : "drug0 nmod treatment nmod start nmod *developed* dobj drug0"
              9 : "drug0 nmod solution nmod administration nmod *sustained* dobj drug0"
              10 : "drug0 nmod bupivacaine nmod block nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We describe a 73-year-old woman who developed serious drug1 with associated thrombocytopenia in the course of treatment with drug2 . "
              2 : "A 21-year-old patient developed drug1 during his nineteenth week of treatment with drug2 for drug-resistant schizophrenia . "
              3 : "A patient is presented with typical hyperthyroidism , who developed a drug1 and a raised creatine phosphokinase after treatment for hyperthyroidism with drug2 ( 100 mg orally , three times a day ) . "
              4 : "METHODS : A patient who developed dramatic , permanent drug1 after a 9-month course of treatment with drug2 and isoniazid for pulmonary tuberculosis is presented . "
              5 : "We present two children with acute lymphocytic leukemia who developed drug1 following administration of a combination of intravenous drug2 and methotrexate during the consolidation phase of chemotherapy . "
              6 : "This communication describes a patient who developed drug1 in the course of treatment with drug2 . "
              7 : "Following the institution of intravenous therapy with drug1 , the patient developed drug2 , hemoptysis , and a pleural friction rub . "
              8 : "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed drug1 within 3 weeks after the start of treatment with drug2 for acute gouty bursitis . "
              9 : "Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an drug1 after the intravenous administration of 50 % solution of drug2 . "
              10 : "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant drug1 after an axillary block with bupivacaine and additional injection of drug2 in the operative field . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      44 : 
        {
          1 : "NN nmod NNS compound NN"
          2 : 13
          3 : 
            {
              1 : "drug0 nmod *reactions* compound drug0"
              2 : "drug0 compound levels nmod *drug0*"
              3 : "drug0 nmod *concentrations* compound drug0"
              4 : "drug0 compound patients nmod *drug0*"
              5 : "drug0 compound salts nmod *drug0*"
              6 : "drug0 nmod *symptoms* compound drug0"
              7 : "drug0 nmod *cases* compound drug0"
              8 : "drug0 compound injections nmod *drug0*"
              9 : "drug0 compound levels nmod *drug0*"
              10 : "drug0 nmod *hemorrhages* compound drug0"
            }
          4 : 
            {
              1 : "Several drug1 reactions to drug2 have been reported , although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy . "
              2 : "Attempts were made to stop and then restart the theophylline therapy at progressively lower doses ; however , with each attempt , the patient 's drug1 , with serum drug2 levels ranging between 99.9 and 149.9 micromol/L ( 18 and 27 microg/mL ) . "
              3 : "The drug1 and plasma concentrations of drug2 , chloroacetaldehyde , and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide . "
              4 : "Methotrexate ( MTX ) is a commonly used second line agent for RA , and there have been several recent reports of drug1 in drug2 RA patients . "
              5 : "The drug1 of drug2 salts is an uncommon cause of life-threatening respiratory failure . "
              6 : "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care ; however , the administration of thymidine potentially may reverse severe drug1 neurologic symptoms such as drug2 and coma . "
              7 : "Two drug1 cases of poisoning by drug2 are described . "
              8 : "drug1 after epidural drug2 injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir . "
              9 : "The newborn manifested a four day course of drug1 with unexplained high drug2 levels in the adult toxic range . "
              10 : "drug1 and splinter hemorrhages from drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      45 : 
        {
          1 : "NN nmod NN nsubjpass VBN nmod NN"
          2 : 13
          3 : 
            {
              1 : "drug0 nmod therapy nsubjpass *stopped* nmod drug0"
              2 : "drug0 nmod *followed* nsubjpass administration nmod drug0"
              3 : "drug0 nmod *known* nsubjpass occurrence nmod drug0"
              4 : "drug0 nmod *related* nsubjpass occurrence nmod drug0"
              5 : "drug0 nmod *followed* nsubjpass administration nmod drug0"
              6 : "drug0 nmod *associated* nsubjpass use nmod drug0"
              7 : "drug0 nmod *found* nsubjpass cause nmod drug0"
              8 : "drug0 nmod *contraindicated* nsubjpass treatment nmod drug0"
              9 : "drug0 nmod *associated* nsubjpass administration nmod drug0"
              10 : "drug0 nmod *questioned* nsubjpass use nmod drug0"
            }
          4 : 
            {
              1 : "Because of a drug1 , initial therapy with drug2 and gentamicin was stopped and substituted with cefazolin . "
              2 : "Administration of drug1 to an infant after a long period of convulsions was followed by drug2 . "
              3 : "The occurrence of acute drug1 is best known for drug2 . "
              4 : "DISCUSSION : The occurrence of drug1 in our patient was related to drug2 . "
              5 : "The administration of `` drug1 '' ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by drug2 and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia . "
              6 : "The use of drug1 has been uncommonly associated with drug2 . "
              7 : "No other endogenous or exogenous cause for the drug1 could be found except for the drug2 . "
              8 : "Treatment of chronic hepatitis C with drug1 ( IFN-alpha ) is relatively contraindicated in patients with psychiatric disorders because of possible severe drug2 . "
              9 : "Administration of drug1 was associated with drug2 in two schizophrenic patients being maintained on concomitant neuroleptic medication . "
              10 : "Treatment of APL in pregnancy is controversial as the use of drug1 has been questioned due to the drug2 of retinoids . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      46 : 
        {
          1 : "NN appos NN compound NN"
          2 : 13
          3 : 
            {
              1 : "drug0 appos *syndrome* compound drug0"
              2 : "drug0 appos *thyrotoxicosis* compound drug0"
              3 : "drug0 appos *anemia* compound drug0"
              4 : "drug0 appos *reaction* compound drug0"
              5 : "drug0 appos *thrombocytopenia* compound drug0"
              6 : "drug0 appos *toxicity* compound drug0"
              7 : "drug0 appos *infusion* compound drug0"
              8 : "drug0 appos *necrolysis* compound drug0"
              9 : "drug0 compound keratopathy appos *drug0*"
              10 : "drug0 appos *syndrome* compound drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : Gemcitabine has mild renal toxicity , but cases of drug1 hemolytic-uremic syndrome ( drug2 ) have been reported . "
              2 : "Since amiodarone was first marketed in 1992 in Japan , the incidence of drug1 thyrotoxicosis ( drug2 ) has been increasing . "
              3 : "drug1 aplastic anemia ( drug2 ) is considered very uncommon . "
              4 : "Here we describe a patient with Crohn 's disease who developed a severe drug1 infusion reaction ( drug2 ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion . "
              5 : "A patient suffering from drug1 thrombocytopenia ( drug2 ) , recurrent arteriothromboses , and acute renal failure after treatment with standard heparin is described . "
              6 : "Since this amount of FAB was insufficient to bind all DGTX present in the serum , cardiac drug1 toxicity ( drug2 ) persisted . "
              7 : "We describe a life threatening side effect of acute drug1 infusion ( drug2 ) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology . "
              8 : "OBJECTIVE : To report a case of drug1 toxic epidermal necrolysis ( drug2 ) in a patient maintained on several other medications more commonly known to be associated with TEN . "
              9 : "RESULTS : Similar to previous findings of drug-induced drug1 , drug2 vortex keratopathy is presumably caused by its lipophilic properties . "
              10 : "The fetal drug1 syndrome ( drug2 ) is characterized by distinctive facial appearance , major and minor malformations , and developmental delay . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      47 : 
        {
          1 : "NN dobj VBD nsubj NN nmod NN"
          2 : 12
          3 : 
            {
              1 : "drug0 dobj *induced* nsubj use nmod drug0"
              2 : "drug0 dobj *induced* nsubj case nmod drug0"
              3 : "drug0 dobj *induced* nsubj administration nmod drug0"
              4 : "drug0 dobj *developed* nsubj patient nmod drug0"
              5 : "drug0 dobj *induced* nsubj withdrawal nmod drug0"
              6 : "drug0 dobj *induced* nsubj use nmod drug0"
              7 : "drug0 dobj *induced* nsubj glomerulonephritis nmod drug0"
              8 : "drug0 dobj *had* nsubj dose nmod drug0"
              9 : "drug0 dobj *induced* nsubj recovery nmod drug0"
              10 : "drug0 dobj *induced* nsubj dose nmod drug0"
            }
          4 : 
            {
              1 : "However , given the clinically significant result to the interaction between tolazoline and cimetidine we report , the use of cimetidine in drug1 induced drug2 should deserve more attention . "
              2 : "A case of drug1 induced drug2 , in a person with Down syndrome , is described . "
              3 : "Administration of excessive drug1 induced drug2 within 4 to 8 hours , followed by rebound hyperglycemia . "
              4 : "One patient on drug1 also developed drug2 . "
              5 : "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis , in whom the withdrawal of drug1 induced a drug2 and a aggravation of the joint condition . "
              6 : "However , given the clinically significant result to the interaction between tolazoline and cimetidine we report , the use of drug1 in tolazoline induced drug2 should deserve more attention . "
              7 : "Glomerulonephritis in drug1 induced drug2 : report of a case and review of the literature . "
              8 : "We thus concluded that an excessive dose of drug1 had probably drug2 or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis . "
              9 : "We describe a 5-year-old girl showed recovery of drug1 induced drug2 with pyridoxine and pyridostigmine treatment . "
              10 : "A high dose of drug1 induced drug2 with the elevation of serum creatinine and blood urea , and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      48 : 
        {
          1 : "NN nmod VBN advcl VBD dobj NN"
          2 : 12
          3 : 
            {
              1 : "drug0 nmod changed advcl *experienced* dobj drug0"
              2 : "drug0 nmod treated advcl *developed* dobj drug0"
              3 : "drug0 nmod treated advcl *developed* dobj drug0"
              4 : "drug0 nmod treated advcl *developed* dobj drug0"
              5 : "drug0 nmod treated advcl *had* dobj drug0"
              6 : "drug0 nmod treated advcl *had* dobj drug0"
              7 : "drug0 nmod treated advcl *developed* dobj drug0"
              8 : "drug0 nmod started advcl *developed* dobj drug0"
              9 : "drug0 nmod treated advcl *developed* dobj drug0"
              10 : "drug0 dobj developed advcl *treated* nmod drug0"
            }
          4 : 
            {
              1 : "CASE : We present an 11-year old male with Budd-Chiari syndrome who experienced profound drug1 after immunosuppressive therapy was changed from drug2 to sirolimus . "
              2 : "A patient developed drug1 while being treated with drug2 . "
              3 : "We present a case report of a patient who developed a drug1 while being treated with oral drug2 for a chronic pain syndrome . "
              4 : "A patient developed drug1 while being treated with drug2 and ethambutol . "
              5 : "The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued , and the 2 women who had drug1 and developed amenorrhea while being treated with drug2 lost weight and resumed menstruating after the change in medication . "
              6 : "We report such a series of patients who had drug1 after being treated with continuous infusion drug2 . "
              7 : "We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening drug1 , a variant of adynamic ileus , while being treated with intravenous drug2 . "
              8 : "We report the case of a patient who developed drug1 ( pericardial effusion , pleural effusion , and pericarditis ) after being started on drug2 , and whose symptoms remitted upon discontinuation of clozapine . "
              9 : "We have recently encountered a patient with acquired haemophilia who developed a drug1 while being treated with drug2 . "
              10 : "CASE SUMMARY : Two children with attention deficit disorder treated with drug1 as a simple drug developed drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      49 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod NN"
          2 : 12
          3 : 
            {
              1 : "drug0 compound injection nmod *case* nmod management nmod drug0"
              2 : "drug0 compound injection nmod track nmod *case* nmod drug0"
              3 : "drug0 compound therapy nmod effect nmod *development* nmod drug0"
              4 : "drug0 compound therapy nmod weakness nmod *case* nmod drug0"
              5 : "drug0 nmod necrosis nmod involvement nmod *toxicity* compound drug0"
              6 : "drug0 compound therapy nmod withdrawal nmod *patient* nmod drug0"
              7 : "drug0 compound treatment nmod association nmod *case* nmod drug0"
              8 : "drug0 compound therapy nmod colitis nmod child nmod *drug0*"
              9 : "drug0 nmod cause nmod *mechanism* nmod degranulation compound drug0"
              10 : "drug0 compound therapy nmod patient nmod *bout* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of successful surgical management of drug1 after percutaneous drug2 injection of a femoral artery pseudoaneurysm in a 69-year-old woman . "
              2 : "We describe a case of drug1 along the needle track after percutaneous drug2 injection ( PEI ) for treatment of hepatocellular carcinoma . "
              3 : "This case highlights the possible development of drug1 as a side effect of drug2 therapy . "
              4 : "A case of drug1 due to diaphragmatic weakness following drug2 therapy for psoriasis is described . "
              5 : "We present a fatal case of subacute drug1 toxicity with associated diffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with drug2 . "
              6 : "The authors present an elderly patient with mixed dementia who developed TD at multiple sites , ( including drug1 [ RD ] , limb dyskinesia , and orofacial dyskinesia ) following abrupt withdrawal of drug2 therapy . "
              7 : "We report a case of drug1 in association with drug2 treatment following chemotherapy for acute myelogenous leukemia . "
              8 : "drug1 in a child with idiopathic ulcerative colitis on long-term drug2 therapy . "
              9 : "We propose a mechanism of drug1 mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of drug2 . "
              10 : "We present a case of significant over-anticoagulation temporally associated with a bout of protracted drug1 in a patient on drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      50 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN"
          2 : 12
          3 : 
            {
              1 : "drug0 nmod risk nmod *associated* nsubjpass treatment nmod drug0"
              2 : "drug0 nmod association nmod *reported* nsubjpass variety nmod drug0"
              3 : "drug0 nmod chemotherapy nmod *observed* nsubjpass recurrence nmod drug0"
              4 : "drug0 nmod development nmod *associated* nsubjpass use nmod drug0"
              5 : "drug0 nmod induction nmod *complicated* nsubjpass treatment nmod drug0"
              6 : "drug0 nmod risk nmod *discouraged* nsubjpass administration nmod drug0"
              7 : "drug0 nmod number nmod *associated* nsubjpass therapy nmod drug0"
              8 : "drug0 nmod recovery nmod *followed* nsubjpass cessation nmod drug0"
              9 : "drug0 nmod cause nmod *suspected* nsubjpass reaction nmod drug0"
              10 : "drug0 nmod relapse nmod *followed* nsubjpass readministration nmod drug0"
            }
          4 : 
            {
              1 : "Despite minimal short-term side effects and apparent efficacy , chronic treatment of MG with drug1 may be associated with increased risk of drug2 . "
              2 : "A wide variety of drug1 have been reported in association with drug2 ; dizziness is the most common . "
              3 : "It should be emphasized that the recurrence of drug1 was observed after the following chemotherapy , including drug2 , whereas the bone marrow still remained completely remitted . "
              4 : "The use of drug1 has been associated with the development of drug2 in transplant recipients . "
              5 : "The authors caution that treatment with drug1 may be complicated by the induction of drug2 . "
              6 : "CONCLUSIONS : Peripheral administration of low-dose drug1 for septic shock should be discouraged because of the risk of drug2 . "
              7 : "Therapy with drug1 may be associated with a number of drug2 , such as Parkinsonism , akathisia , seizure , and depressive disorders . "
              8 : "Cessation of drug1 and the start of corticosteroid therapy were followed by recovery from drug2 . "
              9 : "An adverse reaction to drug1 was strongly suspected as the cause of drug2 . "
              10 : "In one case , the readministration of drug1 was followed by the relapse of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      51 : 
        {
          1 : "NN dobj VBD acl:relcl NN"
          2 : 12
          3 : 
            {
              1 : "drug0 dobj received acl:relcl *drug0*"
              2 : "drug0 dobj developed acl:relcl *drug0*"
              3 : "drug0 dobj developed acl:relcl *drug0*"
              4 : "drug0 dobj developed acl:relcl *drug0*"
              5 : "drug0 dobj developed acl:relcl *drug0*"
              6 : "drug0 dobj developed acl:relcl *drug0*"
              7 : "drug0 dobj developed acl:relcl *drug0*"
              8 : "drug0 dobj developed acl:relcl *drug0*"
              9 : "drug0 dobj received acl:relcl *drug0*"
              10 : "drug0 dobj showed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "This case report describes an adolescent with drug1 who received drug2 ( CY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli . "
              2 : "We describe two ELBW infants affected by hyperkalaemia , treated with drug1 , who developed serious drug2 , that has never been reported before in preterm infants . "
              3 : "The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 drug1 who developed drug2 after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment . "
              4 : "We describe a patient with M4 AML treated with standard chemotherapy followed by drug1 who developed marked drug2 on day 8 of G-CSF therapy . "
              5 : "A drug addict with staphylococcal endocarditis treated with drug1 , who developed drug2 and acute nephritic syndrome is described . "
              6 : "We presented a patient with status asthmaticus treated with a combination of drug1 and prednisone who developed a drug2 . "
              7 : "OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving drug1 who developed drug2 , pancytopenia , splenomegaly , and extreme hyperferritinemia . "
              8 : "Of 371 patients treated with drug1 , three ( 0.8 % ) developed an drug2 in the PUVA-treated areas . "
              9 : "None of them had a history of cardiac disease , and with the possible exception of one case of drug1 , where the patient received drug2 , no predisposing factors could be found . "
              10 : "The case of a patient with infectious mononucleosis treated with drug1 who later showed a drug2 is presented and the previous literature is reviewed . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      52 : 
        {
          1 : "NN conj NN nmod VBN acl NN"
          2 : 12
          3 : 
            {
              1 : "drug0 conj olanzapine nmod caused acl *drug0*"
              2 : "drug0 conj clarithromycin nmod associated acl *drug0*"
              3 : "drug0 conj cyclophosphamide nmod induced acl *drug0*"
              4 : "drug0 conj quinidine nmod induced acl *drug0*"
              5 : "drug0 conj ointment nmod induced acl *drug0*"
              6 : "drug0 conj naproxen nmod caused acl *drug0*"
              7 : "drug0 conj hyperpyrexia nmod characterized acl *drug0*"
              8 : "drug0 conj carcinoma nmod associated acl *drug0*"
              9 : "drug0 conj hyperpyrexia nmod characterized acl *drug0*"
              10 : "drug0 conj bicalutamide nmod induced acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 caused by olanzapine and drug2 . "
              2 : "Lovastatin-induced drug1 possibly associated with clarithromycin and drug2 . "
              3 : "Life-threatening drug1 induced by low dose cyclophosphamide and drug2 . "
              4 : "Atypical ventricular tachycardia ( torsade de pointes ) induced by amiodarone : drug1 previously induced by quinidine and drug2 . "
              5 : "The present case is the first report of drug1 induced by vitamin D3 ointment and drug2 simultaneously . "
              6 : "METHODS : We report two cases of drug1 caused by naproxen and drug2 . "
              7 : "The authors describe a case of combined drug1 and haloperidol toxicity characterized by hyperpyrexia , drug2 , mutism , and development of irreversible tardive dyskinesia . "
              8 : "The possible effects of tamoxifen upon the uterus are discussed in this article , in view of reports of drug1 associated with endometrial carcinoma and drug2 . "
              9 : "The authors describe a case of combined drug1 and haloperidol toxicity characterized by hyperpyrexia , severe rigidity , drug2 , and development of irreversible tardive dyskinesia . "
              10 : "We report a case of drug1 induced by bicalutamide and/or drug2 given as therapy for prostate cancer , in which the pneumonitis was successfully managed by steroid treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      53 : 
        {
          1 : "NN dobj VBZ nsubj NN"
          2 : 12
          3 : 
            {
              1 : "drug0 dobj *has* nsubj drug0"
              2 : "drug0 dobj *has* nsubj drug0"
              3 : "drug0 dobj *induces* nsubj drug0"
              4 : "drug0 dobj *causes* nsubj drug0"
              5 : "drug0 dobj *induces* nsubj drug0"
              6 : "drug0 dobj *induces* nsubj drug0"
              7 : "drug0 dobj *causes* nsubj drug0"
              8 : "drug0 dobj *produces* nsubj drug0"
              9 : "drug0 dobj *causes* nsubj drug0"
              10 : "drug0 dobj *causes* nsubj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 has mild drug2 , but cases of gemcitabine-associated hemolytic-uremic syndrome ( HUS ) have been reported . "
              2 : "BACKGROUND : drug1 has a known drug2 through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation . "
              3 : "Since drug1 induces drug2 from TLR7-expressing plasmacytoid dendritic cell precursors ( PDCs ) , the natural interferon-producing cells of the peripheral blood , we asked whether PDCs are present in psoriatic skin . "
              4 : "OBJECTIVE : drug1 causes few drug2 and is recommended as a treatment drug for severe tardive dyskinesia ( TD ) . "
              5 : "drug1 induces drug2 , which may explain the improvement in this patient 's psoriasis . "
              6 : "The mechanism by which drug1 induces drug2 is thought to be associated with an unknown direct action on breast hormonal receptors . "
              7 : "drug1 causes a drug2 that occurs in approximately 0.67 % of patients taking high doses of the drug . "
              8 : "Additionally , drug1 produces drug2 in approximately 10 % of women . "
              9 : "In addition , drug1 rarely causes drug2 during the early period or when given at lower doses . "
              10 : "In some cases this seems to happen because drug1 causes drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      54 : 
        {
          1 : "NN appos NN nmod NN nmod NN"
          2 : 12
          3 : 
            {
              1 : "drug0 appos interferon-alpha nmod *case* nmod drug0"
              2 : "drug0 nmod *patient* nmod phenytoin appos drug0"
              3 : "drug0 appos antagonist nmod treatment nmod *drug0*"
              4 : "drug0 appos *min* nmod administration nmod drug0"
              5 : "drug0 appos inhibitor nmod administration nmod *drug0*"
              6 : "drug0 appos bevacizumab nmod injection nmod *drug0*"
              7 : "drug0 appos drug nmod administration nmod *drug0*"
              8 : "drug0 appos propylthiouracil nmod *association* nmod drug0"
              9 : "drug0 appos sulfonate nmod administration nmod *drug0*"
              10 : "drug0 appos cisplatin nmod chemotherapy nmod *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVES : The authors described a case of drug1 during interferon-alpha ( drug2 ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease . "
              2 : "INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin ( drug1 ) intoxication with drug2 ( GH ) . "
              3 : "drug1 following treatment with the pantothenic acid antagonist , drug2 . "
              4 : "Approximately 15 min after the first administration of nebulised drug1 the patient became markedly bradypneic ( respiratory rate : 4-5 bpm ) , drug2 ( BP 70/40 mmHg ) , and responded only partially to command . "
              5 : "drug1 following administration of angiotensin I-converting enzyme inhibitor ( drug2 ) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation . "
              6 : "drug1 after intravitreal injection of bevacizumab ( drug2 ) associated with ocular ischemic syndrome . "
              7 : "The authors report a case of focal myocardial necrosis , presenting clinically as an drug1 during the administration of the antineoplastic drug , drug2 , in a patient without coronary artery disease . "
              8 : "An association of drug1 , eosinophilia , skin reaction and hepatitis during propylthiouracil ( drug2 ) therapy for thyrotoxicosis in a 47 year old black female is reported . "
              9 : "drug1 following administration of calcium polystryrene sulfonate ( drug2 ) in a uremic patient . "
              10 : "We report a patient with pulmonary adenocarcinoma complicated by the drug1 ( SIADH ) following systemic chemotherapy with cisplatin ( drug2 ) and vindesine ( VDS ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      55 : 
        {
          1 : "NN compound NN nmod VBG acl NN"
          2 : 12
          3 : 
            {
              1 : "drug0 compound treatment nmod owing acl *drug0*"
              2 : "drug0 compound monotherapy nmod occurring acl *drug0*"
              3 : "drug0 compound therapy nmod occurring acl *drug0*"
              4 : "drug0 compound therapy nmod revealing acl *drug0*"
              5 : "drug0 compound therapy nmod occurring acl *drug0*"
              6 : "drug0 compound dose nmod resulting acl *drug0*"
              7 : "drug0 compound monotherapy nmod resulting acl *drug0*"
              8 : "drug0 compound monotherapy nmod occurring acl *drug0*"
              9 : "drug0 compound therapy nmod resulting acl *drug0*"
              10 : "drug0 compound treatment nmod occurring acl *drug0*"
            }
          4 : 
            {
              1 : "DIAGNOSIS : drug1 possibly owing to drug2 treatment . "
              2 : "CASE REPORT : We hereby report a case of drug1 and myositis occurring on drug2 monotherapy , five months after completing chemoradiation for locally advanced pancreatic cancer . "
              3 : "drug1 occurring after drug2 therapy : case report and review of the literature . "
              4 : "drug1 revealing necrotizing vasculitis during drug2 therapy for rheumatoid arthritis . "
              5 : "drug1 occurring during drug2 therapy for chronic hepatitis C . "
              6 : "METHODS : The patient required insulin desensitization for severe urticaria , angioedema , and occasional drug1 resulting from her drug2 dose . "
              7 : "CASE REPORT : We report a case of drug1 resulting from drug2 monotherapy in a patient with locally advanced pancreatic cancer . "
              8 : "This is the first case of drug1 occurring during the year following drug2 monotherapy in the absence of any other immunosuppressive factor . "
              9 : "drug1 resulting from drug2 therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients . "
              10 : "drug1 occurring during drug2 treatment of severe psoriasis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      56 : 
        {
          1 : "NN compound NN conj NN nmod NN"
          2 : 12
          3 : 
            {
              1 : "drug0 compound therapy conj lisinopril nmod *drug0*"
              2 : "drug0 compound therapy conj cisplatin nmod *drug0*"
              3 : "drug0 nmod association conj *cholestasis* compound drug0"
              4 : "drug0 compound therapy conj *development* nmod drug0"
              5 : "drug0 nmod onset conj *treatment* compound drug0"
              6 : "drug0 compound therapy conj melphalan nmod *drug0*"
              7 : "drug0 compound chemotherapy conj busulfan nmod *drug0*"
              8 : "drug0 compound interaction conj ciprofloxacin nmod *drug0*"
              9 : "drug0 nmod development conj *therapy* compound drug0"
              10 : "drug0 compound treatment conj alfa nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 during lisinopril and drug2 therapy for proteinuria . "
              2 : "drug1 following cisplatin , bleomycin and drug2 therapy for germ cell tumor of the ovary . "
              3 : "The literature on drug1 cholestasis and its association with drug2 is reviewed . "
              4 : "Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship ( score of 5 ) between the patient 's development of drug1 and the drug2 therapy . "
              5 : "DISCUSSION : The Naranjo probability scale indicated a probable relationship between drug1 treatment and the onset of drug2 . "
              6 : "drug1 with melphalan and drug2 therapy . "
              7 : "drug1 after high-dose busulfan and drug2 chemotherapy and radiotherapy for Ewing 's sarcoma : a review of the literature and implications for practice . "
              8 : "drug1 from ciprofloxacin and drug2 interaction . "
              9 : "However , in the mid-to-late 1980s , a series of letters to the editor and case reports announced an association between drug1 therapy in women with breast cancer and the development of drug2 . "
              10 : "drug1 during interferon alfa and drug2 treatment of hepatitis C virus infection : two cases . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      57 : 
        {
          1 : "NN compound NN compound NN"
          2 : 11
          3 : 
            {
              1 : "drug0 compound *therapy* compound drug0"
              2 : "drug0 compound *patient* compound drug0"
              3 : "drug0 compound *tender* compound drug0"
              4 : "drug0 compound *intoxication* compound drug0"
              5 : "drug0 compound *reaction* compound drug0"
              6 : "drug0 compound *syndrome* compound drug0"
              7 : "drug0 compound *installation* compound drug0"
              8 : "drug0 compound *therapy* compound drug0"
              9 : "drug0 compound *complication* compound drug0"
              10 : "drug0 compound *phenotype* compound drug0"
            }
          4 : 
            {
              1 : "drug1 post intravesical drug2 therapy are rare but need to be identified and treated quickly . "
              2 : "Detection of activated eosinophils in nasal polyps of an drug1 drug2 patient . "
              3 : "DISCUSSION : Patients with drug1 drug2 experience tender , red , scaled lids , making contact lens wear difficult . "
              4 : "drug1 acute drug2 intoxication in a child . "
              5 : "A child in whom a drug1 drug2 drug reaction developed which consisted of fever , a pruritic desquamating erythrodermic rash , alopecia , icterus , protein-losing enteropathy , myositis , and nephritis , is described . "
              6 : "drug1 drug2 syndrome during acute lymphoblastic leukemia treatment in children . "
              7 : "drug1 post intravesical drug2 installation . "
              8 : "drug1 complicating drug2 therapy . "
              9 : "drug1 drug2 complication saved life . "
              10 : "The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent drug1 drug2 phenotype . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      58 : 
        {
          1 : "NN appos NN nmod NN"
          2 : 11
          3 : 
            {
              1 : "drug0 appos 0-methoxypsoralen nmod *drug0*"
              2 : "drug0 appos ointment nmod *drug0*"
              3 : "drug0 nmod reaction appos *drug0*"
              4 : "drug0 appos bevacizumab nmod *drug0*"
              5 : "drug0 appos antagonist nmod *drug0*"
              6 : "drug0 appos naltrexone nmod *drug0*"
              7 : "drug0 appos *interaction* nmod drug0"
              8 : "drug0 nmod effect appos *drug0*"
              9 : "drug0 appos acetate nmod *drug0*"
              10 : "drug0 appos arabinoside nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 to 8-methoxypsoralen ( drug2 ) . "
              2 : "Iatrogenic drug1 due to vitamin D3 ointment ( drug2 ) combined with thiazide diuretics in a case of psoriasis . "
              3 : "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called `` 3-week drug1 '' , a rare , but often fatal , immunoallergic reaction to drug2 . "
              4 : "drug1 following intravitreal bevacizumab ( drug2 ) injection . "
              5 : "drug1 by the microtubule antagonist , drug2 . "
              6 : "Many clinicians appear to be concerned about the potential drug1 of the opiate antagonist naltrexone ( drug2 ) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers . "
              7 : "A second possibility is an interaction between drug1 and isradipine , potentially drug2 of isradipine . "
              8 : "drug1 , a rare side effect of drug2 , involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins . "
              9 : "drug1 and subsequent lipoatrophy with subcutaneous glatiramer acetate ( drug2 ) injection for the treatment of multiple sclerosis . "
              10 : "drug1 following prophylactic intrathecal cytosine arabinoside ( drug2 ) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      59 : 
        {
          1 : "NN nmod NN dep NN"
          2 : 11
          3 : 
            {
              1 : "drug0 nmod complication dep *drug0*"
              2 : "drug0 nmod cause dep *drug0*"
              3 : "drug0 nmod association dep *drug0*"
              4 : "drug0 nmod reaction dep *drug0*"
              5 : "drug0 nmod induction dep *drug0*"
              6 : "drug0 nmod role dep *drug0*"
              7 : "drug0 nmod cause dep *drug0*"
              8 : "drug0 nmod cause dep *drug0*"
              9 : "drug0 dep child nmod *drug0*"
              10 : "drug0 dep *differentiation* nmod drug0"
            }
          4 : 
            {
              1 : "drug1 mimicking cutaneous vasculitis in a lupus patient : a complication of drug2 . "
              2 : "This was accepted as evidence for drug1 being the cause of this drug2 . "
              3 : "drug1 in two children with idiopathic neutropenia : association with drug2 ( G-CSF ) therapy . "
              4 : "drug1 , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and dermatitis : a severe adverse reaction to drug2 . "
              5 : "drug1 and seizures in a patient with parkinsonism : induction by drug2 and its confirmation on SEPs . "
              6 : "drug1 : the role of drug2 and its antagonist . "
              7 : "drug1 : a probable cause of drug2 . "
              8 : "drug1 : an unrecognized cause of drug2 in patients undergoing cardiopulmonary bypass . "
              9 : "drug1 with hyponatremia in a child prescribed drug2 for nocturnal enuresis . "
              10 : "Emphasis is given to the differentiation of drug1 induced drug2 from the angiomatous enlargement of the gingiva before any treatment is planned . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      60 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod NN"
          2 : 11
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl spasm nmod *drug0*"
              2 : "drug0 compound therapy nmod associated acl course nmod *drug0*"
              3 : "drug0 compound therapy nmod associated acl *case* nmod drug0"
              4 : "drug0 compound irrigation nmod treated acl patient nmod *drug0*"
              5 : "drug0 compound therapy nmod associated acl infant nmod *drug0*"
              6 : "drug0 compound treatment nmod caused acl *patient* nmod drug0"
              7 : "drug0 compound pseudoproteinuria nmod obscured acl auranofin nmod *drug0*"
              8 : "drug0 compound treatment nmod induced acl *syndrome* nmod drug0"
              9 : "drug0 compound treatment nmod associated acl cardiomyopathy nmod *drug0*"
              10 : "drug0 compound administration nmod caused acl immunodeficiency nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 due to coronary spasm associated with drug2 therapy . "
              2 : "This article presents a case of an drug1 with an unusual course and protracted resolution time associated with drug2 therapy . "
              3 : "A new case of drug1 associated with drug2 therapy in New Zealand . "
              4 : "drug1 in a patient treated by continuous drug2 mediastinal irrigation . "
              5 : "drug1 in an infant associated with maternal drug2 therapy . "
              6 : "In this article , we describe a Japanese patient with drug1 probably caused by drug2 treatment for metastatic renal cell carcinoma . "
              7 : "drug1 due to auranofin obscured by drug2 pseudoproteinuria . "
              8 : "A case of the Rett syndrome with drug1 induced during drug2 treatment . "
              9 : "A case of drug1 with dilated cardiomyopathy associated with drug2 treatment for hepatitis B . "
              10 : "She was diagnosed with drug1 ( LPD ) due to immunodeficiency caused by drug2 administration . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      61 : 
        {
          1 : "NN conj NN nmod NNS dobj VB acl JJ nmod VBN nsubjpass NNS dep NN conj NN"
          2 : 10
          3 : 
            {
              1 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              2 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              3 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              4 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              5 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              6 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              7 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              8 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              9 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              10 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , drug1 , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , drug2 and insomnia . "
              2 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , drug1 , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , dizziness and drug2 . "
              3 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , drug1 , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , dizziness and drug2 . "
              4 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , drug1 and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , drug2 and insomnia . "
              5 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , drug1 and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , dizziness and drug2 . "
              6 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , drug1 , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , drug2 and insomnia . "
              7 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and drug1 ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , drug2 and insomnia . "
              8 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , drug1 , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , drug2 and insomnia . "
              9 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and drug1 ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , dizziness and drug2 . "
              10 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , drug1 , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , dizziness and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      62 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN"
          2 : 10
          3 : 
            {
              1 : "drug0 nmod course nmod *associated* nmod drug0"
              2 : "drug0 nmod administration nmod *presented* nmod drug0"
              3 : "drug0 nmod *developed* nmod dose nmod drug0"
              4 : "drug0 nmod onset nmod *associated* nmod drug0"
              5 : "drug0 nmod ingestion nmod *presented* nmod drug0"
              6 : "drug0 nmod preparation nmod *presented* nmod drug0"
              7 : "drug0 nmod treatment nmod *presented* nmod drug0"
              8 : "drug0 nmod administration nmod *developed* nmod drug0"
              9 : "drug0 nmod dose nmod *presented* nmod drug0"
              10 : "drug0 nmod treatment nmod *presented* nmod drug0"
            }
          4 : 
            {
              1 : "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound drug1 after a short course of drug2 . "
              2 : "A 26-year-old Japanese man , who had been receiving medical attention for ulcerative colitis for one year , presented with drug1 and pustules on his face and trunk , malaise , and fever up to 39 degrees C one day after the administration of drug2 . "
              3 : "After the first oral dose of drug1 , syncope developed together with drug2 . "
              4 : "The concomitant use , however , of drug1 and statin has been associated with the rapid onset of drug2 . "
              5 : "A 65-year-old woman with angina pectoris presented with drug1 after sublingual ingestion of drug2 ( 5 mg ) . "
              6 : "This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative drug1 and hypocalcemic tetany after bowel preparation with drug2 . "
              7 : "The two middle aged women presented with drug1 after prolonged treatment with drug2 . "
              8 : "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with drug1 after the administration of drug2 . "
              9 : "CASE SUMMARY : A 45-year-old HIV-positive man ( CD4 + count 450 cells/mm ( 3 ) and history of AIDS-defining illness ) presented with drug1 after an initial intravenous dose of drug2 for presumed neurosyphilis . "
              10 : "A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an drug1 after a ten-month treatment of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      63 : 
        {
          1 : "NN conj NN dobj VBD nmod NN nmod NN compound NN"
          2 : 10
          3 : 
            {
              1 : "drug0 conj pruritus dobj *developed* nmod day nmod treatment compound drug0"
              2 : "drug0 conj pruritus dobj *developed* nmod day nmod treatment compound drug0"
              3 : "drug0 conj headache dobj *experienced* nmod week nmod therapy compound drug0"
              4 : "drug0 conj pruritus dobj *developed* nmod day nmod treatment compound drug0"
              5 : "drug0 conj pruritus dobj *developed* nmod day nmod treatment compound drug0"
              6 : "drug0 conj loss dobj *developed* nmod week nmod treatment compound drug0"
              7 : "drug0 compound mg nmod therapy nmod *developed* dobj dystonia conj drug0"
              8 : "drug0 compound therapy nmod course nmod *developed* dobj jaundice conj drug0"
              9 : "drug0 conj pruritus dobj *developed* nmod day nmod treatment compound drug0"
              10 : "drug0 conj headache dobj *experienced* nmod week nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "On day 7 of drug1 treatment , the patient developed severe pruritus , drug2 , facial edema , eosinophilia , marked increase in serum creatinine level , and mild hepatitis . "
              2 : "On day 7 of drug1 treatment , the patient developed severe pruritus , macular rash , facial edema , drug2 , marked increase in serum creatinine level , and mild hepatitis . "
              3 : "After 1 week of drug1 therapy the patient experienced headache , confusion , and `` drug2 '' in her vision , without abnormal ophthalmologic findings . "
              4 : "On day 7 of drug1 treatment , the patient developed severe pruritus , macular rash , drug2 , eosinophilia , marked increase in serum creatinine level , and mild hepatitis . "
              5 : "On day 7 of drug1 treatment , the patient developed severe pruritus , macular rash , facial edema , eosinophilia , drug2 , and mild hepatitis . "
              6 : "Despite a response of the meningeal tumor the patient developed in the third week of drug1 treatment a progressive visual loss and drug2 which worsened during subsequent Ara-C treatment and led to death within 3 weeks . "
              7 : "We reported 3 patients who developed acute generalized dystonia and drug1 following an initial therapy with drug2 125-500 mg daily . "
              8 : "A 55-yr-old man developed prolonged jaundice and drug1 after a course of drug2 therapy . "
              9 : "On day 7 of drug1 treatment , the patient developed severe pruritus , macular rash , facial edema , eosinophilia , marked increase in serum creatinine level , and drug2 . "
              10 : "After 1 week of drug1 therapy the patient experienced headache , drug2 , and `` gray areas '' in her vision , without abnormal ophthalmologic findings . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      64 : 
        {
          1 : "NN nmod NNS nmod NN nmod NN"
          2 : 10
          3 : 
            {
              1 : "drug0 nmod features nmod *use* nmod drug0"
              2 : "drug0 nmod treatment nmod *signs* nmod drug0"
              3 : "drug0 nmod *observations* nmod appearance nmod drug0"
              4 : "drug0 nmod treatment nmod *reports* nmod drug0"
              5 : "drug0 nmod chemotherapy nmod *episodes* nmod drug0"
              6 : "drug0 nmod immunosuppression nmod patients nmod *drug0*"
              7 : "drug0 nmod *effects* nmod treatment nmod drug0"
              8 : "drug0 nmod causes nmod list nmod *drug0*"
              9 : "drug0 nmod doses nmod inhalation nmod *drug0*"
              10 : "drug0 nmod days nmod *onset* nmod drug0"
            }
          4 : 
            {
              1 : "The case histories are presented of two patients who developed lung disease associated with the use of drug1 with histological features of drug2 ( BOOP ) , a rare but recognised form of drug induced injury . "
              2 : "We recommend that clinicians monitor patients for signs and symptoms of drug1 , including abdominal pain , during treatment with drug2 . "
              3 : "There have been more than 20 observations of the appearance or aggravation of this drug1 with drug2 and more recently with the combination of interferon alfa plus ribavirin . "
              4 : "There are now reports of drug1 following treatment of childhood cancers with drug2 . "
              5 : "A 31-year-old female developed multiple episodes of drug1 after combination chemotherapy with drug2 , vinblastine and bleomycin for germ cell ovarian cancer stage Ic . "
              6 : "drug1 in renal transplanted patients under immunosuppression with drug2 . "
              7 : "However , in 1993 , a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with drug1 , including one drug2 after the treatment . "
              8 : "Clinicians should include drug1 in their list of possible causes of drug-induced drug2 . "
              9 : "The cases of two asthmatic patients who became drug1 after inhalation of normal doses of drug2 are presented . "
              10 : "DESIGN : We reviewed the medical records of four patients , who were seen by us between July 2000 and February 2004 for sudden onset of a drug1 within days of intrathecal drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      65 : 
        {
          1 : "NN dobj VB nsubj NN nmod NN"
          2 : 10
          3 : 
            {
              1 : "drug0 dobj *cause* nsubj administration nmod drug0"
              2 : "drug0 dobj *control* nsubj desensitization nmod drug0"
              3 : "drug0 dobj *cause* nsubj dose nmod drug0"
              4 : "drug0 dobj *induce* nsubj administration nmod drug0"
              5 : "drug0 dobj *cause* nsubj exposure nmod drug0"
              6 : "drug0 dobj *induce* nsubj therapy nmod drug0"
              7 : "drug0 dobj *cause* nsubj reversal nmod drug0"
              8 : "drug0 dobj *cause* nsubj administration nmod drug0"
              9 : "drug0 dobj *have* nsubj treatment nmod drug0"
              10 : "drug0 dobj *precipitate* nsubj exposure nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : The administration of drug1 to neonates can cause drug2 due to antral hyperplasia . "
              2 : "OBJECTIVE : The purpose of this study was to determine whether desensitization to drug1 , as well as standard insulin desensitization , could control drug2 in a patient allergic to both NPH and regular insulin . "
              3 : "Large dose of drug1 may cause drug2 and glaucoma . "
              4 : "Administration of drug1 in subarachnoid haemorrhage ( SAH ) patients , misdiagnosed as migraine patients , may induce drug2 with potentially dangerous consequences . "
              5 : "Unintended exposure to drug1 early in pregnancy , which is not uncommon , may cause drug2 . "
              6 : "CONCLUSION : Therapy with drug1 may induce drug2 in essential hypertension patients . "
              7 : "The reversal of heparin by drug1 may cause drug2 , characterized by systemic hypotension , pulmonary hypertension , and bronchoconstriction . "
              8 : "It is concluded that simultaneous administration of drug1 and tazobactam/piperacillin may cause marked drug2 . "
              9 : "CONCLUSION : Long-term treatment with drug1 may have a reversible and previously undescribed drug2 . "
              10 : "CONCLUSIONS : Prolonged exposure to drug1 , administered either continuously or intermittently , may precipitate drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      66 : 
        {
          1 : "NN nmod VBG acl NN compound NN"
          2 : 10
          3 : 
            {
              1 : "drug0 nmod presenting acl *withdrawal* compound drug0"
              2 : "drug0 nmod presenting acl *ingestion* compound drug0"
              3 : "drug0 nmod resulting acl *toxicity* compound drug0"
              4 : "drug0 nmod manifesting acl *toxicity* compound drug0"
              5 : "drug0 nmod manifesting acl *neurotoxicity* compound drug0"
              6 : "drug0 nmod resulting acl *ingestion* compound drug0"
              7 : "drug0 nmod resulting acl *ingestion* compound drug0"
              8 : "drug0 nmod consisting acl *syndrome* compound drug0"
              9 : "drug0 nmod presenting acl *hypersensitivity* compound drug0"
              10 : "drug0 nmod resulting acl *reaction* compound drug0"
            }
          4 : 
            {
              1 : "drug1 withdrawal presenting as drug2 . "
              2 : "We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic drug1 ingestion presenting as asymptomatic drug2 ( ELP ) . "
              3 : "We present a case of acute drug1 toxicity resulting in drug2 in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin , and was subsequently given epinephrine by mistake intravenously rather than subcutaneously . "
              4 : "drug1 toxicity manifesting as drug2 . "
              5 : "We report a case of intrathecal drug1 neurotoxicity manifesting as drug2 and aphasia . "
              6 : "We report a case of pediatric drug1 ingestion resulting in drug2 . "
              7 : "We report an unusual case of massive drug1 ingestion resulting in drug2 resulting in death . "
              8 : "A drug1 hypersensitivity syndrome , consisting of drug2 , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy . "
              9 : "drug1 hypersensitivity presenting as drug2 - a case report . "
              10 : "Physicians should be aware of the potential for developing a drug1 radiation recall reaction resulting in hemodynamically significant drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      67 : 
        {
          1 : "NN nmod VBD nsubj NN nmod NN"
          2 : 10
          3 : 
            {
              1 : "drug0 nmod *induced* nsubj dose nmod drug0"
              2 : "drug0 nmod *resulted* nsubj administration nmod drug0"
              3 : "drug0 nmod *led* nsubj introduction nmod drug0"
              4 : "drug0 nmod *resulted* nsubj dose nmod drug0"
              5 : "drug0 nmod *resulted* nsubj bolus nmod drug0"
              6 : "drug0 nmod *resulted* nsubj dose nmod drug0"
              7 : "drug0 nmod *caused* nsubj treatment nmod drug0"
              8 : "drug0 nmod *resulted* nsubj elimination nmod drug0"
              9 : "drug0 nmod *resulted* nsubj treatment nmod drug0"
              10 : "drug0 nmod *resulted* nsubj amount nmod drug0"
            }
          4 : 
            {
              1 : "A high dose of drug1 induced hyperkalaemia with the drug2 , and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious . "
              2 : "Administration of intravenous drug1 in a patient with idiopathic pulmonary hypertension resulted in an drug2 associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance . "
              3 : "The introduction of drug1 ( PAS ) led to drug2 . "
              4 : "In case 1 , a total daily dose of 25 mg sertraline , with nondetectable drug1 and desmethylsertraline blood levels , resulted in a drug2 with symptoms of toxicity . "
              5 : "We postulate that the bolus of drug1 resulted in possible drug2 that resulted in cardiac arrest . "
              6 : "In case 1 , a total daily dose of 25 mg drug1 , with nondetectable sertraline and desmethylsertraline blood levels , resulted in a drug2 with symptoms of toxicity . "
              7 : "Three years later , treatment with drug1 caused another episode of cholestatic hepatitis with drug2 and duct paucity on rebiopsy . "
              8 : "We hypothesize that decreased renal elimination of drug1 induced by the COX-2 inhibitor resulted in enhanced drug2 and immunosuppression causing the EBV-associated lymphoproliferative disease . "
              9 : "Antithyroid treatment with drug1 ( PTU ) resulted in drug2 and after the 12th week of pregnancy treatment was changed to carbimazole ( CBZ ) . "
              10 : "However , the amount of drug1 required to maintain normotension resulted in drug2 and has been discontinued . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      68 : 
        {
          1 : "NN nmod VBG acl NN"
          2 : 10
          3 : 
            {
              1 : "drug0 nmod switching acl *drug0*"
              2 : "drug0 nmod resulting acl *drug0*"
              3 : "drug0 nmod loading acl *drug0*"
              4 : "drug0 nmod appearing acl *drug0*"
              5 : "drug0 nmod occurring acl *drug0*"
              6 : "drug0 nmod switching acl *drug0*"
              7 : "drug0 nmod complicating acl *drug0*"
              8 : "drug0 nmod resulting acl *drug0*"
              9 : "drug0 nmod overdosing acl *drug0*"
              10 : "drug0 nmod overdosing acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a low-risk patient after switching from latanoprost to drug2 . "
              2 : "drug1 resulting from drug2 ( accutane ) therapy . "
              3 : "drug1 during loading with drug2 . "
              4 : "Prominent drug1 appearing with high-dose intravenous drug2 . "
              5 : "drug1 occurring after drug2 . "
              6 : "drug1 in a low-risk patient after switching from drug2 to bimatoprost . "
              7 : "drug1 complicating hairy cell leukaemia treatment with drug2 . "
              8 : "Although adverse reactions to protamine are reported infrequently and are usually mild , we recently observed the first fatal case of drug1 resulting from drug2 . "
              9 : "drug1 ( rebound hyperglycemia ) after overdosing of drug2 was diagnosed in 6 cats with diabetes mellitus . "
              10 : "Rebound drug1 following overdosing of drug2 in cats with diabetes mellitus . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
              10 : 1
            }
        }
      69 : 
        {
          1 : "NN dobj VBG advcl VBD dobj NN conj NN"
          2 : 9
          3 : 
            {
              1 : "drug0 dobj using advcl *developed* dobj anemia conj drug0"
              2 : "drug0 dobj taking advcl *developed* dobj pigmentation conj drug0"
              3 : "drug0 dobj receiving advcl *developed* dobj perspiration conj drug0"
              4 : "drug0 dobj using advcl *developed* dobj anemia conj drug0"
              5 : "drug0 dobj using advcl *developed* dobj anemia conj drug0"
              6 : "drug0 dobj receiving advcl *developed* dobj perspiration conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : A 37-year-old African - American man with G6PD deficiency developed hemolytic anemia , drug1 , orthostatic hypotension , and aseptic meningitis simultaneously after using drug2 . "
              2 : "A patient with ulcerative colitis developed skin pigmentation and drug1 without respiratory symptomatology , while taking drug2 . "
              3 : "We report a case of a young woman with SLE and thrombocytopenia , who developed severe perspiration , drug1 , and seizure after receiving drug2 . "
              4 : "CONCLUSION : A 37-year-old African - American man with G6PD deficiency developed hemolytic anemia , hepatitis , drug1 , and aseptic meningitis simultaneously after using drug2 . "
              5 : "CONCLUSION : A 37-year-old African - American man with G6PD deficiency developed hemolytic anemia , hepatitis , orthostatic hypotension , and drug1 simultaneously after using drug2 . "
              6 : "We report a case of a young woman with SLE and thrombocytopenia , who developed severe perspiration , headache , and drug1 after receiving drug2 . "
            }
          5 : 
            {
              1 : 2
              2 : 1
              3 : 1
              4 : 2
              5 : 2
              6 : 1
            }
        }
      70 : 
        {
          1 : "NN conj NN nmod VBG acl NN compound NN"
          2 : 9
          3 : 
            {
              1 : "drug0 conj fever nmod consisting acl *syndrome* compound drug0"
              2 : "drug0 conj fever nmod consisting acl *syndrome* compound drug0"
              3 : "drug0 conj fever nmod consisting acl *syndrome* compound drug0"
              4 : "drug0 conj fever nmod consisting acl *syndrome* compound drug0"
              5 : "drug0 conj fever nmod consisting acl *syndrome* compound drug0"
              6 : "drug0 conj fever nmod consisting acl *syndrome* compound drug0"
              7 : "drug0 conj weakness nmod manifesting acl *neurotoxicity* compound drug0"
              8 : "drug0 conj fever nmod consisting acl *syndrome* compound drug0"
              9 : "drug0 conj fever nmod consisting acl *syndrome* compound drug0"
            }
          4 : 
            {
              1 : "A drug1 hypersensitivity syndrome , consisting of fever , headache , nausea , drug2 , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy . "
              2 : "A drug1 hypersensitivity syndrome , consisting of fever , drug2 , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy . "
              3 : "A drug1 hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , drug2 , and mononucleosis , has been described in patients treated with the drug for leprosy . "
              4 : "A drug1 hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , drug2 , hemolysis , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy . "
              5 : "A drug1 hypersensitivity syndrome , consisting of fever , headache , drug2 , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy . "
              6 : "A drug1 hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , drug2 , hepatitis , hemolysis , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy . "
              7 : "We report a case of intrathecal drug1 neurotoxicity manifesting as left arm weakness and drug2 . "
              8 : "A drug1 hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , hemolysis , leukopenia , and drug2 , has been described in patients treated with the drug for leprosy . "
              9 : "A drug1 hypersensitivity syndrome , consisting of fever , headache , nausea , vomiting , lymphadenopathy , hepatitis , drug2 , leukopenia , and mononucleosis , has been described in patients treated with the drug for leprosy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      71 : 
        {
          1 : "NN compound NN nmod VBN acl NN conj NN"
          2 : 9
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl *neuropathy* conj drug0"
              2 : "drug0 compound therapy nmod associated acl *cholestasis* conj drug0"
              3 : "drug0 compound use nmod associated acl *syndrome* conj drug0"
              4 : "drug0 compound use nmod associated acl *infarction* conj drug0"
              5 : "drug0 compound infusion nmod associated acl *leucopenia* conj drug0"
              6 : "drug0 compound administration nmod associated acl *angioedema* conj drug0"
              7 : "drug0 compound therapy nmod associated acl *cholestasis* conj drug0"
              8 : "drug0 compound treatment nmod associated acl *sleep* conj drug0"
              9 : "drug0 compound treatment nmod associated acl *hypocalcaemia* conj drug0"
            }
          4 : 
            {
              1 : "Peripheral neuropathy and drug1 associated with drug2 therapy . "
              2 : "Intrahepatic cholestasis and drug1 associated with drug2 therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma . "
              3 : "However , a large case-control study included three cases of either Stevens-Johnson syndrome or drug1 associated with drug2 use , but no details of the cases were given . "
              4 : "Though they are generally considered safe , there have been a few reports of myocardial infarction and drug1 associated with drug2 use . "
              5 : "Transient leucopenia and drug1 associated with drug2 infusion . "
              6 : "Angioedema and drug1 associated with drug2 administration . "
              7 : "Intrahepatic cholestasis and drug1 associated with drug2 therapy . "
              8 : "Prominent eye movements during NREM sleep and drug1 associated with drug2 treatment of depression and obsessive-compulsive disorder . "
              9 : "Symptomatic hypocalcaemia and drug1 associated with drug2 treatment in patients with multiple myeloma . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      72 : 
        {
          1 : "NN nmod VBN nsubjpass NN compound NN"
          2 : 9
          3 : 
            {
              1 : "drug0 nmod *terminated* nsubjpass treatment compound drug0"
              2 : "drug0 nmod *associated* nsubjpass therapy compound drug0"
              3 : "drug0 nmod *characterized* nsubjpass syndrome compound drug0"
              4 : "drug0 nmod *associated* nsubjpass therapy compound drug0"
              5 : "drug0 nmod *characterized* nsubjpass overdose compound drug0"
              6 : "drug0 nmod *superimposed* nsubjpass vasculitis compound drug0"
              7 : "drug0 nmod *associated* nsubjpass neuropathy compound drug0"
              8 : "drug0 nmod *discontinued* nsubjpass chemotherapy compound drug0"
              9 : "drug0 nmod *complicated* nsubjpass therapy compound drug0"
            }
          4 : 
            {
              1 : "drug1 treatment was terminated in 1975 because of drug2 with a diabetes insipidus-like syndrome . "
              2 : "drug1 therapy has been associated with drug2 when used in the treatment of carcinoma . "
              3 : "The fetal drug1 syndrome ( FVS ) is characterized by drug2 , major and minor malformations , and developmental delay . "
              4 : "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis , respectively , in whom drug1 therapy was associated with drug2 due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other . "
              5 : "drug1 overdose is usually characterized by drug2 , dizziness , and mild sedation . "
              6 : "In one patient the vasculitis resolved after termination of the ciprofloxacin therapy ; in the other patient the drug1 hemorrhagic vasculitis was superimposed on a drug2 , leading to progressive gangrene and a below-knee amputation . "
              7 : "drug1 neuropathy is often associated with drug2 and may progress even after discontinuation of treatment , in the phenomenon of ` coasting ' . "
              8 : "Based on the Naranjo algorithm , the adverse reaction observed was probably related to the hydroxyurea treatment ( score = 6 ) ; however , the drug1 chemotherapy could not be discontinued because of the drug2 . "
              9 : "We describe a patient with a liver abscess due to Entamoeba histolytica , in whom drug1 therapy ( total dose , 21 g over 14 days ) was complicated by drug2 , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      73 : 
        {
          1 : "NN appos NN nmod VBN acl NN"
          2 : 9
          3 : 
            {
              1 : "drug0 appos interferon nmod induced acl *drug0*"
              2 : "drug0 appos uracil-tegafur nmod induced acl *drug0*"
              3 : "drug0 appos hopantenate nmod induced acl *drug0*"
              4 : "drug0 appos sulphonate nmod induced acl *drug0*"
              5 : "drug0 appos nevirapine nmod induced acl *drug0*"
              6 : "drug0 appos carmustine nmod induced acl *drug0*"
              7 : "drug0 appos ono-0 nmod induced acl *drug0*"
              8 : "drug0 appos alpha-0a nmod associated acl *drug0*"
              9 : "drug0 appos inhibitor nmod caused acl *drug0*"
            }
          4 : 
            {
              1 : "We report a case of drug1 induced by long-term interferon ( drug2 ) therapy . "
              2 : "drug1 induced by uracil-tegafur ( drug2 ) , a second-generation anticancer agent . "
              3 : "We report a girl with the Rett syndrome who had drug1 probably induced by calcium hopantenate ( drug2 ) . "
              4 : "drug1 induced by sodium polystyrene sulphonate ( drug2 ) in two extremely low birth weight newborns . "
              5 : "We describe a detailed case of drug1 induced by nevirapine ( drug2 ) and treated by liver transplantation . "
              6 : "drug1 induced by carmustine ( drug2 ) . "
              7 : "Acute drug1 induced by ONO-1078 ( drug2 ) , a leukotriene receptor antagonist . "
              8 : "We report the first case of fulminant drug1 ( ARDS ) associated with pegylated interferon alpha-2a ( drug2 ) and ribavirin use for hepatitis C , complicated by subsequent and ultimately fatal sepsis and multiorgan failure . "
              9 : "We report a case of drug-induced drug1 caused by an angiotensin-converting enzyme inhibitor , drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      74 : 
        {
          1 : "NN nmod NN nmod VBN nsubj NN"
          2 : 9
          3 : 
            {
              1 : "drug0 nmod use nmod *related* nsubj drug0"
              2 : "drug0 nsubj *resolved* nmod discontinuation nmod drug0"
              3 : "drug0 nmod discontinuation nmod *resolved* nsubj drug0"
              4 : "drug0 nmod discontinuation nmod *resolved* nsubj drug0"
              5 : "drug0 nsubj *resolved* nmod cessation nmod drug0"
              6 : "drug0 nsubj *resolved* nmod abstinence nmod drug0"
              7 : "drug0 nsubj *developed* nmod dose nmod drug0"
              8 : "drug0 nsubj *resolved* nmod discontinuation nmod drug0"
              9 : "drug0 nmod discontinuation nmod *resolved* nsubj drug0"
            }
          4 : 
            {
              1 : "The temporal relationship suggests that the drug1 may be related to the use of drug2 . "
              2 : "Upon discontinuation of drug1 , her drug2 resolved , and her arthritis became more active . "
              3 : "The drug1 resolved on discontinuation of drug2 . "
              4 : "The drug1 resolved completely soon after the discontinuation of drug2 . "
              5 : "After cessation of drug1 , the drug2 resolved , and the endothelial cell densities were < or = 600/mm . "
              6 : "After abstinence from drug1 his drug2 resolved . "
              7 : "After the first oral dose of drug1 , drug2 developed together with atrioventricular block . "
              8 : "After discontinuation of drug1 the drug2 completely resolved . "
              9 : "drug1 resolved with discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      75 : 
        {
          1 : "NN dep NN appos NN"
          2 : 9
          3 : 
            {
              1 : "drug0 dep *tacrolimus* appos drug0"
              2 : "drug0 dep *tenofovir* appos drug0"
              3 : "drug0 dep *disopyramide* appos drug0"
              4 : "drug0 dep *interferon* appos drug0"
              5 : "drug0 appos mg dep *drug0*"
              6 : "drug0 dep *0-fluorouracil* appos drug0"
              7 : "drug0 dep *methylphenidate* appos drug0"
              8 : "drug0 dep *isoniazid* appos drug0"
              9 : "drug0 dep *carboplatin* appos drug0"
            }
          4 : 
            {
              1 : "Tacrolimus ( drug1 ) - induced drug2 after liver transplant . "
              2 : "We report two cases of tenofovir ( drug1 ) - associated drug2 in perinatally HIV-infected adolescents . "
              3 : "Disopyramide ( drug1 ) - induced drug2 . "
              4 : "BACKGROUND : Interferon ( drug1 ) - associated drug2 is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus , but visual function is usually maintained . "
              5 : "He was started on oral drug1 60 mg twice daily and , on hospital day 2 , his drug2 to 102 x 10 ( 3 ) / mm ( 3 ) ; on hospital day 3 , the platelet count was 36 x 10 ( 3 ) / mm ( 3 ) . "
              6 : "The incidence of 5-fluorouracil ( drug1 ) - related drug2 seems to be dosage and schedule dependent . "
              7 : "Methylphenidate ( drug1 ) - associated drug2 and glaucoma . "
              8 : "OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( drug1 ) drug2 appearing at an inner-city municipal hospital . "
              9 : "We report five cases of carboplatin ( drug1 ) drug2 after weekly low-dose paclitaxel ( 60 mg/m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      76 : 
        {
          1 : "NN compound NN nmod VBD nsubj NN"
          2 : 9
          3 : 
            {
              1 : "drug0 compound treatment nmod *developed* nsubj drug0"
              2 : "drug0 compound discontinuation nmod *ceased* nsubj drug0"
              3 : "drug0 compound administration nmod *induced* nsubj drug0"
              4 : "drug0 compound therapy nmod *occurred* nsubj drug0"
              5 : "drug0 compound treatment nmod *developed* nsubj drug0"
              6 : "drug0 compound treatment nmod *appeared* nsubj drug0"
              7 : "drug0 compound administration nmod *emerged* nsubj drug0"
              8 : "drug0 compound therapy nmod *developed* nsubj drug0"
              9 : "drug0 compound treatment nmod *had* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed in a 69-year-old male with severe chronic tophaceous gout during drug2 treatment . "
              2 : "In the third child , the drug1 ceased after drug2 discontinuation . "
              3 : "drug1 induced in an infant by systemic drug2 administration . "
              4 : "drug1 occurred in one patient during drug2 therapy , although the relationship between the fracture and PSL therapy was uncertain . "
              5 : "drug1 developed during drug2 treatment . "
              6 : "We report the case of a female acromegalic patient in whom multiple drug1 appeared soon after drug2 treatment for uterine fibromatosis . "
              7 : "Three male patients aged 78-83 years are presented , in whom drug1 emerged after drug2 administration . "
              8 : "Although the drug1 developed following oral drug2 therapy , the child had previously received high-dose , multiagent chemotherapy , and rearrangement of the MLL gene was not demonstrated . "
              9 : "One patient had a drug1 and two patients had lower average mean blood pressure values during drug2 treatment , none of which was clinically significant . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      77 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl NN"
          2 : 9
          3 : 
            {
              1 : "drug0 conj citalopram nmod interaction nmod caused acl *drug0*"
              2 : "drug0 conj vancomycin nmod exposure nmod triggered acl *drug0*"
              3 : "drug0 conj melanonychia nmod occurrence nmod associated acl *drug0*"
              4 : "drug0 conj garenoxacin nmod combination nmod induced acl *drug0*"
              5 : "drug0 conj simvastatin nmod use nmod associated acl *drug0*"
              6 : "drug0 conj vancomycin nmod exposure nmod triggered acl *drug0*"
              7 : "drug0 conj fentanyl nmod interaction nmod associated acl *drug0*"
              8 : "drug0 conj lithium nmod use nmod induced acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 caused by interaction between citalopram and drug2 . "
              2 : "DISCUSSION : To our knowledge , this is the first case report illustrating drug1 triggered by exposure to the antibiotics vancomycin , drug2 , and piperacillin/tazobactam . "
              3 : "drug1 associated with concomitant occurrence of diffuse longitudinal melanonychia and drug2 in an elderly subject . "
              4 : "drug1 induced by a combination of garenoxacin and drug2 and other cytochrome P450 , family 3 , subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice . "
              5 : "Rapid onset of drug1 ( rhabdomyolysis ) associated with the combined use of simvastatin and drug2 . "
              6 : "DISCUSSION : To our knowledge , this is the first case report illustrating drug1 triggered by exposure to the antibiotics vancomycin , tobramycin , and drug2 . "
              7 : "OBJECTIVE : To report a case of drug1 associated with interaction between fentanyl and drug2 , as evidenced by medication history , clinical features and reversal following discontinuation of fentanyl . "
              8 : "drug1 induced by concomitant use of lithium and drug2 in patient with Wolff-Parkinson-White syndrome . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 2
              7 : 1
              8 : 1
            }
        }
      78 : 
        {
          1 : "NN dobj VBD conj VBN nmod NN"
          2 : 9
          3 : 
            {
              1 : "drug0 dobj developed conj *treated* nmod drug0"
              2 : "drug0 dobj developed conj *treated* nmod drug0"
              3 : "drug0 dobj had conj *treated* nmod drug0"
              4 : "drug0 dobj developed conj *treated* nmod drug0"
              5 : "drug0 dobj developed conj *treated* nmod drug0"
              6 : "drug0 dobj developed conj *treated* nmod drug0"
              7 : "drug0 dobj developed conj *managed* nmod drug0"
              8 : "drug0 dobj developed conj *treated* nmod drug0"
              9 : "drug0 dobj developed conj *placed* nmod drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARIES : In each case , the patients were treated over 5 years with drug1 and developed drug2 that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic . "
              2 : "We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly drug1 for 12 weeks and developed significant drug2 during treatment . "
              3 : "She was treated with drug1 , but had consistent drug2 1 to 2 hours after administration of enzymes . "
              4 : "A 40-year-old man with a long standing history of rheumatoid arthritis was treated with drug1 over a 6 month period and developed an drug2 . "
              5 : "We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with drug1 and developed a peculiar drug2 in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin . "
              6 : "She was treated with drug1 and subsequently developed drug2 . "
              7 : "A patient with generalized MG was effectively managed with drug1 but developed drug2 after 3 years of treatment . "
              8 : "The presented patient was treated with 200 mg drug1 and developed drug2 6 weeks later ( cortisol and ACTH concentrations were below limits of detection , TCA concentrations were > 3 micrograms/l ) . "
              9 : "We report a case of an infant with complex congenital heart disease who was placed on drug1 for afterload reduction following cardiac surgery and subsequently developed drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      79 : 
        {
          1 : "NN dobj VB xcomp VBN nsubjpass NN"
          2 : 9
          3 : 
            {
              1 : "drug0 dobj cause xcomp *demonstrated* nsubjpass drug0"
              2 : "drug0 dobj produce xcomp *reported* nsubjpass drug0"
              3 : "drug0 dobj have xcomp *shown* nsubjpass drug0"
              4 : "drug0 dobj cause xcomp *reported* nsubjpass drug0"
              5 : "drug0 dobj cause xcomp *known* nsubjpass drug0"
              6 : "drug0 dobj cause xcomp *reported* nsubjpass drug0"
              7 : "drug0 dobj induce xcomp *noted* nsubjpass drug0"
              8 : "drug0 dobj cause xcomp *speculated* nsubjpass drug0"
              9 : "drug0 dobj cause xcomp *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Both drug1 and methotrexate have been independently demonstrated to cause drug2 . "
              2 : "DISCUSSION : drug1 has been reported to produce significant drug2 , with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease , even when administered in conventional dosages and infusion rates . "
              3 : "drug1 , a drug used for the treatment of acne , has been shown to have drug2 . "
              4 : "BACKGROUND : drug1 , a highly specific serotonin reuptake inhibitor , has been reported to cause drug2 in a minority of patients . "
              5 : "drug1 is known to cause drug2 and tubulo-interstitial disease , but the recently described association with proteinuria or nephrotic syndrome is little recognized . "
              6 : "drug1 ( VRC ) has not previously been reported to cause drug2 . "
              7 : "Soon after its introduction in 1952 , drug1 was noted to induce drug2 . "
              8 : "drug1 is speculated to cause drug2 in patients with defective calcium-activated K + channels . "
              9 : "RESULTS : drug1 was observed to cause drug2 , confirmed on rechallenge , scoring 8 ( strong probability ) on an adverse drug reaction probability score . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
              9 : 1
            }
        }
      80 : 
        {
          1 : "NN nmod VBN acl NN nmod NN conj NN"
          2 : 8
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *meningitis* conj drug0"
              2 : "drug0 nmod treated acl patient nmod *meningitis* conj drug0"
              3 : "drug0 nmod treated acl patient nmod *dysfunction* conj drug0"
              4 : "drug0 nmod treated acl patient nmod *meningitis* conj drug0"
              5 : "drug0 conj application nmod *male* acl presented nmod drug0"
            }
          4 : 
            {
              1 : "Aseptic meningitis , hemolytic anemia , drug1 , and orthostatic hypotension in a patient treated with drug2 . "
              2 : "Aseptic meningitis , drug1 , hepatitis , and orthostatic hypotension in a patient treated with drug2 . "
              3 : "Retinal dysfunction and drug1 in a patient treated with drug2 . "
              4 : "Aseptic meningitis , hemolytic anemia , hepatitis , and drug1 in a patient treated with drug2 . "
              5 : "A 33-year-old male presented with drug1 following the application of 4 % hydroquinone in sorbolene cream and drug2 to the face intermittently for 9 months . "
            }
          5 : 
            {
              1 : 2
              2 : 2
              3 : 1
              4 : 2
              5 : 1
            }
        }
      81 : 
        {
          1 : "NN nmod VBD dobj NN"
          2 : 8
          3 : 
            {
              1 : "drug0 nmod *suffered* dobj drug0"
              2 : "drug0 nmod *developed* dobj drug0"
              3 : "drug0 nmod *developed* dobj drug0"
              4 : "drug0 nmod *developed* dobj drug0"
              5 : "drug0 nmod *developed* dobj drug0"
              6 : "drug0 nmod *received* dobj drug0"
              7 : "drug0 nmod *developed* dobj drug0"
              8 : "drug0 nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered drug1 after intrathecal drug2 . "
              2 : "We report a case of a 60-year-old woman affected by squamous lung carcinoma , who developed drug1 during drug2 and etoposide combination chemotherapy . "
              3 : "A 9-year-old boy developed drug1 following intravenous drug2 ( 30 mg/kg per day ) administered for 6 days to treat herpetic encephalitis . "
              4 : "We report 2 patients who developed drug1 following drug2 . "
              5 : "A case of a 53-year-old man who developed drug1 after drug2 and moderate oxygen administration is presented . "
              6 : "A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous drug1 for atypical absence status drug2 is reported . "
              7 : "In this report , one patient who developed drug1 after drug2 and vincristine/vinblastine chemotherapy for AIDS-related Kaposi 's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud 's phenomenon related to the same regimen are presented . "
              8 : "We report a patient of organic bipolar affective disorder who developed drug1 with the atypical antipsychotic drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      82 : 
        {
          1 : "NN conj NN nmod NN nmod VBD dobj NN"
          2 : 8
          3 : 
            {
              1 : "drug0 conj efalizumab nmod treatment nmod *developed* dobj drug0"
              2 : "drug0 conj alpha nmod treatment nmod *developed* dobj drug0"
              3 : "drug0 conj adriamycin nmod therapy nmod *had* dobj drug0"
              4 : "drug0 conj gentamicin nmod treatment nmod *developed* dobj drug0"
              5 : "drug0 conj cyclophosphamide nmod exposure nmod *developed* dobj drug0"
              6 : "drug0 conj prednisolone nmod treatment nmod *observed* dobj drug0"
              7 : "drug0 conj octreotide nmod treatment nmod *developed* dobj drug0"
              8 : "drug0 conj indomethacin nmod treatment nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Herein , we describe 2 patients who developed unusual drug1 after treatment with efalizumab and drug2 . "
              2 : "We report a case with chronic hepatitis C ( CHC ) who developed drug1 after the treatment by interferon alpha and drug2 . "
              3 : "A young woman with epilepsy had drug1 during antineoplastic therapy with adriamycin and drug2 . "
              4 : "The other woman had rheumatoid arthritis and developed drug1 after treatment with gentamicin and drug2 . "
              5 : "This report describes two patients who developed drug1 only after exposure to cyclophosphamide , drug2 , and 5-fluorouracil adjuvant therapy . "
              6 : "We observed transient drug1 in a patient with neuropsychiatric SLE after treatment with prednisolone and drug2 . "
              7 : "We report on a patient with acromegaly who developed severe drug-induced drug1 during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist drug2 . "
              8 : "We report the case of a patient with multiple myeloma who developed acute drug1 following treatment with oral indomethacin and low dose intravenous drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      83 : 
        {
          1 : "NN compound NN nmod NNS nmod VBD dobj NN"
          2 : 8
          3 : 
            {
              1 : "drug0 compound prophylaxis nmod months nmod *developed* dobj drug0"
              2 : "drug0 compound monotherapy nmod months nmod *developed* dobj drug0"
              3 : "drug0 dobj *noted* nmod weeks nmod treatment compound drug0"
              4 : "drug0 compound therapy nmod months nmod *developed* dobj drug0"
              5 : "drug0 compound therapy nmod weeks nmod *had* dobj drug0"
              6 : "drug0 compound injection nmod minutes nmod *developed* dobj drug0"
              7 : "drug0 compound treatment nmod months nmod *developed* dobj drug0"
              8 : "drug0 compound treatment nmod months nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We evaluated a patient who developed a drug1 after 4 months of drug2 prophylaxis for a positive tuberculosis tine test . "
              2 : "This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed drug1 after 23 months of drug2 monotherapy . "
              3 : "After approximately two weeks of drug1 treatment he noted an drug2 in his scalp after eating a piece of chocolate cake . "
              4 : "The second patient developed both drug1 and a refractory pre-patellar bursitis after 50 months of drug2 therapy . "
              5 : "Our patient had drug1 , mild fever , nausea , vomiting , rash , and eosinophilia after 3 weeks of drug2 therapy . "
              6 : "We present here a female patient who developed drug1 within minutes of i.v. drug2 injection and recovered within 24 hours of stopping the drug and with symptomatic treatment . "
              7 : "We describe a patient with idiopathic RLS who developed drug1 after 8 months of drug2 treatment . "
              8 : "Two patients who developed drug1 after several months of drug2 treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      84 : 
        {
          1 : "NN compound NNS nmod NN nmod NN"
          2 : 8
          3 : 
            {
              1 : "drug0 compound beverages nmod ingestion nmod *drug0*"
              2 : "drug0 compound tablets nmod injection nmod *drug0*"
              3 : "drug0 compound injections nmod treatment nmod *drug0*"
              4 : "drug0 nmod dose nmod *hours* compound drug0"
              5 : "drug0 compound reactions nmod case nmod *drug0*"
              6 : "drug0 nmod expression nmod *seizures* compound drug0"
              7 : "drug0 compound patients nmod *report* nmod drug0"
              8 : "drug0 nmod exposure nmod *abnormalities* compound drug0"
            }
          4 : 
            {
              1 : "The possibility of severe rhabdomyolysis should be considered in a patient with drug1 due to massive ingestion of drug2 beverages . "
              2 : "drug1 following accidental intra-arterial injection of dissolved drug2 tablets . "
              3 : "OBJECTIVE : To report a case of a drug1 following treatment of psoriasis with drug2 injections . "
              4 : "She developed a generalized rash and itching , sore throat , and drug1 approximately 4 hours after the first dose of drug2 . "
              5 : "drug1 of a case of drug2 serum sickness-like reactions . "
              6 : "drug1 seizures as singular expression of drug2 . "
              7 : "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of drug1 in drug2 patients . "
              8 : "drug1 and mid-line skeletal abnormalities due to in utero exposure to drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      85 : 
        {
          1 : "NN nmod NN nmod NN nmod NN appos NN"
          2 : 8
          3 : 
            {
              1 : "drug0 nmod treatment nmod *suffering* nmod thrombocytopenia appos drug0"
              2 : "drug0 appos activator nmod therapy nmod *occurrence* nmod drug0"
              3 : "drug0 appos sulfamethoxazole-trimethoprim nmod therapy nmod *hyperkalaemia* nmod drug0"
              4 : "drug0 appos sulfoxide nmod instillation nmod *flare* nmod drug0"
              5 : "drug0 appos diphenylhydantoin nmod patient nmod *development* nmod drug0"
              6 : "drug0 appos sodium nmod ingestion nmod *development* nmod drug0"
              7 : "drug0 nmod treatment nmod *woman* nmod t-mds appos drug0"
              8 : "drug0 nmod administration nmod *disease* nmod ductopenia appos drug0"
            }
          4 : 
            {
              1 : "A patient suffering from heparin-associated thrombocytopenia ( drug1 ) , recurrent arteriothromboses , and acute renal failure after treatment with standard drug2 is described . "
              2 : "We report the occurrence of drug1 due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator ( drug2 ) . "
              3 : "Hyperkalaemia with drug1 by oral therapy of sulfamethoxazole-trimethoprim ( drug2 ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved . "
              4 : "We report the first case of an acute flare of drug1 in a 51-year-old woman after bladder instillation with dimethyl sulfoxide ( drug2 ) for presumed interstitial cystitis . "
              5 : "The development of an drug1 and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin ( drug2 ) therapy for 20 years is reported . "
              6 : "We report for the first time the development of drug1 after an acute ingestion of divalproex sodium ( drug2 ) , resulting in serum concentrations 10 times greater than the therapeutic range . "
              7 : "We report a 44-year-old woman with t-MDS ( drug1 ) following treatment of recurrent anaplastic astrocytoma with drug2 ( TMZ ) . "
              8 : "Cholestatic liver disease with ductopenia ( drug1 ) after administration of drug2 and trimethoprim-sulfamethoxazole . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      86 : 
        {
          1 : "NN nmod NN nmod VBD nmod NN"
          2 : 8
          3 : 
            {
              1 : "drug0 nmod administration nmod *presented* nmod drug0"
              2 : "drug0 nmod dose nmod *progressed* nmod drug0"
              3 : "drug0 nmod introduction nmod *evolved* nmod drug0"
              4 : "drug0 nmod treatment nmod *presented* nmod drug0"
              5 : "drug0 nmod administration nmod *changed* nmod drug0"
              6 : "drug0 nmod injection nmod *suffered* nmod drug0"
              7 : "drug0 nmod dose nmod *progressed* nmod drug0"
              8 : "drug0 nmod treatment nmod *occurred* nmod drug0"
            }
          4 : 
            {
              1 : "STUDY DESIGN : Case report of a 31-year-old woman who presented with drug1 due to intrathecal administration of drug2 . "
              2 : "This patient rapidly progressed from mild neurotoxicity to drug1 after one dose of intrathecal drug2 during his third cycle of chemotherapy . "
              3 : "The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into drug1 after the introduction of drug2 ( OXC ) , as part of a switch off from carbamazepine ( CBZ ) . "
              4 : "METHOD : We describe two patients who presented with drug1 after treatment with drug2 and risperidone , respectively . "
              5 : "We describe two cases of PSVT that changed to drug1 after administration of drug2 . "
              6 : "AIM : To report a patient with diabetic rubeosis who suffered from drug1 and stroke after intravitreal injection of drug2 . "
              7 : "This patient rapidly progressed from drug1 to fatal encephalopathy after one dose of intrathecal drug2 during his third cycle of chemotherapy . "
              8 : "We report a case of interstitial pulmonary disease that occurred together with drug1 during treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      87 : 
        {
          1 : "NN compound NN dobj VBG acl NN"
          2 : 8
          3 : 
            {
              1 : "drug0 compound injection dobj complicating acl *drug0*"
              2 : "drug0 compound therapy dobj complicating acl *drug0*"
              3 : "drug0 compound transplantation dobj complicating acl *drug0*"
              4 : "drug0 compound infusion dobj complicating acl *drug0*"
              5 : "drug0 compound chemotherapy dobj complicating acl *drug0*"
              6 : "drug0 compound therapy dobj complicating acl *drug0*"
              7 : "drug0 compound treatment dobj complicating acl *drug0*"
              8 : "drug0 compound hypothyroidism dobj complicating acl *drug0*"
            }
          4 : 
            {
              1 : "Long-term follow-up after drug1 complicating percutaneous drug2 injection for treatment of hepatocellular carcinoma . "
              2 : "drug1 complicating drug2 therapy in a patient with metastatic gastrointestinal stromal tumor . "
              3 : "Indolent drug1 complicating drug2 non-myeloablative stem cell transplantation . "
              4 : "drug1 complicating drug2 infusion . "
              5 : "drug1 complicating high dose drug2 chemotherapy in a breast cancer patient with an impaired renal function . "
              6 : "drug1 complicating drug2 therapy in a patient with protein C deficiency . "
              7 : "drug1 complicating drug2 treatment for deep vein thrombosis . "
              8 : "drug1 complicating drug2 hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      88 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN nmod NN"
          2 : 8
          3 : 
            {
              1 : "drug0 nmod trial nmod *developed* nsubj case nmod drug0"
              2 : "drug0 nmod recurrence nmod *led* nsubj rechallenge nmod drug0"
              3 : "drug0 nmod demise nmod *led* nsubj initiation nmod drug0"
              4 : "drug0 nmod doubling nmod *resulted* nsubj dose nmod drug0"
              5 : "drug0 nmod doubling nmod *resulted* nsubj dose nmod drug0"
              6 : "drug0 nmod resolution nmod *resulted* nsubj withdrawal nmod drug0"
              7 : "drug0 nmod return nmod *resulted* nsubj course nmod drug0"
              8 : "drug0 nmod resolution nmod *resulted* nsubj discontinuation nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 developed after therapeutic trial of drug2 as sclerosing agent for esophageal varix . "
              2 : "Inadvertent subsequent rechallenge with drug1 led to recurrence of the drug2 , 10 weeks after drug readministration . "
              3 : "Initiation of drug1 led to clinical improvement until the patient 's demise from bacteremic vancomycin-resistant drug2 . "
              4 : "In case 1 , a total daily dose of 25 mg drug1 , with nondetectable sertraline and desmethylsertraline blood levels , resulted in a doubling of the lamotrigine blood level with drug2 . "
              5 : "In case 1 , a total daily dose of 25 mg sertraline , with nondetectable drug1 and desmethylsertraline blood levels , resulted in a doubling of the lamotrigine blood level with drug2 . "
              6 : "Withdrawal of drug1 resulted in resolution of the drug2 . "
              7 : "In one child , a second course of drug1 resulted in a return of the drug2 . "
              8 : "Discontinuation of drug1 and cyclosporine resulted in resolution of drug2 and normalization of renal function . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      89 : 
        {
          1 : "NN dobj VBD conj VBD dobj NN"
          2 : 8
          3 : 
            {
              1 : "drug0 dobj developed conj *received* dobj drug0"
              2 : "drug0 dobj developed conj *received* dobj drug0"
              3 : "drug0 dobj developed conj *received* dobj drug0"
              4 : "drug0 dobj developed conj *received* dobj drug0"
              5 : "drug0 dobj developed conj *received* dobj drug0"
              6 : "drug0 dobj developed conj *received* dobj drug0"
              7 : "drug0 dobj developed conj *received* dobj drug0"
              8 : "drug0 dobj developed conj *received* dobj drug0"
            }
          4 : 
            {
              1 : "We report a third case of a 6-week-old infant with Escherichia coli sepsis who received drug1 and other antibiotics and subsequently developed drug2 . "
              2 : "The authors report a case of a patient who received drug1 for acute myocardial infarction and developed spontaneous drug2 without any evidence of direct trauma . "
              3 : "We report two adults who received drug1 ( GBP ) and subsequently developed drug2 . "
              4 : "The patient received only the ophthalmic drug1 , and it was used for one day , but he developed drug2 . "
              5 : "We describe a case of an NHL patient who received drug1 and developed symptomatic , biopsy-proven multinodular drug2 ( BOOP ) . "
              6 : "METHOD : The authors followed a patient with chronic HCV who received drug1 and ribavirin and who developed drug2 ultimately requiring psychiatric hospitalization . "
              7 : "A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous drug1 and developed drug2 10 days after starting therapy . "
              8 : "In this study , we report on three individual patients who received drug1 and who subsequently developed drug2 after injections of BTX-B at remote sites . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      90 : 
        {
          1 : "NN nmod NN dep NNS nmod NN"
          2 : 8
          3 : 
            {
              1 : "drug0 nmod treatment dep weeks nmod *drug0*"
              2 : "drug0 nmod administration dep weeks nmod *drug0*"
              3 : "drug0 nmod administration dep weeks nmod *drug0*"
              4 : "drug0 nmod treatment dep weeks nmod *drug0*"
              5 : "drug0 nmod injection dep months nmod *drug0*"
              6 : "drug0 nmod initiation dep weeks nmod *drug0*"
              7 : "drug0 nmod administration dep weeks nmod *drug0*"
              8 : "drug0 nmod treatment dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "A 58-year-old woman with rheumatoid arthritis ( RA ) developed fever , skin eruptions , leukocytopenia , and drug1 , 3 weeks after treatment with drug2 . "
              2 : "We report the case of a young man , affected by rheumatoid arthritis who developed a rapid-onset drug1 , hemoptysis , and severe weakness , about 2 weeks after the administration of drug2 . "
              3 : "A 14-year-old female developed drug1 , rash , fever , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of drug2 ( CBZ ; Tegretol ) used against benign Rolandic epilepsy . "
              4 : "A 52-year-old , white female developed low-grade fever , cough , and drug1 after 8 weeks treatment with drug2 for rheumatoid arthritis . "
              5 : "The authors present a case report of a drug1 leading to urethral prolapse , 3 months after the transurethral injection of drug2 . "
              6 : "The first patient developed a drug1 2 weeks after initiation of drug2 , which persisted during the 14 months of therapy and resolved with discontinuation of the medication . "
              7 : "We report the case of a young man , affected by rheumatoid arthritis who developed a rapid-onset short-of-breath , hemoptysis , and drug1 , about 2 weeks after the administration of drug2 . "
              8 : "A 58-year-old woman with rheumatoid arthritis ( RA ) developed drug1 , skin eruptions , leukocytopenia , and thrombocytopenia , 3 weeks after treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      91 : 
        {
          1 : "NN conj NN dobj VBD nsubj NN"
          2 : 8
          3 : 
            {
              1 : "drug0 conj confusion dobj *developed* nsubj drug0"
              2 : "drug0 conj confusion dobj *developed* nsubj drug0"
              3 : "drug0 conj confusion dobj *developed* nsubj drug0"
              4 : "drug0 conj polymyositis dobj *induced* nsubj drug0"
              5 : "drug0 conj confusion dobj *developed* nsubj drug0"
              6 : "drug0 conj deficiency dobj *induced* nsubj drug0"
              7 : "drug0 conj effluvium dobj *induced* nsubj drug0"
              8 : "drug0 conj confusion dobj *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) drug1 developed confusion , agitation , tachycardia , tremors , myoclonic jerks and drug2 , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl . "
              2 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) drug1 developed confusion , agitation , tachycardia , tremors , drug2 and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl . "
              3 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) drug1 developed confusion , agitation , tachycardia , drug2 , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl . "
              4 : "In this case , drug1 induced polymyositis and drug2 is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B . "
              5 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) drug1 developed confusion , agitation , drug2 , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl . "
              6 : "Transient drug1 induced IgA deficiency and permanent drug2 . "
              7 : "drug1 induced anagen effluvium and associated drug2 . "
              8 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) drug1 developed confusion , drug2 , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
              8 : 1
            }
        }
      92 : 
        {
          1 : "NN compound NNS nmod VBG acl NN dep NN conj NN"
          2 : 8
          3 : 
            {
              1 : "drug0 compound features nmod presenting acl *overdose* dep venlafaxine conj drug0"
              2 : "drug0 compound features nmod presenting acl *overdose* dep venlafaxine conj drug0"
              3 : "drug0 compound features nmod presenting acl *overdose* dep venlafaxine conj drug0"
              4 : "drug0 compound features nmod presenting acl *overdose* dep venlafaxine conj drug0"
            }
          4 : 
            {
              1 : "METHOD : Case analysis of a poly-drug overdose ( venlafaxine , topiramate , divalproex sodium , drug1 , and carbamazepine ) presenting with mixed drug2 features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings . "
              2 : "METHOD : Case analysis of a poly-drug overdose ( venlafaxine , topiramate , drug1 , risperidone , and carbamazepine ) presenting with mixed drug2 features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings . "
              3 : "METHOD : Case analysis of a poly-drug overdose ( venlafaxine , topiramate , divalproex sodium , risperidone , and drug1 ) presenting with mixed drug2 features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings . "
              4 : "METHOD : Case analysis of a poly-drug overdose ( venlafaxine , drug1 , divalproex sodium , risperidone , and carbamazepine ) presenting with mixed drug2 features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings . "
            }
          5 : 
            {
              1 : 2
              2 : 2
              3 : 2
              4 : 2
            }
        }
      93 : 
        {
          1 : "NN conj NNS dobj VBP nsubj NNS nmod NN"
          2 : 7
          3 : 
            {
              1 : "drug0 conj reactions dobj *include* nsubj events nmod drug0"
              2 : "drug0 conj reactions dobj *include* nsubj events nmod drug0"
              3 : "drug0 conj reactions dobj *include* nsubj events nmod drug0"
              4 : "drug0 conj reactions dobj *include* nsubj events nmod drug0"
              5 : "drug0 conj reactions dobj *include* nsubj events nmod drug0"
              6 : "drug0 conj reactions dobj *include* nsubj events nmod drug0"
              7 : "drug0 conj reactions dobj *include* nsubj events nmod drug0"
            }
          4 : 
            {
              1 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , drug2 , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
              2 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , drug2 , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
              3 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , drug2 , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
              4 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , drug2 , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
              5 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , drug2 , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
              6 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , drug2 , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
              7 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , drug2 , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      94 : 
        {
          1 : "NN conj NN nmod NNS nmod NNS root , punct JJ root IN acl NN conj NN nmod NN"
          2 : 7
          3 : 
            {
              1 : "drug0 conj failure nmod manifestations nmod drugs root , punct non-steroidal root of acl variety conj *interaction* nmod drug0"
              2 : "drug0 conj failure nmod manifestations nmod drugs root , punct non-steroidal root of acl variety conj *interaction* nmod drug0"
              3 : "drug0 conj failure nmod manifestations nmod drugs root , punct non-steroidal root of acl variety conj *interaction* nmod drug0"
              4 : "drug0 conj failure nmod manifestations nmod drugs root , punct non-steroidal root of acl variety conj *interaction* nmod drug0"
              5 : "drug0 conj failure nmod manifestations nmod drugs root , punct non-steroidal root of acl variety conj *interaction* nmod drug0"
              6 : "drug0 conj failure nmod manifestations nmod drugs root , punct non-steroidal root of acl variety conj *interaction* nmod drug0"
              7 : "drug0 conj failure nmod manifestations nmod drugs root , punct non-steroidal root of acl variety conj *interaction* nmod drug0"
            }
          4 : 
            {
              1 : "Previous studies have demonstrated the interaction of drug1 and a variety of non-steroidal , anti-inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure , pancytopenia , vomiting , drug2 , elevated liver transaminases , jaundice , mucosal ulcerations , and pyrexia . "
              2 : "Previous studies have demonstrated the interaction of drug1 and a variety of non-steroidal , anti-inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure , drug2 , vomiting , diarrhea , elevated liver transaminases , jaundice , mucosal ulcerations , and pyrexia . "
              3 : "Previous studies have demonstrated the interaction of drug1 and a variety of non-steroidal , anti-inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure , pancytopenia , drug2 , diarrhea , elevated liver transaminases , jaundice , mucosal ulcerations , and pyrexia . "
              4 : "Previous studies have demonstrated the interaction of drug1 and a variety of non-steroidal , anti-inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure , pancytopenia , vomiting , diarrhea , drug2 , jaundice , mucosal ulcerations , and pyrexia . "
              5 : "Previous studies have demonstrated the interaction of drug1 and a variety of non-steroidal , anti-inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure , pancytopenia , vomiting , diarrhea , elevated liver transaminases , jaundice , drug2 , and pyrexia . "
              6 : "Previous studies have demonstrated the interaction of drug1 and a variety of non-steroidal , anti-inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure , pancytopenia , vomiting , diarrhea , elevated liver transaminases , jaundice , mucosal ulcerations , and drug2 . "
              7 : "Previous studies have demonstrated the interaction of drug1 and a variety of non-steroidal , anti-inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure , pancytopenia , vomiting , diarrhea , elevated liver transaminases , drug2 , mucosal ulcerations , and pyrexia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      95 : 
        {
          1 : "NN nmod NN nmod JJ nsubj NN"
          2 : 7
          3 : 
            {
              1 : "drug0 nmod development nmod *responsible* nsubj drug0"
              2 : "drug0 nmod case nmod *responsible* nsubj drug0"
              3 : "drug0 nmod reaction nmod *responsible* nsubj drug0"
              4 : "drug0 nmod action nmod *due* nsubj drug0"
              5 : "drug0 nmod effect nmod *secondary* nsubj drug0"
              6 : "drug0 nmod administration nmod *related* nsubj drug0"
              7 : "drug0 nmod occurrence nmod *responsible* nsubj drug0"
            }
          4 : 
            {
              1 : "Data have been published regarding the possibility that drug1 may be responsible for the subsequent development of drug2 in these patients . "
              2 : "After rechallenge with monotherapy pegvisomant , however , the hepatic enzyme disturbances reappeared within a few weeks , indicating that most likely drug1 alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced drug2 . "
              3 : "According to the Naranjo adverse drug reaction probability scale , the likelihood that drug1 was responsible for the adverse drug reaction of drug2 was probable ( score of 6 ) . "
              4 : "Subsequent in vivo/vitro studies clearly demonstrated that the drug1 were due to a synergistic action of drug2 and prochlorperazine , probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems . "
              5 : "drug1 most likely was secondary to the nephrotoxic effect of drug2 on chronically hypoperfused kidneys . "
              6 : "drug1 were temporally related to the administration of the antitumor antibiotics drug2 ( NSC-3053 ) and mithramycin ( NSC-24559 ) . "
              7 : "Beginning ductopenia was present in two , suggesting that drug1 might be responsible for the occurrence of prolonged drug-induced drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      96 : 
        {
          1 : "NN nmod NN nmod VBN acl NN nmod NN"
          2 : 7
          3 : 
            {
              1 : "drug0 nmod hypoparathyroidism nmod treated acl patient nmod *drug0*"
              2 : "drug0 nmod *case* acl published nmod literature nmod drug0"
              3 : "drug0 nmod allergy nmod manifested acl *case* nmod drug0"
              4 : "drug0 nmod use nmod induced acl patient nmod *drug0*"
              5 : "drug0 nmod administration nmod linked acl *case* nmod drug0"
              6 : "drug0 nmod therapy nmod caused acl *case* nmod drug0"
              7 : "drug0 nmod use nmod associated acl interval nmod *drug0*"
            }
          4 : 
            {
              1 : "Unaccountable severe drug1 in a patient treated for hypoparathyroidism with drug2 . "
              2 : "OBJECTIVE : To describe what is believed , as of November 4 , 2003 , to be the first case published in the literature of drug1 ( AIN ) due to drug2 . "
              3 : "We describe a case of drug1 manifested as an allergy to drug2 . "
              4 : "drug1 in a patient with pemphigus vulgaris induced by the use of drug2 and prednisone . "
              5 : "We report a case of drug1 clearly linked to intravenous and intraperitoneal administration of drug2 . "
              6 : "A case of drug1 caused by combination therapy with drug2 and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman . "
              7 : "We report the first case of drug1 with normal QT interval associated with the oral use of drug2 in the absence of other etiologies known to cause these arrhythmias . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      97 : 
        {
          1 : "NN compound NN nmod NNS nmod VBD dobj NN conj NN"
          2 : 7
          3 : 
            {
              1 : "drug0 compound treatment nmod months nmod *developed* dobj polyneuropathy conj drug0"
              2 : "drug0 compound therapy nmod weeks nmod *had* dobj headache conj drug0"
              3 : "drug0 compound therapy nmod weeks nmod *had* dobj headache conj drug0"
              4 : "drug0 compound therapy nmod weeks nmod *had* dobj headache conj drug0"
              5 : "drug0 compound therapy nmod weeks nmod *had* dobj headache conj drug0"
              6 : "drug0 compound therapy nmod months nmod *developed* dobj disease conj drug0"
              7 : "drug0 compound therapy nmod weeks nmod *had* dobj headache conj drug0"
            }
          4 : 
            {
              1 : "A 52-year-old woman developed symmetric sensorimotor polyneuropathy and drug1 after 24 months of drug2 treatment . "
              2 : "Our patient had headache , mild fever , nausea , vomiting , rash , and drug1 after 3 weeks of drug2 therapy . "
              3 : "Our patient had headache , drug1 , nausea , vomiting , rash , and eosinophilia after 3 weeks of drug2 therapy . "
              4 : "Our patient had headache , mild fever , drug1 , vomiting , rash , and eosinophilia after 3 weeks of drug2 therapy . "
              5 : "Our patient had headache , mild fever , nausea , drug1 , rash , and eosinophilia after 3 weeks of drug2 therapy . "
              6 : "The second patient developed both autoimmune thyroid disease and a drug1 after 50 months of drug2 therapy . "
              7 : "Our patient had headache , mild fever , nausea , vomiting , drug1 , and eosinophilia after 3 weeks of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      98 : 
        {
          1 : "NN compound NN dobj VBG dep NNS nmod NN conj NN conj NN"
          2 : 7
          3 : 
            {
              1 : "drug0 compound therapy dobj starting dep weeks nmod eruption conj *fever* conj drug0"
              2 : "drug0 compound treatment dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              3 : "drug0 compound therapy dobj starting dep weeks nmod eruption conj *fever* conj drug0"
              4 : "drug0 compound treatment dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              5 : "drug0 compound therapy dobj starting dep weeks nmod eruption conj *fever* conj drug0"
              6 : "drug0 compound treatment dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              7 : "drug0 compound treatment dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
            }
          4 : 
            {
              1 : "A 22-year-old black man developed fever , chills , fatigue , drug1 , tender lymphadenopathy , and a generalized , pruritic , macular eruption 3 weeks after starting drug2 therapy for acne . "
              2 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , drug1 , and eosinophilia two weeks after receiving trimethoprim ( TMP ) drug2 ( SMX ) treatment . "
              3 : "A 22-year-old black man developed fever , drug1 , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption 3 weeks after starting drug2 therapy for acne . "
              4 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , drug1 , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) drug2 ( SMX ) treatment . "
              5 : "A 22-year-old black man developed fever , chills , drug1 , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption 3 weeks after starting drug2 therapy for acne . "
              6 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , drug1 , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) drug2 ( SMX ) treatment . "
              7 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , drug1 , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) drug2 ( SMX ) treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      99 : 
        {
          1 : "NN appos NN"
          2 : 7
          3 : 
            {
              1 : "drug0 appos *drug0*"
              2 : "drug0 appos *drug0*"
              3 : "drug0 appos *drug0*"
              4 : "drug0 appos *drug0*"
              5 : "drug0 appos *drug0*"
              6 : "drug0 appos *drug0*"
              7 : "drug0 appos *drug0*"
            }
          4 : 
            {
              1 : "The authors postulate that two types of combined lithium-neuroleptic toxicity occur : a drug1 and a lithium toxicity that occurs in combination with phenothiazines , primarily drug2 . "
              2 : "This report describes a case of drug1 , intravenous valproic acid-induced drug2 in a child with juvenile absence epilepsy , documented by video-electroencephalography . "
              3 : "drug1 ( drug2 ) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis . "
              4 : "drug1 during treatment of Parkinson 's disease with a long-acting ergot derivative , drug2 . "
              5 : "From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ) , drug1 ( drug2 ) , and efavirenz ( nausea and temporary memory loss ) . "
              6 : "drug1 induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. drug2 and sertraline , have been previously reported in patients with depression and obsessive-compulsive disorder ( OCD ) . "
              7 : "By means of the in vitro heparin-induced platelet activation ( HIPA ) assay it was shown that standard drug1 and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz , Munich , FRG ) , as well as the enoxaparine Clexane ( Nattermann , Cologne , FRG ) , all induced drug2 with the patient 's serum . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      100 : 
        {
          1 : "NN nmod JJ nsubj NN"
          2 : 7
          3 : 
            {
              1 : "drug0 nmod *responsible* nsubj drug0"
              2 : "drug0 nmod *due* nsubj drug0"
              3 : "drug0 nmod *due* nsubj drug0"
              4 : "drug0 nmod *secondary* nsubj drug0"
              5 : "drug0 nmod *responsible* nsubj drug0"
              6 : "drug0 nmod *responsible* nsubj drug0"
              7 : "drug0 nmod *attributable* nsubj drug0"
            }
          4 : 
            {
              1 : "The temporal sequence of the respiratory insufficiency and the histopathology , when compared to the previous examples in the literature , suggest that drug1 was aetiologically responsible for the drug2 . "
              2 : "CONCLUSIONS : drug1 to cyclosporine are due to drug2 . "
              3 : "We strongly suspect that this drug1 was mainly due to drug2 , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension . "
              4 : "It is presumed that her drug1 was secondary to drug2 because of the similarity to pediatric reports ; the rapid and lasting response to intravenous sodium bicarbonate ; the absence of another etiology ; normal serum potassium , chloride and bicarbonate despite continued spironolactone therapy after recovery . "
              5 : "The clinical course suggests that drug1 , which is present in oolong tea , was mainly responsible for the drug2 as well as the delirium , although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions . "
              6 : "This prompted us to suspect that drug1 might be responsible for drug2 in all three AIDS patients . "
              7 : "Thoracoscopic biopsy to confirm metastasis revealed instead drug1 apparently attributable to drug2 or cyclophosphamide . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      101 : 
        {
          1 : " NN nmod NNS nmod NN nmod NN"
          2 : 7
          3 : 
            {
              1 : " *drug0* nmod days nmod treatment nmod drug0"
              2 : "drug0 nmod treatment nmod *signs* nmod drug0"
              3 : "drug0 nmod treatment nmod weeks nmod *drug0*"
              4 : "drug0 nmod intake nmod *observations* nmod drug0"
              5 : "drug0 nmod administration nmod *cases* nmod drug0"
              6 : "drug0 nmod use nmod *reports* nmod drug0"
              7 : "drug0 nmod use nmod *patients* nmod drug0"
            }
          4 : 
            {
              1 : "CASE REPORT : We report the case of a 58 year old patient who , after 2 days of treatment with drug1 and betamethasone , manifested drug2 . "
              2 : "We recommend that clinicians monitor patients for signs and symptoms of pancreatitis , including drug1 , during treatment with drug2 . "
              3 : "A 51-year-old man developed drug1 following 24 weeks of treatment with recombinant drug2 plus ribavirin for chronic hepatitis C . "
              4 : "Five personal observations of an drug1 in younger individuals after intake of drug2 are described together with three observations from the medical literature . "
              5 : "Three diabetic cases of drug1 due to initial administration of drug2 . "
              6 : "Several case reports of drug1 with use of drug2 , and two cases with use of methazolamide , have appeared in the literature . "
              7 : "Two patients with drug1 after the use of drug2 were evaluated by means of IBZM-SPECT . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      102 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD nsubj NN"
          2 : 7
          3 : 
            {
              1 : "drug0 nmod mg nmod administration nmod *developed* nsubj drug0"
              2 : "drug0 nmod substitution nmod admission nmod *ended* nsubj drug0"
              3 : "drug0 nmod combination nmod administration nmod *developed* nsubj drug0"
              4 : "drug0 nmod therapy nmod duration nmod *continued* nsubj drug0"
              5 : "drug0 nmod therapy nmod month nmod *emerged* nsubj drug0"
              6 : "drug0 nsubj *developed* nmod day nmod tocolysis nmod drug0"
              7 : "drug0 nsubj occurred nmod *increase* nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "In three of these patients the infection was clinically unsuspected ; in the fourth , drug1 developed after administration of 300 mg of drug2 daily for the preceding five days . "
              2 : "In one instance a drug1 resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of drug2 for acetazolamide . "
              3 : "A drug1 characterized by depressed level of consciousness , marked irritability , and ataxia developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of drug2 and pyrilamine maleate . "
              4 : "The drug1 continued for the duration of therapy with drug2 . "
              5 : "This drug1 emerged after 1 month of therapy with drug2 , persisted for as long as salsalate was administered , and cleared within 3 weeks of discontinuing the medication . "
              6 : "On the fifth day of tocolysis with drug1 , nifedipine , terbutaline and betamethasone , drug2 developed in both labia . "
              7 : "Two years later , 24 hours following an increase in the dose of drug1 from 300 to 600 mg/day , drug2 with syncope occurred ; isoproterenol abolished the arrhythmia instantly . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      103 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN"
          2 : 7
          3 : 
            {
              1 : "drug0 dobj receiving acl patients nmod *drug0*"
              2 : "drug0 dobj using acl patients nmod *drug0*"
              3 : "drug0 dobj receiving acl patients nmod *drug0*"
              4 : "drug0 dobj receiving acl patients nmod *drug0*"
              5 : "drug0 dobj receiving acl patients nmod *drug0*"
              6 : "drug0 dobj taking acl patients nmod *drug0*"
              7 : "drug0 dobj taking acl patients nmod *drug0*"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious drug1 in patients receiving drug2 or venlafaxine when metoclopramide is coadministered even in a single , conventional dose . "
              2 : "drug1 and agranulocytosis in patients using drug2 for glaucoma . "
              3 : "Clinicians should be vigilant when monitoring for drug1 in patients receiving drug2 throughout the duration of therapy . "
              4 : "drug1 in leukemic patients receiving drug2 . "
              5 : "drug1 in patients receiving drug2 as long-term adjuvant chemotherapy for stage II breast cancer . "
              6 : "drug1 in patients taking drug2 -- rapid reversal and survival despite high APACHE score . "
              7 : "drug1 in two elderly patients taking drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      104 : 
        {
          1 : "NN nmod NNS nmod VBN nsubjpass NN"
          2 : 7
          3 : 
            {
              1 : "drug0 nmod complications nmod *reported* nsubjpass drug0"
              2 : "drug0 nmod symptoms nmod *suspended* nsubjpass drug0"
              3 : "drug0 nmod medications nmod *caused* nsubjpass drug0"
              4 : "drug0 nmod effects nmod *associated* nsubjpass drug0"
              5 : "drug0 nsubjpass *initiated* nmod effects nmod drug0"
              6 : "drug0 nmod effects nmod *considered* nsubjpass drug0"
              7 : "drug0 nmod doses nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Drug-induced drug1 have been reported as rare complications of drug2 and Neothetazone . "
              2 : "Sixteen hours after the first administration of IFN , drug1 was suspended by the symptoms of drug2 ( CHF ) . "
              3 : "drug1 and eruptions can be caused by many medications , including drug2 . "
              4 : "drug1 can be associated with severe adverse effects such as drug2 , acute renal failure , hemolytic anemia , and thrombocytopenia . "
              5 : "Because of serious side effects of an drug1 causing torsades de pointes , drug2 must be initiated with close monitoring of the QT interval in an inpatient setting . "
              6 : "drug1 and agranulocytosis are considered among the most dangerous adverse effects of drug2 . "
              7 : "Two patients are described in whom subtle drug1 are associated with therapeutic doses of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      105 : 
        {
          1 : "NN dobj VB nsubj NN compound NN"
          2 : 7
          3 : 
            {
              1 : "drug0 dobj *cause* nsubj toxicity compound drug0"
              2 : "drug0 dobj *cause* nsubj use compound drug0"
              3 : "drug0 dobj *cause* nsubj nephrolithiasis compound drug0"
              4 : "drug0 dobj *produce* nsubj od compound drug0"
              5 : "drug0 dobj *induce* nsubj therapy compound drug0"
              6 : "drug0 dobj *cause* nsubj therapy compound drug0"
              7 : "drug0 dobj *cause* nsubj therapy compound drug0"
            }
          4 : 
            {
              1 : "drug1 toxicity can cause drug2 in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies . "
              2 : "RESULTS : drug1 use can cause drug2 . "
              3 : "Physicians should be aware that drug1 nephrolithiasis may cause drug2 . "
              4 : "Massive drug1 OD may produce a drug2 that includes cortical hyperexcitability , a profound burst-suppression EEG pattern , and cranial nerve areflexia . "
              5 : "Since drug1 therapy can induce drug2 , surveillance schemes of women taking tamoxifen have been recommended . "
              6 : "drug1 therapy may cause a drug2 that is reversible upon discontinuing this agent . "
              7 : "Intravenous drug1 therapy in babies may cause drug2 , hypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with `` familial seizure disorders '' may in fact have the long QT interval syndrome . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      106 : 
        {
          1 : "NN dobj VBG acl NN"
          2 : 7
          3 : 
            {
              1 : "drug0 dobj involving acl *drug0*"
              2 : "drug0 dobj involving acl *drug0*"
              3 : "drug0 dobj producing acl *drug0*"
              4 : "drug0 dobj causing acl *drug0*"
              5 : "drug0 dobj causing acl *drug0*"
              6 : "drug0 dobj complicating acl *drug0*"
              7 : "drug0 dobj administering acl *drug0*"
            }
          4 : 
            {
              1 : "Zolpidem tissue concentrations in a multiple drug related drug1 involving drug2 . "
              2 : "The case history and toxicological findings of an infant drug1 involving drug2 , brompheniramine , and dextromethorphan are presented . "
              3 : "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with drug1 and gemcitabine producing drug2 , and simulating a progression of the tumor . "
              4 : "drug1 causing drug2 has been very rarely reported . "
              5 : "We believe this is the first report of intrathecal drug1 causing drug2 . "
              6 : "drug1 complicating long-term drug2 and 5-fluorouracil therapy for gastric carcinoma . "
              7 : "Case report : drug1 after administering intravenous drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
              7 : 1
            }
        }
      107 : 
        {
          1 : "NN conj NN nmod VBN acl NN nsubj NN"
          2 : 6
          3 : 
            {
              1 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj drug0"
              2 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj drug0"
              3 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( SR ) , trade named Rapammune ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , hypertension , hyperlipidemia , and drug2 . "
              2 : "drug1 ( SR ) , trade named Rapammune ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , hypertension , drug2 , and infection . "
              3 : "drug1 ( SR ) , trade named Rapammune ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , drug2 , hyperlipidemia , and infection . "
            }
          5 : 
            {
              1 : 2
              2 : 2
              3 : 2
            }
        }
      108 : 
        {
          1 : "NN conj NN nmod VBN nsubjpass NN compound NN"
          2 : 6
          3 : 
            {
              1 : "drug0 conj upset nmod *characterized* nsubjpass overdose compound drug0"
              2 : "drug0 conj appearance nmod *characterized* nsubjpass syndrome compound drug0"
              3 : "drug0 conj deafness nmod *complicated* nsubjpass therapy compound drug0"
              4 : "drug0 conj upset nmod *characterized* nsubjpass overdose compound drug0"
              5 : "drug0 conj deafness nmod *complicated* nsubjpass therapy compound drug0"
              6 : "drug0 conj appearance nmod *characterized* nsubjpass syndrome compound drug0"
            }
          4 : 
            {
              1 : "drug1 overdose is usually characterized by GI upset , dizziness , and drug2 . "
              2 : "The fetal drug1 syndrome ( FVS ) is characterized by distinctive facial appearance , drug2 , and developmental delay . "
              3 : "We describe a patient with a liver abscess due to Entamoeba histolytica , in whom drug1 therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and drug2 and who relapsed 5 months later with a splenic abscess . "
              4 : "drug1 overdose is usually characterized by GI upset , drug2 , and mild sedation . "
              5 : "We describe a patient with a liver abscess due to Entamoeba histolytica , in whom drug1 therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , drug2 , and ataxia and who relapsed 5 months later with a splenic abscess . "
              6 : "The fetal drug1 syndrome ( FVS ) is characterized by distinctive facial appearance , major and minor malformations , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      109 : 
        {
          1 : "NN conj NNS nmod VBG dobj NN"
          2 : 6
          3 : 
            {
              1 : "drug0 conj infections nmod *taking* dobj drug0"
              2 : "drug0 conj infections nmod *taking* dobj drug0"
              3 : "drug0 conj infections nmod *taking* dobj drug0"
              4 : "drug0 conj infections nmod *taking* dobj drug0"
              5 : "drug0 conj infections nmod *taking* dobj drug0"
              6 : "drug0 conj infections nmod *taking* dobj drug0"
            }
          4 : 
            {
              1 : "Eleven patients developed infection requiring hospitalization while taking drug1 including : lower respiratory tract infections ( 3 ) , drug2 ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ) . "
              2 : "Eleven patients developed infection requiring hospitalization while taking drug1 including : lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable drug2 ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ) . "
              3 : "Eleven patients developed infection requiring hospitalization while taking drug1 including : lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , drug2 ( 1 ) and gastroenteritis ( 1 ) . "
              4 : "Eleven patients developed infection requiring hospitalization while taking drug1 including : lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and drug2 ( 1 ) . "
              5 : "Eleven patients developed infection requiring hospitalization while taking drug1 including : lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , drug2 ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ) . "
              6 : "Eleven patients developed infection requiring hospitalization while taking drug1 including : lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , drug2 ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      110 : 
        {
          1 : "NN dobj VBG acl NN nmod NN nmod NN"
          2 : 6
          3 : 
            {
              1 : "drug0 dobj receiving acl man nmod *involvement* nmod drug0"
              2 : "drug0 dobj taking acl arthritis nmod woman nmod *drug0*"
              3 : "drug0 dobj receiving acl patient nmod *presentation* nmod drug0"
              4 : "drug0 dobj receiving acl patient nmod *development* nmod drug0"
              5 : "drug0 dobj receiving acl patient nmod *case* nmod drug0"
              6 : "drug0 dobj receiving acl patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma , a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis , and a visceral involvement after drug1 in a man receiving drug2 . "
              2 : "drug1 with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking drug2 . "
              3 : "An unusual presentation of spontaneous drug1 in a patient receiving drug2 . "
              4 : "OBJECTIVE : To report on the possible development of drug1 in a patient receiving drug2 after clozapine was withdrawn from the treatment regimen . "
              5 : "We describe a case of drug1 , diagnosed by lung biopsy , in a patient receiving drug2 which responded to corticosteroid therapy . "
              6 : "This report highlights a case of drug-induced drug1 in a patient receiving drug2 for obsessive nocturnal thoughts and auditory disturbances . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      111 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBN nmod NN"
          2 : 6
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl treated nmod drug0"
              2 : "drug0 dobj *developed* nsubj patient acl treated nmod drug0"
              3 : "drug0 dobj *developed* nsubj man acl treated nmod drug0"
              4 : "drug0 dobj *developed* nsubj man acl treated nmod drug0"
              5 : "drug0 dobj *developed* nsubj man acl treated nmod drug0"
              6 : "drug0 dobj *developed* nsubj man acl treated nmod drug0"
            }
          4 : 
            {
              1 : "A 62-year-old woman treated with drug1 for 2 months developed drug2 with a high fever . "
              2 : "A patient with Parkinson 's disease , initially treated with drug1 and subsequently with cabergoline , developed progressive drug2 during the latter therapy . "
              3 : "A 49-year-old man with Crohn 's disease treated with drug1 and mesalamine ( 5-ASA ) developed drug2 and fever . "
              4 : "A 54-year-old man , treated with drug1 , developed drug2 . "
              5 : "CASE SUMMARY : A 39-year-old white Jewish schizophrenic man treated with drug1 developed an drug2 with a peak concentration of 4000 IU/L ( normal < 230 ) . "
              6 : "A 36-year-old man being treated with drug1 , vinblastine , and bleomycin for testicular carcinoma developed a dense drug2 , encephalopathy , and a partial nondominant parietal lobe syndrome . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      112 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD dobj NN"
          2 : 6
          3 : 
            {
              1 : "drug0 compound therapy dobj starting advcl *experienced* dobj drug0"
              2 : "drug0 compound therapy dobj receiving advcl *experienced* dobj drug0"
              3 : "drug0 compound therapy dobj commencing advcl *developed* dobj drug0"
              4 : "drug0 compound treatment dobj receiving advcl *developed* dobj drug0"
              5 : "drug0 compound therapy dobj initiating advcl *developed* dobj drug0"
              6 : "drug0 compound chemotherapy dobj receiving advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a patient who experienced drug1 shortly after starting drug2 therapy . "
              2 : "We describe 2 patients with prior amputation who experienced drug1 ( PLP ) after receiving drug2 therapy . "
              3 : "CASE REPORT : A six-year-old boy with transfusion-dependent beta-thalassaemia developed a drug1 shortly after commencing drug2 therapy . "
              4 : "However , he developed drug1 , hyperkalemia , and hyperuricemia 30 d after receiving the drug2 treatment . "
              5 : "CONCLUSION : A 26-year-old man with bipolar disorder developed drug1 three weeks after initiating drug2 therapy . "
              6 : "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed drug1 shortly after receiving drug2 and gemcitabine chemotherapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      113 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod NN nmod NN"
          2 : 6
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl woman nmod *case* nmod drug0"
              2 : "drug0 nmod treated acl:relcl man nmod *case* nmod drug0"
              3 : "drug0 nmod treated acl:relcl male nmod *case* nmod drug0"
              4 : "drug0 nmod treated acl:relcl patient nmod *case* nmod drug0"
              5 : "drug0 nmod treated acl:relcl man nmod *case* nmod drug0"
              6 : "drug0 nmod treated acl:relcl woman nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "A case of drug1 , confined into an intrauterine polypoid growth , in a woman with a history of breast cancer who was treated with adjuvant drug2 . "
              2 : "We report a case of drug1 in a 23-year-old man with Crohn 's disease who was treated with drug2 ( Pentasa ; Nisshin , Tokyo , Japan ) 3.0 g/day . "
              3 : "We report a case of drug1 in a 14-year-old male with nephrotic syndrome , who was treated with oral drug2 for 6 weeks . "
              4 : "We present the first case of drug1 and endometriosis in a postmenopausal patient who was treated with drug2 for breast cancer . "
              5 : "OBJECTIVE : To report a fatal case of drug1 in a man who was treated with oral drug2 for epididymitis . "
              6 : "We describe the development of drug1 in a woman who was treated with drug2 and review the relationship among ischemic colitis , tegaserod use , and irritable bowel syndrome . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      114 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBD dobj NN"
          2 : 6
          3 : 
            {
              1 : "drug0 nmod therapy dobj starting advcl *experienced* dobj drug0"
              2 : "drug0 nmod dosage dobj receiving advcl *developed* dobj drug0"
              3 : "drug0 nmod therapy dobj commencing advcl *developed* dobj drug0"
              4 : "drug0 nmod dose dobj receiving advcl *experienced* dobj drug0"
              5 : "drug0 nmod treatment dobj undergoing advcl *developed* dobj drug0"
              6 : "drug0 dobj *developed* advcl undergoing dobj treatment nmod drug0"
            }
          4 : 
            {
              1 : "We report 3 cases of HIV-1 infected patients who experienced symptomatic drug1 shortly after starting antiretroviral therapy including the protease inhibitor drug2 . "
              2 : "A 60 year-old woman with chronic renal failure developed acute drug1 after receiving a regular dosage of drug2 . "
              3 : "A girl with cystic fibrosis and cyclic neutropenia developed an drug1 without fever or neutrophilia 7 months after commencing therapy with drug2 . "
              4 : "I report a 35-year-old woman with occult coronary artery disease who experienced drug1 within minutes after receiving a first-time dose of subcutaneous drug2 for migraine . "
              5 : "We report a 46-yr-old woman with ovarian carcinoma who developed drug1 while undergoing treatment with drug2 and cyclophosphamide . "
              6 : "While undergoing treatment with drug1 , he developed drug2 with abdominal pain and fever . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      115 : 
        {
          1 : "NN compound NN nmod NN nmod VBN acl NN"
          2 : 6
          3 : 
            {
              1 : "drug0 compound patient nmod diverticulum nmod caused acl *drug0*"
              2 : "drug0 compound administration nmod seizure nmod associated acl *drug0*"
              3 : "drug0 compound therapy nmod week nmod developed acl *drug0*"
              4 : "drug0 compound therapy nmod termination nmod resolved acl *drug0*"
              5 : "drug0 compound inhaler nmod overuse nmod associated acl *drug0*"
              6 : "drug0 compound cream nmod application nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 caused by a Meckel 's diverticulum in a drug2 patient : is there any connection ? "
              2 : "We report a case of drug1 associated with a grand mal seizure in a 28 month-old child after intra-nasal drug2 administration for high fluid intake with nocturnal enuresis . "
              3 : "A drug1 developed in a patient during the third week of drug2 therapy . "
              4 : "In one patient the drug1 resolved after termination of the drug2 therapy ; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below-knee amputation . "
              5 : "drug1 associated with chronic overuse of an drug2 inhaler . "
              6 : "drug1 associated with dermal application of drug2 cream in a cat . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      116 : 
        {
          1 : "NN nmod NN nmod NN dep NN"
          2 : 6
          3 : 
            {
              1 : "drug0 nmod exposure nmod response dep *drug0*"
              2 : "drug0 dep zafirlukast nmod addition nmod *drug0*"
              3 : "drug0 dep *report* nmod initiation nmod drug0"
              4 : "drug0 dep *rhabdomyolysis* nmod ingestion nmod drug0"
              5 : "drug0 dep clofazimine nmod treatment nmod *drug0*"
              6 : "drug0 dep child nmod *seizure* nmod drug0"
            }
          4 : 
            {
              1 : "drug1 : variable response among monozygotic twins after in utero exposure to drug2 . "
              2 : "Recently , her serum drug1 ( 133.2 micromol/L [ 24 microg/mL ] ) shortly after the addition of zafirlukast ( drug2 , Zeneca Pharmaceuticals , Wilmington , Del ) to her regimen . "
              3 : "CASE REPORT : Soon after initiation of drug1 ( 200 mg/day ) , a 76-year-old man came to us with symptoms of visual `` shining , '' drug2 , color vision anomalies , and gradually decreased vision . "
              4 : "Severe rhabdomyolysis following massive ingestion of drug1 : drug2 with coexisting hyponatremia . "
              5 : "drug1 following the treatment of lepromatous leprosy with clofazimine ( drug2 ; Lamprene ) . "
              6 : "Seizure with drug1 in a child prescribed drug2 for nocturnal enuresis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      117 : 
        {
          1 : "NN nmod NN dep NN conj NN"
          2 : 6
          3 : 
            {
              1 : "drug0 nmod reaction dep *fever* conj drug0"
              2 : "drug0 nmod reaction dep *fever* conj drug0"
              3 : "drug0 nmod reaction dep *fever* conj drug0"
              4 : "drug0 nmod treatment dep *hemianopsia* conj drug0"
              5 : "drug0 nmod reaction dep *fever* conj drug0"
              6 : "drug0 nmod reaction dep *fever* conj drug0"
            }
          4 : 
            {
              1 : "Fever , lymphadenopathy , eosinophilia , lymphocytosis , hepatitis , and drug1 : a severe adverse reaction to drug2 . "
              2 : "Fever , lymphadenopathy , eosinophilia , lymphocytosis , drug1 , and dermatitis : a severe adverse reaction to drug2 . "
              3 : "Fever , lymphadenopathy , drug1 , lymphocytosis , hepatitis , and dermatitis : a severe adverse reaction to drug2 . "
              4 : "Transient left homonymous hemianopsia and drug1 following treatment of testicular carcinoma with drug2 , vinblastine , and bleomycin . "
              5 : "Fever , drug1 , eosinophilia , lymphocytosis , hepatitis , and dermatitis : a severe adverse reaction to drug2 . "
              6 : "Fever , lymphadenopathy , eosinophilia , drug1 , hepatitis , and dermatitis : a severe adverse reaction to drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      118 : 
        {
          1 : "NN nmod VBN acl NN appos NN"
          2 : 6
          3 : 
            {
              1 : "drug0 nmod associated acl *syndrome* appos drug0"
              2 : "drug0 nmod induced acl *tachycardia* appos drug0"
              3 : "drug0 nmod associated acl *syndrome* appos drug0"
              4 : "drug0 nmod associated acl *bevacizumab* appos drug0"
              5 : "drug0 nmod induced acl *dermatosis* appos drug0"
              6 : "drug0 nmod associated acl feature appos *drug0*"
            }
          4 : 
            {
              1 : "We report the first case of fulminant adult respiratory distress syndrome ( drug1 ) associated with drug2 ( pegIFNalpha-2a ) and ribavirin use for hepatitis C , complicated by subsequent and ultimately fatal sepsis and multiorgan failure . "
              2 : "Atypical ventricular tachycardia ( drug1 ) induced by drug2 : arrhythmia previously induced by quinidine and disopyramide . "
              3 : "OBJECTIVE : To report a case of neuroleptic malignant syndrome ( drug1 ) associated with drug2 in a schizophrenic patient and review the literature related to this condition . "
              4 : "Acute vision loss after intravitreal injection of bevacizumab ( drug1 ) associated with drug2 . "
              5 : "OBJECTIVE : To report a case of linear immunoglobulin ( Ig ) A bullous dermatosis ( drug1 ) induced by drug2 . "
              6 : "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a drug1 , a feature never previously associated with drug2 and 5-fluorouracil regimens . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      119 : 
        {
          1 : "NN nmod NN nmod VBG acl NN"
          2 : 6
          3 : 
            {
              1 : "drug0 nmod use nmod resulting acl *drug0*"
              2 : "drug0 nmod administration nmod developing acl *drug0*"
              3 : "drug0 nmod injection nmod resulting acl *drug0*"
              4 : "drug0 nmod treatment nmod resulting acl *drug0*"
              5 : "drug0 nmod treatment nmod occurring acl *drug0*"
              6 : "drug0 nmod administration nmod resulting acl *drug0*"
            }
          4 : 
            {
              1 : "PURPOSE : The aim of this study was to report on the possible development of drug1 resulting from the use of drug2 . "
              2 : "This report presents a case of drug1 developing within hours after administration of drug2 for a low-level Plasmodium falciparum malaria , which was persistent despite halofantrine therapy . "
              3 : "drug1 resulting from accidental injection of drug2 in spinal anesthesia . "
              4 : "drug1 resulting from treatment with drug2 . "
              5 : "We report a case of drug1 occurring during treatment with drug2 for cystic acne . "
              6 : "OBJECTIVE : To describe a case of severe drug1 resulting from peripheral intravenous administration of low-dose drug2 in a patient with catecholamine-resistant septic shock . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      120 : 
        {
          1 : "NN conj NN dobj VBD conj VBN dobj NN"
          2 : 6
          3 : 
            {
              1 : "drug0 conj rash dobj developed conj *prescribed* dobj drug0"
              2 : "drug0 conj rash dobj developed conj *prescribed* dobj drug0"
              3 : "drug0 conj rash dobj developed conj *prescribed* dobj drug0"
              4 : "drug0 conj rash dobj developed conj *prescribed* dobj drug0"
              5 : "drug0 conj rash dobj developed conj *prescribed* dobj drug0"
              6 : "drug0 conj rash dobj developed conj *prescribed* dobj drug0"
            }
          4 : 
            {
              1 : "The current report describes a man who was prescribed drug1 for epilepsy and subsequently developed widespread skin rash , acute kidney injury , high-grade fever , eosinophilia , drug2 , lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer . "
              2 : "The current report describes a man who was prescribed drug1 for epilepsy and subsequently developed widespread skin rash , drug2 , high-grade fever , eosinophilia , liver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer . "
              3 : "The current report describes a man who was prescribed drug1 for epilepsy and subsequently developed widespread skin rash , acute kidney injury , high-grade fever , eosinophilia , liver dysfunction , drug2 and an increase in antihuman herpesvirus-6 immunoglobulin G titer . "
              4 : "The current report describes a man who was prescribed drug1 for epilepsy and subsequently developed widespread skin rash , acute kidney injury , high-grade fever , eosinophilia , liver dysfunction , lymphadenopathy and drug2 . "
              5 : "The current report describes a man who was prescribed drug1 for epilepsy and subsequently developed widespread skin rash , acute kidney injury , drug2 , eosinophilia , liver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer . "
              6 : "The current report describes a man who was prescribed drug1 for epilepsy and subsequently developed widespread skin rash , acute kidney injury , high-grade fever , drug2 , liver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      121 : 
        {
          1 : "NN compound NN nmod NN nsubj NN"
          2 : 6
          3 : 
            {
              1 : "drug0 compound therapy nmod *reaction* nsubj drug0"
              2 : "drug0 compound therapy nmod *complication* nsubj drug0"
              3 : "drug0 compound treatment nmod *complication* nsubj drug0"
              4 : "drug0 compound administration nmod *complication* nsubj drug0"
              5 : "drug0 compound treatment nmod *complication* nsubj drug0"
              6 : "drug0 compound toxicity nmod *sign* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a rarely reported adverse drug reaction due to drug2 therapy . "
              2 : "drug1 is a well-recognized complication of drug2 therapy . "
              3 : "drug1 is a known , although rare , complication of drug2 treatment . "
              4 : "drug1 , named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove , is an uncommon complication of intravenous drug2 administration through small dorsal veins of the hands . "
              5 : "drug1 is a rare complication of drug2 treatment as a result of immune-modulating role of the drug itself . "
              6 : "drug1 is a less common sign of drug2 toxicity that may precede evidence of bone marrow suppression . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      122 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN nmod NN"
          2 : 6
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod *frequency* nmod drug0"
              2 : "drug0 nmod treated acl children nmod *occurrence* nmod drug0"
              3 : "drug0 nmod treated acl patients nmod *incidence* nmod drug0"
              4 : "drug0 nmod treated acl neonates nmod *diagnosis* nmod drug0"
              5 : "drug0 nmod treated acl patients nmod *occurrence* nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To determine the frequency of drug1 in patients treated with drug2 for rheumatoid arthritis at an arthritis referral center . "
              2 : "The occurrence of drug1 in two children treated with drug2 in our unit is unlikely to be coincidental . "
              3 : "Incidence of drug1 in pediatric cancer patients treated with drug2 . "
              4 : "We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed drug1 in neonates treated with drug2 . "
              5 : "The occurrence of severe drug1 in CLL patients treated with drug2 has been reported by several authors . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 2
              4 : 1
              5 : 1
            }
        }
      123 : 
        {
          1 : "NN compound NNS nmod VBN acl NN"
          2 : 6
          3 : 
            {
              1 : "drug0 compound injections nmod caused acl *drug0*"
              2 : "drug0 compound derivatives nmod induced acl *drug0*"
              3 : "drug0 compound wafers nmod associated acl *drug0*"
              4 : "drug0 compound analogues nmod induced acl *drug0*"
              5 : "drug0 compound tablets nmod associated acl *drug0*"
              6 : "drug0 compound irrigations nmod induced acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 caused by parasympathetic dysfunction after drug2 injections . "
              2 : "Prolonged drug1 induced by drug2 derivatives . "
              3 : "drug1 associated with drug2 wafers : two case studies . "
              4 : "drug1 induced by long-acting drug2 analogues in a patient with nonfunctional neuroendocrine tumor . "
              5 : "drug1 possibly associated with controlled-release drug2 tablets . "
              6 : "drug1 and seizures induced by intravesical drug2 irrigations . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      124 : 
        {
          1 : "NN compound NN nmod NN nmod VBN nsubjpass NN"
          2 : 6
          3 : 
            {
              1 : "drug0 compound treatment nmod period nmod *reported* nsubjpass drug0"
              2 : "drug0 compound withdrawal nmod decrease nmod *characterized* nsubjpass drug0"
              3 : "drug0 compound treatment nmod introduction nmod *observed* nsubjpass drug0"
              4 : "drug0 compound therapy nmod complication nmod *described* nsubjpass drug0"
              5 : "drug0 compound treatment nmod complication nmod *recognized* nsubjpass drug0"
              6 : "drug0 compound therapy nmod effect nmod *reported* nsubjpass drug0"
            }
          4 : 
            {
              1 : "1 . drug1 were reported in a male patient with panic disorder during the period of low-dose drug2 treatment ( mean 0.62 + / - 0.15 mg/day ) compared with during the period of high-dose period ( mean 1.08 + / - 0.28 mg/day ) . "
              2 : "drug1 is characterized by a decrease in prostate-specific antigen ( PSA ) after drug2 withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate . "
              3 : "METHODS : drug1 was observed in six severely asthmatic children after introduction of high-dose drug2 treatment ( dry powder ) . "
              4 : "drug1 has been described as a complication of drug2 therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department . "
              5 : "Acute drug1 should be recognized as a potential complication of drug2 treatment . "
              6 : "BACKGROUND : drug1 have been reported as a potential side effect of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      125 : 
        {
          1 : "NN conj NN nmod VBN conj VBD nmod NN nmod NN"
          2 : 6
          3 : 
            {
              1 : "drug0 conj confusion nmod associated conj *recurred* nmod dose nmod drug0"
              2 : "drug0 conj confusion nmod associated conj *recurred* nmod dose nmod drug0"
              3 : "drug0 conj confusion nmod associated conj *recurred* nmod dose nmod drug0"
              4 : "drug0 conj confusion nmod associated conj *recurred* nmod dose nmod drug0"
              5 : "drug0 conj confusion nmod associated conj *recurred* nmod dose nmod drug0"
              6 : "drug0 conj confusion nmod associated conj *recurred* nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "After a second dose of drug1 , these symptoms recurred and were associated with confusion , agitation , drug2 , diaphoresis , tachypnea , tachycardia , and hypertension . "
              2 : "After a second dose of drug1 , these symptoms recurred and were associated with confusion , agitation , fever , diaphoresis , drug2 , tachycardia , and hypertension . "
              3 : "After a second dose of drug1 , these symptoms recurred and were associated with confusion , drug2 , fever , diaphoresis , tachypnea , tachycardia , and hypertension . "
              4 : "After a second dose of drug1 , these symptoms recurred and were associated with confusion , agitation , fever , diaphoresis , tachypnea , tachycardia , and drug2 . "
              5 : "After a second dose of drug1 , these symptoms recurred and were associated with confusion , agitation , fever , drug2 , tachypnea , tachycardia , and hypertension . "
              6 : "After a second dose of drug1 , these symptoms recurred and were associated with confusion , agitation , fever , diaphoresis , tachypnea , drug2 , and hypertension . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      126 : 
        {
          1 : "NN conj NN nmod NN nmod NN compound NN"
          2 : 6
          3 : 
            {
              1 : "drug0 conj urticaria nmod *initiation* nmod infusion compound drug0"
              2 : "drug0 compound therapy nmod *patient* nmod infection conj drug0"
              3 : "drug0 conj necrosis nmod involvement nmod *toxicity* compound drug0"
              4 : "drug0 compound therapy nmod patient nmod *gammopathy* conj drug0"
              5 : "drug0 compound therapy nmod *pneumonitis* nmod effusion conj drug0"
              6 : "drug0 compound treatment nmod *case* nmod leucocytopenia conj drug0"
            }
          4 : 
            {
              1 : "He had an immediate hypersensitivity reaction during the initiation of the drug1 infusion with diffuse urticaria , drug2 , cough , and chest tightness . "
              2 : "We present the case of an adult Crohn 's disease patient with a parvovirus B19 infection and drug1 during long-term drug2 therapy . "
              3 : "We present a fatal case of subacute drug1 toxicity with associated diffuse brain involvement , including bilateral putaminal necrosis and drug2 with ventricular compression . "
              4 : "Monoclonal gammopathy and subsequent drug1 in a patient on chronic drug2 therapy . "
              5 : "Pneumonitis with pleural and pericardial effusion and drug1 during drug2 therapy . "
              6 : "Although adverse effects are usually mild , the author reports here a case of leucocytopenia and drug1 with drug2 treatment that required its discontinuation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      127 : 
        {
          1 : "NN nmod VBN acl:relcl NN"
          2 : 6
          3 : 
            {
              1 : "drug0 nmod induced acl:relcl *drug0*"
              2 : "drug0 nmod known acl:relcl *drug0*"
              3 : "drug0 nmod associated acl:relcl *drug0*"
              4 : "drug0 nmod treated acl:relcl *drug0*"
              5 : "drug0 nmod induced acl:relcl *drug0*"
              6 : "drug0 nmod replaced acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We describe a case of drug1 ( AA ) that was probably induced by drug2 . "
              2 : "The occurrence of neuromuscular blockade and the resulting drug1 during drug2 ( MgSO4 ) administration is well known . "
              3 : "However , follow-up revealed that drug1 when associated with drug2 had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance . "
              4 : "The drug1 seen in this patient , who was treated with drug2 , may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis . "
              5 : "CONCLUSIONS : In our reported case , a local drug1 from macrophages that was induced by the injected drug2 could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone . "
              6 : "To our knowledge this is the first report of pancytopenia due to drug1 , where the usual hypoplasia found is replaced by drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      128 : 
        {
          1 : "NN conj NN nmod NNS compound NN"
          2 : 6
          3 : 
            {
              1 : "drug0 conj ifosfamide nmod *concentrations* compound drug0"
              2 : "drug0 conj restlessness nmod *symptoms* compound drug0"
              3 : "drug0 conj restlessness nmod *symptoms* compound drug0"
              4 : "drug0 conj restlessness nmod *symptoms* compound drug0"
              5 : "drug0 conj ifosfamide nmod *concentrations* compound drug0"
              6 : "drug0 conj encephalopathy nmod *symptoms* compound drug0"
            }
          4 : 
            {
              1 : "The drug1 and plasma concentrations of ifosfamide , chloroacetaldehyde , and drug2 were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide . "
              2 : "The typical drug1 symptoms of restlessness , constant pacing , drug2 , and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia . "
              3 : "The typical drug1 symptoms of restlessness , drug2 , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia . "
              4 : "The typical drug1 symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and drug2 were indistinguishable from those of neuroleptic-induced akathisia . "
              5 : "The drug1 and plasma concentrations of ifosfamide , drug2 , and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide . "
              6 : "The principle treatment for DPD-deficient patients with severe acute 5-FU reactions is supportive care ; however , the administration of thymidine potentially may reverse severe drug1 neurologic symptoms such as encephalopathy and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
              6 : 1
            }
        }
      129 : 
        {
          1 : "NN dobj VBD nmod NNS nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 dobj *developed* nmod doses nmod drug0"
              2 : "drug0 nmod injections nmod *had* dobj drug0"
              3 : "drug0 nmod injections nmod *developed* dobj drug0"
              4 : "drug0 nmod courses nmod *developed* dobj drug0"
              5 : "drug0 dobj *developed* nmod days nmod drug0"
            }
          4 : 
            {
              1 : "On day 4 , following 3 doses of drug1 , the patient developed drug2 attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography ( CTPA ) and intercostal drainage of 1500 mL of frank blood . "
              2 : "However , 1 eye had drug1 after repeated injections of drug2 . "
              3 : "In this study , we report on three individual patients who received BTX-B and who subsequently developed drug1 after injections of drug2 at remote sites . "
              4 : "A young diamond dealer developed drug1 attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent drug2 used as part of a five-drug antiemetic regimen for cisplatin-associated nausea . "
              5 : "Following 7 days of drug1 she developed drug2 and elevated pancreatic enzymes suggesting acute pancreatitis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      130 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBD dobj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod therapy nmod months nmod *developed* dobj drug0"
              2 : "drug0 nmod treatment nmod years nmod *developed* dobj drug0"
              3 : "drug0 nmod initiation nmod days nmod *developed* dobj drug0"
              4 : "drug0 dobj *developed* nmod weeks nmod administration nmod drug0"
              5 : "drug0 dobj *developed* nmod days nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a drug1 after 9 months of therapy with drug2 and leflunomide is described . "
              2 : "A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs , developed a drug1 of the lip following 4 1/2 years of treatment with drug2 . "
              3 : "A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an drug1 within 15 days of initiation of drug2 . "
              4 : "After five and six weeks of continuous oral administration of drug1 , the boys developed drug2 . "
              5 : "After 5 days of treatment with drug1 , the patient developed a drug2 that progressed to toxic epidermal necrolysis , as well as grade 4 pancytopenia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      131 : 
        {
          1 : "NN conj NN nmod VBP nsubj NNS nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 conj diarrhea nmod *consist* nsubj effects nmod drug0"
              2 : "drug0 conj diarrhea nmod *consist* nsubj effects nmod drug0"
              3 : "drug0 conj diarrhea nmod *consist* nsubj effects nmod drug0"
              4 : "drug0 conj diarrhea nmod *consist* nsubj effects nmod drug0"
              5 : "drug0 conj diarrhea nmod *consist* nsubj effects nmod drug0"
            }
          4 : 
            {
              1 : "DISCUSSION : The main adverse effects of drug1 consist of diarrhea , nausea , liver enzyme elevation , hypertension , drug2 , and allergic skin reactions . "
              2 : "DISCUSSION : The main adverse effects of drug1 consist of diarrhea , drug2 , liver enzyme elevation , hypertension , alopecia , and allergic skin reactions . "
              3 : "DISCUSSION : The main adverse effects of drug1 consist of diarrhea , nausea , liver enzyme elevation , drug2 , alopecia , and allergic skin reactions . "
              4 : "DISCUSSION : The main adverse effects of drug1 consist of diarrhea , nausea , liver enzyme elevation , hypertension , alopecia , and drug2 . "
              5 : "DISCUSSION : The main adverse effects of drug1 consist of diarrhea , nausea , drug2 , hypertension , alopecia , and allergic skin reactions . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      132 : 
        {
          1 : "NN nmod NN nmod VB nsubj NN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod risk nmod *place* nsubj administration nmod drug0"
              2 : "drug0 nmod cause nmod *acknowledge* nsubj use nmod drug0"
              3 : "drug0 nmod development nmod *lead* nsubj administration nmod drug0"
              4 : "drug0 nmod incidence nsubj *increase* nmod use nmod drug0"
              5 : "drug0 nmod risk nmod *place* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "Concomitant administration of lithium with drug1 may place patients at risk for drug2 . "
              2 : "The uncomplicated long-term use of adequately-dosed drug1 and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the drug2 . "
              3 : "Administration of drug1 , especially in combination with valproic acid , may lead to the development of drug2 . "
              4 : "With the increasing use of drug1 in transplant patients , the incidence of drug2 may increase . "
              5 : "Concomitant administration of drug1 with olanzapine may place patients at risk for drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      133 : 
        {
          1 : "NN nmod NN conj NN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod development conj *use* nmod drug0"
              2 : "drug0 nmod development conj *use* nmod drug0"
              3 : "drug0 nmod development conj *exposure* nmod drug0"
              4 : "drug0 nmod treatment conj trabeculectomy nmod *drug0*"
              5 : "drug0 nmod development conj *use* nmod drug0"
            }
          4 : 
            {
              1 : "An apparent link is described between the use of drug1 with prednisone to treat pemphigus vulgaris and the development of drug2 . "
              2 : "An apparent link is described between the use of MMF with drug1 to treat pemphigus vulgaris and the development of drug2 . "
              3 : "Although an association between exposure to drug1 and the development of drug2 has been suspected , few cases are reported . "
              4 : "drug1 following trabeculectomy and treatment with drug2 . "
              5 : "Physicians should be aware of the possible association between the use of drug1 and the development of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      134 : 
        {
          1 : "NN nmod NN nmod NN acl VBN nmod NN acl:relcl VBD dobj NN conj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod initiation nmod *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
              2 : "drug0 nmod initiation nmod *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
              3 : "drug0 nmod initiation nmod *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
              4 : "drug0 nmod initiation nmod *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
              5 : "drug0 nmod initiation nmod *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , drug1 , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of drug2 , and all symptoms and signs resolved following discontinuation of fentanyl . "
              2 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , drug1 , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of drug2 , and all symptoms and signs resolved following discontinuation of fentanyl . "
              3 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , tremors , myoclonic jerks and drug1 , consistent with serotonin syndrome , following initiation of drug2 , and all symptoms and signs resolved following discontinuation of fentanyl . "
              4 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , tremors , drug1 and unsteady gait , consistent with serotonin syndrome , following initiation of drug2 , and all symptoms and signs resolved following discontinuation of fentanyl . "
              5 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , drug1 , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of drug2 , and all symptoms and signs resolved following discontinuation of fentanyl . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      135 : 
        {
          1 : "NN conj NN nmod JJ amod NNS compound NN"
          2 : 5
          3 : 
            {
              1 : "drug0 conj etoposide nmod postchemotherapy amod *months* compound drug0"
              2 : "drug0 conj etoposide nmod postchemotherapy amod *months* compound drug0"
              3 : "drug0 conj etoposide nmod postchemotherapy amod *months* compound drug0"
              4 : "drug0 conj etoposide nmod postchemotherapy amod *months* compound drug0"
              5 : "drug0 conj etoposide nmod postchemotherapy amod *months* compound drug0"
            }
          4 : 
            {
              1 : "Herein , we describe a patient with AIDS who presented to medical attention with drug1 48 months postchemotherapy with etoposide , drug2 , vincristine , cyclophosphamide , doxorubicin , and rituximab ( R-EPOCH ) for diffuse large B-cell lymphoma . "
              2 : "Herein , we describe a patient with AIDS who presented to medical attention with drug1 48 months postchemotherapy with etoposide , prednisone , vincristine , cyclophosphamide , drug2 , and rituximab ( R-EPOCH ) for diffuse large B-cell lymphoma . "
              3 : "Herein , we describe a patient with AIDS who presented to medical attention with drug1 48 months postchemotherapy with etoposide , prednisone , vincristine , drug2 , doxorubicin , and rituximab ( R-EPOCH ) for diffuse large B-cell lymphoma . "
              4 : "Herein , we describe a patient with AIDS who presented to medical attention with drug1 48 months postchemotherapy with etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin , and drug2 ( R-EPOCH ) for diffuse large B-cell lymphoma . "
              5 : "Herein , we describe a patient with AIDS who presented to medical attention with drug1 48 months postchemotherapy with etoposide , prednisone , drug2 , cyclophosphamide , doxorubicin , and rituximab ( R-EPOCH ) for diffuse large B-cell lymphoma . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      136 : 
        {
          1 : "NN appos NN nmod NN nsubj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 appos interferon-alpha nmod *side-effect* nsubj drug0"
              2 : "drug0 appos disease nmod *cause* nsubj drug0"
              3 : "drug0 appos propylthiouracil nmod *complication* nsubj drug0"
              4 : "drug0 appos administration nmod *complication* nsubj drug0"
              5 : "drug0 appos syndrome nmod *factor* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a common side-effect of interferon-alpha ( drug2 ) treatment of viral hepatitis C . "
              2 : "INTRODUCTION : Although drug1 used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease ( drug2 ) , few case reports on erlotinib-induced ILD have been issued . "
              3 : "drug1 is a rare and potentially lethal complication of propylthiouracil ( drug2 ) use for hyperthyroidism . "
              4 : "drug1 is an infrequent complication following administration of the angiotensin-converting enzyme ( ACE ) inhibitor , drug2 . "
              5 : "drug1 is a known risk factor for hemolytic uremic syndrome ( drug2 ) , which can often have a rapidly fatal clinical course despite intervention with steroids , plasmapheresis and hemodialysis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      137 : 
        {
          1 : "NN nmod NN nmod VB nsubj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod initiation nmod *occur* nsubj drug0"
              2 : "drug0 nmod use nmod *develop* nsubj drug0"
              3 : "drug0 nsubj *develop* nmod injection nmod drug0"
              4 : "drug0 nmod healing nmod *interfere* nsubj drug0"
              5 : "drug0 nmod treatment nmod *result* nsubj drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware that drug1 can occur after initiation of drug2 . "
              2 : "Our findings suggest that drug1 can develop with the use of low-dose drug2 , within seven days of initiating heparin therapy , and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication . "
              3 : "After intravitreal injection of drug1 , drug2 may rapidly develop in eyes that have been intensively treated , topically and systemically , by corticosteroids for several years . "
              4 : "CONCLUSION : These cases suggest that drug1 may interfere with the healing of drug2 . "
              5 : "These observations indicate that drug1 may result from treatment with drug2 and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      138 : 
        {
          1 : "NN nmod NNS nmod NN nmod NN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod patients nmod *use* nmod dosage nmod drug0"
              2 : "drug0 nmod implication nmod *review* nmod cases nmod drug0"
              3 : "drug0 nmod administration nmod result nmod *reports* nmod drug0"
              4 : "drug0 nmod administration nmod *woman* nmod episodes nmod drug0"
              5 : "drug0 nmod injection nmod *literature* nmod cases nmod drug0"
            }
          4 : 
            {
              1 : "How low can you go ? Use of very low dosage of drug1 in patients with drug2 . "
              2 : "DISCUSSION : A review of the cases of drug1 with implication of drug2 as the cause was performed . "
              3 : "Reports of drug1 as a result of the administration of drug2 and sorbitol are rare . "
              4 : "We introduce a case of a sixty years old woman with several previous episodes of drug1 , conjunctivitis and perspiration immediately after the administration of salmon drug2 with nasal spray or intramuscular administration ( Calsynar ) . "
              5 : "We review the literature on previously reported cases of drug1 after injection of standard drug2 or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      139 : 
        {
          1 : "NN conj NNS dobj VBD nsubj NNS nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 conj transaminases dobj *included* nsubj effects nmod drug0"
              2 : "drug0 conj transaminases dobj *included* nsubj effects nmod drug0"
              3 : "drug0 conj transaminases dobj *included* nsubj effects nmod drug0"
              4 : "drug0 conj transaminases dobj *included* nsubj effects nmod drug0"
              5 : "drug0 conj transaminases dobj *included* nsubj effects nmod drug0"
            }
          4 : 
            {
              1 : "The toxic effects of drug1 included elevated liver transaminases ( 3/4 ) , nausea ( 2/4 ) , abdominal pain ( 2/4 ) , bone pain ( 2/4 ) , mild neutropenia ( 1/4 ) , and drug2 ( 1/4 ) . "
              2 : "The toxic effects of drug1 included elevated liver transaminases ( 3/4 ) , nausea ( 2/4 ) , drug2 ( 2/4 ) , bone pain ( 2/4 ) , mild neutropenia ( 1/4 ) , and mild pruritus ( 1/4 ) . "
              3 : "The toxic effects of drug1 included elevated liver transaminases ( 3/4 ) , nausea ( 2/4 ) , abdominal pain ( 2/4 ) , bone pain ( 2/4 ) , drug2 ( 1/4 ) , and mild pruritus ( 1/4 ) . "
              4 : "The toxic effects of drug1 included elevated liver transaminases ( 3/4 ) , drug2 ( 2/4 ) , abdominal pain ( 2/4 ) , bone pain ( 2/4 ) , mild neutropenia ( 1/4 ) , and mild pruritus ( 1/4 ) . "
              5 : "The toxic effects of drug1 included elevated liver transaminases ( 3/4 ) , nausea ( 2/4 ) , abdominal pain ( 2/4 ) , drug2 ( 2/4 ) , mild neutropenia ( 1/4 ) , and mild pruritus ( 1/4 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      140 : 
        {
          1 : "NN conj NN dep NNS dobj VBD nsubj NNS nmod NN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 conj deficiency dep manifestations dobj *shared* nsubj cases nmod exposure nmod drug0"
              2 : "drug0 conj deficiency dep manifestations dobj *shared* nsubj cases nmod exposure nmod drug0"
              3 : "drug0 conj deficiency dep manifestations dobj *shared* nsubj cases nmod exposure nmod drug0"
              4 : "drug0 conj deficiency dep manifestations dobj *shared* nsubj cases nmod exposure nmod drug0"
              5 : "drug0 conj deficiency dep manifestations dobj *shared* nsubj cases nmod exposure nmod drug0"
            }
          4 : 
            {
              1 : "The reported cases of in utero exposure to drug1 shared the following manifestations with our patient : growth deficiency , developmental delay , craniosynostosis , drug2 , flat nasal bridge , abnormal ears , and distal limb defects including hypoplastic thumbs and oligodactyly . "
              2 : "The reported cases of in utero exposure to drug1 shared the following manifestations with our patient : growth deficiency , drug2 , craniosynostosis , blepharophimosis , flat nasal bridge , abnormal ears , and distal limb defects including hypoplastic thumbs and oligodactyly . "
              3 : "The reported cases of in utero exposure to drug1 shared the following manifestations with our patient : growth deficiency , developmental delay , craniosynostosis , blepharophimosis , drug2 , abnormal ears , and distal limb defects including hypoplastic thumbs and oligodactyly . "
              4 : "The reported cases of in utero exposure to drug1 shared the following manifestations with our patient : growth deficiency , developmental delay , drug2 , blepharophimosis , flat nasal bridge , abnormal ears , and distal limb defects including hypoplastic thumbs and oligodactyly . "
              5 : "The reported cases of in utero exposure to drug1 shared the following manifestations with our patient : growth deficiency , developmental delay , craniosynostosis , blepharophimosis , flat nasal bridge , abnormal ears , and drug2 including hypoplastic thumbs and oligodactyly . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      141 : 
        {
          1 : "NN appos NN nmod NN nmod VBD dobj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 appos phosphate nmod administration nmod *developed* dobj drug0"
              2 : "drug0 dobj *developed* nmod introduction nmod sulphasalazine appos drug0"
              3 : "drug0 appos beta-blocker nmod treatment nmod *developed* dobj drug0"
              4 : "drug0 appos benzalkonium nmod solution nmod *sustained* dobj drug0"
              5 : "drug0 appos methotrexate nmod cycle nmod *presented* dobj drug0"
            }
          4 : 
            {
              1 : "A 57-year-old woman with right bundle branch block + LPH and ventricular premature contractions developed drug1 ( CHB ) following administration of disopyramide phosphate ( drug2 ) . "
              2 : "Presented is a case story of a woman with classical rheumatoid arthritis , who during introduction of sulphasalazine ( drug1 ) therapy developed a severe and lasting drug2 . "
              3 : "We report on a patient who developed drug1 during treatment with the beta-blocker , drug2 . "
              4 : "Infant twins sustained severe drug1 from a concentrated solution of benzalkonium ( drug2 ) chloride prescribed for treatment of candidiasis . "
              5 : "We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented drug1 following the second cycle of high-dose methotrexate ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      142 : 
        {
          1 : "NN compound NN conj NN nmod VBN acl NN"
          2 : 5
          3 : 
            {
              1 : "drug0 compound treatment conj alpha-0b nmod provoked acl *drug0*"
              2 : "drug0 compound therapy conj interferon nmod associated acl *drug0*"
              3 : "drug0 compound therapy conj infliximab nmod associated acl *drug0*"
              4 : "drug0 compound use conj alpha-0a nmod associated acl *drug0*"
              5 : "drug0 compound chemotherapy conj 0-fluorouracil nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 provoked by peginterferon alpha-2b plus drug2 treatment for chronic hepatitis C . "
              2 : "BACKGROUND : To assess the nature , incidence , and risk factors of drug1 associated with pegylated interferon and drug2 combination therapy in chronic hepatitis C patients . "
              3 : "drug1 associated with infliximab and drug2 combination therapy in a child with psoriatic arthritis . "
              4 : "We report the first case of fulminant drug1 ( ARDS ) associated with pegylated interferon alpha-2a ( pegIFNalpha-2a ) and drug2 use for hepatitis C , complicated by subsequent and ultimately fatal sepsis and multiorgan failure . "
              5 : "drug1 associated with 5-fluorouracil and drug2 combined chemotherapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      143 : 
        {
          1 : "NN nmod VB nsubj NN compound NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod *result* nsubj therapy compound drug0"
              2 : "drug0 nmod *result* nsubj overdose compound drug0"
              3 : "drug0 nmod *result* nsubj overdose compound drug0"
              4 : "drug0 nmod *result* nsubj overdose compound drug0"
              5 : "drug0 nmod *result* nsubj poisoning compound drug0"
            }
          4 : 
            {
              1 : "drug1 therapy may result in drug2 that leak renal tubular antigens , which in turn complex with autoantibody and produce an autoimmune membranous nephropathy . "
              2 : "Inadvertent and accidental drug1 overdose might result in potentially drug2 . "
              3 : "CONCLUSIONS : drug1 overdose may result in a severe but reversible drug2 , a previously undescribed phenomenon . "
              4 : "drug1 overdose can rapidly result in profound drug2 , and is associated with a relatively high mortality . "
              5 : "PURPOSE : To report that acute drug1 poisoning may result in severe drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      144 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN compound NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod intoxication nmod *terminated* nsubjpass treatment compound drug0"
              2 : "drug0 nmod compliance nmod *discontinued* nsubjpass therapy compound drug0"
              3 : "drug0 nmod presentation nmod *associated* nsubjpass use compound drug0"
              4 : "drug0 nmod risk nmod *associated* nsubjpass dependency compound drug0"
              5 : "drug0 nmod recurrence nmod *followed* nsubjpass treatment compound drug0"
            }
          4 : 
            {
              1 : "drug1 treatment was terminated in 1975 because of lithium intoxication with a drug2 . "
              2 : "drug1 therapy was discontinued because of poor compliance to the medication and intolerable drug2 . "
              3 : "drug1 use by pregnant women can be associated with a later presentation of drug2 in the neonate than that induced by the use of other drugs . "
              4 : "However , drug1 dependency is associated with the risk of drug2 . "
              5 : "We report the case of a 51-year-old man in whom drug1 treatment was followed by recurrence of drug2 10 years after thyroidectomy was performed and the patient was declared cured . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      145 : 
        {
          1 : "VB xcomp JJ amod NN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 xcomp due amod *case* nmod drug0"
              2 : "drug0 xcomp due amod *case* nmod drug0"
              3 : "drug0 xcomp due amod *case* nmod drug0"
              4 : "drug0 xcomp related amod *case* nmod drug0"
              5 : "drug0 xcomp due amod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 due to drug2 in Tathion eye drops . "
              2 : "A case of drug1 due to drug2 in an ophthalmic solution . "
              3 : "This report describes a case of drug1 due to drug2 in a child with Joubert syndrome . "
              4 : "We describe a case of drug1 probably related to drug2 in a patient with the LEOPARD syndrome , a rare congenital disorder . "
              5 : "We report a case of severe drug1 due to drug2 salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      146 : 
        {
          1 : "NN nmod NN nmod VBN acl NNS conj NN acl VBN nmod NN acl:relcl VBD dobj NN conj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod resolved acl symptoms conj *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
              2 : "drug0 nmod discontinuation nmod resolved acl symptoms conj *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
              3 : "drug0 nmod discontinuation nmod resolved acl symptoms conj *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
              4 : "drug0 nmod discontinuation nmod resolved acl symptoms conj *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
              5 : "drug0 nmod discontinuation nmod resolved acl symptoms conj *patient* acl treated nmod inhibitor acl:relcl developed dobj confusion conj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , drug1 , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of drug2 . "
              2 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , tremors , drug1 and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of drug2 . "
              3 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , drug1 , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of drug2 . "
              4 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , tremors , myoclonic jerks and drug1 , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of drug2 . "
              5 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , drug1 , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      147 : 
        {
          1 : "NN nmod VBD nsubj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod *triggered* nsubj drug0"
              2 : "drug0 nmod *resulted* nsubj drug0"
              3 : "drug0 nmod *contributed* nsubj drug0"
              4 : "drug0 nmod *contributed* nsubj drug0"
              5 : "drug0 nmod *led* nsubj drug0"
            }
          4 : 
            {
              1 : "These data indicated that drug1 possibly triggered production of granulocyte and neutrophil autoantibodies with resultant drug2 . "
              2 : "PURPOSE : To report two cases in which topical drug1 resulted in apparent drug2 and unresponsiveness in an infant . "
              3 : "CONCLUSIONS : It is probable that drug1 contributed to the drug2 and symptomatology in this patient . "
              4 : "It is likely that drug1 contributed to the drug2 in these patients . "
              5 : "CONCLUSION : drug1 led to drug2 and rechallenge caused recurrence of scleritis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      148 : 
        {
          1 : "NN compound NN nmod NNS nmod NN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 compound retinopathy nmod cases nmod *course* nmod drug0"
              2 : "drug0 compound therapy nmod *recommendations* nmod evaluation nmod drug0"
              3 : "drug0 compound therapy nmod patients nmod *hepatitis* nmod drug0"
              4 : "drug0 compound therapy nmod *instances* nmod progression nmod drug0"
              5 : "drug0 nmod occurrence nmod *effects* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Clinical course of drug1 in two cases of drug2 retinopathy observed by optical coherence tomography . "
              2 : "Controversy concerning the nephrotoxicity of lithium is discussed , and recommendations for the evaluation of drug1 during drug2 therapy are provided . "
              3 : "Fulminant hepatitis with drug1 in HIV-infected patients on drug2 therapy . "
              4 : "In addition to disease refractoriness , rare instances of disease progression from chronic phase to drug1 during drug2 therapy have recently been anecdotally reported . "
              5 : "Ophthalmologists should be aware of the ocular side effects of drug1 therapy and carefully monitor patients for the possible occurrence of drug2 and thrombocytopenia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      149 : 
        {
          1 : "NN nmod VB dobj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod *receive* dobj drug0"
              2 : "drug0 nmod *describe* dobj drug0"
              3 : "drug0 nmod *attribute* dobj drug0"
              4 : "drug0 nmod *confirm* dobj drug0"
              5 : "drug0 nmod *cause* dobj drug0"
            }
          4 : 
            {
              1 : "She continued to receive regular drug1 4 times per day over the following 3 years with only occasional drug2 . "
              2 : "PURPOSE : To describe drug1 in a patient with vascular age-related macular degeneration ( AMD ) , following an intravitreal drug2 . "
              3 : "Although it is difficult to solely attribute drug1 to drug2 , we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma . "
              4 : "He was later skin tested to confirm drug1 to drug2 . "
              5 : "Thus cabergoline may cause similar drug1 to drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      150 : 
        {
          1 : "NN nmod NNS dobj VB acl JJ nmod VBN nsubjpass NNS dep NN conj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              2 : "drug0 nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              3 : "drug0 nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              4 : "drug0 nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
              5 : "drug0 nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep levofloxacin conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , drug1 , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including drug2 , dizziness and insomnia . "
              2 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , drug1 , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including drug2 , dizziness and insomnia . "
              3 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , drug1 , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including drug2 , dizziness and insomnia . "
              4 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and drug1 ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including drug2 , dizziness and insomnia . "
              5 : "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , drug1 and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including drug2 , dizziness and insomnia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      151 : 
        {
          1 : " NN nmod NNS nmod NN nmod NN conj NN"
          2 : 5
          3 : 
            {
              1 : " *drug0* nmod days nmod treatment nmod roxithromycin conj drug0"
              2 : "drug0 conj cisplatin nmod chemotherapy nmod *episodes* nmod drug0"
              3 : "drug0 conj spine nmod decrease nmod *effects* nmod drug0"
              4 : "drug0 conj cisplatin nmod chemotherapy nmod *episodes* nmod drug0"
              5 : "drug0 conj peginterferon nmod treatment nmod weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "CASE REPORT : We report the case of a 58 year old patient who , after 2 days of treatment with roxithromycin and drug1 , manifested drug2 . "
              2 : "A 31-year-old female developed multiple episodes of drug1 after combination chemotherapy with cisplatin , vinblastine and drug2 for germ cell ovarian cancer stage Ic . "
              3 : "There are major side effects of drug1 including decrease in both lumbar spine and total hip bone mineral density , drug2 ( especially fractures of spine , hip and wrist ) , joint disorders and increase in the cholesterol level . "
              4 : "A 31-year-old female developed multiple episodes of drug1 after combination chemotherapy with cisplatin , drug2 and bleomycin for germ cell ovarian cancer stage Ic . "
              5 : "A 51-year-old man developed drug1 following 24 weeks of treatment with recombinant alpha-2b peginterferon plus drug2 for chronic hepatitis C . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      152 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN conj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod treatment nmod *reported* nsubjpass hypersensitivity conj drug0"
              2 : "drug0 nmod treatment nmod *detected* nsubjpass tumor conj drug0"
              3 : "drug0 nmod treatment nmod *detected* nsubjpass tumor conj drug0"
              4 : "drug0 conj increase nsubjpass *observed* nmod addition nmod drug0"
              5 : "drug0 nmod administration nmod *caused* nsubjpass ulcer conj drug0"
            }
          4 : 
            {
              1 : "Cardiac hypersensitivity and drug1 have been reported during long-term treatment with drug2 . "
              2 : "Gastric tumor , endometrial carcinoma and drug1 in situ were detected after treatment with drug2 for breast cancer . "
              3 : "Gastric tumor , drug1 and cervical adenocarcinoma in situ were detected after treatment with drug2 for breast cancer . "
              4 : "After the addition of drug1 , a desmethylclomipramine plasma level increase and an drug2 were observed . "
              5 : "We concluded that the colonic ulcer and the drug1 had been caused by the administration of drug2 and sorbitol . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      153 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 conj carboplatin nmod treated acl patient nmod *drug0*"
              2 : "drug0 conj bicalutamide nmod induced acl *recovery* nmod drug0"
              3 : "drug0 conj vitrectomy nmod treated acl endophthalmitis nmod *drug0*"
              4 : "drug0 conj methylprednisolone nmod treated acl asthmaticus nmod *drug0*"
              5 : "drug0 conj bullae nmod presented acl arthritis nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in an advanced ovarian cancer patient treated with carboplatin and drug2 . "
              2 : "Successful recovery from drug1 , induced by bicalutamide and drug2 given as treatment for prostate cancer . "
              3 : "drug1 after endophthalmitis treated with vitrectomy and intravitreal drug2 . "
              4 : "drug1 with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and drug2 . "
              5 : "RESULTS : A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on drug1 for rheumatoid arthritis presented with tense bullae and drug2 on the face and the back of the hands . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      154 : 
        {
          1 : "NN nmod VB nsubj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod *result* nsubj drug0"
              2 : "drug0 nmod *occur* nsubj drug0"
              3 : "drug0 nmod *lead* nsubj drug0"
              4 : "drug0 nmod *occur* nsubj drug0"
              5 : "drug0 nmod *produce* nsubj drug0"
            }
          4 : 
            {
              1 : "It is well-recognized that drug1 may occasionally result in drug2 . "
              2 : "These features have not previously been reported as side effects of glibenclamide therapy , but drug1 may occur with drug2 , a similar sulphonylurea agent . "
              3 : "Used injudiciously , drug1 can lead to drug2 , return of severe pain , and other adverse effects . "
              4 : "This report suggests that drug1 can occur due to drug2 , in particular when it is given with prednisone , a side effect well documented in the transplantation literature when the triple combination of MMF , cyclosporine and prednisone is used . "
              5 : "We postulate that drug1 , possibly together with ganciclovir , can produce transient brain stem or neuromuscular dysfunction with drug2 in occasional patients . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      155 : 
        {
          1 : "NN conj NN appos NN nmod VBD ccomp VBD nsubj NN compound NN"
          2 : 5
          3 : 
            {
              1 : "drug0 conj rash appos fever nmod consisted ccomp *developed* nsubj reaction compound drug0"
              2 : "drug0 conj rash appos fever nmod consisted ccomp *developed* nsubj reaction compound drug0"
              3 : "drug0 conj rash appos fever nmod consisted ccomp *developed* nsubj reaction compound drug0"
              4 : "drug0 conj rash appos fever nmod consisted ccomp *developed* nsubj reaction compound drug0"
              5 : "drug0 conj rash appos fever nmod consisted ccomp *developed* nsubj reaction compound drug0"
            }
          4 : 
            {
              1 : "A child in whom a drug1 hypersensitivity drug reaction developed which consisted of fever , a pruritic desquamating erythrodermic rash , alopecia , icterus , drug2 , myositis , and nephritis , is described . "
              2 : "A child in whom a drug1 hypersensitivity drug reaction developed which consisted of fever , a pruritic desquamating erythrodermic rash , alopecia , icterus , protein-losing enteropathy , drug2 , and nephritis , is described . "
              3 : "A child in whom a drug1 hypersensitivity drug reaction developed which consisted of fever , a pruritic desquamating erythrodermic rash , alopecia , drug2 , protein-losing enteropathy , myositis , and nephritis , is described . "
              4 : "A child in whom a drug1 hypersensitivity drug reaction developed which consisted of fever , a pruritic desquamating erythrodermic rash , alopecia , icterus , protein-losing enteropathy , myositis , and drug2 , is described . "
              5 : "A child in whom a drug1 hypersensitivity drug reaction developed which consisted of fever , a pruritic desquamating erythrodermic rash , drug2 , icterus , protein-losing enteropathy , myositis , and nephritis , is described . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      156 : 
        {
          1 : "NN nsubjpass VBN advcl VBD nsubj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nsubjpass discontinued advcl *disappeared* nsubj drug0"
              2 : "drug0 nsubj developed advcl *administered* nsubjpass drug0"
              3 : "drug0 nsubj *vanished* advcl withdrawn nsubjpass drug0"
              4 : "drug0 nsubjpass discontinued advcl *regressed* nsubj drug0"
              5 : "drug0 nsubj *ceased* advcl reduced nsubjpass drug0"
            }
          4 : 
            {
              1 : "The drug1 disappeared after drug2 was discontinued . "
              2 : "To treat hepatitis B , drug1 was administered until the proximal drug2 developed . "
              3 : "When drug1 was withdrawn , drug2 vanished and the child remained symptom-free . "
              4 : "The drug1 regressed when the drug2 was discontinued . "
              5 : "When the drug1 was reduced , the drug2 promptly ceased . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      157 : 
        {
          1 : "NN dobj VBD nmod NNS dep NN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 dobj *experienced* nmod days dep initiation nmod drug0"
              2 : "drug0 nmod cessation dep weeks nmod *developed* dobj drug0"
              3 : "drug0 nmod thrombolysis dep hours nmod *developed* dobj drug0"
              4 : "drug0 nmod treatment dep days nmod *developed* dobj drug0"
              5 : "drug0 nmod administration dep days nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Eleven days after initiation of therapy with drug1 , the patient experienced drug2 and was noted to have recurrent episodes of polymorphous ventricular tachycardia . "
              2 : "An adolescent male developed drug1 and pseudocyst of the pancreas 16 weeks after cessation of intramuscular drug2 . "
              3 : "A 58-year old patient is reported who developed an drug1 22 hours after successful thrombolysis with drug2 for life-threatening pulmonary emboli . "
              4 : "A rare case of advanced ovarian carcinoma who developed drug1 25 days after treatment with weekly drug2 . "
              5 : "A twelve year-old-girl with idiopathic partial epilepsy with secondary generalization , developed drug1 10 days after the administration of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      158 : 
        {
          1 : "NN nmod NN nmod NN nsubj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod treatment nmod *effect* nsubj drug0"
              2 : "drug0 nmod conjunction nmod *phenomenon* nsubj drug0"
              3 : "drug0 nmod effect nmod *result* nsubj drug0"
              4 : "drug0 nmod administration nmod *complication* nsubj drug0"
              5 : "drug0 nmod treatment nmod *effect* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 are a major adverse effect during the treatment with drug2 . "
              2 : "CONCLUSIONS : drug1 is a rare phenomenon in conjunction with drug2 but should be considered in cases of acute respiratory distress following commencement of LMWH . "
              3 : "These findings suggest that the drug1 are the result of a toxic effect of drug2 when used in the doses and duration described . "
              4 : "drug1 is a rare complication following the administration of intravenous drug2 ( IVIG ) . "
              5 : "drug1 is a serious side effect of antiemetic treatment with drug2 and this serious complication should be incorporated in the current guidelines . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      159 : 
        {
          1 : "NN compound NN nmod VBD dobj NNS nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 compound treatment nmod *observed* dobj cases nmod drug0"
              2 : "drug0 nmod symptoms dobj *developed* nmod coadministration compound drug0"
              3 : "drug0 compound therapy nmod *developed* dobj episodes nmod drug0"
              4 : "drug0 compound therapy nmod *had* dobj episodes nmod drug0"
              5 : "drug0 compound exposure nmod *developed* dobj symptoms nmod drug0"
            }
          4 : 
            {
              1 : "We observed 2 cases of drug1 after a high-dose drug2 treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence . "
              2 : "During drug1 coadministration , four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine , such as drug2 , dizziness , and ataxia , which resolved within 5 days after clarithromycin discontinuation . "
              3 : "Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of drug1 during maintenance drug2 therapy . "
              4 : "A 73-year-old woman with non-Hodgkin 's lymphoma had two episodes of severe , bilateral , drug1 after drug2 therapy . "
              5 : "RESULTS : Three patients who developed symptoms of drug1 ( IBD ) during drug2 exposure are described along with pathology findings . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      160 : 
        {
          1 : "NN conj NN dobj VB nsubj NNS acl VBN nmod NN"
          2 : 5
          3 : 
            {
              1 : "drug0 conj agitation dobj *include* nsubj effects acl associated nmod drug0"
              2 : "drug0 conj agitation dobj *include* nsubj effects acl associated nmod drug0"
              3 : "drug0 conj agitation dobj *include* nsubj effects acl associated nmod drug0"
              4 : "drug0 conj agitation dobj *include* nsubj effects acl associated nmod drug0"
              5 : "drug0 conj agitation dobj *include* nsubj effects acl associated nmod drug0"
            }
          4 : 
            {
              1 : "Behavioral side effects associated with drug1 may include agitation , aggression , hyperactivity , irritability , property destruction , and drug2 . "
              2 : "Behavioral side effects associated with drug1 may include agitation , aggression , hyperactivity , drug2 , property destruction , and temper tantrums . "
              3 : "Behavioral side effects associated with drug1 may include agitation , drug2 , hyperactivity , irritability , property destruction , and temper tantrums . "
              4 : "Behavioral side effects associated with drug1 may include agitation , aggression , hyperactivity , irritability , drug2 , and temper tantrums . "
              5 : "Behavioral side effects associated with drug1 may include agitation , aggression , drug2 , irritability , property destruction , and temper tantrums . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      161 : 
        {
          1 : "NN nmod NN nsubj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 nmod *drug-trigger* nsubj drug0"
              2 : "drug0 nmod *effect* nsubj drug0"
              3 : "drug0 nmod *effect* nsubj drug0"
              4 : "drug0 nmod *cause* nsubj drug0"
              5 : "drug0 nmod *cause* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 are the best verified drug-trigger for drug2 and Stevens-Johnson syndrome . "
              2 : "drug1 can be a serious side effect of drug2 in patients already on antidiabetic medications known to cause hypoglycemia , such as sulfonylureas , meglitinides , and insulin . "
              3 : "CONCLUSIONS : Clinicians should be aware that drug1 is a potential novel adverse drug effect of drug2 . "
              4 : "This case suggests that drug1 , a derivative of cytosine arabinoside ( 1-beta-D-arabinofuranosylcytosine ) could be a cause of reversible drug2 . "
              5 : "drug1 is a rare cause of drug2 , and few cases have been reported . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
              5 : 1
            }
        }
      162 : 
        {
          1 : "NN compound NN conj NN nmod VBD dobj NN"
          2 : 5
          3 : 
            {
              1 : "drug0 compound chemotherapy conj bleomycin nmod *developed* dobj drug0"
              2 : "drug0 compound chemotherapy conj cisplatin nmod *developed* dobj drug0"
              3 : "drug0 compound use conj alpha-0a nmod *developed* dobj drug0"
              4 : "drug0 compound administration conj bleomycin nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "In this report , one patient who developed drug1 after bleomycin and drug2 chemotherapy for AIDS-related Kaposi 's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud 's phenomenon related to the same regimen are presented . "
              2 : "We report a case of a 60-year-old woman affected by squamous lung carcinoma , who developed drug1 during cisplatin and drug2 combination chemotherapy . "
              3 : "AIM : Report of a case of a woman patient who developed drug1 after pegylated interferon alpha-2a and drug2 use for chronic hepatitis C . "
              4 : "A case of a 53-year-old man who developed drug1 after bleomycin and moderate drug2 administration is presented . "
            }
          5 : 
            {
              1 : 2
              2 : 1
              3 : 1
              4 : 1
            }
        }
      163 : 
        {
          1 : "NN conj NN dobj VBD acl:relcl NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj fever dobj developed acl:relcl *drug0*"
              2 : "drug0 conj fever dobj developed acl:relcl *drug0*"
              3 : "drug0 conj fever dobj developed acl:relcl *drug0*"
              4 : "drug0 conj proteinuria dobj developed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving drug1 who developed fever , drug2 , splenomegaly , and extreme hyperferritinemia . "
              2 : "OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving drug1 who developed fever , pancytopenia , splenomegaly , and drug2 . "
              3 : "OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving drug1 who developed fever , pancytopenia , drug2 , and extreme hyperferritinemia . "
              4 : "A drug addict with staphylococcal endocarditis treated with drug1 , who developed massive proteinuria and drug2 is described . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      164 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod known acl:relcl *occurrence* nmod drug0"
              2 : "drug0 nmod treated acl:relcl patient nmod *drug0*"
              3 : "drug0 nmod aggravated acl:relcl *case* nmod drug0"
              4 : "drug0 nmod treated acl:relcl *woman* nmod drug0"
            }
          4 : 
            {
              1 : "The occurrence of drug1 and the resulting potentiation of muscle relaxants during drug2 ( MgSO4 ) administration is well known . "
              2 : "We report here on a heretofore undescribed drug1 in a patient with a long-standing history of refractory CLL that was treated with drug2 . "
              3 : "This is the first histologically confirmed case of drug1 that was aggravated by drug2 . "
              4 : "CASE : We report a case of a woman with severe human insulin-induced drug1 who has been treated exclusively with drug2 since the onset of IDDM . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      165 : 
        {
          1 : "NN compound NN nmod NN nmod VBG acl NN"
          2 : 4
          3 : 
            {
              1 : "drug0 compound therapy nmod cyst nmod arising acl *drug0*"
              2 : "drug0 compound therapy nmod cyst nmod arising acl *drug0*"
              3 : "drug0 compound therapy nmod patient nmod developing acl *drug0*"
              4 : "drug0 compound therapy nmod result nmod occurring acl *drug0*"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 arising from an endometriotic cyst in a postmenopausal woman under drug2 therapy is rare . "
              2 : "drug1 arising from an endometriotic cyst in a postmenopausal woman under drug2 therapy for breast cancer : a case report . "
              3 : "drug1 and endometriosis developing in a postmenopausal breast cancer patient during drug2 therapy : a case report and review of the literature . "
              4 : "OBJECTIVE : To report the finding of drug1 occurring as a result of drug2 therapy of hyperplasia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      166 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod administration nmod occurred acl:relcl *case* nmod drug0"
              2 : "drug0 nmod treatment nmod occurred acl:relcl *case* nmod drug0"
              3 : "drug0 nmod discontinuation nmod occurred acl:relcl *case* nmod drug0"
              4 : "drug0 nmod patient nmod occurred acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "The authors report a case of drug1 ( UI ) that occurred in a woman after administration of drug2 . "
              2 : "We report a case of drug1 that occurred together with lymphocytic colitis during treatment with drug2 . "
              3 : "The authors describe a case of drug1 that occurred after discontinuation of drug2 , and antidepressant which may also have neuroleptic effects . "
              4 : "The authors describe a case of drug1 that occurred in a patient on drug2 and lithium carbonate . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      167 : 
        {
          1 : "NN conj NN nmod NN nmod JJ amod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj ganciclovir nmod therapy nmod refractory amod *drug0*"
              2 : "drug0 conj lopinavir/ritonavir nmod interaction nmod related amod *drug0*"
              3 : "drug0 conj phosphate nmod administration nmod secondary amod *drug0*"
              4 : "drug0 conj ganciclovir nmod therapy nmod refractory amod *drug0*"
            }
          4 : 
            {
              1 : "We report an allogeneic bone marrow transplant recipient who developed drug1 refractory to sequential therapy with ganciclovir , foscarnet , and drug2 . "
              2 : "OBJECTIVE : To describe a case of exacerbated drug1 potentially related to an interaction between lopinavir/ritonavir and drug2 ( VPA ) and propose a mechanism of action for this interaction . "
              3 : "We report a case of acute drug1 secondary to rectal administration of sodium phosphate and drug2 ( Fleet enema ) . "
              4 : "We report an allogeneic bone marrow transplant recipient who developed drug1 refractory to sequential therapy with ganciclovir , drug2 , and cidofovir . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      168 : 
        {
          1 : "NN conj NN dep NNS nmod NN compound NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj granulocytopenia dep *complications* nmod treatment compound drug0"
              2 : "drug0 conj granulocytopenia dep *complications* nmod treatment compound drug0"
              3 : "drug0 conj aphasia dep *complications* nmod therapy compound drug0"
              4 : "drug0 conj granulocytopenia dep *complications* nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Multiple complications of drug1 treatment : granulocytopenia , drug2 , skin reaction and hepatitis with lymphocyte sensitization . "
              2 : "Multiple complications of drug1 treatment : granulocytopenia , eosinophilia , drug2 and hepatitis with lymphocyte sensitization . "
              3 : "Cerebrovascular complications of drug1 therapy in children with leukemia : aphasia and other drug2 . "
              4 : "Multiple complications of drug1 treatment : granulocytopenia , eosinophilia , skin reaction and drug2 with lymphocyte sensitization . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      169 : 
        {
          1 : "NN dobj VBG dep NNS nmod NN conj NN conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              2 : "drug0 dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              3 : "drug0 dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              4 : "drug0 dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , drug1 , and eosinophilia two weeks after receiving drug2 ( TMP ) - sulfamethoxazole ( SMX ) treatment . "
              2 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , drug1 , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving drug2 ( TMP ) - sulfamethoxazole ( SMX ) treatment . "
              3 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , drug1 , atypical lymphocytosis , and eosinophilia two weeks after receiving drug2 ( TMP ) - sulfamethoxazole ( SMX ) treatment . "
              4 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , drug1 , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving drug2 ( TMP ) - sulfamethoxazole ( SMX ) treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      170 : 
        {
          1 : "NN nmod NN nmod NN nmod NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod administration nmod *factor* nmod case nmod drug0"
              2 : "drug0 nmod combination nmod self-injection nmod *case* nmod drug0"
              3 : "drug0 nmod dose nmod infusion nmod *episode* nmod drug0"
              4 : "drug0 nmod tuberculosis nmod patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We believe that mucositis was a contributing factor to this case of drug1 after administration of drug2 , with a mechanism similar to that reported with thermal injury . "
              2 : "We report a case of drug1 after intracavernous self-injection of a combination of drug2 and papaverine . "
              3 : "An episode of subacute drug1 after the infusion of a moderate dose of drug2 ( 1500 mg/m2 ) ( MTX ) is reported in a young adult with metastastic gastric cancer . "
              4 : "A case of drug1 in patient of lepromatous leprosy with pulmonary tuberculosis due to drug2 is described . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      171 : 
        {
          1 : "NN compound NN nmod VB nsubj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 compound therapy nmod *develop* nsubj drug0"
              2 : "drug0 compound therapy nmod *develop* nsubj drug0"
              3 : "drug0 compound administration nmod *occur* nsubj drug0"
              4 : "drug0 compound therapy nmod *occur* nsubj drug0"
            }
          4 : 
            {
              1 : "We describe a patient with the antiphospholipid syndrome who had drug1 develop from drug2 therapy at sites distant from injection sites . "
              2 : "When drug1 develop during drug2 therapy , hyponatremia must be considered as part of the differential diagnosis . "
              3 : "Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy , even in platinum-sensitive cases , because CBDCA drug1 can occur even with low-dose drug2 administration . "
              4 : "From these data , drug1 with brainstem and thalamic lesions may occur in WD patients after an initial drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      172 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBN nsubjpass NN"
          2 : 4
          3 : 
            {
              1 : "drug0 dobj taking acl patients nmod *considered* nsubjpass drug0"
              2 : "drug0 dobj receiving acl children nmod *observed* nsubjpass drug0"
              3 : "drug0 dobj receiving acl patients nmod *reported* nsubjpass drug0"
              4 : "drug0 dobj receiving acl patients nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 should be considered in asthmatic patients taking drug2 who present with fever , pulmonary infiltrates , and hypoxia . "
              2 : "Painful drug1 were observed in two children receiving drug2 ( G-CSF ) for treatment of idiopathic neutropenia . "
              3 : "drug1 , an epileptic disorder in which typical convulsive activity is absent , has previously been reported in only 4 patients receiving drug2 . "
              4 : "OBJECTIVES : A delayed drug1 has been observed in patients receiving drug2 ( MTX ) for childhood leukemia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      173 : 
        {
          1 : "NN conj NN dep NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj nausea dep *drug0*"
              2 : "drug0 dep *bleomycin* conj drug0"
              3 : "drug0 conj cataract dep *drug0*"
              4 : "drug0 conj colic dep *drug0*"
            }
          4 : 
            {
              1 : "From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ) , nelfinavir ( cutaneous rash ) , and drug1 ( nausea and drug2 ) . "
              2 : "Bleomycin and drug1 toxicity simulating drug2 to the lungs in childhood cancer . "
              3 : "drug1 ( Ritalin ) - associated cataract and drug2 . "
              4 : "From 1996 to 2002 several medications were changed due to their adverse effects : drug1 ( renal colic and drug2 ) , nelfinavir ( cutaneous rash ) , and efavirenz ( nausea and temporary memory loss ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      174 : 
        {
          1 : "NN conj NN nmod NN appos NNS nmod VBG advcl VBG dobj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj speech nmod difficulty appos headaches nmod complaining advcl *taking* dobj drug0"
              2 : "drug0 conj speech nmod difficulty appos headaches nmod complaining advcl *taking* dobj drug0"
            }
          4 : 
            {
              1 : "He had been taking drug1 for approximately eight days when he revisited his family physician , complaining of headaches , dizziness , difficulty with speech , weakness , and drug2 of his body and legs , where a maculopapular rash was noted . "
              2 : "He had been taking drug1 for approximately eight days when he revisited his family physician , complaining of headaches , dizziness , difficulty with speech , drug2 , and itching on the trunk of his body and legs , where a maculopapular rash was noted . "
            }
          5 : 
            {
              1 : 2
              2 : 2
            }
        }
      175 : 
        {
          1 : "NN appos NN nmod JJ amod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 appos acetate nmod secondary amod *drug0*"
              2 : "drug0 appos diethylstilbestrol nmod related amod *drug0*"
              3 : "drug0 appos trimethoprim-sulfamethoxazole nmod secondary amod *drug0*"
              4 : "drug0 appos interferon-beta nmod secondary amod *drug0*"
            }
          4 : 
            {
              1 : "Drug induced drug1 secondary to leuprolide acetate ( drug2 ) therapy for prostate carcinoma . "
              2 : "This is a unique autopsy case of drug1 closely related to diethylstilbestrol ( drug2 ) therapy for prostatic cancer . "
              3 : "We report a case of Stevens-Johnson drug1 ( SJS/TEN ) secondary to trimethoprim-sulfamethoxazole ( drug2 ) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus ( CA-MRSA ) infection . "
              4 : "Drug induced drug1 secondary to interferon-beta ( drug2 ) in multiple sclerosis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      176 : 
        {
          1 : "NN conj NN dobj VBD nsubj JJ nmod NN acl:relcl VBD dobj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj fever dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj drug0"
              2 : "drug0 conj fever dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj drug0"
              3 : "drug0 conj fever dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj drug0"
              4 : "drug0 conj fever dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj drug0"
            }
          4 : 
            {
              1 : "A 7-year-old with congenital toxoplasmosis who took drug1 and sulfadiazine for reactivated chorioretinitis developed fever , severe cutaneous involvement , drug2 , abdominal pain and transaminitis , persisting weeks after withholding medicines . "
              2 : "A 7-year-old with congenital toxoplasmosis who took drug1 and sulfadiazine for reactivated chorioretinitis developed fever , drug2 , swelling , abdominal pain and transaminitis , persisting weeks after withholding medicines . "
              3 : "A 7-year-old with congenital toxoplasmosis who took drug1 and sulfadiazine for reactivated chorioretinitis developed fever , severe cutaneous involvement , swelling , abdominal pain and drug2 , persisting weeks after withholding medicines . "
              4 : "A 7-year-old with congenital toxoplasmosis who took drug1 and sulfadiazine for reactivated chorioretinitis developed fever , severe cutaneous involvement , swelling , drug2 and transaminitis , persisting weeks after withholding medicines . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      177 : 
        {
          1 : "VB amod NN nmod JJ amod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 amod administration nmod due amod *drug0*"
              2 : "drug0 amod administration nmod related amod *drug0*"
              3 : "drug0 amod administration nmod related amod *drug0*"
              4 : "drug0 amod dress/dihs nmod due amod *drug0*"
            }
          4 : 
            {
              1 : "To our knowledge , this is the first reported case of drug1 due to drug2 administration . "
              2 : "To date , eight cases of TEN and one of drug1 related to drug2 administration have been reported in the literature . "
              3 : "drug1 related to drug2 administration . "
              4 : "This is the first report of drug1 due to drug2 DRESS/DIHS . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      178 : 
        {
          1 : "NN nmod NN nmod VBP dobj NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod administration nmod *report* dobj case nmod drug0"
              2 : "drug0 nmod treatment nmod *present* dobj case nmod drug0"
              3 : "drug0 nmod administration nmod *report* dobj case nmod drug0"
              4 : "drug0 nmod treatment nmod *present* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 three weeks following the administration of drug2 for the treatment of Crohn 's disease ( CD ) . "
              2 : "Here we present the case of a drug1 with involvement of the palms in a patient with hepatitis C after systemic treatment with drug2 and ribavirin . "
              3 : "We report a case of drug1 compatible with type 1 Brugada syndrome following administration of drug2 in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels . "
              4 : "We present a unique case of drug1 in a patient with myeloma following treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      179 : 
        {
          1 : "NN conj NN nsubj JJ parataxis VBN conj JJ nsubj NN appos NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj impairment nsubj common parataxis limited conj *effective* nsubj b appos drug0"
              2 : "drug0 conj impairment nsubj common parataxis limited conj *effective* nsubj b appos drug0"
              3 : "drug0 conj impairment nsubj common parataxis limited conj *effective* nsubj b appos drug0"
              4 : "drug0 conj impairment nsubj common parataxis limited conj *effective* nsubj b appos drug0"
            }
          4 : 
            {
              1 : "Amphotericin B ( drug1 ) is effective , but its use is limited by toxicity : renal impairment , anaemia , drug2 , malaise , and hypokalaemia are common . "
              2 : "Amphotericin B ( drug1 ) is effective , but its use is limited by toxicity : renal impairment , drug2 , fever , malaise , and hypokalaemia are common . "
              3 : "Amphotericin B ( drug1 ) is effective , but its use is limited by toxicity : renal impairment , anaemia , fever , drug2 , and hypokalaemia are common . "
              4 : "Amphotericin B ( drug1 ) is effective , but its use is limited by toxicity : renal impairment , anaemia , fever , malaise , and drug2 are common . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      180 : 
        {
          1 : "NN compound NN nmod NNS nmod VBN acl NN"
          2 : 4
          3 : 
            {
              1 : "drug0 compound treatment nmod symptoms nmod associated acl *drug0*"
              2 : "drug0 compound pneumonitis nmod cases nmod seen acl *drug0*"
              3 : "drug0 compound withdrawal nmod doses nmod associated acl *drug0*"
              4 : "drug0 compound therapy nmod months nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "In this report we described a case of juvenile idiopathic arthritis patient who developed drug1 ( true thymic hyperplasia ) , mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under drug2 treatment . "
              2 : "drug1 or granulomas , classically seen in previously reported cases of drug2 pneumonitis , were not observed . "
              3 : "This paper reports on a 6.9-year-old autistic male who developed repeated episodes of drug1 associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following drug2 withdrawal , as well as during subsequent thioridazine administration . "
              4 : "A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with drug1 associated with hemoptysis after 27 months of drug2 therapy and a cumulative dose of 1 , 200 g . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      181 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBD dobj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 dobj starting acl weeks nmod *developed* dobj drug0"
              2 : "drug0 dobj *developed* nmod weeks acl beginning dobj drug0"
              3 : "drug0 dobj adding acl days nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "CASES : `` A '' was an 8-year-old boy with attention deficit and chronic tic disorder who developed drug1 within 2 weeks of starting drug2 . "
              2 : "Within 3 weeks of beginning continuous daily drug1 and rifampin therapy for pulmonary tuberculosis , a patient developed drug2 . "
              3 : "An 83-year-old man receiving glipizide 10 mg bid developed drug1 within three days of adding drug2 ( TMP/SMX ) to his regimen . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 2
            }
        }
      182 : 
        {
          1 : "NN nmod NN dobj VB nsubj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod effect dobj *represent* nsubj drug0"
              2 : "drug0 nmod treatment dobj *complicate* nsubj drug0"
              3 : "drug0 nmod risk dobj *increase* nsubj drug0"
              4 : "drug0 nmod occurrence dobj *precipitate* nsubj drug0"
            }
          4 : 
            {
              1 : "It is concluded that drug1 ' on CT scans may represent an accumulative effect of drug2 and that ACTH should be given with the utmost discretion , and in as low a dose as possible . "
              2 : "CONCLUSION : drug1 may complicate treatment with drug2 . "
              3 : "drug1 may increase the risk of drug2 . "
              4 : "drug1 ( IFN-alpha ) may precipitate or exacerbate the occurrence of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      183 : 
        {
          1 : "NN appos NN compound NN dep NN dobj VBG dep NNS nmod NN conj NN conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 appos sulfamethoxazole compound treatment dep trimethoprim dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              2 : "drug0 appos sulfamethoxazole compound treatment dep trimethoprim dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              3 : "drug0 appos sulfamethoxazole compound treatment dep trimethoprim dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              4 : "drug0 appos sulfamethoxazole compound treatment dep trimethoprim dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , drug1 , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( drug2 ) treatment . "
              2 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , drug1 , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( drug2 ) treatment . "
              3 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , drug1 , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( drug2 ) treatment . "
              4 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , drug1 , and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( drug2 ) treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      184 : 
        {
          1 : "NN nmod NN dobj VBD nsubj NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod episode dobj *caused* nsubj treatment nmod drug0"
              2 : "drug0 nmod withdrawal dobj *followed* nsubj improvement nmod drug0"
              3 : "drug0 nmod exacerbation dobj *triggered* nsubj withdrawal nmod drug0"
              4 : "drug0 nmod resolution dobj *caused* nsubj discontinuation nmod drug0"
            }
          4 : 
            {
              1 : "Three years later , treatment with drug1 caused another episode of drug2 with cholestasis and duct paucity on rebiopsy . "
              2 : "Significant clinical improvement of the drug1 followed withdrawal of the drug2 . "
              3 : "Abrupt , accidental withdrawal of drug1 triggered severe exacerbation of the drug2 associated with inspiratory stridor and acute respiratory difficulties , prompting emergency admission . "
              4 : "Discontinuation of the drug1 caused resolution of the drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      185 : 
        {
          1 : "NN nmod VBN acl NNS nmod NNS nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod *cases* nmod drug0"
              2 : "drug0 nmod treated acl patients nmod *cases* nmod drug0"
              3 : "drug0 nmod treated acl patients nmod *cases* nmod drug0"
              4 : "drug0 nmod treated acl recipients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "We report two cases of drug1 in HIV-1-infected patients treated with drug2 ( ddI ) . "
              2 : "AIM : To report three cases of extensive drug1 in cirrhotic patients treated with the vasoconstrictor agent drug2 ( Glypressin ) . "
              3 : "We report two new cases of drug1 in two patients with hepatitis C virus infection treated with drug2 and ribavirin . "
              4 : "We now present four cases of drug1 in kidney transplant recipients treated with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      186 : 
        {
          1 : "NN conj NN nsubj JJ parataxis JJ nsubj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj impairment nsubj common parataxis *effective* nsubj drug0"
              2 : "drug0 conj impairment nsubj common parataxis *effective* nsubj drug0"
              3 : "drug0 conj impairment nsubj common parataxis *effective* nsubj drug0"
              4 : "drug0 conj impairment nsubj common parataxis *effective* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( AmB ) is effective , but its use is limited by toxicity : renal impairment , anaemia , drug2 , malaise , and hypokalaemia are common . "
              2 : "drug1 ( AmB ) is effective , but its use is limited by toxicity : renal impairment , drug2 , fever , malaise , and hypokalaemia are common . "
              3 : "drug1 ( AmB ) is effective , but its use is limited by toxicity : renal impairment , anaemia , fever , malaise , and drug2 are common . "
              4 : "drug1 ( AmB ) is effective , but its use is limited by toxicity : renal impairment , anaemia , fever , drug2 , and hypokalaemia are common . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      187 : 
        {
          1 : "NN nmod NN nmod VBD dobj NN appos NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod infusion nmod *developed* dobj syndrome appos drug0"
              2 : "drug0 nmod treatment nmod *developed* dobj leukaemia appos drug0"
              3 : "drug0 nmod week nmod *reported* dobj weakness appos drug0"
              4 : "drug0 nmod administration nmod *developed* dobj block appos drug0"
            }
          4 : 
            {
              1 : "We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome ( drug1 ) after a single infusion of drug2 . "
              2 : "A 58-yr-old male patient with essential thrombocythaemia ( ET ) developed chronic myeloid leukaemia ( drug1 ) after continuous uneventful treatment with drug2 for 18 yr . "
              3 : "Patient A reported right leg weakness ( drug1 ) during week 4 of drug2 ( 1600 mg/m2 ) . "
              4 : "A 57-year-old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( drug1 ) following administration of drug2 ( Norpace ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      188 : 
        {
          1 : "NN appos NN dobj VBG dep NNS nmod NN conj NN conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 appos trimethoprim dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              2 : "drug0 appos trimethoprim dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              3 : "drug0 appos trimethoprim dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
              4 : "drug0 appos trimethoprim dobj receiving dep weeks nmod eosinophilia conj *fever* conj drug0"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , drug1 , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( drug2 ) - sulfamethoxazole ( SMX ) treatment . "
              2 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , drug1 , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( drug2 ) - sulfamethoxazole ( SMX ) treatment . "
              3 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , drug1 , and eosinophilia two weeks after receiving trimethoprim ( drug2 ) - sulfamethoxazole ( SMX ) treatment . "
              4 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , drug1 , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( drug2 ) - sulfamethoxazole ( SMX ) treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      189 : 
        {
          1 : "NN compound NN nmod NN nmod VBD nsubj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 compound treatment nmod day nmod *appeared* nsubj drug0"
              2 : "drug0 compound therapy nmod withdrawal nmod *regressed* nsubj drug0"
              3 : "drug0 compound therapy nmod patient nmod *occurred* nsubj drug0"
              4 : "drug0 compound hypokalemia nmod route nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 on the anterior surface of both legs appeared on the 55th day of drug2 treatment . "
              2 : "The drug1 regressed after withdrawal of drug2 therapy in one patient and were arrested with the addition of hydroxychloroquine in the other . "
              3 : "Well-differentiated drug1 ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on drug2 therapy 5 years after mastectomy for breast carcinoma . "
              4 : "It was concluded that drug1 occurred by a non-renal ( intestinal ) route in drug2 hypokalemia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      190 : 
        {
          1 : "NN conj NN dobj VBD advcl VBN nsubjpass NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj ileus dobj *developed* advcl started nsubjpass drug0"
              2 : "drug0 conj ileus dobj *developed* advcl started nsubjpass drug0"
              3 : "drug0 conj pain dobj *presented* advcl administered nsubjpass drug0"
              4 : "drug0 conj ileus dobj *developed* advcl started nsubjpass drug0"
            }
          4 : 
            {
              1 : "Ten days after drug1 was started , he developed paralytic ileus , drug2 , mild left ptosis , and absence of deep reflexes , with severe paralysis of the lower extremities and mild weakness of the upper extremities . "
              2 : "Ten days after drug1 was started , he developed paralytic ileus , neurogenic bladder , drug2 , and absence of deep reflexes , with severe paralysis of the lower extremities and mild weakness of the upper extremities . "
              3 : "While drug1 was administered , the patient presented thoracic pain and drug2 due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum . "
              4 : "Ten days after drug1 was started , he developed paralytic ileus , neurogenic bladder , mild left ptosis , and drug2 , with severe paralysis of the lower extremities and mild weakness of the upper extremities . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      191 : 
        {
          1 : "NN conj NN nmod NNS nmod VBN nsubjpass NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj hepatitis nmod effects nmod *associated* nsubjpass drug0"
              2 : "drug0 conj hepatitis nmod effects nmod *associated* nsubjpass drug0"
              3 : "drug0 conj d-penicillamine nmod complications nmod *reported* nsubjpass drug0"
              4 : "drug0 conj hepatitis nmod effects nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 can be associated with severe adverse effects such as hepatitis , acute renal failure , drug2 , and thrombocytopenia . "
              2 : "drug1 can be associated with severe adverse effects such as hepatitis , drug2 , hemolytic anemia , and thrombocytopenia . "
              3 : "Drug-induced drug1 have been reported as rare complications of D-penicillamine and drug2 . "
              4 : "drug1 can be associated with severe adverse effects such as hepatitis , acute renal failure , hemolytic anemia , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      192 : 
        {
          1 : "NN conj NN nmod VBG advcl VBP dobj NN acl:relcl VBD dobj NN amod JJ nmod NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj hypokalemia nmod resulting advcl *discuss* dobj patient acl:relcl developed dobj dysfunction amod secondary nmod therapy nmod drug0"
              2 : "drug0 conj hypokalemia nmod resulting advcl *discuss* dobj patient acl:relcl developed dobj dysfunction amod secondary nmod therapy nmod drug0"
              3 : "drug0 conj hypokalemia nmod resulting advcl *discuss* dobj patient acl:relcl developed dobj dysfunction amod secondary nmod therapy nmod drug0"
              4 : "drug0 conj hypokalemia nmod resulting advcl *discuss* dobj patient acl:relcl developed dobj dysfunction amod secondary nmod therapy nmod drug0"
            }
          4 : 
            {
              1 : "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with drug1 , resulting in refractory hypokalemia , drug2 , hypomagnesemia , metabolic alkalosis , and polyuria . "
              2 : "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with drug1 , resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , metabolic alkalosis , and drug2 . "
              3 : "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with drug1 , resulting in refractory hypokalemia , hypocalcemia , drug2 , metabolic alkalosis , and polyuria . "
              4 : "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with drug1 , resulting in refractory hypokalemia , hypocalcemia , hypomagnesemia , drug2 , and polyuria . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      193 : 
        {
          1 : "NN dobj VB"
          2 : 4
          3 : 
            {
              1 : "drug0 dobj *drug0*"
              2 : "drug0 dobj *drug0*"
              3 : "drug0 dobj *drug0*"
              4 : "drug0 dobj *drug0*"
            }
          4 : 
            {
              1 : "We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to drug1 drug2 . "
              2 : "Review of the literature relating to drug1 drug2 suggests a hypersensitivity origin for this disorder , but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis . "
              3 : "Can drug1 therapy impact drug2 ? "
              4 : "The patient 's defects may be due to drug1 drug2 or could represent a previously undescribed syndrome affecting ectodermal structures . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      194 : 
        {
          1 : "NN conj NN dobj VBP nsubj NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj hypertension dobj *include* nsubj grade nmod drug0"
              2 : "drug0 conj hypertension dobj *include* nsubj grade nmod drug0"
              3 : "drug0 conj hypertension dobj *include* nsubj grade nmod drug0"
              4 : "drug0 conj hypertension dobj *include* nsubj grade nmod drug0"
            }
          4 : 
            {
              1 : "The more common grade 3 or 4 adverse effects of drug1 include hypertension , drug2 , hand-foot syndrome , elevated lipase and lymphopenia . "
              2 : "The more common grade 3 or 4 adverse effects of drug1 include hypertension , fatigue , hand-foot syndrome , elevated lipase and drug2 . "
              3 : "The more common grade 3 or 4 adverse effects of drug1 include hypertension , fatigue , hand-foot syndrome , drug2 and lymphopenia . "
              4 : "The more common grade 3 or 4 adverse effects of drug1 include hypertension , fatigue , drug2 , elevated lipase and lymphopenia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      195 : 
        {
          1 : "NN appos NN nmod NN dep NNS nmod NNS conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 appos carbamazepine nmod administration dep weeks nmod *symptoms* conj drug0"
              2 : "drug0 appos carbamazepine nmod administration dep weeks nmod *symptoms* conj drug0"
              3 : "drug0 appos carbamazepine nmod administration dep weeks nmod *symptoms* conj drug0"
              4 : "drug0 appos carbamazepine nmod administration dep weeks nmod *symptoms* conj drug0"
            }
          4 : 
            {
              1 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , fever , leukopenia and drug1 ( ANA ) two weeks after administration of carbamazepine ( drug2 ; Tegretol ) used against benign Rolandic epilepsy . "
              2 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , drug1 , fever , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( drug2 ; Tegretol ) used against benign Rolandic epilepsy . "
              3 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , drug1 , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( drug2 ; Tegretol ) used against benign Rolandic epilepsy . "
              4 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , fever , drug1 and positive anti-nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( drug2 ; Tegretol ) used against benign Rolandic epilepsy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      196 : 
        {
          1 : "NN nmod NN dep NNS nmod NNS conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod administration dep weeks nmod *symptoms* conj drug0"
              2 : "drug0 nmod administration dep weeks nmod *symptoms* conj drug0"
              3 : "drug0 nmod administration dep weeks nmod *symptoms* conj drug0"
              4 : "drug0 nmod administration dep weeks nmod *symptoms* conj drug0"
            }
          4 : 
            {
              1 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , drug1 , fever , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of drug2 ( CBZ ; Tegretol ) used against benign Rolandic epilepsy . "
              2 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , fever , drug1 and positive anti-nuclear antibody ( ANA ) two weeks after administration of drug2 ( CBZ ; Tegretol ) used against benign Rolandic epilepsy . "
              3 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , fever , leukopenia and drug1 ( ANA ) two weeks after administration of drug2 ( CBZ ; Tegretol ) used against benign Rolandic epilepsy . "
              4 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , drug1 , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of drug2 ( CBZ ; Tegretol ) used against benign Rolandic epilepsy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      197 : 
        {
          1 : "NN conj NNS nmod VBG advcl VBG dobj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj headaches nmod complaining advcl *taking* dobj drug0"
              2 : "drug0 conj headaches nmod complaining advcl *taking* dobj drug0"
            }
          4 : 
            {
              1 : "He had been taking drug1 for approximately eight days when he revisited his family physician , complaining of headaches , dizziness , drug2 , weakness , and itching on the trunk of his body and legs , where a maculopapular rash was noted . "
              2 : "He had been taking drug1 for approximately eight days when he revisited his family physician , complaining of headaches , drug2 , difficulty with speech , weakness , and itching on the trunk of his body and legs , where a maculopapular rash was noted . "
            }
          5 : 
            {
              1 : 2
              2 : 2
            }
        }
      198 : 
        {
          1 : "NN nmod VBN xcomp VBN nsubjpass NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod associated xcomp *known* nsubjpass drug0"
              2 : "drug0 nmod related xcomp *thought* nsubjpass drug0"
              3 : "drug0 nmod associated xcomp *considered* nsubjpass drug0"
              4 : "drug0 nmod caused xcomp *believed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is known to be associated with drug2 . "
              2 : "Thus , drug1 in our cases are thought to be related to drug2 and cefotiam . "
              3 : "In this case , drug1 was considered to be probably associated with drug2 according to the Naranjo probability scale . "
              4 : "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy , the drug1 was believed to be caused by drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      199 : 
        {
          1 : "NN dobj VBD advcl VBN nsubjpass NN"
          2 : 4
          3 : 
            {
              1 : "drug0 dobj *developed* advcl started nsubjpass drug0"
              2 : "drug0 nsubjpass used advcl *developed* dobj drug0"
              3 : "drug0 nsubjpass added advcl *developed* dobj drug0"
              4 : "drug0 dobj *began* advcl stopped nsubjpass drug0"
            }
          4 : 
            {
              1 : "Ten days after drug1 was started , he developed drug2 , neurogenic bladder , mild left ptosis , and absence of deep reflexes , with severe paralysis of the lower extremities and mild weakness of the upper extremities . "
              2 : "A patient is described who developed a poorly differentiated drug1 after drug2 was used to treat his rheumatoid arthritis . "
              3 : "A 51-yr-old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria developed drug1 when drug2 was added to the nadolol and dyazide treatment for his high blood pressure . "
              4 : "The day after drug1 was stopped , while he was still receiving clomipramine 150 mg/d , he began drug2 , started sweating profusely , shivering , and became tremulous , agitated , and confused . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      200 : 
        {
          1 : "NN compound NN nmod VBG dobj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 compound overdose nmod *managing* dobj drug0"
              2 : "drug0 compound arm nmod *developing* dobj drug0"
              3 : "drug0 compound chemotherapy nmod *causing* dobj drug0"
              4 : "drug0 compound therapy nmod *revealing* dobj drug0"
            }
          4 : 
            {
              1 : "Managing drug1 in severe drug2 overdose without recourse to extracorporeal therapy . "
              2 : "In this healthy population , the relative risk of developing drug1 in the drug2 arm was 2.54 , although when stratified by age , in women over 50 , the risk grew to 4.01 . "
              3 : "Dihydropyrimidine dehydrogenase deficiency : a pharmacogenetic defect causing drug1 to drug2 chemotherapy . "
              4 : "Sensory neuropathy revealing drug1 during drug2 therapy for rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      201 : 
        {
          1 : "NN nmod NN dep NNS nmod NN conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod treatment dep days nmod loss conj *drug0*"
              2 : "drug0 nmod administration dep weeks nmod *short-of-breath* conj drug0"
              3 : "drug0 nmod treatment dep weeks nmod dyspnea conj *drug0*"
              4 : "drug0 nmod course dep days nmod consciousness conj *drug0*"
            }
          4 : 
            {
              1 : "We describe a case of advanced ovarian carcinoma who developed difficulty walking because of drug1 in the lower extremities and loss of proprioception 25 days after treatment with weekly drug2 ( 80 mg/m ( 2 ) x3 ) . "
              2 : "We report the case of a young man , affected by rheumatoid arthritis who developed a rapid-onset short-of-breath , drug1 , and severe weakness , about 2 weeks after the administration of drug2 . "
              3 : "A 52-year-old , white female developed drug1 , cough , and dyspnea after 8 weeks treatment with drug2 for rheumatoid arthritis . "
              4 : "This patient developed sequential symptoms including alternative drug1 , dysarthria and altered consciousness 5 days after the second course of drug2 ( 8 gm/m2 by 6 h continuous infusion ) with leucovorin rescue . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      202 : 
        {
          1 : " NN nsubj NN compound NN"
          2 : 4
          3 : 
            {
              1 : " *drug0* nsubj overdose compound drug0"
              2 : " *drug0* nsubj pancreatitis compound drug0"
              3 : " *drug0* nsubj ileus compound drug0"
              4 : " *drug0* nsubj enteropathy compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 overdose can be drug2 in children and infants . "
              2 : "drug1 pancreatitis is an uncommon but potential drug2 of the treatment of leukemia . "
              3 : "drug1 paralytic ileus is a potential drug2 of this first-in-class anticancer proteasome inhibitor . "
              4 : "drug1 enteropathy caused by crystal deposition can be drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      203 : 
        {
          1 : " NN amod VB"
          2 : 4
          3 : 
            {
              1 : " *drug0* amod drug0"
              2 : " *drug0* amod drug0"
              3 : " *drug0* amod drug0"
            }
          4 : 
            {
              1 : "This is the first report of acute kidney injury due to drug1 drug2 . "
              2 : "The cause is presumed to be secondary to hypercoagulability due to drug1 drug2 . "
              3 : "Massive plasmocytosis due to drug1 drug2 . "
            }
          5 : 
            {
              1 : 2
              2 : 1
              3 : 1
            }
        }
      204 : 
        {
          1 : "NN conj NN dobj VBD nsubj JJ nmod NN acl:relcl VBD dobj NN conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj fever dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj pyrimethamine conj drug0"
              2 : "drug0 conj fever dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj pyrimethamine conj drug0"
              3 : "drug0 conj fever dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj pyrimethamine conj drug0"
              4 : "drug0 conj fever dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj pyrimethamine conj drug0"
            }
          4 : 
            {
              1 : "A 7-year-old with congenital toxoplasmosis who took pyrimethamine and drug1 for reactivated chorioretinitis developed fever , severe cutaneous involvement , swelling , drug2 and transaminitis , persisting weeks after withholding medicines . "
              2 : "A 7-year-old with congenital toxoplasmosis who took pyrimethamine and drug1 for reactivated chorioretinitis developed fever , severe cutaneous involvement , drug2 , abdominal pain and transaminitis , persisting weeks after withholding medicines . "
              3 : "A 7-year-old with congenital toxoplasmosis who took pyrimethamine and drug1 for reactivated chorioretinitis developed fever , drug2 , swelling , abdominal pain and transaminitis , persisting weeks after withholding medicines . "
              4 : "A 7-year-old with congenital toxoplasmosis who took pyrimethamine and drug1 for reactivated chorioretinitis developed fever , severe cutaneous involvement , swelling , abdominal pain and drug2 , persisting weeks after withholding medicines . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      205 : 
        {
          1 : "NN conj NN dobj VBD nsubj NN acl VBN nmod NN conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj hemianopsia dobj *developed* nsubj man acl treated nmod cisplatinum conj drug0"
              2 : "drug0 conj hemianopsia dobj *developed* nsubj man acl treated nmod cisplatinum conj drug0"
              3 : "drug0 conj hemianopsia dobj *developed* nsubj man acl treated nmod cisplatinum conj drug0"
              4 : "drug0 conj hemianopsia dobj *developed* nsubj man acl treated nmod cisplatinum conj drug0"
            }
          4 : 
            {
              1 : "A 36-year-old man being treated with cisplatinum , vinblastine , and drug1 for testicular carcinoma developed a dense left homonymous hemianopsia , encephalopathy , and a drug2 . "
              2 : "A 36-year-old man being treated with cisplatinum , drug1 , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia , encephalopathy , and a drug2 . "
              3 : "A 36-year-old man being treated with cisplatinum , drug1 , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia , drug2 , and a partial nondominant parietal lobe syndrome . "
              4 : "A 36-year-old man being treated with cisplatinum , vinblastine , and drug1 for testicular carcinoma developed a dense left homonymous hemianopsia , drug2 , and a partial nondominant parietal lobe syndrome . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      206 : 
        {
          1 : "NN nmod VBN acl NN nsubj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod associated acl *complication* nsubj drug0"
              2 : "drug0 nmod associated acl *drug* nsubj drug0"
              3 : "drug0 nmod associated acl *agent* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a severe complication associated with drug2 ( BCNU ) therapy . "
              2 : "drug1 ( SR ) , trade named Rapammune ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with drug2 , hypertension , hyperlipidemia , and infection . "
              3 : "BACKGROUND : drug1 is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with drug2 and nail hyperpigmentation . "
            }
          5 : 
            {
              1 : 1
              2 : 2
              3 : 1
            }
        }
      207 : 
        {
          1 : "NN nmod CD dep IN amod NN nmod VBD dobj NNS conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod 0 dep of amod ingestion nmod *experienced* dobj hallucinations conj drug0"
              2 : "drug0 nmod 0 dep of amod ingestion nmod *experienced* dobj hallucinations conj drug0"
              3 : "drug0 nmod 0 dep of amod ingestion nmod *experienced* dobj hallucinations conj drug0"
              4 : "drug0 nmod 0 dep of amod ingestion nmod *experienced* dobj hallucinations conj drug0"
            }
          4 : 
            {
              1 : "The patient experienced hallucinations , agitation , drug1 , tachycardia and seizures after ingestion of 1050 ( 48 mg/kg ) of extended-release drug2 . "
              2 : "The patient experienced hallucinations , agitation , vomiting , tachycardia and drug1 after ingestion of 1050 ( 48 mg/kg ) of extended-release drug2 . "
              3 : "The patient experienced hallucinations , drug1 , vomiting , tachycardia and seizures after ingestion of 1050 ( 48 mg/kg ) of extended-release drug2 . "
              4 : "The patient experienced hallucinations , agitation , vomiting , drug1 and seizures after ingestion of 1050 ( 48 mg/kg ) of extended-release drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      208 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NNS nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod use nmod *reported* nsubjpass cases nmod drug0"
              2 : "drug0 nmod exposure nmod *associated* nsubjpass changes nmod drug0"
              3 : "drug0 nmod injection nmod *treated* nsubjpass patients nmod drug0"
              4 : "drug0 nmod association nmod *described* nsubjpass cases nmod drug0"
            }
          4 : 
            {
              1 : "Three cases of drug1 in two women and one man have previously been reported with the use of intravenous drug2 . "
              2 : "CONCLUSIONS : Symptoms and pathologic changes of drug1 are associated with exposure to drug2 . "
              3 : "METHODS : Two patients with exudative drug1 were treated sequentially with an intravitreal injection of drug2 and developed signs of severe but painless infectious endophthalmitis 2 days later . "
              4 : "Two cases of widespread drug1 are described in association with drug2 , a recently introduced calcium antagonist . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      209 : 
        {
          1 : "NN nmod NN dobj VBG acl NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod course dobj paralleling acl *drug0*"
              2 : "drug0 nmod infusion dobj complicating acl *drug0*"
              3 : "drug0 nmod drop dobj receiving acl *drug0*"
              4 : "drug0 nmod therapy dobj complicating acl *drug0*"
            }
          4 : 
            {
              1 : "A patient developed drug1 paralleling the course of drug2 ( IFN alpha ) therapy for chronic hepatitis C . "
              2 : "drug1 complicating the first infusion of drug2 . "
              3 : "A 5-month-old infant became lethargic and drug1 after receiving 1 drop of drug2 in each eye . "
              4 : "Such a case induced by drug1 complicating long-term therapy with drug2 in a 45 year old woman with pre-excitation is presented . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      210 : 
        {
          1 : "NN compound NN nmod VBN acl NN appos NN"
          2 : 4
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl *hormone* appos drug0"
              2 : "drug0 compound treatment nmod associated acl *syndrome* appos drug0"
              3 : "drug0 compound monotherapy nmod associated acl *syndrome* appos drug0"
              4 : "drug0 compound use nmod induced acl *syndrome* appos drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To describe onset of syndrome of inappropriate antidiuretic hormone ( drug1 ) associated with drug2 therapy for advanced breast cancer . "
              2 : "The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome ( drug1 ) associated with drug2 treatment . "
              3 : "OBJECTIVE : To document a case of serotonin syndrome ( drug1 ) associated with drug2 monotherapy , review the previously reported cases of SS associated with this tetracyclic antidepressant , and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction . "
              4 : "Posterior reversible encephalopathy syndrome ( drug1 ) induced by drug2 use in a patient with collapsing focal glomeruloesclerosis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      211 : 
        {
          1 : "NN appos NN nmod NN compound NN"
          2 : 4
          3 : 
            {
              1 : "drug0 appos hormone nmod *syndrome* compound drug0"
              2 : "drug0 appos *reaction* nmod therapy compound drug0"
              3 : "drug0 compound therapy nmod effect appos *drug0*"
              4 : "drug0 compound infusion nmod *pneumonia* appos drug0"
            }
          4 : 
            {
              1 : "drug1 syndrome of inappropriate antidiuretic hormone ( drug2 ) in a patient with neuroendocrine tumor of the cervix : a case report and review of the literature . "
              2 : "We report in detail an unusual adverse reaction to drug1 therapy , a drug-induced drug2 . "
              3 : "drug1 , an undesired effect of drug2 therapy in a patient with Hurler 's syndrome undergoing bone marrow transplantation . "
              4 : "Severe adenovirus pneumonia ( drug1 ) following drug2 infusion for the treatment of Crohn 's disease . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      212 : 
        {
          1 : " VB nsubj NN"
          2 : 4
          3 : 
            {
              1 : " *drug0* nsubj drug0"
              2 : " *drug0* nsubj drug0"
              3 : " *drug0* nsubj drug0"
              4 : " *drug0* nsubj drug0"
            }
          4 : 
            {
              1 : "The authors suggest that drug1 may drug2 in patients with schizophrenia and that some patients , especially those with anxiety , may have difficulty managing the increase . "
              2 : "CONCLUSIONS : Intrathecal drug1 can drug2 and ejaculation in some patients . "
              3 : "Recent studies have shown that under experimental conditions drug1 may drug2 in patients with primary hypothyroidism . "
              4 : "CONCLUSION : The findings in these two patients suggest that drug1 may drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      213 : 
        {
          1 : "NN nsubjpass VBN advcl VBG dobj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nsubjpass *reversed* advcl stopping dobj drug0"
              2 : "drug0 dobj taking advcl *diagnosed* nsubjpass drug0"
              3 : "drug0 nsubjpass observed advcl *discontinuing* dobj drug0"
              4 : "drug0 dobj taking advcl *diagnosed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "After stopping drug1 , drug2 may be reversed . "
              2 : "CASE : A drug1 was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking drug2 for osteoporosis prevention . "
              3 : "We suggest discontinuing drug1 if drug2 is observed . "
              4 : "We report a case of a women in whom a drug1 was diagnosed while she was taking drug2 , which is also a selective estrogen receptor modulator . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      214 : 
        {
          1 : "NN conj NN nmod VBN nsubjpass NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj asthma nmod *manifested* nsubjpass hypersensitivity nmod drug0"
              2 : "drug0 conj methemoglobinemia nmod *followed* nsubjpass administration nmod drug0"
              3 : "drug0 conj asthma nmod *manifested* nsubjpass hypersensitivity nmod drug0"
              4 : "drug0 conj asthma nmod *manifested* nsubjpass hypersensitivity nmod drug0"
            }
          4 : 
            {
              1 : "Hypersensitivity to drug1 can be manifested as acute asthma , drug2 and/or angioedema , or a systemic anaphylactoid reaction . "
              2 : "The administration of `` drug1 '' ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and drug2 in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia . "
              3 : "Hypersensitivity to drug1 can be manifested as acute asthma , urticaria and/or angioedema , or a drug2 . "
              4 : "Hypersensitivity to drug1 can be manifested as acute asthma , urticaria and/or drug2 , or a systemic anaphylactoid reaction . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      215 : 
        {
          1 : "NN dobj VBD nmod NNS dep NN nmod NN compound NN"
          2 : 4
          3 : 
            {
              1 : "drug0 dobj *had* nmod days dep administration nmod enema compound drug0"
              2 : "drug0 dobj *developed* nmod years dep beginning nmod therapy compound drug0"
              3 : "drug0 compound mg/d nmod treatment dep months nmod *developed* dobj drug0"
              4 : "drug0 compound prescription nmod commencement dep months nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Two days after administration of drug1 enema , he had drug2 , and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon . "
              2 : "Four years after the beginning of drug1 therapy , he acutely developed drug2 and severe ketonuria with positive islet cell antibody , and then 28 units/day of insulin injection was started . "
              3 : "CONCLUSIONS : We present a case of a patient with CML who developed drug1 12 months after starting treatment with drug2 400 mg/d . "
              4 : "We describe a 74-year-old man with rheumatoid arthritis ( RA ) who developed drug1 ( SIADH ) 1.5 months after commencement of drug2 prescription when his arthritis was improved . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      216 : 
        {
          1 : "NN dep NN dep NN nmod NN nsubj VBN dep NNS nmod NNS conj NN"
          2 : 4
          3 : 
            {
              1 : "drug0 dep cbz dep carbamazepine nmod administration nsubj used dep weeks nmod *symptoms* conj drug0"
              2 : "drug0 dep cbz dep carbamazepine nmod administration nsubj used dep weeks nmod *symptoms* conj drug0"
              3 : "drug0 dep cbz dep carbamazepine nmod administration nsubj used dep weeks nmod *symptoms* conj drug0"
              4 : "drug0 dep cbz dep carbamazepine nmod administration nsubj used dep weeks nmod *symptoms* conj drug0"
            }
          4 : 
            {
              1 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , drug1 , fever , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; drug2 ) used against benign Rolandic epilepsy . "
              2 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , fever , drug1 and positive anti-nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; drug2 ) used against benign Rolandic epilepsy . "
              3 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , fever , leukopenia and drug1 ( ANA ) two weeks after administration of carbamazepine ( CBZ ; drug2 ) used against benign Rolandic epilepsy . "
              4 : "A 14-year-old female developed systemic lupus erythematosus ( SLE ) - like symptoms , rash , drug1 , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; drug2 ) used against benign Rolandic epilepsy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      217 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN nsubjpass NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod picture nmod suppression nmod *associated* nsubjpass drug0"
              2 : "drug0 nmod dose nmod completion nmod *seen* nsubjpass drug0"
              3 : "drug0 nmod administration nmod complication nmod *known* nsubjpass drug0"
              4 : "drug0 nmod therapy nmod complication nmod *recognized* nsubjpass drug0"
            }
          4 : 
            {
              1 : "The results clearly demonstrate that drug1 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical drug2 . "
              2 : "During the first treatment , drug1 and ataxia were seen after completion of the patient 's eighth and final dose of drug2 . "
              3 : "drug1 is known as a rare complication following the administration of drug2 ( sodium polystryrene sulfonate ) in sorbitol . "
              4 : "drug1 has been recognized as a complication of tocolytic therapy with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      218 : 
        {
          1 : "NN conj NN dep NN nmod VB conj VBN nsubjpass NN appos NN"
          2 : 4
          3 : 
            {
              1 : "drug0 conj damage dep form nmod produce conj *reported* nsubjpass form appos drug0"
              2 : "drug0 conj damage dep form nmod produce conj *reported* nsubjpass form appos drug0"
              3 : "drug0 conj damage dep form nmod produce conj *reported* nsubjpass form appos drug0"
              4 : "drug0 conj damage dep form nmod produce conj *reported* nsubjpass form appos drug0"
            }
          4 : 
            {
              1 : "The latter form ( drug1 ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form -- liver damage , acute and chronic pulmonary reactions , peripheral neuropathy , drug2 and allergic reactions -- and does so just as rapidly and floridly ; one such case is reported here . "
              2 : "The latter form ( drug1 ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form -- liver damage , drug2 , peripheral neuropathy , blood dyscrasias and allergic reactions -- and does so just as rapidly and floridly ; one such case is reported here . "
              3 : "The latter form ( drug1 ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form -- liver damage , acute and chronic pulmonary reactions , drug2 , blood dyscrasias and allergic reactions -- and does so just as rapidly and floridly ; one such case is reported here . "
              4 : "The latter form ( drug1 ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form -- liver damage , acute and chronic pulmonary reactions , peripheral neuropathy , blood dyscrasias and drug2 -- and does so just as rapidly and floridly ; one such case is reported here . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      219 : 
        {
          1 : "NN compound NN dep NN"
          2 : 4
          3 : 
            {
              1 : "drug0 compound intoxication dep *drug0*"
              2 : "drug0 dep *treatment* compound drug0"
              3 : "drug0 compound teratogenicity dep *drug0*"
              4 : "drug0 compound reaction dep *drug0*"
            }
          4 : 
            {
              1 : "Severe drug1 following massive ingestion of oolong tea : drug2 intoxication with coexisting hyponatremia . "
              2 : "Despite a response of the meningeal tumor the patient developed in the third week of drug1 treatment a drug2 and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks . "
              3 : "drug1 and athelia : drug2 teratogenicity or a new syndrome ? "
              4 : "Neonatal drug1 : intravenous drug2 adverse reaction . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      220 : 
        {
          1 : "NN compound NN nmod NN compound NN"
          2 : 4
          3 : 
            {
              1 : "drug0 compound withdrawal nmod *psa* compound drug0"
              2 : "drug0 compound injection nmod *week* compound drug0"
              3 : "drug0 compound administration nmod *attack* compound drug0"
              4 : "drug0 compound toxicity nmod *case* compound drug0"
            }
          4 : 
            {
              1 : "Flutamide withdrawal syndrome is characterized by a drug1 ( PSA ) after drug2 withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate . "
              2 : "Patient 1 presented drug1 1 week after intravenous drug2 injection . "
              3 : "Although dyspnea associated with verapamil administration has been reported , this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an drug1 attack following sustained-release drug2 administration . "
              4 : "We present a drug1 case of subacute drug2 toxicity with associated diffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      221 : 
        {
          1 : "NN dobj VBD acl:relcl NN compound NN"
          2 : 4
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl *irrigation* compound drug0"
              2 : "drug0 dobj had acl:relcl *teratogenicity* compound drug0"
              3 : "drug0 dobj demonstrated acl:relcl *enteritis* compound drug0"
              4 : "drug0 dobj showed acl:relcl *toxicity* compound drug0"
            }
          4 : 
            {
              1 : "We describe a 63 year old woman with a suppurative mediastinitis , treated with continuous drug1 irrigation who developed an drug2 . "
              2 : "We report an additional case of drug1 teratogenicity in which the patient had drug2 , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and abnormalities of the corticospinal tracts . "
              3 : "This report describes a case of drug1 ulcerating enteritis in which the small bowel x-ray demonstrated drug2 , ulceration , and marked separation of loops of bowel . "
              4 : "We present two cases of drug1 pulmonary toxicity in which the initial HRCT showed a drug2 and associated distortion of the lung parenchyma , thought to represent established fibrosis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      222 : 
        {
          1 : "NN compound NN nmod VBN acl NN compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound treatment nmod associated acl *disorder* compound drug0"
              2 : "drug0 compound syndrome nmod referred acl *complex* compound drug0"
              3 : "drug0 compound therapy nmod associated acl *syndrome* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and REM sleep behavior disorder associated with drug2 treatment of depression and obsessive-compulsive disorder . "
              2 : "Its overall toxicity is considerably less compared to standard induction chemotherapy ; however , it is associated with a high incidence of a drug1 complex referred to as `` drug2 syndrome . '' This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis . "
              3 : "drug1 and cerebellar syndrome associated with drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      223 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD nsubj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound therapy dobj beginning advcl *occurred* nsubj drug0"
              2 : "drug0 compound chemotherapy dobj receiving advcl *occurred* nsubj drug0"
              3 : "drug0 compound infusion dobj receiving advcl *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning drug2 therapy . "
              2 : "Severe drug1 occurred in 2 patients ( 6.1 % ) after receiving drug2 combination chemotherapy for ovarian malignancies . "
              3 : "An drug1 and cardiomyopathy developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical drug2 infusion for hemorrhagic cystitis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      224 : 
        {
          1 : "NN dobj VBP acl:relcl NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj develop acl:relcl *drug0*"
              2 : "drug0 dobj develop acl:relcl *drug0*"
              3 : "drug0 dobj develop acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Patients receiving drug1 who develop only drug2 should be evaluated for an adverse drug reaction , as well as for sepsis and fevers of neutropenia , and it may be necessary to discontinue the drug . "
              2 : "Patients treated with drug1 who develop `` drug2 '' should be suspected of having captopril-associated liver damage . "
              3 : "Conversely , diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving drug1 who develop drug2 seen on chest roentgenograms . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      225 : 
        {
          1 : "NN dobj VBG advcl VBD conj VBD dobj NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj commencing advcl stopped conj *developed* dobj fever conj drug0"
              2 : "drug0 dobj commencing advcl stopped conj *developed* dobj fever conj drug0"
              3 : "drug0 dobj commencing advcl stopped conj *developed* dobj fever conj drug0"
            }
          4 : 
            {
              1 : "He developed fever , drug1 , diarrhea , and malaise and stopped taking on the third day after commencing drug2 . "
              2 : "He developed fever , nausea , drug1 , and malaise and stopped taking on the third day after commencing drug2 . "
              3 : "He developed fever , nausea , diarrhea , and drug1 and stopped taking on the third day after commencing drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      226 : 
        {
          1 : "NN dobj VBG advcl VBD nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj starting advcl *presented* nmod drug0"
              2 : "drug0 dobj commencing advcl *presented* nmod drug0"
              3 : "drug0 dobj taking advcl *progressed* nmod drug0"
            }
          4 : 
            {
              1 : "This is an image and brief case report of a 13-year-old boy who presented with drug1 and systemic symptoms after starting drug2 . "
              2 : "We report a 4-year-old girl who presented with drug1 , a focal seizure and hypertension 10 days after commencing drug2 to treat enuresis . "
              3 : "OBJECTIVES : To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to drug1 while taking drug2 and to perform a review of the literature . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      227 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj alfa nmod treated acl patient nmod *development* nmod drug0"
              2 : "drug0 conj prednisolone nmod treated acl erythematosus nmod child nmod *drug0*"
              3 : "drug0 conj methylprednisolone nmod treated acl asthmaticus nmod *myopathy* nmod drug0"
            }
          4 : 
            {
              1 : "Development of essential drug1 in a patient treated with interferon alfa and drug2 for hairy cell leukemia . "
              2 : "This is a case report of fatal drug1 in a child with systemic lupus erythematosus being treated with prednisolone and drug2 . "
              3 : "Acute myopathy with selective drug1 following status asthmaticus treated with methylprednisolone and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      228 : 
        {
          1 : "NN nmod NN nmod NN nmod NN conj NN compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod period nmod persistence conj *reaction* compound drug0"
              2 : "drug0 compound therapy conj lamivudine nmod transplantation nmod *outcome* nmod drug0"
              3 : "drug0 compound lotion conj acenocoumarol nmod interaction nmod relation nmod *drug0*"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken mequitazine for 6 months , and there were strong positive photopatch test results with immediate drug1 reaction , cross-reaction to promethazine , decreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the drug2 . "
              2 : "Favorable outcome of de novo drug1 after liver transplantation with lamivudine and drug2 therapy . "
              3 : "drug1 in relation to an interaction between acenocoumarol and topical drug2 lotion . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      229 : 
        {
          1 : "NN nmod VBN nsubjpass NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod *associated* nsubjpass leukemia conj drug0"
              2 : "drug0 nmod *implicated* nsubjpass ethambutol conj drug0"
              3 : "drug0 nmod *shown* nsubjpass hydroxyurea conj drug0"
            }
          4 : 
            {
              1 : "Chronic myelogenous leukemia ( CML ) , hepatitis C , and drug1 ( IFNalpha ) have all been associated with drug2 . "
              2 : "RESULTS : Ethambutol , and to a lesser extent drug1 , are both implicated in the drug2 . "
              3 : "Hydroxyurea ( HU ) and drug1 ( SPB ) have been shown to drug2 ( Hb F ) levels in patients with thalassemia intermedia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      230 : 
        {
          1 : "NN compound NN nmod VBD nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound treatment nmod *complained* nmod drug0"
              2 : "drug0 nmod *complained* nmod dose compound drug0"
              3 : "drug0 compound administration nmod *presented* nmod drug0"
            }
          4 : 
            {
              1 : "We report on a 37-year-old female who complained of moderate drug1 during drug2 treatment . "
              2 : "With the first drug1 dose , the patient complained of drug2 that was most severe during the cyclosporine infusion . "
              3 : "We report a case of AILD in an 80-year-old male who presented with a drug1 and fever following drug2 administration . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      231 : 
        {
          1 : "NN nmod NN nmod VBN acl NN nsubj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod use nmod associated acl *effect* nsubj drug0"
              2 : "drug0 nmod co-administration nmod associated acl *reaction* nsubj drug0"
              3 : "drug0 nmod use nmod associated acl *complication* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a very rare adverse effect associated with the use of drug2 , and only four cases of amiodarone-induced pancreatitis have been reported in literature . "
              2 : "Based on the Naranjo probability scale , drug1 was a probable adverse reaction associated with co-administration of drug2 and fentanyl . "
              3 : "drug1 is a rare complication associated with the use of drug2 for the treatment of tuberculosis , usually occurring well into the course of therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      232 : 
        {
          1 : "NN nmod VBG advcl VBG dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod complaining advcl *taking* dobj drug0"
              2 : "drug0 dobj receiving advcl *leading* nmod drug0"
            }
          4 : 
            {
              1 : "He had been taking drug1 for approximately eight days when he revisited his family physician , complaining of drug2 , dizziness , difficulty with speech , weakness , and itching on the trunk of his body and legs , where a maculopapular rash was noted . "
              2 : "We describe a patient with acute leukemia who developed Horner 's syndrome and a severe demyelinating peripheral neuropathy leading to drug1 after receiving high-dose drug2 . "
            }
          5 : 
            {
              1 : 2
              2 : 1
            }
        }
      233 : 
        {
          1 : "NN conj NN nmod NN nmod VBD nsubj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj carbamazepine nmod cessation nmod *subsided* nsubj drug0"
              2 : "drug0 conj sulfate nmod treatment nmod *developed* nsubj drug0"
              3 : "drug0 conj sulfate nmod treatment nmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 subsided after the cessation of carbamazepine and drug2 . "
              2 : "drug1 developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate , drug2 , and asparaginase . "
              3 : "drug1 developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate , prednisone , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      234 : 
        {
          1 : "NN nmod NNS dobj VBG advcl VBD dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod doses dobj taking advcl *developed* dobj drug0"
              2 : "drug0 nmod doses dobj receiving advcl *developed* dobj drug0"
              3 : "drug0 nmod courses dobj receiving advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A patient with seropositive rheumatoid arthritis developed drug1 while taking weekly doses of drug2 ( MTX ) . "
              2 : "Described here are 2 patients who developed drug1 of the kidneys after receiving high cumulative doses of the new anticancer drug drug2 . "
              3 : "We describe a patient with acute myeloblastic leukemia ( AML ) who developed drug1 after receiving several courses of chemotherapy , including drug2 ( M-CSF ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      235 : 
        {
          1 : "NN nmod VBG advcl VBN acl NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod transitioning advcl induced acl *drug0*"
              2 : "drug0 nmod replacing advcl induced acl *drug0*"
              3 : "drug0 nmod transitioning advcl induced acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 induced by transitioning from phenelzine to drug2 : four patient reports . "
              2 : "drug1 induced by replacing fluvoxamine with drug2 . "
              3 : "drug1 induced by transitioning from drug2 to venlafaxine : four patient reports . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      236 : 
        {
          1 : "VB xcomp JJ amod NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 xcomp secondary amod *cardiomyopathy* conj drug0"
              2 : "drug0 xcomp secondary amod *agranulocytosis* conj drug0"
              3 : "drug0 xcomp secondary amod *rash* conj drug0"
            }
          4 : 
            {
              1 : "However , acute cardiomyopathy and drug1 secondary to drug2 use has been rarely reported . "
              2 : "We present the management of agranulocytosis and drug1 secondary to drug2 with recombinant human granulocyte colony stimulating factor ( G-CSF ) . "
              3 : "We report the case of a 27-year-old Indian woman who developed maculopapular rash and drug1 secondary to drug2 administration . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      237 : 
        {
          1 : "NN nmod NN dep NNS compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod report dep *symptoms* compound drug0"
              2 : "drug0 nmod cause dep *hus* compound drug0"
              3 : "drug0 nmod course dep *days* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and obsessive-compulsive symptoms ( OCS ) : case report and review of atypical antipsychotic-induced drug2 . "
              2 : "drug1 HUS : an unusual cause of drug2 in nephrotic syndrome . "
              3 : "This patient developed sequential symptoms including alternative hemiparesis , dysarthria and drug1 5 days after the second course of drug2 ( 8 gm/m2 by 6 h continuous infusion ) with leucovorin rescue . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      238 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBD nsubj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod withdrawal nmod hours nmod *improved* nsubj drug0"
              2 : "drug0 nmod treatment nmod days nmod *resulted* nsubj drug0"
              3 : "drug0 nmod treatment nmod months nmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 improved dramatically within 72 hours of the withdrawal of drug2 . "
              2 : "drug1 resulted after 19 days of treatment with drug2 and amphotericin B . "
              3 : "drug1 ( TTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1/2 months of treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      239 : 
        {
          1 : "NN nmod NN dobj VBD nsubj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod influence dobj *had* nsubj drug0"
              2 : "drug0 nmod treatment dobj *followed* nsubj drug0"
              3 : "drug0 nmod development dobj *induced* nsubj drug0"
            }
          4 : 
            {
              1 : "Intravitreal drug1 may have had an influence on the drug2 in the posterior pole of the patient . "
              2 : "This is , to the best of our knowledge , the first report of a case in which drug1 followed treatment with both drug2 and methimazole in the same patient . "
              3 : "We assume that drug1 induced the de novo development of drug2 in our patient . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      240 : 
        {
          1 : "NN nmod NN nmod NNP conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod cause nmod *isoniazid* conj drug0"
              2 : "drug0 nmod treatment nmod *polyarthritis* conj drug0"
              3 : "drug0 nmod treatment nmod *polyarthritis* conj drug0"
            }
          4 : 
            {
              1 : "Isoniazid and drug1 as a cause of drug2 . "
              2 : "Polyarthritis , hepatitis and drug1 after treatment with drug2 and rifampicin . "
              3 : "Polyarthritis , drug1 and anti-native DNA antibodies after treatment with drug2 and rifampicin . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      241 : 
        {
          1 : "NN conj NN dobj VBD conj VBD dobj NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj hypertension dobj developed conj *received* dobj injection nmod drug0"
              2 : "drug0 conj hypertension dobj developed conj *received* dobj injection nmod drug0"
              3 : "drug0 conj hypertension dobj developed conj *received* dobj injection nmod drug0"
            }
          4 : 
            {
              1 : "She received an accidental 450-mg bolus injection of drug1 intrathecally and developed hypertension , drug2 , intracerebral hemorrhage , and respiratory failure . "
              2 : "She received an accidental 450-mg bolus injection of drug1 intrathecally and developed hypertension , status epilepticus , drug2 , and respiratory failure . "
              3 : "She received an accidental 450-mg bolus injection of drug1 intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      242 : 
        {
          1 : "NN nmod VBN acl NN nmod NN nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod induced acl arthritis nmod remission nmod *association* nmod drug0"
              2 : "drug0 nmod treated acl syndrome nmod patient nmod *failure* nmod drug0"
              3 : "drug0 nmod treated acl sclerosis nmod patient nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "This case demonstrates the association of selective drug1 with remission in rheumatoid arthritis induced by drug2 as well as aurothiomalate and sulphasalazine . "
              2 : "Acute renal failure with drug1 in a patient with minimal change nephrotic syndrome treated with drug2 . "
              3 : "Development of drug1 in a patient with multiple sclerosis treated with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      243 : 
        {
          1 : "NN dobj VBD conj VBN dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj developed conj *prescribed* dobj drug0"
              2 : "drug0 dobj developed conj *given* dobj drug0"
              3 : "drug0 dobj developed conj *given* dobj drug0"
            }
          4 : 
            {
              1 : "The current report describes a man who was prescribed drug1 for epilepsy and subsequently developed widespread drug2 , acute kidney injury , high-grade fever , eosinophilia , liver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer . "
              2 : "Presentation of three palliative care patients who were given drug1 as an analgesic and subsequently developed significant and debilitating drug2 . "
              3 : "A patient with an allergy to a macrolide antibiotic was given drug1 and developed a drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      244 : 
        {
          1 : "NN conj NN nmod NN nmod NN nmod NNS nmod:tmod VBD dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj etoglucid nmod cancer nmod chemotherapy nmod years nmod:tmod *developed* dobj drug0"
              2 : "drug0 conj etoglucid nmod cancer nmod chemotherapy nmod years nmod:tmod *developed* dobj drug0"
              3 : "drug0 conj daunomycin nmod combination nmod treatment nmod months nmod:tmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Two cases are reported of patients who developed a drug1 several years after intravesical chemotherapy of superficial bladder cancer with etoglucid , drug2 , and mitomycin C . "
              2 : "Two cases are reported of patients who developed a drug1 several years after intravesical chemotherapy of superficial bladder cancer with etoglucid , doxorubicin , and drug2 . "
              3 : "We report the case of a 14-year-old female with acute promyelocytic leukemia who developed drug1 only 4 months into treatment with a combination of daunomycin and drug2 ( ATRA ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      245 : 
        {
          1 : "NN appos NN dobj VBD nsubj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 appos tachycardia dobj *induced* nsubj drug0"
              2 : "drug0 appos tachycardia dobj *induced* nsubj drug0"
              3 : "drug0 appos psoriasis dobj *provoked* nsubj drug0"
            }
          4 : 
            {
              1 : "A 44-year-old woman is described in whom amiodarone , disopyramide , and drug1 , administered alone separately , induced atypical ventricular tachycardia ( drug2 , torsade de pointes ) . "
              2 : "A 44-year-old woman is described in whom drug1 , disopyramide , and quinidine , administered alone separately , induced atypical ventricular tachycardia ( drug2 , torsade de pointes ) . "
              3 : "We report a patient in whom the anti-depressant drug1 ( Molipaxin , Roussel ) , a serotonin antagonist , provoked generalized pustular psoriasis ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      246 : 
        {
          1 : "NN conj NN nmod VBN acl NN nsubj NN appos NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj rapamycin/sirolimus appos drug0"
              2 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj rapamycin/sirolimus appos drug0"
              3 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj rapamycin/sirolimus appos drug0"
            }
          4 : 
            {
              1 : "Rapamycin/sirolimus ( drug1 ) , trade named Rapammune ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , drug2 , hyperlipidemia , and infection . "
              2 : "Rapamycin/sirolimus ( drug1 ) , trade named Rapammune ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , hypertension , hyperlipidemia , and drug2 . "
              3 : "Rapamycin/sirolimus ( drug1 ) , trade named Rapammune ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , hypertension , drug2 , and infection . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      247 : 
        {
          1 : "NN dobj VBZ nsubj NN compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj *causes* nsubj overdose compound drug0"
              2 : "drug0 dobj *induces* nsubj application compound drug0"
              3 : "drug0 dobj *induces* nsubj ingestion compound drug0"
            }
          4 : 
            {
              1 : "drug1 overdose causes an drug2 , many similar to reported adverse effects during therapeutic use . "
              2 : "Chronic drug1 application induces drug2 . "
              3 : "Acute drug1 ingestion induces drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      248 : 
        {
          1 : "NN conj NN dobj VBD nsubj NNS compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj hirsutism dobj *included* nsubj effects compound drug0"
              2 : "drug0 conj hirsutism dobj *included* nsubj effects compound drug0"
              3 : "drug0 conj hirsutism dobj *included* nsubj effects compound drug0"
            }
          4 : 
            {
              1 : "drug1 side effects included hirsutism , hypertension , drug2 , and abnormalities in liver function tests . "
              2 : "drug1 side effects included hirsutism , drug2 , increased blood levels of urea and creatinine , and abnormalities in liver function tests . "
              3 : "drug1 side effects included hirsutism , hypertension , increased blood levels of urea and creatinine , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      249 : 
        {
          1 : " NN nsubj NNS nmod NN"
          2 : 3
          3 : 
            {
              1 : " *drug0* nsubj side-effects nmod drug0"
              2 : "drug0 nmod *causes* nsubj drug0"
              3 : "drug0 nmod *effects* nsubj drug0"
            }
          4 : 
            {
              1 : "The main side-effects of drug1 combined with HT were drug2 , localized pain , myelo-suppression and liver dysfunction , but these were transient and eventually disappeared . "
              2 : "drug1 and its isomer quinidine are well-known causes of drug2 , due to excessive insulin secretion . "
              3 : "The observations suggest that drug1 and pain are side effects of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      250 : 
        {
          1 : " NN nsubj NNS nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : " *drug0* nsubj hazards nmod treatment nmod drug0"
              2 : "drug0 nmod therapy nmod *complications* nsubj drug0"
              3 : "drug0 nmod treatment nmod *hazards* nsubj drug0"
            }
          4 : 
            {
              1 : "Although major hazards of treatment of hypophosphatemic osteomalacia with drug1 and calcitriol are drug2 and vitamin D intoxication , potassium loss also should be kept in mind . "
              2 : "drug1 are well-documented complications of therapy with drug2 , even when small doses are used . "
              3 : "Although myelosuppression is mild , drug1 and superinfection are potential hazards of treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      251 : 
        {
          1 : "NN nmod NN nmod VBD advmod RB"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod administration nmod *developed* advmod drug0"
              2 : "drug0 nmod tocolysis nmod *developed* advmod drug0"
              3 : "drug0 nmod infusion nmod *developed* advmod drug0"
            }
          4 : 
            {
              1 : "We report on a patient with renal artery stenosis who had only 1 kidney and in whom drug1 developed with transient anuria after the administration of drug2 . "
              2 : "Four patients in whom drug1 developed during tocolysis with drug2 are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed . "
              3 : "We describe a patient in whom drug1 developed during intrabiliary infusion of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      252 : 
        {
          1 : "NN conj VBN dep VBD nmod NN conj NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj defined dep *developed* nmod chemotherapy conj injection nmod drug0"
              2 : "drug0 conj defined dep *developed* nmod chemotherapy conj injection nmod drug0"
              3 : "drug0 conj defined dep *developed* nmod chemotherapy conj injection nmod drug0"
            }
          4 : 
            {
              1 : "Shortly after chemotherapy and an injection of drug1 , the patient developed poorly defined , rapidly progressive erythema , edema , and drug2 . "
              2 : "Shortly after chemotherapy and an injection of drug1 , the patient developed poorly defined , drug2 , edema , and pain in his right forearm . "
              3 : "Shortly after chemotherapy and an injection of drug1 , the patient developed poorly defined , rapidly progressive erythema , drug2 , and pain in his right forearm . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      253 : 
        {
          1 : "NN nmod VBN acl NN nmod NN compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *syndrome* compound drug0"
              2 : "drug0 nmod manifested acl *case* nmod vasculitis compound drug0"
              3 : "drug0 compound administration nmod *coagulation* acl associated nmod drug0"
            }
          4 : 
            {
              1 : "This case of linezolid-associated acute interstitial nephritis within the context of a drug1 ( DRESS ) syndrome in a patient treated with drug2 raises concerns about the presumed renal safety of this drug . "
              2 : "CONCLUSION : This rare case of drug1 ANCA-associated vasculitis manifested with drug2 in combination with systemic involvement . "
              3 : "Disseminated intravascular coagulation associated with drug1 or hemoglobinuria following drug2 intravenous administration for immune thrombocytopenic purpura . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      254 : 
        {
          1 : "NN nsubj VBD nmod NN nmod NN nmod NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nsubj *developed* nmod day nmod tocolysis nmod sulfate conj drug0"
              2 : "drug0 nsubj *developed* nmod day nmod tocolysis nmod sulfate conj drug0"
              3 : "drug0 nsubj *developed* nmod day nmod tocolysis nmod sulfate conj drug0"
            }
          4 : 
            {
              1 : "On the fifth day of tocolysis with magnesium sulfate , nifedipine , drug1 and betamethasone , drug2 developed in both labia . "
              2 : "On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and drug1 , drug2 developed in both labia . "
              3 : "On the fifth day of tocolysis with magnesium sulfate , drug1 , terbutaline and betamethasone , drug2 developed in both labia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      255 : 
        {
          1 : "NN dep NNS nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dep weeks nmod *drug0*"
              2 : "drug0 dep weeks nmod *drug0*"
              3 : "drug0 dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "A 53-year-old man developed drug1 4 weeks after drug2 was increased from 4 mg once/day to 4 mg twice/day . "
              2 : "A 77-year-old man developed drug1 2 weeks after starting drug2 . "
              3 : "A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and drug1 two weeks after starting drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      256 : 
        {
          1 : "NN nmod NNS nmod NNS dep NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod doses nmod *reactions* dep diarrhea conj drug0"
              2 : "drug0 nmod doses nmod *reactions* dep diarrhea conj drug0"
              3 : "drug0 nmod doses nmod *reactions* dep diarrhea conj drug0"
            }
          4 : 
            {
              1 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for 5-FU catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , mucositis , drug1 , neurotoxicity ) to standard doses of drug2 . "
              2 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for 5-FU catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , drug1 , myelosuppression , neurotoxicity ) to standard doses of drug2 . "
              3 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for 5-FU catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , drug1 , mucositis , myelosuppression , neurotoxicity ) to standard doses of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      257 : 
        {
          1 : "NN nmod NN nmod VBD dobj NNS conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod administration nmod *developed* dobj eruptions conj drug0"
              2 : "drug0 nmod extravasation nmod *developed* dobj cellulitis conj drug0"
              3 : "drug0 nmod introduction nmod *developed* dobj signs conj drug0"
            }
          4 : 
            {
              1 : "However , one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea , and another four patients developed eruptions , drug1 , and tachycardia soon after administration of drug2 . "
              2 : "This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and drug1 following the extravasation of intravenous drug2 into the soft tissues of the left hand and forearm . "
              3 : "We present a depressive patient who developed mild parkinsonian signs and drug1 after the introduction of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      258 : 
        {
          1 : "NN nmod VBG advcl VBD dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod receiving advcl *developed* dobj drug0"
              2 : "drug0 nmod receiving advcl *experienced* dobj drug0"
              3 : "drug0 nmod receiving advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed drug1 while receiving continuous bladder irrigations with drug2 . "
              2 : "A 21-year-old man with Tourette 's syndrome , pedophilia , Asperger 's syndrome , and multiple sclerosis experienced drug1 after receiving therapy with drug2 . "
              3 : "A 16-year-old boy developed drug1 , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with drug2 and lithium . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      259 : 
        {
          1 : "NN compound NN nmod NNS nmod VBN nsubjpass NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound therapy nmod patients nmod *described* nsubjpass drug0"
              2 : "drug0 nsubjpass *seen* nmod days nmod treatment compound drug0"
              3 : "drug0 compound hemorrhage nmod patients nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 and ventricular tachyarrhymias have been described in patients on drug2 therapy . "
              2 : "During the first days of drug1 treatment a rapid drug2 was seen ( normal values reached until day 7 ) , together with a slight decrease in peripheral blood leukocytes . "
              3 : "drug1 and acute renal failure were observed in two patients with drug2 gastrointestinal hemorrhage . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      260 : 
        {
          1 : "NN appos NN nmod NN nmod NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 appos propylthiouracil nmod *association* nmod granulocytopenia conj drug0"
              2 : "drug0 appos propylthiouracil nmod *association* nmod granulocytopenia conj drug0"
              3 : "drug0 appos propylthiouracil nmod *association* nmod granulocytopenia conj drug0"
            }
          4 : 
            {
              1 : "An association of granulocytopenia , eosinophilia , drug1 and hepatitis during propylthiouracil ( drug2 ) therapy for thyrotoxicosis in a 47 year old black female is reported . "
              2 : "An association of granulocytopenia , drug1 , skin reaction and hepatitis during propylthiouracil ( drug2 ) therapy for thyrotoxicosis in a 47 year old black female is reported . "
              3 : "An association of granulocytopenia , eosinophilia , skin reaction and drug1 during propylthiouracil ( drug2 ) therapy for thyrotoxicosis in a 47 year old black female is reported . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      261 : 
        {
          1 : "NN dobj VBG advcl VBN dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj taking advcl *developed* dobj drug0"
              2 : "drug0 dobj taking advcl *developed* dobj drug0"
              3 : "drug0 dobj demonstrated advcl *receiving* dobj drug0"
            }
          4 : 
            {
              1 : "A 69-year-old man developed drug1 after taking drug2 for ten months . "
              2 : "A 57-year-old man developed drug1 while taking drug2 . "
              3 : "Four patients receiving high-dose drug1 for greater than 1 year have demonstrated similar drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      262 : 
        {
          1 : "NN nmod NN dobj VBG dep NNS nmod VBD nsubj NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod treatment dobj initiating dep weeks nmod *developed* nsubj fever conj drug0"
              2 : "drug0 nmod treatment dobj initiating dep weeks nmod *developed* nsubj fever conj drug0"
              3 : "drug0 nmod treatment dobj initiating dep weeks nmod *developed* nsubj fever conj drug0"
            }
          4 : 
            {
              1 : "In both cases , high fever , drug1 , liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with drug2 . "
              2 : "In both cases , high fever , skin rash , drug1 and atypical lymphocytosis developed 3 weeks after initiating treatment with drug2 . "
              3 : "In both cases , high fever , skin rash , liver dysfunction and drug1 developed 3 weeks after initiating treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      263 : 
        {
          1 : "NN nmod NN nmod VBP dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod response nmod *develop* dobj drug0"
              2 : "drug0 nmod use nmod *develop* dobj drug0"
              3 : "drug0 nmod development nmod *link* dobj drug0"
            }
          4 : 
            {
              1 : "Some patients develop drug1 in response to drug2 . "
              2 : "CONCLUSION : Hypersensitivity reaction should be considered in patients who develop drug1 and deterioration of pulmonary function following the use of drug2 by inhalation or by intravenous administration . "
              3 : "Although a few case reports link drug1 with the development of drug2 , albendazole has not been associated with the development of this condition . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      264 : 
        {
          1 : "NN nmod NN dep NNS nmod VBD dobj NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod treatment dep weeks nmod *developed* dobj fever conj drug0"
              2 : "drug0 nmod cessation dep weeks nmod *developed* dobj pancreatitis conj drug0"
              3 : "drug0 nmod treatment dep weeks nmod *developed* dobj fever conj drug0"
            }
          4 : 
            {
              1 : "A 58-year-old woman with rheumatoid arthritis ( RA ) developed fever , skin eruptions , drug1 , and thrombocytopenia , 3 weeks after treatment with drug2 . "
              2 : "An adolescent male developed acute pancreatitis and drug1 16 weeks after cessation of intramuscular drug2 . "
              3 : "A 58-year-old woman with rheumatoid arthritis ( RA ) developed fever , drug1 , leukocytopenia , and thrombocytopenia , 3 weeks after treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      265 : 
        {
          1 : "NN conj NN dobj VBG acl JJ dep CD dep VBD nsubj NNS acl:relcl VBN dobj NNS nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj infusion dobj involving acl other dep one dep *experienced* nsubj patients acl:relcl received dobj courses nmod drug0"
              2 : "drug0 conj infusion dobj involving acl other dep one dep *experienced* nsubj patients acl:relcl received dobj courses nmod drug0"
              3 : "drug0 conj infusion dobj involving acl other dep one dep *experienced* nsubj patients acl:relcl received dobj courses nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with ovarian cancer who had received multiple courses of drug1 without complications experienced hypersensitivity reactions to cisplatin : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and drug2 . "
              2 : "Two patients with ovarian cancer who had received multiple courses of drug1 without complications experienced hypersensitivity reactions to cisplatin : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested drug2 , general erythema , and fever . "
              3 : "Two patients with ovarian cancer who had received multiple courses of drug1 without complications experienced hypersensitivity reactions to cisplatin : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , drug2 , and fever . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      266 : 
        {
          1 : "NN conj NN dobj VBD nmod NN nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj fever dobj *developed* nmod institution nmod therapy nmod drug0"
              2 : "drug0 conj fever dobj *developed* nmod institution nmod therapy nmod drug0"
              3 : "drug0 nmod hyperthyroidism nmod treatment nmod *developed* dobj weakness conj drug0"
            }
          4 : 
            {
              1 : "Following the institution of intravenous therapy with drug1 , the patient developed fever , drug2 , and a pleural friction rub . "
              2 : "Following the institution of intravenous therapy with drug1 , the patient developed fever , hemoptysis , and a drug2 . "
              3 : "A patient is presented with typical hyperthyroidism , who developed a severe proximal muscle weakness and a drug1 after treatment for hyperthyroidism with drug2 ( 100 mg orally , three times a day ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      267 : 
        {
          1 : "NN xcomp VBG acl NN dobj VB nsubj NN nmod NNS nmod NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 xcomp resembling acl condition dobj *induce* nsubj treatment nmod drugs nmod cyclosporine conj drug0"
              2 : "drug0 xcomp resembling acl condition dobj *induce* nsubj treatment nmod drugs nmod cyclosporine conj drug0"
              3 : "drug0 xcomp resembling acl condition dobj *induce* nsubj treatment nmod drugs nmod cyclosporine conj drug0"
            }
          4 : 
            {
              1 : "Moreover , treatment with immunosuppressive drugs such as cyclosporine , cisplatin , drug1 , and interferon-alpha can induce a condition resembling drug2 . "
              2 : "Moreover , treatment with immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and drug1 can induce a condition resembling drug2 . "
              3 : "Moreover , treatment with immunosuppressive drugs such as cyclosporine , drug1 , tacrolimus , and interferon-alpha can induce a condition resembling drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      268 : 
        {
          1 : "NN nmod NN nmod VBD xcomp NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod overdose nmod *became* xcomp drug0"
              2 : "drug0 nmod injection nmod *became* xcomp drug0"
              3 : "drug0 nmod drop nmod *became* xcomp drug0"
            }
          4 : 
            {
              1 : "METHODS : A 55-year-old woman became drug1 after overdose with drug2 ( LTG ) and valproic acid ( VPA ) tablets . "
              2 : "Both patients suddenly became drug1 after injection of drug2 into a disk . "
              3 : "An 11-day-old infant became drug1 and apneic after a single drop of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      269 : 
        {
          1 : "NN nmod NN nmod VBD dobj NNS nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod treatment nmod *developed* dobj signs nmod drug0"
              2 : "drug0 nmod treatment nmod *produced* dobj cases nmod drug0"
              3 : "drug0 nmod symptoms dobj *presented* nmod administration nmod drug0"
            }
          4 : 
            {
              1 : "We describe a 43-year-old man who developed signs and symptoms of drug1 during treatment with drug2 . "
              2 : "First , a review of the literature produced 41 anecdotic cases of drug1 or agranulocytosis during treatment with drug2 ( Zyprexa ) reported in a total of 24 publications . "
              3 : "After administration of drug1 concomitantly with an increase in the dose of Dantrolene , she presented the clinical symptoms and laboratory finding of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      270 : 
        {
          1 : "NN conj NN nmod VBN acl NN nsubj NN appos NN acl VBN xcomp NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj rapamycin/sirolimus appos trade acl named xcomp drug0"
              2 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj rapamycin/sirolimus appos trade acl named xcomp drug0"
              3 : "drug0 conj myelosuppression nmod associated acl *drug* nsubj rapamycin/sirolimus appos trade acl named xcomp drug0"
            }
          4 : 
            {
              1 : "Rapamycin/sirolimus ( SR ) , trade named drug1 ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , hypertension , drug2 , and infection . "
              2 : "Rapamycin/sirolimus ( SR ) , trade named drug1 ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , drug2 , hyperlipidemia , and infection . "
              3 : "Rapamycin/sirolimus ( SR ) , trade named drug1 ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with myelosuppression , hypertension , hyperlipidemia , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      271 : 
        {
          1 : "NN compound NN nmod NN nmod VBD acl:relcl NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound therapy nmod discontinuation nmod disappeared acl:relcl *drug0*"
              2 : "drug0 compound administration nmod effect nmod occurred acl:relcl *drug0*"
              3 : "drug0 compound therapy nmod cessation nmod resolved acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "The electrocardiogram ( ECG ) , which was read as normal prior to ritodrine infusion , demonstrated a drug1 which disappeared upon discontinuation of drug2 therapy . "
              2 : "PURPOSE : To describe drug1 that occurred as an adverse effect of recombinant and natural drug2 administration . "
              3 : "It was restarted 6 weeks later , and 10 weeks after that , the patient presented with drug1 , which resolved rapidly after cessation of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      272 : 
        {
          1 : "NN nmod VB nsubj NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod *cause* nsubj administration nmod drug0"
              2 : "drug0 nmod *reduce* nsubj addition nmod drug0"
              3 : "drug0 nmod *predispose* nsubj overdose nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : The administration of drug1 to neonates can cause gastric-outlet obstruction due to drug2 . "
              2 : "CONCLUSIONS : The value of multihormonal therapy in breast carcinoma is not established , and the addition of progestogens to drug1 may not reduce of developing drug2 , including carcinoma . "
              3 : "Overdose of drug1 in combination with renal insufficiency , hypocalcemia , or compromise of intestinal integrity may predispose horses to drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      273 : 
        {
          1 : "NN compound NN nmod JJ nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound anesthesia nmod *sensitive* nmod drug0"
              2 : "drug0 compound injection nmod *typical* nmod drug0"
              3 : "drug0 compound administration nmod *prone* nmod drug0"
            }
          4 : 
            {
              1 : "Patients with vitamin B12 deficiency are exceedingly sensitive to drug1 following drug2 anesthesia . "
              2 : "CONCLUSIONS : The fundus picture shown in these cases may be typical of drug1 after drug2 injection . "
              3 : "Since elevated cortisol levels in Cushing 's disease poses a threat for pancreatitis , there is a possibility that patients with Cushing 's disease might be more prone to drug1 following drug2 administration . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      274 : 
        {
          1 : "NN nmod NNS nmod NN nmod VBN nsubjpass NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod reactions nmod list nmod *added* nsubjpass drug0"
              2 : "drug0 nmod antibodies nmod administration nmod *associated* nsubjpass drug0"
              3 : "drug0 nmod patients nmod % nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "These cases and a review of the literature suggested that drug1 , though rare , should be added to the list of adverse reactions to drug2 . "
              2 : "drug1 has been associated with the administration of other monoclonal antibodies , such as drug2 , gemtuzumab ozogamicin , and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines . "
              3 : "drug1 ( AST and ALT > 5 to 20 upper limit normal ) or higher has been observed in as many as 1.4 % of MS patients on drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      275 : 
        {
          1 : "NN compound NN conj NN nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound combination conj cisplatin nmod treatment nmod *drug0*"
              2 : "drug0 compound therapy conj interferon-alfa nmod *development* nmod drug0"
              3 : "drug0 compound therapy conj 0b nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "drug1 during treatment with cisplatin and drug2 combination . "
              2 : "Late development of drug1 after interferon-alfa and drug2 therapy for chronic hepatitis C : a case report . "
              3 : "Development of drug1 during interferon alpha 2b and drug2 combination therapy for chronic hepatitis C -- a case report and review of the literature . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      276 : 
        {
          1 : "NN conj NN dep NNS dobj VBP nsubj NNS nmod NNS compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj dizziness dep effects dobj *include* nsubj events nmod doses compound drug0"
              2 : "drug0 conj dizziness dep effects dobj *include* nsubj events nmod doses compound drug0"
              3 : "drug0 conj dizziness dep effects dobj *include* nsubj events nmod doses compound drug0"
            }
          4 : 
            {
              1 : "Common adverse events ( frequency 10 % ) of drug1 doses up to 600 mg/day include nonspecific central nervous system effects ( e.g. , dizziness , ataxia , diplopia , and drug2 ) . "
              2 : "Common adverse events ( frequency 10 % ) of drug1 doses up to 600 mg/day include nonspecific central nervous system effects ( e.g. , dizziness , drug2 , diplopia , and somnolence ) . "
              3 : "Common adverse events ( frequency 10 % ) of drug1 doses up to 600 mg/day include nonspecific central nervous system effects ( e.g. , dizziness , ataxia , drug2 , and somnolence ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      277 : 
        {
          1 : "NN compound NN nmod VBP dobj NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound ingestion nmod *present* dobj case nmod drug0"
              2 : "drug0 compound injection nmod *describe* dobj case nmod drug0"
              3 : "drug0 compound treatment nmod *describe* dobj development nmod drug0"
            }
          4 : 
            {
              1 : "We present a case of drug1 after drug2 ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis . "
              2 : "In this article , we describe another case of drug1 following repeated drug2 injection , presented as localized panniculitis in the area around the injection sites , in a 46-year-old female patient who was treated with glatiramer acetate for 18 months . "
              3 : "We describe the exceptional development of drug1 and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after drug2 treatment followed by autologous peripheral blood stem-cell transplantation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      278 : 
        {
          1 : "NN compound NN nmod NNS nmod VBN acl NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound pneumonitis nmod cases nmod seen acl *eosinophilia* conj drug0"
              2 : "drug0 compound treatment nmod symptoms nmod associated acl *enlargement* conj drug0"
              3 : "drug0 compound treatment nmod symptoms nmod associated acl *enlargement* conj drug0"
            }
          4 : 
            {
              1 : "Pulmonary eosinophilia or drug1 , classically seen in previously reported cases of drug2 pneumonitis , were not observed . "
              2 : "In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true thymic hyperplasia ) , drug1 and pleurisy associated with systemic symptoms under drug2 treatment . "
              3 : "In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true thymic hyperplasia ) , mediastinal lymphadenopathy and drug1 associated with systemic symptoms under drug2 treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      279 : 
        {
          1 : "NN nmod VBN acl NN nmod VBG acl NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod occurring acl *drug0*"
              2 : "drug0 nmod treated acl patient nmod terminating acl *drug0*"
              3 : "drug0 nmod treated acl epithelioma nmod arising acl *drug0*"
            }
          4 : 
            {
              1 : "A case report of the drug1 occurring in a patient being treated with drug2 for a brown recluse spider bite is presented . "
              2 : "drug1 terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with drug2 . "
              3 : "drug1 arising in a basal-cell epithelioma treated with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      280 : 
        {
          1 : "NN nmod VBG dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod *taking* dobj drug0"
              2 : "drug0 nmod *precipitating* dobj drug0"
              3 : "drug0 nmod *taking* dobj drug0"
            }
          4 : 
            {
              1 : "After 5 weeks of therapy , she stopped taking drug1 due to drug2 . "
              2 : "We observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio , indicating that dose and rate of infusion may be important factors in precipitating drug1 with drug2 . "
              3 : "Eleven patients developed infection requiring hospitalization while taking drug1 including : drug2 ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      281 : 
        {
          1 : "NN nmod NN dobj VBD nmod NN compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod episode dobj *experienced* nmod therapy compound drug0"
              2 : "drug0 compound therapy nmod *developed* dobj nephritis nmod drug0"
              3 : "drug0 compound therapy nmod *presented* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "A patient , while on intravenous drug1 therapy for preterm labor , experienced an episode of drug2 . "
              2 : "In the following case report , a patient developed acute interstitial nephritis with drug1 and exfoliative dermatitis following drug2 therapy . "
              3 : "The authors presented a case of drug1 during drug2 therapy , while she has been on lithium for 6 years . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      282 : 
        {
          1 : "NN conj NN nmod NNS nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj drowsiness nmod *symptoms* nmod drug0"
              2 : "drug0 conj cyclosporin nmod patients nmod *drug0*"
              3 : "drug0 conj drowsiness nmod *symptoms* nmod drug0"
            }
          4 : 
            {
              1 : "During clarithromycin coadministration , four out of the seven patients developed moderate-to-severe toxic symptoms of drug1 , such as drowsiness , drug2 , and ataxia , which resolved within 5 days after clarithromycin discontinuation . "
              2 : "drug1 in bone marrow transplant patients on cyclosporin and drug2 . "
              3 : "During clarithromycin coadministration , four out of the seven patients developed moderate-to-severe toxic symptoms of drug1 , such as drowsiness , dizziness , and drug2 , which resolved within 5 days after clarithromycin discontinuation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      283 : 
        {
          1 : "NN conj NNS nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj sulfonylureas nmod *drug0*"
              2 : "drug0 nmod *seizures* conj drug0"
              3 : "drug0 conj sulfonylureas nmod *drug0*"
            }
          4 : 
            {
              1 : "Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause drug1 , such as sulfonylureas , drug2 , and insulin . "
              2 : "Seizures and drug1 following intravenous pulse drug2 in children with primary glomerulonephritis . "
              3 : "Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause drug1 , such as sulfonylureas , meglitinides , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      284 : 
        {
          1 : "NN dobj VBD nsubj NN nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj *induced* nsubj detection nmod patient nmod drug0"
              2 : "drug0 dobj *induced* nsubj caution nmod use nmod drug0"
              3 : "drug0 dobj *induced* nsubj caution nmod use nmod drug0"
            }
          4 : 
            {
              1 : "Detection of antineutrophil cytoplasmic antibody in a patient with drug1 induced drug2 . "
              2 : "Caution with use of cimetidine in drug1 induced drug2 . "
              3 : "Caution with use of drug1 in tolazoline induced drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      285 : 
        {
          1 : "NN conj NN nmod VBN root , punct NNS nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj erythema nmod presented root , punct *months* nmod treatment nmod drug0"
              2 : "drug0 conj erythema nmod presented root , punct *months* nmod treatment nmod drug0"
              3 : "drug0 conj erythema nmod presented root , punct *months* nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who , after 2 months of treatment with drug1 , presented with rapidly progressive erythema , drug2 , nausea and vomiting , and fever . "
              2 : "We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who , after 2 months of treatment with drug1 , presented with rapidly progressive erythema , scaling , drug2 and vomiting , and fever . "
              3 : "We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who , after 2 months of treatment with drug1 , presented with rapidly progressive erythema , scaling , nausea and drug2 , and fever . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      286 : 
        {
          1 : "NN dobj VB acl NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj cause acl *potential* nmod drug0"
              2 : "drug0 dobj trigger acl *potential* nmod drug0"
              3 : "drug0 dobj induce acl *capacity* nmod drug0"
            }
          4 : 
            {
              1 : "We stress the potential of drug1 to cause drug2 , which usually resembles severe chronic active hepatitis . "
              2 : "This supports the well-reported potential of drug1 to trigger drug2 . "
              3 : "The capacity of drug1 to induce drug2 is thought to be due to its antagonist activity on alpha-adrenergic receptors . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      287 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBN nmod NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj man acl treated nmod prednisone conj drug0"
              2 : "drug0 dobj *developed* nsubj man acl treated nmod cisplatinum conj drug0"
              3 : "drug0 dobj *developed* nsubj man acl treated nmod cisplatinum conj drug0"
            }
          4 : 
            {
              1 : "A 49-year-old man with Crohn 's disease treated with prednisone and drug1 ( 5-ASA ) developed drug2 and fever . "
              2 : "A 36-year-old man being treated with cisplatinum , vinblastine , and drug1 for testicular carcinoma developed a dense drug2 , encephalopathy , and a partial nondominant parietal lobe syndrome . "
              3 : "A 36-year-old man being treated with cisplatinum , drug1 , and bleomycin for testicular carcinoma developed a dense drug2 , encephalopathy , and a partial nondominant parietal lobe syndrome . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      288 : 
        {
          1 : "NN nsubj VBD advcl VBN nsubjpass NNS nmod NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nsubj developed advcl *given* nsubjpass chemotherapeutics nmod vincristine conj drug0"
              2 : "drug0 nsubj developed advcl *given* nsubjpass chemotherapeutics nmod vincristine conj drug0"
              3 : "drug0 nsubj developed advcl *given* nsubjpass chemotherapeutics nmod vincristine conj drug0"
            }
          4 : 
            {
              1 : "The chemotherapeutics , including vincristine , actinomycin D , and drug1 in case 1 and vincristine and actinomycin D in case 2 , were given before the drug2 developed . "
              2 : "The chemotherapeutics , including vincristine , drug1 , and epirubicin in case 1 and vincristine and actinomycin D in case 2 , were given before the drug2 developed . "
              3 : "The chemotherapeutics , including vincristine , actinomycin D , and epirubicin in case 1 and vincristine and drug1 in case 2 , were given before the drug2 developed . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      289 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod administration nmod *presented* nmod erythema conj drug0"
              2 : "drug0 nmod preparation nmod *presented* nmod hypophosphatemia conj drug0"
              3 : "drug0 nmod onset nmod *associated* nmod colchicine conj drug0"
            }
          4 : 
            {
              1 : "A 26-year-old Japanese man , who had been receiving medical attention for ulcerative colitis for one year , presented with diffuse erythema and drug1 on his face and trunk , malaise , and fever up to 39 degrees C one day after the administration of drug2 . "
              2 : "This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative hypophosphatemia and drug1 after bowel preparation with drug2 . "
              3 : "The concomitant use , however , of colchicine and drug1 has been associated with the rapid onset of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      290 : 
        {
          1 : "NN conj NN appos NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj fluoxetine appos *drug0*"
              2 : "drug0 appos *syndrome* conj drug0"
              3 : "drug0 appos *heparin* conj drug0"
            }
          4 : 
            {
              1 : "drug1 induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and drug2 , have been previously reported in patients with depression and obsessive-compulsive disorder ( OCD ) . "
              2 : "The authors postulate that two types of combined lithium-neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a drug1 that occurs in combination with phenothiazines , primarily drug2 . "
              3 : "By means of the in vitro heparin-induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz , Munich , FRG ) , as well as the enoxaparine drug1 ( Nattermann , Cologne , FRG ) , all induced drug2 with the patient 's serum . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      291 : 
        {
          1 : "NN nmod NN nmod VB dobj NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod administration nmod *present* dobj case nmod drug0"
              2 : "drug0 nmod administration nmod *report* dobj case nmod drug0"
              3 : "drug0 nmod injection nmod *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "PURPOSE : To present a case of drug1 following the administration of nebulised drug2 . "
              2 : "OBJECTIVE : To report a case of drug1 following the administration of drug2 and Dantrolene . "
              3 : "PURPOSE : To report a case of severe corticosteroid-induced drug1 after intravitreal injection of drug2 in a 34-year-old man without a history of glaucoma . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      292 : 
        {
          1 : "NN nmod NN nmod NN advcl VBD dobj NN nmod NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod course nmod day advcl *developed* dobj constellation nmod dermatitis conj drug0"
              2 : "drug0 nmod course nmod day advcl *developed* dobj constellation nmod dermatitis conj drug0"
              3 : "drug0 nmod course nmod day advcl *developed* dobj constellation nmod dermatitis conj drug0"
            }
          4 : 
            {
              1 : "A 34-year-old lady developed a constellation of dermatitis , fever , lymphadenopathy and drug1 , beginning on the 17th day of a course of oral drug2 for sero-negative rheumatoid arthritis . "
              2 : "A 34-year-old lady developed a constellation of dermatitis , drug1 , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral drug2 for sero-negative rheumatoid arthritis . "
              3 : "A 34-year-old lady developed a constellation of dermatitis , fever , drug1 and hepatitis , beginning on the 17th day of a course of oral drug2 for sero-negative rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      293 : 
        {
          1 : "NN conj NN nmod VBN acl NN compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj prolongation nmod associated acl *use* compound drug0"
              2 : "drug0 conj confusion nmod presented acl *abuse* compound drug0"
              3 : "drug0 conj confusion nmod presented acl *abuse* compound drug0"
            }
          4 : 
            {
              1 : "Chronic drug1 use associated with QT prolongation and drug2 . "
              2 : "A 33-year-old man with a history of recreational drug1 abuse presented to the emergency department with confusion , drug2 , and distention . "
              3 : "A 33-year-old man with a history of recreational drug1 abuse presented to the emergency department with confusion , abdominal pain , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      294 : 
        {
          1 : "NN nmod NN nmod NNS nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod therapy nmod months nmod *development* nmod drug0"
              2 : "drug0 nmod treatment nmod days nmod *development* nmod drug0"
              3 : "drug0 nmod cause nmod *reports* nmod literature nmod drug0"
            }
          4 : 
            {
              1 : "The development of drug1 ( SLE ) after 38 months of therapy with drug2 ( rIFN-gamma ) was observed in a patient with rheumatoid arthritis . "
              2 : "We report the development of drug1 in a patient with acute promyleocytic leukemia ( APL ) within 10 days of treatment with drug2 at a dose of 40 mg orally twice daily . "
              3 : "However , there are few reports in the literature of drug1 as a cause of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      295 : 
        {
          1 : "NN nmod NN nmod NN nmod NNS nmod:tmod VBD dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod therapy nmod initiation nmod weeks nmod:tmod *developed* dobj drug0"
              2 : "drug0 nmod combination nmod treatment nmod months nmod:tmod *developed* dobj drug0"
              3 : "drug0 nmod cancer nmod chemotherapy nmod years nmod:tmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "She developed a drug1 3 weeks following initiation of therapy with drug2 . "
              2 : "We report the case of a 14-year-old female with acute promyelocytic leukemia who developed drug1 only 4 months into treatment with a combination of drug2 and all-trans retinoic acid ( ATRA ) . "
              3 : "Two cases are reported of patients who developed a drug1 several years after intravesical chemotherapy of superficial bladder cancer with drug2 , doxorubicin , and mitomycin C . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      296 : 
        {
          1 : "NN nsubj VBD nmod NNS dep NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nsubj *occurred* nmod days dep injection nmod drug0"
              2 : "drug0 nmod injection dep minutes nmod *occurred* nsubj drug0"
              3 : "drug0 nmod initiation dep weeks nmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "Three days after intravitreal injection of drug1 , drug2 occurred . "
              2 : "A drug1 occurred a few minutes after injection of the morphine antagonist drug2 . "
              3 : "drug1 developed in a young woman 8 weeks after the initiation of drug2 for treatment of pelvic endometriosis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      297 : 
        {
          1 : "NN compound NN nmod NN conj NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound infusion nmod initiation conj *onset* nmod drug0"
              2 : "drug0 nmod onset conj *initiation* nmod therapy compound drug0"
              3 : "drug0 nmod potential conj *nature* nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : There was a temporal relationship between the onset of drug1 and initiation of drug2 infusion . "
              2 : "Mean time between initiation of drug1 therapy and onset of drug2 was 7.4 + / - 3.5 months , or 21.9 + / - 10.9 doses of gemcitabine . "
              3 : "This case and a review of the literature show the severe and unpredictable nature of drug1 toxicity and its potential for irreversible drug2 despite careful ophthalmologic monitoring . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      298 : 
        {
          1 : "NN conj NNP nmod NNS nmod NN nmod VBN nsubjpass NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj parkinsonism nmod symptoms nmod number nmod *associated* nsubjpass therapy nmod drug0"
              2 : "drug0 conj parkinsonism nmod symptoms nmod number nmod *associated* nsubjpass therapy nmod drug0"
              3 : "drug0 conj parkinsonism nmod symptoms nmod number nmod *associated* nsubjpass therapy nmod drug0"
            }
          4 : 
            {
              1 : "Therapy with drug1 may be associated with a number of neuropsychiatric symptoms , such as Parkinsonism , akathisia , seizure , and drug2 . "
              2 : "Therapy with drug1 may be associated with a number of neuropsychiatric symptoms , such as Parkinsonism , akathisia , drug2 , and depressive disorders . "
              3 : "Therapy with drug1 may be associated with a number of neuropsychiatric symptoms , such as Parkinsonism , drug2 , seizure , and depressive disorders . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      299 : 
        {
          1 : "NN nmod VBG advcl VBD dobj NN conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod receiving advcl *developed* dobj rigidity conj drug0"
              2 : "drug0 nmod receiving advcl *developed* dobj fever conj drug0"
              3 : "drug0 nmod switching advcl *developed* dobj hyperemia conj drug0"
            }
          4 : 
            {
              1 : "A 16-year-old boy developed fever , generalized rigidity , drug1 , and increased serum transaminase and creatine kinase levels while receiving treatment with drug2 and lithium . "
              2 : "A 16-year-old boy developed fever , drug1 , leukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with drug2 and lithium . "
              3 : "METHODS : A 68-year-old man developed intense conjunctival hyperemia and drug1 after switching from drug2 to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      300 : 
        {
          1 : "NN conj NN dobj VBG acl JJ dep CD dep VBD dobj NNS nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj infusion dobj involving acl other dep one dep *experienced* dobj reactions nmod drug0"
              2 : "drug0 conj infusion dobj involving acl other dep one dep *experienced* dobj reactions nmod drug0"
              3 : "drug0 conj infusion dobj involving acl other dep one dep *experienced* dobj reactions nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to drug1 : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and drug2 . "
              2 : "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to drug1 : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested drug2 , general erythema , and fever . "
              3 : "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to drug1 : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , drug2 , and fever . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      301 : 
        {
          1 : "NN nmod NN xcomp VBN nsubjpass NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod cause xcomp *determined* nsubjpass drug0"
              2 : "drug0 nmod cause xcomp *believed* nsubjpass drug0"
              3 : "drug0 nmod cause xcomp *thought* nsubjpass drug0"
            }
          4 : 
            {
              1 : "After other potential causes of liver toxicity were excluded , drug1 was determined to be the cause of his drug2 . "
              2 : "Retrospectively , drug1 was believed to be the cause of the drug2 because of its structural similarity to D-penicillamine , which was the subject of an abundance of reports of mammary hyperplasia . "
              3 : "CONCLUSIONS : Sustained-release drug1 is thought to be the cause of the drug2 in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      302 : 
        {
          1 : "NN dobj VBD nsubj NNS acl VBN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj women acl treated nmod drug0"
              2 : "drug0 dobj *showed* nsubj animals acl treated nmod drug0"
              3 : "drug0 dobj *developed* nsubj patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "CASES : Two postmenopausal women treated with drug1 and progestational agents for breast carcinoma developed drug2 and intermittent spotting . "
              2 : "Animals treated with drug1 showed a highly drug2 in the substantia nigra , and 20 % contraction of the TH stained dendritic arbour . "
              3 : "Two patients treated with drug1 ( 5-FU ) for disseminated adenocarcinoma of the colon developed drug2 typical of 5-FU neurotoxicity . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      303 : 
        {
          1 : "NN compound NN nmod VBD acl:relcl NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound treatment nmod worsened acl:relcl *drug0*"
              2 : "drug0 compound treatment nmod occurred acl:relcl *drug0*"
              3 : "drug0 compound discontinuation nmod resolved acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a drug1 and loss of consciousness which worsened during subsequent drug2 treatment and led to death within 3 weeks . "
              2 : "The objective of this report is to describe a case of fixed drug drug1 that occurred during drug2 treatment . "
              3 : "During clarithromycin coadministration , four out of the seven patients developed moderate-to-severe drug1 of carbamazepine , such as drowsiness , dizziness , and ataxia , which resolved within 5 days after drug2 discontinuation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      304 : 
        {
          1 : "NN conj NN nmod NNS dobj VBD nsubj NN acl:relcl VBD dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj cholestasis nmod findings dobj *had* nsubj patient acl:relcl received dobj drug0"
              2 : "drug0 conj cholestasis nmod findings dobj *had* nsubj patient acl:relcl received dobj drug0"
              3 : "drug0 conj cholestasis nmod findings dobj *had* nsubj patient acl:relcl received dobj drug0"
            }
          4 : 
            {
              1 : "One patient who received drug1 had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and drug2 ( ductopenia ) . "
              2 : "One patient who received drug1 had liver biopsy findings of marked cholestasis , drug2 , bile duct injury and bile duct paucity ( ductopenia ) . "
              3 : "One patient who received drug1 had liver biopsy findings of marked cholestasis , portal inflammation , drug2 and bile duct paucity ( ductopenia ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      305 : 
        {
          1 : "NN nmod NN nmod VBN advcl VBD dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod dose nmod treated advcl *developed* dobj drug0"
              2 : "drug0 nmod tacrolimus nmod changed advcl *experienced* dobj drug0"
              3 : "drug0 nmod dose nmod treated advcl *experienced* dobj drug0"
            }
          4 : 
            {
              1 : "A patient suffering from a rare enzyme deficiency developed a drug1 after having been treated with one single dose of drug2 . "
              2 : "CASE : We present an 11-year old male with Budd-Chiari syndrome who experienced profound drug1 after immunosuppressive therapy was changed from tacrolimus to drug2 . "
              3 : "We describe a patient who experienced drug1 and an episode of confusion while treated with a small , stable dose of oral drug2 in the setting of mild renal insufficiency . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      306 : 
        {
          1 : "NN conj NN nsubj NNS nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj *fever* nsubj side-effects nmod drug0"
              2 : "drug0 conj *fever* nsubj side-effects nmod drug0"
              3 : "drug0 conj *fever* nsubj side-effects nmod drug0"
            }
          4 : 
            {
              1 : "The main side-effects of drug1 combined with HT were low-grade fever , localized pain , myelo-suppression and drug2 , but these were transient and eventually disappeared . "
              2 : "The main side-effects of drug1 combined with HT were low-grade fever , drug2 , myelo-suppression and liver dysfunction , but these were transient and eventually disappeared . "
              3 : "The main side-effects of drug1 combined with HT were low-grade fever , localized pain , drug2 and liver dysfunction , but these were transient and eventually disappeared . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      307 : 
        {
          1 : "NN compound NN nmod NN nmod VBP dobj NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound therapy nmod initiation nmod *illustrate* dobj development nmod drug0"
              2 : "drug0 compound administration nmod side-effect nmod *report* dobj syndrome nmod drug0"
              3 : "drug0 compound treatment nmod side-effect nmod *highlight* dobj occurrence nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : The 3 cases presented here illustrate the development of drug1 after the initiation of drug2 therapy in women with epilepsy . "
              2 : "We report the syndrome of inappropriate drug1 as a much earlier side-effect of drug2 administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures . "
              3 : "These cases highlight the occurrence of drug1 as an uncommon side-effect of drug2 treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      308 : 
        {
          1 : "NN compound NN nmod NNS nmod VBD nsubj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound treatment nmod months nmod *appeared* nsubj drug0"
              2 : "drug0 compound therapy nmod days nmod *appeared* nsubj drug0"
              3 : "drug0 compound administration nmod hours nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "Both the drug1 and the multiple skin cancers first appeared after approximately 6 months of drug2 treatment . "
              2 : "drug1 appeared 8 to 17 days after beginning drug2 therapy and was characterized by creatinine clearances 4 to 10 ml/min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq/liter , proteinuria , and cylindruria . "
              3 : "drug1 , hypoxemia , and pleuritic chest pain occurred within 24 hours of drug2 administration , and there was no other apparent explanation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      309 : 
        {
          1 : "NN conj NN dobj VBD conj NN nmod VBN dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj agitation dobj developed conj nausea nmod *administered* dobj drug0"
              2 : "drug0 conj agitation dobj developed conj nausea nmod *administered* dobj drug0"
              3 : "drug0 conj agitation dobj developed conj nausea nmod *administered* dobj drug0"
            }
          4 : 
            {
              1 : "She was administered drug1 because of nausea and , within 2 hours , developed agitation , dysarthria , diaphoresis , and a drug2 . "
              2 : "She was administered drug1 because of nausea and , within 2 hours , developed agitation , dysarthria , drug2 , and a movement disorder . "
              3 : "She was administered drug1 because of nausea and , within 2 hours , developed agitation , drug2 , diaphoresis , and a movement disorder . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      310 : 
        {
          1 : "NN conj NN dep NNS nmod NN nmod VBG acl NNS nmod NN nmod VB nsubj NNS appos NN amod JJ nmod NN compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj diarrhea dep reactions nmod risk nmod putting acl patients nmod % nmod *occur* nsubj deficiencies appos enzyme amod responsible nmod catabolism compound drug0"
              2 : "drug0 conj diarrhea dep reactions nmod risk nmod putting acl patients nmod % nmod *occur* nsubj deficiencies appos enzyme amod responsible nmod catabolism compound drug0"
              3 : "drug0 conj diarrhea dep reactions nmod risk nmod putting acl patients nmod % nmod *occur* nsubj deficiencies appos enzyme amod responsible nmod catabolism compound drug0"
            }
          4 : 
            {
              1 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for drug1 catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , drug2 , mucositis , myelosuppression , neurotoxicity ) to standard doses of 5-FU . "
              2 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for drug1 catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , mucositis , drug2 , neurotoxicity ) to standard doses of 5-FU . "
              3 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for drug1 catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , drug2 , myelosuppression , neurotoxicity ) to standard doses of 5-FU . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      311 : 
        {
          1 : "NN conj NN nmod NNS nmod VBN conj VBN nsubjpass NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj nephrotoxicity nmod effects nmod associated conj *used* nsubjpass drug0"
              2 : "drug0 conj nephrotoxicity nmod effects nmod associated conj *used* nsubjpass drug0"
              3 : "drug0 conj nephrotoxicity nmod effects nmod associated conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is widely used against methicillin-resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , drug2 , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as `` red man syndrome '' and anaphylaxis . "
              2 : "drug1 is widely used against methicillin-resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , gastrointestinal disturbances , drug2 , and two types of hypersensitivity reactions - an anaphylactoid reaction known as `` red man syndrome '' and anaphylaxis . "
              3 : "drug1 is widely used against methicillin-resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , drug2 , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as `` red man syndrome '' and anaphylaxis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      312 : 
        {
          1 : "NN compound NN nmod NNS nmod VBD nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound therapy nmod months nmod *progressed* nmod drug0"
              2 : "drug0 compound therapy nmod weeks nmod *presented* nmod drug0"
              3 : "drug0 nmod *arrived* nmod weeks nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Despite a hematologic response in all 3 patients , none of them achieved cytogenetic remission , and all progressed to drug1 at 7 to 10 months of drug2 therapy . "
              2 : "We report two young patients with cystic fibrosis who presented with drug1 after 2-3 weeks of oral drug2 therapy . "
              3 : "After three weeks of drug1 therapy , the patient arrived at the emergency department ( ED ) with drug2 and aggressive behavior . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      313 : 
        {
          1 : "NN nmod NN nmod VBN dobj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod regimen nmod *developed* dobj drug0"
              2 : "drug0 dobj *observed* nmod study nmod drug0"
              3 : "drug0 nmod course nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Four weeks earlier she had developed drug1 during a regimen of drug2 , lynestrenol and sodium valproate . "
              2 : "In a phase II study of drug1 in patients with breast cancer we have recently observed drug2 , even at lower doses , which resulted in two drug-related deaths . "
              3 : "A 67-year-old man developed drug1 shortly after a 10-day course of oral drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      314 : 
        {
          1 : "NN conj NN nmod NN dobj VBD acl:relcl NN compound NN"
          2 : 3
          3 : 
            {
              1 : "drug0 conj vermis nmod agenesis dobj had acl:relcl *teratogenicity* compound drug0"
              2 : "drug0 conj vermis nmod agenesis dobj had acl:relcl *teratogenicity* compound drug0"
              3 : "drug0 conj vermis nmod agenesis dobj had acl:relcl *teratogenicity* compound drug0"
            }
          4 : 
            {
              1 : "We report an additional case of drug1 teratogenicity in which the patient had agenesis of the cerebellar vermis , drug2 , hydrocephalus , and abnormalities of the corticospinal tracts . "
              2 : "We report an additional case of drug1 teratogenicity in which the patient had agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , hydrocephalus , and drug2 . "
              3 : "We report an additional case of drug1 teratogenicity in which the patient had agenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias , drug2 , and abnormalities of the corticospinal tracts . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      315 : 
        {
          1 : "NN nmod NN nsubjpass VBN advcl VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod dose nsubjpass reduced advcl *disappeared* nsubj drug0"
              2 : "drug0 nmod administration nsubjpass resumed advcl *recurred* nsubj drug0"
            }
          4 : 
            {
              1 : "These drug1 gradually disappeared when the dose of drug2 was reduced . "
              2 : "drug1 recurred when the administration of drug2 was resumed . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      316 : 
        {
          1 : "NN conj NN nmod VBD nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj toxicity nmod *resulted* nsubj elimination nmod drug0"
              2 : "drug0 conj cholestasis nmod *caused* nsubj treatment nmod drug0"
            }
          4 : 
            {
              1 : "We hypothesize that decreased renal elimination of drug1 induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and drug2 causing the EBV-associated lymphoproliferative disease . "
              2 : "Three years later , treatment with drug1 caused another episode of cholestatic hepatitis with cholestasis and drug2 on rebiopsy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      317 : 
        {
          1 : "NN nmod NN conj VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod case conj *associated* nsubjpass drug0"
              2 : "drug0 nmod report conj *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is frequently associated with dermatologic toxicity , but this is only the second case of drug2 described in connection with this drug . "
              2 : "CONCLUSION : Fixed drug drug1 is associated with many drugs but this is the first such report with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      318 : 
        {
          1 : "NN nmod NN dobj VBG acl NN nmod NN acl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod therapy dobj initiating acl hr nmod *patient* acl presented nmod drug0"
            }
          4 : 
            {
              1 : "The patient presented with drug1 and thrombocytopenia within 48 hr of initiating therapy with drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      319 : 
        {
          1 : "NN compound NN dobj VBG dep NNS nmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound treatment dobj starting dep months nmod *developed* dobj drug0"
              2 : "drug0 compound therapy dobj starting dep months nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 21-year-old woman suffering from bipolar affective disorder developed drug1 ( SLE ) with characteristic laboratory findings , 18 months after starting drug2 maintenance treatment . "
              2 : "We report a 53-year-old-man who developed drug1 ( RMD ) 2 months after starting drug2 therapy for hypercholesterolemia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      320 : 
        {
          1 : "NN nmod VBD nsubj NN nmod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *resulted* nsubj treatment nmod propylthiouracil appos drug0"
              2 : "drug0 nmod *led* nsubj introduction nmod acid appos drug0"
            }
          4 : 
            {
              1 : "Antithyroid treatment with propylthiouracil ( drug1 ) resulted in drug2 and after the 12th week of pregnancy treatment was changed to carbimazole ( CBZ ) . "
              2 : "The introduction of para-aminosalicylic acid ( drug1 ) led to drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      321 : 
        {
          1 : "NN compound NN nmod NN nsubj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod *complication* nsubj thrombocytopenia conj drug0"
              2 : "drug0 compound therapy nmod *effect* nsubj proteinuria conj drug0"
            }
          4 : 
            {
              1 : "Heparin-associated thrombocytopenia and drug1 is a severe complication of systemic drug2 therapy . "
              2 : "Though proteinuria and drug1 is a rare adverse effect of drug2 therapy , physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      322 : 
        {
          1 : "NN compound NN nmod NN nmod NN acl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound administration nmod *series* nmod dic acl associated nmod drug0"
              2 : "drug0 nmod associated acl haematoma nmod onset nmod *therapy* compound drug0"
            }
          4 : 
            {
              1 : "This review presents the first case series of DIC associated with drug1 or hemoglobinuria following drug2 administration for ITP . "
              2 : "A 65-year-old man on drug1 therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with drug2 was assessed in the clinic following a referral from an optometrist . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      323 : 
        {
          1 : "NN conj VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj *discontinued* nsubjpass drug0"
              2 : "drug0 nsubjpass detected conj *drug0*"
            }
          4 : 
            {
              1 : "drug1 was discontinued and the drug2 resolved after the woman took diphenhydramine for 1 week . "
              2 : "A selective association between drug1 and extensive , prominent drug2 was detected , utilizing Fisher 's exact one-tailed statistic ( p less than 0.00001 for each comparison ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      324 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj cyanosis nmod presented acl:relcl *drug0*"
              2 : "drug0 conj cyanosis nmod presented acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We report 4 patients , 2 on methylphenidate and 2 on drug1 who presented with acral cyanosis , drug2 , or Raynaud phenomenon . "
              2 : "We report 4 patients , 2 on methylphenidate and 2 on drug1 who presented with acral cyanosis , livedo reticularis , or drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      325 : 
        {
          1 : "NN appos NN nmod NNS dobj VBG advcl VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos factor nmod courses dobj receiving advcl *developed* dobj drug0"
              2 : "drug0 appos methotrexate nmod doses dobj taking advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We describe a patient with acute myeloblastic leukemia ( AML ) who developed drug1 after receiving several courses of chemotherapy , including macrophage-colony-stimulating factor ( drug2 ) . "
              2 : "A patient with seropositive rheumatoid arthritis developed drug1 while taking weekly doses of methotrexate ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      326 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound use nmod associated acl insipidus nmod setting nmod *drug0*"
              2 : "drug0 compound therapy nmod associated acl syndrome nmod manifestation nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in the setting of underlying chronic nephrogenic diabetes insipidus associated with drug2 use . "
              2 : "drug1 as a clinical manifestation of hemolytic-uremic syndrome associated with drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      327 : 
        {
          1 : "NN conj NN dobj VBZ acl:relcl NN nmod NN nmod VBN nsubjpass NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj insensitivity dobj accompanies acl:relcl dysfunction nmod presence nmod *pronounced* nsubjpass effects nmod drug0"
              2 : "drug0 conj insensitivity dobj accompanies acl:relcl dysfunction nmod presence nmod *pronounced* nsubjpass effects nmod drug0"
            }
          4 : 
            {
              1 : "We conjectured that the side effects of drug1 , such as anti-natriuresis and increased vascular permeability , might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity , drug2 and hypoalbuminaemia . "
              2 : "We conjectured that the side effects of drug1 , such as anti-natriuresis and increased vascular permeability , might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity , hyperinsulinaemia and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      328 : 
        {
          1 : "NN nmod NN dep NNS nmod VBD nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod administration dep days nmod *died* nmod drug0"
              2 : "drug0 nmod *presented* nmod days dep dose nmod drug0"
            }
          4 : 
            {
              1 : "We report here a 26-year-old female with diffuse large B-cell lymphoma who died of drug1 81 days after the administration of high-dose drug2 ( 600 mg/m2 ) . "
              2 : "Five days after the fourth dose of drug1 , she presented with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      329 : 
        {
          1 : "NN conj NN dobj VB nsubj NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj apnea dobj *cause* nsubj therapy compound drug0"
              2 : "drug0 conj apnea dobj *cause* nsubj therapy compound drug0"
            }
          4 : 
            {
              1 : "Intravenous drug1 therapy in babies may cause apnea , drug2 , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with `` familial seizure disorders '' may in fact have the long QT interval syndrome . "
              2 : "Intravenous drug1 therapy in babies may cause apnea , hypotension , and drug2 ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with `` familial seizure disorders '' may in fact have the long QT interval syndrome . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      330 : 
        {
          1 : "NN conj NN nmod VBP acl:relcl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj fever nmod present acl:relcl *drug0*"
              2 : "drug0 conj fever nmod present acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Pneumocystis pneumonia should be considered in asthmatic patients taking drug1 who present with fever , pulmonary infiltrates , and drug2 . "
              2 : "Pneumocystis pneumonia should be considered in asthmatic patients taking drug1 who present with fever , drug2 , and hypoxia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      331 : 
        {
          1 : "NN conj NN dep NNS dobj VBG advcl VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj omeprazole dep inhibitors dobj taking advcl *observed* nsubjpass drug0"
              2 : "drug0 conj omeprazole dep inhibitors dobj taking advcl *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was observed in five female patients after taking proton pump inhibitors omeprazole , drug2 , or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses . "
              2 : "drug1 was observed in five female patients after taking proton pump inhibitors omeprazole , lansoprazole , or drug2 for 7-15 days for peptic acid diseases in recommended standard doses . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      332 : 
        {
          1 : "NN dobj VBD acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj induced acl *drug0*"
            }
          4 : 
            {
              1 : "These two cases highlight the importance of considering drug1 induced drug2 when dealing with HIV-positive individuals . "
            }
          5 : 
            {
              1 : 2
            }
        }
      333 : 
        {
          1 : "NN conj NN nmod NNS nmod VBN nsubjpass NNS acl VBG dobj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj insufficiency nmod factors nmod *evaluated* nsubjpass patients acl receiving dobj injections nmod drug0"
              2 : "drug0 conj insufficiency nmod factors nmod *evaluated* nsubjpass patients acl receiving dobj injections nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Patients receiving intravitreal injections of drug1 should be evaluated for potential systemic risk factors such as carotid insufficiency , drug2 and poorly controlled diabetes mellitus . "
              2 : "CONCLUSIONS : Patients receiving intravitreal injections of drug1 should be evaluated for potential systemic risk factors such as carotid insufficiency , coagulopathy and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      334 : 
        {
          1 : "NN appos NN nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos acetate nmod *panniculitis* conj drug0"
              2 : "drug0 appos *interaction* nmod clarithromycin conj drug0"
            }
          4 : 
            {
              1 : "Localized panniculitis and subsequent drug1 with subcutaneous glatiramer acetate ( drug2 ) injection for the treatment of multiple sclerosis . "
              2 : "A second possibility is an interaction between clarithromycin and drug1 , potentially drug2 of isradipine . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      335 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj cough nmod characterized acl toxicity nmod *associated* nsubjpass drug0"
              2 : "drug0 conj cough nmod characterized acl toxicity nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 , a new antiarrhythmic agent , has been associated with pulmonary toxicity characterized by cough , dyspnea and drug2 . "
              2 : "drug1 , a new antiarrhythmic agent , has been associated with pulmonary toxicity characterized by cough , drug2 and diffuse pulmonary infiltrates . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      336 : 
        {
          1 : "NN appos NN nmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos cis-diamine-dichloroplatinum nmod *developed* dobj drug0"
              2 : "drug0 appos cis-diamine-dichloroplatinum nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Six patients with no previous signs or symptoms suggestive of coronary artery disease developed drug1 shortly after cis-diamine-dichloroplatinum II ( drug2 ) - based chemotherapy . "
              2 : "Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary drug1 shortly after cis-diamine-dichloroplatinum II ( drug2 ) - based chemotherapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      337 : 
        {
          1 : "NN nmod NN xcomp VBZ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod cause xcomp *seems* nsubj drug0"
              2 : "drug0 nmod toxicity xcomp *appears* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 seems to be the probable cause of the drug2 . "
              2 : "This drug1 appears to be a distinct cutaneous toxicity of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      338 : 
        {
          1 : "NN conj NN nmod VBN acl NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj phenobarbital nmod treated acl epileptics nmod *drug0*"
              2 : "drug0 conj phenobarbital nmod treated acl epileptics nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in epileptics treated with phenobarbital , drug2 and fluoresone : two case reports . "
              2 : "drug1 in epileptics treated with phenobarbital , phenytoin and drug2 : two case reports . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      339 : 
        {
          1 : "NN conj NNS nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj enzymes nmod *association* nmod drug0"
              2 : "drug0 nmod dose nmod hours conj *drug0*"
            }
          4 : 
            {
              1 : "Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of drug1 with elevated hepato-biliary enzymes and drug2 . "
              2 : "She developed a drug1 and itching , sore throat , and dizziness approximately 4 hours after the first dose of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      340 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patient acl:relcl taking dobj drug0"
              2 : "drug0 dobj *developed* nsubj patient acl:relcl taking dobj drug0"
            }
          4 : 
            {
              1 : "Among 12 thyrotoxic patients , a patient with arrhythmogenic right ventricular dysplasia , who had been taking drug1 for 4 years , developed drug2 with subacute onset , accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ) , or thyrotropin-binding inhibiting immunoglobulin ( TBII ) . "
              2 : "A 17-year-old female patient who had been taking oral drug1 ( 50 mg twice daily ) for 3 weeks for acne developed an drug2 that progressed to an exfoliative dermatitis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      341 : 
        {
          1 : "NN nmod NN dep NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod cause dep *toxicity* compound drug0"
              2 : "drug0 nmod cause dep *withdrawal* compound drug0"
            }
          4 : 
            {
              1 : "drug1 toxicity : an easily missed cause of drug2 . "
              2 : "drug1 withdrawal : a cause of prolonged drug2 in the intensive care unit . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      342 : 
        {
          1 : "NN conj NN nmod NN nmod JJ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj actinomycin-d nmod administration nmod *related* nsubj drug0"
              2 : "drug0 conj desferrioxamine nmod action nmod *due* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 were temporally related to the administration of the antitumor antibiotics actinomycin-D ( NSC-3053 ) and drug2 ( NSC-24559 ) . "
              2 : "Subsequent in vivo/vitro studies clearly demonstrated that the drug1 were due to a synergistic action of desferrioxamine and drug2 , probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      343 : 
        {
          1 : "NN compound NNS nmod VBG acl NN dep NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound features nmod presenting acl *overdose* dep drug0"
            }
          4 : 
            {
              1 : "METHOD : Case analysis of a poly-drug overdose ( drug1 , topiramate , divalproex sodium , risperidone , and carbamazepine ) presenting with mixed drug2 features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings . "
            }
          5 : 
            {
              1 : 2
            }
        }
      344 : 
        {
          1 : "NN conj NN nsubj VBD nmod NN nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj bleeding nsubj *occurred* nmod dose nmod mg nmod drug0"
              2 : "drug0 nmod combination nmod administration nmod *developed* nsubj encephalopathy conj drug0"
            }
          4 : 
            {
              1 : "On the next day , after a total dose of only 600 mg of drug1 , gingival bleeding and drug2 occurred . "
              2 : "A toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and drug1 developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of drug2 and pyrilamine maleate . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      345 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod control nmod *resulted* nsubj reduction nmod dosage compound drug0"
              2 : "drug0 nmod use nmod *resulted* nsubj hypocalcemia nmod concentration compound drug0"
            }
          4 : 
            {
              1 : "Reduction of drug1 dosage rather than insulin therapy resulted in better control of drug2 . "
              2 : "A case is reported in which severe hypocalcemia , with a drug1 ( PTH ) concentration , resulted from the therapeutic use of drug2 for toxemia of pregnancy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      346 : 
        {
          1 : "NN compound NN nmod NN nmod VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound solution nmod use nmod *admitted* nmod drug0"
              2 : "drug0 compound therapy nmod consequence nmod *presented* nmod drug0"
            }
          4 : 
            {
              1 : "In this article , we present the case of a vitiligo patient who was admitted to our facility with an drug1 after the topical use of drug2 solution as a suntanning agent . "
              2 : "RESULTS : A previously healthy 42-year-old woman presented with drug1 as a consequence of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      347 : 
        {
          1 : "NN compound NN dobj VBD conj VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound maleate dobj received conj *had* dobj drug0"
              2 : "drug0 dobj developed conj *received* dobj mg/m0 compound drug0"
            }
          4 : 
            {
              1 : "The patient whose case is reviewed had drug1 and received drug2 maleate for 13 years . "
              2 : "During her third cycle , she again received drug1 100 mg/m2 over 30 minutes and developed drug2 , urticaria , and edema . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      348 : 
        {
          1 : "NN conj NN dobj VBD nsubj NN acl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj hemianopsia dobj *developed* nsubj man acl treated nmod drug0"
              2 : "drug0 conj hemianopsia dobj *developed* nsubj man acl treated nmod drug0"
            }
          4 : 
            {
              1 : "A 36-year-old man being treated with drug1 , vinblastine , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia , drug2 , and a partial nondominant parietal lobe syndrome . "
              2 : "A 36-year-old man being treated with drug1 , vinblastine , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia , encephalopathy , and a drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      349 : 
        {
          1 : "NN compound NN nmod NN nmod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound use nmod *association* nmod insipidus appos drug0"
              2 : "drug0 appos methotrexate nmod dose nmod *aplasia* compound drug0"
            }
          4 : 
            {
              1 : "The association of central diabetes insipidus ( drug1 ) with drug2 use is rare . "
              2 : "A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed drug1 and bone marrow aplasia 4 and 7 days , respectively , following a single dose of 40 mg/m2 methotrexate ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      350 : 
        {
          1 : "NN nmod NN nmod JJ amod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod therapy nmod related amod *disease* appos drug0"
              2 : "drug0 nmod administration nmod secondary amod *eosinophilia* appos drug0"
            }
          4 : 
            {
              1 : "Interstitial lung disease ( drug1 ) related to therapy with the drug drug2 has been well reported . "
              2 : "We report two cases of cerebrospinal fluid eosinophilia ( drug1 ) secondary to the intraventricular administration of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      351 : 
        {
          1 : "NN compound NN nmod NN dep NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod relationship dep *hyperglycemia* conj drug0"
              2 : "drug0 compound therapy nmod side-effect dep *anaemia* conj drug0"
            }
          4 : 
            {
              1 : "Hyperglycemia and drug1 : possible relationship to drug2 therapy . "
              2 : "Concurrent acute megaloblastic anaemia and drug1 : a severe side-effect of low-dose drug2 therapy during rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      352 : 
        {
          1 : "NN dep NNS nmod VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dep months nmod *appeared* nsubj drug0"
              2 : "drug0 dep days nmod *emerged* nsubj drug0"
            }
          4 : 
            {
              1 : "Destructive drug1 appeared 4-6 months after starting drug2 , followed by Graves ' hyperthyroidism within 8 to 11 months . "
              2 : "drug1 suddenly emerged 10 days after starting drug2 and resolved within 3 days of discontinuation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      353 : 
        {
          1 : "NN conj NN dobj VBD acl:relcl NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj polyarthritis dobj developed acl:relcl *rifampicin* conj drug0"
              2 : "drug0 conj polyarthritis dobj developed acl:relcl *rifampicin* conj drug0"
            }
          4 : 
            {
              1 : "After seven months ' continuous treatment for suspected tuberculosis with rifampicin and drug1 a nine-year-old boy developed polyarthritis , rash and drug2 in association with anti-native DNA antibodies and positive antinuclear factor . "
              2 : "After seven months ' continuous treatment for suspected tuberculosis with rifampicin and drug1 a nine-year-old boy developed polyarthritis , drug2 and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      354 : 
        {
          1 : "NN conj NN nmod NNS dobj VB acl JJ nmod VBN nsubjpass NNS dep NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep drug0"
              2 : "drug0 conj headache nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : The new quinolone derivatives ( drug1 , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , dizziness and drug2 . "
              2 : "CONCLUSION : The new quinolone derivatives ( drug1 , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including headache , drug2 and insomnia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      355 : 
        {
          1 : "NN conj NN nmod VBG advcl VBD dobj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj olanzapine nmod receiving advcl *developed* dobj rigidity conj drug0"
              2 : "drug0 conj olanzapine nmod receiving advcl *developed* dobj fever conj drug0"
            }
          4 : 
            {
              1 : "A 16-year-old boy developed fever , generalized rigidity , drug1 , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and drug2 . "
              2 : "A 16-year-old boy developed fever , drug1 , leukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      356 : 
        {
          1 : "NN dobj VBG dep NNS nmod NN nmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj taking dep weeks nmod fever nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed drug1 with high fever 3 weeks after taking drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      357 : 
        {
          1 : "NN compound NN nmod VBN nsubjpass NN conj NN nmod NNS compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound attack nmod *followed* nsubjpass seizure conj % nmod administrations compound drug0"
            }
          4 : 
            {
              1 : "Three of these patients had convulsions attributed to imipenem/cilastatin ; 3.6 % of the patients had seizure , or 2 % of drug1 administrations was followed by a drug2 attack . "
            }
          5 : 
            {
              1 : 2
            }
        }
      358 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod withdrawal nmod *patient* nmod dyskinesia conj drug0"
              2 : "drug0 compound therapy nmod withdrawal nmod *patient* nmod dyskinesia conj drug0"
            }
          4 : 
            {
              1 : "The authors present an elderly patient with mixed dementia who developed TD at multiple sites , ( including respiratory dyskinesia [ RD ] , limb dyskinesia , and drug1 ) following abrupt withdrawal of drug2 therapy . "
              2 : "The authors present an elderly patient with mixed dementia who developed TD at multiple sites , ( including respiratory dyskinesia [ RD ] , drug1 , and orofacial dyskinesia ) following abrupt withdrawal of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      359 : 
        {
          1 : "NN nmod VBD acl:relcl NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod manifested acl:relcl *lupus* compound drug0"
              2 : "drug0 nmod presented acl:relcl *therapy* compound drug0"
            }
          4 : 
            {
              1 : "It is suggested that the patient had drug1 lupus , which manifested with drug2 and pulmonary parenchymal involvement in the absence of joint symptoms . "
              2 : "We report a patient receiving chronic drug1 therapy who presented with a transient drug2 occurring in the setting of underlying chronic NDI . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      360 : 
        {
          1 : "NN compound NN nmod NN nmod VBP nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound treatment nmod association nmod *appear* nsubj drug0"
              2 : "drug0 compound therapy nmod course nmod *occur* nsubj drug0"
            }
          4 : 
            {
              1 : "Special care should be taken when drug1 appear in association with drug2 treatment . "
              2 : "drug1 , including retinal hemorrhage and `` cotton-wool '' spots , often occur within the first 8 weeks in the course of drug2 therapy in patients with chronic hepatitis C . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      361 : 
        {
          1 : "NN conj NN nmod NN dobj VBD nmod NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj oedema nmod anasarca dobj *developed* nmod introduction nmod therapy compound drug0"
              2 : "drug0 conj oedema nmod anasarca dobj *developed* nmod introduction nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Soon after introduction of drug1 therapy , she developed severe anasarca , including marked peripheral oedema , drug2 and pleural effusion . "
              2 : "Soon after introduction of drug1 therapy , she developed severe anasarca , including marked peripheral oedema , ascites and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      362 : 
        {
          1 : "NN conj NN dobj VBD nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj anaemia dobj *induced* nsubj case nmod drug0"
              2 : "drug0 conj exacerbation dobj *induced* nsubj withdrawal nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 induced anaemia and drug2 in a patient infected with HIV . "
              2 : "We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis , in whom the withdrawal of drug1 induced a generalised pustular exacerbation and a drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      363 : 
        {
          1 : "NN compound NN nmod NN nmod VBN nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound dosage nmod increase nmod *related* nsubj drug0"
              2 : "drug0 compound therapy nmod discontinuation nmod *improved* nsubj drug0"
            }
          4 : 
            {
              1 : "On the second day of hospitalization , it was noted that the patient 's drug1 and sinus bradycardia could be related to a recent increase in his drug2 dosage . "
              2 : "Their drug1 improved on discontinuation of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      364 : 
        {
          1 : "NN dobj VBG conj VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj taking conj *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "Antibiotic-associated drug1 ( pseudomembranous colitis ) developed in four patients with spinal cord injury and taking oral drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      365 : 
        {
          1 : "NN dobj VBG advcl VBN nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj using advcl *admitted* nmod signs nmod drug0"
            }
          4 : 
            {
              1 : "We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of drug1 after using drug2 ( TMP/SMX ) . "
            }
          5 : 
            {
              1 : 2
            }
        }
      366 : 
        {
          1 : "NN dobj VBD parataxis VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj developed parataxis *restarted* nsubjpass drug0"
              2 : "drug0 nsubjpass added parataxis *developed* dobj drug0"
            }
          4 : 
            {
              1 : "drug1 was restarted 2 months later ; the patient again developed a drug2 . "
              2 : "A 7-year-old boy developed a drug1 at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later drug2 ( 2-propylpentanoic acid , VPA ) was added to the therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      367 : 
        {
          1 : "NN nmod VBG acl NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod resulting acl *case* nmod overdosage compound drug0"
              2 : "drug0 nmod presenting acl *man* nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "In this paper we report a case of drug1 overdosage resulting in drug2 and hypoxemia , which was successfully treated with calcium gluconate . "
              2 : "We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection , on drug1 treatment , presenting with drug2 and acute liver failure . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      368 : 
        {
          1 : "NN conj NN nmod NN nmod NN nmod VBD acl:relcl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj oxaliplatin nmod chemotherapy nmod cycle nmod developed acl:relcl *case* nmod drug0"
              2 : "drug0 conj oxaliplatin nmod chemotherapy nmod cycle nmod developed acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We present a case of drug1 that developed during the 4th cycle of combination chemotherapy with oxaliplatin , drug2 and leucovorin . "
              2 : "We present a case of drug1 that developed during the 4th cycle of combination chemotherapy with oxaliplatin , 5-fluorouracil and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      369 : 
        {
          1 : "NN nmod NNS nmod NN nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod medications nmod *response* nsubj drug0"
              2 : "drug0 nmod patients nmod *factor* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a drug-related response to various medications , such as drug2 , which the patient was receiving . "
              2 : "CONCLUSIONS : drug1 may be the causative factor in patients with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      370 : 
        {
          1 : "NN conj NN nmod NN dep NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj cisplatinum nmod treatment dep *hemianopsia* conj drug0"
              2 : "drug0 conj cisplatinum nmod treatment dep *hemianopsia* conj drug0"
            }
          4 : 
            {
              1 : "Transient left homonymous hemianopsia and drug1 following treatment of testicular carcinoma with cisplatinum , vinblastine , and drug2 . "
              2 : "Transient left homonymous hemianopsia and drug1 following treatment of testicular carcinoma with cisplatinum , drug2 , and bleomycin . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      371 : 
        {
          1 : "NN compound NN nmod VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod *presented* nmod drug0"
              2 : "drug0 compound treatment nmod *associated* nmod drug0"
            }
          4 : 
            {
              1 : "A 64-year-old man presented with drug1 during postoperative drug2 therapy against malignant melanoma . "
              2 : "Sagittal sinus thrombosis associated with drug1 after drug2 treatment : case report and review of the literature . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      372 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBD dobj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod mg dobj ingesting advcl *presented* dobj episode nmod drug0"
              2 : "drug0 nmod dose dobj receiving advcl *had* dobj syndrome nmod drug0"
            }
          4 : 
            {
              1 : "A 55-year-old woman presented an episode of drug1 and labial angioedema 60 minutes after ingesting 500 mg of drug2 for a skin abscess . "
              2 : "We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of drug1 after receiving a high dose of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      373 : 
        {
          1 : "NN nsubjpass VBN advcl VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nsubjpass *stopped* advcl induced nsubjpass drug0"
              2 : "drug0 nsubjpass *reported* advcl tolerated nsubjpass drug0"
            }
          4 : 
            {
              1 : "Because drug1 may be induced by IFN therapy , the drug2 was stopped . "
              2 : "Although drug1 is well tolerated by the majority of patients with this disease , a potentially drug2 of this kind of treatment has been reported : `` the retinoic acid syndrome '' . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      374 : 
        {
          1 : "NN xcomp VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 xcomp *found* nsubjpass drug0"
              2 : "drug0 xcomp *suggested* nsubjpass drug0"
            }
          4 : 
            {
              1 : "His drug1 was found to be due to the drug2 he was on and he made a complete recovery on withdrawing the beta-blocker . "
              2 : "drug1 is suggested to be drug2 both through direct genotoxic and epigenetic mechanisms . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      375 : 
        {
          1 : "NN conj NN nmod NN dobj VBD nsubj NNS nmod NN acl:relcl NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj plate nmod discoloration dobj *showed* nsubj cases nmod leprosum acl:relcl doses nmod drug0"
              2 : "drug0 conj plate nmod discoloration dobj *showed* nsubj cases nmod leprosum acl:relcl doses nmod drug0"
            }
          4 : 
            {
              1 : "Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of drug1 , showed discoloration of nail plate , drug2 and onycholysis . "
              2 : "Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of drug1 , showed discoloration of nail plate , subungual hyperkeratosis and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      376 : 
        {
          1 : "NN appos NN nmod NNS nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos disease nmod complications nmod *associated* nsubjpass drug0"
              2 : "drug0 appos failure nmod symptoms nmod *suspended* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 has been associated with bronchopulmonary complications of inflammatory bowel disease ( drug2 ) in adults . "
              2 : "Sixteen hours after the first administration of IFN , drug1 was suspended by the symptoms of congestive heart failure ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      377 : 
        {
          1 : "NN nmod NN nmod NNS nsubj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treatment nmod *hazards* nsubj immunosuppression conj drug0"
              2 : "drug0 conj *hyperparathyroidism* nsubj hazards nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Although myelosuppression is mild , immunosuppression and drug1 are potential hazards of treatment with drug2 . "
              2 : "Although major hazards of treatment of hypophosphatemic osteomalacia with drug1 and calcitriol are secondary hyperparathyroidism and drug2 , potassium loss also should be kept in mind . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      378 : 
        {
          1 : "NN compound NN nmod NNS conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound toxicity nmod potentials conj *drug0*"
              2 : "drug0 compound hepatotoxicity nmod cases conj *drug0*"
            }
          4 : 
            {
              1 : "A drug1 , denervation supersensitivity , and abnormal visual-evoked potentials in drug2 toxicity , to our knowledge , have not been previously reported . "
              2 : "Although this combination agent has been associated with a hypersensitivity syndrome involving drug1 , pediatric cases of drug2 hepatotoxicity are rare . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      379 : 
        {
          1 : "NN compound NN dobj VBG dep JJ root DT nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving dep adolescent root an nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in an adolescent receiving drug2 combination therapy . "
            }
          5 : 
            {
              1 : 2
            }
        }
      380 : 
        {
          1 : "NN conj NN nmod VBG xcomp VBD acl:relcl NNS nmod NNS dobj VBD nmod NN nmod NN nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj necrosis nmod evolving xcomp disseminated acl:relcl hands nmod lesions dobj *developed* nmod day nmod administration nmod dose nmod drug0"
              2 : "drug0 conj necrosis nmod evolving xcomp disseminated acl:relcl hands nmod lesions dobj *developed* nmod day nmod administration nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "On the fifth day after administration of a high dose of drug1 ( 2 g/m2 intravenously every 12 hours ) , she developed bullous lesions on the hands and soles that disseminated , evolving to necrosis , sepsis , and drug2 on the 22nd day . "
              2 : "On the fifth day after administration of a high dose of drug1 ( 2 g/m2 intravenously every 12 hours ) , she developed bullous lesions on the hands and soles that disseminated , evolving to necrosis , drug2 , and death on the 22nd day . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      381 : 
        {
          1 : "NN nmod NN nmod VBD conj VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod use nmod increased conj *developed* dobj drug0"
              2 : "drug0 nmod administration nmod developed conj *exhibited* dobj drug0"
            }
          4 : 
            {
              1 : "Case 1 , a 62-year-old woman , developed drug1 with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of drug2 for chronic active hepatitis C . "
              2 : "However , one patient exhibited drug1 including cardiac arrest and apnea , and another four patients developed eruptions , hypotension , and tachycardia soon after administration of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      382 : 
        {
          1 : "NN conj NN dobj VB nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj pneumonitis dobj *cause* nsubj drug0"
              2 : "drug0 conj nephrolithiasis dobj *cause* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 can rarely cause interstitial pneumonitis and drug2 . "
              2 : "The HIV protease inhibitor drug1 may cause nephrolithiasis and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      383 : 
        {
          1 : "NN dep IN dep RB advmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dep after dep shortly advmod *developed* dobj drug0"
              2 : "drug0 dep after dep shortly advmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Six patients with no previous signs or symptoms suggestive of coronary artery disease developed drug1 shortly after drug2 ( cisplatin ) - based chemotherapy . "
              2 : "Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary drug1 shortly after drug2 ( cisplatin ) - based chemotherapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      384 : 
        {
          1 : "NN compound NN nmod NN nmod VBP dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound treatment nmod introduction nmod *describe* dobj drug0"
              2 : "drug0 compound cardiotoxicity nmod manifestation nmod *emphasize* dobj drug0"
            }
          4 : 
            {
              1 : "We describe drug1 in a 32 year old hypertensive woman following the introduction of drug2 treatment . "
              2 : "In addition to the recognized arrhythmic complications , the authors emphasize drug1 as a possible further manifestation of drug2 cardiotoxicity . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      385 : 
        {
          1 : "NN compound NN nmod VBZ dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod *concerns* dobj drug0"
              2 : "drug0 compound administration nmod *prevents* dobj drug0"
            }
          4 : 
            {
              1 : "The case concerns the drug1 of a 29-year-old male during drug2 therapy started 2 weeks before . "
              2 : "Correction of serum electrolyte imbalance prevents drug1 during drug2 administration . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      386 : 
        {
          1 : "NN conj NN nmod NNS conj NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj pneumonia nmod infections conj lymphocytopenia nmod *immunosuppression* compound drug0"
              2 : "drug0 conj pneumonia nmod infections conj lymphocytopenia nmod *immunosuppression* compound drug0"
            }
          4 : 
            {
              1 : "DIAGNOSIS : Severe drug1 immunosuppression , exacerbated by corticosteroids , with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia , brain abscess with Listeria monocytogenes , and drug2 . "
              2 : "DIAGNOSIS : Severe drug1 immunosuppression , exacerbated by corticosteroids , with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia , drug2 , and cutaneous Kaposi 's sarcoma . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      387 : 
        {
          1 : "NN nmod NN dobj VBG acl NN nmod NN acl VBN nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod therapy dobj initiating acl hr nmod *patient* acl presented nmod anemia conj drug0"
            }
          4 : 
            {
              1 : "The patient presented with fulminant microangiopathic hemolytic anemia and drug1 within 48 hr of initiating therapy with drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      388 : 
        {
          1 : "NN nmod NN conj NN nmod VBN acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod instance conj agent nmod associated acl *drug0*"
              2 : "drug0 nmod development conj hyperpyrexia nmod characterized acl *drug0*"
            }
          4 : 
            {
              1 : "This case represents the third example of drug1 associated with an anti-inflammatory agent and the first instance due to drug2 . "
              2 : "The authors describe a case of combined drug1 and haloperidol toxicity characterized by hyperpyrexia , severe rigidity , mutism , and development of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      389 : 
        {
          1 : "NN nmod NNS nmod:tmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod times nmod:tmod *received* dobj drug0"
            }
          4 : 
            {
              1 : "Eighty-two patients with various malignancies who received drug1 143 times for drug2 between March 1994 and October 1999 in Department of Pediatric Oncology , Gazi University , were identified . "
            }
          5 : 
            {
              1 : 2
            }
        }
      390 : 
        {
          1 : "NN compound NN nmod NN nmod JJ amod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod erythematosus nmod related amod *drug0*"
              2 : "drug0 compound therapy nmod institution nmod related amod *drug0*"
            }
          4 : 
            {
              1 : "drug1 related to systemic lupus erythematosus after drug2 therapy . "
              2 : "This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis , who developed new onset of drug1 temporally related to the institution of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      391 : 
        {
          1 : "NN appos NN root IN acl NN dobj VBG advcl VBD nmod NN appos NN nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos immunoglobulin root of acl course dobj completing advcl *presented* nmod nausea appos shortness nmod breath conj drug0"
              2 : "drug0 appos immunoglobulin root of acl course dobj completing advcl *presented* nmod nausea appos shortness nmod breath conj drug0"
            }
          4 : 
            {
              1 : "We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea , shortness of breath , drug1 , and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( drug2 ) . "
              2 : "We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea , shortness of breath , azotemia , and drug1 shortly after completing a course of intravenous immunoglobulin ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      392 : 
        {
          1 : "NN compound NN nmod VBD dobj NNS conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound injection nmod *developed* dobj symptoms conj drug0"
              2 : "drug0 compound therapy nmod *developed* dobj seizures conj drug0"
            }
          4 : 
            {
              1 : "The first patient developed mild nitritoid symptoms and drug1 in a band-like distribution , corresponding to T10-T12 dermatomes , shortly after drug2 ( GSTM ) injection . "
              2 : "We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and drug1 after drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      393 : 
        {
          1 : "NN appos NN dobj VBG acl NNS nmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos trimethoprim/sulfamethoxazole dobj adding acl days nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "An 83-year-old man receiving glipizide 10 mg bid developed drug1 within three days of adding trimethoprim/sulfamethoxazole ( drug2 ) to his regimen . "
            }
          5 : 
            {
              1 : 2
            }
        }
      394 : 
        {
          1 : "NN appos NN conj NN nmod NN nmod NN nmod NNS nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos administration conj spray nmod administration nmod *woman* nmod episodes nmod rhinitis conj drug0"
              2 : "drug0 appos administration conj spray nmod administration nmod *woman* nmod episodes nmod rhinitis conj drug0"
            }
          4 : 
            {
              1 : "We introduce a case of a sixty years old woman with several previous episodes of rhinitis , conjunctivitis and drug1 immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( drug2 ) . "
              2 : "We introduce a case of a sixty years old woman with several previous episodes of rhinitis , drug1 and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      395 : 
        {
          1 : "NN conj NN dobj VBG acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj pseudoephedrine dobj involving acl *drug0*"
              2 : "drug0 conj pseudoephedrine dobj involving acl *drug0*"
            }
          4 : 
            {
              1 : "The case history and toxicological findings of an infant drug1 involving pseudoephedrine , brompheniramine , and drug2 are presented . "
              2 : "The case history and toxicological findings of an infant drug1 involving pseudoephedrine , drug2 , and dextromethorphan are presented . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      396 : 
        {
          1 : "NN nmod VBN acl NNS nmod VB nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod *develop* nsubj drug0"
              2 : "drug0 nmod treated acl patients nmod *develop* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Significant drug1 such as an irreversible decrease of visual acuity may develop in patients treated with drug2 . "
              2 : "We conclude that drug1 may develop in patients treated with high-dose drug2 for Graves ' ophthalmopathy , and increased blood pressure may herald this complication . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      397 : 
        {
          1 : "NN compound NN nmod NN nmod VBD dobj NNS conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod day nmod *experienced* dobj twitches conj drug0"
              2 : "drug0 compound therapy nmod day nmod *experienced* dobj twitches conj drug0"
            }
          4 : 
            {
              1 : "The patient experienced muscle twitches , drug1 , and anxiety on day 17 of drug2 therapy . "
              2 : "The patient experienced muscle twitches , tremulousness , and drug1 on day 17 of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      398 : 
        {
          1 : "NN dobj VBP acl:relcl NNS nmod NN nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj produce acl:relcl drugs nmod list nmod *added* nsubjpass drug0"
              2 : "drug0 dobj include acl:relcl effects nmod spectrum nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce drug2 . "
              2 : "Although useful in the management of chronic alcoholism , drug1 is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae , which now include drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      399 : 
        {
          1 : "NN compound NN conj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound level conj *lethargy* conj drug0"
              2 : "drug0 conj *colitis* conj use compound drug0"
            }
          4 : 
            {
              1 : "We present the case of a postictal patient with lethargy , drug1 , otherwise normal liver function tests , and a therapeutic drug2 level . "
              2 : "We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis , drug1 use , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      400 : 
        {
          1 : "NN conj NN nmod NN nmod NN nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj sulfonate nmod administration nmod result nmod *reports* nmod drug0"
              2 : "drug0 conj alfa nmod injection nmod *literature* nmod cases nmod drug0"
            }
          4 : 
            {
              1 : "Reports of drug1 as a result of the administration of calcium polystyrene sulfonate and drug2 are rare . "
              2 : "We review the literature on previously reported cases of drug1 after injection of standard interferon alfa or drug2 and discuss the different pathophysiologic mechanisms that might be involved . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      401 : 
        {
          1 : "NN nmod NN dobj VBD nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod presence dobj *demonstrated* nmod months nmod drug0"
              2 : "drug0 nmod times nmod *presented* dobj episode nmod drug0"
            }
          4 : 
            {
              1 : "Case 2 demonstrated after 40 months on drug1 the presence of a drug2 , t ( 1 ; 5 ) ( p36 ; q31 ) in 90 % of the cells . "
              2 : "Two children , 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis , presented an episode of drug1 and transient blindness at different times after i.v. pulse drug2 ( IVPMP ) treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      402 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NNS nmod VBG dobj NNS compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj lethargy nmod presented acl:relcl months nmod *taking* dobj sachets compound drug0"
              2 : "drug0 conj lethargy nmod presented acl:relcl months nmod *taking* dobj sachets compound drug0"
            }
          4 : 
            {
              1 : "After taking drug1 sachets twice daily for two months she presented with lethargy , drug2 and drowsiness . "
              2 : "After taking drug1 sachets twice daily for two months she presented with lethargy , confusion and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      403 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treatment nmod *noted* nsubj children nmod drug0"
              2 : "drug0 nmod treatment nmod *occured* nsubj epivodes nmod drug0"
            }
          4 : 
            {
              1 : "FINDINGS : Six children with drug1 noted after treatment with high-dose drug2 were found to have adrenal suppression . "
              2 : "The epivodes of drug1 occured under treatment with drug2 , risperidone , and amisulpride . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      404 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl:relcl treated nmod drug0"
              2 : "drug0 dobj *developed* nsubj girl acl:relcl vaccinated nmod drug0"
            }
          4 : 
            {
              1 : "A 48-year-old woman who was treated for thyrotoxicosis with drug1 developed drug2 . "
              2 : "An 8-year-old girl , who had been vaccinated with drug1 without subsequent regional reactions , developed drug2 7 months later . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      405 : 
        {
          1 : "NN compound NN nmod VBN nsubjpass NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound psa nmod *characterized* nsubjpass syndrome compound drug0"
              2 : "drug0 compound diagnosis nmod *considered* nsubjpass neurotoxicity compound drug0"
            }
          4 : 
            {
              1 : "drug1 withdrawal syndrome is characterized by a drug2 ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate . "
              2 : "drug1 neurotoxicity should be considered in drug2 differential diagnosis , serial electroencephalograms being the most valuable . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      406 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod use nmod delayed acl:relcl *drug0*"
              2 : "drug0 nmod use nmod related acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We describe a case of intraoperative gelatine-induced drug1 whose diagnosis was delayed as the use of drug2 during surgical procedures was omitted for two times in patient 's medical records . "
              2 : "CONCLUSIONS : In these 3 cases , the unique positive ocular finding was drug1 , which may be related to the use of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      407 : 
        {
          1 : "NN compound NN nmod NN nsubjpass VBN advcl NNS nsubj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound bradycardia nmod possibility nsubjpass *recognized* advcl effects nsubj hypotension conj drug0"
              2 : "drug0 compound bradycardia nmod possibility nsubjpass *recognized* advcl effects nsubj hypotension conj drug0"
            }
          4 : 
            {
              1 : "Though hypotension , drug1 , and constipation are well-documented possible adverse effects , the possibility of drug2 bradycardia is less well recognized and is rare . "
              2 : "Though hypotension , dry mouth , and drug1 are well-documented possible adverse effects , the possibility of drug2 bradycardia is less well recognized and is rare . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      408 : 
        {
          1 : "NN appos NN nmod JJ amod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos trimethoprim-sulfamethoxazole nmod secondary amod *necrolysis* appos drug0"
            }
          4 : 
            {
              1 : "We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis ( drug1 ) secondary to trimethoprim-sulfamethoxazole ( drug2 ) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus ( CA-MRSA ) infection . "
            }
          5 : 
            {
              1 : 2
            }
        }
      409 : 
        {
          1 : "NN dobj VBG acl NNS nmod NNS nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj receiving acl patients nmod reactions nmod *risk* nmod drug0"
              2 : "drug0 dobj receiving acl patients nmod *cases* nmod onset nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Clinicians should be aware of a risk of drug1 with serious extrapyramidal reactions in patients receiving drug2 or venlafaxine when metoclopramide is coadministered even in a single , conventional dose . "
              2 : "Our literature review revealed an additional six cases of onset of drug1 in MS patients receiving drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      410 : 
        {
          1 : "NN conj NN acl VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj *episode* acl lasted nsubj drug0"
              2 : "drug0 nsubj lasted acl episode conj *drug0*"
            }
          4 : 
            {
              1 : "The clinical aspect closely resembled classical transient global amnesia but the episode after drug1 lasted longer ( 24 hours to three days ) and a more or less extensive drug2 persisted permanently . "
              2 : "The clinical aspect closely resembled classical drug1 but the episode after drug2 lasted longer ( 24 hours to three days ) and a more or less extensive retrograde amnesia persisted permanently . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      411 : 
        {
          1 : "NN nmod VBN nsubjpass NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *linked* nsubjpass cases nmod drug0"
              2 : "drug0 nmod *associated* nsubjpass reports nmod drug0"
            }
          4 : 
            {
              1 : "To the best of our knowledge only two previous cases of drug1 have been linked to treatment of HCL with purine analogs , both with drug2 . "
              2 : "Only a few reports of overt drug1 are associated with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      412 : 
        {
          1 : "NN nmod NN dep NNS nmod NN conj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod course dep days nmod consciousness conj *hemiparesis* conj drug0"
              2 : "drug0 nmod treatment dep weeks nmod dyspnea conj *fever* conj drug0"
            }
          4 : 
            {
              1 : "This patient developed sequential symptoms including alternative hemiparesis , drug1 and altered consciousness 5 days after the second course of drug2 ( 8 gm/m2 by 6 h continuous infusion ) with leucovorin rescue . "
              2 : "A 52-year-old , white female developed low-grade fever , drug1 , and dyspnea after 8 weeks treatment with drug2 for rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      413 : 
        {
          1 : "NN compound NN nmod VBN advcl VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod described advcl *developed* dobj drug0"
              2 : "drug0 compound cream nmod treated advcl *showed* dobj drug0"
            }
          4 : 
            {
              1 : "The case of a bipolar patient who developed drug1 with severe exophthalmos while on drug2 therapy is described . "
              2 : "A second patient with a similar glucose tolerance test result showed drug1 when treated similarly with drug2 cream 0.1 % . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      414 : 
        {
          1 : "NN compound NN nmod VBG nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound injection nmod *corresponding* nmod drug0"
              2 : "drug0 compound treatment nmod *presenting* nmod drug0"
            }
          4 : 
            {
              1 : "The first patient developed mild nitritoid symptoms and pain in a band-like distribution , corresponding to drug1 , shortly after drug2 ( GSTM ) injection . "
              2 : "However here we reported two patients , presenting with drug1 during high dose drug2 treatment for familiar mediterranean fever ( FMF ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      415 : 
        {
          1 : "NN nmod NN nmod NN conj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod rechallenge nmod failure conj *rash* conj drug0"
              2 : "drug0 nmod rechallenge nmod failure conj *rash* conj drug0"
            }
          4 : 
            {
              1 : "He developed recurrent skin rash , fever , drug1 , and acute renal failure after rechallenge with drug2 . "
              2 : "He developed recurrent skin rash , drug1 , hypereosinophilia , and acute renal failure after rechallenge with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      416 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound chemotherapy dobj undergoing acl patients nmod *microangiopathy* nmod drug0"
              2 : "drug0 compound chemotherapy dobj undergoing acl patients nmod failure nmod *drug0*"
            }
          4 : 
            {
              1 : "Thrombotic microangiopathy with drug1 in two patients undergoing drug2 chemotherapy . "
              2 : "drug1 with renal failure in two patients undergoing drug2 chemotherapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      417 : 
        {
          1 : "NN conj NN appos NN nmod VBD nsubj NN nmod NN nmod NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod methotrexate nmod rescue compound drug0"
              2 : "drug0 conj hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod methotrexate nmod rescue compound drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with drug1 rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , drug2 and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described . "
              2 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with drug1 rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and drug2 with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      418 : 
        {
          1 : "NN conj NN nmod NNS dobj VBP nsubj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj leukopenia nmod reactions dobj *include* nsubj events nmod drug0"
              2 : "drug0 conj leukopenia nmod reactions dobj *include* nsubj events nmod drug0"
            }
          4 : 
            {
              1 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and drug2 , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
              2 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , drug2 , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      419 : 
        {
          1 : "NN nmod NN nmod NN nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod development nmod *reason* nsubj displacement nmod drug0"
              2 : "drug0 nmod development nmod *factor* nsubj use nmod drug0"
            }
          4 : 
            {
              1 : "Although the two local anesthetics usually do not cause methemoglobinemia , we suspect that the displacement of drug1 from protein binding by bupivacaine , in combination with metabolic acidosis and treatment with other oxidants , was the reason for the development of drug2 . "
              2 : "These findings support previous studies that showed that the use of drug1 during the antecedent illness may be a risk factor for the development of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      420 : 
        {
          1 : "NN conj NNS nmod VBN nsubjpass NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj seizures nmod *associated* nsubjpass intoxication nmod drug0"
              2 : "drug0 conj seizures nmod *associated* nsubjpass intoxication nmod drug0"
            }
          4 : 
            {
              1 : "Acute severe intoxication with drug1 is associated with seizures , drug2 and respiratory depression . "
              2 : "Acute severe intoxication with drug1 is associated with seizures , coma and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      421 : 
        {
          1 : "NN conj NN nmod VBN conj VBN dep VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj levomepromazine nmod treated conj admitted dep *occurred* nsubj drug0"
              2 : "drug0 conj levomepromazine nmod treated conj admitted dep *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "A drug1 occurred in a patient with an history of depression with hypomanic rebounds , admitted for a manic episode and treated with levomepromazine , diazepam and drug2 . "
              2 : "A drug1 occurred in a patient with an history of depression with hypomanic rebounds , admitted for a manic episode and treated with levomepromazine , drug2 and lithium carbonate . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      422 : 
        {
          1 : " NN nsubj NN"
          2 : 2
          3 : 
            {
              1 : " *drug0* nsubj drug0"
              2 : " *drug0* nsubj drug0"
            }
          4 : 
            {
              1 : "In one case , drug1 was the only potential drug2 exposed to the fetus . "
              2 : "We conclude that ( a ) drug1 is a drug2 , ( b ) a distinct phenotype exists , and ( c ) the safety of CP in pregnancy is in serious question . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      423 : 
        {
          1 : "NN appos NN nmod VBN acl NNS nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos terlipressin nmod treated acl patients nmod *cases* nmod drug0"
              2 : "drug0 appos didanosine nmod treated acl patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "AIM : To report three cases of extensive drug1 in cirrhotic patients treated with the vasoconstrictor agent terlipressin ( drug2 ) . "
              2 : "We report two cases of drug1 in HIV-1-infected patients treated with didanosine ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      424 : 
        {
          1 : "NN nsubjpass VBN acl:relcl NN nmod NN nmod VBG conj NN nmod NN appos NNS nmod VBG advcl VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nsubjpass noted acl:relcl body nmod trunk nmod itching conj speech nmod difficulty appos headaches nmod complaining advcl *taking* dobj drug0"
            }
          4 : 
            {
              1 : "He had been taking drug1 for approximately eight days when he revisited his family physician , complaining of headaches , dizziness , difficulty with speech , weakness , and itching on the trunk of his body and legs , where a drug2 was noted . "
            }
          5 : 
            {
              1 : 2
            }
        }
      425 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBD nmod NN appos NN nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod course dobj completing advcl *presented* nmod nausea appos shortness nmod breath conj drug0"
              2 : "drug0 nmod course dobj completing advcl *presented* nmod nausea appos shortness nmod breath conj drug0"
            }
          4 : 
            {
              1 : "We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea , shortness of breath , drug1 , and hyperkalemia shortly after completing a course of intravenous drug2 ( IVIG ) . "
              2 : "We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea , shortness of breath , azotemia , and drug1 shortly after completing a course of intravenous drug2 ( IVIG ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      426 : 
        {
          1 : "NN nmod VBN advcl VBD dobj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod switched advcl *experienced* dobj relapse nmod drug0"
              2 : "drug0 nmod switched advcl *experienced* dobj relapse nmod drug0"
            }
          4 : 
            {
              1 : "CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of drug1 after being switched from drug2 to zidovudine and how the case was managed at the Infectious Diseases Institute , Kampala , Uganda . "
              2 : "CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of drug1 after being switched from stavudine to drug2 and how the case was managed at the Infectious Diseases Institute , Kampala , Uganda . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      427 : 
        {
          1 : "NN conj NN dobj VBD acl:relcl NN nmod NN nmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj cisplatin dobj included acl:relcl regimen nmod course nmod *developed* dobj drug0"
              2 : "drug0 conj cisplatin dobj included acl:relcl regimen nmod course nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a child with yolk sac tumor who developed drug1 after the first course of chemotherapy regimen that included cisplatin , drug2 and bleomycin . "
              2 : "We report a child with yolk sac tumor who developed drug1 after the first course of chemotherapy regimen that included cisplatin , etoposide and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      428 : 
        {
          1 : "NN conj NN dobj VBD conj VBD dobj NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj pruritus dobj developed conj *received* dobj mg/m0 compound drug0"
              2 : "drug0 conj pruritus dobj developed conj *received* dobj mg/m0 compound drug0"
            }
          4 : 
            {
              1 : "During her third cycle , she again received drug1 100 mg/m2 over 30 minutes and developed palmar pruritus , drug2 , and edema . "
              2 : "During her third cycle , she again received drug1 100 mg/m2 over 30 minutes and developed palmar pruritus , urticaria , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      429 : 
        {
          1 : "NN conj NN dobj VBG acl NNS nmod VBN acl NN nmod VBP dobj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj bromocil dobj containing acl herbicides nmod exposed acl patient nmod *report* dobj case nmod drug0"
              2 : "drug0 conj bromocil dobj containing acl herbicides nmod exposed acl patient nmod *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and drug2 . "
              2 : "We report a case of drug1 associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , drug2 and aminotriazole . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      430 : 
        {
          1 : "NN conj NN root , punct NN root , punct PRP nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj fever root , punct myelosuppression root , punct them nmod *drug0*"
              2 : "drug0 conj fever root , punct myelosuppression root , punct them nmod *drug0*"
            }
          4 : 
            {
              1 : "Thirty-six patients with AL received , in a three-month period , 51 cycles of combined chemotherapy which included , in all of them , drug1 ( ARA-C ) ; among them , along with myelosuppression , five experienced fever , infectious complications , drug2 and severe myalgias . "
              2 : "Thirty-six patients with AL received , in a three-month period , 51 cycles of combined chemotherapy which included , in all of them , drug1 ( ARA-C ) ; among them , along with myelosuppression , five experienced fever , infectious complications , gastrointestinal tract symptoms and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      431 : 
        {
          1 : " NN amod NN"
          2 : 2
          3 : 
            {
              1 : " *drug0* amod drug0"
              2 : " *drug0* amod drug0"
            }
          4 : 
            {
              1 : "drug1 and low-dosage drug2 . "
              2 : "drug1 and dextroamphetamine-induced drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      432 : 
        {
          1 : "NN dobj VBG acl NN nmod VB"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj taking acl man nmod *drug0*"
              2 : "drug0 dobj taking acl woman nmod *drug0*"
            }
          4 : 
            {
              1 : "Marked QT prolongation and torsades de pointes secondary to drug1 in an elderly man taking drug2 for atrial fibrillation : a cautionary tale . "
              2 : "Acute abdomen due to drug1 in a premenopausal woman taking drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      433 : 
        {
          1 : "NN nmod VBN acl NN nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod characterized acl toxicity nmod *associated* nsubjpass drug0"
              2 : "drug0 nmod treated acl woman nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 , a new antiarrhythmic agent , has been associated with pulmonary toxicity characterized by drug2 , dyspnea and diffuse pulmonary infiltrates . "
              2 : "A drug1 was observed in a non-alcoholic woman treated with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      434 : 
        {
          1 : "NN conj NN root , punct NN root , punct PRP nmod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj fever root , punct myelosuppression root , punct them nmod *arabinoside* appos drug0"
              2 : "drug0 conj fever root , punct myelosuppression root , punct them nmod *arabinoside* appos drug0"
            }
          4 : 
            {
              1 : "Thirty-six patients with AL received , in a three-month period , 51 cycles of combined chemotherapy which included , in all of them , cytosine arabinoside ( drug1 ) ; among them , along with myelosuppression , five experienced fever , infectious complications , gastrointestinal tract symptoms and drug2 . "
              2 : "Thirty-six patients with AL received , in a three-month period , 51 cycles of combined chemotherapy which included , in all of them , cytosine arabinoside ( drug1 ) ; among them , along with myelosuppression , five experienced fever , infectious complications , drug2 and severe myalgias . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      435 : 
        {
          1 : "NN compound NN nmod VBN nsubjpass NNP conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound component nmod *attributed* nsubjpass alopecia conj drug0"
              2 : "drug0 compound component nmod *attributed* nsubjpass alopecia conj drug0"
            }
          4 : 
            {
              1 : "Alopecia , drug1 , and vomiting were attributed to the drug2 component of the therapy . "
              2 : "Alopecia , nausea , and drug1 were attributed to the drug2 component of the therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      436 : 
        {
          1 : "NN compound NN dep NN nmod VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound administration dep week nmod *mandated* nsubj drug0"
              2 : "drug0 compound injection dep month nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 mandated endotracheal intubation 1 week after drug2 administration and led to death 4 weeks after admission . "
              2 : "drug1 occurred 1 month after the second drug2 injection in patients 1 and 3 , and 1 month after the first ranibizumab in patient 2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      437 : 
        {
          1 : "NN conj VBD nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj *induced* nsubj dose nmod drug0"
              2 : "drug0 conj *induced* nsubj dose nmod drug0"
            }
          4 : 
            {
              1 : "A high dose of drug1 induced hyperkalaemia with the elevation of serum creatinine and blood urea , and drug2 after several days of the drug administration in these patients ; one patient became unconscious . "
              2 : "A high dose of drug1 induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients ; drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      438 : 
        {
          1 : "NN nmod VBN nsubjpass NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *characterized* nsubjpass interferon appos drug0"
              2 : "drug0 nmod *associated* nsubjpass tacrolimus appos drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : Interferon ( drug1 ) - associated retinopathy is typically characterized by drug2 and cotton wool spots at the posterior fundus , but visual function is usually maintained . "
              2 : "Tacrolimus ( drug1 ) , an immunosuppressant , has been associated with drug2 in adults after liver transplant . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      439 : 
        {
          1 : "NN nmod VBN nsubjpass NNS acl VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *monitored* nsubjpass patients acl receiving dobj drug0"
              2 : "drug0 nmod *monitored* nsubjpass children acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "Myasthenic patients receiving drug1 should be closely monitored for possible drug2 . "
              2 : "Children receiving drug1 should be monitored for drug2 and the development of neurological symptoms associated with an elevation of body temperature . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      440 : 
        {
          1 : "NN nmod VBD acl:relcl NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod developed acl:relcl *cases* nmod drug0"
              2 : "drug0 nmod underwent acl:relcl *yrs* nmod drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : We describe the ophthalmic features and clinical course of two cases of drug1 ( ASPPC ) that developed after intravitreal drug2 ( IVTA ) injection . "
              2 : "We describe a 41 yr old leprosy patient treated for 10 yrs with drug1 who underwent laparotomy for severe drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      441 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl cancer nmod *treatment* compound drug0"
              2 : "drug0 dobj developed acl:relcl *patient* nmod overdose compound drug0"
            }
          4 : 
            {
              1 : "METHODS : A case is presented of a 45-year-old woman on prolonged drug1 treatment for ovarian cancer who developed drug2 and recovered after drug discontinuation . "
              2 : "METHODS : Repeated blood samples were drawn in a patient with severe drug1 overdose who developed drug2 and nonoliguric renal failure . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      442 : 
        {
          1 : "NN compound NN nmod VBG acl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound chemotherapy nmod occurring acl *pattern* nmod drug0"
              2 : "drug0 compound therapy nmod resulting acl *form* nmod drug0"
            }
          4 : 
            {
              1 : "We report an unusual pattern of drug1 occurring after drug2 chemotherapy . "
              2 : "A severe form of drug1 resulting from drug2 therapy has not been described in the literature . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      443 : 
        {
          1 : "NN compound NN nmod VBD acl:relcl NNS nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound discontinuation nmod resolved acl:relcl *symptoms* nmod drowsiness conj drug0"
              2 : "drug0 compound discontinuation nmod resolved acl:relcl *symptoms* nmod drowsiness conj drug0"
            }
          4 : 
            {
              1 : "During clarithromycin coadministration , four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine , such as drowsiness , drug1 , and ataxia , which resolved within 5 days after drug2 discontinuation . "
              2 : "During clarithromycin coadministration , four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine , such as drowsiness , dizziness , and drug1 , which resolved within 5 days after drug2 discontinuation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      444 : 
        {
          1 : "NN conj NN nmod NN nmod VBD nsubj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj clozapine nmod treatment nmod *occured* nsubj epivodes nmod drug0"
              2 : "drug0 conj clozapine nmod treatment nmod *occured* nsubj epivodes nmod drug0"
            }
          4 : 
            {
              1 : "The epivodes of drug1 occured under treatment with clozapine , drug2 , and amisulpride . "
              2 : "The epivodes of drug1 occured under treatment with clozapine , risperidone , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      445 : 
        {
          1 : "NN nmod NN nsubj NNS acl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *risk* nsubj children acl treated nmod drug0"
              2 : "drug0 nmod *risk* nsubj children acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Children with acute lymphoblastic leukemia ( ALL ) , treated with drug1 are at risk for cerebral thrombosis or hemorrhage because of drug2 . "
              2 : "Children with acute lymphoblastic leukemia ( ALL ) , treated with drug1 are at risk for drug2 or hemorrhage because of coagulation protein deficiencies . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      446 : 
        {
          1 : "NN conj NN dobj VBD acl:relcl NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj narrowing dobj demonstrated acl:relcl *enteritis* compound drug0"
              2 : "drug0 conj narrowing dobj demonstrated acl:relcl *enteritis* compound drug0"
            }
          4 : 
            {
              1 : "This report describes a case of drug1 ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing , drug2 , and marked separation of loops of bowel . "
              2 : "This report describes a case of drug1 ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing , ulceration , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      447 : 
        {
          1 : "NN dobj VBD nsubj NNS acl VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj volunteers acl receiving dobj drug0"
              2 : "drug0 dobj *developed* nsubj patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole , three of six young female volunteers receiving drug1 and two young female volunteers receiving pantoprazole developed drug2 within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid . "
              2 : "Five patients receiving drug1 for the treatment of obsessive compulsive disorder or major depression developed drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      448 : 
        {
          1 : "NN compound NN nmod NN dobj VBD advmod JJ nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod suspension dobj *necessitated* advmod due nmod discomfort conj drug0"
              2 : "drug0 compound therapy nmod suspension dobj *necessitated* advmod due nmod discomfort conj drug0"
            }
          4 : 
            {
              1 : "Due to discomfort , drug1 and lagophthalmos , the haematoma necessitated suspension of drug2 therapy and a surgical evacuation . "
              2 : "Due to discomfort , diplopia and drug1 , the haematoma necessitated suspension of drug2 therapy and a surgical evacuation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      449 : 
        {
          1 : "NN conj NN nmod VBG acl NN nmod NN nmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj cisplatin nmod consisting acl chemotherapy nmod cycle nmod *developed* dobj drug0"
              2 : "drug0 conj cisplatin nmod consisting acl chemotherapy nmod cycle nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related drug1 during the second cycle of neoadjuvant chemotherapy consisting of cisplatin , drug2 , and methotrexate . "
              2 : "A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related drug1 during the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      450 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NN nmod CD conj CD nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj cyanosis nmod presented acl:relcl dextroamphetamine nmod 0 conj *0* nmod drug0"
              2 : "drug0 conj cyanosis nmod presented acl:relcl dextroamphetamine nmod 0 conj *0* nmod drug0"
            }
          4 : 
            {
              1 : "We report 4 patients , 2 on drug1 and 2 on dextroamphetamine who presented with acral cyanosis , livedo reticularis , or drug2 . "
              2 : "We report 4 patients , 2 on drug1 and 2 on dextroamphetamine who presented with acral cyanosis , drug2 , or Raynaud phenomenon . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      451 : 
        {
          1 : "NN dobj VBG acl NN nmod VBN nsubjpass NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj developing acl risk nmod *balanced* nsubjpass use nmod drug0"
              2 : "drug0 dobj containing acl chemotherapy nmod *reported* nsubjpass occurrence nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : The chronic use of drug1 for rheumatic diseases , or as an anti-malarial drug , should be balanced against the risk of developing potentially lethal drug2 . "
              2 : "The occurrence of a drug1 is reported after chemotherapy containing drug2 , in a man with no risk factors for coronary heart disease . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      452 : 
        {
          1 : "NN nmod VBN acl NN nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treated acl glaucoma nmod patients nmod *drug0*"
              2 : "drug0 nmod exacerbated acl adriamycin nmod courses nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in two patients with narrow angle glaucoma treated with drug2 . "
              2 : "drug1 after widely separated courses of adriamycin exacerbated by drug2 and mithramycin . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      453 : 
        {
          1 : "NN nsubj VBD conj VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nsubj cleared conj *discontinued* nsubjpass drug0"
              2 : "drug0 nsubj abated conj *discontinued* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Therefore , drug1 was permanently discontinued and the drug2 cleared again . "
              2 : "drug1 was discontinued , and drug2 gradually abated . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      454 : 
        {
          1 : "NN compound NN nsubjpass VBN advcl VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nsubjpass stopped advcl *disappeared* nsubj drug0"
              2 : "drug0 compound therapy nsubjpass discontinued advcl *disappeared* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 disappeared after drug2 therapy was stopped . "
              2 : "The drug1 disappeared from the ovaries in 2 of the women after drug2 therapy was discontinued , and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      455 : 
        {
          1 : "NN nmod NN nmod VBD dobj NN amod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod course nmod *developed* dobj anaemia amod drug0"
              2 : "drug0 nmod administration nmod *developed* dobj bronchospasm amod drug0"
            }
          4 : 
            {
              1 : "We report the case of a 40-year-old woman who developed drug1 and aplastic anaemia following a course of oral drug2 . "
              2 : "CASE PRESENTATION : We report a patient with CF who developed drug1 and severe persistent bronchospasm following repeated administration of preservative-free drug2 by inhalation , beginning at 16 months of age . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      456 : 
        {
          1 : "NN compound NN nmod NN nmod VBG acl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod response nmod occurring acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 occurring as an allergic response to drug2 therapy ( Bactrim , Septra ) in a Jehovah 's Witness patient . "
            }
          5 : 
            {
              1 : 2
            }
        }
      457 : 
        {
          1 : "NN dobj VB acl:relcl NNS nmod NN nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj cause acl:relcl agents nmod list nmod *added* nsubjpass drug0"
              2 : "drug0 dobj induce acl:relcl drugs nmod list nmod *added* nsubjpass drug0"
            }
          4 : 
            {
              1 : "The patient 's clinical presentation , histologic features on liver biopsy and favorable course after stopping the drug suggest that drug1 can be added to the list of agents which can cause drug2 . "
              2 : "drug1 should be added to the list of drugs that can induce drug2 in HIV patients . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      458 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod administration nmod *based* nmod onset nmod drug0"
              2 : "drug0 nmod exposure nmod *supported* nmod course nmod drug0"
            }
          4 : 
            {
              1 : "The diagnosis was based on the rapid onset of drug1 , presence of eosinophilia , skin rash , and characteristic renal biopsy finding , following the administration of drug2 . "
              2 : "The diagnosis was supported by the temporal course of drug1 during exposure to drug2 and improvement on its discontinuation ; the pattern repeated with rechallenge . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      459 : 
        {
          1 : "NN conj VBG dobj VBD nmod NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj swelling dobj *had* nmod initiation nmod infusion compound drug0"
              2 : "drug0 conj swelling dobj *had* nmod initiation nmod infusion compound drug0"
            }
          4 : 
            {
              1 : "He had an immediate hypersensitivity reaction during the initiation of the drug1 infusion with diffuse urticaria , facial swelling , drug2 , and chest tightness . "
              2 : "He had an immediate hypersensitivity reaction during the initiation of the drug1 infusion with diffuse urticaria , facial swelling , cough , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      460 : 
        {
          1 : "NN nmod NNS nmod VBN acl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod doses nmod exposed acl woman nmod *drug0*"
              2 : "drug0 nmod doses nmod exposed acl volunteer nmod *drug0*"
            }
          4 : 
            {
              1 : "This report describes an unexpected drug-induced drug1 in a previously healthy young woman exposed to 2 doses of drug2 and artesunate . "
              2 : "Acute drug1 in a healthy normal volunteer exposed to 2 oral doses of drug2 and artesunate . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      461 : 
        {
          1 : "NN conj NN nmod NN nmod VBD conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj ciprofloxacin nmod discontinuation nmod dropped conj *drug0*"
            }
          4 : 
            {
              1 : "Since the drug1 immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and drug2 and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count , these two antibiotics were regarded causative . "
            }
          5 : 
            {
              1 : 2
            }
        }
      462 : 
        {
          1 : "NN conj NN nmod JJ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj rhabdomyolysis nmod *responsible* nsubj drug0"
              2 : "drug0 conj bleomycin nmod *attributable* nsubj drug0"
            }
          4 : 
            {
              1 : "The clinical course suggests that drug1 , which is present in oolong tea , was mainly responsible for the rhabdomyolysis as well as the drug2 , although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions . "
              2 : "Thoracoscopic biopsy to confirm metastasis revealed instead drug1 apparently attributable to bleomycin or drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      463 : 
        {
          1 : "NN dobj VBN nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *worsened* nsubj drug0"
              2 : "drug0 dobj *promoted* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This observation of `` on-off '' risperidone treatment suggests that drug1 may have worsened both drug2 of the mitochondrial disorder in this adolescent . "
              2 : "On the other hand , drug1 may have promoted the drug2 from meningioma . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      464 : 
        {
          1 : "NN conj NN appos NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod drug0"
              2 : "drug0 conj hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose drug1 with folinic acid rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , drug2 and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described . "
              2 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose drug1 with folinic acid rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and drug2 with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      465 : 
        {
          1 : "NN conj NN dobj VBD acl:relcl NN nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj mucositis dobj suffered acl:relcl patient nmod *effects* nmod drug0"
              2 : "drug0 conj mucositis dobj suffered acl:relcl patient nmod *effects* nmod drug0"
            }
          4 : 
            {
              1 : "We describe the side effects of drug1 in a colon cancer patient who suffered severe mucositis , desquamating dermatitis , prolonged myelosuppression , and drug2 that required admission to the intensive care unit . "
              2 : "We describe the side effects of drug1 in a colon cancer patient who suffered severe mucositis , desquamating dermatitis , drug2 , and neurologic toxicity that required admission to the intensive care unit . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      466 : 
        {
          1 : "NN conj NN appos CD dep VBD nsubj NNS acl:relcl VBN dobj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj erythema appos one dep *experienced* nsubj patients acl:relcl received dobj courses nmod drug0"
              2 : "drug0 conj erythema appos one dep *experienced* nsubj patients acl:relcl received dobj courses nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with ovarian cancer who had received multiple courses of drug1 without complications experienced hypersensitivity reactions to cisplatin : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and drug2 ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever . "
              2 : "Two patients with ovarian cancer who had received multiple courses of drug1 without complications experienced hypersensitivity reactions to cisplatin : one , involving intrahepatic artery infusion , manifested general erythema , drug2 , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      467 : 
        {
          1 : "NN dobj VBD acl:relcl JJ amod NN dobj VBZ conj VBN nsubjpass NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl recipient amod transplant dobj describes conj *described* nsubjpass pneumonitis compound drug0"
            }
          4 : 
            {
              1 : "drug1 pneumonitis has been described previously in renal transplant recipients , and this report describes a stable heart-lung transplant recipient who developed a drug2 that reversed after ceasing SR therapy . "
            }
          5 : 
            {
              1 : 2
            }
        }
      468 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl receiving dobj drug0"
              2 : "drug0 dobj *had* nsubj patient acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "PATIENT AND METHOD : A 34-year-old woman with chronic hepatitis C , genotype 3 , receiving drug1 and ribavirin for 6 months , developed drug2 and anemia 6 months after the end of treatment . "
              2 : "A patient receiving drug1 for a serious staphylococcal infection had a drug2 characterized by a malar rash , pain and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      469 : 
        {
          1 : "NN nmod VBN dep JJ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod associated dep *likely* nsubj drug0"
              2 : "drug0 nmod caused dep *likely* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 are most likely associated with drug2 . "
              2 : "It was postulated that the drug1 was most likely caused by drug2 or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge , pharmacokinetic data , and well-tolerance of fluorouracil . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      470 : 
        {
          1 : "NN appos NN dobj VBG advcl VBN nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos trimethoprim/sulfamethoxazole dobj using advcl *admitted* nmod signs nmod drug0"
            }
          4 : 
            {
              1 : "We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of drug1 after using trimethoprim/sulfamethoxazole ( drug2 ) . "
            }
          5 : 
            {
              1 : 2
            }
        }
      471 : 
        {
          1 : "NN dobj VBG acl NNS nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj receiving acl patients nmod *cases* nmod drug0"
              2 : "drug0 dobj taking acl patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "The authors report two cases of drug1 of methotrexate in patients receiving drug2 , with severe toxicity . "
              2 : "OBJECTIVE : To describe two cases of drug1 in patients taking drug2 that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      472 : 
        {
          1 : "NN conj NN nmod VBN acl NN dobj VB nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj hypotension nmod characterized acl deterioration dobj *cause* nsubj reversal nmod drug0"
              2 : "drug0 conj hypotension nmod characterized acl deterioration dobj *cause* nsubj reversal nmod drug0"
            }
          4 : 
            {
              1 : "The reversal of heparin by drug1 may cause severe hemodynamic deterioration , characterized by systemic hypotension , drug2 , and bronchoconstriction . "
              2 : "The reversal of heparin by drug1 may cause severe hemodynamic deterioration , characterized by systemic hypotension , pulmonary hypertension , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      473 : 
        {
          1 : "NN conj NN nmod NN nsubjpass VBN advcl VBN acl NN appos NN nmod VB nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj mmf nmod combination nsubjpass used advcl documented acl effect appos mmf nmod *occur* nsubj drug0"
              2 : "drug0 conj mmf nmod combination nsubjpass used advcl documented acl effect appos mmf nmod *occur* nsubj drug0"
            }
          4 : 
            {
              1 : "This report suggests that drug1 can occur due to MMF , in particular when it is given with prednisone , a side effect well documented in the transplantation literature when the triple combination of MMF , drug2 and prednisone is used . "
              2 : "This report suggests that drug1 can occur due to MMF , in particular when it is given with prednisone , a side effect well documented in the transplantation literature when the triple combination of MMF , cyclosporine and drug2 is used . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      474 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treatment nmod seizure nmod followed acl *drug0*"
              2 : "drug0 nmod treatment nmod initiation nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated drug1 followed by a seizure during consolidation treatment with drug2 . "
              2 : "We report two patients with drug1 ( ejaculation without orgasm ) associated with initiation of treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      475 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBG acl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod resulting acl setting nmod *drug0*"
              2 : "drug0 nmod treated acl:relcl gestation nmod occurring acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report marked drug1 and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with drug2 for atrial fibrillation . "
              2 : "We present a case of drug1 occurring in a woman at 16 weeks ' gestation who was being treated with drug2 for a urinary tract infection . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      476 : 
        {
          1 : "NN compound NN nmod VBD dobj NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod *developed* dobj leukaemia appos drug0"
              2 : "drug0 compound treatment nmod *developed* dobj anemia appos drug0"
            }
          4 : 
            {
              1 : "We report two cases that developed acute myeloid leukaemia ( drug1 ) during drug2 therapy for breast cancer . "
              2 : "We report the case of a patient with chronic lymphocytic leukemia ( CLL ) who developed fatal intravascular autoimmune hemolytic anemia ( drug1 ) after drug2 treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      477 : 
        {
          1 : "NN conj NN nmod NNS dobj VBD nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj drowsiness nmod symptoms dobj *developed* nmod coadministration compound drug0"
              2 : "drug0 conj drowsiness nmod symptoms dobj *developed* nmod coadministration compound drug0"
            }
          4 : 
            {
              1 : "During drug1 coadministration , four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine , such as drowsiness , dizziness , and drug2 , which resolved within 5 days after clarithromycin discontinuation . "
              2 : "During drug1 coadministration , four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine , such as drowsiness , drug2 , and ataxia , which resolved within 5 days after clarithromycin discontinuation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      478 : 
        {
          1 : "NN nmod NN nmod VBD conj VBD dobj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod use nmod increased conj *developed* dobj neuritis nmod drug0"
              2 : "drug0 nmod development dobj prevented conj *led* nmod removal nmod drug0"
            }
          4 : 
            {
              1 : "Case 1 , a 62-year-old woman , developed bilateral optic neuritis with drug1 and increased deep tendon reflex in the lower extremities after a seven-month use of drug2 for chronic active hepatitis C . "
              2 : "Charcoal haemoperfusion and cysteamine therapy led to the rapid removal of the drug1 from the body and consequently prevented the development of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      479 : 
        {
          1 : "NN nmod JJ conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *allergic* conj drug0"
              2 : "drug0 conj anti-natriuresis nmod *drug0*"
            }
          4 : 
            {
              1 : "Allergic and drug1 to drug2 . "
              2 : "We conjectured that the side effects of drug1 , such as anti-natriuresis and drug2 , might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity , hyperinsulinaemia and hypoalbuminaemia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      480 : 
        {
          1 : "NN conj NN nmod VBN acl NN conj NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj hyperpyrexia nmod characterized acl *lithium* conj toxicity compound drug0"
              2 : "drug0 conj hyperpyrexia nmod characterized acl *lithium* conj toxicity compound drug0"
            }
          4 : 
            {
              1 : "The authors describe a case of combined lithium and drug1 toxicity characterized by hyperpyrexia , drug2 , mutism , and development of irreversible tardive dyskinesia . "
              2 : "The authors describe a case of combined lithium and drug1 toxicity characterized by hyperpyrexia , severe rigidity , drug2 , and development of irreversible tardive dyskinesia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      481 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl disease nmod *drug0*"
              2 : "drug0 dobj developed acl:relcl disease nmod *drug0*"
            }
          4 : 
            {
              1 : "A case is reported of a 40 year old woman treated with intraventricular drug1 for leptomeningeal disease who developed progressive drug2 . "
              2 : "We report the case of a man , treated with drug1 for Crohn 's disease who developed drug-induced drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      482 : 
        {
          1 : "NN nmod VBG advcl VBG acl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod switching advcl occurring acl *case* nmod drug0"
              2 : "drug0 nmod switching advcl occurring acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "PURPOSE : To report a case of angiographically documented drug1 occurring after switching a pseudophakic patient from latanoprost to drug2 . "
              2 : "PURPOSE : To report a case of angiographically documented drug1 occurring after switching a pseudophakic patient from drug2 to bimatoprost . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      483 : 
        {
          1 : "NN conj NN dep VBP advcl VBN nsubjpass NN nmod NNS compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj fever dep have advcl *considered* nsubjpass possibility nmod reactions compound drug0"
              2 : "drug0 conj fever dep have advcl *considered* nsubjpass possibility nmod reactions compound drug0"
            }
          4 : 
            {
              1 : "The possibility of drug1 hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms , particularly fever , drug2 , and lymphadenopathy . "
              2 : "The possibility of drug1 hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms , particularly fever , rash , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      484 : 
        {
          1 : "NN nmod VBN advcl VBG dobj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *presented* advcl receiving dobj dose nmod drug0"
              2 : "drug0 nmod treatment dobj starting advcl *hospitalized* nmod drug0"
            }
          4 : 
            {
              1 : "We describe a patient who , after receiving his first dose of drug1 to relieve neuropathic pain , presented with a drug2 . "
              2 : "A 79-year-old man with ischemic heart disease , chronic atrial fibrillation , chronic renal failure , hypothyroidism , and gout arthritis was hospitalized because of drug1 , myalgia , and leg weakness , shortly after starting treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      485 : 
        {
          1 : "NN dobj VBD advcl VBN dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *developed* advcl received dobj drug0"
              2 : "drug0 dobj *developed* advcl given dobj drug0"
            }
          4 : 
            {
              1 : "After having received drug1 on day 1 of the second course , the patient developed drug2 , subfebrile temperatures and dyspnea within 48 h . "
              2 : "She was admitted following a fall and , after being given drug1 , developed drug2 and a period of unresponsiveness . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      486 : 
        {
          1 : "NN compound NN dobj VBG advcl VBP dobj NN acl:relcl VBD dobj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving advcl *report* dobj patient acl:relcl developed dobj myositis conj drug0"
              2 : "drug0 compound therapy dobj receiving advcl *report* dobj patient acl:relcl developed dobj myositis conj drug0"
            }
          4 : 
            {
              1 : "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis , drug1 , and possible vasculitis , after receiving drug2 therapy . "
              2 : "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis , synovitis , and drug1 , after receiving drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      487 : 
        {
          1 : "NN conj NN nmod NN appos NNS dobj VBP nsubj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj proteinuria nmod hypoalbuminemia appos reactions dobj *include* nsubj events nmod drug0"
              2 : "drug0 conj proteinuria nmod hypoalbuminemia appos reactions dobj *include* nsubj events nmod drug0"
            }
          4 : 
            {
              1 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , drug2 , and minor neurological and gastrointestinal complaints . "
              2 : "Less common adverse events to drug1 include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      488 : 
        {
          1 : "NN nmod NNS nmod NN nmod VBN nsubjpass NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod symptoms nmod number nmod *associated* nsubjpass therapy nmod drug0"
              2 : "drug0 nmod effects nmod list nmod *added* nsubjpass development nmod drug0"
            }
          4 : 
            {
              1 : "Therapy with drug1 may be associated with a number of neuropsychiatric symptoms , such as drug2 , akathisia , seizure , and depressive disorders . "
              2 : "The possible development of a drug-induced drug1 or lupus-like syndrome should be added to the list of rare toxic effects of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      489 : 
        {
          1 : "NN conj NN nmod NN nmod VBN dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj carbamazepine nmod regimen nmod *developed* dobj drug0"
              2 : "drug0 conj carbamazepine nmod regimen nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Four weeks earlier she had developed drug1 during a regimen of carbamazepine , drug2 and sodium valproate . "
              2 : "Four weeks earlier she had developed drug1 during a regimen of carbamazepine , lynestrenol and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      490 : 
        {
          1 : "NN conj NN nmod NNS nmod NN acl:relcl NNS nmod JJ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj phenytoin nmod congeners nmod treatment acl:relcl patients nmod *present* nsubj drug0"
              2 : "drug0 conj phenytoin nmod congeners nmod treatment acl:relcl patients nmod *present* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 was present in two epileptic patients who were under long-term treatment with congeners of phenytoin , drug2 , and acetazolamide . "
              2 : "drug1 was present in two epileptic patients who were under long-term treatment with congeners of phenytoin , phenobarbital , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      491 : 
        {
          1 : "NN conj VBG amod NNS appos NN nsubj NNS acl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj vomiting amod reactions appos *nausea* nsubj effects acl associated nmod drug0"
              2 : "drug0 conj vomiting amod reactions appos *nausea* nsubj effects acl associated nmod drug0"
            }
          4 : 
            {
              1 : "The most common side effects associated with drug1 are nausea , vomiting , hypotension , drug2 and allergic reactions . "
              2 : "The most common side effects associated with drug1 are nausea , vomiting , drug2 , hypocalcemia and allergic reactions . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      492 : 
        {
          1 : "NN compound NNS dobj VBD nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound dips dobj *revealed* nmod treatment compound drug0"
              2 : "drug0 compound treatment nmod *had* dobj values compound drug0"
            }
          4 : 
            {
              1 : "After drug1 treatment , additional sleep studies revealed an drug2 and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea . "
              2 : "One patient had a lower average heart rate and two patients had drug1 values during drug2 treatment , none of which was clinically significant . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      493 : 
        {
          1 : " CD compound CD"
          2 : 2
          3 : 
            {
              1 : " *drug0* compound drug0"
              2 : " *drug0* compound drug0"
            }
          4 : 
            {
              1 : "The site of thrombosis and the chronological relationship with the IIR implicates a drug1 to drug2 in the causation of the venous thrombosis in this case . "
              2 : "We describe a patient who had a drug1 to drug2 develop during her second course of PUVA treatment for psoriasis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      494 : 
        {
          1 : "NN dobj VBD nsubj NNS nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patients nmod therapy compound drug0"
              2 : "drug0 dobj *developed* nsubj men nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Two patients on long-term drug1 therapy developed the drug2 . "
              2 : "Two 65-year-old white men with coronary heart disease , given drug1 therapy for dyslipidemia for 5 months , developed drug2 that was associated with increases in dose and that was relieved with discontinuance of niacin treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      495 : 
        {
          1 : "NN conj NN dobj VBZ acl:relcl NN dobj VB nsubj NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj hyperexcitability dobj includes acl:relcl encephalopathy dobj *produce* nsubj od compound drug0"
              2 : "drug0 conj hyperexcitability dobj includes acl:relcl encephalopathy dobj *produce* nsubj od compound drug0"
            }
          4 : 
            {
              1 : "Massive drug1 OD may produce a reversible encephalopathy that includes cortical hyperexcitability , a profound burst-suppression EEG pattern , and drug2 . "
              2 : "Massive drug1 OD may produce a reversible encephalopathy that includes cortical hyperexcitability , a drug2 , and cranial nerve areflexia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      496 : 
        {
          1 : "NN dep NNS nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dep *complications* nmod treatment compound drug0"
              2 : "drug0 dep *complications* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Multiple complications of drug1 treatment : drug2 , eosinophilia , skin reaction and hepatitis with lymphocyte sensitization . "
              2 : "Cerebrovascular complications of drug1 therapy in children with leukemia : drug2 and other neuropsychological deficits . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      497 : 
        {
          1 : "NN dobj VB nsubj NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *induce* nsubj c appos drug0"
              2 : "drug0 dobj *induce* nsubj methotrexate appos drug0"
            }
          4 : 
            {
              1 : "In rare cases mitomycin C ( drug1 ) may induce cancer-associated drug2 , which is characterized by hemolytic anemia , thrombocytopenia and progressive renal failure . "
              2 : "BACKGROUND : Methotrexate ( drug1 ) may induce drug2 , which in some psoriatics will lead to fibrosis or cirrhosis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      498 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj receiving acl patients nmod diagnosis nmod *considered* nsubjpass drug0"
              2 : "drug0 dobj causing acl agents nmod list nmod *added* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Conversely , drug1 should be considered in the differential diagnosis of patients receiving drug2 who develop bilateral pulmonary infiltrates seen on chest roentgenograms . "
              2 : "CONCLUSION : drug1 should be added to the list of agents causing drug2 involving the corneal epithelium . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      499 : 
        {
          1 : "NN dobj VBD nsubj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *included* nsubj effects nmod drug0"
              2 : "drug0 dobj *induced* nsubj cases nmod drug0"
            }
          4 : 
            {
              1 : "The toxic effects of drug1 included drug2 ( 3/4 ) , nausea ( 2/4 ) , abdominal pain ( 2/4 ) , bone pain ( 2/4 ) , mild neutropenia ( 1/4 ) , and mild pruritus ( 1/4 ) . "
              2 : "We report three cases of drug1 induced drug2 in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      500 : 
        {
          1 : "NN dobj VBG conj VBD nsubj NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj taking conj *developed* nsubj colitis appos drug0"
            }
          4 : 
            {
              1 : "Antibiotic-associated colitis ( drug1 ) developed in four patients with spinal cord injury and taking oral drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      501 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBN nmod NNS compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl treated nmod days compound drug0"
              2 : "drug0 dobj *developed* nsubj woman acl managed nmod infusions compound drug0"
            }
          4 : 
            {
              1 : "METHODS : A 79-year-old woman being treated with drug1 5 days per week for a nodular basal cell developed a drug2 over the treatment area after 7 weeks of therapy . "
              2 : "A 45-year-old woman with steroid-dependent Crohn 's colitis , successfully managed with maintenance drug1 infusions and methotrexate , developed a drug2 eight months after her initial infusion . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      502 : 
        {
          1 : "NN compound NNS dobj VBG acl NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound injections dobj receiving acl patients nmod *drug0*"
              2 : "drug0 compound overdoses dobj receiving acl children nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in two patients receiving drug2 injections for rheumatoid arthritis . "
              2 : "Hydrocortisone may decrease the incidence of mortality associated with drug1 in children receiving drug2 overdoses . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      503 : 
        {
          1 : "NN compound NN nmod VBN nsubjpass NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound ttp/hus nmod *seen* nsubjpass thrombocytopenia conj drug0"
              2 : "drug0 compound withdrawal nmod *reduced* nsubjpass impairment conj drug0"
            }
          4 : 
            {
              1 : "We conclude that while thrombocytopenia and drug1 can be seen in drug2 TTP/HUS , the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP ( i.e. , severely decreased ADAMTS13 with an inhibitor ) . "
              2 : "The hearing impairment and drug1 were gradually reduced after drug2 withdrawal and corticosteroid and azathioprine treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      504 : 
        {
          1 : "NN nsubjpass VBN advcl JJ nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nsubjpass coadministered advcl *aware* nmod risk nmod drug0"
              2 : "drug0 nsubjpass coadministered advcl *aware* nmod risk nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Clinicians should be aware of a risk of drug1 with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when drug2 is coadministered even in a single , conventional dose . "
              2 : "CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious drug1 in patients receiving sertraline or venlafaxine when drug2 is coadministered even in a single , conventional dose . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      505 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBD dobj NNS compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treatment dobj starting advcl *had* dobj months compound drug0"
              2 : "drug0 nmod mg dobj receiving advcl *developed* dobj minutes compound drug0"
            }
          4 : 
            {
              1 : "A 43-year-old woman with multiple sclerosis ( MS ) had drug1 21 months after starting treatment with drug2 ( subcutaneous administration ) . "
              2 : "We report the case of a 20-year-old female with polyarteritis nodosa ( PAN ) who developed drug1 25 minutes after receiving 30 mg of intravenous drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      506 : 
        {
          1 : "NN nmod NN nmod NN dobj VBZ nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod use nmod need dobj *emphasizes* nsubj development nmod drug0"
            }
          4 : 
            {
              1 : "The potential development of drug1 , a severe life-threatening illness , emphasizes the need for judicious use of drug2 and close monitoring and follow-up for patients who were given TMP-Sx for SSTIs . "
            }
          5 : 
            {
              1 : 2
            }
        }
      507 : 
        {
          1 : "NN appos NN dobj VBG acl NNS nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos methotrexate dobj receiving acl patients nmod *observed* nsubjpass drug0"
              2 : "drug0 appos factor dobj receiving acl children nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "OBJECTIVES : A delayed drug1 has been observed in patients receiving methotrexate ( drug2 ) for childhood leukemia . "
              2 : "Painful drug1 were observed in two children receiving granulocyte colony-stimulating factor ( drug2 ) for treatment of idiopathic neutropenia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      508 : 
        {
          1 : "NN conj NNP nmod NNS nmod VBG advcl VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj creon nmod preparations nmod switching advcl *occurred* nsubj drug0"
              2 : "drug0 conj creon nmod preparations nmod switching advcl *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 occurred on switching to different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and drug2 . "
              2 : "The drug1 occurred on switching to different pancreatic enzymes preparations , ie , Creon 10 , drug2 , and Pancrease MT 16 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      509 : 
        {
          1 : "NN dobj VBD advcl NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj developed advcl *monotherapy* compound drug0"
              2 : "drug0 dobj exhibited advcl *treatment* compound drug0"
            }
          4 : 
            {
              1 : "A 28 year old white schizophrenic male has been under drug1 monotherapy for about one year when he developed drug2 . "
              2 : "She had been on drug1 20 mg/day treatment for 2 years when she first exhibited drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      510 : 
        {
          1 : "NN dobj VBZ nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *exacerbates* nsubj interaction nmod drug0"
            }
          4 : 
            {
              1 : "Possible interaction between drug1 and valproic Acid exacerbates drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      511 : 
        {
          1 : "NN dobj VBG advcl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj receiving advcl *admitted* nmod drug0"
              2 : "drug0 dobj ingesting advcl *presented* nmod drug0"
            }
          4 : 
            {
              1 : "A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for drug1 while receiving drug2 and clopidogrel . "
              2 : "An adult male presented with drug1 after ingesting drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      512 : 
        {
          1 : "NN compound NN nmod VBN acl NN dep NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound use nmod associated acl *effect* dep drug0"
              2 : "drug0 compound therapy nmod induced acl *myositis* dep drug0"
            }
          4 : 
            {
              1 : "RESULTS : Both patients experienced a previously unreported side effect -- drug1 -- associated with drug2 use . "
              2 : "We describe a case of disseminated muscular cysticercosis followed by myositis ( drug1 , diffuse myalgia , weakness of the lower limbs , and inflammatory reaction around dying cysticerci ) induced by drug2 therapy , an event not described previously . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      513 : 
        {
          1 : "NN dobj VBD nsubj NN conj NN acl VBG nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patient conj therapy acl consisting nmod cyclosporin conj drug0"
              2 : "drug0 dobj *developed* nsubj patient conj therapy acl consisting nmod cyclosporin conj drug0"
            }
          4 : 
            {
              1 : "In this report , a patient who had undergone a renal transplantation as a result of malignant hypertension , and who was on immunosuppressive therapy consisting of cyclosporin , prednisone and drug1 , developed drug2 of the central retinal vein 5 years following the transplantation . "
              2 : "In this report , a patient who had undergone a renal transplantation as a result of malignant hypertension , and who was on immunosuppressive therapy consisting of cyclosporin , drug1 and azathioprine , developed drug2 of the central retinal vein 5 years following the transplantation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      514 : 
        {
          1 : "NN nmod VBN acl NN nmod NN nmod VBN acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treated acl acromegaly nmod male nmod complicated acl *drug0*"
              2 : "drug0 nmod treated acl carrier nmod hepatotoxicity nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "We report a case of drug1 ( intrahepatic stone ) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with drug2 . "
              2 : "drug1 associated with mild hepatotoxicity in an HIV carrier treated with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      515 : 
        {
          1 : "NN conj NN nsubj VBD dep VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj fever nsubj *developed* dep receiving dobj drug0"
              2 : "drug0 conj fever nsubj *developed* dep receiving dobj drug0"
            }
          4 : 
            {
              1 : "In this report , we describe a patient receiving drug1 in whom dyspnea , fever , hypoxia , and drug2 developed . "
              2 : "In this report , we describe a patient receiving drug1 in whom dyspnea , fever , drug2 , and diffuse pulmonary infiltrates developed . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      516 : 
        {
          1 : "NN nmod NN nmod NN nmod NNS nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod administration nmod *woman* nmod episodes nmod rhinitis conj drug0"
              2 : "drug0 nmod administration nmod *woman* nmod episodes nmod rhinitis conj drug0"
            }
          4 : 
            {
              1 : "We introduce a case of a sixty years old woman with several previous episodes of rhinitis , drug1 and perspiration immediately after the administration of salmon drug2 with nasal spray or intramuscular administration ( Calsynar ) . "
              2 : "We introduce a case of a sixty years old woman with several previous episodes of rhinitis , conjunctivitis and drug1 immediately after the administration of salmon drug2 with nasal spray or intramuscular administration ( Calsynar ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      517 : 
        {
          1 : "NN dobj VBG advcl VB dobj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj replacing advcl *present* dobj case nmod drug0"
              2 : "drug0 nmod development dobj detect advcl *receiving* dobj drug0"
            }
          4 : 
            {
              1 : "AIMS : To present a case of drug1 after replacing drug2 with milnacipran hydrochloride , and to analyse this effect based on receptor occupancy theory . "
              2 : "We recommended periodic examination of the serum proteins in patients receiving drug1 in order to detect development of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      518 : 
        {
          1 : "NN dobj VB nsubj NN nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj *cause* nsubj administration nmod ciprofloxacin conj drug0"
            }
          4 : 
            {
              1 : "It is concluded that simultaneous administration of ciprofloxacin and drug1 may cause marked drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      519 : 
        {
          1 : "NN nmod NN nmod NN advcl VBN nsubjpass NNS nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod association nmod *report* advcl used nsubjpass combinations nmod belladonna conj drug0"
              2 : "drug0 nmod association nmod *report* advcl used nsubjpass combinations nmod belladonna conj drug0"
            }
          4 : 
            {
              1 : "Although combinations of belladonna , ergotamine , and drug1 have been used for medical treatment of menopausal symptoms since the 1960s , this is the first known case report of its association with drug2 . "
              2 : "Although combinations of belladonna , drug1 , and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s , this is the first known case report of its association with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      520 : 
        {
          1 : "NN nmod VBN acl NNS nmod JJ xcomp VBP nsubj NNS acl VBN nmod NNS conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treated acl women nmod common xcomp *seem* nsubj disorders acl characterized nmod disorders conj drug0"
              2 : "drug0 nmod treated acl women nmod common xcomp *seem* nsubj disorders acl characterized nmod disorders conj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders , polycystic ovaries , and drug1 seem to be common among women treated with drug2 for epilepsy . "
              2 : "BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders , drug1 , and hyperandrogenism seem to be common among women treated with drug2 for epilepsy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      521 : 
        {
          1 : "NN nmod VB dobj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *report* dobj occurrence nmod drug0"
              2 : "drug0 nmod *summarize* dobj literature nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report the occurrence of drug1 to intraperitoneal drug2 in 3 patients . "
              2 : "We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of drug1 to drug2 in which doses were known and stated to be within recommended guidelines . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      522 : 
        {
          1 : "NN dobj VBG advcl VBD conj VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj commencing advcl stopped conj *developed* dobj drug0"
              2 : "drug0 dobj receiving advcl *underwent* conj developed dobj drug0"
            }
          4 : 
            {
              1 : "He developed drug1 , nausea , diarrhea , and malaise and stopped taking on the third day after commencing drug2 . "
              2 : "Herein we report four patients who underwent liver transplantation and developed drug1 while receiving drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      523 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBZ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj receiving acl groups nmod *occurs* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 readily occurs in at least certain population groups receiving drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      524 : 
        {
          1 : " NN compound NN conj NN"
          2 : 2
          3 : 
            {
              1 : " *drug0* compound antacid conj drug0"
              2 : "drug0 conj *eosinophilia* compound drug0"
            }
          4 : 
            {
              1 : "Antacid and drug1 drug2 : a case report and review of the literature . "
              2 : "Inhaled drug1 solution-associated recurrent eosinophilia and drug2 in a patient with cystic fibrosis : a case report . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      525 : 
        {
          1 : "NN conj NN nmod NNS nmod NN nmod NN nmod VBN acl NN dobj VBD nsubj NNS acl:relcl VBD nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj agitation nmod feelings nmod affect nmod development nmod followed acl response dobj *had* nsubj outpatients acl:relcl participated nmod trial nmod drug0"
              2 : "drug0 conj agitation nmod feelings nmod affect nmod development nmod followed acl response dobj *had* nsubj outpatients acl:relcl participated nmod trial nmod drug0"
            }
          4 : 
            {
              1 : "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of drug1 had an initial good response to the medication followed by development of intolerable affect , including feelings of agitation and depression and drug2 and insomnia . "
              2 : "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of drug1 had an initial good response to the medication followed by development of intolerable affect , including feelings of agitation and drug2 and periods of crying and insomnia . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      526 : 
        {
          1 : "NN conj NN nmod VBN dobj NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj urticaria nmod *required* dobj desensitization compound drug0"
              2 : "drug0 conj urticaria nmod *required* dobj desensitization compound drug0"
            }
          4 : 
            {
              1 : "METHODS : The patient required drug1 desensitization for severe urticaria , angioedema , and occasional drug2 resulting from her insulin dose . "
              2 : "METHODS : The patient required drug1 desensitization for severe urticaria , drug2 , and occasional wheezing resulting from her insulin dose . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      527 : 
        {
          1 : "NN conj NN nmod VBN acl NN dobj VBD nsubj NN acl VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj rash nmod characterized acl syndrome dobj *had* nsubj patient acl receiving dobj drug0"
              2 : "drug0 conj rash nmod characterized acl syndrome dobj *had* nsubj patient acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "A patient receiving drug1 for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash , drug2 and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips . "
              2 : "A patient receiving drug1 for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash , pain and drug2 , and tender erythematous and hemorrhagic lesions of the finger tips . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      528 : 
        {
          1 : "NN conj NN nmod NNS nmod VBN acl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj amodiaquine nmod doses nmod exposed acl woman nmod *drug0*"
              2 : "drug0 conj amodiaquine nmod doses nmod exposed acl volunteer nmod *drug0*"
            }
          4 : 
            {
              1 : "This report describes an unexpected drug-induced drug1 in a previously healthy young woman exposed to 2 doses of amodiaquine and drug2 . "
              2 : "Acute drug1 in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      529 : 
        {
          1 : "NN conj NN nmod VBN acl:relcl NN dobj VB nsubj NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj anemia nmod characterized acl:relcl syndrome dobj *induce* nsubj c appos drug0"
              2 : "drug0 conj anemia nmod characterized acl:relcl syndrome dobj *induce* nsubj c appos drug0"
            }
          4 : 
            {
              1 : "In rare cases mitomycin C ( drug1 ) may induce cancer-associated hemolytic uremic syndrome , which is characterized by hemolytic anemia , thrombocytopenia and drug2 . "
              2 : "In rare cases mitomycin C ( drug1 ) may induce cancer-associated hemolytic uremic syndrome , which is characterized by hemolytic anemia , drug2 and progressive renal failure . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      530 : 
        {
          1 : "NN nmod NNS dobj VBD acl:relcl NN conj NN nmod NN conj NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod symptoms dobj exhibited acl:relcl patient conj sarcoma nmod *bleomycin* conj chemotherapy compound drug0"
            }
          4 : 
            {
              1 : "In this report , one patient who developed gangrene after bleomycin and drug1 chemotherapy for AIDS-related Kaposi 's sarcoma and another HIV-infected patient who exhibited symptoms of drug2 related to the same regimen are presented . "
            }
          5 : 
            {
              1 : 2
            }
        }
      531 : 
        {
          1 : "NN conj NN nmod NN nmod NN nmod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj clindamycin nmod administration nmod *disease* nmod ductopenia appos drug0"
              2 : "drug0 appos diphenylhydantoin nmod patient nmod *development* nmod gammopathy conj drug0"
            }
          4 : 
            {
              1 : "Cholestatic liver disease with ductopenia ( drug1 ) after administration of clindamycin and drug2 . "
              2 : "The development of an IgG lambda-type monoclonal gammopathy and subsequent drug1 in an epilepsy patient on diphenylhydantoin ( drug2 ) therapy for 20 years is reported . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      532 : 
        {
          1 : "NN compound NN nmod VBD nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound use nmod *occurred* nsubj diagnosis nmod drug0"
              2 : "drug0 compound therapy nmod *occurred* nsubj case nmod drug0"
            }
          4 : 
            {
              1 : "Diagnosis of drug1 occurred in this patient during drug2 use , suggesting a newly defined side effect of anastrozole . "
              2 : "One case of drug1 occurred during drug2 therapy for a previous surgical operation to the knee is reported . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      533 : 
        {
          1 : "NN xcomp VBN advcl VBG dobj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 xcomp *found* advcl receiving dobj doses nmod drug0"
            }
          4 : 
            {
              1 : "After receiving 3 doses of drug1 , she was found to be drug2 . "
            }
          5 : 
            {
              1 : 2
            }
        }
      534 : 
        {
          1 : "NN conj NN dep VBP nsubj NNS acl VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj fever dep *have* nsubj patients acl receiving dobj drug0"
              2 : "drug0 conj fever dep *have* nsubj patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving drug1 have unusual symptoms , particularly fever , drug2 , and lymphadenopathy . "
              2 : "The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving drug1 have unusual symptoms , particularly fever , rash , and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      535 : 
        {
          1 : "NN conj NN dobj VBD advcl VBN dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj cough dobj *developed* advcl received dobj drug0"
              2 : "drug0 conj cough dobj *developed* advcl received dobj drug0"
            }
          4 : 
            {
              1 : "After having received drug1 on day 1 of the second course , the patient developed dry cough , drug2 and dyspnea within 48 h . "
              2 : "After having received drug1 on day 1 of the second course , the patient developed dry cough , subfebrile temperatures and drug2 within 48 h . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      536 : 
        {
          1 : "NN conj NN nmod NN nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj sulfonate nmod administration nmod *caused* nsubjpass drug0"
              2 : "drug0 conj stroke nmod cause nmod *implicated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "We concluded that the drug1 and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and drug2 . "
              2 : "drug1 ( PPA ) recently has been publicly implicated as a cause of stroke and other drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      537 : 
        {
          1 : "NN compound NN nmod NN dobj VBG advcl VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound regimen nmod course dobj receiving advcl *occurred* nsubj drug0"
              2 : "drug0 compound therapy nmod trial dobj beginning advcl *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "Three months following splenectomy , drug1 occurred in the muscles of both thighs while the patient was receiving the third course of the drug2 regimen . "
              2 : "In the second case , five drug1 due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of drug2 maintenance therapy for complex ventricular ectopy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      538 : 
        {
          1 : "NN nmod NN amod JJ conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *therapy* amod bulbar conj drug0"
              2 : "drug0 nmod *reaction* amod rare conj drug0"
            }
          4 : 
            {
              1 : "Bulbar and drug1 complicating therapy with high-dose drug2 in children with leukemia . "
              2 : "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called `` 3-week sulphasalazine syndrome '' , a rare , but often drug1 , immunoallergic reaction to drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      539 : 
        {
          1 : "NN nmod NNS nmod NN dep NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *cases* nmod carboplatin dep drug0"
              2 : "drug0 dep *occurrence* nmod effects nmod drug0"
            }
          4 : 
            {
              1 : "We report five cases of carboplatin ( CBDCA ) drug1 after weekly low-dose drug2 ( 60 mg/m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy . "
              2 : "In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low-dose drug1 : an drug2 and a pneumonitis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      540 : 
        {
          1 : "NN nmod NNS dobj VBZ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod reactions dobj *causes* nsubj drug0"
              2 : "drug0 nmod effects dobj *causes* nsubj drug0"
            }
          4 : 
            {
              1 : "Therefore , although drug1 reportedly causes fewer adverse reactions for drug2 than third-generation quinolone antibiotics , one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP . "
              2 : "drug1 , an opium alkaloid , frequently causes side effects such as drug2 and facial flushing , but serious cutaneous adverse drug reactions are seldom observed . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      541 : 
        {
          1 : "NN nmod VBN dep VBN nmod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod caused dep *diagnosed* nmod causes nmod drug0"
              2 : "drug0 nmod associated dep *achieved* nmod doses nmod drug0"
            }
          4 : 
            {
              1 : "Without other causes for the drug1 , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by drug2 . "
              2 : "Prolonged responses were achieved with low doses of drug1 ( 3-10 mg/kg/day ) and higher doses were associated with drug2 or hepatic toxicity and no further increases in Hb . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      542 : 
        {
          1 : "NN appos NN dep NN dobj VBD nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos avt dep tachycardia dobj *induced* nsubj drug0"
              2 : "drug0 appos avt dep tachycardia dobj *induced* nsubj drug0"
            }
          4 : 
            {
              1 : "A 44-year-old woman is described in whom drug1 , disopyramide , and quinidine , administered alone separately , induced atypical ventricular tachycardia ( AVT , drug2 ) . "
              2 : "A 44-year-old woman is described in whom amiodarone , disopyramide , and drug1 , administered alone separately , induced atypical ventricular tachycardia ( AVT , drug2 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      543 : 
        {
          1 : "NN dobj VB xcomp VBN conj NN nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj cause xcomp reported conj *drug* nsubj drug0"
              2 : "drug0 dobj cause xcomp reported conj *ingredient* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is the most frequently implicated drug , but other agents have been reported to cause drug2 . "
              2 : "DISCUSSION : drug1 is the active ingredient in several over-the-counter laxative preparations and has only rarely been reported to cause drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      544 : 
        {
          1 : "NN dobj VBG dep NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj taking dep years nmod *drug0*"
              2 : "drug0 dobj receiving dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "RESULTS : A patient developed a drug1 45 years after taking drug2 for 18 months as prophylaxis against malaria . "
              2 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and drug1 two weeks after receiving drug2 ( TMP ) - sulfamethoxazole ( SMX ) treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      545 : 
        {
          1 : "NN compound NN conj NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound syndrome conj *nephritis* compound drug0"
              2 : "drug0 compound consideration conj *overdose* compound drug0"
            }
          4 : 
            {
              1 : "drug1 acute interstitial nephritis and drug2 ( DRESS ) syndrome . "
              2 : "The association of drug1 overdose and drug2 merits consideration . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      546 : 
        {
          1 : "NN compound NN nmod JJ amod NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod due amod *symptoms* nmod drug0"
              2 : "drug0 compound therapy nmod due amod *patients* nmod drug0"
            }
          4 : 
            {
              1 : "The clinical symptoms of drug1 due to long-term drug2 therapy simulate hypertrophic pyloric stenosis . "
              2 : "We report 3 patients with drug1 due to drug2 therapy , 2 with fatal fulminant hepatitis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      547 : 
        {
          1 : "NN compound NN nmod VBN acl NNS compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound administration nmod associated acl *eruptions* compound drug0"
              2 : "drug0 compound use nmod associated acl *changes* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and maculopapular eruptions associated with drug2 administration . "
              2 : "CONCLUSIONS : We report this case of the concomitant appearance of drug1 and nail changes associated with drug2 use . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      548 : 
        {
          1 : "NN conj NNS nmod NNS dobj VBD nsubj NN acl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj ascites nmod signs dobj *developed* nsubj patient acl treated nmod drug0"
              2 : "drug0 conj ascites nmod signs dobj *developed* nsubj patient acl treated nmod drug0"
            }
          4 : 
            {
              1 : "A patient with chronic myeloid leukaemia treated with drug1 for 4-5 years , developed signs of busulphan toxicity and portal hypertension with ascites , drug2 and jaundice . "
              2 : "A patient with chronic myeloid leukaemia treated with drug1 for 4-5 years , developed signs of busulphan toxicity and portal hypertension with ascites , oesophageal varices and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      549 : 
        {
          1 : "NN dobj VBG advcl VBG acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj taking advcl requiring acl *drug0*"
              2 : "drug0 dobj receiving advcl leading acl *drug0*"
            }
          4 : 
            {
              1 : "Eleven patients developed drug1 requiring hospitalization while taking drug2 including : lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ) . "
              2 : "We describe a patient with acute leukemia who developed Horner 's syndrome and a drug1 leading to death after receiving high-dose drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      550 : 
        {
          1 : "NN compound NN nmod NNS nmod VBD nsubj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound treatment nmod months nmod *appeared* nsubj melanonychia conj drug0"
              2 : "drug0 compound initiation nmod days nmod *appeared* nsubj fever conj drug0"
            }
          4 : 
            {
              1 : "Both the longitudinal melanonychia and the drug1 first appeared after approximately 6 months of drug2 treatment . "
              2 : "Fever and drug1 appeared at 10 days after drug2 initiation , and then the drug was discontinued . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      551 : 
        {
          1 : "NN compound NN nmod NNS nmod VBD nsubj NNP conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound administration nmod hours nmod *occurred* nsubj dyspnea conj drug0"
              2 : "drug0 compound administration nmod hours nmod *occurred* nsubj dyspnea conj drug0"
            }
          4 : 
            {
              1 : "Dyspnea , hypoxemia , and drug1 occurred within 24 hours of drug2 administration , and there was no other apparent explanation . "
              2 : "Dyspnea , drug1 , and pleuritic chest pain occurred within 24 hours of drug2 administration , and there was no other apparent explanation . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      552 : 
        {
          1 : "NN nsubjpass VBN ccomp VBD parataxis VBD dobj NNS acl VBN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nsubjpass followed ccomp had parataxis *had* dobj convulsions acl attributed nmod drug0"
            }
          4 : 
            {
              1 : "Three of these patients had convulsions attributed to drug1 ; 3.6 % of the patients had drug2 , or 2 % of imipenem/cilastatin administrations was followed by a seizure attack . "
            }
          5 : 
            {
              1 : 2
            }
        }
      553 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBN nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treatment dobj starting advcl *hospitalized* nmod fatigue conj drug0"
              2 : "drug0 nmod treatment dobj starting advcl *hospitalized* nmod fatigue conj drug0"
            }
          4 : 
            {
              1 : "A 79-year-old man with ischemic heart disease , chronic atrial fibrillation , chronic renal failure , hypothyroidism , and gout arthritis was hospitalized because of fatigue , drug1 , and leg weakness , shortly after starting treatment with drug2 . "
              2 : "A 79-year-old man with ischemic heart disease , chronic atrial fibrillation , chronic renal failure , hypothyroidism , and gout arthritis was hospitalized because of fatigue , myalgia , and drug1 , shortly after starting treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      554 : 
        {
          1 : "NN compound NN nmod NNS nsubj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod *effects* nsubj depletion conj drug0"
              2 : "drug0 compound therapy nmod *effects* nsubj depletion conj drug0"
            }
          4 : 
            {
              1 : "CD4 T-lymphocyte depletion , myelosuppression , and subsequent drug1 are the major side effects of drug2 therapy . "
              2 : "CD4 T-lymphocyte depletion , drug1 , and subsequent severe infections are the major side effects of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      555 : 
        {
          1 : "NN nmod VBN nmod NNS nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod *seen* nmod days nmod treatment compound drug0"
              2 : "drug0 compound therapy nmod months nmod *associated* nmod drug0"
            }
          4 : 
            {
              1 : "During the first days of drug1 treatment a rapid decrease in the D-dimers was seen ( normal values reached until day 7 ) , together with a drug2 . "
              2 : "A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with drug1 after 27 months of drug2 therapy and a cumulative dose of 1 , 200 g . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      556 : 
        {
          1 : "NN appos NN nmod NN nmod NNS nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos gamma nmod therapy nmod months nmod *development* nmod drug0"
              2 : "drug0 nmod therapy nmod months nmod *development* nmod erythematosus appos drug0"
            }
          4 : 
            {
              1 : "The development of drug1 ( SLE ) after 38 months of therapy with recombinant human interferon gamma ( drug2 ) was observed in a patient with rheumatoid arthritis . "
              2 : "The development of systemic lupus erythematosus ( drug1 ) after 38 months of therapy with drug2 ( rIFN-gamma ) was observed in a patient with rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      557 : 
        {
          1 : "NN compound NN nmod NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound administration nmod *case* nmod owing compound drug0"
              2 : "drug0 compound therapy nmod *septicemia* nmod outcome compound drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of drug1 owing to drug2 administration in a patient with mucositis secondary to chemotherapy . "
              2 : "Recurrent septicemia with drug1 outcome during and after drug2 therapy in severe ulcerative colitis . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      558 : 
        {
          1 : "NN compound NNS nmod VBD dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound injections nmod *experienced* dobj drug0"
              2 : "drug0 compound injections nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "The second patient experienced drug1 following several drug2 injections prior experiencing a cerebrovascular accident within several hours of her next injection . "
              2 : "We report the first case of a human immunodeficiency virus type 1 ( HIV-1 ) - infected individual receiving combination antiretroviral therapy , which included ritonavir , who developed drug1 with profound complications after epidural drug2 injections . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      559 : 
        {
          1 : "NN conj NN appos CD dep VBD dobj NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj erythema appos one dep *experienced* dobj reactions nmod drug0"
              2 : "drug0 conj erythema appos one dep *experienced* dobj reactions nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to drug1 : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and drug2 ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever . "
              2 : "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to drug1 : one , involving intrahepatic artery infusion , manifested general erythema , drug2 , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      560 : 
        {
          1 : "NN dobj VBD acl:relcl NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl *rifampicin* conj drug0"
              2 : "drug0 dobj developed acl:relcl *theophylline* conj drug0"
            }
          4 : 
            {
              1 : "After seven months ' continuous treatment for suspected tuberculosis with rifampicin and drug1 a nine-year-old boy developed drug2 , rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor . "
              2 : "We presented a patient with status asthmaticus treated with a combination of theophylline and drug1 who developed a drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      561 : 
        {
          1 : "NN nmod VBN acl NN nmod VBP dobj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *present* dobj case nmod drug0"
              2 : "drug0 nmod treated acl patient nmod *present* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We present a case of drug1 in an advanced ovarian cancer patient treated with drug2 and gemcitabine , and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up . "
              2 : "We present a case of drug1 in a patient treated with drug2 for acne vulgaris . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      562 : 
        {
          1 : "NN nmod NN nmod NN nmod NN nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod period nmod *cross-reaction* nmod promethazine conj drug0"
              2 : "drug0 conj phentolamine nmod combination nmod self-injection nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken mequitazine for 6 months , and there were strong positive photopatch test results with immediate erythema reaction , cross-reaction to promethazine , drug1 , and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the drug2 . "
              2 : "We report a case of drug1 after intracavernous self-injection of a combination of phentolamine and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      563 : 
        {
          1 : "NN nmod NN dobj VBZ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod reaction dobj *suggests* nsubj drug0"
              2 : "drug0 nmod incidence dobj *increases* nsubj drug0"
            }
          4 : 
            {
              1 : "In the absence of mucositis or diarrhea , drug1 following a single low dose of the drug suggests an ` allergic ' or acute hypersensitivity reaction to drug2 in this patient . "
              2 : "Although its side effects are few , drug1 increases the incidence of drug2 , which theoretically should be preventable with progestational agents . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      564 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NN nmod NN nmod NNS compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj bradycardia nmod resulted acl:relcl *case* nmod overdose nmod tablets compound drug0"
              2 : "drug0 conj bradycardia nmod resulted acl:relcl *case* nmod overdose nmod tablets compound drug0"
            }
          4 : 
            {
              1 : "We report a case of unintentional overdose of oral drug1 tablets that resulted in bradycardia , drug2 , and muscarinic symptoms in a patient with Sjogren 's syndrome . "
              2 : "We report a case of unintentional overdose of oral drug1 tablets that resulted in bradycardia , mild hypotension , and drug2 in a patient with Sjogren 's syndrome . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      565 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj taking acl patients nmod *occurrence* nmod drug0"
              2 : "drug0 dobj receiving acl patients nmod *occurrence* nmod drug0"
            }
          4 : 
            {
              1 : "This case had radiation fibrosis , so we suggest that radiation fibrosis may be another contributor of the occurrence of drug1 in patients taking drug2 . "
              2 : "Potential mechanisms involved in the occurrence of drug1 in patients receiving drug2 are also discussed . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      566 : 
        {
          1 : "NN compound NN nmod VBN acl NNS conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound use nmod associated acl *cancers* conj drug0"
              2 : "drug0 compound treatment nmod associated acl *carcinomas* conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : We report this case of the concomitant appearance of multiple skin cancers and drug1 associated with drug2 use . "
              2 : "OBJECTIVE : The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and drug1 associated with drug2 treatment , and to describe a successful therapeutic approach using imiquimod 5 % . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      567 : 
        {
          1 : "NN conj NN nmod VBG acl NN nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj rash nmod presenting acl *man* nmod treatment compound drug0"
              2 : "drug0 conj hypotension nmod resulting acl *case* nmod overdosage compound drug0"
            }
          4 : 
            {
              1 : "We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection , on drug1 treatment , presenting with herpetic rash and drug2 . "
              2 : "In this paper we report a case of drug1 overdosage resulting in prolonged hypotension and drug2 , which was successfully treated with calcium gluconate . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      568 : 
        {
          1 : "NN dobj VB conj VBZ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj cause conj *shortens* nsubj drug0"
              2 : "drug0 dobj induce conj *inhibits* nsubj drug0"
            }
          4 : 
            {
              1 : "However , drug1 shortens the antegrade refractoriness of accessory atrioventricular connections and may cause drug2 during atrial fibrillation . "
              2 : "drug1 inhibits the conversion of tryptophan to niacin and may induce drug2 , particularly in poorly nourished patients . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      569 : 
        {
          1 : "NN nmod NN nmod NN nmod VBG acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treatment nmod patient nmod occurring acl *drug0*"
              2 : "drug0 nmod treatment nmod onset nmod coinciding acl *drug0*"
            }
          4 : 
            {
              1 : "The authors report a case of acute drug1 ( AP ) occurring in a patient under treatment with drug2 ( CBZ ) for post-traumatic petit mal epilepsy , and review the current literature of drug-induced AP . "
              2 : "We report 5 cases of drug1 coinciding with the onset of treatment with drug2 in patients with severe drug-resistant hypertension . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      570 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj mofetil nmod use nmod induced acl patient nmod *drug0*"
              2 : "drug0 conj methotrexate nmod therapy nmod caused acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "drug1 in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and drug2 . "
              2 : "A case of drug1 caused by combination therapy with methotrexate and drug2 in the treatment of severe psoriasis is presented in a 47-year-old woman . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      571 : 
        {
          1 : "NN nsubjpass VBN advcl VBN nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nsubjpass stopped advcl *resolved* nsubj drug0"
              2 : "drug0 nsubj *resolved* advcl stopped nsubjpass drug0"
            }
          4 : 
            {
              1 : "SUBSEQUENT COURSE : The drug1 resolved almost completely once the drug2 was stopped and after immunosuppressive treatment . "
              2 : "When drug1 was stopped the drug2 resolved . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      572 : 
        {
          1 : "NN conj NN nmod VBN conj JJ nsubj NN nmod NNS nmod NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj vasodilatation nmod related conj *uncertain* nsubj cause nmod effects nmod therapy compound drug0"
              2 : "drug0 conj vasodilatation nmod related conj *uncertain* nsubj cause nmod effects nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "The cause of these previously unreported side effects of drug1 therapy is uncertain but may be related to prostaglandin-mediated vasodilatation , drug2 , and potentiation of inflammation in the gingiva with referral of pain to the teeth . "
              2 : "The cause of these previously unreported side effects of drug1 therapy is uncertain but may be related to prostaglandin-mediated vasodilatation , hyperalgesia of sensory nerve receptors , and drug2 with referral of pain to the teeth . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      573 : 
        {
          1 : "NN nmod VBG xcomp VB nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod resulting xcomp *interfere* nmod glucuronidation nmod drug0"
              2 : "drug0 nmod leading xcomp *interfere* nmod glucuronidation nmod drug0"
            }
          4 : 
            {
              1 : "It was hypothesized that valproic acid may interfere with glucuronidation of drug1 , leading to increased serum lamotrigine levels , or perhaps alter the drug 's metabolism , resulting in drug2 . "
              2 : "It was hypothesized that valproic acid may interfere with glucuronidation of drug1 , leading to drug2 , or perhaps alter the drug 's metabolism , resulting in accumulation of a toxic intermediate metabolite . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      574 : 
        {
          1 : "NN conj NN nmod NNS nmod NN nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj infliximab nmod antibodies nmod administration nmod *associated* nsubjpass drug0"
              2 : "drug0 conj infliximab nmod antibodies nmod administration nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 has been associated with the administration of other monoclonal antibodies , such as infliximab , drug2 , and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines . "
              2 : "drug1 has been associated with the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and drug2 and is believed to be directly mediated by release of proinflammatory cytokines . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      575 : 
        {
          1 : "NN nmod NN nmod VBN conj JJ nsubj NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod development nmod followed conj *effective* nsubj introduction nmod drug0"
              2 : "drug0 nmod diagnosis nmod considered conj *responsible* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "Introduction of drug1 was also clinically effective but followed by development of drug2 . "
              2 : "CONCLUSION : The administration of drug1 was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      576 : 
        {
          1 : "NN nmod VBN acl:relcl NNS nmod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod associated acl:relcl *cases* nmod sleep appos drug0"
              2 : "drug0 nmod associated acl:relcl *cases* nmod syndrome appos drug0"
            }
          4 : 
            {
              1 : "We report five cases of restless legs syndrome ( RLS ) and periodic limb movements during sleep ( drug1 ) that were probably associated with drug2 . "
              2 : "We report five cases of restless legs syndrome ( drug1 ) and periodic limb movements during sleep ( PLMS ) that were probably associated with drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      577 : 
        {
          1 : "NN nmod JJ amod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod secondary amod *necrolysis* appos drug0"
            }
          4 : 
            {
              1 : "We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis ( drug1 ) secondary to drug2 ( TMP-Sx ) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus ( CA-MRSA ) infection . "
            }
          5 : 
            {
              1 : 2
            }
        }
      578 : 
        {
          1 : "NN conj NNS nmod VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj arrhythmias nmod *reported* nsubjpass drug0"
              2 : "drug0 conj hemorrhages nmod *characterized* nsubjpass drug0"
            }
          4 : 
            {
              1 : "DISCUSSION : drug1 has been reported to produce significant cardiac toxicity , with ventricular arrhythmias and drug2 reported in overdoses in children and in adults with preexisting cardiac disease , even when administered in conventional dosages and infusion rates . "
              2 : "BACKGROUND : drug1 ( IFN ) - associated retinopathy is typically characterized by retinal hemorrhages and drug2 at the posterior fundus , but visual function is usually maintained . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      579 : 
        {
          1 : " NN nmod:poss NN"
          2 : 2
          3 : 
            {
              1 : " *drug0* nmod:poss drug0"
              2 : " *drug0* nmod:poss drug0"
            }
          4 : 
            {
              1 : "In this article lithium is not discussed , although there are a number of concerns about drug1 's potential drug2 , and it has been implicated in Epstein 's anomaly , a congenital heart defect among infants born to women taking lithium ; as with other medications , however , the data have specific limitations . "
              2 : "Despite a postulated dopaminergic mechanism , there seems to have been only one previous report of drug1 's drug2 in a schizophrenic patient . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      580 : 
        {
          1 : "NN appos NN nmod VBN acl NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 appos therapy nmod treated acl *case* nmod drug0"
              2 : "drug0 appos carmustine nmod treated acl patient nmod *drug0*"
            }
          4 : 
            {
              1 : "We report a case of drug-induced drug1 ( KS ) on the sole of the right foot in a 71-year-old man , treated for 6 months with corticosteroid therapy ( drug2 25 mg/day ) for pericardial effusion . "
              2 : "We report a drug1 in a patient treated with carmustine ( drug2 ) for a brain tumor . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      581 : 
        {
          1 : "NN dobj VBG acl:relcl NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj receiving acl:relcl *cases* nmod drug0"
              2 : "drug0 dobj receiving acl:relcl *patients* nmod drug0"
            }
          4 : 
            {
              1 : "We report four cases of hemodynamically significant drug1 in patients with refractory lymphoma who were receiving drug2 , all of whom had a history of mediastinal radiation without subcarinal blocking . "
              2 : "The authors suggest that in patients with drug1 who are receiving drug2 , cessation of colchicine therapy should be considered . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      582 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod VBD nsubj NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound sodium dobj receiving acl patient nmod *occurred* nsubj shock conj drug0"
              2 : "drug0 compound sodium dobj receiving acl patient nmod *occurred* nsubj shock conj drug0"
            }
          4 : 
            {
              1 : "Anaphylactoid shock , drug1 , and anuric renal failure requiring dialysis occurred in a patient receiving drug2 sodium for toothache . "
              2 : "Anaphylactoid shock , disseminated intravascular coagulation , and drug1 requiring dialysis occurred in a patient receiving drug2 sodium for toothache . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      583 : 
        {
          1 : "NN nmod JJ xcomp VBN nsubjpass NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod responsible xcomp *believed* nsubjpass drug0"
              2 : "drug0 nmod responsible xcomp *believed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Because of its structural similarity to the other vinca alkaloids , drug1 is believed to be responsible for drug2 in our patient . "
              2 : "drug1 , an ester-type local anesthetic , was believed responsible for apparent drug2 in a cat . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      584 : 
        {
          1 : "NN compound NN dobj VBG dep NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy dobj starting dep weeks nmod *drug0*"
              2 : "drug0 compound treatment dobj receiving dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "A 22-year-old black man developed fever , chills , fatigue , night sweats , tender lymphadenopathy , and a drug1 3 weeks after starting drug2 therapy for acne . "
              2 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and drug1 two weeks after receiving trimethoprim ( TMP ) drug2 ( SMX ) treatment . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      585 : 
        {
          1 : "NN nsubjpass VBN acl:relcl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nsubjpass observed acl:relcl *drug0*"
              2 : "drug0 nsubjpass presented acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "In a 61-year-old man receiving chronic low-dosage drug1 an drug2 was observed . "
              2 : "A typical case of drug1 associated drug2 is presented . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      586 : 
        {
          1 : "NN compound NNS conj NN nmod NN nmod VBN acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound antibiotics conj cephalosporin nmod use nmod associated acl *drug0*"
              2 : "drug0 compound antibiotics conj cephalosporin nmod use nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "Nine azotemic patients who developed a drug1 associated with the use of either cephalosporin or drug2 antibiotics are reported . "
              2 : "drug1 associated with the use of cephalosporin or drug2 antibiotics in acute and chronic renal failure . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      587 : 
        {
          1 : "NN nmod NN nmod VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod use nmod *developing* dobj drug0"
              2 : "drug0 nmod development nmod *starting* dobj drug0"
            }
          4 : 
            {
              1 : "She died within six weeks of developing drug1 coupled with liver failure due to haemosiderosis despite regular use of drug2 . "
              2 : "The mean time from starting drug1 to the development of drug2 was 4 months . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      588 : 
        {
          1 : "NN conj NN nmod NN nmod NNP conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj ethambutol nmod treatment nmod *polyarthritis* conj drug0"
              2 : "drug0 conj ethambutol nmod treatment nmod *polyarthritis* conj drug0"
            }
          4 : 
            {
              1 : "Polyarthritis , hepatitis and drug1 after treatment with ethambutol and drug2 . "
              2 : "Polyarthritis , drug1 and anti-native DNA antibodies after treatment with ethambutol and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      589 : 
        {
          1 : "NN dobj VBG advcl VB dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 dobj taking advcl *develop* dobj drug0"
              2 : "drug0 dobj avoiding advcl *prevent* dobj drug0"
            }
          4 : 
            {
              1 : "Surprisingly , we found that three patients appeared to develop drug1 while taking drug2 . "
              2 : "Recognizing early signs of HMSN , such as areflexia and pes cavus deformity , can prevent drug1 of polychemotherapy by avoiding drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      590 : 
        {
          1 : "NN nmod VBN advcl VBD dobj NN dep NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod started advcl *developed* dobj polyserositis dep effusion conj drug0"
              2 : "drug0 nmod started advcl *developed* dobj polyserositis dep effusion conj drug0"
            }
          4 : 
            {
              1 : "We report the case of a patient who developed polyserositis ( pericardial effusion , pleural effusion , and drug1 ) after being started on drug2 , and whose symptoms remitted upon discontinuation of clozapine . "
              2 : "We report the case of a patient who developed polyserositis ( pericardial effusion , drug1 , and pericarditis ) after being started on drug2 , and whose symptoms remitted upon discontinuation of clozapine . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      591 : 
        {
          1 : "NN conj NN nmod VBZ conj VBN nsubjpass NN compound NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj anxiety nmod consists conj *reported* nsubjpass withdrawal compound drug0"
              2 : "drug0 conj anxiety nmod consists conj *reported* nsubjpass withdrawal compound drug0"
            }
          4 : 
            {
              1 : "Although drug1 withdrawal has been previously reported and usually consists of anxiety , diaphoresis , and drug2 , this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal . "
              2 : "Although drug1 withdrawal has been previously reported and usually consists of anxiety , drug2 , and palpitations , this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      592 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD acl:relcl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod mg/day nmod treatment nmod occurred acl:relcl *drug0*"
              2 : "drug0 nmod hyperthyroidism nmod treatment nmod developed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "A 74-year-old patient with idiopathic Parkinson 's disease was evaluated for drug1 that occurred after long-term treatment with 400 mg/day of drug2 . "
              2 : "A patient is presented with typical drug1 , who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with drug2 ( 100 mg orally , three times a day ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      593 : 
        {
          1 : "NN conj NN nmod VBN acl:relcl NN dobj VB nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj anemia nmod characterized acl:relcl syndrome dobj *induce* nsubj drug0"
              2 : "drug0 conj anemia nmod characterized acl:relcl syndrome dobj *induce* nsubj drug0"
            }
          4 : 
            {
              1 : "In rare cases drug1 ( MMC ) may induce cancer-associated hemolytic uremic syndrome , which is characterized by hemolytic anemia , drug2 and progressive renal failure . "
              2 : "In rare cases drug1 ( MMC ) may induce cancer-associated hemolytic uremic syndrome , which is characterized by hemolytic anemia , thrombocytopenia and drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      594 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod NN nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound administration nmod *treatment* nmod carbimazole nmod pregnancy nmod drug0"
              2 : "drug0 compound therapy nmod psoriasis nmod patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "Successful treatment with carbimazole of a hyperthyroid pregnancy with drug1 after drug2 administration : a case report . "
              2 : "A case of drug1 in a patient with chronic plaque psoriasis under drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      595 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod NN appos NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound therapy nmod withdrawal nmod *patient* nmod dyskinesia appos drug0"
              2 : "drug0 compound administration nmod *syndrome* nmod secretion nmod adh appos drug0"
            }
          4 : 
            {
              1 : "The authors present an elderly patient with mixed dementia who developed TD at multiple sites , ( including respiratory dyskinesia [ drug1 ] , limb dyskinesia , and orofacial dyskinesia ) following abrupt withdrawal of drug2 therapy . "
              2 : "Syndrome of inappropriate secretion of ADH ( drug1 ) following drug2 administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      596 : 
        {
          1 : "NN compound NN dobj VBG dep NNS nmod NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound treatment dobj receiving dep weeks nmod eosinophilia conj *drug0*"
              2 : "drug0 compound therapy dobj starting dep weeks nmod eruption conj *drug0*"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with drug1 , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) drug2 ( SMX ) treatment . "
              2 : "A 22-year-old black man developed drug1 , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption 3 weeks after starting drug2 therapy for acne . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      597 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound treatment nmod initiation dep years nmod *drug0*"
              2 : "drug0 compound therapy nmod initiation dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "An 11-year-old boy developed a drug1 2 years after initiation of drug2 treatment for graft-versus-host disease . "
              2 : "A 60-year-old woman with diabetes mellitus ( type 2 ) developed an drug1 6 weeks after the initiation of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      598 : 
        {
          1 : "NN nmod NN nmod VBN conj VBP dobj NN nmod NN acl:relcl VBD dobj NN dep NN conj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod remitted conj *report* dobj case nmod patient acl:relcl developed dobj polyserositis dep effusion conj drug0"
              2 : "drug0 nmod discontinuation nmod remitted conj *report* dobj case nmod patient acl:relcl developed dobj polyserositis dep effusion conj drug0"
            }
          4 : 
            {
              1 : "We report the case of a patient who developed polyserositis ( pericardial effusion , drug1 , and pericarditis ) after being started on clozapine , and whose symptoms remitted upon discontinuation of drug2 . "
              2 : "We report the case of a patient who developed polyserositis ( pericardial effusion , pleural effusion , and drug1 ) after being started on clozapine , and whose symptoms remitted upon discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      599 : 
        {
          1 : "NN nmod VBD nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *complained* nsubj patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Three of 50 patients treated with drug1 ( 1 mg/kg/day ) for cystic acne complained of drug2 and/or excessive glare sensitivity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      600 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod regimen nmod *correlated* nsubj woman acl presented nmod drug0"
            }
          4 : 
            {
              1 : "A 35-year-old woman presented with drug1 correlated to an i.v. regimen of drug2 as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum . "
            }
          5 : 
            {
              1 : 1
            }
        }
      601 : 
        {
          1 : "NN dobj VBD conj VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *received* dobj injection nmod drug0"
            }
          4 : 
            {
              1 : "She received an accidental 450-mg bolus injection of drug1 intrathecally and developed drug2 , status epilepticus , intracerebral hemorrhage , and respiratory failure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      602 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl woman nmod *case* acl confined nmod drug0"
            }
          4 : 
            {
              1 : "A case of high-grade endometrial stromal sarcoma , confined into an drug1 , in a woman with a history of breast cancer who was treated with adjuvant drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      603 : 
        {
          1 : "NN conj NN nmod NN dep NNS nmod NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj failure nmod biopsy dep years nmod spite nmod *led* nsubj drug0"
            }
          4 : 
            {
              1 : "However , continued low-dose drug1 led , in spite of normal liver tests , 8 years after the last biopsy to liver failure and drug2 in 1 of our patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      604 : 
        {
          1 : "NN appos NN conj NN nmod NN nmod NN nmod NNS nmod:tmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acid conj daunomycin nmod combination nmod treatment nmod months nmod:tmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report the case of a 14-year-old female with acute promyelocytic leukemia who developed drug1 only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      605 : 
        {
          1 : "NN appos NN nmod NN nmod NN nmod VBG advcl VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos drug nmod administration nmod infarction nmod presenting advcl *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "The authors report a case of drug1 , presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug , drug2 , in a patient without coronary artery disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      606 : 
        {
          1 : "NN nmod VBN acl:relcl NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod exposed acl:relcl children nmod *explored* dobj drug0"
            }
          4 : 
            {
              1 : "We explored drug1 in two children who have been exposed prenatally to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      607 : 
        {
          1 : "NN nmod CD dep IN amod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod 0 dep of amod ingestion nmod *experienced* dobj drug0"
            }
          4 : 
            {
              1 : "The patient experienced drug1 , agitation , vomiting , tachycardia and seizures after ingestion of 1050 ( 48 mg/kg ) of extended-release drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      608 : 
        {
          1 : "NN nmod VBZ conj VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consists conj *reported* nsubjpass withdrawal compound drug0"
            }
          4 : 
            {
              1 : "Although drug1 withdrawal has been previously reported and usually consists of drug2 , diaphoresis , and palpitations , this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal . "
            }
          5 : 
            {
              1 : 1
            }
        }
      609 : 
        {
          1 : "NN compound NN dep NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion dep days nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 58-year-old man with advanced renal cell carcinoma developed grade 3 drug1 ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency five days after drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      610 : 
        {
          1 : "NN conj NN nmod VBN acl NNS nmod NN nmod VBD nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pain nmod associated acl glands nmod development nmod *complained* nmod end nmod cycle nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "At the end of his fifth cycle of drug1 therapy , the patient complained of the development of abnormally large mammary glands associated with pain and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      611 : 
        {
          1 : "NN compound NN nmod NN nsubj NN dep VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *complication* nsubj syndrome dep named nmod drug0"
            }
          4 : 
            {
              1 : "Purple glove syndrome , named for its distinctive drug1 and swelling of the hands in the distribution of a glove , is an uncommon complication of intravenous drug2 administration through small dorsal veins of the hands . "
            }
          5 : 
            {
              1 : 1
            }
        }
      612 : 
        {
          1 : "NN appos NN nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos isotretinoin nmod resulting acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 resulting from isotretinoin ( drug2 ) therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      613 : 
        {
          1 : "NN compound NN nmod VBN acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound arteriospasm nmod caused acl *patients* nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with imminent drug1 caused by drug2 arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation , vasodilation , and sympathetic blockade produced no improvement . "
            }
          5 : 
            {
              1 : 1
            }
        }
      614 : 
        {
          1 : "NN compound NN nmod NN nmod RB advmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod course nmod early advmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a 13 year-old male who developed life-threatening drug1 early in the course of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      615 : 
        {
          1 : "NN dobj VBD ccomp VBP nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induced ccomp *report* nmod result nmod interaction nmod drug0"
            }
          4 : 
            {
              1 : "However , given the clinically significant result to the interaction between drug1 and cimetidine we report , the use of cimetidine in tolazoline induced drug2 should deserve more attention . "
            }
          5 : 
            {
              1 : 1
            }
        }
      616 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj simvastatin nmod use nmod associated acl *weakness* appos drug0"
            }
          4 : 
            {
              1 : "Rapid onset of muscle weakness ( drug1 ) associated with the combined use of simvastatin and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      617 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN conj NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod *presented* nmod face conj trunk conj day compound drug0"
            }
          4 : 
            {
              1 : "A 26-year-old Japanese man , who had been receiving medical attention for ulcerative colitis for one year , presented with diffuse erythema and pustules on his face and trunk , malaise , and drug1 one day after the administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      618 : 
        {
          1 : "NN conj NN dep NNS nmod VBN acl NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj cytarabine dep agents nmod provoked acl occasions nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We describe a patient who developed drug1 on three separate occasions provoked by two different chemotherapeutic agents -- cytarabine and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      619 : 
        {
          1 : "NN nmod VBN acl NN nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of drug1 in a patient treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      620 : 
        {
          1 : "NN nsubjpass VBN ccomp VB xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass recommended ccomp have xcomp *shown* nsubjpass drug0"
            }
          4 : 
            {
              1 : "As drug1 has been shown to have drug2 , blood count monitoring is recommended in patients receiving this drug for long-term therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      621 : 
        {
          1 : "NN compound NNS nmod VBN nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound levels nmod *related* nsubj symptoms nmod drug0"
            }
          4 : 
            {
              1 : "Symptoms and signs of drug1 were related to low plasma drug2 levels , abating 75 minutes after oral levodopa administration and reappearing after 3 hours , closely mirroring the rapid rise and fall of plasma levodopa concentration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      622 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl VBN advcl JJ amod JJ xcomp VB"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *demonstrated* nsubj ecg acl:relcl read advcl normal amod prior xcomp drug0"
            }
          4 : 
            {
              1 : "The electrocardiogram ( ECG ) , which was read as normal prior to drug1 infusion , demonstrated a drug2 which disappeared upon discontinuation of ritodrine therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      623 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod JJ xcomp VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod considered acl:relcl carcinomatosa nmod due xcomp developed acl:relcl *mg* nmod drug0"
            }
          4 : 
            {
              1 : "Four days after the initial injection of 3.6 mg of drug1 , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      624 : 
        {
          1 : "NN nsubjpass VBN advcl NN nsubj NNS nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass *kept* advcl hyperparathyroidism nsubj hazards nmod treatment nmod phosphate conj drug0"
            }
          4 : 
            {
              1 : "Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and drug1 are secondary hyperparathyroidism and vitamin D intoxication , drug2 also should be kept in mind . "
            }
          5 : 
            {
              1 : 1
            }
        }
      625 : 
        {
          1 : "NN conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *prescribed* dobj drug0"
            }
          4 : 
            {
              1 : "We present a case of a diabetic patient taking glyburide who was prescribed drug1 and developed drug2 , which persisted for over 24 hours . "
            }
          5 : 
            {
              1 : 1
            }
        }
      626 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NN dobj VBD nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj necrolysis nmod progressed acl:relcl lesion dobj *developed* nmod days nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "After 5 days of treatment with drug1 , the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis , as well as grade 4 drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      627 : 
        {
          1 : "NN compound NN nmod VBN nsubjpass NN nmod NNS acl:relcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod *taken* nsubjpass occurrence nmod symptoms acl:relcl ascribed nmod drug0"
            }
          4 : 
            {
              1 : "The occurrence of symptoms that could be ascribed to an drug1 should always be taken seriously during the first drug2 infusion and investigated aggressively . "
            }
          5 : 
            {
              1 : 1
            }
        }
      628 : 
        {
          1 : "NN appos NN dobj VBN advcl VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos propylthiouracil dobj received advcl detected acl *drug0*"
            }
          4 : 
            {
              1 : "A teenage girl with crescentic glomerulonephritis had drug1 ( ANCA ) detected after she had received propylthiouracil ( drug2 ) for hyperthyroidism without cutaneous vasculitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      629 : 
        {
          1 : "NN compound NN nmod NN dobj VBD conj NN acl:relcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound thrombocytopenia nmod etiology dobj confirmed conj *evening* acl:relcl triggered dobj episode nmod drug0"
            }
          4 : 
            {
              1 : "Even after a strict warning , he took another quinine tablet that evening , which triggered his fifth episode of severe drug1 , and confirmed the etiology of drug2 thrombocytopenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      630 : 
        {
          1 : "NN nmod NN dep NN nmod VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose dep week nmod *followed* nmod drug0"
            }
          4 : 
            {
              1 : "A 65-year-old female patient presented with jaundice followed 2 days later by drug1 and tachypnea which worsened when patient was lying flat , 1 week after the fourth dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      631 : 
        {
          1 : "NN dobj VB xcomp VBN acl NNS nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp known acl medications nmod patients nmod *effect* nmod drug0"
            }
          4 : 
            {
              1 : "Hypoglycemia can be a serious side effect of drug1 in patients already on antidiabetic medications known to cause drug2 , such as sulfonylureas , meglitinides , and insulin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      632 : 
        {
          1 : "NN appos NN conj NN nmod NN nmod NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos administration conj spray nmod administration nmod *woman* nmod episodes nmod drug0"
            }
          4 : 
            {
              1 : "We introduce a case of a sixty years old woman with several previous episodes of drug1 , conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      633 : 
        {
          1 : "NN conj NN nmod VBN acl:relcl NN nmod VBN nsubjpass NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj prednisolone nmod treated acl:relcl infant nmod *detected* nsubjpass infection acl associated nmod drug0"
            }
          4 : 
            {
              1 : "Prenatal cytomegalovirus ( CMV ) infection associated with severe drug1 was detected in an infant whose mother had been treated with prednisolone and drug2 for systemic lupus erythematosus ( SLE ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      634 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod *developed* nsubj case nmod male nmod drug0"
            }
          4 : 
            {
              1 : "This paper reports an autopsy case of a 78-year-old male with drug1 developed after long-termed administration of drug2 ( PDES ) for prostatic cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      635 : 
        {
          1 : "NN nsubjpass VBN advcl VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass observed advcl *stopped* nmod hours nmod drug0"
            }
          4 : 
            {
              1 : "After 39 hours on drug1 , the infusion was stopped when minor drug2 was observed with a concurrent activated partial thromboplastin time ( aPTT ) of 100 seconds . "
            }
          5 : 
            {
              1 : 1
            }
        }
      636 : 
        {
          1 : "NN nmod VBG acl NN nmod VBZ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod leading acl pattern nmod *presents* nsubj injury compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      637 : 
        {
          1 : "NN nsubj VBD advcl VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *cleared* advcl discontinued dobj drug0"
            }
          4 : 
            {
              1 : "After the patient discontinued drug1 , the drug2 cleared completely within 5 weeks without any systemic medication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      638 : 
        {
          1 : "NN conj NN nmod NN nmod VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj alpha nmod treatment nmod *present* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "Here we present the case of a drug1 with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      639 : 
        {
          1 : "NN appos NN compound NN nmod VBP dobj NN nmod NN nmod VBG conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acid compound intoxication nmod *describe* dobj management nmod patient nmod swelling conj drug0"
            }
          4 : 
            {
              1 : "INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and drug1 ( ICP ) after severe sodium valproic acid ( drug2 ) intoxication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      640 : 
        {
          1 : "NN compound NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound *effects* compound drug0"
            }
          4 : 
            {
              1 : "We report on a child with drug1 drug2 hepatotoxic effects despite this supplementation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      641 : 
        {
          1 : "NN nmod NN nsubjpass VBN acl:relcl NN dobj VB nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod pattern nsubjpass noted acl:relcl insult dobj *cause* nsubj toxicity compound drug0"
            }
          4 : 
            {
              1 : "drug1 toxicity can cause severe central nervous system insult in which a characteristic pattern of drug2 is noted on brain imaging studies . "
            }
          5 : 
            {
              1 : 1
            }
        }
      642 : 
        {
          1 : "NN nmod VB xcomp JJ amod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use xcomp secondary amod *hemorrhage* conj drug0"
            }
          4 : 
            {
              1 : "Intracranial hemorrhage and drug1 secondary to use of drug2 during induction therapy of acute lymphocytic leukemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      643 : 
        {
          1 : "NN dobj VB xcomp VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp known conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Both drug1 and AZA are widely used and are known to cause drug2 in a proportion of patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      644 : 
        {
          1 : "NN compound NN nmod NNS dobj VBN nsubjpass NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod effects dobj *reported* nsubjpass comedones conj drug0"
            }
          4 : 
            {
              1 : "The multiple comedones and drug1 are newly reported adverse effects of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      645 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj included acl:relcl regimen nmod course nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a child with yolk sac tumor who developed drug1 after the first course of chemotherapy regimen that included drug2 , etoposide and bleomycin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      646 : 
        {
          1 : "NN compound NNS nmod NN dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound drops nmod initiation dep hours nmod *drug0*"
            }
          4 : 
            {
              1 : "METHODS : A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a drug1 12 hours after initiation of therapy with drug2 eye drops . "
            }
          5 : 
            {
              1 : 1
            }
        }
      647 : 
        {
          1 : "RB advmod RB advmod VBZ acl:relcl DT acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 advmod soon advmod develops acl:relcl *those* acl administering dobj drug0"
            }
          4 : 
            {
              1 : "ARDS is rarely associated with rituximab infusion for lympho-proliferative disorders , but it should be considered by those administering drug1 , especially when a patient develops drug2 soon after infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      648 : 
        {
          1 : "NN nmod NN dep NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod induction dep *myoclonus* conj drug0"
            }
          4 : 
            {
              1 : "Myoclonus and drug1 in a patient with parkinsonism : induction by drug2 and its confirmation on SEPs . "
            }
          5 : 
            {
              1 : 1
            }
        }
      649 : 
        {
          1 : "NN appos NN dep NNS nmod NN nmod VBG acl NNS nmod NN nmod VB nsubj NNS appos NN amod JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos diarrhea dep reactions nmod risk nmod putting acl patients nmod % nmod *occur* nsubj deficiencies appos enzyme amod responsible nmod catabolism compound drug0"
            }
          4 : 
            {
              1 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for drug1 catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , mucositis , myelosuppression , drug2 ) to standard doses of 5-FU . "
            }
          5 : 
            {
              1 : 1
            }
        }
      650 : 
        {
          1 : "NN conj NN nmod VBN advcl VBG advcl VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj adenocarcinoma nmod *considered* advcl deciding advcl warranted nsubjpass therapy compound drug0"
            }
          4 : 
            {
              1 : "In deciding if drug1 therapy is warranted , all potentially life-threatening adverse events associated with tamoxifen should be considered , including endometrial adenocarcinoma or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      651 : 
        {
          1 : "NN nmod NN dobj VBD conj VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod reaction dobj had conj *had* dobj appearance nmod drug0"
            }
          4 : 
            {
              1 : "This case presentation is of a patient who had the clinical appearance of drug1 , but actually had an oro-pharyngeal dystonic reaction to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      652 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod induced acl:relcl *cases* nmod drug0"
            }
          4 : 
            {
              1 : "This article describes two cases of drug1 , at least one of which was almost certainly induced by the use of drug2 , and one case of agranulocytosis related to the use of methazolamide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      653 : 
        {
          1 : "NN nsubj JJ ccomp VBP nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj responsible ccomp *suggest* nsubj sequence nmod drug0"
            }
          4 : 
            {
              1 : "The temporal sequence of the drug1 and the histopathology , when compared to the previous examples in the literature , suggest that drug2 was aetiologically responsible for the lung disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      654 : 
        {
          1 : "NN nmod VBD acl:relcl NN dobj VBD nsubj NN acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod progressed acl:relcl eruption dobj *developed* nsubj patient acl:relcl taking dobj drug0"
            }
          4 : 
            {
              1 : "A 17-year-old female patient who had been taking oral drug1 ( 50 mg twice daily ) for 3 weeks for acne developed an eruption that progressed to an drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      655 : 
        {
          1 : "NN appos NN nmod NN dep NNS nmod VBG nmod NNS conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos spray nmod use dep weeks nmod *swelling* nmod lips conj cavity conj drug0"
            }
          4 : 
            {
              1 : "We report a 43-year-old woman who developed sore throat , swelling of the lips and oral cavity and drug1 , 2 weeks after the use of budesonide spray ( drug2 ) for treatment of bronchial asthma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      656 : 
        {
          1 : "NN dobj VBG acl NN dobj VBD nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj suggesting acl pain dobj *developed* nmod days nmod drug0"
            }
          4 : 
            {
              1 : "Following 7 days of drug1 she developed severe abdominal pain and elevated pancreatic enzymes suggesting drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      657 : 
        {
          1 : "NN conj NN dobj VBN nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj barrier dobj *destroyed* nsubj dose nmod drug0"
            }
          4 : 
            {
              1 : "We thus concluded that an excessive dose of drug1 had probably destroyed the gastric mucosal barrier or drug2 and thus eventually led to the development of hemorrhagic gastritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      658 : 
        {
          1 : "NN nmod VBN acl:relcl NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl:relcl *cases* nmod syndrome conj drug0"
            }
          4 : 
            {
              1 : "We report five cases of restless legs syndrome ( RLS ) and drug1 ( PLMS ) that were probably associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      659 : 
        {
          1 : "NN compound NNS nmod VBN acl NN nmod VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound salts nmod treated acl patient nmod *overcome* dobj drug0"
            }
          4 : 
            {
              1 : "We have successfully overcome drug1 in an RA patient treated with drug2 salts , using granulocyte colony-stimulating factor ( G-CSF ) , reducing the duration of neutropenia and risk of infection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      660 : 
        {
          1 : "NN nmod VBN acl NN nmod VBG acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod composed acl chemotherapy nmod undergoing acl:relcl girl nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of reversible drug1 in a 16-year-old girl with acute myelogenous leukemia ( AML ) , who is undergoing during consolidation chemotherapy composed of drug2 ( N4-behenoyl-1-beta-D-arabinofuranosyl cytosine ) and idarubicin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      661 : 
        {
          1 : "NN nmod NN conj JJ xcomp VBD acl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod encephalopathy conj severe xcomp caused acl *administration* compound drug0"
            }
          4 : 
            {
              1 : "In a female with acute lymphoblastic leukemia , inadvertent drug1 administration intrathecally caused severe , life-threatening , acute encephalopathy with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      662 : 
        {
          1 : "NN dep NNS nmod VBN acl:relcl NNS nsubj VBD ccomp VBD nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep causes nmod associated acl:relcl cases nsubj were ccomp *showed* nsubj study nmod deaths nmod drug0"
            }
          4 : 
            {
              1 : "A retrospective epidemiological study of deaths from drug1 ( HAS ) in the U.S. showed that during 1964 -- 74 there were 168 such cases , of which 37 ( 22 % ) were associated with previously known causes ( drug2 , ` Thorotrast ' , and inorganic arsenic ) and 4 ( 3.1 % ) of the remaining 131 cases with the use of androgenic-anabolic steroids . "
            }
          5 : 
            {
              1 : 1
            }
        }
      663 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod VBN advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound neurotoxicity nmod development nmod vulnerability nmod *associated* advcl characterized nmod drug0"
            }
          4 : 
            {
              1 : "When the acute manic state is characterized by marked drug1 and intense anxiety , it may be associated with increased vulnerability to the development of severe drug2 neurotoxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      664 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occurrence nmod effects nmod associated conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      665 : 
        {
          1 : "NN appos JJ amod NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos intermediate amod insulins nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was observed with both intermediate ( neutral drug2 ) and long-acting ( protamine zinc iletin ) insulins , and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat . "
            }
          5 : 
            {
              1 : 1
            }
        }
      666 : 
        {
          1 : "NN compound NN nmod NN dobj VBG advcl VBD nsubj NNS amod JJ nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod trial dobj beginning advcl *occurred* nsubj arrests amod due nmod tachycardia conj drug0"
            }
          4 : 
            {
              1 : "In the second case , five cardiac arrests due to ventricular tachycardia and drug1 occurred during several hours after beginning a trial of drug2 maintenance therapy for complex ventricular ectopy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      667 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl CD conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod had acl:relcl one conj *drug0*"
            }
          4 : 
            {
              1 : "We report four patients , three of whom first developed drug1 and one who had an aggravation of the condition during treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      668 : 
        {
          1 : "NN nmod JJ csubj VBG dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *aware* csubj treating dobj patients nmod drug0"
            }
          4 : 
            {
              1 : "Physicians treating patients with drug1 for juvenile rheumatoid arthritis must be aware of this drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      669 : 
        {
          1 : "NN nmod NNS nmod VBD conj VBN nsubjpass NN nmod NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consequences nmod died conj *followed* nsubjpass administration nmod spirits appos drug0"
            }
          4 : 
            {
              1 : "The administration of `` sweet spirits of nitre '' ( drug1 ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      670 : 
        {
          1 : "NN compound NNS dobj VBD conj NNS parataxis VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound levels dobj had conj patients parataxis *reported* nsubjpass cases nmod drug0"
            }
          4 : 
            {
              1 : "Several cases of lithium-induced drug1 have been reported to date ; all of them were elderly patients and a half had `` therapeutic '' drug2 serum levels . "
            }
          5 : 
            {
              1 : 1
            }
        }
      671 : 
        {
          1 : "NN appos NN compound NN nmod VBD acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acetonide compound injection nmod developed acl:relcl *cases* nmod drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : We describe the ophthalmic features and clinical course of two cases of drug1 ( ASPPC ) that developed after intravitreal triamcinolone acetonide ( drug2 ) injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      672 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fenclofenac nmod induced acl arthritis nmod remission nmod *association* nmod drug0"
            }
          4 : 
            {
              1 : "This case demonstrates the association of selective drug1 with remission in rheumatoid arthritis induced by fenclofenac as well as drug2 and sulphasalazine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      673 : 
        {
          1 : "NN compound NN nmod NN nmod VBG acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod year nmod occurring acl arthritis nmod woman nmod *drug0*"
            }
          4 : 
            {
              1 : "Peculiar drug1 in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of drug2 treatment are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      674 : 
        {
          1 : "NN nmod NN nmod NN acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod complication acl:relcl *dermatosis* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an acute febrile neutrophilic dermatosis that is a known complication of the administration of drug2 , a drug that causes increased neutrophil proliferation and differentiation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      675 : 
        {
          1 : "NN dobj VBG acl NN nmod JJ advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj provoking acl risk nmod *aware* advcl used nsubjpass combination nmod drug0"
            }
          4 : 
            {
              1 : "Because the combination of drug1 and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi 's sarcoma , clinicians should be aware of the risk of provoking drug2 in patients who develop Raynaud 's phenomenon under chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      676 : 
        {
          1 : "VB xcomp JJ amod NN nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp secondary amod involvement nmod *case* nmod paresthesia conj drug0"
            }
          4 : 
            {
              1 : "To our knowledge , we describe the first reported case of isolated paresthesia and drug1 , without systemic involvement , secondary to drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      677 : 
        {
          1 : "NN compound NN nmod NN nmod VBN dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod course nmod *developed* dobj edema conj drug0"
            }
          4 : 
            {
              1 : "With the use of optical coherence tomography ( OCT ) , two patients with IFN-associated retinopathy who had developed macular edema and drug1 during the clinical course of drug2 therapy were observed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      678 : 
        {
          1 : "NN nmod NN nmod VBN xcomp JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod induced xcomp *likely* nsubj drug0"
            }
          4 : 
            {
              1 : "Interestingly , the use of carboplatin ( CBDCA ) and VDS in the subsequent treatment course was well tolerated indicating that the drug1 was most likely to have been induced by administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      679 : 
        {
          1 : "NN nmod VBN advcl VBD dobj NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod started advcl *developed* dobj polyserositis dep drug0"
            }
          4 : 
            {
              1 : "We report the case of a patient who developed polyserositis ( drug1 , pleural effusion , and pericarditis ) after being started on drug2 , and whose symptoms remitted upon discontinuation of clozapine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      680 : 
        {
          1 : "NN nmod VBD parataxis VBN dep IN advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod died parataxis demonstrated dep because advcl *started* nmod drug0"
            }
          4 : 
            {
              1 : "He was started on drug1 , 0.25 mg daily , because of echocardiographically demonstrated left ventricular dilatation and functional impairment ; he died of drug2 15 days later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      681 : 
        {
          1 : "NN nmod NN nmod VBD conj VBP dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod occurred conj *present* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "We present two cases of drug1 under anaesthesia where return of spontaneous circulation was refractory to epinephrine , but occurred following the administration of the alpha-agonist drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      682 : 
        {
          1 : "NN compound NN nmod NN nmod NN acl VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *series* nmod dic acl associated nmod hemoglobinemia conj drug0"
            }
          4 : 
            {
              1 : "This review presents the first case series of DIC associated with acute hemoglobinemia or drug1 following drug2 administration for ITP . "
            }
          5 : 
            {
              1 : 1
            }
        }
      683 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod resolved acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "A case history of a 15-year-old boy who developed incapacitating drug1 that resolved during treatment with drug2 is presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      684 : 
        {
          1 : "NN compound NN dep IN nmod VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound ingestion dep after nmod *experienced* dobj angio-oedema conj drug0"
            }
          4 : 
            {
              1 : "A 51-year old physically fit woman experienced angio-oedema and drug1 after drug2 ingestion requiring noradrenaline infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      685 : 
        {
          1 : "NN nmod NNS conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod reports conj *agent* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( MTX ) is a commonly used second line agent for RA , and there have been several recent reports of drug2 in MTX-treated RA patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      686 : 
        {
          1 : "NN nmod NN dobj VB xcomp VB xcomp VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod potential dobj enhance xcomp act xcomp *appear* nsubj drug0"
            }
          4 : 
            {
              1 : "Intravenous drug1 and methotrexate appear to act synergistically to enhance the potential for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      687 : 
        {
          1 : "NN dobj VBP nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *induce* nsubj concentrations nmod drug0"
            }
          4 : 
            {
              1 : "Preliminary results suggest that the higher concentrations of drug1 induce drug2 from blood cells , and that this phenomenon is more marked in diabetic , and particularly diabetic-allergic , individuals . "
            }
          5 : 
            {
              1 : 1
            }
        }
      688 : 
        {
          1 : "NN dobj VB acl JJ nmod VBG acl NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause acl potential nmod containing acl drug nmod *recognized* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      689 : 
        {
          1 : "NN appos NN dobj VBG dep VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos carbamazepine dobj adding dep *triggered* nsubjpass patients nmod drug0"
            }
          4 : 
            {
              1 : "In this report we present four patients treated with a combination of different psychotropic drugs , in whom drug1 was triggered either by adding carbamazepine ( drug2 ) to a treatment regimen , or by increasing its dosage . "
            }
          5 : 
            {
              1 : 1
            }
        }
      690 : 
        {
          1 : "NN compound NN nmod VBG dep VBN nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod abating dep *related* nsubj symptoms nmod drug0"
            }
          4 : 
            {
              1 : "Symptoms and signs of drug1 were related to low plasma levodopa levels , abating 75 minutes after oral drug2 administration and reappearing after 3 hours , closely mirroring the rapid rise and fall of plasma levodopa concentration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      691 : 
        {
          1 : "NN nmod VBG advcl VBP dobj NN acl:relcl VBD dobj NN amod JJ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulting advcl *discuss* dobj patient acl:relcl developed dobj dysfunction amod secondary nmod therapy nmod drug0"
            }
          4 : 
            {
              1 : "We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with drug1 , resulting in drug2 , hypocalcemia , hypomagnesemia , metabolic alkalosis , and polyuria . "
            }
          5 : 
            {
              1 : 1
            }
        }
      692 : 
        {
          1 : "NN appos NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos *symptoms* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and obsessive-compulsive symptoms ( drug2 ) : case report and review of atypical antipsychotic-induced OCS . "
            }
          5 : 
            {
              1 : 1
            }
        }
      693 : 
        {
          1 : "NN compound VBG conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound developing conj *drug0*"
            }
          4 : 
            {
              1 : "Recently , some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with drug1 ( MTX ) and drug2 developing . "
            }
          5 : 
            {
              1 : 1
            }
        }
      694 : 
        {
          1 : "NN compound NN nmod NN ccomp VBZ xcomp VB dobj NN nmod NNS acl:relcl VBP"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod complication ccomp *is* xcomp increase dobj awareness nmod physicians acl:relcl drug0"
            }
          4 : 
            {
              1 : "The purpose of this review is to increase awareness among physicians and other health care professionals that drug1 may be a rare but potentially severe complication of drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      695 : 
        {
          1 : "NN nmod VBG xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod leading xcomp *decreased* nsubjpass metabolism nmod drug0"
            }
          4 : 
            {
              1 : "In patients with cirrhosis , the metabolism of drug1 is decreased , leading to drug2 and possible CNS depressive effects similar to hepatic encephalopathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      696 : 
        {
          1 : "NN dobj VB advcl VBP nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *develop* advcl eat nsubj patients nmod drug0"
            }
          4 : 
            {
              1 : "When tuberculosis patients on drug1 eat certain varieties of fish they may develop a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      697 : 
        {
          1 : "NN dobj VBD conj VBD nmod NNS dep NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj showed conj *had* nmod days dep administration nmod enema compound drug0"
            }
          4 : 
            {
              1 : "Two days after administration of drug1 enema , he had profuse hematochezia , and a sigmoidoscopy showed diffuse drug2 and sigmoid colon . "
            }
          5 : 
            {
              1 : 1
            }
        }
      698 : 
        {
          1 : "NN nmod NN appos NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose drug1 with folinic acid rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with drug2 and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      699 : 
        {
          1 : "NN nmod NN nmod VBG acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod resulting acl *necrolysis* appos drug0"
            }
          4 : 
            {
              1 : "We report a fatal case of toxic epidermal necrolysis ( drug1 ) resulting from a high dose of drug2 ( ARA-C ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      700 : 
        {
          1 : "NN appos NN nmod NN dep NNS nmod VBG acl NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos spray nmod use dep weeks nmod swelling acl *woman* acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "We report a 43-year-old woman who developed drug1 , swelling of the lips and oral cavity and dysphagia , 2 weeks after the use of budesonide spray ( drug2 ) for treatment of bronchial asthma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      701 : 
        {
          1 : "NN nmod VBN acl NN nmod NN dobj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl dystonia nmod exacerbation dobj *triggered* nsubj withdrawal nmod drug0"
            }
          4 : 
            {
              1 : "Abrupt , accidental withdrawal of drug1 triggered severe exacerbation of the cranial dystonia associated with drug2 and acute respiratory difficulties , prompting emergency admission . "
            }
          5 : 
            {
              1 : 1
            }
        }
      702 : 
        {
          1 : "NN conj NN dep JJ amod NN nmod NN nmod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj c dep = amod ara nmod combination nmod administration nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We present two children with acute lymphocytic leukemia who developed drug1 following administration of a combination of intravenous ara = C and drug2 during the consolidation phase of chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      703 : 
        {
          1 : "NN compound NN nmod NN nmod VBD nsubj NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound withdrawal nmod week nmod *regressed* nsubj symptoms conj drug0"
            }
          4 : 
            {
              1 : "Symptoms and drug1 quickly regressed within 1 week of drug2 withdrawal . "
            }
          5 : 
            {
              1 : 1
            }
        }
      704 : 
        {
          1 : "NN dep NN appos NN nmod NNS dobj VBN acl:relcl NNS nmod NNS nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep arabinoside appos cytarabine nmod doses dobj received acl:relcl patients nmod organs nmod *found* nsubjpass evidence nmod drug0"
            }
          4 : 
            {
              1 : "Autopsy evidence of drug1 was found in visceral organs of four leukemic patients who had received large doses of cytarabine ( cytosine arabinoside ; drug2 ) shortly before their death . "
            }
          5 : 
            {
              1 : 1
            }
        }
      705 : 
        {
          1 : "NN nmod VBN nsubjpass JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *induced* nsubjpass erythematous conj drug0"
            }
          4 : 
            {
              1 : "Clinicians should be aware that an erythematous and drug1 may be induced by drug2 , and be familiar with the pharmacologic and supportive measures necessary for its treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      706 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induced acl:relcl dose nmod *received* dobj drug0"
            }
          4 : 
            {
              1 : "The female patient received drug1 in a daily dose of 400 mg , which induced drug2 after 2 months . "
            }
          5 : 
            {
              1 : 1
            }
        }
      707 : 
        {
          1 : "NN conj NN nmod VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj alcohol nmod *noted* nsubjpass reports nmod drug0"
            }
          4 : 
            {
              1 : "Two reports of drug1 are noted with alcohol and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      708 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod angina nmod treatment nmod *observed* nsubjpass block compound drug0"
            }
          4 : 
            {
              1 : "drug1 and intermittent sinoatrial ( S-A ) block was observed in a 57-year-old woman , under treatment for angina with 80 mg drug2 daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      709 : 
        {
          1 : "NN nmod JJ amod NN dobj VBD nsubj NNS acl VBN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod typical amod dysfunction dobj *developed* nsubj patients acl treated nmod 0-fluorouracil appos drug0"
            }
          4 : 
            {
              1 : "Two patients treated with 5-fluorouracil ( drug1 ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      710 : 
        {
          1 : "NN nmod NNS nsubj VBP conj VBZ nsubj NNP appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod reports nsubj are conj *increases* nsubj rifampin appos drug0"
            }
          4 : 
            {
              1 : "Rifampin ( drug1 ) increases hepatic microsomal enzyme activity , and there are case reports of RFP-induced drug2 , all associated with Hashimoto 's thyroiditis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      711 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod VBD nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod start dep months nmod *occurred* nsubj symptoms nmod drug0"
            }
          4 : 
            {
              1 : "Typical symptoms of active drug1 occurred 11 , 12 , and 26 months after start of drug2 therapy , respectively . "
            }
          5 : 
            {
              1 : 1
            }
        }
      712 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj thirst nmod complained acl:relcl retinitis nmod *treatment* nmod drug0"
            }
          4 : 
            {
              1 : "We present a patient with human immunodeficiency virus infection under treatment with drug1 for CMV retinitis who complained of thirst and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      713 : 
        {
          1 : "NN conj NN nmod VB acl:relcl NN dobj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fibrosis nmod lead acl:relcl damage dobj *induce* nsubj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 ( MTX ) may induce liver damage , which in some psoriatics will lead to fibrosis or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      714 : 
        {
          1 : "NN nsubj VBD acl:relcl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj developed acl:relcl *flush* compound drug0"
            }
          4 : 
            {
              1 : "On the 3rd day , an inferior vena cava ( IVC ) filter was placed with a drug1 flush , after which massive drug2 developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      715 : 
        {
          1 : "NN appos NN compound NN dep NN dobj VBG dep NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos sulfamethoxazole compound treatment dep trimethoprim dobj receiving dep weeks nmod eosinophilia conj *drug0*"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with drug1 , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( drug2 ) treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      716 : 
        {
          1 : "NN nmod NNS nsubjpass VBN advcl VB acl:relcl NN xcomp VBP dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod drugs nsubjpass used advcl occur acl:relcl sign xcomp *consider* dobj drug0"
            }
          4 : 
            {
              1 : "We consider drug1 to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as drug2 or clozapine are used in combination with CBZ . "
            }
          5 : 
            {
              1 : 1
            }
        }
      717 : 
        {
          1 : "NN compound NN nmod VBD dobj NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *developed* dobj nephritis nmod failure conj drug0"
            }
          4 : 
            {
              1 : "In the following case report , a patient developed acute interstitial nephritis with renal failure and drug1 following drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      718 : 
        {
          1 : "NN nmod NNS nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod symptoms nmod came acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "CASE REPORT : Soon after initiation of drug1 ( 200 mg/day ) , a 76-year-old man came to us with symptoms of drug2 , '' glare , color vision anomalies , and gradually decreased vision . "
            }
          5 : 
            {
              1 : 1
            }
        }
      719 : 
        {
          1 : "NN nmod VBD conj VBD xcomp JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complained conj *remained* xcomp abstinent nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Case 2 : A 43-year-old male alcoholic remained completely abstinent with drug1 treatment for 5 years and complained of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      720 : 
        {
          1 : "NN nmod NNS dobj VB xcomp VBN conj VBD nmod NNS dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episodes dobj have xcomp noted conj *experienced* nmod days dep initiation nmod drug0"
            }
          4 : 
            {
              1 : "Eleven days after initiation of therapy with drug1 , the patient experienced syncope and was noted to have recurrent episodes of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      721 : 
        {
          1 : "NN nmod VBN acl NNS nmod NNS nmod VBN nsubjpass JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl women nmod infants nmod *described* nsubjpass nonspecific conj drug0"
            }
          4 : 
            {
              1 : "Nonspecific but drug1 have been described in the infants of women treated with drug2 in the first trimester of their pregnancies . "
            }
          5 : 
            {
              1 : 1
            }
        }
      722 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBD dobj NN nmod NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mg dobj ingesting advcl *presented* dobj episode nmod urticaria conj minutes compound drug0"
            }
          4 : 
            {
              1 : "A 55-year-old woman presented an episode of acute urticaria and drug1 60 minutes after ingesting 500 mg of drug2 for a skin abscess . "
            }
          5 : 
            {
              1 : 1
            }
        }
      723 : 
        {
          1 : "NN amod NN dobj VBD nsubj CD nmod NNS acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 amod disease dobj *had* nsubj one nmod subjects acl:relcl using dobj drug0"
            }
          4 : 
            {
              1 : "One of the subjects who was using extemporaneous topical drug1 had drug2 and arteriosclerotic disease and the other died of a myocardial infarction . "
            }
          5 : 
            {
              1 : 1
            }
        }
      724 : 
        {
          1 : "NN nmod VBG dep JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod bingeing dep nocturnal amod *drug0*"
            }
          4 : 
            {
              1 : "drug1 nocturnal bingeing with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      725 : 
        {
          1 : "NN nmod VB nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *present* nsubj patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Patients treated with drug1 may present with drug2 and thrombotic cerebrovascular events . "
            }
          5 : 
            {
              1 : 1
            }
        }
      726 : 
        {
          1 : "NN appos NN nmod VBN acl:relcl NN nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos syndrome nmod associated acl:relcl *agent* nsubj c appos drug0"
            }
          4 : 
            {
              1 : "Mitomycin C ( drug1 ) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      727 : 
        {
          1 : "NN nsubj NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj event dep *drug0*"
            }
          4 : 
            {
              1 : "drug1 ( 5-FU ) - associated drug2 is an uncommon event . "
            }
          5 : 
            {
              1 : 1
            }
        }
      728 : 
        {
          1 : "NN conj NNS dobj VB xcomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj infections dobj potentiate xcomp *appeared* nsubj drug0"
            }
          4 : 
            {
              1 : "The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which drug1 appeared to potentiate opportunistic infections and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      729 : 
        {
          1 : "NN nmod JJ amod NNS dobj VBD nmod NN nmod NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consistent amod signs dobj *developed* nmod analysis nmod patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "During analysis of 28 patients receiving drug1 with concomitant radiation ( XRT ) for pancreatic cancer ( resected or locally advanced ) , two patients developed signs and symptoms consistent with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      730 : 
        {
          1 : "NN conj JJ nmod NN nmod NN nmod VBD nsubj NN acl VBN nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pentobarbital nmod combination nmod administration nmod *developed* nsubj encephalopathy acl characterized nmod level nmod consciousness conj drug0"
            }
          4 : 
            {
              1 : "A toxic encephalopathy characterized by depressed level of consciousness , drug1 , and ataxia developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of pentobarbital and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      731 : 
        {
          1 : "NN nmod NNS nsubj VBD acl:relcl NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cases nsubj diagnosed acl:relcl % nmod *accounted* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 in these 69 pregnancies accounted for 33.3 % ( 5 of 15 ) cases of drug2 diagnosed in 100 , 756 consecutive births . "
            }
          5 : 
            {
              1 : 1
            }
        }
      732 : 
        {
          1 : "NN compound NN nmod NNS amod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound overdose nmod *movements* amod due nmod drug0"
            }
          4 : 
            {
              1 : "Ballistic movements due to drug1 after intravenous drug2 overdose : report of two cases . "
            }
          5 : 
            {
              1 : 1
            }
        }
      733 : 
        {
          1 : "NN compound NN nmod NN nsubjpass VBN nmod NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nmod history nsubjpass *obtained* nmod patients nmod dysfunction conj drug0"
            }
          4 : 
            {
              1 : "In patients with swallowing dysfunction and drug1 , a history of drug2 use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      734 : 
        {
          1 : "NN compound NN dobj VBG acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl:relcl *patients* nmod drug0"
            }
          4 : 
            {
              1 : "Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing drug1 who are receiving drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      735 : 
        {
          1 : "CD nmod CD"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *drug0*"
            }
          4 : 
            {
              1 : "The patient suffered a drug1 to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      736 : 
        {
          1 : "NN compound NN nmod NNS nmod NN dep NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod months nmod *man* dep syndrome conj preparation compound drug0"
            }
          4 : 
            {
              1 : "A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody , positive drug1 ( LE ) cell preparation , and diffuse proliferative glomerulonephritis following 26 months of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      737 : 
        {
          1 : "NN dobj VBD nsubj NN nmod NN acl VBN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj case nmod carcinoma acl treated nmod regimen compound drug0"
            }
          4 : 
            {
              1 : "RESULTS : One case of recurrent primary peritoneal carcinoma previously treated with a drug1 regimen , developed a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      738 : 
        {
          1 : "NN nmod NN nmod VBG dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod troglitazone nmod switching dep months nmod *drug0*"
            }
          4 : 
            {
              1 : "A 75-year-old man developed drug1 6 months after switching from troglitazone to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      739 : 
        {
          1 : "NN nmod NN dep NNS nmod VBN acl NN nmod NN acl VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment dep months nmod diagnosed acl *man* nmod history acl fistulizing nmod drug0"
            }
          4 : 
            {
              1 : "The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom drug1 was diagnosed 9 months after treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      740 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod self-medication nmod patient nmod *admitted* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case admitted with a first-detected , drug1 in a healthy patient after self-medication with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      741 : 
        {
          1 : "NN nmod NNS nmod JJ xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod due xcomp *stopped* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Occasionally , despite good therapeutic response , drug1 must be stopped due to dangerous side effects such as drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      742 : 
        {
          1 : "NN xcomp VBN dep VBN xcomp JJ nmod NN acl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp termed dep *judged* xcomp consistent nmod injury acl associated nmod administration nmod drug0"
            }
          4 : 
            {
              1 : "The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of drug1 , also termed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      743 : 
        {
          1 : "NN compound NN nmod NN nsubj NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *complication* nsubj heparin dep drug0"
            }
          4 : 
            {
              1 : "Severe heparin associated drug1 is a rare complication of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      744 : 
        {
          1 : "NN nmod NN nmod VBZ nsubj NN acl:relcl VBZ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod risk nmod *places* nsubj immunosuppression acl:relcl occurs nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "The mild immunosuppression that occurs with drug1 therapy probably places patients with rheumatoid arthritis at added risk of developing drug2 , but coincidence can not be excluded . "
            }
          5 : 
            {
              1 : 1
            }
        }
      745 : 
        {
          1 : "NN compound NN nmod VBD acl:relcl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod worsened acl:relcl *loss* conj drug0"
            }
          4 : 
            {
              1 : "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and drug1 which worsened during subsequent drug2 treatment and led to death within 3 weeks . "
            }
          5 : 
            {
              1 : 1
            }
        }
      746 : 
        {
          1 : "NN nmod:npmod JJ nmod NN dobj VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod:npmod diuretic nmod combination dobj taking advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Two patients developed drug1 when taking a combination of a drug2 diuretic and propranolol . "
            }
          5 : 
            {
              1 : 1
            }
        }
      747 : 
        {
          1 : "RB advmod JJ nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 advmod severe nmod *treated* nmod drug0"
            }
          4 : 
            {
              1 : "However , we recently saw two patients with renal tuberculosis treated with drug1 in whom drug2 from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function . "
            }
          5 : 
            {
              1 : 1
            }
        }
      748 : 
        {
          1 : "NN appos NN nmod NN nmod NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos methotrexate nmod dose nmod *rash* conj days compound drug0"
            }
          4 : 
            {
              1 : "A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and drug1 4 and 7 days , respectively , following a single dose of 40 mg/m2 methotrexate ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      749 : 
        {
          1 : "NN dep NNS nmod VBD nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep weeks nmod *developed* nsubj signs nmod drug0"
            }
          4 : 
            {
              1 : "Skin rash began after 2 weeks of treatment , and signs of drug1 developed 3 weeks after drug2 had been started . "
            }
          5 : 
            {
              1 : 1
            }
        }
      750 : 
        {
          1 : "NN root , punct NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct *initiation* nmod ointment compound drug0"
            }
          4 : 
            {
              1 : "After initiation of topical drug1 ointment ( 20 micro g/g of tacalcitol ) 10 g/day for the skin lesions , both the drug2 gradually . "
            }
          5 : 
            {
              1 : 1
            }
        }
      751 : 
        {
          1 : "NN conj NN nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj multiforme nmod *drug-trigger* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 are the best verified drug-trigger for erythema multiforme and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      752 : 
        {
          1 : "NN dep NN nsubjpass VBN parataxis VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep valproate nsubjpass added parataxis *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 7-year-old boy developed a drug1 at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later valproate ( drug2 , VPA ) was added to the therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      753 : 
        {
          1 : "NN nsubj JJ advcl VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj rare advcl *reported* nsubjpass reactions nmod drug0"
            }
          4 : 
            {
              1 : "Several hypersensitivity reactions to drug1 have been reported , although drug2 to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      754 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl days nmod began acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We report a case of biopsy proven drug1 whose symptoms began within 10 days of receiving drug2 therapy for prostate cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      755 : 
        {
          1 : "NN nmod VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod enhanced conj *induced* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was induced and enhanced by drug2 , developing into generalized seizures . "
            }
          5 : 
            {
              1 : 1
            }
        }
      756 : 
        {
          1 : "NN nmod VBN acl NN nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl *drug* nsubj rapamycin/sirolimus appos drug0"
            }
          4 : 
            {
              1 : "Rapamycin/sirolimus ( drug1 ) , trade named Rapammune ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with drug2 , hypertension , hyperlipidemia , and infection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      757 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod combination nmod administration nmod *developed* nsubj encephalopathy acl characterized nmod drug0"
            }
          4 : 
            {
              1 : "A toxic encephalopathy characterized by drug1 , marked irritability , and ataxia developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of drug2 and pyrilamine maleate . "
            }
          5 : 
            {
              1 : 1
            }
        }
      758 : 
        {
          1 : "NN nmod VBG xcomp VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulting xcomp *interfere* nsubj drug0"
            }
          4 : 
            {
              1 : "It was hypothesized that drug1 may interfere with glucuronidation of lamotrigine , leading to increased serum lamotrigine levels , or perhaps alter the drug 's metabolism , resulting in drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      759 : 
        {
          1 : "NN conj JJ nmod NN nmod NN nmod VBD nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pentobarbital nmod combination nmod administration nmod *developed* nsubj encephalopathy acl characterized nmod drug0"
            }
          4 : 
            {
              1 : "A toxic encephalopathy characterized by drug1 , marked irritability , and ataxia developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of pentobarbital and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      760 : 
        {
          1 : "NN conj NN nmod NN nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj oxybutynin nmod administration nmod *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of drug1 following the administration of Oxybutynin and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      761 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod ingestion nmod attributed acl:relcl woman nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 ( AGEP ) in a 50-year-old woman that was attributed to the ingestion of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      762 : 
        {
          1 : "NN conj NN root , punct NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj akathisia root , punct *prophylaxis* compound drug0"
            }
          4 : 
            {
              1 : "k bipolar manic-depressive patient , developed while on drug1 prophylaxis , akathisia at therapeutic serum lithium levels and subsequently drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      763 : 
        {
          1 : "NN dobj VBZ acl:relcl NN dobj VB nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj includes acl:relcl encephalopathy dobj *produce* nsubj od compound drug0"
            }
          4 : 
            {
              1 : "Massive drug1 OD may produce a reversible encephalopathy that includes drug2 , a profound burst-suppression EEG pattern , and cranial nerve areflexia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      764 : 
        {
          1 : "NN conj NNS nmod NN dobj VBD parataxis JJ nsubj NNS acl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj studies nmod evidence dobj had parataxis *slow* nsubj patients acl treated nmod cc nmod drug0"
            }
          4 : 
            {
              1 : "Postoperatively , the first two patients treated with 1 to 2 cc of drug1 were slow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and drug2 on cranial computerized tomography , while the other had a moderate-sized frontal hematoma with intracranial hypertension . "
            }
          5 : 
            {
              1 : 1
            }
        }
      765 : 
        {
          1 : "NN compound NNS nmod VBN acl NNS amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusions nmod used acl *veins* amod drug0"
            }
          4 : 
            {
              1 : "Markedly drug1 immediately overlying veins used for multiple drug2 infusions was noted . "
            }
          5 : 
            {
              1 : 1
            }
        }
      766 : 
        {
          1 : "NN dobj VB xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj produce xcomp *known* nsubjpass treatment nmod drug0"
            }
          4 : 
            {
              1 : "Treatment with drug1 is known to produce an drug2 ( antinuclear antibodies , anti-double-stranded DNA ) , but not clinical disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      767 : 
        {
          1 : "NN nmod VBN acl:relcl NNS nmod VBD nsubj NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl yrs nmod *developed* nsubj diarrhoea conj drug0"
            }
          4 : 
            {
              1 : "Diarrhoea , T-CD4 + lymphopenia and drug1 developed in a male 60 yrs of age , who was treated with drug2 and 5-fluorouracil for unresectable rectum carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      768 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBG acl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod resulting acl setting nmod *prolongation* conj drug0"
            }
          4 : 
            {
              1 : "We report marked QT prolongation and drug1 in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with drug2 for atrial fibrillation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      769 : 
        {
          1 : "NN dobj VB advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj exacerbate advcl *avoided* nsubjpass use nmod drug0"
            }
          4 : 
            {
              1 : "However , the use of drug1 should be avoided with any patient who is purging , since it may exacerbate the drug2 , thereby increasing the risk of cardiac toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      770 : 
        {
          1 : "NN nsubjpass VBN dep NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass given dep days nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "Following several of these courses of therapy , drug1 occurred 9 to 12 days after the drug2 was given . "
            }
          5 : 
            {
              1 : 1
            }
        }
      771 : 
        {
          1 : "NN compound NN nmod NN nmod VBD conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod course nmod reduced conj *developed* dobj drug0"
            }
          4 : 
            {
              1 : "With the use of optical coherence tomography ( OCT ) , two patients with IFN-associated retinopathy who had developed drug1 and reduced visual acuity during the clinical course of drug2 therapy were observed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      772 : 
        {
          1 : "NN nmod JJ xcomp VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod due xcomp developed acl:relcl *mg* nmod drug0"
            }
          4 : 
            {
              1 : "Four days after the initial injection of 3.6 mg of drug1 , severe dyspnea developed due to drug2 , which was considered as a flare-up . "
            }
          5 : 
            {
              1 : 1
            }
        }
      773 : 
        {
          1 : "NN compound NN nmod NNS nmod NN nmod VBN nsubjpass NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod effects nmod list nmod *included* nsubjpass neuritis nmod combination nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Optic neuritis in combination with other drug1 , simulating multiple sclerosis , should be included in the list of adverse effects of recombinant and natural drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      774 : 
        {
          1 : "NN nsubjpass VBN nmod NNS nmod NN nmod NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass *initiated* nmod effects nmod increase nmod interval acl causing dobj drug0"
            }
          4 : 
            {
              1 : "Because of serious side effects of an increase in the QT interval causing drug1 , drug2 must be initiated with close monitoring of the QT interval in an inpatient setting . "
            }
          5 : 
            {
              1 : 1
            }
        }
      775 : 
        {
          1 : "NN conj NN conj NN nmod VBN acl NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj aurothiomalate conj fenclofenac nmod induced acl arthritis nmod remission nmod *association* nmod drug0"
            }
          4 : 
            {
              1 : "This case demonstrates the association of selective drug1 with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      776 : 
        {
          1 : "NN nmod NN dobj VBN nsubj NN nmod NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development dobj *promoted* nsubj combination nmod smoking conj therapy compound drug0"
            }
          4 : 
            {
              1 : "In this case , it was suspected that a combination of cigarette smoking , pulmonary fibrosis , and low-dose drug1 therapy might have promoted the development of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      777 : 
        {
          1 : "NN nmod NN nmod VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episode nmod followed conj *given* nsubjpass drug0"
            }
          4 : 
            {
              1 : "After a two-month interruption of interferon administration , natural drug1 was given but followed by another episode of the same drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      778 : 
        {
          1 : "NN conj NN nmod NNS dobj VBD nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj toxicity nmod signs dobj *developed* nsubj patient acl treated nmod drug0"
            }
          4 : 
            {
              1 : "A patient with chronic myeloid leukaemia treated with drug1 for 4-5 years , developed signs of busulphan toxicity and drug2 with ascites , oesophageal varices and jaundice . "
            }
          5 : 
            {
              1 : 1
            }
        }
      779 : 
        {
          1 : "NN nmod VBG advcl VBD acl:relcl NN conj NNS nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod receiving advcl developed acl:relcl patient conj levels nmod coincident amod *drug0*"
            }
          4 : 
            {
              1 : "We report four cases of drug1 coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      780 : 
        {
          1 : "NN nmod NN nmod NN nmod NN nmod NN nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod initiation nmod patient nmod *lack* nmod control nmod diabetes conj drug0"
            }
          4 : 
            {
              1 : "Case report : lack of control of diabetes and drug1 in a patient on initiation and rechallenge of therapy with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      781 : 
        {
          1 : "NN nmod NN nmod NNS nsubjpass VBN conj VBN nsubjpass NN acl VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod evaluation nmod recommendations nsubjpass provided conj *discussed* nsubjpass controversy acl concerning dobj nephrotoxicity nmod drug0"
            }
          4 : 
            {
              1 : "Controversy concerning the nephrotoxicity of drug1 is discussed , and recommendations for the evaluation of drug2 during lithium therapy are provided . "
            }
          5 : 
            {
              1 : 1
            }
        }
      782 : 
        {
          1 : "NN nmod VBN acl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod induced acl injury nmod *considered* nsubjpass onset nmod drug0"
            }
          4 : 
            {
              1 : "New onset of drug1 may be considered as an immune-mediated injury induced by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      783 : 
        {
          1 : "NN nmod VBN nsubj NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *associated* nsubj agranulocytosis conj drug0"
            }
          4 : 
            {
              1 : "Agranulocytosis and drug1 associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      784 : 
        {
          1 : "NN dobj VBG acl NN nmod VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl woman nmod masquerading acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 masquerading as cutaneous vasculitis in a woman receiving drug2 for lupus nephritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      785 : 
        {
          1 : "NN dobj VBG advcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking advcl *drug0*"
            }
          4 : 
            {
              1 : "A 53-year-old man developed drug1 without rigidity while taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      786 : 
        {
          1 : "NN compound NN nmod VBN advcl VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod maintained advcl *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We report a rare case of recurrent ( stuttering ) drug1 in a patient with protein C deficiency while maintained on drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      787 : 
        {
          1 : "NN conj NN nmod VBN advcl VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj sertraline nmod coadministered advcl occurring acl *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report 2 cases of serotonin syndrome with serious drug1 occurring when metoclopramide was coadministered with sertraline or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      788 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBN acl NN nmod NN nmod VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod explained acl:relcl decrease nmod associated acl pressure nmod increase nmod *resulted* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "Administration of intravenous drug1 in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      789 : 
        {
          1 : "NN conj VBN nsubjpass NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *withheld* nsubjpass intake conj drug0"
            }
          4 : 
            {
              1 : "Oral intake and drug1 were withheld and the drug2 spontaneously resolved after 2 days . "
            }
          5 : 
            {
              1 : 1
            }
        }
      790 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod *disappeared* nsubj myoclonus conj drug0"
            }
          4 : 
            {
              1 : "Myoclonus and drug1 disappeared after discontinuation of drug2 and the introduction of valproate sodium ( VPA ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      791 : 
        {
          1 : "NN nsubj JJ dep NN nmod VBN conj JJ nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj common dep toxicity nmod limited conj *effective* nsubj b appos drug0"
            }
          4 : 
            {
              1 : "Amphotericin B ( drug1 ) is effective , but its use is limited by toxicity : drug2 , anaemia , fever , malaise , and hypokalaemia are common . "
            }
          5 : 
            {
              1 : 1
            }
        }
      792 : 
        {
          1 : "NN compound NN nmod VBN xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound toxicity nmod caused xcomp *considered* nsubjpass drug0"
            }
          4 : 
            {
              1 : "In patients with a known access to INH , drug1 should be considered to be caused by drug2 toxicity unless proved otherwise . "
            }
          5 : 
            {
              1 : 1
            }
        }
      793 : 
        {
          1 : "NN compound NN dep JJ dep DT root IN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound toxicity dep newborn dep a root in acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a newborn : drug2 toxicity or lab error ? "
            }
          5 : 
            {
              1 : 1
            }
        }
      794 : 
        {
          1 : "NN dobj VBD dep VBN advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed dep *resolved* advcl changed nmod drug0"
            }
          4 : 
            {
              1 : "When SASP was changed to drug1 ( 5-ASA ) , his skin eruptions were resolved , however , he developed drug2 and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance . "
            }
          5 : 
            {
              1 : 1
            }
        }
      795 : 
        {
          1 : "NN nmod NN nsubj VBD dep NN dep WRB dep NNS nmod VBG advcl VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nsubj was dep dose dep when dep deaths nmod leading advcl *reported* dobj drug0"
            }
          4 : 
            {
              1 : "The pharmaceutical company producing Halfan has reported 8 drug1 , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with drug2 , there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency . "
            }
          5 : 
            {
              1 : 1
            }
        }
      796 : 
        {
          1 : "NN nmod NN nmod NN nmod NNS nmod VBN acl:relcl NN nmod NN nmod VBD xcomp VB dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dosing nmod reinstitution nmod hours nmod resolved acl:relcl infection nmod evidence nmod *continued* xcomp have dobj fever conj drug0"
            }
          4 : 
            {
              1 : "The patient continued to have fever and drug1 without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      797 : 
        {
          1 : "NN appos NN root , punct NN root , punct PRP nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos fever root , punct myelosuppression root , punct them nmod *arabinoside* appos drug0"
            }
          4 : 
            {
              1 : "Thirty-six patients with AL received , in a three-month period , 51 cycles of combined chemotherapy which included , in all of them , cytosine arabinoside ( drug1 ) ; among them , along with myelosuppression , five experienced fever , drug2 , gastrointestinal tract symptoms and severe myalgias . "
            }
          5 : 
            {
              1 : 1
            }
        }
      798 : 
        {
          1 : "NN nmod VBD nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *complained* nmod end nmod cycle nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "At the end of his fifth cycle of drug1 therapy , the patient complained of the drug2 associated with pain and peri-areolar erythema . "
            }
          5 : 
            {
              1 : 1
            }
        }
      799 : 
        {
          1 : "NN nmod NN conj NN nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod return conj syndrome nmod *lead* nsubj drug0"
            }
          4 : 
            {
              1 : "Used injudiciously , drug1 can lead to withdrawal syndrome , return of drug2 , and other adverse effects . "
            }
          5 : 
            {
              1 : 1
            }
        }
      800 : 
        {
          1 : "NN compound NNS nmod NN dobj VBD nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound dosages nmod reduction dobj *subsided* nsubj events nmod drug0"
            }
          4 : 
            {
              1 : "The events of drug1 subsided following reduction in drug2 dosages . "
            }
          5 : 
            {
              1 : 1
            }
        }
      801 : 
        {
          1 : "NN compound NN dep IN advmod VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound ingestion dep after advmod *experienced* dobj shock compound drug0"
            }
          4 : 
            {
              1 : "A 51-year old physically fit woman experienced drug1 and hypotensive shock after drug2 ingestion requiring noradrenaline infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      802 : 
        {
          1 : "NN nmod VBG advcl VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod underdosing advcl resulting acl *drug0*"
            }
          4 : 
            {
              1 : "Baclofen drug1 resulting from underdosing of oral drug2 should be considered as a potential source of prolonged fever in the intensive care unit . "
            }
          5 : 
            {
              1 : 1
            }
        }
      803 : 
        {
          1 : "NN nmod NN dobj VBP nsubj NN nmod NNS conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod accumulation dobj *implicate* nsubj insufficiency nmod patients conj timing nmod drug0"
            }
          4 : 
            {
              1 : "The renal insufficiency of three patients and the timing of the drug1 implicate accumulation of drug2 as a contributing factor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      804 : 
        {
          1 : "NN nmod NNS nmod VBN xcomp VBN acl:relcl NN appos NN nmod VBZ ccomp VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod concentrations nmod inhibited xcomp known acl:relcl enzyme appos p0 nmod occurs ccomp *is* nsubj explanation nmod drug0"
            }
          4 : 
            {
              1 : "One explanation for the noted drug1 is that metabolism occurs mainly by cytochrome P450 ( CYP 1A2 ) , an enzyme that is known to be inhibited with high concentrations of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      805 : 
        {
          1 : "NN compound NN nmod VB nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound arf nmod *result* nsubj infusion compound drug0"
            }
          4 : 
            {
              1 : "High-dose intravenous drug1 infusion in various clinical settings may result in drug2 ( ARF ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      806 : 
        {
          1 : "NN conj NN nmod NN nmod VBN nsubjpass NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj 0-fu nmod use nmod *reported* nsubjpass prolongation nmod half-life conj drug0"
            }
          4 : 
            {
              1 : "However , prolongation of 5-FU half-life and an drug1 have been reported with the concurrent use of 5-FU and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      807 : 
        {
          1 : "NN conj VBD conj VBD advcl VBN advcl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj became conj *began* advcl stopped advcl receiving dobj mg/d compound drug0"
            }
          4 : 
            {
              1 : "The day after clozapine was stopped , while he was still receiving drug1 150 mg/d , he began behaving oddly , started sweating profusely , shivering , and became tremulous , agitated , and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      808 : 
        {
          1 : "NN appos NN compound NN nmod VBD acl:relcl NNS nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acetonide compound injection nmod developed acl:relcl *cases* nmod chorioretinitis appos drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( drug1 ) that developed after intravitreal triamcinolone acetonide ( drug2 ) injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      809 : 
        {
          1 : "NN nmod VBD conj VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod relapsed conj *complicated* nsubjpass therapy compound drug0"
            }
          4 : 
            {
              1 : "We describe a patient with a liver abscess due to Entamoeba histolytica , in whom drug1 therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      810 : 
        {
          1 : "NN dobj VBG advcl VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving advcl *developed* dobj attack compound drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To describe a patient with asymptomatic bronchial asthma and hypertension who developed an drug1 attack after receiving sustained-release drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      811 : 
        {
          1 : "NN nsubj JJ parataxis VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj common parataxis *cause* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( Daivonex R ; Leo Pharmaceuticals , Zurich , Switzerland ) may cause irritation of the skin , whereas drug2 are less common . "
            }
          5 : 
            {
              1 : 1
            }
        }
      812 : 
        {
          1 : "NN nmod VBN nsubjpass NN nmod NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *followed* nsubjpass administration nmod spirits appos drug0"
            }
          4 : 
            {
              1 : "The administration of `` sweet spirits of nitre '' ( drug1 ) was followed by drug2 and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      813 : 
        {
          1 : "NN conj NN dobj VBD dep VBN advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj weakness dobj developed dep *resolved* advcl changed nmod drug0"
            }
          4 : 
            {
              1 : "When SASP was changed to drug1 ( 5-ASA ) , his skin eruptions were resolved , however , he developed weakness and drug2 in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance . "
            }
          5 : 
            {
              1 : 1
            }
        }
      814 : 
        {
          1 : "NN appos NN nmod NNS nmod VBN nsubjpass NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos agent nmod patients nmod *reported* nsubjpass effects nmod disorientation conj drug0"
            }
          4 : 
            {
              1 : "Comparable adverse effects , such as disorientation and drug1 , have been reported in patients in the analogous agent , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      815 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod NN nmod VB"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion dobj receiving acl patients nmod minority nmod *drug0*"
            }
          4 : 
            {
              1 : "These multiple overlapping factors probably lead to drug1 in a minority of patients receiving drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      816 : 
        {
          1 : "NN nmod NNS conj VBG acl NNS dobj LS parataxis VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod agents conj diluting acl effects dobj b parataxis *divided* nsubjpass causes nmod drug0"
            }
          4 : 
            {
              1 : "Potential causes of methamphetamine-related drug1 can be divided into four categories resulting from ( a ) direct pharmacologic and physical effects of methamphetamine ; ( b ) the toxic effects of diluting or `` cutting '' agents such as drug2 and quinine ; ( c ) effects related to the route of drug administration ( intravenous , inhalation , smoking ) ; and ( d ) manufacture-related effects of exposure to unintentional caustic contaminants in the final product . "
            }
          5 : 
            {
              1 : 1
            }
        }
      817 : 
        {
          1 : "NN compound NN dobj VB acl JJ dobj VBP dep VBZ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound fibrosis dobj cause acl potential dobj have dep *taxanes* nmod drug0"
            }
          4 : 
            {
              1 : "Physicians should keep in mind that taxanes such as drug1 have the potential to cause drug2 and lung fibrosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      818 : 
        {
          1 : "VB xcomp VBN acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp exposed acl children nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in two children exposed to drug2 in utero . "
            }
          5 : 
            {
              1 : 1
            }
        }
      819 : 
        {
          1 : "NN nmod JJ acl:relcl NNS nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod responsible acl:relcl drugs nmod list nmod *added* nsubjpass drug0"
            }
          4 : 
            {
              1 : "We suggest that drug1 should be added to the list of drugs that may be responsible for a drug-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      820 : 
        {
          1 : "NN conj NN nmod VBN acl:relcl NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj propylthiouracil nmod treated acl:relcl woman nmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed in a 24-year-old black woman who had been treated with propylthiouracil and drug2 for hyperthyroidism . "
            }
          5 : 
            {
              1 : 1
            }
        }
      821 : 
        {
          1 : "NN nmod NNS dobj VBD nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episodes dobj *experienced* nmod months nmod drug0"
            }
          4 : 
            {
              1 : "Three months after starting drug1 , she experienced episodes of drug2 and dizziness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      822 : 
        {
          1 : "NN nmod VBN acl NN nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl boy nmod *associated* nmod drug0"
            }
          4 : 
            {
              1 : "This report describes a case of acute compromise of renal function associated with drug1 in a 7-year-old boy treated with the ACE inhibitor drug2 and the ARB losartan . "
            }
          5 : 
            {
              1 : 1
            }
        }
      823 : 
        {
          1 : "NN compound NN nmod VBP dobj NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod *describe* dobj development nmod aml conj drug0"
            }
          4 : 
            {
              1 : "We describe the exceptional development of AML and drug1 in a patient with previously diagnosed CLL in minimal residual disease status after drug2 treatment followed by autologous peripheral blood stem-cell transplantation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      824 : 
        {
          1 : "NN compound NN nmod VB xcomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod occur xcomp *started* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 started to occur during drug2 treatment , and a Holter electrocardiogram showed multiple abnormalities , with an episode of sustained ventricular tachycardia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      825 : 
        {
          1 : "VB conj VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *associated* nsubjpass therapy compound drug0"
            }
          4 : 
            {
              1 : "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis , respectively , in whom drug1 therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to drug2 in the other . "
            }
          5 : 
            {
              1 : 1
            }
        }
      826 : 
        {
          1 : "NN appos NN dep NN dobj VBD conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos avt dep tachycardia dobj induced conj *drug0*"
            }
          4 : 
            {
              1 : "A 44-year-old woman is described in whom amiodarone , drug1 , and quinidine , administered alone separately , induced atypical ventricular tachycardia ( AVT , drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      827 : 
        {
          1 : "NN dobj VBG acl NN nmod VBG nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patient nmod *occurring* nsubj case nmod drug0"
            }
          4 : 
            {
              1 : "Thus any case of drug1 occurring in a patient receiving drug2 is alarming to clinicians . "
            }
          5 : 
            {
              1 : 1
            }
        }
      828 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl patients nmod *diagnosed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was diagnosed at endoscopy in two patients receiving drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      829 : 
        {
          1 : "NN appos NN dobj VBG xcomp VB"
          2 : 1
          3 : 
            {
              1 : "drug0 appos 0-fluorouracil dobj following xcomp *drug0*"
            }
          4 : 
            {
              1 : "PURPOSE/OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency , which predisposes patients with cancer to potentially drug1 following 5-fluorouracil ( drug2 ) - based chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      830 : 
        {
          1 : "NN nmod VBN acl:relcl NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl yrs nmod developed acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 , T-CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age , who was treated with drug2 and 5-fluorouracil for unresectable rectum carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      831 : 
        {
          1 : "NN nmod NNS dobj VBG advcl VB nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod lesions dobj developing advcl *reduce* nsubj addition nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : The value of multihormonal therapy in breast carcinoma is not established , and the addition of progestogens to drug1 may not reduce of developing endometrial lesions , including drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      832 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl infant nmod *detected* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 associated with severe brain damage was detected in an infant whose mother had been treated with drug2 and azathioprine for systemic lupus erythematosus ( SLE ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      833 : 
        {
          1 : "NN nmod NN conj NN appos NN nmod VBD nsubj NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod hyperphosphataemia conj hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod methotrexate nmod rescue compound drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with drug1 rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with drug2 and tetany , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      834 : 
        {
          1 : "NN conj VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *followed* nsubjpass administration nmod drug0"
            }
          4 : 
            {
              1 : "The administration of `` drug1 '' ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin drug2 from the consequences of hypoxemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      835 : 
        {
          1 : "NN dobj VBG advcl VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj stopping advcl *resolved* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 resolved after stopping drug2 for 4 weeks in Patient A , with no recurrence after reinitiating CAP alone at 2000 mg/m2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      836 : 
        {
          1 : "NN root , punct RB root , punct VBD dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct therefore root , punct was dep *cause* nmod drug0"
            }
          4 : 
            {
              1 : "The most likely cause of drug1 in this patient was , therefore , drug2 , which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      837 : 
        {
          1 : "NN compound NN nmod NNS nmod VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod months nmod *developed* dobj syndrome compound drug0"
            }
          4 : 
            {
              1 : "A 52-year-old woman developed drug1 and cerebellar syndrome after 24 months of drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      838 : 
        {
          1 : "NN nmod VBN acl NN nmod NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl syndrome nmod patient nmod changes nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      839 : 
        {
          1 : "NN compound NN nmod NN nmod VB"
          2 : 1
          3 : 
            {
              1 : "drug0 compound exposure nmod response nmod *drug0*"
            }
          4 : 
            {
              1 : "This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to drug1 in response to drug2 exposure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      840 : 
        {
          1 : "NN nmod NN nmod VBP dobj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod ingestion nmod *report* dobj case nmod infant nmod drug0"
            }
          4 : 
            {
              1 : "We report the case of an 11-month-old female infant with a drug1 after ingestion of drug2 whose mental status markedly improved with administration of naloxone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      841 : 
        {
          1 : "NN compound NNS nmod NN nmod NN nmod VB xcomp VBN conj JJ xcomp JJ acl:relcl NN appos NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound increases nmod use nmod frequency nmod occur xcomp expected conj underreported xcomp likely acl:relcl reaction appos sp nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "In this report , we present a case of drug1 associated with SP , an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of drug2 increases . "
            }
          5 : 
            {
              1 : 1
            }
        }
      842 : 
        {
          1 : "NN dep VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep associated acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 associated , painful , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      843 : 
        {
          1 : "NN conj NN nmod NNS nmod VBD acl:relcl NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj irritability nmod problems nmod complained acl:relcl ptsd nmod treatment nmod *use* nmod drug0"
            }
          4 : 
            {
              1 : "We describe two cases that illustrate the use of drug1 in the treatment of veterans with PTSD who complained of serious problems with irritability or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      844 : 
        {
          1 : "NN dobj VBD ccomp VBP nmod NN nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induced ccomp *report* nmod result nmod interaction nmod tolazoline conj drug0"
            }
          4 : 
            {
              1 : "However , given the clinically significant result to the interaction between tolazoline and drug1 we report , the use of cimetidine in tolazoline induced drug2 should deserve more attention . "
            }
          5 : 
            {
              1 : 1
            }
        }
      845 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBD acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod developed acl:relcl *case* nmod dka conj drug0"
            }
          4 : 
            {
              1 : "We report a case of reversible DKA and new-onset drug1 that developed in a demented patient who was treated with drug2 for 14 days . "
            }
          5 : 
            {
              1 : 1
            }
        }
      846 : 
        {
          1 : "NN compound VBG conj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound developing conj *methotrexate* appos drug0"
            }
          4 : 
            {
              1 : "Recently , some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with Methotrexate ( drug1 ) and drug2 developing . "
            }
          5 : 
            {
              1 : 1
            }
        }
      847 : 
        {
          1 : "NN nmod NN nmod VBN advcl VBD dobj NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod treated advcl *experienced* dobj nausea conj episode nmod drug0"
            }
          4 : 
            {
              1 : "We describe a patient who experienced chronic nausea and an episode of drug1 while treated with a small , stable dose of oral drug2 in the setting of mild renal insufficiency . "
            }
          5 : 
            {
              1 : 1
            }
        }
      848 : 
        {
          1 : "NN nmod NNS nmod VBG advcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod preparations nmod switching advcl *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 occurred on switching to different pancreatic enzymes preparations , ie , drug2 , Viokase , and Pancrease MT 16 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      849 : 
        {
          1 : "NN dobj VB xcomp VBN conj VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj have xcomp observed conj *rechallenged* nmod discontinuation nmod drug0"
            }
          4 : 
            {
              1 : "Following discontinuation of drug1 , she was rechallenged and again was observed to have drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      850 : 
        {
          1 : "NN dobj VB advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *cause* advcl used nsubjpass drug0"
            }
          4 : 
            {
              1 : "The authors think that although drug1 is widely used and well tolerated , it can cause drug2 , which are reversible after drug withdrawal . "
            }
          5 : 
            {
              1 : 1
            }
        }
      851 : 
        {
          1 : "NN nmod NN nmod NN nmod VBG dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod infusion nmod completion nmod *impending* dobj toxicity conj drug0"
            }
          4 : 
            {
              1 : "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme drug1 and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose drug2 ( MTX ) ( 12 g/m2 ) , and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      852 : 
        {
          1 : "NN compound NN nmod NN nmod VBG nmod VBN dep VBP dobj NN acl:relcl VBD dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod site nmod swelling nmod complicated dep *describe* dobj patient acl:relcl developed dobj reaction appos drug0"
            }
          4 : 
            {
              1 : "Here we describe a patient with Crohn 's disease who developed a severe infliximab infusion reaction ( drug1 ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      853 : 
        {
          1 : "NN conj NN nmod NN dobj VBD dep NNS nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj alfa-0a nmod therapy dobj began dep weeks nmod *woman* acl presented nmod drug0"
            }
          4 : 
            {
              1 : "OBSERVATIONS : A 48-year-old woman presented with drug1 10 weeks after she began antiviral therapy with peginterferon alfa-2a and drug2 for chronic hepatitis C infection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      854 : 
        {
          1 : "NN appos DT nmod VBN nsubjpass NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos those nmod *monitored* nsubjpass patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "That review suggested that patients receiving drug1 be monitored for those and other potential complications of hemoglobinemia , particularly drug2 ( DIC ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      855 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving advcl *experienced* dobj pain appos drug0"
            }
          4 : 
            {
              1 : "We describe 2 patients with prior amputation who experienced phantom limb pain ( drug1 ) after receiving drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      856 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN nmod VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod event nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "METHODS : We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if drug1 had occurred as an adverse event in patients treated with drug2 between November 1998 and January 2000 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      857 : 
        {
          1 : "NN nmod VBN dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod started dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "This patient , who had a history of osteoarthritis , had severe drug1 5 weeks after being started on drug2 for increasing pain in the joints . "
            }
          5 : 
            {
              1 : 1
            }
        }
      858 : 
        {
          1 : "NN dobj VB xcomp VB nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj produce xcomp *interact* nsubj sarcoidosis conj drug0"
            }
          4 : 
            {
              1 : "This case suggests that sarcoidosis and drug1 , two entities not frequently associated with myotonia , may interact in a synergistic manner to produce severe clinical drug2 in humans . "
            }
          5 : 
            {
              1 : 1
            }
        }
      859 : 
        {
          1 : "NN compound NN nmod JJ nmod NN nmod NN nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *aware* nmod risk nmod aiha nmod patients nmod history nmod drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware of the risk of severe AIHA in CLL patients with a history of drug1 or positivation of the DAT during previous drug2 administration , or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      860 : 
        {
          1 : "NN dobj VB acl:relcl NNS nmod NN nmod VBN xcomp VBN acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induce acl:relcl drugs nmod list nmod added xcomp needed acl:relcl *effect* nmod drug0"
            }
          4 : 
            {
              1 : "In summary , we report herein the first case of SIADH believed to be an adverse effect of drug1 , which may therefore needed to be added to the list of drugs which can induce drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      861 : 
        {
          1 : "NN appos NN nmod NN dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos carbamazepine nmod administration dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "A 14-year-old female developed drug1 , rash , fever , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( drug2 ; Tegretol ) used against benign Rolandic epilepsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      862 : 
        {
          1 : "NN conj JJ nmod VBN acl NN dobj VB xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj sudden nmod characterized acl phenomenon dobj avoid xcomp *recommended* nsubjpass dose nmod drug0"
            }
          4 : 
            {
              1 : "A small initial dose of drug1 ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and drug2 after the administration of the first dose of prazosin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      863 : 
        {
          1 : "NN nmod NN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "drug1 , which is a leading cause of drug2 in the above group of drugs was withdrawn . "
            }
          5 : 
            {
              1 : 1
            }
        }
      864 : 
        {
          1 : "NN compound NN nmod NN nsubj NN acl VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *complication* nsubj syndrome acl named nmod discoloration conj drug0"
            }
          4 : 
            {
              1 : "Purple glove syndrome , named for its distinctive purple discoloration and drug1 in the distribution of a glove , is an uncommon complication of intravenous drug2 administration through small dorsal veins of the hands . "
            }
          5 : 
            {
              1 : 1
            }
        }
      865 : 
        {
          1 : "NN dep NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep months nmod *dehiscence* conj drug0"
            }
          4 : 
            {
              1 : "PURPOSE : To report a case of traumatic flap dehiscence and drug1 34 months after drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      866 : 
        {
          1 : "NN conj NN dep NN nmod VBD acl:relcl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj bleomycin dep chemotherapy nmod developed acl:relcl *ischemia* conj drug0"
            }
          4 : 
            {
              1 : "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and drug1 that developed after combined chemotherapy ( bleomycin and drug2 ) used to treat a metastatic squamous cell carcinoma of the hypopharynx . "
            }
          5 : 
            {
              1 : 1
            }
        }
      867 : 
        {
          1 : "NN nmod NN nmod NN nsubj NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod *risk* nsubj patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "Patients receiving drug1 are at increased risk for the development of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      868 : 
        {
          1 : "NN appos NN nmod NN nmod VBP dobj NN nmod NN acl VBN nmod NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos cisplatin nmod chemotherapy nmod *report* dobj patient nmod adenocarcinoma acl complicated nmod syndrome nmod secretion nmod hormone appos drug0"
            }
          4 : 
            {
              1 : "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( drug1 ) following systemic chemotherapy with cisplatin ( drug2 ) and vindesine ( VDS ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      869 : 
        {
          1 : "NN nmod NN nmod NN dep NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mg nmod treatment dep weeks nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "The first case concerns a 70-year-old man who developed severe drug1 7 weeks after treatment with 500 mg of drug2 daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      870 : 
        {
          1 : "NN nsubjpass VBN advcl VBN parataxis JJ nmod NNS acl VBG dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass found advcl withdrawn parataxis *mandatory* nmod patients acl receiving dobj doses nmod drug0"
            }
          4 : 
            {
              1 : "Monitoring of liver function tests should be mandatory in patients receiving high doses of drug1 ; the drug should be withdrawn immediately if drug2 are found . "
            }
          5 : 
            {
              1 : 1
            }
        }
      871 : 
        {
          1 : "NN xcomp VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp *appears* nsubj toxicity nmod drug0"
            }
          4 : 
            {
              1 : "The ocular toxicity of drug1 , previously described as conjunctivitis , appears to be a drug2 of moderate severity which requires further study . "
            }
          5 : 
            {
              1 : 1
            }
        }
      872 : 
        {
          1 : "NN compound NNS nmod NN nsubj VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound values nmod deterioration nsubj *was* nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "After treatment with drug1 , there was a rapid deterioration with drug2 values . "
            }
          5 : 
            {
              1 : 1
            }
        }
      873 : 
        {
          1 : "NN nmod NN nmod VBG dobj VBN ccomp VB xcomp VBP nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episode nmod precipitating dobj represented ccomp conclude xcomp *lead* nsubj evidence nmod levels nmod drug0"
            }
          4 : 
            {
              1 : "The evidence of high plasmatic levels of drug1 and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      874 : 
        {
          1 : "NN compound NNS nmod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound derivatives nmod treatment nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Two patients with osteomyelitis who developed drug1 during treatment with drug2 derivatives are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      875 : 
        {
          1 : "NN dobj VB xcomp VBN conj VBZ acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp reported conj undergoes acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "The most likely cause of liver failure in this patient was , therefore , drug1 , which undergoes hepatic metabolism and has been reported to cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      876 : 
        {
          1 : "NN nmod VBG advcl VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulting advcl *treated* nmod ointment conj drug0"
            }
          4 : 
            {
              1 : "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and drug1 , respectively , resulting in drug2 and hypercalcemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      877 : 
        {
          1 : "NN conj NN dobj VBD nsubj NN acl:relcl VBD dobj NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj stiffness dobj *developed* nsubj woman acl:relcl had dobj history nmod injections compound drug0"
            }
          4 : 
            {
              1 : "A 47 year-old woman who had a 4-year history of intramuscular drug1 injections in the lower extremities , developed gradual stiffness and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      878 : 
        {
          1 : "NN nsubj NN ccomp VBN advcl VBN nsubjpass NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj effect ccomp *recognized* advcl shown nsubjpass introduction nmod wafers compound drug0"
            }
          4 : 
            {
              1 : "While the introduction of drug1 wafers ( Gliadel wafers ) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma , it is recognized that clinically significant drug2 is a potential adverse effect . "
            }
          5 : 
            {
              1 : 1
            }
        }
      879 : 
        {
          1 : "NN nsubj VBD conj VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj disappeared conj *decreased* nmod period nmod drug0"
            }
          4 : 
            {
              1 : "After 3 - to 13-month period of therapy without drug1 , glucose levels of all patients decreased and drug2 disappeared . "
            }
          5 : 
            {
              1 : 1
            }
        }
      880 : 
        {
          1 : "NN dobj VBG acl:relcl NNS nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl:relcl factors nmod patients nmod *risk* nmod drug0"
            }
          4 : 
            {
              1 : "The risk of new-onset drug1 in patients with diabetic risk factors who are taking drug2 or other atypical antipsychotics should be kept in mind . "
            }
          5 : 
            {
              1 : 1
            }
        }
      881 : 
        {
          1 : "NN compound NN nmod NN nmod JJ dep JJ nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod completion nmod early dep *present* nsubj signs nmod drug0"
            }
          4 : 
            {
              1 : "Although his renal function recovered completely with high-dose leucovorin , hemodialysis , charcoal hemoperfusion , and carboxypeptidase G2 , we present this case to emphasize that signs of drug1 may be present as early as 2 hours after the completion of a 4-hour drug2 infusion , and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      882 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod initiation nmod *patient* nmod syndrome acl presented nmod drug0"
            }
          4 : 
            {
              1 : "A patient with the Wolff-Parkinson-White syndrome presented with drug1 following initiation of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      883 : 
        {
          1 : "NN compound NN dobj VBG acl:relcl NN nmod VBN acl NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl:relcl man nmod developed acl autoantibodies conj *drug0*"
            }
          4 : 
            {
              1 : "drug1 , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43-year-old man , who was receiving long-term drug2 therapy for chronic ulcerative colitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      884 : 
        {
          1 : "NN conj NN nmod NN nmod NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj infliximab nmod therapy nmod months nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a drug1 after 9 months of therapy with infliximab and drug2 is described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      885 : 
        {
          1 : "NN nmod NNS dobj VBG acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses dobj receiving acl patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "This report details a case of drug1 in a patient receiving ` standard ' doses of drug2 as part of the antiemetic regimen used in cisplatin-based combination chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      886 : 
        {
          1 : "NN compound NNS nsubj VB advcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound concentrations nsubj explain advcl *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : The observation that drug1 developed with a delay of 24 to 48 hours after drug2 peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases . "
            }
          5 : 
            {
              1 : 1
            }
        }
      887 : 
        {
          1 : "VB xcomp VBN xcomp VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp contributed xcomp *appears* nsubj drug0"
            }
          4 : 
            {
              1 : "The cases are important in documenting that drug-induced dystonias do occur in patients with dementia , that drug1 appears to have contributed to drug2 among elderly patients , and that the categorization of dystonic reactions needs further clarification . "
            }
          5 : 
            {
              1 : 1
            }
        }
      888 : 
        {
          1 : "NN nmod NN nmod VBZ dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause nmod *indicates* dobj cream compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This report indicates drug1 vaginal cream as the most probable cause of drug2 due to the temporal relationship between the occurrence of diarrhea and clindamycin administration , lack of concomitant medications , and documentation of C. difficile toxin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      889 : 
        {
          1 : "NN appos NN nmod VBN acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos sulfate nmod known acl:relcl *occurrence* nmod drug0"
            }
          4 : 
            {
              1 : "The occurrence of drug1 and the resulting potentiation of muscle relaxants during magnesium sulfate ( drug2 ) administration is well known . "
            }
          5 : 
            {
              1 : 1
            }
        }
      890 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod VBN dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod parkinsonism nmod result nmod *required* dobj placement conj drug0"
            }
          4 : 
            {
              1 : "One patient required nursing home placement and a drug1 as a result of the worsening parkinsonism during drug2 treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      891 : 
        {
          1 : "NN compound NN dobj VBG advcl VBP dobj NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving advcl *report* dobj patient acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed drug1 , synovitis , and possible vasculitis , after receiving drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      892 : 
        {
          1 : "NN compound NN nmod NN conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound intoxication nmod failure conj *vision* conj drug0"
            }
          4 : 
            {
              1 : "We cared for a patient with progressive renal impairment who presented with blurred vision , drug1 and cardiac failure due to chronic drug2 intoxication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      893 : 
        {
          1 : "NN conj NN nmod NN appos NN nmod VBZ ccomp VBD conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj promethazine nmod cross-reaction appos reaction nmod results ccomp were conj *taken* dobj drug0"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken drug1 for 6 months , and there were strong positive photopatch test results with immediate erythema reaction , cross-reaction to promethazine , drug2 , and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      894 : 
        {
          1 : "NN compound NN dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound discontinuation dep years nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 several years after drug2 discontinuation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      895 : 
        {
          1 : "NN compound NN nmod VBG acl NN nmod NN conj NN nmod JJ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod occurring acl fixation nmod case conj administration nmod *aware* nmod risk nmod drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware of the risk of severe drug1 in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration , or in case of secondary fixation of complement to the red cell membrane occurring during drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      896 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod start dep months nmod occurring acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "Here , we describe a case of drug1 occurring 4 months after the start of drug2 treatment , probably induced by the immunomodulatory effects of interferon . "
            }
          5 : 
            {
              1 : 1
            }
        }
      897 : 
        {
          1 : "NN nmod NN nmod VBN xcomp VBN acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod exposure nmod arisen xcomp thought acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "A case of drug1 which is thought to have arisen from the patient 's intrauterine exposure to drug2 is presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      898 : 
        {
          1 : "NN compound NN nmod NNS nmod NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod months nmod *man* dep drug0"
            }
          4 : 
            {
              1 : "A 61-year-old man developed drug1 with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis following 26 months of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      899 : 
        {
          1 : "NN dep JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep due amod *drug0*"
            }
          4 : 
            {
              1 : "A 30-year-old pharmacist suffered from drug1 due to drug2 ( NBD-Cl ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      900 : 
        {
          1 : "NN dobj VBD conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induced conj *drug0*"
            }
          4 : 
            {
              1 : "A 44-year-old woman is described in whom amiodarone , drug1 , and quinidine , administered alone separately , induced drug2 ( AVT , torsade de pointes ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      901 : 
        {
          1 : "NN nmod NN dobj VBG xcomp VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod existence dobj suggesting xcomp *controlled* nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "The induced hyperglycaemia could not be controlled sufficiently , despite a high dose of drug1 ( > 110 units/day ) , suggesting the existence of drug2 and hyperinsulinaemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      902 : 
        {
          1 : "NN conj NN nmod NNS dobj VBP conj VBP ccomp VBD nsubj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hepatitis nmod cases dobj comprise conj *constitute* ccomp reported nsubj cases nmod hepatotoxicity compound drug0"
            }
          4 : 
            {
              1 : "Our cases constitute the most severe cases of drug1 hepatotoxicity reported so far , and comprise the first cases of ( sub ) fulminant hepatitis and drug2 related to benzarone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      903 : 
        {
          1 : "NN nmod NN nmod NN conj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *caution* nmod usage conj recognition nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "Caution in longterm usage and early recognition of drug1 toxicity as a drug2 are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      904 : 
        {
          1 : "NN root IN dep VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root that dep *noted* nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "After only the third dose of drug1 , it was noted that the patient 's drug2 to 48 beats/minute . "
            }
          5 : 
            {
              1 : 1
            }
        }
      905 : 
        {
          1 : "NN nmod NNS nmod VBN conj VBN dep NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod signs nmod presented conj dissolved dep *tablets* compound drug0"
            }
          4 : 
            {
              1 : "A 22-year-old drug-abuser injected drug1 tablets dissolved in tap water into her left femoral artery and presented with clinical signs of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      906 : 
        {
          1 : "NN dobj VBG acl NN nmod NN nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl arthritis nmod patient nmod developing acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 developing in a patient with rheumatoid arthritis taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      907 : 
        {
          1 : "NN nmod JJ nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *positive* nsubj test nmod ui nmod drug0"
            }
          4 : 
            {
              1 : "The intramuscular challenge test with 25 UI of drug1 was positive with an immediate drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      908 : 
        {
          1 : "NN conj NN nmod NN nmod NN dobj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj furazolidone nmod mixture nmod administration dobj *followed* nsubj episode nmod drug0"
            }
          4 : 
            {
              1 : "A second episode of drug1 followed the intravaginal administration of a mixture of furazolidone and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      909 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBZ dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod regimen dobj adding advcl *describes* dobj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This case describes the clinically significant drug1 in an elderly patient after adding a chemotherapy regimen of drug2 and 5-FU to a previous regimen of warfarin alone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      910 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patient acl treated conj drug0"
            }
          4 : 
            {
              1 : "A patient with Parkinson 's disease , initially treated with bromocriptine and subsequently with drug1 , developed progressive drug2 during the latter therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      911 : 
        {
          1 : "NN dobj VBD advcl VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj received advcl developed acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "The authors present a case of drug1 that developed in a child with metastatic neuroblastoma 18 months after he received oral drug2 , given for palliation purpose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      912 : 
        {
          1 : "NN nmod NN nmod VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod chemotherapy nmod *presenting* nmod drug0"
            }
          4 : 
            {
              1 : "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with drug1 after chemotherapy with drug2 and gemcitabine producing severe respiratory insufficiency , and simulating a progression of the tumor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      913 : 
        {
          1 : "NN nmod NNS parataxis VBD nmod CD nmod CD acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cases parataxis *occurred* nmod 0 nmod 0 acl exposed nmod drug0"
            }
          4 : 
            {
              1 : "Masculinization of a female fetus occurred in 5 of 39 ( 12.8 % ) exposed to drug1 ; all were cases of drug2 not requiring surgical treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      914 : 
        {
          1 : "NN nmod VBN acl NN nsubjpass VBN advcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patient nsubjpass started advcl *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed when a diabetic patient , previously treated with drug2 , was started on another oral sulfonylurea drug , chlorpropamide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      915 : 
        {
          1 : "NN nmod NN dobj VB acl:relcl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod evidence dobj precede acl:relcl *sign* nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "Painful erosion of psoriatic plaques is a less common sign of drug1 toxicity that may precede evidence of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      916 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBN nmod NN conj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj man acl treated nmod prednisone conj mesalamine appos drug0"
            }
          4 : 
            {
              1 : "A 49-year-old man with Crohn 's disease treated with prednisone and mesalamine ( drug1 ) developed drug2 and fever . "
            }
          5 : 
            {
              1 : 1
            }
        }
      917 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod course nmod *developed* dobj vasculitis nmod drug0"
            }
          4 : 
            {
              1 : "We describe a 73-year-old woman who developed serious systemic vasculitis with associated drug1 in the course of treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      918 : 
        {
          1 : "NN nmod NN nmod VBP dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effect nmod *report* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "The authors report two cases of drug1 ( ADRs ) as a side effect of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      919 : 
        {
          1 : "NN nmod NN nmod NN nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod complication nmod *report* dobj occurrence nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report the occurrence of drug1 as a complication of treatment with drug2 and to consider the possible underlying mechanisms for this association . "
            }
          5 : 
            {
              1 : 1
            }
        }
      920 : 
        {
          1 : "NN dobj VB xcomp VBN acl NNS nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp known acl drugs nmod list nmod *added* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 should be added to the list of drugs known to cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      921 : 
        {
          1 : "NN compound NN nmod NNS conj NNS dobj VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound hepatotoxicity nmod cases conj eruptions dobj involving acl *drug0*"
            }
          4 : 
            {
              1 : "Although this combination agent has been associated with a drug1 involving cutaneous skin eruptions , pediatric cases of drug2 hepatotoxicity are rare . "
            }
          5 : 
            {
              1 : 1
            }
        }
      922 : 
        {
          1 : "NN dobj VBP parataxis VB parataxis VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj have parataxis *cause* parataxis related nsubj drug0"
            }
          4 : 
            {
              1 : "Intravenous verapamil therapy in babies may cause apnea , hypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; drug1 may be related to the death ; children with `` familial seizure disorders '' may in fact have the drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      923 : 
        {
          1 : "NN appos NN nmod VBN acl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos bis-chloronitrosourea nmod associated acl *complication* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a severe complication associated with bis-chloronitrosourea ( drug2 ) therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      924 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment dobj receiving advcl *developed* dobj failure conj drug0"
            }
          4 : 
            {
              1 : "However , he developed acute renal failure , drug1 , and hyperuricemia 30 d after receiving the drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      925 : 
        {
          1 : "NN compound NN conj VBD conj VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound cream conj *had* conj developed dobj hyperglycemia conj drug0"
            }
          4 : 
            {
              1 : "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and drug1 during a period of topical administration of a corticosteroid cream , drug2 cream 0.1 % , under occlusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      926 : 
        {
          1 : "NN compound NN nmod NN nmod VBN dep VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound injection nmod complication nmod recognized dep *described* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Native drug1 , though recognized as a severe complication of drug2 injection , has not been well described in the literature . "
            }
          5 : 
            {
              1 : 1
            }
        }
      927 : 
        {
          1 : "NN conj NN compound NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj oxybutynin compound administration nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 following Oxybutynin and drug2 administration : a case report . "
            }
          5 : 
            {
              1 : 1
            }
        }
      928 : 
        {
          1 : "NN nmod NN nmod VBN acl NNS conj NN amod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod resolved acl symptoms conj *patient* amod consistent nmod drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with drug1 , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      929 : 
        {
          1 : "NN nmod VBG advcl NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod receiving advcl *rigidity* conj levels compound drug0"
            }
          4 : 
            {
              1 : "A 16-year-old boy developed fever , generalized rigidity , leukocytosis , and drug1 levels while receiving treatment with drug2 and lithium . "
            }
          5 : 
            {
              1 : 1
            }
        }
      930 : 
        {
          1 : "NN compound NN dobj VBD nsubj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound contralateral dobj *developed* nsubj woman nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "A 52-year-old Black woman on drug1 therapy for post-traumatic epilepsy developed drug2 contralateral to the injury . "
            }
          5 : 
            {
              1 : 1
            }
        }
      931 : 
        {
          1 : "NN conj NN dep NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj cataract dep *methylphenidate* appos drug0"
            }
          4 : 
            {
              1 : "Methylphenidate ( drug1 ) - associated cataract and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      932 : 
        {
          1 : "NN compound NN nmod NN dobj VBD advmod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod suspension dobj *necessitated* advmod due nmod drug0"
            }
          4 : 
            {
              1 : "Due to drug1 , diplopia and lagophthalmos , the haematoma necessitated suspension of drug2 therapy and a surgical evacuation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      933 : 
        {
          1 : "NN conj NN dobj VBD parataxis VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj jaundice dobj developed parataxis *disappeared* nmod therapy nmod drug0"
            }
          4 : 
            {
              1 : "After therapy with parenteral drug1 ( 2300 mg in 3 days ) and other measures , signs of congestive heart failure disappeared ; subsequently the patient developed jaundice , drug2 and fall in prothrombin time , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      934 : 
        {
          1 : "NN dobj VBD acl:relcl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl *drug* appos drug0"
            }
          4 : 
            {
              1 : "After treatment with a beta-sympathomimetic drug ( drug1 ) one fetus developed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      935 : 
        {
          1 : "NN nmod NN xcomp VBZ advcl VBZ dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presentation xcomp appears advcl *implicates* dobj drug0"
            }
          4 : 
            {
              1 : "This report rules out other causes of toxic epidermal necrolysis and implicates drug1 in what appears to be an atypical presentation of drug-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      936 : 
        {
          1 : "NN compound NNS nmod VBN acl CD root , punct CD root -LRB- punct NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound diuretics nmod combined acl 0 root , punct 0 root ( punct ointment nmod *drug0*"
            }
          4 : 
            {
              1 : "Iatrogenic drug1 due to vitamin D3 ointment ( 1 , 24 ( OH ) 2D3 ) combined with drug2 diuretics in a case of psoriasis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      937 : 
        {
          1 : "NN nmod NNS amod JJ"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *effects* amod drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware of the potentially drug1 side effects of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      938 : 
        {
          1 : "JJ amod NN conj CD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 amod agent conj *one* nsubj use nmod drug0"
            }
          4 : 
            {
              1 : "Currently the use of drug1 is one of the few specific measures available , and as a potentially drug2 and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage . "
            }
          5 : 
            {
              1 : 1
            }
        }
      939 : 
        {
          1 : "NN nsubjpass VBN advcl VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass coadministered advcl occurring acl *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report 2 cases of serotonin syndrome with serious drug1 occurring when drug2 was coadministered with sertraline or venlafaxine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      940 : 
        {
          1 : "NN nmod NN conj NN dobj VBD advcl VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod period conj disorder dobj *developed* advcl given dobj drug0"
            }
          4 : 
            {
              1 : "She was admitted following a fall and , after being given drug1 , developed movement disorder and a period of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      941 : 
        {
          1 : "NN appos NN root IN acl NN dobj VBG advcl VBD nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos immunoglobulin root of acl course dobj completing advcl *presented* nmod nausea conj drug0"
            }
          4 : 
            {
              1 : "We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea , drug1 , azotemia , and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      942 : 
        {
          1 : "NN nmod NNS nmod VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod challenges nmod *resulted* nmod drug0"
            }
          4 : 
            {
              1 : "METHODS : Double-blind , placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite drug1 within 1 to 1.5 hours after challenges with drug2 and Pancrease MT 16 , but not with placebo . "
            }
          5 : 
            {
              1 : 1
            }
        }
      943 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod VBG acl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl boy nmod resulting acl *toxicity* compound drug0"
            }
          4 : 
            {
              1 : "We present a case of acute drug1 toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed drug2 to intravenous immunoglobulin , and was subsequently given epinephrine by mistake intravenously rather than subcutaneously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      944 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj initiating acl days nmod *develop* nsubj drug0"
            }
          4 : 
            {
              1 : "Our findings suggest that drug1 can develop with the use of low-dose heparin , within seven days of initiating drug2 therapy , and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      945 : 
        {
          1 : "NN dobj VBD nsubj NNS acl VBN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patients acl treated nmod 0-fluorouracil appos drug0"
            }
          4 : 
            {
              1 : "Two patients treated with 5-fluorouracil ( drug1 ) for disseminated adenocarcinoma of the colon developed drug2 typical of 5-FU neurotoxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      946 : 
        {
          1 : "NN nmod NN nmod NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod weeks dep *drug0*"
            }
          4 : 
            {
              1 : "A 57-year-old man developed drug1 four weeks after Helicobacter pylori eradication therapy including drug2 followed by lansoprazole monotherapy for gastroesophageal reflux disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      947 : 
        {
          1 : "NN compound NN nmod NN dep JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound neurotoxicity nmod manifestation dep *likely* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 in this patient was most likely a manifestation of drug2 neurotoxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      948 : 
        {
          1 : "NN conj NN nmod VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj olanzapine nmod receiving advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 16-year-old boy developed drug1 , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      949 : 
        {
          1 : "NN nmod VBN acl NN dep CD nmod VBD nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod followed acl mmhg dep 0/0 nmod *decreased* nmod test nmod administration nmod drug0"
            }
          4 : 
            {
              1 : "In a postural challenge test after administration of drug1 ( 5 mg ) , blood pressure decreased from 120/67 to 65/35 mmHg , followed by drug2 with a sudden decrease in pulse rate from 85 to 60 beats/min . "
            }
          5 : 
            {
              1 : 1
            }
        }
      950 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN acl NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod day nmod infected acl patients nmod *eruption* conj drug0"
            }
          4 : 
            {
              1 : "We report 2 cases of maculopapular eruption and drug1 in patients infected with human immunodeficiency virus ( HIV ) on the 2nd day of first administration of drug2 , a protease inhibitor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      951 : 
        {
          1 : "NN nmod VBN advcl VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod exposed advcl *develop* dobj drug0"
            }
          4 : 
            {
              1 : "OBJECTIVES : To describe clinical and pathologic findings in patients noted to develop drug1 when exposed to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      952 : 
        {
          1 : "NN nmod VBD acl:relcl NN nmod NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented acl:relcl *case* nmod woman nmod disorder nmod sodium appos drug0"
            }
          4 : 
            {
              1 : "We report a case of 48-year-old woman with seizure disorder on divalproex sodium ( drug1 ) who presented with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      953 : 
        {
          1 : "NN nmod NN nmod NNS dobj VBN ccomp VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod emergence nmod questions dobj raised ccomp *causes* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of drug2 after its use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      954 : 
        {
          1 : "NN nmod NN nmod JJ nsubj NNS appos DT conj VBG dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod risk nmod *aware* nsubj clinicians appos those conj receiving dobj drugs nmod drug0"
            }
          4 : 
            {
              1 : "Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including drug1 , should be aware of the risk of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      955 : 
        {
          1 : "NN nmod NNS nmod NNS dobj VBG ccomp VBP advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod signs nmod patients dobj monitoring ccomp *recommend* advcl administered nsubjpass drug0"
            }
          4 : 
            {
              1 : "Until additional data are available , if intravenous drug1 is administered concurrently with lithium , we recommend closely monitoring patients for signs of drug2 and measuring serum lithium levels every second or third day . "
            }
          5 : 
            {
              1 : 1
            }
        }
      956 : 
        {
          1 : "NN dobj VB xcomp VBN nsubjpass NNS conj NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induce xcomp *thought* nsubjpass factors conj drugs dep drug0"
            }
          4 : 
            {
              1 : "However , other factors or drugs ( e.g. drug1 ) are thought to induce drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      957 : 
        {
          1 : "NN nmod NNS dobj VBD acl:relcl NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod symptoms dobj exhibited acl:relcl patient conj sarcoma nmod *drug0*"
            }
          4 : 
            {
              1 : "In this report , one patient who developed gangrene after drug1 and vincristine/vinblastine chemotherapy for AIDS-related Kaposi 's sarcoma and another HIV-infected patient who exhibited symptoms of drug2 related to the same regimen are presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      958 : 
        {
          1 : "NN compound NN dep NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dep hours nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurred 24 hours after intravenous drug2 therapy and 10 hours after subcutaneous terbutaline therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      959 : 
        {
          1 : "NN appos NN nmod NNS nsubjpass VBN conj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos syndrome nmod cases nsubjpass reported conj *has* nsubj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 has mild renal toxicity , but cases of gemcitabine-associated hemolytic-uremic syndrome ( drug2 ) have been reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      960 : 
        {
          1 : "NN dobj VBG advcl VBD nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj injecting advcl *developed* nmod abdomen nmod form nmod drug0"
            }
          4 : 
            {
              1 : "46-year-old woman developed painful ulcers over her lower abdomen in the form of drug1 after injecting drug2 subcutaneously for multiple sclerosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      961 : 
        {
          1 : "NN nmod NN nmod VBD dobj VBG conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *developed* dobj swelling conj drug0"
            }
          4 : 
            {
              1 : "Two patients are described who developed testicular swelling and drug1 during treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      962 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NN nmod NN conj JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj methimazole nmod pregnancy nmod treated acl woman nmod *born* nsubjpass girl nmod atresia conj mild nmod drug0"
            }
          4 : 
            {
              1 : "An infant girl with choanal atresia , athelia , minor anomalies , and mild to moderate drug1 was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      963 : 
        {
          1 : "NN conj NNS nmod VB xcomp VBN acl NNS nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj phenothiazines nmod occur xcomp known acl *risks* nsubj neutropenia conj drug0"
            }
          4 : 
            {
              1 : "Neutropenia and drug1 are risks known to occur with phenothiazines and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      964 : 
        {
          1 : "NN dobj VBG advcl VBD nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj commencing advcl *presented* nmod blindness conj drug0"
            }
          4 : 
            {
              1 : "We report a 4-year-old girl who presented with acute bilateral blindness , a drug1 and hypertension 10 days after commencing drug2 to treat enuresis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      965 : 
        {
          1 : "NN nmod NN nmod VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *performed* nmod patients nmod drug0"
            }
          4 : 
            {
              1 : "We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with drug1 during treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      966 : 
        {
          1 : "VB amod NNS nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 amod concretions nmod due amod *drug0*"
            }
          4 : 
            {
              1 : "A 65-year-old woman , in the intensive care unit because of septic shock and acute renal failure , had a drug1 due to drug2 concretions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      967 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *had* nsubj woman acl:relcl taken dobj drug0"
            }
          4 : 
            {
              1 : "RESULTS : A 52-year-old woman with Parkinson disease who had taken drug1 for 6 years had drug2 for 2 months at baseline . "
            }
          5 : 
            {
              1 : 1
            }
        }
      968 : 
        {
          1 : "VB conj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *alters* nsubj drug0"
            }
          4 : 
            {
              1 : "In addition to its known effect on gallbladder stasis , drug1 alters bile acid composition and may thus drug2 and stone formation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      969 : 
        {
          1 : "NN compound NN nmod NN nmod VBD advmod RB"
          2 : 1
          3 : 
            {
              1 : "drug0 compound toxicity nmod sign nmod *developed* advmod drug0"
            }
          4 : 
            {
              1 : "We describe two patients in whom drug1 developed as the presenting sign of drug2 toxicity and review the literature , emphasizing the risk factors associated with this manifestation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      970 : 
        {
          1 : "NN appos NN dobj VBG acl NNS nmod VBN nsubjpass NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos factor dobj receiving acl children nmod *observed* nsubjpass lesions compound drug0"
            }
          4 : 
            {
              1 : "drug1 neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor ( drug2 ) for treatment of idiopathic neutropenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      971 : 
        {
          1 : "NN appos NN compound NN nmod VBD dobj NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos thiomalate compound injection nmod *developed* dobj symptoms conj drug0"
            }
          4 : 
            {
              1 : "The first patient developed mild nitritoid symptoms and drug1 in a band-like distribution , corresponding to T10-T12 dermatomes , shortly after gold sodium thiomalate ( drug2 ) injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      972 : 
        {
          1 : "NN dep CD dep JJ dep IN amod NN nmod VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep 0 dep topical dep of amod use nmod attributed advcl *suffered* dobj drug0"
            }
          4 : 
            {
              1 : "One patient suffered drug1 , attributed to the use of topical 1 : 1000 drug2 during surgery . "
            }
          5 : 
            {
              1 : 1
            }
        }
      973 : 
        {
          1 : "NN dobj VBG advcl VBD nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj administering advcl *occurred* nsubj episodes nmod drug0"
            }
          4 : 
            {
              1 : "In the first patient , two episodes of drug1 requiring cardioversion occurred in close temporal sequence with administering drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      974 : 
        {
          1 : "NN nmod NN conj VBZ dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod documentation conj *indicates* dobj cream compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This report indicates drug1 vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration , lack of concomitant medications , and documentation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      975 : 
        {
          1 : "NN nmod NNS nsubj VBP conj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod reports nsubj are conj *increases* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( RFP ) increases hepatic microsomal enzyme activity , and there are case reports of RFP-induced drug2 , all associated with Hashimoto 's thyroiditis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      976 : 
        {
          1 : "NN dobj VBG acl:relcl NNS nmod VB xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl:relcl patients nmod occur xcomp *known* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is known to occur in patients who are taking drug2 , particularly the elderly . "
            }
          5 : 
            {
              1 : 1
            }
        }
      977 : 
        {
          1 : "NN nmod JJ xcomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod responsible xcomp *appeared* nsubj drug0"
            }
          4 : 
            {
              1 : "Five patients are described in whom only drug1 appeared responsible for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      978 : 
        {
          1 : "NN nmod VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *identified* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "A MEDLINE search identified all the reported cases of drug1 to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      979 : 
        {
          1 : "NN nmod NN conj NN nmod VBN acl NNS nmod VBP advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod combination conj hu nmod treated acl patients nmod *describe* advcl determined nmod drug0"
            }
          4 : 
            {
              1 : "We describe the clinical response , as determined by drug1 and decreased transfusion needs , in five patients with thalassemia intermedia treated with HU alone or in combination with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      980 : 
        {
          1 : "NN dobj VBG advcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving advcl *developed* dobj evidence nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with rheumatoid arthritis developed evidence of drug1 while receiving drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      981 : 
        {
          1 : "NN dobj VBD conj VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *started* nsubjpass therapy nmod drug0"
            }
          4 : 
            {
              1 : "After therapy for diabetic coma with drug1 ( containing the preservative cresol ) and electrolyte solutions was started , the patient complained of increasing myalgia , developed a drug2 and respiratory and metabolic acidosis and lost consciousness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      982 : 
        {
          1 : "NN conj NN dobj VB nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj cataract dobj *cause* nsubj dose nmod drug0"
            }
          4 : 
            {
              1 : "Large dose of drug1 may cause cataract and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      983 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod VBN advcl VBN nmod NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound neurotoxicity nmod development nmod vulnerability nmod *associated* advcl characterized nmod symptoms conj drug0"
            }
          4 : 
            {
              1 : "When the acute manic state is characterized by marked psychotic symptoms and drug1 , it may be associated with increased vulnerability to the development of severe drug2 neurotoxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      984 : 
        {
          1 : "NN nsubj VBD acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj induced acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 after drug2 induced vasomotor reaction . "
            }
          5 : 
            {
              1 : 1
            }
        }
      985 : 
        {
          1 : "NN nmod VBN acl:relcl NN dobj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod characterized acl:relcl syndrome dobj *induce* nsubj drug0"
            }
          4 : 
            {
              1 : "In rare cases drug1 ( MMC ) may induce cancer-associated hemolytic uremic syndrome , which is characterized by drug2 , thrombocytopenia and progressive renal failure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      986 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBD acl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod years nmod developed acl *woman* nmod disease conj drug0"
            }
          4 : 
            {
              1 : "RESULTS : In a 22-year-old Thai woman with Graves ' disease , tinnitus , drug1 , and vertigo developed after 3 years of therapy with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      987 : 
        {
          1 : "NN compound NN dobj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound aplasia dobj *induced* nsubj case nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 induced drug2 and bone marrow aplasia in a patient infected with HIV . "
            }
          5 : 
            {
              1 : 1
            }
        }
      988 : 
        {
          1 : "NN compound NN nmod NN nsubjpass VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nmod history nsubjpass *obtained* nmod patients nmod drug0"
            }
          4 : 
            {
              1 : "In patients with drug1 and pneumonia , a history of drug2 use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      989 : 
        {
          1 : "NN nmod NN nmod NN dep NNS nmod VBD acl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod initiation dep days nmod demonstrated acl *evidence* nmod leucopenia conj drug0"
            }
          4 : 
            {
              1 : "The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and drug1 , and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis , demonstrated 20 days after the initiation of antithyroid therapy with 20 mg drug2 daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      990 : 
        {
          1 : "NN nmod VBG xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulting xcomp *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "IV drug1 was used as the initial treatment for his hyperadrenergic state , resulting in a drug2 but a paroxsymal increase in blood pressure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      991 : 
        {
          1 : "NN nsubj VB parataxis VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj play parataxis *recognized* nsubjpass association nmod drug0"
            }
          4 : 
            {
              1 : "The association between drug1 and priapism is often recognized ; drug2 could play a role in the pathogenesis of this side effect . "
            }
          5 : 
            {
              1 : 1
            }
        }
      992 : 
        {
          1 : "NN conj NN compound NN dobj VBG advcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj dapsone compound therapy dobj starting advcl *developing* dobj drug0"
            }
          4 : 
            {
              1 : "A 25-year-old man with a history of mid-borderline ( BB ) Hansen 's disease developing a drug1 after starting dapsone and drug2 therapy is presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      993 : 
        {
          1 : "NN nmod VBN acl NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod developed acl *drug0*"
            }
          4 : 
            {
              1 : "A drug1 developed in a patient treated with drug2 for acute deep vein thrombosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      994 : 
        {
          1 : "NN conj VBG nmod NNS conj NNS nmod NN nmod NN nmod VBN acl NN dobj VBD nsubj NNS acl:relcl VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj crying nmod periods conj feelings nmod affect nmod development nmod followed acl response dobj *had* nsubj outpatients acl:relcl participated nmod trial nmod drug0"
            }
          4 : 
            {
              1 : "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of drug1 had an initial good response to the medication followed by development of intolerable affect , including feelings of agitation and depression and periods of crying and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      995 : 
        {
          1 : "NN dobj VBG acl NN nmod NN nmod JJ amod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl man nmod ischemia nmod secondary amod *pointes* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and torsades de pointes secondary to acute ischemia in an elderly man taking drug2 for atrial fibrillation : a cautionary tale . "
            }
          5 : 
            {
              1 : 1
            }
        }
      996 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod years nmod *developed* dobj insufficiency compound drug0"
            }
          4 : 
            {
              1 : "A 7-year-old girl developed drug1 and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with drug2 and/or prednisone for idiopathic auto-immune haemolytic anaemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      997 : 
        {
          1 : "NN dobj VBD nsubj NNS acl:relcl VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patients acl:relcl received dobj chemotherapy compound drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARIES : Two patients who received drug1 chemotherapy developed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      998 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound t.i.d. nmod treated acl woman nmod *documented* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was documented in an 81-year-old woman treated with adjunctive drug2 100 mg t.i.d. for chronic congestive heart failure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      999 : 
        {
          1 : "NN nmod NN nsubj NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *toxicity* nsubj rash nmod syndrome appos drug0"
            }
          4 : 
            {
              1 : "Severe rash , including the Stevens-Johnson syndrome ( drug1 ) , is the major toxicity of drug2 and is described in the package labeling with a prominent , boxed warning . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1000 : 
        {
          1 : "NN dobj VBG conj VBP dobj NN nmod NN nmod NN acl VBG nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj simulating conj *report* dobj case nmod patient nmod carcinoma acl presenting nmod chemotherapy nmod drug0"
            }
          4 : 
            {
              1 : "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with drug1 and gemcitabine producing severe respiratory insufficiency , and simulating a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1001 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod VBN acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl angiography nmod demonstrated acl *infarction* nmod drug0"
            }
          4 : 
            {
              1 : "We believe this is the first report of myocardial infarction due to drug1 , demonstrated by angiography associated with drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1002 : 
        {
          1 : "NN nmod NN dobj VB xcomp VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod prevalence dobj show xcomp *considered* nmod drug0"
            }
          4 : 
            {
              1 : "Like other atypical neuroleptics drug1 is considered to show a reduced prevalence of drug2 when compared to classical neuroleptic drugs . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1003 : 
        {
          1 : "NN dobj VBP advcl VBN nmod NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj develop advcl *considered* nmod women acl treated nmod drug0"
            }
          4 : 
            {
              1 : "An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with drug1 for epilepsy , especially if they develop drug2 during treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1004 : 
        {
          1 : "NN conj NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj inhibitor nmod *acted* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 acted as a CYP3A4 inhibitor , drug2 and provoking an increase in serum levels and clinical toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1005 : 
        {
          1 : "NN conj NNS nmod NNS conj NN dep NNS dobj VBD nsubj NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj thumbs nmod defects conj deficiency dep manifestations dobj *shared* nsubj cases nmod exposure nmod drug0"
            }
          4 : 
            {
              1 : "The reported cases of in utero exposure to drug1 shared the following manifestations with our patient : growth deficiency , developmental delay , craniosynostosis , blepharophimosis , flat nasal bridge , abnormal ears , and distal limb defects including hypoplastic thumbs and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1006 : 
        {
          1 : "NN nmod VBN acl:relcl NNS nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patients nmod *importance* nmod observation nmod drug0"
            }
          4 : 
            {
              1 : "This case suggests the importance of careful observation for drug1 in patients who are treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1007 : 
        {
          1 : "NN nmod VBG acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod overdosing acl *hyperglycemia* appos drug0"
            }
          4 : 
            {
              1 : "Posthypoglycemic hyperglycemia ( drug1 ) after overdosing of drug2 was diagnosed in 6 cats with diabetes mellitus . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1008 : 
        {
          1 : "NN nsubj VBN conj VBN nsubjpass NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj resolved conj *stopped* nsubjpass drugs appos drug0"
            }
          4 : 
            {
              1 : "The disease-modifying drugs he was taking , drug1 and methotrexate , were stopped , and the drug2 resolved spontaneously without the use of chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1009 : 
        {
          1 : "NN appos NN dep NN nsubjpass VBN parataxis VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acid dep valproate nsubjpass added parataxis *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 7-year-old boy developed a drug1 at the age of 5 years ( phenobarbitone therapy ) ; 1.5 years later valproate ( 2-propylpentanoic acid , drug2 ) was added to the therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1010 : 
        {
          1 : "NN conj NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj infecction nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "In this paper , we report a case of 3 years-old boy who developed drug1 following a viral respiratory infecction and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1011 : 
        {
          1 : "NN nmod NNS nmod VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod associated conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is widely used against methicillin-resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as drug2 , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as `` red man syndrome '' and anaphylaxis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1012 : 
        {
          1 : "NN nmod VBG acl:relcl NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod receiving acl:relcl patients nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurred in two patients with probable Alzheimer 's disease who were receiving long-term treatment with drug2 , an irreversible acetylcholinesterase inhibitor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1013 : 
        {
          1 : "NN nmod NN advcl VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *patient* advcl reported nsubjpass withdrawal compound drug0"
            }
          4 : 
            {
              1 : "Although drug1 withdrawal has been previously reported and usually consists of anxiety , diaphoresis , and palpitations , this is the first reported patient with drug2 and status epilepticus secondary to gabapentin withdrawal . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1014 : 
        {
          1 : "NN appos NN nmod NN nmod VBG conj VBD dobj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos inhibitor nmod administration nmod vomiting conj *observed* dobj patients acl followed nmod drug0"
            }
          4 : 
            {
              1 : "We observed 3 diabetic patients with intolerable dizziness followed by drug1 and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1015 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod NN nmod VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl neoplasia nmod spectrum nmod *adds* nsubj pattern nmod drug0"
            }
          4 : 
            {
              1 : "This unusual pattern of drug1 adds to the spectrum of uterine neoplasia associated with drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1016 : 
        {
          1 : "NN nmod NN nmod VBG dobj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *developing* dobj failure acl coupled nmod drug0"
            }
          4 : 
            {
              1 : "She died within six weeks of developing congestive heart failure coupled with drug1 due to haemosiderosis despite regular use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1017 : 
        {
          1 : "NN nmod VBN conj JJ nmod NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated conj *related* nmod chemotherapy acl containing dobj drug0"
            }
          4 : 
            {
              1 : "PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing drug1 and to be associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1018 : 
        {
          1 : "NN dobj VBG xcomp VBP advcl VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj bearing xcomp *suggest* advcl offers nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Although drug1 offers clinicians a combination of strong efficacy and good safety , we suggest bearing drug2 in mind when prescribing this drug , especially in frail , elderly patients with underlying chronic conditions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1019 : 
        {
          1 : "NN compound NN nmod NN dobj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod complication dobj *represents* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 represents a potential complication of chronic drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1020 : 
        {
          1 : "NN conj NNS nmod VB xcomp VBN acl NNS nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj phenothiazines nmod occur xcomp known acl *risks* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 and agranulocytosis are risks known to occur with phenothiazines and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1021 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl VBD advcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *showed* nsubj male acl:relcl remained advcl taking dobj drug0"
            }
          4 : 
            {
              1 : "Case 4 : A 61-year-old male alcoholic who remained completely abstinent while taking drug1 for 3 years showed slight drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1022 : 
        {
          1 : "NN compound NN nmod JJ amod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod related amod disability conj *drug0*"
            }
          4 : 
            {
              1 : "The potential for progressive drug1 and subsequent disability related to intraventricular drug2 therapy is discussed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1023 : 
        {
          1 : "NN nmod JJ root , punct NN dep NN root , root IN dep JJ dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod second root , punct methotrexate dep case root , root by dep related dep *drug0*"
            }
          4 : 
            {
              1 : "We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed drug1 and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered drug2 and cranial irradiation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1024 : 
        {
          1 : "NN nmod NN dobj VBN conj VBN ccomp VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use dobj discontinued conj *suspected* ccomp associated nmod drug0"
            }
          4 : 
            {
              1 : "It was highly suspected that finasteride was associated with the drug1 , and the patient therefore discontinued use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1025 : 
        {
          1 : "NN dobj VBG acl NN nmod VBN acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl mother nmod born acl infant nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We present the first case of drug1 in an infant born to a mother taking drug2 during her pregnancy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1026 : 
        {
          1 : "NN nmod VBD nsubj NN nmod NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *resulted* nsubj dose nmod sertraline conj levels compound drug0"
            }
          4 : 
            {
              1 : "In case 1 , a total daily dose of 25 mg sertraline , with nondetectable sertraline and drug1 blood levels , resulted in a drug2 with symptoms of toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1027 : 
        {
          1 : "NN nsubjpass VBN advcl JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass reported advcl *responsible* nsubj drug0"
            }
          4 : 
            {
              1 : "The clinical course suggests that drug1 , which is present in oolong tea , was mainly responsible for the rhabdomyolysis as well as the delirium , although severe drug2 has been reported to cause rhabdomyolysis on rare occasions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1028 : 
        {
          1 : "NN nmod NN nmod JJ amod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod secondary amod *hormone* conj drug0"
            }
          4 : 
            {
              1 : "A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound drug1 secondary to the administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1029 : 
        {
          1 : "NN conj NN nmod NN dobj VBG acl NN nmod VBD acl:relcl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj methotrexate nmod infusion dobj containing acl protocol nmod received acl:relcl girl nmod *reported* nsubjpass episode nmod drug0"
            }
          4 : 
            {
              1 : "An episode of drug1 is reported in a 13-year-old girl who , after standard radiotherapy for a posterior fossa medulloblastoma , received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 methotrexate and 12 mg intrathecal drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1030 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod resulting acl *drug0*"
            }
          4 : 
            {
              1 : "We report marked QT prolongation and torsades de pointes in a setting of drug1 resulting from acute myocardial ischemia in a patient who was being treated with drug2 for atrial fibrillation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1031 : 
        {
          1 : "NN compound NN nmod VBP dobj NNS acl:relcl VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound outcome nmod *describe* dobj patients acl:relcl developed dobj reaction compound drug0"
            }
          4 : 
            {
              1 : "We describe 2 patients with cutaneous lupus erythematosus who developed severe drug1 reaction after low dose therapy , with a drug2 outcome in one . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1032 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound t.i.d. dobj receiving acl woman nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "The authors describe a case of drug1 in a 48-year-old woman receiving drug2 ( 150 mg t.i.d. for 8 years ) and leading to surgical mitral valve replacement . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1033 : 
        {
          1 : "NN nmod NN nmod IN advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod infusion nmod during advcl *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was observed during and immediately after an infusion of drug2 in two patients with severe hepatic disease and moderate renal insufficiency . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1034 : 
        {
          1 : "NN xcomp VBG acl NN dobj VB nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp resembling acl condition dobj *induce* nsubj treatment nmod drugs nmod drug0"
            }
          4 : 
            {
              1 : "Moreover , treatment with immunosuppressive drugs such as drug1 , cisplatin , tacrolimus , and interferon-alpha can induce a condition resembling drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1035 : 
        {
          1 : "NN compound NN nmod NNS nsubjpass VBN advcl VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod patients nsubjpass *monitored* advcl avoid dobj drug0"
            }
          4 : 
            {
              1 : "However , in order to avoid drug1 , patients under drug2 therapy should be monitored every 6 months with nerve conduction studies while taking the drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1036 : 
        {
          1 : "NN nmod VBN nsubjpass NNP appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *involved* nsubjpass zolpidem appos drug0"
            }
          4 : 
            {
              1 : "Zolpidem ( drug1 ) , a relatively new nonbenzodiazepine sedative-hypnotic , was involved in the drug2 of a 39-year-old obese male who was being treated for depression and insomnia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1037 : 
        {
          1 : "NN nmod NN nsubj VBD dep NN dep WRB dep VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nsubj was dep dose dep when dep *leading* nmod drug0"
            }
          4 : 
            {
              1 : "The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 drug1 , when a higher dose than recommended was used , there was recent or concomitant treatment with drug2 , there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1038 : 
        {
          1 : "NN nmod VBN acl NN dobj VBD nsubj NNS nmod NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl hyperactivity dobj *demonstrated* nsubj studies nmod monitoring nmod levels compound drug0"
            }
          4 : 
            {
              1 : "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma drug1 levels demonstrated marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1039 : 
        {
          1 : "NN dobj VBD nsubj NNS nmod NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *demonstrated* nsubj studies nmod monitoring nmod levels compound drug0"
            }
          4 : 
            {
              1 : "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma drug1 levels demonstrated drug2 during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms , associated with painful dysesthesia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1040 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod NN acl:relcl VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound spray nmod use dep weeks nmod *woman* acl:relcl developed dobj throat conj drug0"
            }
          4 : 
            {
              1 : "We report a 43-year-old woman who developed sore throat , drug1 and dysphagia , 2 weeks after the use of drug2 spray ( Budefat ) for treatment of bronchial asthma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1041 : 
        {
          1 : "NN nmod NN nmod VBP dobj NNS nmod NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effect nmod *report* dobj cases nmod reactions appos drug0"
            }
          4 : 
            {
              1 : "The authors report two cases of acute dystonic reactions ( drug1 ) as a side effect of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1042 : 
        {
          1 : "NN compound NN nmod NNS nmod NN conj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod months nmod dyspnoea conj *patient* acl presented nmod drug0"
            }
          4 : 
            {
              1 : "A female patient with HER2 positive , metastatic breast cancer presented with drug1 , and a plural effusion dyspnoea after several months of drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1043 : 
        {
          1 : "NN conj NN nmod VBN acl:relcl NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj prednisolone nmod treated acl:relcl infant nmod *detected* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and drug2 for systemic lupus erythematosus ( SLE ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1044 : 
        {
          1 : "NN compound NN nmod VBG conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound intoxication nmod *broadening* conj drug0"
            }
          4 : 
            {
              1 : "We cared for a patient with progressive renal impairment who presented with blurred vision , QRS broadening and drug1 due to chronic drug2 intoxication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1045 : 
        {
          1 : "NN nmod NN nmod VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod resulting acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a fatal case of drug1 ( TEN ) resulting from a high dose of drug2 ( ARA-C ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1046 : 
        {
          1 : "NN conj JJ xcomp VBD conj VBD advcl VBN advcl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj tremulous xcomp became conj *began* advcl stopped advcl receiving dobj mg/d compound drug0"
            }
          4 : 
            {
              1 : "The day after clozapine was stopped , while he was still receiving drug1 150 mg/d , he began behaving oddly , started sweating profusely , shivering , and became tremulous , drug2 , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1047 : 
        {
          1 : "NN nmod JJ ccomp NN nmod JJ conj VB nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod responsible ccomp notion nmod consistent conj *result* nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "These observations indicate that submassive hepatic necrosis may result from treatment with drug1 and are consistent with the notion that sensitization mechanisms may be responsible for the drug2 induced by this drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1048 : 
        {
          1 : "NN nmod NN nmod NN dobj VBZ parataxis CD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod potential nmod evaluation dobj requires parataxis *one* nsubj use nmod drug0"
            }
          4 : 
            {
              1 : "Currently the use of drug1 is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1049 : 
        {
          1 : "NN nmod NNS nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses nmod subsequent amod *drug0*"
            }
          4 : 
            {
              1 : "drug1 subsequent to high doses of drug2 for chronic myeloid leukemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1050 : 
        {
          1 : "NN nmod VB dep VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod lead dep *added* nsubj drug0"
            }
          4 : 
            {
              1 : "In patients with chronic heart failure , drug1 added to conventional treatment may lead to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1051 : 
        {
          1 : "NN conj NN nmod NN nmod NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj phenylephrine nmod use nmod *specifics* nmod cases nmod drug0"
            }
          4 : 
            {
              1 : "We report the specifics of 12 cases of drug1 after the intraoperative use of topical phenylephrine , submucosal drug2 , or both . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1052 : 
        {
          1 : "NN dobj VBD acl:relcl NNS nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj received acl:relcl patients nmod developed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Observations in our patient suggest that the drug1 that developed in previously reported patients who received drug2 and levamisole may have been caused at least partly by levamisole . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1053 : 
        {
          1 : "NN compound NN nmod VB acl:relcl NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound toxicity nmod result acl:relcl *concentrations* compound drug0"
            }
          4 : 
            {
              1 : "The present report suggests that clarithromycin coadministration induces drug1 concentrations , which may result in drug2 toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1054 : 
        {
          1 : "NN nmod NN dobj VBG advcl JJ nmod NNS conj VBG compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use dobj stopping advcl *supportive* nmod symptoms conj resolving compound drug0"
            }
          4 : 
            {
              1 : "Treatment of ELP in children is generally supportive , with the symptoms and drug1 resolving within months after stopping the use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1055 : 
        {
          1 : "NN compound NN nmod VBN acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod induced acl:relcl *spectrum* nmod drug0"
            }
          4 : 
            {
              1 : "We believe that these skin eruptions belong to a spectrum of drug1 that can be induced or aggravated by drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1056 : 
        {
          1 : "NN nmod JJ acl:relcl NNS dobj VBD nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod fragile acl:relcl cells dobj *injured* nsubj toxicity compound drug0"
            }
          4 : 
            {
              1 : "We hypothesize that drug1 toxicity injured the muscle cells , which were fragile due to the drug2 induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1057 : 
        {
          1 : "NN compound NN nmod JJ nmod NN nmod NN nmod NNS nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *aware* nmod risk nmod aiha nmod patients nmod history nmod aiha conj drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or drug1 during previous drug2 administration , or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1058 : 
        {
          1 : "NN compound NNS nmod NNS nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound drops nmod *effects* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 , thickness , and pigmentation are well-documented side effects of drug2 analog glaucoma drops . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1059 : 
        {
          1 : "NN nmod VBN acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl:relcl *cases* nmod drug0"
            }
          4 : 
            {
              1 : "We report five cases of drug1 ( RLS ) and periodic limb movements during sleep ( PLMS ) that were probably associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1060 : 
        {
          1 : "NN conj NN nmod NNS nmod VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj viokase nmod challenges nmod *resulted* nmod drug0"
            }
          4 : 
            {
              1 : "METHODS : Double-blind , placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite drug1 within 1 to 1.5 hours after challenges with Viokase and drug2 , but not with placebo . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1061 : 
        {
          1 : "NN nmod NNS dobj VB nsubj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complications dobj *cause* nsubj injections compound drug0"
            }
          4 : 
            {
              1 : "However , repeated intracameral drug1 injections may cause unwanted complications such as drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1062 : 
        {
          1 : "NN nmod VBN advcl VBG advcl VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *considered* advcl deciding advcl warranted nsubjpass therapy compound drug0"
            }
          4 : 
            {
              1 : "In deciding if drug1 therapy is warranted , all potentially life-threatening adverse events associated with tamoxifen should be considered , including drug2 or uterine sarcoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1063 : 
        {
          1 : "NN nmod VBN acl NNS nmod VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod manifested acl changes nmod *describing* dobj relationship nmod drug0"
            }
          4 : 
            {
              1 : "The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of drug1 to metabolic changes manifested as drug2 and weight gain . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1064 : 
        {
          1 : "NN nmod VBN advcl VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated advcl *developed* dobj dysfunction compound drug0"
            }
          4 : 
            {
              1 : "A patient developed drug1 and hepatic dysfunction while being treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1065 : 
        {
          1 : "NN nmod NN nmod VB nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod destruction nmod *act* nmod drug0"
            }
          4 : 
            {
              1 : "The pathophysiological mechanisms remain unknown , although the drug could act through drug1 after destruction of CD20 positive cells by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1066 : 
        {
          1 : "NN nsubjpass VBN ccomp VBP acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass stopped ccomp point acl:relcl *recurrence* nmod drug0"
            }
          4 : 
            {
              1 : "The patient had recurrence of drug1 and angioedema a year and a half later , at which point the drug2 was stopped and she was desensitized to regular insulin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1067 : 
        {
          1 : "NN nsubj VBD dep NN nmod VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj occurred dep propylthiouracil nmod *given* dobj drug0"
            }
          4 : 
            {
              1 : "The patient was given drug1 instead of propylthiouracil but , 10 weeks later , drug2 again occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1068 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod VB xcomp VBZ conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl hus nmod appear xcomp seems conj *feature* nmod drug0"
            }
          4 : 
            {
              1 : "Pulmonary hemorrhage is an uncommon feature in the drug1 , and seems to appear especially in the HUS associated with drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1069 : 
        {
          1 : "NN dep DT dep IN nmod VBN acl:relcl NN nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep the dep with nmod associated acl:relcl *agent* nsubj c appos drug0"
            }
          4 : 
            {
              1 : "Mitomycin C ( drug1 ) is an alkylating agent that has been recently associated with the drug2 ( HUS ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1070 : 
        {
          1 : "NN nmod NNS nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod *develop* nsubj drug0"
            }
          4 : 
            {
              1 : "We suggest that drug1 may develop in chronic hepatitis C patients during drug2 and/or ribavirin treatment , and diagnostic tests for this adverse effect should be performed during the follow-ups . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1071 : 
        {
          1 : "NN nmod NNS dobj VB xcomp VBN conj VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod levels dobj have xcomp found conj *developed* dobj drug0"
            }
          4 : 
            {
              1 : "The patient developed drug1 and was found to have extremely elevated levels of drug2 in his blood and dialysis fluid . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1072 : 
        {
          1 : "NN nsubj VBD advcl VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj developed advcl *given* nsubjpass chemotherapeutics nmod drug0"
            }
          4 : 
            {
              1 : "The chemotherapeutics , including drug1 , actinomycin D , and epirubicin in case 1 and vincristine and actinomycin D in case 2 , were given before the drug2 developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1073 : 
        {
          1 : "NN nmod VBD ccomp VBD nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consisted ccomp *developed* nsubj reaction compound drug0"
            }
          4 : 
            {
              1 : "A child in whom a drug1 hypersensitivity drug reaction developed which consisted of drug2 , a pruritic desquamating erythrodermic rash , alopecia , icterus , protein-losing enteropathy , myositis , and nephritis , is described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1074 : 
        {
          1 : "NN nmod VBG advcl VBN conj VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod switching advcl cured conj *suffering* nmod drug0"
            }
          4 : 
            {
              1 : "The third patient had been suffering from serious drug1 while on risperidone , and was cured after switching to drug2 , but thereafter the patient suffered from RLS at nighttime . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1075 : 
        {
          1 : "NN root , punct RB dep NN dobj VBD dep VBD advcl VBN advcl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct profusely dep sweating dobj started dep *began* advcl stopped advcl receiving dobj mg/d compound drug0"
            }
          4 : 
            {
              1 : "The day after clozapine was stopped , while he was still receiving drug1 150 mg/d , he began behaving oddly , started sweating profusely , drug2 , and became tremulous , agitated , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1076 : 
        {
          1 : "NN compound NN nmod NNS acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound myopathy nmod features acl:relcl *variation* nmod size conj drug0"
            }
          4 : 
            {
              1 : "Muscle biopsy revealed variation in muscle fiber size and few drug1 which were features of drug2 myopathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1077 : 
        {
          1 : "NN compound NN nmod NNS conj NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound monotherapy nmod months conj months nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Two of our patients developed drug1 after 23 months and 34 months of drug2 monotherapy , respectively . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1078 : 
        {
          1 : "NN compound NNS nmod VB xcomp VBD conj VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound levels nmod produce xcomp failed conj *added* nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Sodium phenylbutyrate was added to treatment with drug1 in two patients , but failed to produce an increase in total Hb despite drug2 levels . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1079 : 
        {
          1 : "NN dobj VBD acl NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induced acl *patients* conj drug0"
            }
          4 : 
            {
              1 : "Atrial fibrillation was induced by diltiazem in two patients and drug1 induced drug2 in one patient . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1080 : 
        {
          1 : "NN nmod NN dobj VBG acl NN nmod VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment dobj receiving acl patient nmod *confirmed* dobj occurrence nmod drug0"
            }
          4 : 
            {
              1 : "We report the first biopsy confirmed occurrence of drug1 in a patient receiving treatment with drug2 for metastatic renal cell cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1081 : 
        {
          1 : "NN dobj VB xcomp VBD conj VBN dobj NN acl VBG nmod NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj develop xcomp went conj *manifested* dobj evidence acl impending nmod completion nmod infusion nmod methotrexate appos drug0"
            }
          4 : 
            {
              1 : "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate ( drug1 ) ( 12 g/m2 ) , and went on to develop drug2 with life-threatening hyperkalemia 29 hours later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1082 : 
        {
          1 : "NN nmod NN dobj VB acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod tincture dobj compound acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 to compound tincture of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1083 : 
        {
          1 : "NN compound NN nmod VBP dobj NN nmod JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod *present* dobj patient nmod severe conj drug0"
            }
          4 : 
            {
              1 : "Herein , we present a patient with severe and drug1 after long-acting drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1084 : 
        {
          1 : "NN nmod NN appos NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cross-reaction appos *reaction* compound drug0"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken mequitazine for 6 months , and there were strong positive photopatch test results with immediate drug1 reaction , cross-reaction to drug2 , decreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1085 : 
        {
          1 : "NN conj JJ nmod NN dobj VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj diuretic nmod combination dobj taking advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Two patients developed drug1 when taking a combination of a thiazide diuretic and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1086 : 
        {
          1 : "NN conj NN dobj VBG advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj aspirin dobj receiving advcl *admitted* nmod drug0"
            }
          4 : 
            {
              1 : "A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for drug1 while receiving aspirin and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1087 : 
        {
          1 : "NN dobj VBG acl NN nmod NN nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl man nmod ischemia nmod secondary amod *drug0*"
            }
          4 : 
            {
              1 : "Marked QT prolongation and drug1 secondary to acute ischemia in an elderly man taking drug2 for atrial fibrillation : a cautionary tale . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1088 : 
        {
          1 : "NN nmod NN nmod VBD nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *developed* nmod sensation nmod vibration conj drug0"
            }
          4 : 
            {
              1 : "Case 1 , a 62-year-old woman , developed bilateral optic neuritis with decreased sensation of vibration and drug1 in the lower extremities after a seven-month use of drug2 for chronic active hepatitis C . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1089 : 
        {
          1 : "NN nsubjpass VBN dep VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass discontinued dep *resolved* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 resolved once drug2 was discontinued and serum transaminases returned to baseline normal values . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1090 : 
        {
          1 : "NN compound NN nmod NN nmod JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod result nmod *evident* nsubj drug0"
            }
          4 : 
            {
              1 : "In each of the three reported patients , drug1 with deepening of the lid sulcus was evident as the result of topical drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1091 : 
        {
          1 : "NN compound NN nmod VBN acl NNS dobj VBD conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound relapse nmod followed acl phases dobj developed conj *prescribed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "We have described three patients with hepatitis C for whom drug1 and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by drug2 relapse due to Graves ' disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1092 : 
        {
          1 : "NN nmod VBD nmod:tmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *complained* nmod:tmod day nmod administration compound drug0"
            }
          4 : 
            {
              1 : "The day after drug1 administration , the patient complained of drug2 and urinary retention . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1093 : 
        {
          1 : "NN dobj VBG acl NNS nmod NNS nmod NN nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl patients nmod reactions nmod part nmod *occur* nsubj drug0"
            }
          4 : 
            {
              1 : "This case illustrates that the drug1 associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1094 : 
        {
          1 : "NN compound NNS nmod NN dep CD nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound patients nmod % dep 0.0 nmod *encountered* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 has been encountered from 0.2 to 61.7 % in drug2 patients , mostly with a transient course and spontaneous remission . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1095 : 
        {
          1 : "NN compound NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod expression nmod detected acl induction nmod *accompanied* nsubjpass drug0"
            }
          4 : 
            {
              1 : "The drug1 was accompanied by a massive induction of lesional type I interferon activity , detected by MxA expression after drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1096 : 
        {
          1 : "NN nmod NN nmod VBD dobj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *developed* dobj neuritis acl combined nmod drug0"
            }
          4 : 
            {
              1 : "Case 2 , a 29-year-old woman , developed bilateral optic neuritis combined with drug1 as well as bowel and bladder dysfunction after a 22-month use of drug2 for chronic myelogenous leukemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1097 : 
        {
          1 : "NN nmod NN nmod NNS root , punct JJ amod DT root IN dep CD nmod VBG nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod effects root , punct unpredictable amod the root of dep one nmod *emerging* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is emerging as one of the most unpredictable and potentially serious , adverse effects of treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1098 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN acl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod initiation nmod *suspected* nsubjpass immunosuppression acl elicited nmod administration nmod drug0"
            }
          4 : 
            {
              1 : "Immunosuppression elicited by the extensive administration of drug1 was suspected for the initiation of the generalized drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1099 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj citalopram nmod co-administration nmod associated acl *reaction* nsubj drug0"
            }
          4 : 
            {
              1 : "Based on the Naranjo probability scale , drug1 was a probable adverse reaction associated with co-administration of citalopram and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1100 : 
        {
          1 : "NN conj NN dobj VBD dep NNS dep VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj loss dobj *developed* dep days dep receiving dobj injection nmod drug0"
            }
          4 : 
            {
              1 : "Three days after receiving intravitreal injection of drug1 ( 1.25 mg in 0.1 ml ) , he developed acute vision loss and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1101 : 
        {
          1 : "NN dobj VB nsubj NN acl:relcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *explain* nsubj hyperproduction acl:relcl induced nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : In our reported case , a local hyperproduction of TNF-alpha from macrophages that was induced by the injected drug1 could explain the drug2 of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1102 : 
        {
          1 : "NN nmod VBD advmod RB"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *developed* advmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report the case of a young woman with Graves ' disease in whom drug1 developed because of drug2 ( PTU ) - induced antineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1103 : 
        {
          1 : "NN nmod NN nmod VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod favor nmod *argues* nsubj association nmod drug0"
            }
          4 : 
            {
              1 : "We believe the temporal association of the drug1 in this patient , in the absence of other offending agents , argues strongly in favor of drug2 as a cause of liver enzyme abnormalities . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1104 : 
        {
          1 : "NN nmod NNS conj CD conj NNS nsubj NN nmod NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses conj 0.0 conj *months* nsubj time nmod initiation conj onset nmod drug0"
            }
          4 : 
            {
              1 : "Mean time between initiation of gemcitabine therapy and onset of drug1 was 7.4 + / - 3.5 months , or 21.9 + / - 10.9 doses of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1105 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD nsubj NN acl VBG nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod substitution nmod admission nmod *ended* nsubj reaction acl resulting nmod trauma conj drug0"
            }
          4 : 
            {
              1 : "In one instance a systemic hypoglycemic reaction resulting in head trauma and drug1 ended in an emegency hospital admission following the substitution of drug2 for acetazolamide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1106 : 
        {
          1 : "NN nmod VBG xcomp VB"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod manifesting xcomp *drug0*"
            }
          4 : 
            {
              1 : "Allergic reaction to drug1 manifesting as drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1107 : 
        {
          1 : "NN nmod VBG acl NN nmod VBG acl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulting acl toxicity nmod resulting acl *ingestion* compound drug0"
            }
          4 : 
            {
              1 : "We report an unusual case of massive drug1 ingestion resulting in neurological and cardiovascular toxicity resulting in drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1108 : 
        {
          1 : "NN dobj VB xcomp JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj avoid xcomp *necessary* nsubj adjustment nmod drug0"
            }
          4 : 
            {
              1 : "It is increasingly recognized that dose adjustment of oral drug1 in renal failure is necessary to avoid drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1109 : 
        {
          1 : "NN conj NN nmod VBG xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj decrease nmod resulting xcomp *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "IV drug1 was used as the initial treatment for his hyperadrenergic state , resulting in a decrease in heart rate but a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1110 : 
        {
          1 : "NN nmod NN nmod VBG dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod occurring dep *case* nmod drug0"
            }
          4 : 
            {
              1 : "Only one case of drug1 occurring after pulse therapy with drug2 for onychomycosis and requiring transplantation has been reported previously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1111 : 
        {
          1 : "NN compound NN nmod VBG advcl VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound product nmod switching advcl *experienced* dobj symptoms nmod drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with drug1 ( TSH ) concentrations after switching from 1 drug2 product to another . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1112 : 
        {
          1 : "NN nmod IN advmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod while advmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Both patients developed drug1 while on drug2 and apparently adequate dexamethasone replacement therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1113 : 
        {
          1 : "NN compound NN nmod JJ amod NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod secondary amod *boy* acl:relcl had dobj drug0"
            }
          4 : 
            {
              1 : "We report a 5-year-old boy with CF who had a drug1 due to submucosal fibrosis of the transverse colon , secondary to drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1114 : 
        {
          1 : "NN conj NN conj NN nmod VBN nsubjpass NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj sepsis conj reaction nmod *evaluated* nsubjpass patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "Patients receiving drug1 who develop only fever should be evaluated for an adverse drug reaction , as well as for sepsis and drug2 , and it may be necessary to discontinue the drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1115 : 
        {
          1 : "NN nmod VB acl:relcl NNS dobj VBZ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod result acl:relcl concentrations dobj *induces* nsubj coadministration compound drug0"
            }
          4 : 
            {
              1 : "The present report suggests that drug1 coadministration induces increased plasma carbamazepine concentrations , which may result in drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1116 : 
        {
          1 : "NN compound NN nsubjpass VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nsubjpass begun advcl *experienced* dobj drug0"
            }
          4 : 
            {
              1 : "Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex drug1 and altered mental status after drug2 treatment was begun or its dosage increased . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1117 : 
        {
          1 : "NN appos JJ nmod NNS dobj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos antibiotic nmod effects dobj *recognized* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1118 : 
        {
          1 : "NN conj NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fluoxetine nmod *itch* conj drug0"
            }
          4 : 
            {
              1 : "Itch and drug1 from chocolate during fluoxetine and drug2 treatment : case report . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1119 : 
        {
          1 : "NN dobj VBG advcl VBN conj VBD nsubj NN acl:relcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj having advcl diagnosed conj *developed* nsubj woman acl:relcl received dobj dose nmod drug0"
            }
          4 : 
            {
              1 : "A 59-year-old woman with myasthenia gravis who received a large dose of drug1 developed postoperative psychosis and was diagnosed as having drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1120 : 
        {
          1 : "NN nmod NN dobj VBD acl:relcl NNS nmod NN dobj VBG advcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod recall dobj developed acl:relcl patients nmod number dobj bringing advcl *manifestation* nmod drug0"
            }
          4 : 
            {
              1 : "The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of drug1 , thereby bringing the number of patients who developed radiation recall to drug2 and were discussed in the current study to 13 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1121 : 
        {
          1 : "NN compound NN conj NN nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy conj aspirin nmod *complication* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a serious complication of aspirin and drug2 ( dual ) anti-platelet therapy with a high morbidity and mortality . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1122 : 
        {
          1 : "NN compound NNS dobj VBG acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound prophylaxis dobj receiving acl patient nmod meningioma nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 from a meningioma in a patient receiving drug2 prophylaxis : a case report . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1123 : 
        {
          1 : "NN nmod NN nmod VBD xcomp VB nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *began* xcomp suffer nmod rash conj drug0"
            }
          4 : 
            {
              1 : "A 10-year-old asthmatic boy began to suffer from urticarial rash and drug1 after 8 weeks ' treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1124 : 
        {
          1 : "NN compound NN nmod NN nmod NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod withdrawal nmod *patient* acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "The authors present an elderly patient with mixed dementia who developed drug1 at multiple sites , ( including respiratory dyskinesia [ RD ] , limb dyskinesia , and orofacial dyskinesia ) following abrupt withdrawal of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1125 : 
        {
          1 : "NN nmod VBD conj NN dobj VBD nsubj CD nmod NNS acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod died conj hypertension dobj *had* nsubj one nmod subjects acl:relcl using dobj drug0"
            }
          4 : 
            {
              1 : "One of the subjects who was using extemporaneous topical drug1 had hypertension and arteriosclerotic disease and the other died of a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1126 : 
        {
          1 : "NN compound NN dobj VBG dep NNS nmod VBG dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj starting dep months nmod *rippling* dobj disease appos drug0"
            }
          4 : 
            {
              1 : "We report a 53-year-old-man who developed rippling muscle disease ( drug1 ) 2 months after starting drug2 therapy for hypercholesterolemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1127 : 
        {
          1 : "NN nmod NNS dep NNS nmod VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod features dep years nmod *treated* nmod doses nmod drug0"
            }
          4 : 
            {
              1 : "A patient who had been treated with large doses of drug1 for several years developed features of secondary drug2 after thyroid hormone withdrawal . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1128 : 
        {
          1 : "NN nmod VB nsubj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *appear* nsubj reactions compound drug0"
            }
          4 : 
            {
              1 : "Serious drug1 hypersensitivity reactions may appear as drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1129 : 
        {
          1 : "NN xcomp VBD nsubj NN acl:relcl VBN dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp *became* nsubj patient acl:relcl consumed dobj quantities nmod drug0"
            }
          4 : 
            {
              1 : "A 36-y-o patient with schizophrenia , who had consumed gradually increasing quantities of drug1 that eventually reached 15 L each day , became drug2 and was admitted to a psychiatric hospital . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1130 : 
        {
          1 : "NN nmod VBN acl JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod induced acl *cardiovascular* conj drug0"
            }
          4 : 
            {
              1 : "We report here a case of cardiovascular and drug1 induced by drug2 in a toddler . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1131 : 
        {
          1 : "NN conj NN nmod NN dobj VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj diamorphine nmod solution dobj injected acl *drug0*"
            }
          4 : 
            {
              1 : "A patient presented with a drug1 having injected a solution of diamorphine and drug2 into his radial artery . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1132 : 
        {
          1 : "NN conj NN nmod NNS nmod VBN advcl VB nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj subacute nmod patients nmod reported advcl *develop* nmod patients nmod thyroiditis compound drug0"
            }
          4 : 
            {
              1 : "These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with drug1 destructive thyroiditis , as reported in patients with destructive thyroiditis , such as subacute and silent drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1133 : 
        {
          1 : "NN nmod NN nmod JJ amod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod due amod patients nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in hepatitis C patients due to combination therapy with drug2 and ribavirin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1134 : 
        {
          1 : "NN nmod VBG acl NNS dep CD nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod undergoing acl patients dep one nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 were observed in one out of 23 patients undergoing chemotherapy with high-dose drug2 ( HD-MTX ) for osteogenic sarcoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1135 : 
        {
          1 : "NN compound NN nmod VBZ conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod occurs conj *factor* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a predisposing factor for premature ductal closure and often occurs after maternal drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1136 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *developed* nsubj blindness conj drug0"
            }
          4 : 
            {
              1 : "Total blindness with a transient tonic pupillary response , denervation supersensitivity , and drug1 developed in a 54-year-old man after the use of drug2 for leg cramps . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1137 : 
        {
          1 : "NN nsubj NN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj factor acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We present a case of drug1 in which drug2 might presumably be the aetiological factor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1138 : 
        {
          1 : "NN nmod NN dep NN nmod VBD nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose dep week nmod *followed* nmod dyspnea conj drug0"
            }
          4 : 
            {
              1 : "A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and drug1 which worsened when patient was lying flat , 1 week after the fourth dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1139 : 
        {
          1 : "NN nmod VBP nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *consist* nsubj effects nmod drug0"
            }
          4 : 
            {
              1 : "DISCUSSION : The main adverse effects of drug1 consist of drug2 , nausea , liver enzyme elevation , hypertension , alopecia , and allergic skin reactions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1140 : 
        {
          1 : "NN compound NN dep RB advmod VBD acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dep after advmod occurred acl:relcl *cases* nmod drug0"
            }
          4 : 
            {
              1 : "We describe two cases of drug1 that occurred after long term drug2 therapy for ulcerative colitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1141 : 
        {
          1 : "NN nmod JJ nmod NN nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod rare nmod *cause* nsubj vincristine conj drug0"
            }
          4 : 
            {
              1 : "We conclude that vincristine and drug1 were the cause of this rare from of drug2 and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1142 : 
        {
          1 : "VB xcomp JJ amod NN nmod VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp due amod neuropathy nmod *associated* nsubjpass therapy compound drug0"
            }
          4 : 
            {
              1 : "We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis , respectively , in whom drug1 therapy was associated with peripheral neuropathy due to drug2 in one patient and to progression of preexisting mononeuritis multiplex in the other . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1143 : 
        {
          1 : "NN conj NN nmod NNS nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj marijuana nmod effects nmod resulting acl *drug0*"
            }
          4 : 
            {
              1 : "Marked drug1 resulting from the synergistic effects of marijuana and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1144 : 
        {
          1 : "NN dobj VBD conj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *stopped* nsubj patient nmod drug0"
            }
          4 : 
            {
              1 : "One other patient on drug1 stopped taking it and developed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1145 : 
        {
          1 : "NN nmod VBN conj VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated conj *developed* dobj skin conj drug0"
            }
          4 : 
            {
              1 : "We describe a relatively healthy , 9-year-old boy who developed a CA-MRSA skin and drug1 and was treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1146 : 
        {
          1 : "NN dobj VBG conj VBP dobj NN nmod NN nmod NN acl VBG nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj simulating conj *report* dobj case nmod patient nmod carcinoma acl presenting nmod chemotherapy nmod docetaxel conj drug0"
            }
          4 : 
            {
              1 : "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and drug1 producing severe respiratory insufficiency , and simulating a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1147 : 
        {
          1 : "NN dep VBP nsubj NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep *have* nsubj patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving drug1 have unusual symptoms , particularly drug2 , rash , and lymphadenopathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1148 : 
        {
          1 : "NN nmod NN dep NNS nmod JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod withdrawal dep years nmod *present* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 is still present 3 years after the withdrawal of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1149 : 
        {
          1 : "NN nmod NN dep NNS nmod VBD dobj NN conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose dep hours nmod *developed* dobj rash conj itching conj drug0"
            }
          4 : 
            {
              1 : "She developed a generalized rash and itching , drug1 , and dizziness approximately 4 hours after the first dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1150 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBG xcomp VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod hospital nmod admissions nmod resulting xcomp *treated* nmod drug0"
            }
          4 : 
            {
              1 : "This article presents a patient with hypoparathyroidism who was treated with drug1 and calcitriol resulting in two admissions to the hospital for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1151 : 
        {
          1 : "NN nsubjpass VBN ccomp VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass determined ccomp *excluded* nmod causes nmod drug0"
            }
          4 : 
            {
              1 : "After other potential causes of drug1 were excluded , drug2 was determined to be the cause of his acute liver toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1152 : 
        {
          1 : "NN conj NN nmod VBN advcl VBG acl NNS nmod VB dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj sertraline nmod coadministered advcl occurring acl disorders nmod *report* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report 2 cases of drug1 with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1153 : 
        {
          1 : "NN compound NN nmod NN nmod NNS nmod:tmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound mg nmod addition nmod months nmod:tmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed in two epileptic patients some months after the addition of oral drug2 750 mg daily to the phenobarbital and phenytoin already being administered . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1154 : 
        {
          1 : "NN nmod NN nmod VBN conj JJ nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod indicated conj *paramount* nsubj knowledge nmod effects nmod drug0"
            }
          4 : 
            {
              1 : "Knowledge regarding potential adverse effects of drug1 is paramount and dose modification is indicated with development of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1155 : 
        {
          1 : "NN nmod NN dobj VB ccomp JJ amod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod risk dobj increase ccomp antibiotic amod *macrolide* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a macrolide antibiotic that may increase the risk of lovastatin-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1156 : 
        {
          1 : "NN compound NN nmod JJ amod NN dobj VBZ nsubj NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod secondary amod change dobj *suggests* nsubj development nmod leukemia conj drug0"
            }
          4 : 
            {
              1 : "The development of erythroid leukemia plus drug1 in these two men suggests mutagenic change secondary to drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1157 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj actinomycin-d nmod exacerbated acl adriamycin nmod courses nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 after widely separated courses of adriamycin exacerbated by actinomycin-D and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1158 : 
        {
          1 : "NN xcomp VBD dep VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp thought dep *admitted* nmod failure conj drug0"
            }
          4 : 
            {
              1 : "Four months after receiving an orthotopic liver transplant , a 51-year-old man was admitted for progressive liver failure and drug1 thought to be due to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1159 : 
        {
          1 : "NN conj NNP nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj efalizumab nmod patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "A case of drug1 in a patient on Efalizumab and drug2 for treatment of refractory palmopustular psoriasis and psoriatic arthritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1160 : 
        {
          1 : "NN conj NN nmod VBG advcl VBN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hypercalciuria nmod resulting advcl *treated* nmod ointment compound drug0"
            }
          4 : 
            {
              1 : "We experienced a male patient with psoriasis and hypertension whose conditions were treated with drug1 ointment and thiazide , respectively , resulting in hypercalciuria and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1161 : 
        {
          1 : "NN nsubj VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj appeared acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Twenty-four hours after the administration of drug1 , a drug2 appeared on his trunk and upper limbs . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1162 : 
        {
          1 : "NN compound NN dobj VBG advcl VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj initiating advcl *avoid* dobj drug0"
            }
          4 : 
            {
              1 : "In view of our experience in the present case , it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid drug1 after initiating drug2 therapy regardless of the dosage . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1163 : 
        {
          1 : "NN dobj VBD conj VBD acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj mimicked conj caused acl:relcl *interaction* nmod propafenone conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This is the first report of a possible interaction between propafenone and drug1 , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1164 : 
        {
          1 : "NN dobj VBN dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj reported dep *cases* nmod drug0"
            }
          4 : 
            {
              1 : "CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in drug1 ( CS ) - treated patients are reported : an isolated drug2 in a farmer treated with CS for asthma , a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis , and a visceral involvement after cutaneous leishmaniasis in a man receiving CS . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1165 : 
        {
          1 : "NN nmod NN nsubj VBZ advcl VBP dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod exposure nsubj *appears* advcl induce dobj drug0"
            }
          4 : 
            {
              1 : "Although other nitrites induce drug1 , exposure to drug2 during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1166 : 
        {
          1 : "NN dobj VBG acl:relcl NNS nmod VBD acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl:relcl patients nmod occurred acl:relcl *cases* nmod drug0"
            }
          4 : 
            {
              1 : "The case resembles two previously reported cases of drug1 which occurred in patients with Wilson 's disease who were receiving drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1167 : 
        {
          1 : "NN compound NN nmod NN acl VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *coagulation* acl associated nmod hemoglobinemia conj drug0"
            }
          4 : 
            {
              1 : "Disseminated intravascular coagulation associated with acute hemoglobinemia or drug1 following drug2 intravenous administration for immune thrombocytopenic purpura . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1168 : 
        {
          1 : "NN dobj VB acl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induce acl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 was the third drug to induce drug2 in this patient ; she received 200 mg/day six days per week for six months . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1169 : 
        {
          1 : "NN conj JJ nmod NN nmod NN nmod VBD nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pentobarbital nmod combination nmod administration nmod *developed* nsubj encephalopathy conj drug0"
            }
          4 : 
            {
              1 : "A toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and drug1 developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of pentobarbital and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1170 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod caused acl immunodeficiency nmod *disorder* appos drug0"
            }
          4 : 
            {
              1 : "She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder ( drug1 ) due to immunodeficiency caused by drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1171 : 
        {
          1 : "NN dobj VB nsubj NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *control* nsubj desensitization conj desensitization compound drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin , as well as standard drug1 desensitization , could control drug2 in a patient allergic to both NPH and regular insulin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1172 : 
        {
          1 : "VB amod NN nmod JJ amod NN nmod CD conj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 amod administration nmod related amod sjs nmod one conj *cases* nmod drug0"
            }
          4 : 
            {
              1 : "To date , eight cases of drug1 and one of SJS related to drug2 administration have been reported in the literature . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1173 : 
        {
          1 : "NN dobj VBD nsubj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *included* nsubj effects compound drug0"
            }
          4 : 
            {
              1 : "drug1 side effects included drug2 , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1174 : 
        {
          1 : "NN conj NN dobj VBG xcomp VBD nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj distress dobj worsening xcomp *developed* nsubj man acl treated nmod drug0"
            }
          4 : 
            {
              1 : "A 49-year-old man with Crohn 's disease treated with drug1 and mesalamine ( 5-ASA ) developed worsening respiratory distress and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1175 : 
        {
          1 : "NN nmod VBN acl JJ amod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl recipient amod transplant nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 and thrombosis of the central retinal vein in a renal transplant recipient treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1176 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl NNS conj VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cessation nmod normalized acl:relcl patients conj *given* nsubjpass depression compound drug0"
            }
          4 : 
            {
              1 : "Six patients developed drug1 and five patients bone marrow depression , blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1177 : 
        {
          1 : "NN compound NN dep NNS nmod VBD acl:relcl NN dobj VBG advcl VBD advmod RB"
          2 : 1
          3 : 
            {
              1 : "drug0 compound discontinuation dep months nmod persisted acl:relcl therapy dobj starting advcl *developed* advmod drug0"
            }
          4 : 
            {
              1 : "In addition , a 31-year-old man with obsessive-compulsive disorder developed drug1 soon after starting fluoxetine therapy , which persisted at PSG study 19 months after drug2 discontinuation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1178 : 
        {
          1 : "NN conj JJ conj VBD nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj erythematous conj *had* nsubj patient acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "A patient receiving drug1 for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash , pain and erythema of the cartilage of both ears , and tender erythematous and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1179 : 
        {
          1 : "NN nmod NN nmod VBG nmod NN nmod NNS conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *walking* nmod pain nmod extremities conj days compound drug0"
            }
          4 : 
            {
              1 : "We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and drug1 25 days after treatment with weekly drug2 ( 80 mg/m ( 2 ) x3 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1180 : 
        {
          1 : "NN nmod NNS nmod NNS dep NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses nmod *reactions* dep diarrhea appos drug0"
            }
          4 : 
            {
              1 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for 5-FU catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , diarrhea , stomatitis , mucositis , myelosuppression , drug1 ) to standard doses of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1181 : 
        {
          1 : "NN dobj VBD conj VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj started conj *began* advcl stopped nsubjpass drug0"
            }
          4 : 
            {
              1 : "The day after drug1 was stopped , while he was still receiving clomipramine 150 mg/d , he began behaving oddly , started drug2 , shivering , and became tremulous , agitated , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1182 : 
        {
          1 : "NN nmod NN dobj VBZ acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation dobj necessitates acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "It carries a well-known risk of drug1 and agranulocytosis , which necessitates the immediate discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1183 : 
        {
          1 : "NN compound NNS dobj VB parataxis NN nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound symptoms dobj reverse parataxis *care* nsubj treatment nmod patients nmod drug0"
            }
          4 : 
            {
              1 : "The principle treatment for DPD-deficient patients with drug1 is supportive care ; however , the administration of thymidine potentially may reverse severe drug2 neurologic symptoms such as encephalopathy and coma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1184 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBN xcomp VB"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *had* nsubj man acl exposed xcomp drug0"
            }
          4 : 
            {
              1 : "A healthy , 30-year-old man , exposed to drug1 on two separate occasions , had an incapacitating drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1185 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod NN nmod VBN parataxis JJR nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound syndrome nmod referred acl complex nmod incidence nmod associated parataxis *less* nsubj drug0"
            }
          4 : 
            {
              1 : "Its overall drug1 is considerably less compared to standard induction chemotherapy ; however , it is associated with a high incidence of a potentially fatal symptom complex referred to as `` drug2 syndrome . '' This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1186 : 
        {
          1 : "NN nmod NN nsubj NNS nmod NNS acl VBN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *factor* nsubj antibodies nmod antigens acl induced nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "These findings are consistent with an immune-complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits , and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by drug1 therapy may be a causative factor in the drug2 associated with gold therapy in rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1187 : 
        {
          1 : "NN compound NN dobj VBP acl:relcl DT dep NNS acl VBG dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound need dobj experience acl:relcl those dep *patients* acl taking dobj doses nmod drug0"
            }
          4 : 
            {
              1 : "The authors conclude that among patients taking high doses of oral drug1 only those who experience drug2 need to be ophthalmologically evaluated . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1188 : 
        {
          1 : "NN nmod IN dep VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod while dep *developed* dobj erythema conj drug0"
            }
          4 : 
            {
              1 : "We report the case of a 60-year-old woman who developed erythema and drug1 while on drug2 for breast cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1189 : 
        {
          1 : "NN nmod NN nmod NN acl:relcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *case* acl:relcl occurred nsubj drug0"
            }
          4 : 
            {
              1 : "We report a case in which drug1 occurred in an asymptomatic falx meningioma known beforehand , after the internal use of low-dose drug2 for 16 months . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1190 : 
        {
          1 : "NN nmod NN nsubjpass VBN conj VBN xcomp VB nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nsubjpass described conj *known* xcomp occur nmod association nmod drug0"
            }
          4 : 
            {
              1 : "A variety of movement disorders are known to occur in association with drug1 ( CBZ ) therapy in adults and children , but development of drug2 has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1191 : 
        {
          1 : "NN compound NN nmod NNS dobj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod effects dobj *reported* nsubjpass drug0"
            }
          4 : 
            {
              1 : "The drug1 and ruptured epidermoid cysts are newly reported adverse effects of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1192 : 
        {
          1 : "NN appos NN dobj VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos cyclophosphamide dobj received acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "This case report describes an adolescent with drug1 who received cyclophosphamide ( drug2 ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1193 : 
        {
          1 : "NN appos NNS compound NN conj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos symptoms compound syndrome conj eosinophilia nmod *nephritis* compound drug0"
            }
          4 : 
            {
              1 : "drug1 acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( drug2 ) syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1194 : 
        {
          1 : "NN conj NNS nmod NN nmod NN conj NN nmod NN dobj VBD dep VBN advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj legs nmod dysesthesia nmod worsening conj arm nmod weakness dobj developed dep *resolved* advcl changed nmod drug0"
            }
          4 : 
            {
              1 : "When SASP was changed to drug1 ( 5-ASA ) , his skin eruptions were resolved , however , he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1195 : 
        {
          1 : "NN nmod VBG xcomp VBN nsubjpass NNS acl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod leading xcomp *warned* nsubjpass patients acl prescribed nsubjpass drug0"
            }
          4 : 
            {
              1 : "Elderly patients for whom drug1 has been prescribed should be warned of the occurrence of hypotension , leading to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1196 : 
        {
          1 : "NN dobj VBD advcl VBN advcl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *began* advcl stopped advcl receiving dobj mg/d compound drug0"
            }
          4 : 
            {
              1 : "The day after clozapine was stopped , while he was still receiving drug1 150 mg/d , he began drug2 , started sweating profusely , shivering , and became tremulous , agitated , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1197 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NN nsubj NNP acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod association nmod banned acl:relcl *drug* nsubj dipyrone acl known nmod drug0"
            }
          4 : 
            {
              1 : "Dipyrone , also known as drug1 , is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1198 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl NNS nmod VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod relapse nmod resulted acl:relcl courses nmod *treated* nmod alternative nmod drug0"
            }
          4 : 
            {
              1 : "Both patients were then treated with a carboplatin alternative to drug1 in the following courses , which resulted in neither a relapse of the drug2 nor a recurrence of the malignancies up to this time . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1199 : 
        {
          1 : "NN appos NN nmod NN dobj VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos interferon-alpha nmod course dobj paralleling acl *drug0*"
            }
          4 : 
            {
              1 : "A patient developed drug1 paralleling the course of interferon-alpha ( drug2 ) therapy for chronic hepatitis C . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1200 : 
        {
          1 : "NN dobj VBG advcl VBN conj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj withholding advcl healed conj *respond* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 did not respond to antibiotic treatment and healed shortly after withholding drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1201 : 
        {
          1 : "NN nmod VBD acl:relcl NN nmod NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulted acl:relcl *case* nmod overdose nmod tablets compound drug0"
            }
          4 : 
            {
              1 : "We report a case of unintentional overdose of oral drug1 tablets that resulted in drug2 , mild hypotension , and muscarinic symptoms in a patient with Sjogren 's syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1202 : 
        {
          1 : "NN nmod NN nmod NN nmod NNS nmod VBN acl:relcl NN nmod NN nmod VB dobj NN amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dosing nmod reinstitution nmod hours nmod resolved acl:relcl infection nmod evidence nmod *have* dobj instability amod drug0"
            }
          4 : 
            {
              1 : "The patient continued to have drug1 and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1203 : 
        {
          1 : "NN nmod NN nmod JJ acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod related acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "The authors describe drug1 , which is related to the use of low-dose drug2 in a patient with essential thrombocythemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1204 : 
        {
          1 : "NN nsubjpass VBN advcl VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass reported advcl considered conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is frequently used in the treatment of tuberculosis , and , although drug2 have been reported with the use of ethambutol , this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1205 : 
        {
          1 : "NN conj NN nmod VBD nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj vision nmod *complained* nsubj patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Three of 50 patients treated with drug1 ( 1 mg/kg/day ) for cystic acne complained of poor night vision and/or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1206 : 
        {
          1 : "NN appos NN nmod NN nmod NN nmod VBG acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos cyclosporine nmod withdrawal nmod recovery nmod collapsing acl patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We describe a case of drug1 in a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) with complete recovery after withdrawal of cyclosporine ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1207 : 
        {
          1 : "NN nsubjpass VBN ccomp VBP acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass stopped ccomp point acl:relcl *recurrence* nmod urticaria conj drug0"
            }
          4 : 
            {
              1 : "The patient had recurrence of urticaria and drug1 a year and a half later , at which point the drug2 was stopped and she was desensitized to regular insulin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1208 : 
        {
          1 : "NN compound NN nmod NN nmod VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound glaucoma nmod result nmod *cause* dobj drug0"
            }
          4 : 
            {
              1 : "This treatment has the potential to cause drug1 as a result of intractable drug2 glaucoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1209 : 
        {
          1 : "NN conj NN nmod VBG advcl VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj gangrene nmod leading advcl *superimposed* nsubjpass vasculitis compound drug0"
            }
          4 : 
            {
              1 : "In one patient the vasculitis resolved after termination of the ciprofloxacin therapy ; in the other patient the drug1 hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1210 : 
        {
          1 : "NN appos NN nmod NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos treosulfan nmod treatment nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurred in eight women following long-term treatment with Treosulfan ( = drug2 ) for ovarian carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1211 : 
        {
          1 : "NN conj NN nmod VBN acl:relcl NNS nmod VBD nsubj NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj oxaliplatinum nmod treated acl:relcl yrs nmod *developed* nsubj diarrhoea conj drug0"
            }
          4 : 
            {
              1 : "Diarrhoea , T-CD4 + lymphopenia and drug1 developed in a male 60 yrs of age , who was treated with oxaliplatinum and drug2 for unresectable rectum carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1212 : 
        {
          1 : "NN nmod NN nmod NN conj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod infusion nmod failure conj *administration* nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "A case report is presented concerning the administration of ketanserin in the treatment of drug1 and right ventricular failure following the infusion of drug2 in a patient undergoing coronary artery bypass surgery and mitral valve replacement . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1213 : 
        {
          1 : "NN appos CD dep VBD nsubj NNS acl:relcl VBN dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos one dep *experienced* nsubj patients acl:relcl received dobj courses nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with ovarian cancer who had received multiple courses of drug1 without complications experienced hypersensitivity reactions to cisplatin : one , involving intrahepatic artery infusion , manifested drug2 , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1214 : 
        {
          1 : "NN nmod VBD nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *developed* nsubj woman acl treated nmod drug0"
            }
          4 : 
            {
              1 : "A 62-year-old woman treated with drug1 for 2 months developed interstitial pneumonitis with a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1215 : 
        {
          1 : "NN compound NN nmod NNS nmod VBN acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod months nmod associated acl crescents nmod *drug0*"
            }
          4 : 
            {
              1 : "A 56-year-old woman with scleroderma developed drug1 with epithelial crescents associated with hemoptysis after 27 months of drug2 therapy and a cumulative dose of 1 , 200 g . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1216 : 
        {
          1 : "NN nmod NN nmod VBN conj VBP dobj NN nmod NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod remitted conj *report* dobj case nmod patient acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "We report the case of a patient who developed drug1 ( pericardial effusion , pleural effusion , and pericarditis ) after being started on clozapine , and whose symptoms remitted upon discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1217 : 
        {
          1 : "NN conj NN nsubj NNS nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *hyperparathyroidism* nsubj hazards nmod treatment nmod phosphate conj drug0"
            }
          4 : 
            {
              1 : "Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and drug1 are secondary hyperparathyroidism and drug2 , potassium loss also should be kept in mind . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1218 : 
        {
          1 : "NN nsubj VBD conj VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj developed conj *treated* nmod drug0"
            }
          4 : 
            {
              1 : "A patient with coccidioidal meningitis was treated with intrathecally administered drug1 , and an drug2 with EEG abnormalities developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1219 : 
        {
          1 : "NN nmod NNS nmod JJ xcomp JJ amod PRP dobj VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod signs nmod alert xcomp important amod it dobj *makes* nsubj use nmod drug0"
            }
          4 : 
            {
              1 : "We suggest that nicotinic acid was the cause of his liver disease , that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure , and that the probable increased use of drug1 for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1220 : 
        {
          1 : "NN nmod VBN dep VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod caused dep *diagnosed* nmod drug0"
            }
          4 : 
            {
              1 : "Without other causes for the hyponatremia , she was diagnosed with the drug1 , presumably caused by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1221 : 
        {
          1 : "NN conj NN nmod NNS conj VBG acl NNS dobj LS parataxis VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj lidocaine nmod agents conj diluting acl effects dobj b parataxis *divided* nsubjpass causes nmod drug0"
            }
          4 : 
            {
              1 : "Potential causes of methamphetamine-related drug1 can be divided into four categories resulting from ( a ) direct pharmacologic and physical effects of methamphetamine ; ( b ) the toxic effects of diluting or `` cutting '' agents such as lidocaine and drug2 ; ( c ) effects related to the route of drug administration ( intravenous , inhalation , smoking ) ; and ( d ) manufacture-related effects of exposure to unintentional caustic contaminants in the final product . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1222 : 
        {
          1 : "NN appos NN conj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos vindesine conj cisplatin nmod chemotherapy nmod *drug0*"
            }
          4 : 
            {
              1 : "We report a patient with pulmonary adenocarcinoma complicated by the drug1 ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1223 : 
        {
          1 : "NN nmod NN nmod IN advmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod while advmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We describe a 10-year-old boy with ulcerative colitis who developed drug1 while on long-term treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1224 : 
        {
          1 : "NN dobj VBD nmod NNS acl VBG dobj NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nmod weeks acl beginning dobj isoniazid conj therapy compound drug0"
            }
          4 : 
            {
              1 : "Within 3 weeks of beginning continuous daily isoniazid and drug1 therapy for pulmonary tuberculosis , a patient developed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1225 : 
        {
          1 : "NN dobj VBP nsubj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *include* nsubj signs nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "Well-known signs of drug1 toxicity include drug2 and oral and gastrointestinal ulceration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1226 : 
        {
          1 : "NN compound NN dobj VBG advcl VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A case of a 21-year-old woman who had developed mild drug1 while receiving drug2 therapy is described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1227 : 
        {
          1 : "NN nmod NN nmod NNS nsubjpass VBN conj VBN ccomp VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod recommendations nsubjpass presented conj *described* ccomp reviewed nsubjpass mechanisms nmod drug0"
            }
          4 : 
            {
              1 : "Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced drug1 are reviewed , and specific treatment recommendations for the use of drug2 in spinal cord injured patients are presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1228 : 
        {
          1 : "NN dobj VBG acl NN conj NN nmod VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj causing acl immunosuppression conj toxicity nmod *resulted* nsubj elimination nmod drug0"
            }
          4 : 
            {
              1 : "We hypothesize that decreased renal elimination of drug1 induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1229 : 
        {
          1 : "NN nmod NN nmod VBD dobj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod *developed* dobj lesions compound drug0"
            }
          4 : 
            {
              1 : "We describe two dark-skinned patients who developed drug1 and tongue lesions during combination therapy with drug2 and ribavirin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1230 : 
        {
          1 : "NN nmod VBN conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented conj *prescribed* dobj drug0"
            }
          4 : 
            {
              1 : "This case report describes a patient who was previously prescribed drug1 ( Fosamax ) and presented with postoperative drug2 and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1231 : 
        {
          1 : "NN compound NN nmod NN nsubjpass VBN advcl NNS nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound bradycardia nmod possibility nsubjpass *recognized* advcl effects nsubj drug0"
            }
          4 : 
            {
              1 : "Though drug1 , dry mouth , and constipation are well-documented possible adverse effects , the possibility of drug2 bradycardia is less well recognized and is rare . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1232 : 
        {
          1 : "NN nmod NN nmod VBP acl:relcl JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod attribute acl:relcl *adolescent* nmod drug0"
            }
          4 : 
            {
              1 : "We report on a young adolescent with drug1 which we attribute to the use of drug2 for acne . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1233 : 
        {
          1 : "NN dobj VBN ccomp VBZ nsubj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj worsened ccomp *suggests* nsubj observation nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This observation of `` on-off '' drug1 treatment suggests that risperidone may have worsened both drug2 of the mitochondrial disorder in this adolescent . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1234 : 
        {
          1 : "NN nmod NN dep NNS nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment dep days nmod occurred acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of rapidly occurring drug1 that occurred in a geriatric patient 3 days after treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1235 : 
        {
          1 : "NN conj NN dep NN nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj bleomycin dep chemotherapy nmod developed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We describe a 57-year-old man with acral erythrocyanosis progressing to drug1 and gangrene that developed after combined chemotherapy ( bleomycin and drug2 ) used to treat a metastatic squamous cell carcinoma of the hypopharynx . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1236 : 
        {
          1 : "NN compound NN nmod NN nsubj DT nmod NNS nmod NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound toxicity nmod *risk* nsubj those nmod findings nmod specimens conj drug0"
            }
          4 : 
            {
              1 : "Similar to reports in patients receiving gefitinib , those with pathologic findings of UIP on resected lung specimens or known drug1 may be at particular risk for drug2 pulmonary toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1237 : 
        {
          1 : "NN dobj VBD conj VBD nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *had* nsubj patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Two patients treated with drug1 had histories suggestive of a bipolar disorder and developed lithium-responsive drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1238 : 
        {
          1 : "NN nsubjpass VBN acl:relcl NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass used acl:relcl patient nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurred in 1 patient in whom intravesical drug2 was used to control massive persistent hemorrhage from radiation cystitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1239 : 
        {
          1 : "NN nsubj VBD acl:relcl NN conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj appeared acl:relcl medication conj *taken* dobj drug0"
            }
          4 : 
            {
              1 : "All patients had taken drug1 for variable time periods ( range 16-80 days ; mean : 40 ) and were on the medication when the drug2 first appeared . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1240 : 
        {
          1 : "NN compound NN dobj VB xcomp VBN acl NN nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj pulse xcomp exposed acl patient nmod *report* dobj occurrence nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report the occurrence of drug1 in a patient exposed to pulse drug2 therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1241 : 
        {
          1 : "NN compound NN nmod NN nmod VBD nsubj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nmod association nmod *occurred* nsubj episodes nmod proceeding compound drug0"
            }
          4 : 
            {
              1 : "We have cared for three children in whom four episodes of drug1 proceeding to opisthotonus occurred in association with drug2 use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1242 : 
        {
          1 : "NN nmod VB dobj NN amod JJ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *summarize* dobj information amod available nmod literature nmod drug0"
            }
          4 : 
            {
              1 : "PURPOSE : To investigate the concentration-side effect relationship in a patient with severe acyclovir-induced neurotoxicity and to summarize the information available in the literature about drug1 due to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1243 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl woman nmod *described* nsubjpass case nmod drug0"
            }
          4 : 
            {
              1 : "A clinically atypical , neuropathologically verified case of drug1 is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence ( 1970 to 1973 ) with drug2 processed from pooled cadaveric pituitary glands . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1244 : 
        {
          1 : "NN nmod NNS nmod VB nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complications nmod *result* nsubj therapy nmod drug0"
            }
          4 : 
            {
              1 : "Thrombolytic therapy with drug1 ( tPA ) for acute myocardial infarction may result in major bleeding complications such as drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1245 : 
        {
          1 : "NN nsubj VBD ccomp VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *disappeared* ccomp reduced nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "After the dose of drug1 was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer , the drug2 disappeared a few hours later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1246 : 
        {
          1 : "VB xcomp VBN acl NN nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp exposed acl infant nmod *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of drug1 in an infant exposed to drug2 through breast-feeding . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1247 : 
        {
          1 : "NN conj NN dobj VBD nsubj NNS acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj ulceration dobj *developed* nsubj patients acl:relcl receiving dobj drug0"
            }
          4 : 
            {
              1 : "Two patients who were receiving drug1 by infusion developed duodenal ulceration and subsequent drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1248 : 
        {
          1 : "NN nmod VB xcomp JJ amod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use xcomp secondary amod *seizures* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and focal seizures secondary to use of drug2 during induction therapy of acute lymphocytic leukemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1249 : 
        {
          1 : "NN nmod VBN acl NN nmod VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *terminating* nmod drug0"
            }
          4 : 
            {
              1 : "Myelodysplasia terminating in drug1 in a hairy cell leukemia patient treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1250 : 
        {
          1 : "NN nmod VBN nsubjpass NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *associated* nsubjpass colchicine conj therapy compound drug0"
            }
          4 : 
            {
              1 : "Both colchicine and drug1 therapy may be associated with drug2 , which usually occurs after several months of therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1251 : 
        {
          1 : "NN conj NN dobj VBD conj VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fever dobj developed conj *started* nsubjpass therapy nmod drug0"
            }
          4 : 
            {
              1 : "After therapy for diabetic coma with drug1 ( containing the preservative cresol ) and electrolyte solutions was started , the patient complained of increasing myalgia , developed a high fever and drug2 and lost consciousness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1252 : 
        {
          1 : "NN compound NNS nmod NNS dobj VBD parataxis NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound diagnoses nmod criteria dobj increased parataxis *period* nmod combination nmod drug0"
            }
          4 : 
            {
              1 : "RESULTS : After 4 - to 14-month period of therapy with the combination of drug1 ( 2.5 mg/day ) and fosinopril ( 10 mg/day ) in three patients and 6-month period of monotherapy with indapamide ( 2.5 mg/day ) in one patient , glucose levels of all patients increased and achieve criteria of drug2 diagnoses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1253 : 
        {
          1 : "NN compound NN dobj VBG dep NNS nmod VBD dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment dobj starting dep months nmod *developed* dobj erythematosus appos drug0"
            }
          4 : 
            {
              1 : "A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus ( drug1 ) with characteristic laboratory findings , 18 months after starting drug2 maintenance treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1254 : 
        {
          1 : "NN nmod NN dobj VBD nsubj NN acl:relcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod risk dobj *had* nsubj diabetes acl:relcl associated nmod drug0"
            }
          4 : 
            {
              1 : "However , follow-up revealed that gestational diabetes when associated with drug1 had a lesser risk of emerging drug2 and impaired glucose tolerance . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1255 : 
        {
          1 : "NN appos NN nmod NN nmod NN nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos carbamazepine nmod treatment nmod patient nmod occurring acl *drug0*"
            }
          4 : 
            {
              1 : "The authors report a case of acute drug1 ( AP ) occurring in a patient under treatment with carbamazepine ( drug2 ) for post-traumatic petit mal epilepsy , and review the current literature of drug-induced AP . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1256 : 
        {
          1 : "NN dobj VBD nmod:tmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *experienced* nmod:tmod hours nmod injection compound drug0"
            }
          4 : 
            {
              1 : "Ten hours after the second drug1 injection , the patient experienced a drug2 located mainly on the limbs . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1257 : 
        {
          1 : "NN nmod NNS dobj VBD nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod signs dobj *developed* nsubj woman acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : A woman receiving drug1 every 12 hours developed signs and symptoms of drug2 after the second dose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1258 : 
        {
          1 : "NN nmod NNS dobj VBG conj NN dep IN dep VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses dobj receiving conj marijuana dep while dep *experienced* dobj drug0"
            }
          4 : 
            {
              1 : "A young patient experienced marked drug1 while smoking marijuana and receiving therapeutic doses of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1259 : 
        {
          1 : "NN compound NN nmod NN nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound cream nmod use nmod *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of drug1 ( CDIC ) after use of drug2 vaginal cream . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1260 : 
        {
          1 : "NN nmod NNS nmod VBN nsubjpass NNS acl VBG dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod factors nmod *evaluated* nsubjpass patients acl receiving dobj injections nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Patients receiving intravitreal injections of drug1 should be evaluated for potential systemic risk factors such as drug2 , coagulopathy and poorly controlled diabetes mellitus . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1261 : 
        {
          1 : "NN conj NN dobj VB xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj failure dobj cause xcomp *known* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is known to cause acute renal failure and drug2 , but the recently described association with proteinuria or nephrotic syndrome is little recognized . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1262 : 
        {
          1 : "NN dobj VBD nsubj NNS acl:relcl VBN dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *experienced* nsubj patients acl:relcl received dobj courses nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with ovarian cancer who had received multiple courses of drug1 without complications experienced drug2 to cisplatin : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1263 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN nmod VBD nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl glands nmod development nmod *complained* nmod end nmod cycle nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "At the end of his fifth cycle of drug1 therapy , the patient complained of the development of abnormally large mammary glands associated with drug2 and peri-areolar erythema . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1264 : 
        {
          1 : "NN compound NN conj NN nmod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy conj cyclophosphamide nmod exposure nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "This report describes two patients who developed drug1 only after exposure to cyclophosphamide , methotrexate , and drug2 adjuvant therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1265 : 
        {
          1 : "NN compound NN nmod VBP dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod *develop* dobj drug0"
            }
          4 : 
            {
              1 : "The condition should be suspected in patients who develop unexplained drug1 or collapse following drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1266 : 
        {
          1 : "NN appos NNS conj NN nmod NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos symptoms conj eosinophilia nmod rash nmod context nmod *case* nmod nephritis compound drug0"
            }
          4 : 
            {
              1 : "This case of drug1 acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( drug2 ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1267 : 
        {
          1 : "NN nmod VBG acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod receiving acl patient nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report on the possible development of drug1 in a patient receiving clomipramine after drug2 was withdrawn from the treatment regimen . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1268 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod *describe* dobj drug0"
            }
          4 : 
            {
              1 : "PURPOSE : To describe drug1 in a patient with Parkinson disease who was treated with long-term drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1269 : 
        {
          1 : "NN dep NNS nmod NN nmod VBG acl NNS nmod NN nmod VB nsubj NNS appos NN amod JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep reactions nmod risk nmod putting acl patients nmod % nmod *occur* nsubj deficiencies appos enzyme amod responsible nmod catabolism compound drug0"
            }
          4 : 
            {
              1 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for drug1 catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , drug2 , stomatitis , mucositis , myelosuppression , neurotoxicity ) to standard doses of 5-FU . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1270 : 
        {
          1 : "NN nmod VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *developed* advcl started nsubjpass drug0"
            }
          4 : 
            {
              1 : "Ten days after drug1 was started , he developed paralytic ileus , neurogenic bladder , mild left ptosis , and absence of deep reflexes , with drug2 and mild weakness of the upper extremities . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1271 : 
        {
          1 : "NN compound NN nmod NNS conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound toxicity nmod potentials conj *response* conj drug0"
            }
          4 : 
            {
              1 : "A transient tonic pupillary response , drug1 , and abnormal visual-evoked potentials in drug2 toxicity , to our knowledge , have not been previously reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1272 : 
        {
          1 : "NN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 14-year-old girl with newly diagnosed SLE developed a drug1 while on drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1273 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod VB xcomp VBN nsubjpass NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl children nmod occur xcomp *believed* nsubjpass syndrome appos drug0"
            }
          4 : 
            {
              1 : "Reye syndrome ( drug1 ) is believed to occur infrequently among children receiving long-term drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1274 : 
        {
          1 : "NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod pregnancy nmod treated acl woman nmod *born* nsubjpass girl nmod atresia conj drug0"
            }
          4 : 
            {
              1 : "An infant girl with choanal atresia , drug1 , minor anomalies , and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with drug2 and propranolol . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1275 : 
        {
          1 : "NN nmod NN nmod JJ advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod related advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report two patients who developed intense drug1 clearly related to the administration of drug2 as an adjuvant therapy for melanoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1276 : 
        {
          1 : "NN compound NN nmod VB advcl VB advcl VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod make advcl *detect* advcl develop dobj drug0"
            }
          4 : 
            {
              1 : "Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop drug1 , in order to make a early diagnosis of thyroid disorders during the drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1277 : 
        {
          1 : "NN nmod NN nmod NN dobj VB nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occurrence nmod possibility dobj *consider* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "During and after drug1 therapy we should consider the possibility of occurrence of drug2 as well as other autoimmune diseases and observe the clinical course carefully . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1278 : 
        {
          1 : "NN dobj VB xcomp VBN advcl VBG dobj NN acl VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj exhibit xcomp *noted* advcl conducting dobj protocol acl evaluating dobj efficacy nmod drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARIES : While conducting a protocol evaluating the efficacy of intraperitoneal drug1 and hyperthermia in the treatment of recurrent ovarian cancer , 3 patients were noted to exhibit drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1279 : 
        {
          1 : "NN nmod VB acl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use acl *diagnosis* nmod owing compound drug0"
            }
          4 : 
            {
              1 : "RESULTS : A clinical diagnosis of drug1 owing to use of the PDE5 inhibitor drug2 ( Cialis ) was made . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1280 : 
        {
          1 : "NN dobj VBG acl NN dobj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developing acl risk dobj *increase* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( RA ) may further increase the risk of developing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1281 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *reported* nsubjpass prolongation nmod half-life conj drug0"
            }
          4 : 
            {
              1 : "However , prolongation of 5-FU half-life and an drug1 have been reported with the concurrent use of drug2 and warfarin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1282 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl exposures nmod list nmod *added* nsubjpass drug0"
            }
          4 : 
            {
              1 : "We propose that drug1 be added to the list of exposures potentially associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1283 : 
        {
          1 : "NN compound NN nmod IN dep VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod while dep *developed* dobj drug0"
            }
          4 : 
            {
              1 : "RESULTS : Our patient developed drug1 while on drug2 treatment as a consequence of long-term immunosuppression . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1284 : 
        {
          1 : "NN nmod NN nmod VBZ conj JJ ccomp VBZ advcl VBZ nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod frequency nmod does conj effective ccomp *appears* advcl consists nsubj literature nmod use nmod drug0"
            }
          4 : 
            {
              1 : "Although the literature on the use of drug1 in elderly patients with dementia consists largely of uncontrolled trials , case reports , and chart reviews , it appears that this agent is effective for managing agitation in this population and does so with a low frequency of drug2 ( EPS ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1285 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment dobj receiving acl disorder nmod patient nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "This case report describes the development of asymptomatic drug1 ( VFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1286 : 
        {
          1 : "NN nmod NN nmod NN nmod VBZ acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod association nmod has acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "One type of SMON is associated with drug1 which has a very high frequency of occurrence in association with administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1287 : 
        {
          1 : "NN compound NNS nmod NNS dep NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound effects nmod *cases* dep case conj drug0"
            }
          4 : 
            {
              1 : "Since recent studies have reported no negative interactions with concurrent use , we here report three cases ( one case of a prolonged seizure , a serotonin syndrome and a drug1 ) of severe drug2 side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1288 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion dobj receiving advcl *developed* nsubj encephalopathy conj drug0"
            }
          4 : 
            {
              1 : "An encephalopathy and drug1 developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical drug2 infusion for hemorrhagic cystitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1289 : 
        {
          1 : "NN nmod JJ amod NN acl VBN nmod NN acl:relcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consistent amod *patient* acl treated nmod inhibitor acl:relcl developed nsubj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) drug1 developed confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with drug2 , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1290 : 
        {
          1 : "NN nmod VBD nmod NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *progressed* nmod induction nmod anesthesia nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "After induction of general anesthesia and administration of a standard dose of intravenous drug1 , her cardiac rhythm progressed to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1291 : 
        {
          1 : "NN nsubj VB advcl VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *occur* advcl used nsubjpass doses nmod drug0"
            }
          4 : 
            {
              1 : "INTERPRETATION : When high doses of drug1 are used , drug2 and adrenal suppression may occur . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1292 : 
        {
          1 : "NN conj VBN root , punct NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj presented root , punct *months* nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who , after 2 months of treatment with drug1 , presented with rapidly progressive erythema , scaling , nausea and vomiting , and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1293 : 
        {
          1 : "NN nmod NN appos NN nmod VBD nsubj NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod methotrexate nmod rescue compound drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with drug1 rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with drug2 and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1294 : 
        {
          1 : "NN nmod NN nsubj CD nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *development* nsubj one nmod side-effects nmod drug0"
            }
          4 : 
            {
              1 : "One of the side-effects of intravitreal drug1 is the development of drug2 , and it is known that cataract extraction can exacerbate macular degeneration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1295 : 
        {
          1 : "VB amod NN nmod JJ amod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 amod intoxication nmod due amod *course* nmod drug0"
            }
          4 : 
            {
              1 : "The course of drug1 due to drug2 intoxication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1296 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod *presented* nmod face conj trunk conj drug0"
            }
          4 : 
            {
              1 : "A 26-year-old Japanese man , who had been receiving medical attention for ulcerative colitis for one year , presented with diffuse erythema and pustules on his face and trunk , drug1 , and fever up to 39 degrees C one day after the administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1297 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBN acl NNS nmod NN appos NN nmod VBN conj VBN advcl VBP nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl women nmod born acl infants nmod defect appos anomaly nmod implicated conj *discussed* advcl are nsubj number nmod concerns nmod drug0"
            }
          4 : 
            {
              1 : "In this article lithium is not discussed , although there are a number of concerns about lithium 's potential drug1 , and it has been implicated in Epstein 's anomaly , a congenital heart defect among infants born to women taking drug2 ; as with other medications , however , the data have specific limitations . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1298 : 
        {
          1 : "NN appos NN compound NN dep NN dobj VBG dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos sulfamethoxazole compound treatment dep trimethoprim dobj receiving dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and drug1 two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( drug2 ) treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1299 : 
        {
          1 : "NN compound NN nmod NNS nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *effects* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 , myelosuppression , and subsequent severe infections are the major side effects of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1300 : 
        {
          1 : "NN dobj VBG acl NNS dobj VBP acl:relcl NNS conj JJ nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patients dobj put acl:relcl factors conj *aware* nmod signs nmod drug0"
            }
          4 : 
            {
              1 : "Clinicians should be aware of the signs and symptoms of drug1 during treatment , as well as predisposing factors that put patients receiving drug2 at risk for neurotoxic effects . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1301 : 
        {
          1 : "NN nmod NNS dobj VBD nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod signs dobj *developed* nsubj patient acl treated nmod drug0"
            }
          4 : 
            {
              1 : "A patient with chronic myeloid leukaemia treated with drug1 for 4-5 years , developed signs of busulphan toxicity and portal hypertension with drug2 , oesophageal varices and jaundice . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1302 : 
        {
          1 : "NN nmod JJ amod NN dobj VBD xcomp VBN nsubjpass NNS dep NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod related amod ataxia dobj developed xcomp *added* nsubjpass inhibitors dep ritonavir conj drug0"
            }
          4 : 
            {
              1 : "Protease inhibitors ( ritonavir and drug1 ) were added to the treatment and the patient developed progressive ataxia related to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1303 : 
        {
          1 : "NN nmod VBN acl NN dobj VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod known acl reaction dobj associated conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is widely used against methicillin-resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as `` drug2 '' and anaphylaxis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1304 : 
        {
          1 : "NN nmod NN nmod VBN acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod associated acl *weakness* appos drug0"
            }
          4 : 
            {
              1 : "Rapid onset of muscle weakness ( drug1 ) associated with the combined use of drug2 and colchicine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1305 : 
        {
          1 : "NN dobj VBG acl NN nmod NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl patient nmod preparation nmod caused acl *drug0*"
            }
          4 : 
            {
              1 : "Postoperative drug1 caused by fleet phospho-soda preparation in a patient taking drug2 : report of a case . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1306 : 
        {
          1 : "NN nmod VBD conj VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod suffered conj *suffering* nmod drug0"
            }
          4 : 
            {
              1 : "The third patient had been suffering from serious akathisia while on drug1 , and was cured after switching to olanzapine , but thereafter the patient suffered from drug2 at nighttime . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1307 : 
        {
          1 : "NN nmod NN nmod VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *presented* nmod repair nmod drug0"
            }
          4 : 
            {
              1 : "PURPOSE : To report patients who presented to the oculoplastics department for repair of drug1 after topical use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1308 : 
        {
          1 : "NN dobj VBD conj VBP dep VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj suffered conj *describe* dep treated nmod drug0"
            }
          4 : 
            {
              1 : "We describe a patient with Wilson 's disease who presented with neurologic disease , was treated with drug1 , and suffered sudden drug2 coincident with therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1309 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj overanticoagulation nmod resulted acl:relcl *interaction* nmod lotion compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : This report describes a case of a probable interaction between topical drug1 lotion 1 % and acenocoumarol that resulted in overanticoagulation and a life-threatening drug2 in this elderly patient . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1310 : 
        {
          1 : "NN dobj VBD conj VBP dobj NN nmod NN acl:relcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *present* dobj case nmod woman acl:relcl treated nmod drug0"
            }
          4 : 
            {
              1 : "We present a case of an elderly woman with a pre-existing history of ischaemic heart disease , who was treated with drug1 , and developed drug2 within the first week of treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1311 : 
        {
          1 : "NN dobj VBG acl NNS nmod NNS nsubjpass VBN advcl VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl women nmod schemes nsubjpass *recommended* advcl induce dobj drug0"
            }
          4 : 
            {
              1 : "Since tamoxifen therapy can induce drug1 , surveillance schemes of women taking drug2 have been recommended . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1312 : 
        {
          1 : "NN nmod NN nmod NN dep NN nmod VBG nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod infusion dep hour nmod *feeling* nmod headache conj drug0"
            }
          4 : 
            {
              1 : "The patient described feeling cold with worsening headache and drug1 approximately one hour after infusion of the first dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1313 : 
        {
          1 : "NN nsubj VBZ ccomp NN nmod VB conj VBP acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj damages ccomp evidence nmod add conj correspond acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "These are the first reported patients to show drug1 that correspond to bitemporal visual field defects and add to the growing evidence that drug2 damages the retina . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1314 : 
        {
          1 : "NN nmod NN dobj VBG acl NNS nmod NN nmod NN xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment dobj undergoing acl patients nmod % nmod complication xcomp *noted* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 has been noted to be a complication in 2-16 % of patients undergoing treatment with drug2 for a variety of pediatric neoplasms . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1315 : 
        {
          1 : "NN appos NN conj NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos *heparin* conj heparins dep drug0"
            }
          4 : 
            {
              1 : "By means of the in vitro heparin-induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins drug1 and Fraxiparin ( Sanofi Labaz , Munich , FRG ) , as well as the enoxaparine Clexane ( Nattermann , Cologne , FRG ) , all induced drug2 with the patient 's serum . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1316 : 
        {
          1 : "NN compound NN appos NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy appos years nmod age nmod *drug0*"
            }
          4 : 
            {
              1 : "A 7-year-old boy developed a drug1 at the age of 5 years ( drug2 therapy ) ; 1.5 years later valproate ( 2-propylpentanoic acid , VPA ) was added to the therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1317 : 
        {
          1 : "NN compound NN nmod NN dep NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound toxicity nmod complication dep *myelinolysis* acl manifested nmod drug0"
            }
          4 : 
            {
              1 : "Central pontine myelinolysis manifested by drug1 : a possible complication of drug2 toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1318 : 
        {
          1 : "NN conj NN nmod NN nmod NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj 0-fluorocytosine nmod treatment nmod days nmod *resulted* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 resulted after 19 days of treatment with 5-fluorocytosine and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1319 : 
        {
          1 : "NN nmod JJ root , punct NN dep NN root , root IN dep JJ dep NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod second root , punct methotrexate dep case root , root by dep related dep *leukoencephalopathy* conj drug0"
            }
          4 : 
            {
              1 : "We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and drug1 related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered drug2 and cranial irradiation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1320 : 
        {
          1 : "NN nmod NN dep VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mg dep *receiving* dobj drug0"
            }
          4 : 
            {
              1 : "She was receiving drug1 300 mg/day ; carbamazepine 200 mg four times daily had been discontinued four days before admission because of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1321 : 
        {
          1 : "NN compound NNS nsubj VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound symptoms nsubj *recovered* advcl discontinued nsubjpass drug0"
            }
          4 : 
            {
              1 : "After drug1 was discontinued , the drug2 symptoms recovered gradually . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1322 : 
        {
          1 : "NN nmod NN dep NN nmod VBD dep VBP dobj NN nmod NN acl:relcl VBN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose dep month nmod identified dep *report* dobj case nmod woman acl:relcl infected conj drug0"
            }
          4 : 
            {
              1 : "We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed drug1 , identified 1 month after a single dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1323 : 
        {
          1 : "NN nmod NN nmod VBG dep NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod citalopram nmod switching dep months nmod *recurred* nsubj drug0"
            }
          4 : 
            {
              1 : "In this case , unlike those previously reported , drug1 recurred 5 months after switching from citalopram to drug2 , which is believed to be a safe antidepressant . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1324 : 
        {
          1 : "NN nmod NN nmod VBD conj VBD dobj NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod developed conj *exhibited* dobj reactions nmod arrest conj drug0"
            }
          4 : 
            {
              1 : "However , one patient exhibited severe hypersensitivity reactions including cardiac arrest and drug1 , and another four patients developed eruptions , hypotension , and tachycardia soon after administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1325 : 
        {
          1 : "NN nmod VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *is* nsubj documentation nmod drug0"
            }
          4 : 
            {
              1 : "There is documentation of drug1 with drug2 when administered at dosages generally pronounced as being safe . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1326 : 
        {
          1 : "NN dobj VBG advcl VBP dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving advcl *develop* dobj drug0"
            }
          4 : 
            {
              1 : "Fludarabine induced lung toxicity must be considered in all patients who develop unexplained drug1 while receiving drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1327 : 
        {
          1 : "NN dobj VBG acl NN nmod JJ amod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl chemotherapy nmod secondary amod *disease* appos drug0"
            }
          4 : 
            {
              1 : "In four patients , thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease ( drug1 ) secondary to intensive chemotherapy containing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1328 : 
        {
          1 : "NN dobj VB conj JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause conj *corrosive* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : drug1 is corrosive and may cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1329 : 
        {
          1 : "NN dobj VBG acl:relcl NN nmod NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl:relcl infection nmod patient nmod *presented* nsubjpass case nmod drug0"
            }
          4 : 
            {
              1 : "A case of drug1 is presented in a patient with a left ventricular assist device drive-line infection who was receiving drug2 , an antibiotic used for serious infections with gram-positive organisms . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1330 : 
        {
          1 : "NN nmod NN dobj VBD nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod anasarca dobj *developed* nmod introduction nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Soon after introduction of drug1 therapy , she developed severe anasarca , including marked drug2 , ascites and pleural effusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1331 : 
        {
          1 : "NN nmod NN nmod IN dep VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod chemotherapy nmod while dep *developed* dobj dysfunction conj drug0"
            }
          4 : 
            {
              1 : "We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an drug1 while on chemotherapy with drug2 , a methotrexate analog . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1332 : 
        {
          1 : "NN nsubjpass VBN conj VBD nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass reported conj *tolerated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Intravenous drug1 is generally well tolerated , but drug2 has been reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1333 : 
        {
          1 : "NN xcomp VBD conj VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp became conj *began* advcl stopped nsubjpass drug0"
            }
          4 : 
            {
              1 : "The day after drug1 was stopped , while he was still receiving clomipramine 150 mg/d , he began behaving oddly , started sweating profusely , shivering , and became drug2 , agitated , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1334 : 
        {
          1 : "NN dobj VBD conj VB advcl VBN dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj convert advcl *received* dobj administration nmod drug0"
            }
          4 : 
            {
              1 : "A 74-year-old man received oral administration of drug1 , a pure sodium channel blocker with slow recovery kinetics , to convert paroxysmal atrial fibrillation to sinus rhythm and developed drug2 two days later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1335 : 
        {
          1 : "NN nmod NN nmod VB dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod infusion nmod *report* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report 2 cases of drug1 ( NCSE ) following infusion of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1336 : 
        {
          1 : "NN conj NN dep NN dobj VBG acl NNS nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj cya dep drug dobj receiving acl patients nmod *complication* nsubj drug0"
            }
          4 : 
            {
              1 : "In conclusion , drug1 is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( CyA or drug2 ) , even under monotherapy or with a low steroid dose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1337 : 
        {
          1 : "NN nmod NN nsubj VB acl NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nsubj suggest acl fall nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "The development of drug1 associated with a sudden fall in hemoglobin after the administration of drug2 should strongly suggest the possibility of diffuse subfascial hematoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1338 : 
        {
          1 : "NN nmod NN dobj VBG dep NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cycle dobj completing dep weeks nmod *fever* conj drug0"
            }
          4 : 
            {
              1 : "A 73-year-old woman presented with fever and drug1 2 weeks after completing the third cycle of drug2 for chronic lymphocytic leukemia ( CLL ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1339 : 
        {
          1 : "NN conj NN dobj VBG acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj sertraline dobj receiving acl patients nmod *drug0*"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious drug1 in patients receiving sertraline or drug2 when metoclopramide is coadministered even in a single , conventional dose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1340 : 
        {
          1 : "VB ccomp JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 ccomp related amod *drug0*"
            }
          4 : 
            {
              1 : "We describe 2 cases of drug1 related to drug2 use and review the literature on this newly recognized association . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1341 : 
        {
          1 : "NN dobj VB acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause acl:relcl *interactions* nmod drug0"
            }
          4 : 
            {
              1 : "The patient 's other comorbidities and medications have not been suggested as possible interactions with drug1 that can cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1342 : 
        {
          1 : "NN nmod NN dep NNS nmod NN acl VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injection dep months nmod *reaction* acl leading nmod drug0"
            }
          4 : 
            {
              1 : "The authors present a case report of a granulomatous reaction leading to drug1 , 3 months after the transurethral injection of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1343 : 
        {
          1 : "NN compound NN nmod NN nmod VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod month nmod occurred acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 that occurred during the second month of drug2 therapy for chronic active hepatitis C . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1344 : 
        {
          1 : "NN nmod NN nmod NN nmod NN nmod VBZ dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occurrence nmod relationship nmod cause nmod *indicates* dobj cream compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This report indicates drug1 vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of drug2 and clindamycin administration , lack of concomitant medications , and documentation of C. difficile toxin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1345 : 
        {
          1 : "NN appos NN nmod RP advmod NN nmod NN nmod VB dobj NNS acl:relcl VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos carbamazepine nmod off advmod switch nmod part nmod *describe* dobj patients acl:relcl evolved nmod drug0"
            }
          4 : 
            {
              1 : "The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into drug1 after the introduction of oxcarbazepine ( OXC ) , as part of a switch off from carbamazepine ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1346 : 
        {
          1 : "NN appos NN conj NN nmod NN nmod VBD xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acid conj lamotrigine nmod overdose nmod *became* xcomp drug0"
            }
          4 : 
            {
              1 : "METHODS : A 55-year-old woman became drug1 after overdose with lamotrigine ( LTG ) and valproic acid ( drug2 ) tablets . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1347 : 
        {
          1 : "NN nsubj JJ conj VBD xcomp VB"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj reversible conj *led* xcomp drug0"
            }
          4 : 
            {
              1 : "However , peripheral neuropathy and bone marrow depression led to drug1 withdrawal in seven patients , and drug2 may not be fully reversible in all patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1348 : 
        {
          1 : "NN nmod VBN acl NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl *infiltrates* conj drug0"
            }
          4 : 
            {
              1 : "Pulmonary infiltrates and drug1 associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1349 : 
        {
          1 : "NN dobj VB conj VBP nsubj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause conj *prolong* nsubj antimicrobials compound drug0"
            }
          4 : 
            {
              1 : "It has been reported that drug1 antimicrobials prolong the corrected QT interval but rarely cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1350 : 
        {
          1 : "NN conj NN nmod NN dobj VBD nsubj NN acl:relcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj mellitus nmod risk dobj *had* nsubj diabetes acl:relcl associated nmod drug0"
            }
          4 : 
            {
              1 : "However , follow-up revealed that gestational diabetes when associated with drug1 had a lesser risk of emerging diabetes mellitus and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1351 : 
        {
          1 : "NN conj JJ nmod VBN dep VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hematologic nmod associated dep *achieved* nmod doses nmod drug0"
            }
          4 : 
            {
              1 : "Prolonged responses were achieved with low doses of drug1 ( 3-10 mg/kg/day ) and higher doses were associated with mild reversible hematologic or drug2 and no further increases in Hb . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1352 : 
        {
          1 : "NN parataxis VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 parataxis *reinstated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "In two patients drug1 was reinstated after risperidone was discontinued ; drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1353 : 
        {
          1 : "NN conj NN nmod VBN acl NNS nmod VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj mellitus nmod manifested acl changes nmod *describing* dobj relationship nmod drug0"
            }
          4 : 
            {
              1 : "The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of drug1 to metabolic changes manifested as uncontrolled diabetes mellitus and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1354 : 
        {
          1 : "NN compound NNS nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound users nmod *injury* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 may sometimes be a major injury in drug2 users because high doses or inappropriate use of the drug may render the skin extremely sensitive . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1355 : 
        {
          1 : "NN nmod JJ amod NN dep NNS nmod VBN conj VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod due amod admission dep weeks nmod discontinued conj *taking* dobj drug0"
            }
          4 : 
            {
              1 : "She had been taking drug1 for 6 months , but had discontinued the agent 2 weeks before admission due to progressive drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1356 : 
        {
          1 : "NN dobj VBG acl NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj using acl therapy nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "PURPOSE : To report a case of drug1 associated with ovulation induction therapy using drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1357 : 
        {
          1 : "NN nmod VBZ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *presents* nsubj injury compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 liver injury presents with a drug2 with damage to the interlobular bile ducts , possibly leading to ductopenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1358 : 
        {
          1 : "NN dep NN dep NN nmod NN nsubj VBN dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep cbz dep carbamazepine nmod administration nsubj used dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "A 14-year-old female developed drug1 , rash , fever , leukopenia and positive anti-nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; drug2 ) used against benign Rolandic epilepsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1359 : 
        {
          1 : "NN dobj VBG acl NN nmod VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj reinitiating acl recurrence nmod *resolved* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 resolved after stopping CAP for 4 weeks in Patient A , with no recurrence after reinitiating drug2 alone at 2000 mg/m2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1360 : 
        {
          1 : "NN nmod NNS nmod VBN nsubjpass NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod *considered* nsubjpass granulocytopenia conj drug0"
            }
          4 : 
            {
              1 : "Granulocytopenia and drug1 are considered among the most dangerous adverse effects of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1361 : 
        {
          1 : "NN nmod NNS nmod JJ amod JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod due amod *brief* nsubj treatment nmod drug0"
            }
          4 : 
            {
              1 : "We present a case report of a patient with alveolar hydatid disease , whose treatment with drug1 was brief due to side effects of drug2 and granulocytopenia ; and review the features of this disease which , with increasing international migration , may be encountered more frequently in Australia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1362 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBG xcomp VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod hospital nmod admissions nmod resulting xcomp *treated* nmod carbonate conj drug0"
            }
          4 : 
            {
              1 : "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and drug1 resulting in two admissions to the hospital for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1363 : 
        {
          1 : "NN nmod NN conj NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment conj term nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a 59-year-old patient with chronic myeloid leukemia , who developed drug1 after short term and sequential treatment with drug2 and busulfan . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1364 : 
        {
          1 : "NN compound NN nmod NN nmod NNS nmod NN conj VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod abstinence nmod years nmod fever conj *complained* nmod drug0"
            }
          4 : 
            {
              1 : "Case 3 : A 29-year-old female alcoholic complained of general drug1 and a slight fever after 1.5 years of abstinence with drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1365 : 
        {
          1 : "NN conj NN nmod NNS nsubjpass VBN advcl VB acl:relcl NN xcomp VBP dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj lithium nmod drugs nsubjpass used advcl occur acl:relcl sign xcomp *consider* dobj drug0"
            }
          4 : 
            {
              1 : "We consider drug1 to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as lithium or drug2 are used in combination with CBZ . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1366 : 
        {
          1 : "NN nmod NN nsubjpass VBD conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod association nsubjpass recognized conj *known* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is known to cause acute renal failure and tubulo-interstitial disease , but the recently described association with drug2 or nephrotic syndrome is little recognized . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1367 : 
        {
          1 : "NN dobj VBG acl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj producing acl *docetaxel* conj drug0"
            }
          4 : 
            {
              1 : "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and drug1 producing drug2 , and simulating a progression of the tumor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1368 : 
        {
          1 : "NN conj NN nmod NN nmod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj ethambutol nmod treatment nmod course nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "METHODS : A patient who developed dramatic , permanent drug1 after a 9-month course of treatment with ethambutol and drug2 for pulmonary tuberculosis is presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1369 : 
        {
          1 : "NN nmod NNS dobj VBD csubj VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod symptoms dobj *aggravated* csubj increasing dobj dosage compound drug0"
            }
          4 : 
            {
              1 : "Increasing the drug1 dosage severely aggravated the symptoms of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1370 : 
        {
          1 : "NN nmod JJ amod NN dobj VBD nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod typical amod dysfunction dobj *developed* nsubj patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Two patients treated with drug1 ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1371 : 
        {
          1 : "NN nmod VBN xcomp VBP advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated xcomp are advcl *taken* nsubjpass recognition nmod drug0"
            }
          4 : 
            {
              1 : "Thus , clinical recognition of drug1 should be taken into account when rheumatoid arthritis patients are to be treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1372 : 
        {
          1 : "NN compound NN nmod NN dobj VBD acl:relcl NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod link dobj demonstrated acl:relcl pattern nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "Our patient developed both drug1 and renal tubular acidosis with a temporal pattern that demonstrated a link between drug2 therapy and these abnormalities . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1373 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBD acl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod years nmod developed acl *woman* conj drug0"
            }
          4 : 
            {
              1 : "RESULTS : In a 22-year-old Thai woman with Graves ' disease , tinnitus , hearing impairment in the left ear ( with progression to the right ear ) , and drug1 developed after 3 years of therapy with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1374 : 
        {
          1 : "NN dobj VBD conj VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *taking* dobj drug0"
            }
          4 : 
            {
              1 : "We report a case of a patient with mild chronic renal insufficiency who had been taking drug1 for over a year and developed drug2 within 3 weeks after the start of treatment with colchicine for acute gouty bursitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1375 : 
        {
          1 : "NN nmod NN dep NN nmod NN nmod VBG nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cessation dep h nmod recovery nmod *occurring* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurring 24 h after chloroquine therapy , with full recovery 48 h after cessation of drug2 , has not been described previously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1376 : 
        {
          1 : "NN nmod NN nmod NN dep NNS nmod VBD acl NN conj NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod initiation dep days nmod demonstrated acl *evidence* conj features nmod degeneration nmod drug0"
            }
          4 : 
            {
              1 : "The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis , and biopsy features of fatty liver parenchyma degeneration with drug1 and bile stasis , demonstrated 20 days after the initiation of antithyroid therapy with 20 mg drug2 daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1377 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented acl *changes* nmod injection compound drug0"
            }
          4 : 
            {
              1 : "In this article , we describe another case of subcutaneous changes following repeated drug1 injection , presented as drug2 in the area around the injection sites , in a 46-year-old female patient who was treated with glatiramer acetate for 18 months . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1378 : 
        {
          1 : "NN dobj VBP nsubj VB"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *induce* nsubj drug0"
            }
          4 : 
            {
              1 : "Can drug1 and betamethasone induce drug2 ? A case report . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1379 : 
        {
          1 : "NN dobj VBG acl NN nmod VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patient nmod *occurs* nsubj drug0"
            }
          4 : 
            {
              1 : "Typically , drug-induced drug1 occurs in a patient receiving a semisynthetic drug2 for two weeks or more . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1380 : 
        {
          1 : "RB advmod VBD dep VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 advmod *developed* dep receiving dobj drug0"
            }
          4 : 
            {
              1 : "In this report , we describe a patient receiving drug1 in whom drug2 , fever , hypoxia , and diffuse pulmonary infiltrates developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1381 : 
        {
          1 : "NN conj NNS nmod NN dobj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj corticosteroids nmod treatment dobj *followed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 probably followed the treatment of Wegener 's granulomatosis with corticosteroids and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1382 : 
        {
          1 : "NN appos NN compound NN appos CD dobj VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos nitrosourea compound therapy appos 0 dobj following acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 following 1 , 3-bis ( 2-chloroethyl ) -1 - nitrosourea ( drug2 ) therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1383 : 
        {
          1 : "NN nmod NN nmod VBN xcomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod associated xcomp *seemed* nsubj drug0"
            }
          4 : 
            {
              1 : "Nevertheless , the drug1 seemed to be most closely associated with the administration of the drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1384 : 
        {
          1 : "NN nmod NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "Aggressive management of doxorubicin-induced drug1 associated with ` low ' doses of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1385 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod NNS conj NNP nmod NN nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl leukemia nmod patients conj ribavirin nmod association nmod *treated* nmod drug0"
            }
          4 : 
            {
              1 : "We report 5 patients ( 3 patients with chronic hepatitis C treated with drug1 in association with oral ribavirin and two patients with chronic myelocytic leukemia ) who developed drug2 at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1386 : 
        {
          1 : "NN appos NN nmod NN nmod NN nmod NN amod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos activator nmod therapy nmod *occurrence* nmod failure amod due nmod drug0"
            }
          4 : 
            {
              1 : "We report the occurrence of renal failure due to drug1 following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1387 : 
        {
          1 : "NN nmod NN nmod VBN acl NNS conj NN acl VBN nmod NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod resolved acl symptoms conj *patient* acl treated nmod inhibitor acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed drug1 , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1388 : 
        {
          1 : "NN nmod JJ amod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod secondary amod *necrolysis* compound drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 epidermal necrolysis ( SJS/TEN ) secondary to drug2 ( TMP-Sx ) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus ( CA-MRSA ) infection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1389 : 
        {
          1 : "NN dobj VBD dep NNS dep VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* dep days dep receiving dobj injection nmod drug0"
            }
          4 : 
            {
              1 : "Three days after receiving intravitreal injection of drug1 ( 1.25 mg in 0.1 ml ) , he developed drug2 and change of consciousness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1390 : 
        {
          1 : "NN nsubj JJ advcl VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *reversible* advcl cause nsubj drug0"
            }
          4 : 
            {
              1 : "While both drug1 and digoxin can cause permanent visual changes , the drug2 are often reversible . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1391 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl:relcl NN dobj VBG acl NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj clarithromycin nmod use nmod precipitated acl:relcl lovastatin dobj taking acl patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To describe two cases of drug1 in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1392 : 
        {
          1 : "NN conj NNS dobj VBD acl:relcl NNS acl:relcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj seizures dobj experienced acl:relcl *children* acl:relcl associated nsubjpass drug0"
            }
          4 : 
            {
              1 : "A review of the literature found 11 children and 2 adults in whom intranasal drug1 was associated with hyponatremia , all of whom experienced seizures or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1393 : 
        {
          1 : "NN root , punct NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct *test* nmod administration nmod drug0"
            }
          4 : 
            {
              1 : "In a postural challenge test after administration of drug1 ( 5 mg ) , drug2 from 120/67 to 65/35 mmHg , followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1394 : 
        {
          1 : "NN nmod NNS nmod NNS root , punct JJ root IN acl NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod manifestations nmod drugs root , punct non-steroidal root of acl variety conj *interaction* nmod drug0"
            }
          4 : 
            {
              1 : "Previous studies have demonstrated the interaction of drug1 and a variety of non-steroidal , anti-inflammatory drugs ( NSAIDs ) with various clinical manifestations including drug2 , pancytopenia , vomiting , diarrhea , elevated liver transaminases , jaundice , mucosal ulcerations , and pyrexia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1395 : 
        {
          1 : "NN compound NN nmod NNS dobj VBN advcl VBD dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound monotherapy nmod doses dobj received advcl *developed* dobj lymphoma appos drug0"
            }
          4 : 
            {
              1 : "A 40-year-old man with relapsing-remitting multiple sclerosis ( MS ) developed primary central nervous system lymphoma ( drug1 ) after having received 21 doses of drug2 monotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1396 : 
        {
          1 : "NN dep NNS nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep inhibitors nmod secondary amod *drug0*"
            }
          4 : 
            {
              1 : "In the present paper the authors describe 2 female patients who developed drug1 secondary to the selective serotonin reuptake inhibitors drug2 and sertraline , as well as a third who developed this side effect on venlafaxine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1397 : 
        {
          1 : "NN nmod NNS nmod NN nmod VBN nsubjpass NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod list nmod *added* nsubjpass development nmod vasculitis conj drug0"
            }
          4 : 
            {
              1 : "The possible development of a drug-induced vasculitis or drug1 should be added to the list of rare toxic effects of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1398 : 
        {
          1 : "NN nmod JJ conj NN parataxis JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod responsible conj agent parataxis *effective* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy ; however , it is a vasospastic agent and may have been responsible for the drug2 in one patient . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1399 : 
        {
          1 : "NN nmod VBN acl:relcl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod induced acl:relcl *anemia* appos drug0"
            }
          4 : 
            {
              1 : "We describe a case of severe aplastic anemia ( drug1 ) that was probably induced by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1400 : 
        {
          1 : "NN appos NN dep VBD acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos dizziness dep caused acl:relcl *interaction* nmod propafenone conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This is the first report of a possible interaction between propafenone and drug1 , which caused propafenone adverse effects ( eg , dizziness , drug2 ) and mimicked coronary artery disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1401 : 
        {
          1 : "NN nmod VBN advcl VB dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod started advcl *develop* dobj acidosis compound drug0"
            }
          4 : 
            {
              1 : "A 60-year-old white man with chronic bronchitis was noted to develop drug1 and metabolic acidosis four days after being started on methazolamide ( drug2 ) for an ophthalmologic problem . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1402 : 
        {
          1 : "NN nsubj VBN conj VBD advcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj resolved conj *improved* advcl discontinuing dobj drug0"
            }
          4 : 
            {
              1 : "After discontinuing drug1 and starting systemic steroids , her symptomatology rapidly improved , and her drug2 and radiographic abnormalities both resolved . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1403 : 
        {
          1 : "NN nmod NNS nmod VB nsubj NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cases nmod *result* nsubj prevalence conj treatment nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : The increasing prevalence of Type 2 diabetes and its treatment with drug1 might result in more cases of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1404 : 
        {
          1 : "NN appos NN dobj VBG dep NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos trimethoprim dobj receiving dep weeks nmod eosinophilia conj *drug0*"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with drug1 , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( drug2 ) - sulfamethoxazole ( SMX ) treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1405 : 
        {
          1 : "NN conj NN nmod NNS dobj VBD acl:relcl NN nmod NN dobj VBP parataxis VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj paclitaxel nmod cycles dobj received acl:relcl woman nmod case dobj describe parataxis *reported* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 caused by paclitaxel toxicity has not been reported In this report , we describe the case of a 62-year-old woman who received six cycles of paclitaxel and drug2 as combination chemotherapy for advanced ovarian cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1406 : 
        {
          1 : "NN dobj VB xcomp VBN ccomp VB nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj take xcomp continued ccomp *say* nmod episodes nmod drug0"
            }
          4 : 
            {
              1 : "Only after three subsequent episodes of severe , symptomatic drug1 over the next four weeks did he say , upon repeat questioning , that he had continued to take drug2 for night leg cramps . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1407 : 
        {
          1 : "NN appos NN conj NN nmod NN nmod VBP dobj NN nmod NN acl VBN nmod NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos vindesine conj cisplatin nmod chemotherapy nmod *report* dobj patient nmod adenocarcinoma acl complicated nmod syndrome nmod secretion nmod hormone appos drug0"
            }
          4 : 
            {
              1 : "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( drug1 ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1408 : 
        {
          1 : "NN appos NN nmod NN nmod VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos oxcarbazepine nmod introduction nmod *evolved* nmod drug0"
            }
          4 : 
            {
              1 : "The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into drug1 after the introduction of oxcarbazepine ( drug2 ) , as part of a switch off from carbamazepine ( CBZ ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1409 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound syndrome nmod context nmod *case* nmod nephritis compound drug0"
            }
          4 : 
            {
              1 : "This case of drug1 acute interstitial nephritis within the context of a drug2 ( DRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1410 : 
        {
          1 : "NN conj NN nmod VBN advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj phenylbutazone nmod described advcl *associated* nmod drug0"
            }
          4 : 
            {
              1 : "It should be recognized that ibuprofen may be associated with drug1 in the same fashion as previously described with phenylbutazone and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1411 : 
        {
          1 : "NN compound NN nmod VBD conj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod occurred conj *persisted* nsubj drug0"
            }
          4 : 
            {
              1 : "Despite administration of phenytoin and lorazepam , the drug1 persisted and occurred only during drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1412 : 
        {
          1 : "NN dobj VBD conj NN nmod VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj nausea nmod *administered* dobj drug0"
            }
          4 : 
            {
              1 : "She was administered drug1 because of nausea and , within 2 hours , developed drug2 , dysarthria , diaphoresis , and a movement disorder . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1413 : 
        {
          1 : "VB xcomp VBD nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp *led* nsubj neuropathy conj drug0"
            }
          4 : 
            {
              1 : "However , peripheral neuropathy and drug1 led to drug2 withdrawal in seven patients , and neuropathy may not be fully reversible in all patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1414 : 
        {
          1 : "NN nmod NN nmod RB conj NN nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod combination nmod recently conj alfa nmod *observations* nmod appearance nmod drug0"
            }
          4 : 
            {
              1 : "There have been more than 20 observations of the appearance or aggravation of this drug1 with interferon alfa and more recently with the combination of drug2 plus ribavirin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1415 : 
        {
          1 : "NN nmod NN dobj VBG acl NN nmod NN dobj JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod role dobj exemplifying acl hepatitis nmod cause dobj *likely* nsubj drug0"
            }
          4 : 
            {
              1 : "In this case drug1 was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1416 : 
        {
          1 : "NN nmod VBN acl NN nmod NN nmod VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl pressure nmod increase nmod *resulted* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "Administration of intravenous drug1 in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a drug2 that is best explained by an increase in pulmonary vascular resistance . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1417 : 
        {
          1 : "NN nmod NN nmod VBD dobj NN amod JJ nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *developed* dobj syndrome amod related nmod glomerulopathy nmod evidence nmod drug0"
            }
          4 : 
            {
              1 : "We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of drug1 after treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1418 : 
        {
          1 : "NN dobj VBD advmod RB nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* advmod prior nmod use nmod drug0"
            }
          4 : 
            {
              1 : "Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of drug1 developed drug2 following an MP pulse therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1419 : 
        {
          1 : "NN appos NNS nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos agents nmod *effect* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a relatively rare side effect with the newer atypical antipsychotic agents , particularly drug2 , and is easily misdiagnosed in children . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1420 : 
        {
          1 : "NN conj NNS nmod VBN acl NNS nmod VBN nsubjpass VB nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj corticosteroids nmod treated acl patients nmod *described* nsubjpass flare nmod sarcoma appos drug0"
            }
          4 : 
            {
              1 : "Flare of Kaposi 's sarcoma ( drug1 ) is well described in immunosuppressed patients treated with corticosteroids and drug2 , but has not yet been reported during treatment with imatinib . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1421 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl patients nmod percent nmod *reported* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 have been reported in less than one percent of the patients receiving drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1422 : 
        {
          1 : "NN appos NN compound NN nmod VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos thiomalate compound injection nmod *corresponding* nmod drug0"
            }
          4 : 
            {
              1 : "The first patient developed mild nitritoid symptoms and pain in a band-like distribution , corresponding to drug1 , shortly after gold sodium thiomalate ( drug2 ) injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1423 : 
        {
          1 : "NN nmod NN nmod VBN advcl VBD xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dosage nmod withdrawn advcl *became* xcomp drug0"
            }
          4 : 
            {
              1 : "A case is presented in which a 68-year-old man became drug1 after being withdrawn from a low dosage of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1424 : 
        {
          1 : "NN nmod NNS nsubjpass VBN advcl VBG nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nsubjpass *observed* advcl growing nsubj use nmod drug0"
            }
          4 : 
            {
              1 : "However , as the use of drug1 is growing , adverse side effects , including drug2 , should be observed with an increased frequency . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1425 : 
        {
          1 : "NN appos NN nmod VB acl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos tadalafil nmod use acl *diagnosis* nmod owing compound drug0"
            }
          4 : 
            {
              1 : "RESULTS : A clinical diagnosis of drug1 owing to use of the PDE5 inhibitor tadalafil ( drug2 ) was made . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1426 : 
        {
          1 : "NN dobj VBD nsubj NNS acl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patients acl receiving dobj treatment compound drug0"
            }
          4 : 
            {
              1 : "Three patients receiving drug1 salt treatment for rheumatoid arthritis developed severe drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1427 : 
        {
          1 : "NN conj NN nmod NN dobj VBD dep VBN advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj arm nmod weakness dobj developed dep *resolved* advcl changed nmod drug0"
            }
          4 : 
            {
              1 : "When SASP was changed to drug1 ( 5-ASA ) , his skin eruptions were resolved , however , he developed weakness and atrophy in his right arm as well as progressive drug2 in his legs and gait disturbance . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1428 : 
        {
          1 : "NN nmod VBN dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *required* dobj desensitization compound drug0"
            }
          4 : 
            {
              1 : "METHODS : The patient required drug1 desensitization for drug2 , angioedema , and occasional wheezing resulting from her insulin dose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1429 : 
        {
          1 : "NN dobj VBG acl:relcl NNS nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl:relcl patients nmod *seen* nsubjpass type nmod drug0"
            }
          4 : 
            {
              1 : "Although this type of drug1 has been previously seen in patients with cancer who are receiving drug2 , this is , to our knowledge , the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1430 : 
        {
          1 : "NN nmod VBG advcl VBN conj JJ conj VBN dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod switching advcl removed conj able conj *required* dobj placement conj drug0"
            }
          4 : 
            {
              1 : "One patient required nursing home placement and a drug1 as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from drug2 to clozapine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1431 : 
        {
          1 : "NN nmod NN nmod NN conj NN nmod VBN advcl VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod reversal conj history nmod evidenced advcl *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of drug1 associated with interaction between fentanyl and citalopram , as evidenced by medication history , clinical features and reversal following discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1432 : 
        {
          1 : "NN dobj VBG acl NN nmod VBG nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl patient nmod *occurring* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurring in a patient taking drug2 plus methotrexate for rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1433 : 
        {
          1 : "NN compound NN nmod VBN acl NN appos NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod induced acl *myositis* appos fever conj drug0"
            }
          4 : 
            {
              1 : "We describe a case of disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , drug1 , and inflammatory reaction around dying cysticerci ) induced by drug2 therapy , an event not described previously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1434 : 
        {
          1 : "NN compound NN nmod NN nmod VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound mg nmod therapy nmod *developed* dobj syndrome compound drug0"
            }
          4 : 
            {
              1 : "We reported 3 patients who developed drug1 and akinetic rigid syndrome following an initial therapy with drug2 125-500 mg daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1435 : 
        {
          1 : "NN compound NNS nsubj VBD advcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound concentrations nsubj remained advcl *persisted* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 persisted more than 6 months while drug2 concentrations remained detectable for at least 80 days . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1436 : 
        {
          1 : "VB xcomp VBD conj VBD nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp led conj *worsened* nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent drug1 treatment and led to drug2 within 3 weeks . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1437 : 
        {
          1 : "NN xcomp VBZ acl:relcl NN dobj VB acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp resembles acl:relcl hepatotoxicity dobj cause acl *potential* nmod drug0"
            }
          4 : 
            {
              1 : "We stress the potential of drug1 to cause hepatotoxicity , which usually resembles drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1438 : 
        {
          1 : "NN nmod VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *describe* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We describe a case of needle-track drug1 of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous drug2 ( PEI ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1439 : 
        {
          1 : "NN nmod VB csubj VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *lead* csubj switching nmod drug0"
            }
          4 : 
            {
              1 : "DISCUSSION : This case shows that switching to drug1 potentially can lead to a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1440 : 
        {
          1 : "NN nmod NN dobj VBD advcl VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose dobj received advcl *developed* dobj herniation compound drug0"
            }
          4 : 
            {
              1 : "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed drug1 and brainstem herniation after she received a single dose of intravenous drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1441 : 
        {
          1 : "NN nmod NN nmod NN nmod NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod drug nmod exposure nmod association dep *drug0*"
            }
          4 : 
            {
              1 : "drug1 : possible association with long-term exposure to an anti-epileptic drug of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1442 : 
        {
          1 : "NN appos NN nmod VBN nsubjpass NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos congenita nmod *associated* nsubjpass drugs appos drug0"
            }
          4 : 
            {
              1 : "However , there remain questions concerning whether these drugs , especially drug1 ( MMI ) , may be associated with aplasia cutis congenita ( drug2 ) and how best to avoid impairment of fetal thyroid function during their use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1443 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod *determined* nsubjpass concentrations compound drug0"
            }
          4 : 
            {
              1 : "The drug1 and plasma concentrations of ifosfamide , chloroacetaldehyde , and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1444 : 
        {
          1 : "VB xcomp VBN acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp exposed acl infant nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in an infant exposed to drug2 in breast milk . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1445 : 
        {
          1 : "NN appos NN nmod VBZ ccomp VBD conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos reaction nmod results ccomp were conj *taken* dobj drug0"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken drug1 for 6 months , and there were strong positive photopatch test results with immediate erythema reaction , drug2 , decreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1446 : 
        {
          1 : "NN nmod VBN acl NN dobj VBD nsubj NN acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod accompanied acl thyrotoxicosis dobj *developed* nsubj patient acl:relcl taking dobj drug0"
            }
          4 : 
            {
              1 : "Among 12 thyrotoxic patients , a patient with arrhythmogenic right ventricular dysplasia , who had been taking drug1 for 4 years , developed thyrotoxicosis with subacute onset , accompanied by drug2 ( TRAb ) , or thyrotropin-binding inhibiting immunoglobulin ( TBII ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1447 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl:relcl received dobj dose nmod drug0"
            }
          4 : 
            {
              1 : "A 59-year-old woman with myasthenia gravis who received a large dose of drug1 developed drug2 and was diagnosed as having bromide intoxication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1448 : 
        {
          1 : "NN nmod VBN acl NN nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod induced acl nephrotoxicity nmod *type* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is one type of nephrotoxicity induced by drug2 , and it is reversible in mild cases when appropriately treated . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1449 : 
        {
          1 : "NN nmod NN nmod VBN acl NN dep CD nmod VBD nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod syncope nmod followed acl mmhg dep 0/0 nmod *decreased* nmod test nmod administration nmod drug0"
            }
          4 : 
            {
              1 : "In a postural challenge test after administration of drug1 ( 5 mg ) , blood pressure decreased from 120/67 to 65/35 mmHg , followed by syncope with a drug2 from 85 to 60 beats/min . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1450 : 
        {
          1 : "NN dobj VBP acl:relcl NNS nmod NN dobj VBG acl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj have acl:relcl patients nmod edema dobj revealing acl *technique* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : During and after drug1 therapy , OCT is a useful examination technique for revealing macular edema in patients who have drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1451 : 
        {
          1 : "NN nsubjpass VBN acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass reviewed acl:relcl *cases* nmod drug0"
            }
          4 : 
            {
              1 : "The 9 other reported cases of drug1 induced drug2 have been reviewed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1452 : 
        {
          1 : "NN nmod NN nmod VBN advcl VB acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod combination nmod used advcl occur acl:relcl *sign* nmod drug0"
            }
          4 : 
            {
              1 : "We consider asterixis to be an easily overlooked sign of drug1 , which may occur even at low or moderate dosage levels , if certain drugs as lithium or clozapine are used in combination with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1453 : 
        {
          1 : "NN nmod VBN acl NNS nmod VB dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod started acl days nmod *develop* dobj failure conj drug0"
            }
          4 : 
            {
              1 : "A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and drug1 four days after being started on methazolamide ( drug2 ) for an ophthalmologic problem . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1454 : 
        {
          1 : "NN conj NN nmod VBG advcl NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj olanzapine nmod receiving advcl *rigidity* conj levels compound drug0"
            }
          4 : 
            {
              1 : "A 16-year-old boy developed fever , generalized rigidity , leukocytosis , and drug1 levels while receiving treatment with olanzapine and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1455 : 
        {
          1 : "NN nmod VBN acl:relcl NNS nmod VBN nsubj NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl yrs nmod *developed* nsubj diarrhoea conj drug0"
            }
          4 : 
            {
              1 : "Diarrhoea , drug1 and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age , who was treated with drug2 and 5-fluorouracil for unresectable rectum carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1456 : 
        {
          1 : "NN nmod NN dobj VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod accumulation dobj *implicate* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 of three patients and the timing of the seizures implicate accumulation of drug2 as a contributing factor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1457 : 
        {
          1 : "NN compound NN nmod NN root IN dep RB advmod VBN nsubjpass NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod administration root after dep shortly advmod *demonstrated* nsubjpass prolongation nmod interval conj drug0"
            }
          4 : 
            {
              1 : "We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and drug1 on electrocardiogram was demonstrated reproducibly shortly after the administration of oral drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1458 : 
        {
          1 : "NN compound NN nmod VB dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound injection nmod *report* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "PURPOSE : To report two cases of drug1 following intravitreal drug2 injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1459 : 
        {
          1 : "NN dobj VBN xcomp VBP advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj caused xcomp *appear* advcl shown nsubjpass drug0"
            }
          4 : 
            {
              1 : "Although high-dose drug1 has been shown to be useful in the treatment of primary osteogenic sarcoma , the tumoricidal effects of therapy appear to have caused a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1460 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod thrombocythemia nmod evolving acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 evolving from essential thrombocythemia in two patients treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1461 : 
        {
          1 : "NN dobj VBG dep JJ dep NNS nmod VBD dobj NNS amod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving dep first dep weeks nmod *developed* dobj symptoms amod suggestive nmod drug0"
            }
          4 : 
            {
              1 : "A 55-year-old woman developed symptoms suggestive of drug1 12 weeks after first receiving drug2 for hypertension . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1462 : 
        {
          1 : "NN dobj VBD nsubj NNS acl VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patients acl treated nmod doses nmod drug0"
            }
          4 : 
            {
              1 : "Two patients treated for chronic myeloid leukemia with high doses of drug1 ( 1100 mg/m2 and 1240 mg/m2 , respectively ) developed a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1463 : 
        {
          1 : "NN conj NNS nsubj VBN nmod NNS conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj symptoms nsubj *resolved* nmod hours conj cessation nmod drug0"
            }
          4 : 
            {
              1 : "Within 24 hours of fluid restriction and cessation of drug1 , her symptoms and drug2 resolved . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1464 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mg/kg/d nmod received acl:relcl patients nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "INTERVENTIONS AND RESULTS : drug1 were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1465 : 
        {
          1 : "NN compound NN conj NN nmod VBN acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use conj alpha-0a nmod associated acl *syndrome* appos drug0"
            }
          4 : 
            {
              1 : "We report the first case of fulminant adult respiratory distress syndrome ( drug1 ) associated with pegylated interferon alpha-2a ( pegIFNalpha-2a ) and drug2 use for hepatitis C , complicated by subsequent and ultimately fatal sepsis and multiorgan failure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1466 : 
        {
          1 : "NN conj NN nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj downgrowth nmod secondary amod *drug0*"
            }
          4 : 
            {
              1 : "drug1 secondary to epithelial downgrowth and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1467 : 
        {
          1 : "NN appos NN conj NN nmod NN nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acid conj lopinavir/ritonavir nmod interaction nmod related amod *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVE : To describe a case of exacerbated drug1 potentially related to an interaction between lopinavir/ritonavir and valproic acid ( drug2 ) and propose a mechanism of action for this interaction . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1468 : 
        {
          1 : "NN nsubj VBZ ccomp NN nmod VB conj VBP nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj damages ccomp evidence nmod add conj *correspond* nmod drug0"
            }
          4 : 
            {
              1 : "These are the first reported patients to show mfERG abnormalities that correspond to drug1 and add to the growing evidence that drug2 damages the retina . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1469 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod NN nmod VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod start dep months nmod number nmod *increased* advcl had dobj drug0"
            }
          4 : 
            {
              1 : "Although they had only a few drug1 at diagnosis , the nodules increased in number and size 3 to 4 months after the start of drug2 therapy in both patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1470 : 
        {
          1 : "NN nmod VBG xcomp VBD advcl VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod worsening xcomp *developed* advcl undergoing dobj treatment nmod drug0"
            }
          4 : 
            {
              1 : "While undergoing treatment with drug1 , he developed worsening diarrhea with drug2 and fever . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1471 : 
        {
          1 : "NN appos NN compound NN nmod VBD conj VBP dobj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acid compound intoxication nmod raised conj *describe* dobj management nmod patient nmod drug0"
            }
          4 : 
            {
              1 : "INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with drug1 and raised intracranial pressure ( ICP ) after severe sodium valproic acid ( drug2 ) intoxication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1472 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj carboplatin nmod treated acl patient nmod *present* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We present a case of drug1 in an advanced ovarian cancer patient treated with carboplatin and drug2 , and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1473 : 
        {
          1 : "NN nmod JJ amod NN dobj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consistent amod pain dobj *precipitated* nsubj drug0"
            }
          4 : 
            {
              1 : "We present the case of a patient who had undergone cholecystectomy previously , but in whom drug1 given in the Emergency Department precipitated pain consistent with drug2 ; the pain resolved promptly after administration of naloxone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1474 : 
        {
          1 : "NN nmod NNS nmod NN nmod NN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod reports nmod abundance nmod subject acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Retrospectively , bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to drug1 , which was the subject of an abundance of reports of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1475 : 
        {
          1 : "NN nmod VBN root , punct NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented root , punct *months* nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who , after 2 months of treatment with drug1 , presented with drug2 , scaling , nausea and vomiting , and fever . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1476 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl NNS conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cessation nmod normalized acl:relcl patients conj *given* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Six patients developed peripheral neuropathy and five patients drug1 , blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1477 : 
        {
          1 : "NN nmod VBN acl:relcl JJ nmod NN nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod given acl:relcl particular nmod mmf nmod *occur* nsubj drug0"
            }
          4 : 
            {
              1 : "This report suggests that drug1 can occur due to MMF , in particular when it is given with drug2 , a side effect well documented in the transplantation literature when the triple combination of MMF , cyclosporine and prednisone is used . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1478 : 
        {
          1 : "NN dobj VBG advcl VBZ nsubj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj precipitating advcl *is* nsubj role nmod administration compound drug0"
            }
          4 : 
            {
              1 : "There is a putative role of drug1 administration in precipitating or activating drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1479 : 
        {
          1 : "NN nmod NN nmod NNS nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injection nmod patients nmod *describe* dobj occurrence nmod drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : To describe the occurrence of drug1 in four patients following injection of drug2 intravitreally . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1480 : 
        {
          1 : "NN conj NN nmod NN nmod VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj quetiapine nmod treatment nmod *presented* nmod drug0"
            }
          4 : 
            {
              1 : "METHOD : We describe two patients who presented with drug1 after treatment with quetiapine and drug2 , respectively . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1481 : 
        {
          1 : "NN compound NN dep NNS nmod VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound reaction dep effects nmod associated conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is widely used against methicillin-resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an drug2 reaction known as `` red man syndrome '' and anaphylaxis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1482 : 
        {
          1 : "NN compound NN nmod VBG acl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod occurring acl *pelvis* conj drug0"
            }
          4 : 
            {
              1 : "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and drug1 occurring after chronic drug2 therapy for nonHodgkin 's lymphoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1483 : 
        {
          1 : "NN nmod NNS nmod VBD dobj NN nmod NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod times nmod *presented* dobj episode nmod seizures conj drug0"
            }
          4 : 
            {
              1 : "Two children , 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis , presented an episode of seizures and drug1 at different times after i.v. pulse drug2 ( IVPMP ) treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1484 : 
        {
          1 : "NN nmod NNS nmod NN dobj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod products nmod derivation dobj *suggested* nsubj examination nmod drug0"
            }
          4 : 
            {
              1 : "Histological examination of the drug1 suggested its derivation from breakdown products of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1485 : 
        {
          1 : "NN dep NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep drug nmod *concentrations* compound drug0"
            }
          4 : 
            {
              1 : "drug1 tissue concentrations in a multiple drug related drug2 involving Ambien . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1486 : 
        {
          1 : "NN nmod VBN advcl VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated advcl *developed* dobj papilloedema conj drug0"
            }
          4 : 
            {
              1 : "A patient developed papilloedema and drug1 while being treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1487 : 
        {
          1 : "NN conj NN nmod NNS dobj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hyperhidrosis nmod effects dobj *causes* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 , an opium alkaloid , frequently causes side effects such as hyperhidrosis and drug2 , but serious cutaneous adverse drug reactions are seldom observed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1488 : 
        {
          1 : "NN conj NNP dobj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj siadh dobj *cause* nsubj drug0"
            }
          4 : 
            {
              1 : "Clinicians should be aware of the possibility that drug1 may cause SIADH and possibly drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1489 : 
        {
          1 : "NN nmod NN nmod JJ dep JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod related dep likely amod *drug0*"
            }
          4 : 
            {
              1 : "drug1 likely related to the use of drug2 for chronic constipation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1490 : 
        {
          1 : "NN dep NNS appos NN dobj VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep alkaloids appos s dobj taking advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a case of a previously healthy , postmenopausal woman who developed drug1 while taking Bellamine S ( belladonna alkaloids ; drug2 ; phenobarbital ) for hot flashes . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1491 : 
        {
          1 : "NN compound NNS nsubj VBD conj VBG conj VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound symptoms nsubj disappeared conj *taking* conj stopped dobj medications nmod drug0"
            }
          4 : 
            {
              1 : "She continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained-release drug1 , and her drug2 symptoms disappeared . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1492 : 
        {
          1 : "NN nmod NNS nmod NN acl:relcl NNS nmod JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod congeners nmod treatment acl:relcl patients nmod *present* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 was present in two epileptic patients who were under long-term treatment with congeners of drug2 , phenobarbital , and acetazolamide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1493 : 
        {
          1 : "NN compound NN nmod NN nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *effect* nsubj syndrome compound drug0"
            }
          4 : 
            {
              1 : "Though drug1 and nephrotic syndrome is a rare adverse effect of drug2 therapy , physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1494 : 
        {
          1 : "NN compound NNS dobj VBG acl NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound combinations dobj receiving acl patients nmod *reports* nmod drug0"
            }
          4 : 
            {
              1 : "This is the first reported case of BOOP associated with single-agent rituximab , and along with two other patients we describe , as well as two prior reports of drug1 in NHL patients receiving drug2 combinations , strengthens the possibility of a causal relationship . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1495 : 
        {
          1 : "NN nmod VBD acl:relcl NN nmod CD conj CD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented acl:relcl dextroamphetamine nmod 0 conj *0* nmod drug0"
            }
          4 : 
            {
              1 : "We report 4 patients , 2 on drug1 and 2 on dextroamphetamine who presented with drug2 , livedo reticularis , or Raynaud phenomenon . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1496 : 
        {
          1 : "NN nmod VB dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *provide* dobj benefits nmod drug0"
            }
          4 : 
            {
              1 : "Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of drug1 without significant drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1497 : 
        {
          1 : "NN conj NN nmod NNS nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hyaluronate nmod injections nmod *admitted* nmod drug0"
            }
          4 : 
            {
              1 : "One patient was an 80-year-old woman who was admitted for drug1 after several intraarticular injections of sodium hyaluronate and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1498 : 
        {
          1 : "NN nmod VBZ nsubj NN nmod NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *implicates* nsubj site nmod thrombosis conj relationship nmod drug0"
            }
          4 : 
            {
              1 : "The site of thrombosis and the chronological relationship with the drug1 implicates a hypersensitivity to drug2 in the causation of the venous thrombosis in this case . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1499 : 
        {
          1 : "NN nmod VBG acl NN nmod VBN nsubjpass NN acl:relcl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod suffering acl unit nmod *admitted* nsubjpass boy acl:relcl treated nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "An 11-year-old boy who was treated with a relatively high dose of drug1 ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1500 : 
        {
          1 : "NN dobj VBZ dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj has dep *drug0*"
            }
          4 : 
            {
              1 : "drug1 ( Clinoril ) , a nonsteroidal anti-inflammatory agent , has few reported drug2 , all of which have been associated with systemic disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1501 : 
        {
          1 : "NN nmod NN nmod VBD dobj JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *displayed* dobj psychotic conj drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To our knowledge , this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and drug1 during treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1502 : 
        {
          1 : "NN dep VB conj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep aggravate conj *induce* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 may induce , or aggravate , pre-existing , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1503 : 
        {
          1 : "NN nmod NN nmod NN conj NN nmod VBN conj JJ nsubj NN nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod referral nmod potentiation conj vasodilatation nmod related conj *uncertain* nsubj cause nmod effects nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "The cause of these previously unreported side effects of drug1 therapy is uncertain but may be related to prostaglandin-mediated vasodilatation , hyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1504 : 
        {
          1 : "NN nsubjpass VBN conj JJ nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass limited conj *rare* nsubj effects nmod drug0"
            }
          4 : 
            {
              1 : "Allergic side effects of drug1 are rare , and reported drug2 from AZA are very limited in Japan . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1505 : 
        {
          1 : "NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *resulted* nsubj overkill nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose drug1 with folinic acid rescue , resulted in the drug2 ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1506 : 
        {
          1 : "NN nmod NNS nsubj NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *causes* nsubj quinine conj drug0"
            }
          4 : 
            {
              1 : "Quinine and its isomer drug1 are well-known causes of drug2 , due to excessive insulin secretion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1507 : 
        {
          1 : "NN appos NNP dobj VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos kalimate dobj following acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a rare case of drug1 following Kalimate ( drug2 ) , an analogue of Kayexalate without sorbitol in a 34-yr-old man . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1508 : 
        {
          1 : "NN dobj VBD conj VBD dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *received* dobj gabapentin appos drug0"
            }
          4 : 
            {
              1 : "We report two adults who received gabapentin ( drug1 ) and subsequently developed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1509 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl cancer nmod *egfr-inhibitor* appos drug0"
            }
          4 : 
            {
              1 : "We describe a case of a man treated with an EGFR-inhibitor ( drug1 ) for a cell lung cancer who developed drug2 localized in an uncommon area and with an atypical evolution . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1510 : 
        {
          1 : "NN root , punct NN root , punct PRP nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct myelosuppression root , punct them nmod *arabinoside* appos drug0"
            }
          4 : 
            {
              1 : "Thirty-six patients with AL received , in a three-month period , 51 cycles of combined chemotherapy which included , in all of them , cytosine arabinoside ( drug1 ) ; among them , along with myelosuppression , five experienced drug2 , infectious complications , gastrointestinal tract symptoms and severe myalgias . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1511 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod initiation dep months nmod *developed* dobj features nmod drug0"
            }
          4 : 
            {
              1 : "A 67-year-old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of drug1 3 months after initiation of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1512 : 
        {
          1 : "NN dobj LS parataxis VBN nsubjpass NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj b parataxis *divided* nsubjpass causes nmod keratitis compound drug0"
            }
          4 : 
            {
              1 : "Potential causes of drug1 keratitis can be divided into four categories resulting from ( a ) direct pharmacologic and physical effects of methamphetamine ; ( b ) the drug2 of diluting or `` cutting '' agents such as lidocaine and quinine ; ( c ) effects related to the route of drug administration ( intravenous , inhalation , smoking ) ; and ( d ) manufacture-related effects of exposure to unintentional caustic contaminants in the final product . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1513 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN nmod VBD nsubj CD nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod series nmod *occurred* nsubj seven nmod cases nmod drug0"
            }
          4 : 
            {
              1 : "Seven of the eight cases of drug1 occurred in a series of 553 patients treated with drug2 for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient-years up to February 1978 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1514 : 
        {
          1 : "NN nmod NN conj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod association conj *complications* nmod drug0"
            }
          4 : 
            {
              1 : "We discuss a variety of bronchopulmonary complications of drug1 and their association with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1515 : 
        {
          1 : "NN compound NN nmod NN dobj VB nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound formation nmod risk dobj *clarify* nsubj study nmod groups nmod drug0"
            }
          4 : 
            {
              1 : "A study following large patient groups on drug1 and a combination of theophylline and steroids might clarify the risk of drug2 formation in patients being treated with these medications for asthma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1516 : 
        {
          1 : "NN conj NN nmod VBN nsubjpass NN nmod NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj methemoglobinemia nmod *followed* nsubjpass administration nmod spirits appos drug0"
            }
          4 : 
            {
              1 : "The administration of `` sweet spirits of nitre '' ( drug1 ) was followed by acute methemoglobinemia and drug2 in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1517 : 
        {
          1 : "NN conj NN nmod NNS dobj VBD nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj tightness nmod episodes dobj *experienced* nmod months nmod drug0"
            }
          4 : 
            {
              1 : "Three months after starting drug1 , she experienced episodes of chest tightness and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1518 : 
        {
          1 : "NN nmod NNS nmod VBN nmod NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complaints nmod *presented* nmod days dep drug0"
            }
          4 : 
            {
              1 : "Four days after intravenous drug1 , the patient presented to emergency room with complaints of drug2 and bronchospasm . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1519 : 
        {
          1 : "NN dep VBD acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep caused acl:relcl *interaction* nmod propafenone conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This is the first report of a possible interaction between propafenone and drug1 , which caused propafenone adverse effects ( eg , drug2 , falls ) and mimicked coronary artery disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1520 : 
        {
          1 : "NN compound NN dobj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound vigilance dobj *cause* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Under certain circumstances topical drug1 can cause drug2 necessitating vigilance in follow-up of patients on topical brimonidine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1521 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod NNS nmod VBN nsubjpass NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj chemotherapy nmod treated acl leukemia nmod patients nmod *reported* nsubjpass cancers nmod types nmod drug0"
            }
          4 : 
            {
              1 : "Second cancers including various types of drug1 have been reported in patients with hairy cell leukemia treated with chemotherapy or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1522 : 
        {
          1 : "NN nmod NN nmod NNS acl VBG dobj NNS acl VBG dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *studies* acl describing dobj patients acl experiencing dobj recurrences nmod drug0"
            }
          4 : 
            {
              1 : "There are , however , case studies describing patients experiencing recurrences of drug1 following treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1523 : 
        {
          1 : " NN nsubj NNS acl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : " *drug0* nsubj patients acl treated nmod cc nmod drug0"
            }
          4 : 
            {
              1 : "Postoperatively , the first two patients treated with 1 to 2 cc of drug1 were drug2 ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography , while the other had a moderate-sized frontal hematoma with intracranial hypertension . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1524 : 
        {
          1 : "NN compound NN nmod VBP dobj NN nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *report* dobj case nmod hyponatremia acl associated nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of hyponatremia associated with a drug1 in a 28 month-old child after intra-nasal drug2 administration for high fluid intake with nocturnal enuresis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1525 : 
        {
          1 : "NN dobj VBZ acl:relcl NN nmod NN nmod VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj accompanies acl:relcl dysfunction nmod presence nmod *pronounced* nsubjpass effects nmod drug0"
            }
          4 : 
            {
              1 : "We conjectured that the side effects of drug1 , such as anti-natriuresis and increased vascular permeability , might be pronounced in the presence of the hepatic dysfunction that accompanies drug2 , hyperinsulinaemia and hypoalbuminaemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1526 : 
        {
          1 : "NN nmod NN nmod NNS nmod NN dep NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injection nmod eyes nmod *man* dep defects conj drug0"
            }
          4 : 
            {
              1 : "RESULTS : A 34-year-old man acquired visual field defects and drug1 in both eyes after intravitreal injection of drug2 for diabetic macular edema . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1527 : 
        {
          1 : "NN nmod VBG advcl VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod leading advcl *interfere* nsubj drug0"
            }
          4 : 
            {
              1 : "It was hypothesized that drug1 may interfere with glucuronidation of lamotrigine , leading to drug2 , or perhaps alter the drug 's metabolism , resulting in accumulation of a toxic intermediate metabolite . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1528 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD dobj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj starting advcl *developed* dobj days compound drug0"
            }
          4 : 
            {
              1 : "A 53-year-old male , without any prior history of psychosis , developed drug1 4 days after starting low-dose drug2 therapy for a macroprolactinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1529 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBN acl NNS nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl women nmod born acl infants nmod defect appos *drug0*"
            }
          4 : 
            {
              1 : "In this article lithium is not discussed , although there are a number of concerns about lithium 's potential teratogenicity , and it has been implicated in drug1 , a congenital heart defect among infants born to women taking drug2 ; as with other medications , however , the data have specific limitations . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1530 : 
        {
          1 : "NN conj NN dobj VB acl JJ dobj VBP dep VBZ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pneumonitis dobj cause acl potential dobj have dep *taxanes* nmod drug0"
            }
          4 : 
            {
              1 : "Physicians should keep in mind that taxanes such as drug1 have the potential to cause pneumonitis and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1531 : 
        {
          1 : "NN nmod VBP conj JJ nsubj NNS amod JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consist conj *uncommon* nsubj effects amod secondary nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Central nervous system effects secondary to drug1 treatment are uncommon and usually consist only of drug2 or mild headache , although rare occurrences of seizures and hallucinations have been reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1532 : 
        {
          1 : "NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod pregnancy nmod treated acl woman nmod *born* nsubjpass girl nmod drug0"
            }
          4 : 
            {
              1 : "An infant girl with drug1 , athelia , minor anomalies , and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with drug2 and propranolol . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1533 : 
        {
          1 : "NN conj NN dobj VBD nsubj NN acl VBG dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj malaise dobj *developed* nsubj woman acl receiving dobj alpha-0a conj drug0"
            }
          4 : 
            {
              1 : "PATIENT AND METHOD : A 34-year-old woman with chronic hepatitis C , genotype 3 , receiving pegylated interferon alpha-2a and drug1 for 6 months , developed progressive malaise and drug2 6 months after the end of treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1534 : 
        {
          1 : "NN conj JJ nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj severe nmod leading acl *drug0*"
            }
          4 : 
            {
              1 : "The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis , and given the interaction of this drug with drug1 leading to severe and even potentially drug2 , the combination use of these drugs should be avoided . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1535 : 
        {
          1 : "NN nmod VBG acl NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod switching acl *man* dep drug0"
            }
          4 : 
            {
              1 : "METHODS : A 68-year-old man developed drug1 and cystoid macula edema after switching from drug2 to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1536 : 
        {
          1 : "NN compound NNS nsubjpass VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound reactions nsubjpass *reported* nmod drug0"
            }
          4 : 
            {
              1 : "With drug1 , drug2 reactions have only very rarely been reported , and histologic data are lacking . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1537 : 
        {
          1 : "NN nmod NNS dobj VBG acl NN dobj VB xcomp VBN acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod symptoms dobj inducing acl propensity dobj have xcomp believed acl:relcl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms , including drug2 ( TD ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1538 : 
        {
          1 : "NN nmod NN nmod VBN advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effect nmod *considered* advcl excluded nsubjpass occurrence nmod drug0"
            }
          4 : 
            {
              1 : "Although both the spontaneous occurrence of drug1 and the psychosis as a sign of CNS involvement of SLE can not be excluded , SLE could be considered as an adverse effect of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1539 : 
        {
          1 : "NN compound NN nmod VBD acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound discontinuation nmod resolved acl:relcl *symptoms* nmod drug0"
            }
          4 : 
            {
              1 : "During clarithromycin coadministration , four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine , such as drug1 , dizziness , and ataxia , which resolved within 5 days after drug2 discontinuation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1540 : 
        {
          1 : "NN dobj VBP nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *induce* nsubj roxithromycin conj drug0"
            }
          4 : 
            {
              1 : "Can roxithromycin and drug1 induce drug2 ? A case report . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1541 : 
        {
          1 : "NN conj NN nmod NNS nmod JJ amod JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj alopecia nmod effects nmod due amod *brief* nsubj treatment nmod drug0"
            }
          4 : 
            {
              1 : "We present a case report of a patient with alveolar hydatid disease , whose treatment with drug1 was brief due to side effects of alopecia and drug2 ; and review the features of this disease which , with increasing international migration , may be encountered more frequently in Australia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1542 : 
        {
          1 : "NN nmod NNS dobj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod parameters dobj *affected* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 apparently adversely affected both the clinical and biochemical parameters of the drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1543 : 
        {
          1 : "NN nsubj VBD nmod NN nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *were* nmod series nmod cases nmod use nmod drug0"
            }
          4 : 
            {
              1 : "In a series of 104 cases of intentional or inadvertent use of drug1 at differing gestations in pregnancy , there were eight spontaneous drug2 , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1544 : 
        {
          1 : "NN conj NNS nmod NNS nsubjpass VBN advcl JJ nsubj NNS amod JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj seizures nmod occurrences nsubjpass reported advcl *uncommon* nsubj effects amod secondary nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Central nervous system effects secondary to drug1 treatment are uncommon and usually consist only of minor dizziness or mild headache , although rare occurrences of seizures and drug2 have been reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1545 : 
        {
          1 : "NN nsubjpass VBN advcl VBN conj VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass withdrawn advcl improved conj *had* dobj drug0"
            }
          4 : 
            {
              1 : "Both had drug1 and abnormal computed tomographic scans , and their condition improved when drug2 was withdrawn and corticosteroid treatment commenced . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1546 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment dobj undergoing acl patients nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in patients undergoing drug2 treatment has been reported , although a definite attribution to bortezomib administration has not been established . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1547 : 
        {
          1 : "NN nsubjpass VBN acl:relcl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass observed acl:relcl *lupus* compound drug0"
            }
          4 : 
            {
              1 : "To our knowledge , this is the first case of drug1 lupus in which drug2 has been observed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1548 : 
        {
          1 : "NN compound NN dobj VBD advcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment dobj received advcl *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "In a patient with severe renovascular hypertension , drug1 developed after she received drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1549 : 
        {
          1 : "NN compound NN nmod NN nmod VBG acl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod patient nmod developing acl *carcinoma* conj drug0"
            }
          4 : 
            {
              1 : "Ovarian endometrioid carcinoma and drug1 developing in a postmenopausal breast cancer patient during drug2 therapy : a case report and review of the literature . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1550 : 
        {
          1 : "NN dep NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep patient nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was observed in a patient given drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1551 : 
        {
          1 : "NN conj NN nmod VBN acl NN conj NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj beta-0a nmod treated acl sclerosis conj *seizures* conj drug0"
            }
          4 : 
            {
              1 : "Seizures and drug1 in a patient with Tourette 's syndrome , Asperger 's syndrome , and multiple sclerosis treated with interferon beta-1a and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1552 : 
        {
          1 : "NN compound NN conj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment conj interferon nmod *onset* compound drug0"
            }
          4 : 
            {
              1 : "drug1 onset after pegylated interferon and drug2 treatment of chronic hepatitis C . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1553 : 
        {
          1 : "NN nmod NN nmod NN acl VBN nmod NN acl VBN nmod NNS amod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *female* acl documented nmod pancreatitis acl presented nmod symptoms amod consistent nmod drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 57-year-old female with cardiomyopathy and `` sulfa '' ( trimethoprim/sulfamethoxazole ) allergy documented as pancreatitis presented with symptoms consistent with drug1 after use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1554 : 
        {
          1 : "NN nmod NN dep NNS nmod NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod biopsy dep years nmod spite nmod *led* nsubj drug0"
            }
          4 : 
            {
              1 : "However , continued low-dose drug1 led , in spite of normal liver tests , 8 years after the last biopsy to drug2 and death in 1 of our patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1555 : 
        {
          1 : "NN nmod NN dobj VB conj VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod relationship dobj review conj *treated* nmod drug0"
            }
          4 : 
            {
              1 : "We describe the development of ischemic colitis in a woman who was treated with drug1 and review the relationship among drug2 , tegaserod use , and irritable bowel syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1556 : 
        {
          1 : "NN nsubjpass VBN advcl VBN parataxis VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass stopped advcl resolved parataxis *diagnosed* nmod drug0"
            }
          4 : 
            {
              1 : "He was diagnosed with possible drug1 ; his symptoms resolved after drug2 was stopped but before clozapine was restarted eight days later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1557 : 
        {
          1 : "NN nmod VBN acl NNS dobj VBG dep WRB dep JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients dobj managing dep when dep *important* nsubj recognition nmod drug0"
            }
          4 : 
            {
              1 : "Recognition of a potential drug-induced drug1 is important when managing pediatric oncology patients previously treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1558 : 
        {
          1 : "NN nmod VBD acl:relcl NN nmod VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulted acl:relcl spasm nmod *resulted* nsubj bolus nmod drug0"
            }
          4 : 
            {
              1 : "We postulate that the bolus of drug1 resulted in possible coronary spasm that resulted in drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1559 : 
        {
          1 : "NN root , punct VBN dep DT root IN nmod VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct delayed dep a root with nmod *associated* nsubjpass dosages nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Low dosages of drug1 used for malaria prophylaxis can be associated with a delayed , drug2 indistinguishable from chloroquine maculopathy in certain patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1560 : 
        {
          1 : "NN nmod NN nmod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod *compatible* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of ST elevation in right precordial leads compatible with drug1 following administration of drug2 in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1561 : 
        {
          1 : "NN conj NN nmod VBP acl:relcl NNS amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fever nmod present acl:relcl *drugs* amod drug0"
            }
          4 : 
            {
              1 : "Physicians should be cognizant of this potential complication in patients receiving drug1 or thalidomide-like drugs who present with fever and drug2 and fail to improve despite treatment with broad-spectrum antibiotics . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1562 : 
        {
          1 : "NN dobj VBG acl NN nmod JJ xcomp VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patient nmod fatal xcomp proved acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Second , we report a case of drug1 , which proved to be fatal in a schizophrenia patient receiving drug2 and thiazide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1563 : 
        {
          1 : "NN conj NN nmod VBG advcl VBG acl NN nmod NN nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj myopia nmod resulting advcl shallowing acl diaphragm nmod displacement nmod effusion nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing , resulting in acute myopia and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1564 : 
        {
          1 : "NN nmod NN nmod VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod *experienced* dobj cessation nmod drug0"
            }
          4 : 
            {
              1 : "Three patients with niacin-induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography , and a fourth patient with no fundus abnormality experienced cessation of drug1 upon discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1565 : 
        {
          1 : "NN compound NN nmod VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound injection nmod corresponding advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "The first patient developed drug1 and pain in a band-like distribution , corresponding to T10-T12 dermatomes , shortly after drug2 ( GSTM ) injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1566 : 
        {
          1 : "NN conj NN dep NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj gefitinib dep inhibitors nmod observed acl *drug0*"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 though rare is occasionally observed with EGFR inhibitors gefitinib or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1567 : 
        {
          1 : "NN compound NN nmod RB advmod VBD advmod RB"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod early advmod *developed* advmod drug0"
            }
          4 : 
            {
              1 : "Experience with five patients in whom drug1 developed early during drug2 therapy is reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1568 : 
        {
          1 : "NN nmod NN nmod VBN acl NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod attributed acl pegvisomant nmod treatment nmod patient nmod *drug0*"
            }
          4 : 
            {
              1 : "Drug-induced drug1 in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1569 : 
        {
          1 : "NN nmod NN dobj VB advcl VB dobj NN nmod NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presence dobj reveal advcl *carry* dobj study nmod patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "The authors intend to carry out a case-control study on patients treated with drug1 for breast carcinoma to reveal the possible presence of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1570 : 
        {
          1 : "NN nmod VBN advcl VBN conj VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated advcl *gained* conj developed dobj drug0"
            }
          4 : 
            {
              1 : "The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued , and the 2 women who had gained weight and developed drug1 while being treated with drug2 lost weight and resumed menstruating after the change in medication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1571 : 
        {
          1 : "NN appos NN nmod NNS dobj VBN acl:relcl NNS nmod NNS nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos cytarabine nmod doses dobj received acl:relcl patients nmod organs nmod *found* nsubjpass evidence nmod drug0"
            }
          4 : 
            {
              1 : "Autopsy evidence of drug1 was found in visceral organs of four leukemic patients who had received large doses of cytarabine ( drug2 ; Ara-C ) shortly before their death . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1572 : 
        {
          1 : "NN dobj VBD nsubj JJ acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj indian acl controlled nmod drug0"
            }
          4 : 
            {
              1 : "A 62-year-old Indian with diabetic nephropathy controlled with drug1 , developed drug2 for which he was treated with rifampicin , isoniazid and ethambutol . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1573 : 
        {
          1 : "NN nmod JJ advmod VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod due advmod *combating* dobj drug0"
            }
          4 : 
            {
              1 : "Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated drug1 due to absorbed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1574 : 
        {
          1 : "NN dobj VB xcomp VBN acl JJ amod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj produce xcomp known acl derivative amod aposafranine appos *drug0*"
            }
          4 : 
            {
              1 : "One of these was drug1 , an aniline aposafranine derivative known to produce a drug2 in the tissues of patients treated with this drug or lepromatous leprosy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1575 : 
        {
          1 : "NN nmod VBP acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod present acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Pneumocystis pneumonia should be considered in asthmatic patients taking drug1 who present with drug2 , pulmonary infiltrates , and hypoxia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1576 : 
        {
          1 : "NN nmod NN nmod VB xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod association nmod occur xcomp *known* nsubjpass variety nmod drug0"
            }
          4 : 
            {
              1 : "A variety of drug1 are known to occur in association with drug2 ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1577 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod NN dobj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj stridor nmod associated acl dystonia nmod exacerbation dobj *triggered* nsubj withdrawal nmod drug0"
            }
          4 : 
            {
              1 : "Abrupt , accidental withdrawal of drug1 triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and drug2 , prompting emergency admission . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1578 : 
        {
          1 : "NN nmod VBN conj VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated conj *presenting* nmod drug0"
            }
          4 : 
            {
              1 : "To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy , we conducted a retrospective survey of 25 additional patients with Wilson 's disease who met the criteria of presenting with drug1 and having been treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1579 : 
        {
          1 : "NN nmod NNS nmod VBN dep VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod induced dep *describe* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "Here , we describe a case of drug1 occurring 4 months after the start of interferon alpha treatment , probably induced by the immunomodulatory effects of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1580 : 
        {
          1 : "NN nmod NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod *symptoms* nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : We report a typical symptoms of drug1 ( CBS ) in patients with severe AMD after intravitreal drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1581 : 
        {
          1 : "NN compound NN nmod NNS nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *effects* nsubj sludge compound drug0"
            }
          4 : 
            {
              1 : "drug1 and bile sludge are common side effects of drug2 therapy but rarely become symptomatic or require treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1582 : 
        {
          1 : "NN compound NN dobj VB"
          2 : 1
          3 : 
            {
              1 : "drug0 compound drug dobj *drug0*"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 a drug2 prescription drug licensed to treat severe , recalcitrant nodular acne . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1583 : 
        {
          1 : "NN nmod VBN acl NNS nmod VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod predisposed acl patients nmod *using* dobj drug0"
            }
          4 : 
            {
              1 : "Extra caution should be taken in using drug1 or its long-acting analog in patients otherwise predisposed to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1584 : 
        {
          1 : "NN nmod VBN acl NNS nmod JJ xcomp VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl women nmod common xcomp *seem* nsubj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 characterized by menstrual disorders , polycystic ovaries , and hyperandrogenism seem to be common among women treated with drug2 for epilepsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1585 : 
        {
          1 : "NN conj NN dobj VBD nmod NNS dep NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hyperglycemia dobj *developed* nmod years dep beginning nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Four years after the beginning of drug1 therapy , he acutely developed moderate hyperglycemia and drug2 with positive islet cell antibody , and then 28 units/day of insulin injection was started . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1586 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBN nmod NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj man acl treated nmod chemotherapy acl:relcl included dobj drug0"
            }
          4 : 
            {
              1 : "A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included drug1 , developed life threatening drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1587 : 
        {
          1 : "NN nmod NNS nmod VBD acl:relcl NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod problems nmod complained acl:relcl ptsd nmod treatment nmod *use* nmod drug0"
            }
          4 : 
            {
              1 : "We describe two cases that illustrate the use of drug1 in the treatment of veterans with PTSD who complained of serious problems with drug2 or angry outbursts . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1588 : 
        {
          1 : "NN conj NN nmod NN nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj thrombosis nmod *risk* nsubj children acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Children with acute lymphoblastic leukemia ( ALL ) , treated with drug1 are at risk for cerebral thrombosis or drug2 because of coagulation protein deficiencies . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1589 : 
        {
          1 : "NN nmod VBN nsubjpass NNS appos NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *associated* nsubjpass drugs appos methimazole appos drug0"
            }
          4 : 
            {
              1 : "However , there remain questions concerning whether these drugs , especially methimazole ( drug1 ) , may be associated with drug2 ( ACC ) and how best to avoid impairment of fetal thyroid function during their use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1590 : 
        {
          1 : "NN compound NN nmod NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "A review of the literature revealed two other cases of drug1 in patients after long-term drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1591 : 
        {
          1 : "NN conj NN nmod VBN acl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj beta-0a nmod treated acl sclerosis conj *drug0*"
            }
          4 : 
            {
              1 : "drug1 and extrapyramidal symptoms in a patient with Tourette 's syndrome , Asperger 's syndrome , and multiple sclerosis treated with interferon beta-1a and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1592 : 
        {
          1 : "NN conj NN dobj VBG xcomp VBD nsubj NN acl VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj distress dobj worsening xcomp *developed* nsubj man acl treated nmod prednisone conj drug0"
            }
          4 : 
            {
              1 : "A 49-year-old man with Crohn 's disease treated with prednisone and drug1 ( 5-ASA ) developed worsening respiratory distress and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1593 : 
        {
          1 : "NN root , punct RB root , punct VBZ dep NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct paradoxically root , punct is dep *effect* nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "The most serious dental side effect of drug1 treatment ( particularly when it is administered intravenously ) is , paradoxically , drug2 or the maxilla represented by exposed nonhealing bone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1594 : 
        {
          1 : "NN nsubj JJ ccomp VBG advcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj responsible ccomp indicating advcl *reappeared* nsubj drug0"
            }
          4 : 
            {
              1 : "After rechallenge with monotherapy pegvisomant , however , the drug1 reappeared within a few weeks , indicating that most likely drug2 alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1595 : 
        {
          1 : "NN nmod JJ nmod NN dep NNS nmod VB"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod low-risk nmod surgery dep months nmod *drug0*"
            }
          4 : 
            {
              1 : "METHODS : A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to drug1 9 months after cataract surgery in an eye at low-risk for this drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1596 : 
        {
          1 : "NN compound NN nmod NNS dobj VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound monotherapy nmod doses dobj received advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 40-year-old man with relapsing-remitting multiple sclerosis ( MS ) developed drug1 ( PCNSL ) after having received 21 doses of drug2 monotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1597 : 
        {
          1 : "NN conj NN nmod NN nmod VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj ifn nmod therapy nmod *developed* dobj skin conj drug0"
            }
          4 : 
            {
              1 : "We describe two dark-skinned patients who developed hyperpigmented skin and drug1 during combination therapy with IFN and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1598 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl VBD dobj NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl:relcl had dobj history nmod injections compound drug0"
            }
          4 : 
            {
              1 : "A 47 year-old woman who had a 4-year history of intramuscular drug1 injections in the lower extremities , developed drug2 and weakness of the lower extremities . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1599 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBD xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod drop dobj receiving advcl *became* xcomp drug0"
            }
          4 : 
            {
              1 : "A 5-month-old infant became drug1 and poorly responsive after receiving 1 drop of drug2 in each eye . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1600 : 
        {
          1 : "NN nmod NNS nsubjpass VBN advcl JJ nsubj NNS amod JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occurrences nsubjpass reported advcl *uncommon* nsubj effects amod secondary nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Central nervous system effects secondary to drug1 treatment are uncommon and usually consist only of minor dizziness or mild headache , although rare occurrences of drug2 and hallucinations have been reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1601 : 
        {
          1 : "NN nmod NN nmod VBN acl NN dobj VBD nsubj NNS acl:relcl VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod followed acl response dobj *had* nsubj outpatients acl:relcl participated nmod trial nmod drug0"
            }
          4 : 
            {
              1 : "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of drug1 had an initial good response to the medication followed by development of drug2 , including feelings of agitation and depression and periods of crying and insomnia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1602 : 
        {
          1 : "NN dobj VBP acl:relcl NNS nmod NN dobj VBG acl NN nmod JJ advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj develop acl:relcl patients nmod necrosis dobj provoking acl risk nmod *aware* advcl used nsubjpass combination nmod drug0"
            }
          4 : 
            {
              1 : "Because the combination of drug1 and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi 's sarcoma , clinicians should be aware of the risk of provoking acral necrosis in patients who develop drug2 under chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1603 : 
        {
          1 : "NN appos NNS conj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos symptoms conj eosinophilia nmod *reaction* compound drug0"
            }
          4 : 
            {
              1 : "drug1 Drug Reaction with Eosinophilia and Systemic Symptoms ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1604 : 
        {
          1 : "NN compound NN nsubj VB advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound hypersensitivity nsubj occur advcl *correlated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Our report suggested that CBDCA drug1 was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy , even in platinum-sensitive cases , because drug2 hypersensitivity can occur even with low-dose CBDCA administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1605 : 
        {
          1 : "NN appos NN dobj VBD conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos tachycardia dobj induced conj *drug0*"
            }
          4 : 
            {
              1 : "A 44-year-old woman is described in whom amiodarone , drug1 , and quinidine , administered alone separately , induced atypical ventricular tachycardia ( drug2 , torsade de pointes ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1606 : 
        {
          1 : "NN conj NN nmod NN dobj VBD dep VBN advcl VBN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj arm nmod weakness dobj developed dep *resolved* advcl changed nmod acid appos drug0"
            }
          4 : 
            {
              1 : "When SASP was changed to 5-aminosalicylic acid ( drug1 ) , his skin eruptions were resolved , however , he developed weakness and atrophy in his right arm as well as progressive drug2 in his legs and gait disturbance . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1607 : 
        {
          1 : "NN nsubj VBZ acl:relcl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj develops acl:relcl *relapse* compound drug0"
            }
          4 : 
            {
              1 : "When drug1 alcoholics relapse into drinking , more severe drug2 develops in the liver . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1608 : 
        {
          1 : "NN nmod JJ advmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod due advmod *induced* dobj drug0"
            }
          4 : 
            {
              1 : "Acute drug induced drug1 due to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1609 : 
        {
          1 : "NN conj NN appos NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *reaction* appos cross-reaction nmod drug0"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken mequitazine for 6 months , and there were strong positive photopatch test results with immediate erythema reaction , cross-reaction to drug1 , decreased MED to both UVA and UVB , and drug2 over a 3-year follow-up period after discontinuation of the mequitazine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1610 : 
        {
          1 : "NN nmod NNS nmod VB nsubj NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complications nmod *result* nsubj therapy nmod activator appos drug0"
            }
          4 : 
            {
              1 : "Thrombolytic therapy with tissue plasminogen activator ( drug1 ) for acute myocardial infarction may result in major bleeding complications such as drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1611 : 
        {
          1 : "NN nmod VBN acl NN nmod NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl disease nmod patients nmod *reported* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 has been reported in patients with malignant disease treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1612 : 
        {
          1 : "NN conj NN dobj VBG xcomp VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj over-activation dobj causing xcomp *acted* nsubj drug0"
            }
          4 : 
            {
              1 : "This severe illness was likely caused by minocycline , and we speculate that drug1 may have acted as a superantigen , causing lymphocyte over-activation and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1613 : 
        {
          1 : "NN nmod NNS dobj VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses dobj given advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 64-year-old man with schizophrenia developed drug1 when given higher doses of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1614 : 
        {
          1 : "NN conj NN nmod VBP conj JJ nsubj NNS amod JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj dizziness nmod consist conj *uncommon* nsubj effects amod secondary nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Central nervous system effects secondary to drug1 treatment are uncommon and usually consist only of minor dizziness or drug2 , although rare occurrences of seizures and hallucinations have been reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1615 : 
        {
          1 : "NN conj NNS nmod NN advcl VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj seizures nmod *patient* advcl reported nsubjpass withdrawal compound drug0"
            }
          4 : 
            {
              1 : "Although drug1 withdrawal has been previously reported and usually consists of anxiety , diaphoresis , and palpitations , this is the first reported patient with generalized seizures and drug2 secondary to gabapentin withdrawal . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1616 : 
        {
          1 : "NN conj NN nmod VBN conj VBN dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hypophosphatemia nmod presented conj *prescribed* dobj alendronate appos drug0"
            }
          4 : 
            {
              1 : "This case report describes a patient who was previously prescribed alendronate ( drug1 ) and presented with postoperative hypophosphatemia and drug2 after bowel preparation with Fleet Phospho-Soda . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1617 : 
        {
          1 : "NN nmod VBN advcl JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *associated* advcl unclear nsubj cause nmod drug0"
            }
          4 : 
            {
              1 : "Although the essential cause of drug1 is unclear , its onset has occasionally been associated with drug therapy , in particular drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1618 : 
        {
          1 : "NN appos NNS dep NNS nmod NN dobj VB xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos antibodies dep autoantibodies nmod increase dobj produce xcomp *known* nsubjpass treatment nmod drug0"
            }
          4 : 
            {
              1 : "Treatment with drug1 is known to produce an increase of autoantibodies ( antinuclear antibodies , drug2 ) , but not clinical disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1619 : 
        {
          1 : "NN compound NN nmod NNS nmod VBN nsubjpass NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound hemorrhage nmod patients nmod *observed* nsubjpass myoglobinuria conj drug0"
            }
          4 : 
            {
              1 : "Myoglobinuria and drug1 were observed in two patients with drug2 gastrointestinal hemorrhage . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1620 : 
        {
          1 : "NN nmod NN amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *nephritis* amod drug0"
            }
          4 : 
            {
              1 : "drug1 and interstitial nephritis in drug2 , heroin-related infective endocarditis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1621 : 
        {
          1 : "NN nmod VBN conj JJ nsubj NN nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod related conj *uncertain* nsubj cause nmod effects nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "The cause of these previously unreported side effects of drug1 therapy is uncertain but may be related to drug2 , hyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1622 : 
        {
          1 : "NN nsubj VBD dep VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *developed* dep receiving dobj drug0"
            }
          4 : 
            {
              1 : "In this report , we describe a patient receiving drug1 in whom dyspnea , drug2 , hypoxia , and diffuse pulmonary infiltrates developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1623 : 
        {
          1 : "NN dobj VBG xcomp VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj causing xcomp *ingested* dobj mg nmod drug0"
            }
          4 : 
            {
              1 : "We present a case of a 20-year-old woman who ingested 900 mg of drug1 causing refractory drug2 resistant to treatment with intravenous dextrose , glucagon , and diazoxide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1624 : 
        {
          1 : "NN nmod NNS nmod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injections nmod administration nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report 5 patients ( 3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral ribavirin and two patients with chronic myelocytic leukemia ) who developed drug1 at sites of injection after the administration of weekly subcutaneous injections of drug2 at different doses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1625 : 
        {
          1 : "NN dobj VBD nsubj NN conj NN acl VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patient conj therapy acl consisting nmod drug0"
            }
          4 : 
            {
              1 : "In this report , a patient who had undergone a renal transplantation as a result of malignant hypertension , and who was on immunosuppressive therapy consisting of drug1 , prednisone and azathioprine , developed drug2 of the central retinal vein 5 years following the transplantation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1626 : 
        {
          1 : "NN compound NN nsubjpass VBN advcl VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nsubjpass withdrawn advcl *persist* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 and some electrophysiological abnormalities persist when drug2 therapy is withdrawn . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1627 : 
        {
          1 : "NN compound NN nmod VBN advcl VB dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound neptazane nmod started advcl *develop* dobj acidosis compound drug0"
            }
          4 : 
            {
              1 : "A 60-year-old white man with chronic bronchitis was noted to develop drug1 and metabolic acidosis four days after being started on drug2 ( Neptazane ) for an ophthalmologic problem . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1628 : 
        {
          1 : "NN compound NN conj NN nmod NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration conj diarrhea nmod occurrence nmod relationship nmod *cause* nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of drug1 due to the temporal relationship between the occurrence of diarrhea and drug2 administration , lack of concomitant medications , and documentation of C. difficile toxin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1629 : 
        {
          1 : "NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NN nmod NN conj JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod pregnancy nmod treated acl woman nmod *born* nsubjpass girl nmod atresia conj mild nmod drug0"
            }
          4 : 
            {
              1 : "An infant girl with choanal atresia , athelia , minor anomalies , and mild to moderate drug1 was born to a woman treated for hyperthyroidism throughout pregnancy with drug2 and propranolol . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1630 : 
        {
          1 : "NN nmod VBN nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *contributed* nsubj activation acl induced nmod drug0"
            }
          4 : 
            {
              1 : "We speculate that platelet activation induced by drug1 may have contributed to drug2 and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1631 : 
        {
          1 : "NN nmod NN nmod NN nmod NN conj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod period nmod persistence conj *reaction* appos drug0"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken mequitazine for 6 months , and there were strong positive photopatch test results with immediate erythema reaction , drug1 , decreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1632 : 
        {
          1 : "NN nmod NNS dobj VBD nsubj NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod findings dobj *had* nsubj patient acl:relcl received dobj drug0"
            }
          4 : 
            {
              1 : "One patient who received drug1 had liver biopsy findings of drug2 , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1633 : 
        {
          1 : "NN conj NNS nmod VBN acl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj events nmod associated acl *agent* nsubj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1634 : 
        {
          1 : "NN conj NN dobj VBG acl NN nmod VBG nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj etanercept dobj taking acl patient nmod *occurring* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurring in a patient taking etanercept plus drug2 for rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1635 : 
        {
          1 : "NN compound NN dobj VBG acl:relcl NN nmod VBD nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl:relcl man nmod *developed* nsubj pneumonitis conj drug0"
            }
          4 : 
            {
              1 : "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and drug1 developed in a 43-year-old man , who was receiving long-term drug2 therapy for chronic ulcerative colitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1636 : 
        {
          1 : "NN appos NN nmod NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos diethylstilbestrol nmod administration nmod *developed* nsubj case nmod male nmod drug0"
            }
          4 : 
            {
              1 : "This paper reports an autopsy case of a 78-year-old male with drug1 developed after long-termed administration of phosphate diethylstilbestrol ( drug2 ) for prostatic cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1637 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod NN nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl patient nmod meningioma nmod originating acl *drug0*"
            }
          4 : 
            {
              1 : "A case of drug1 originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic drug2 therapy is presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1638 : 
        {
          1 : "NN dep NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep agents nmod *experienced* dobj drug0"
            }
          4 : 
            {
              1 : "We present findings from three patients who experienced a drug1 apparently due to the antiepileptic agents drug2 and carbamazepine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1639 : 
        {
          1 : "NN dobj VBZ nsubj NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *exacerbates* nsubj interaction nmod lopinavir/ritonavir conj drug0"
            }
          4 : 
            {
              1 : "Possible interaction between lopinavir/ritonavir and drug1 exacerbates drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1640 : 
        {
          1 : "NN nmod NNS nsubj VB parataxis VB nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episodes nsubj cause parataxis *cause* nsubj therapy compound drug0"
            }
          4 : 
            {
              1 : "Intravenous drug1 therapy in babies may cause apnea , hypotension , and bradycardia ; continued episodes of drug2 in a child may cause sudden death ; quinidine may be related to the death ; children with `` familial seizure disorders '' may in fact have the long QT interval syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1641 : 
        {
          1 : "NN nmod NN xcomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effect xcomp *appeared* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 appeared to be a common side effect of drug2 and generally responded well to treatment with the beta-adrenergic antagonist propranolol , dose reduction , or both . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1642 : 
        {
          1 : "NN nmod NN nmod NN nmod NN amod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod *occurrence* nmod failure amod due nmod drug0"
            }
          4 : 
            {
              1 : "We report the occurrence of renal failure due to drug1 following thrombolytic therapy with intravenous drug2 ( t-PA ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1643 : 
        {
          1 : "NN dobj VBD nsubj NNS nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *had* nsubj patients nmod symptoms compound drug0"
            }
          4 : 
            {
              1 : "Three patients with drug1 visual symptoms had drug2 without leakage on fluorescein angiography , and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1644 : 
        {
          1 : "NN appos NN nmod NN nmod VBD dobj NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos olanzapine nmod treatment nmod *produced* dobj cases nmod neutropenia conj drug0"
            }
          4 : 
            {
              1 : "First , a review of the literature produced 41 anecdotic cases of neutropenia or drug1 during treatment with olanzapine ( drug2 ) reported in a total of 24 publications . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1645 : 
        {
          1 : "NN nmod NN nmod VBD conj VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod developed conj *exhibited* dobj reactions nmod drug0"
            }
          4 : 
            {
              1 : "However , one patient exhibited severe hypersensitivity reactions including drug1 and apnea , and another four patients developed eruptions , hypotension , and tachycardia soon after administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1646 : 
        {
          1 : "NN compound NNS nmod VB xcomp VBD conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound levels nmod produce xcomp failed conj *added* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was added to treatment with HU in two patients , but failed to produce an increase in total Hb despite drug2 levels . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1647 : 
        {
          1 : "NN nsubj VBZ nmod NNS acl:relcl VBP dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *progresses* nmod abstainers acl:relcl take dobj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : In some abstainers who take drug1 for several years , thin drug2 progresses along with the emergence of ground-glass hepatocytes . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1648 : 
        {
          1 : "NN conj NN dobj VBG acl NN nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj il-0 dobj receiving acl patient nmod responded acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We report a case of drug1 , which responded well to steroid therapy , in a patient receiving IL-2 plus drug2 for metastatic renal cell carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1649 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NN dobj VBG acl NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod precipitated acl:relcl lovastatin dobj taking acl patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To describe two cases of drug1 in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics drug2 and azithromycin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1650 : 
        {
          1 : "NN nmod VBN acl NN nmod VBN acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl cml nmod affected acl patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : We report a case of drug1 in a patient affected by CML treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1651 : 
        {
          1 : "NN nmod NN nmod NN nmod VBG dobj NN amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod infusion nmod completion nmod *impending* dobj elevation amod drug0"
            }
          4 : 
            {
              1 : "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending drug1 and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose drug2 ( MTX ) ( 12 g/m2 ) , and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1652 : 
        {
          1 : "NN dobj VBD xcomp VBN nsubjpass NNS dep NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed xcomp *added* nsubjpass inhibitors dep ritonavir conj drug0"
            }
          4 : 
            {
              1 : "Protease inhibitors ( ritonavir and drug1 ) were added to the treatment and the patient developed drug2 related to carbamazepine toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1653 : 
        {
          1 : "NN compound NN nmod NN dobj VBG acl NNS nmod VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound drug nmod treatment dobj starting acl weeks nmod *developed* dobj symptoms nmod drug0"
            }
          4 : 
            {
              1 : "We report 4 patients who developed symptoms of drug1 within 2 weeks of starting treatment with a drug2 drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1654 : 
        {
          1 : "NN conj NN dobj VBD acl:relcl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj coma dobj developed acl:relcl *patient* nmod overdose compound drug0"
            }
          4 : 
            {
              1 : "METHODS : Repeated blood samples were drawn in a patient with severe drug1 overdose who developed coma and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1655 : 
        {
          1 : "NN dobj VB nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *cause* nsubj amiodarone conj drug0"
            }
          4 : 
            {
              1 : "While both amiodarone and drug1 can cause permanent drug2 , the ocular effects are often reversible . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1656 : 
        {
          1 : "NN nmod NN nsubjpass VBN parataxis NN advcl VBN nsubjpass NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occurrence nsubjpass emphasized parataxis *release* advcl described nsubjpass increases nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Although transient increases in ectopy after drug1 therapy have been described , presumably due to catecholamine release , the occurrence of life-threatening drug2 leading to cardiac arrest has not previously been emphasized . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1657 : 
        {
          1 : "NN dep NN nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep enzyme nmod secondary amod *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of chronic , nonproductive drug1 secondary to the angiotensin-converting enzyme ( ACE ) inhibitor drug2 , with complete resolution after switching to another ACE inhibitor , fosinopril . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1658 : 
        {
          1 : "NN nmod NN nsubj VBN ccomp VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod state nsubj raised ccomp *causes* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 typically causes a long-lasting state of drug2 and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1659 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl patients nmod *finding* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is another common finding among patients receiving drug2 therapy , but rarely does it result in prominent symptoms other than transient pallor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1660 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj received acl:relcl woman nmod *present* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We present a case of ethylenediamine-induced drug1 in a 46-year-old woman who received parenteral drug2 for an acute asthma exacerbation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1661 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj received acl:relcl patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 in a patient with advanced non-small cell lung cancer who received drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1662 : 
        {
          1 : "NN compound NN nmod JJ amod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod secondary amod *syndrome* nmod hormone appos drug0"
            }
          4 : 
            {
              1 : "We present a case of the syndrome of inappropriate antidiuretic hormone ( drug1 ) secondary to drug2 therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1663 : 
        {
          1 : "NN nmod NN nmod NN dep NNS nmod VBD acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod initiation dep days nmod demonstrated acl *evidence* nmod drug0"
            }
          4 : 
            {
              1 : "The main clinical features of this 58-year-old female patient were laboratory evidence of drug1 and cholestasis , and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis , demonstrated 20 days after the initiation of antithyroid therapy with 20 mg drug2 daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1664 : 
        {
          1 : "NN dep NNS dobj VBP nsubj NNS nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep effects dobj *include* nsubj events nmod doses compound drug0"
            }
          4 : 
            {
              1 : "Common adverse events ( frequency 10 % ) of drug1 doses up to 600 mg/day include nonspecific central nervous system effects ( e.g. , drug2 , ataxia , diplopia , and somnolence ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1665 : 
        {
          1 : "NN conj NNS nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj patients nmod leucopenia nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "RESULTS : drug1 was associated with leucopenia in two patients and clinically apparent drug2 in one patient . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1666 : 
        {
          1 : "NN compound NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound abusers nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "We report four cases of drug1 in drug2 abusers . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1667 : 
        {
          1 : "NN appos NN nmod VBD nsubj NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod methotrexate nmod rescue compound drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with drug1 rescue , resulted in the ` phosphate shower syndrome ' ( drug2 , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1668 : 
        {
          1 : "VB xcomp VBD conj VBD acl:relcl NN dobj VBD nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp led conj worsened acl:relcl loss dobj *developed* nmod week nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Despite a response of the meningeal tumor the patient developed in the third week of drug1 treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to drug2 within 3 weeks . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1669 : 
        {
          1 : "NN dobj VB xcomp VBN acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp reported acl:relcl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is one drug that has been reported to cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1670 : 
        {
          1 : "NN nmod VBN acl NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod characterized acl *lithium* conj toxicity compound drug0"
            }
          4 : 
            {
              1 : "The authors describe a case of combined lithium and drug1 toxicity characterized by drug2 , severe rigidity , mutism , and development of irreversible tardive dyskinesia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1671 : 
        {
          1 : "NN conj NNP nmod NN nmod VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj amitriptyline nmod patient nmod occurred acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "The authors describe a case of drug1 that occurred in a patient on amitriptyline and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1672 : 
        {
          1 : "NN compound NN nmod NN nmod NN dep NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound system nmod patch nmod application dep days nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 58-year-old woman developed drug1 four days after the application of a patch of transdermal drug2 delivery system ( TRANSDERM-V ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1673 : 
        {
          1 : "NN amod NNS conj VBD nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 amod lesions conj *had* nsubj patient acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "A patient receiving drug1 for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash , pain and erythema of the cartilage of both ears , and drug2 and hemorrhagic lesions of the finger tips . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1674 : 
        {
          1 : "NN nmod NN nmod VBN conj VBP dobj NN nmod NN acl:relcl VBD dobj NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod remitted conj *report* dobj case nmod patient acl:relcl developed dobj polyserositis dep drug0"
            }
          4 : 
            {
              1 : "We report the case of a patient who developed polyserositis ( drug1 , pleural effusion , and pericarditis ) after being started on clozapine , and whose symptoms remitted upon discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1675 : 
        {
          1 : "NN nmod NNS dobj VBD conj VBN nsubjpass NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod phases dobj developed conj *prescribed* nsubjpass ifn-alpha conj drug0"
            }
          4 : 
            {
              1 : "We have described three patients with hepatitis C for whom IFN-alpha and drug1 were prescribed and who developed two successive phases of silent drug2 followed by hyperthryroidism relapse due to Graves ' disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1676 : 
        {
          1 : "NN nmod NN nsubj NN ccomp VBD csubj VBD nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod type nsubj nature ccomp *indicated* csubj performed nmod patients nmod cirrhosis compound drug0"
            }
          4 : 
            {
              1 : "Studies performed 10 years ago on 25 patients with drug1 liver cirrhosis indicated that this type of drug2 was not of an aggressive nature . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1677 : 
        {
          1 : "NN compound NNS nmod NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound wafers nmod implantation nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "Following are two clinical case reports demonstrating profound drug1 associated with implantation of drug2 wafers . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1678 : 
        {
          1 : "NN conj NN dep NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj inhibitor dep *enzyme* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an angiotensin-converting enzyme ( ACE ) inhibitor and their drug2 are documented , but little has been published concerning the usefulness of patch test when they occur . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1679 : 
        {
          1 : "NN conj NN dobj VBD nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pain dobj *developed* nmod days nmod drug0"
            }
          4 : 
            {
              1 : "Following 7 days of drug1 she developed severe abdominal pain and drug2 suggesting acute pancreatitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1680 : 
        {
          1 : "NN dobj VB xcomp VBD advcl VBP dobj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj represent xcomp thought advcl *present* dobj cases nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "We present two cases of drug1 pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma , thought to represent established drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1681 : 
        {
          1 : "NN nsubj VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj resolved conj *discontinued* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was discontinued until completion of radiotherapy , and the drug2 resolved . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1682 : 
        {
          1 : "NN compound NN nmod NN acl VBN xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound monotherapy nmod *posture* acl called xcomp drug0"
            }
          4 : 
            {
              1 : "A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion , called drug1 , during drug2 monotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1683 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj man acl receiving dobj bid compound drug0"
            }
          4 : 
            {
              1 : "An 83-year-old man receiving drug1 10 mg bid developed drug2 within three days of adding trimethoprim/sulfamethoxazole ( TMP/SMX ) to his regimen . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1684 : 
        {
          1 : "NN dobj VBG advcl VBD nmod NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj commencing advcl *presented* nmod blindness conj days compound drug0"
            }
          4 : 
            {
              1 : "We report a 4-year-old girl who presented with acute bilateral blindness , a focal seizure and drug1 10 days after commencing drug2 to treat enuresis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1685 : 
        {
          1 : "NN nmod NNS dobj VB xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod degrees dobj induce xcomp *known* nsubjpass drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 , an aversive agent widely used in Japan , is known to induce various degrees of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1686 : 
        {
          1 : "NN appos NN nmod VBD advmod RB"
          2 : 1
          3 : 
            {
              1 : "drug0 appos propylthiouracil nmod *developed* advmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report the case of a young woman with Graves ' disease in whom drug1 developed because of propylthiouracil ( drug2 ) - induced antineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1687 : 
        {
          1 : "NN nmod NN nmod VBP dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *develop* dobj eosinophilia conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and drug1 following the use of drug2 by inhalation or by intravenous administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1688 : 
        {
          1 : "NN nmod VB nsubj JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *occur* nsubj severe conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Severe and drug1 may occur after intravitreal drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1689 : 
        {
          1 : "NN nsubjpass VBN ccomp VBP nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass related ccomp *suggest* nsubj concentrations nmod drug0"
            }
          4 : 
            {
              1 : "Although they had complex medical problems , the high serum concentrations of drug1 at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the drug2 were related to the ampicillin therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1690 : 
        {
          1 : "NN compound NN nmod NNS nsubjpass VBN advcl VBP nsubj JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound cream nmod amounts nsubjpass used advcl *develop* nsubj neurologic conj drug0"
            }
          4 : 
            {
              1 : "Awareness of this route of intoxication might be important in patients in whom neurologic or drug1 develop while large amounts of drug2 cream are being used . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1691 : 
        {
          1 : "NN dep VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep caused acl:relcl *interaction* nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This is the first report of a possible interaction between drug1 and citalopram , which caused propafenone adverse effects ( eg , drug2 , falls ) and mimicked coronary artery disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1692 : 
        {
          1 : "NN dobj VB conj NN nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause conj *effect* nsubj reactions nmod drug0"
            }
          4 : 
            {
              1 : "Acute pulmonary reactions to drug1 are an uncommon side effect of therapy and can cause minor or life-threatening drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1693 : 
        {
          1 : "NN nmod VBN advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod described advcl *associated* nmod drug0"
            }
          4 : 
            {
              1 : "It should be recognized that ibuprofen may be associated with drug1 in the same fashion as previously described with drug2 and indomethacin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1694 : 
        {
          1 : "NN dobj VBD conj NNS acl:relcl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *patients* acl:relcl treated nmod form nmod drug0"
            }
          4 : 
            {
              1 : "We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate , both of whom had been treated with steroidal anti-androgen therapy in the form of drug1 prior to radical or palliative pelvic irradiation , and who subsequently developed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1695 : 
        {
          1 : "NN compound NN nsubj VBN advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nsubj occurred advcl *considered* nsubjpass diagnosis nmod drug0"
            }
          4 : 
            {
              1 : "In patients with swallowing dysfunction and pneumonia , a history of mineral oil use should be obtained and a diagnosis of drug1 should be considered in the differential diagnoses if drug2 use has occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1696 : 
        {
          1 : "NN nsubjpass VBN acl:relcl NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass given acl:relcl meq/l conj na nmod *drug0*"
            }
          4 : 
            {
              1 : "One patient developed drug1 with serum Na + of 108 mEq/L when drug2 was given to control hypertension . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1697 : 
        {
          1 : "NN nmod NN dobj VBD parataxis JJ nsubj NNS acl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod evidence dobj had parataxis *slow* nsubj patients acl treated nmod cc nmod drug0"
            }
          4 : 
            {
              1 : "Postoperatively , the first two patients treated with 1 to 2 cc of drug1 were slow to awaken ; one had evidence of drug2 by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography , while the other had a moderate-sized frontal hematoma with intracranial hypertension . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1698 : 
        {
          1 : "NN compound NN root IN root RB advmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration root after root shortly advmod *demonstrated* dobj drug0"
            }
          4 : 
            {
              1 : "However , each infant demonstrated drug1 shortly after drug2 administration and required cardiopulmonary resuscitation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1699 : 
        {
          1 : "NN conj NN nmod NN nmod VBP dobj NN nmod NN acl VBN nmod NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj cisplatin nmod chemotherapy nmod *report* dobj patient nmod adenocarcinoma acl complicated nmod syndrome nmod secretion nmod hormone appos drug0"
            }
          4 : 
            {
              1 : "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( drug1 ) following systemic chemotherapy with cisplatin ( CDDP ) and drug2 ( VDS ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1700 : 
        {
          1 : "NN dobj VBN conj VBP dobj NN nmod NN acl VBG nmod NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj given conj *present* dobj case nmod toxicity acl resulting nmod boy acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed drug1 to intravenous immunoglobulin , and was subsequently given drug2 by mistake intravenously rather than subcutaneously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1701 : 
        {
          1 : "NN nmod NN nmod NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod factor nmod *association* nmod stimulation nmod drug0"
            }
          4 : 
            {
              1 : "The association with prolonged unopposed estrogen-like stimulation with drug1 as a possible factor in the development of drug2 is discussed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1702 : 
        {
          1 : "NN dobj VBG acl DT nmod VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj administering acl those nmod considered conj *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is rarely associated with rituximab infusion for lympho-proliferative disorders , but it should be considered by those administering drug2 , especially when a patient develops severe pulmonary symptoms soon after infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1703 : 
        {
          1 : "NN nmod VBG xcomp VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod developing xcomp *induced* nmod drug0"
            }
          4 : 
            {
              1 : "Myoclonus was induced and enhanced by drug1 , developing into drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1704 : 
        {
          1 : "NN dep RB advmod VBN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep later advmod *placed* nmod adriamycin appos drug0"
            }
          4 : 
            {
              1 : "She was placed on adjuvant Adriamycin ( drug1 ) chemotherapy , but 6 months later drug2 of Adriamycin toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1705 : 
        {
          1 : "NN nmod NN dobj VBG dep NNS nmod NN acl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment dobj starting dep months nmod *woman* acl presented nmod history nmod drug0"
            }
          4 : 
            {
              1 : "A 57-year-old woman presented with a 3-week history of drug1 , 6 months after starting treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1706 : 
        {
          1 : "NN nmod NNS nmod VBP dobj NN nmod JJ appos NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cycles nmod *report* dobj patient nmod recurrent appos episodes nmod drug0"
            }
          4 : 
            {
              1 : "We report a patient with recurrent , increasingly severe episodes of drug1 , ultimately complicated by a severe bullous eruption , following successive cycles of high-dose drug2 for the treatment of acute lymphoblastic leukaemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1707 : 
        {
          1 : "NN conj NN nmod NN conj NN appos NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hypocalcaemia nmod hyperphosphataemia conj hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose drug1 with folinic acid rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and drug2 , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1708 : 
        {
          1 : "NN dobj VBD acl:relcl NNS nmod VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj took acl:relcl patients nmod *experienced* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "We experienced 2 cases of mequitazine-induced drug1 in patients who took drug2 for their dermatologic problems . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1709 : 
        {
          1 : "NN dobj VBG dep NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving dep weeks nmod eosinophilia conj *drug0*"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with drug1 , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and eosinophilia two weeks after receiving drug2 ( TMP ) - sulfamethoxazole ( SMX ) treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1710 : 
        {
          1 : "NN conj NN dep NNS nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj paroxetine dep inhibitors nmod secondary amod *drug0*"
            }
          4 : 
            {
              1 : "In the present paper the authors describe 2 female patients who developed drug1 secondary to the selective serotonin reuptake inhibitors paroxetine and drug2 , as well as a third who developed this side effect on venlafaxine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1711 : 
        {
          1 : "NN nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *started* nmod drug0"
            }
          4 : 
            {
              1 : "He was started on drug1 , 0.25 mg daily , because of echocardiographically demonstrated drug2 and functional impairment ; he died of ventricular fibrillation 15 days later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1712 : 
        {
          1 : "NN nmod NN nmod VBD nsubjpass NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dosage nmod *correlated* nsubjpass probability acl developing dobj drug0"
            }
          4 : 
            {
              1 : "The probability of developing drug1 in this study was not significantly correlated to the total cumulative dosage of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1713 : 
        {
          1 : "NN conj NN nmod NN appos NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj acidosis nmod hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose drug1 with folinic acid rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and drug2 ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1714 : 
        {
          1 : "NN compound NN conj NN nmod VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment conj nadolol nmod added advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 51-yr-old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria developed drug1 when captopril was added to the nadolol and drug2 treatment for his high blood pressure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1715 : 
        {
          1 : "NN nmod NNS dobj VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod features dobj developed acl:relcl *dose* nmod drug0"
            }
          4 : 
            {
              1 : "The case reported here is of a child given a large dose of intravenous drug1 ( 16 mg/kg ) over 3 hours , who subsequently developed features of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1716 : 
        {
          1 : "NN conj JJ nmod VB nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hemorrhagic nmod *present* nsubj patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Patients treated with drug1 may present with hemorrhagic and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1717 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBN nmod NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl managed nmod infusions conj drug0"
            }
          4 : 
            {
              1 : "A 45-year-old woman with steroid-dependent Crohn 's colitis , successfully managed with maintenance infliximab infusions and drug1 , developed a drug2 eight months after her initial infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1718 : 
        {
          1 : "NN compound NN nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod *make* dobj diagnosis nmod drug0"
            }
          4 : 
            {
              1 : "Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis , in order to make a early diagnosis of drug1 during the drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1719 : 
        {
          1 : "NN compound NN nmod VBN nsubjpass NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *reported* nsubjpass arrhythmias conj drug0"
            }
          4 : 
            {
              1 : "Arrhythmias and drug1 have been reported during drug2 administration but no effective technique has been described to prevent them . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1720 : 
        {
          1 : "NN nmod VBN acl NN nmod VBG nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *occurring* nsubj cancer compound drug0"
            }
          4 : 
            {
              1 : "drug1 and lung cancer occurring in a chronic lymphocytic leukemia patient treated with drug2 and autologous peripheral blood stem-cell transplantation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1721 : 
        {
          1 : "NN appos NN nmod VB nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos failure nmod *result* nsubj infusion compound drug0"
            }
          4 : 
            {
              1 : "High-dose intravenous drug1 infusion in various clinical settings may result in acute renal failure ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1722 : 
        {
          1 : "NN conj NN dobj VBN acl:relcl NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj edema dobj developed acl:relcl *patients* nmod retinopathy compound drug0"
            }
          4 : 
            {
              1 : "With the use of optical coherence tomography ( OCT ) , two patients with drug1 retinopathy who had developed macular edema and drug2 during the clinical course of IFN therapy were observed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1723 : 
        {
          1 : "NN nmod VBN acl NN dobj VBD conj VBP dobj NN nmod NN acl:relcl VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod followed acl hypertension dobj developed conj *present* dobj case nmod woman acl:relcl received dobj doses nmod drug0"
            }
          4 : 
            {
              1 : "Here we present the case of a woman who received high doses of drug1 ( 1 g iv daily ) for active Graves ' ophthalmopathy , and developed severe hypertension followed by drug2 on the fifth day of treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1724 : 
        {
          1 : "NN nmod VBN advcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated advcl *risk* nmod drug0"
            }
          4 : 
            {
              1 : "Patients from endemic areas referred to transplant centers may be at high risk for drug1 when treated with long-term drug2 for graft-versus-host disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1725 : 
        {
          1 : "NN appos NN nmod NNS dobj VBG acl NN dobj VB xcomp VBN acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos dyskinesia nmod symptoms dobj inducing acl propensity dobj have xcomp believed acl:relcl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms , including tardive dyskinesia ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1726 : 
        {
          1 : "NN appos NN nmod VBN acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos acid nmod treated acl:relcl man nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 in a 23-year-old man with Crohn 's disease who was treated with 5-aminosalicylic acid ( drug2 ; Nisshin , Tokyo , Japan ) 3.0 g/day . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1727 : 
        {
          1 : "NN compound NN nmod IN advmod VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod during advmod *had* dobj evidence nmod drug0"
            }
          4 : 
            {
              1 : "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of drug1 during and immediately after drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1728 : 
        {
          1 : "NN appos NN nmod VBN acl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos maleate nmod induced acl *dysfunction* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and hepatic dysfunction apparently induced by perhexiline maleate ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1729 : 
        {
          1 : "VB acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 acl *relationship* nmod drug0"
            }
          4 : 
            {
              1 : "The Naranjo probability scale indicated a probable relationship between drug1 and exposure to drug2 through breast-feeding in this infant . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1730 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod VB xcomp VBZ conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl hus nmod appear xcomp seems conj *feature* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1731 : 
        {
          1 : "NN conj JJ amod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj effective amod *treatment* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an effective but drug2 treatment for psoriasis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1732 : 
        {
          1 : "NN nmod NNS dobj VBN nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod rates dobj *demonstrated* nsubj studies nmod drug0"
            }
          4 : 
            {
              1 : "Post marketing studies of drug1 ( IFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1733 : 
        {
          1 : "NN compound NN nsubj VBN advcl VBN conj VBN nmod NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nsubj occurred advcl considered conj *obtained* nmod patients nmod dysfunction conj drug0"
            }
          4 : 
            {
              1 : "In patients with swallowing dysfunction and drug1 , a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if drug2 use has occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1734 : 
        {
          1 : "NN conj NN dobj VBD nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj malaise dobj *developed* nsubj woman acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "PATIENT AND METHOD : A 34-year-old woman with chronic hepatitis C , genotype 3 , receiving drug1 and ribavirin for 6 months , developed progressive malaise and drug2 6 months after the end of treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1735 : 
        {
          1 : "NN nmod NN nmod NN nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod *complication* nsubj signs nmod drug0"
            }
          4 : 
            {
              1 : "Clinical signs of drug1 are an uncommon complication following oral administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1736 : 
        {
          1 : "NN nmod NNS dobj VBD acl:relcl NN nmod NN dobj VBP parataxis VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cycles dobj received acl:relcl woman nmod case dobj describe parataxis *reported* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 caused by paclitaxel toxicity has not been reported In this report , we describe the case of a 62-year-old woman who received six cycles of drug2 and carboplatin as combination chemotherapy for advanced ovarian cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1737 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD nsubj NN acl VBN nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod combination nmod administration nmod *developed* nsubj encephalopathy acl characterized nmod level nmod consciousness conj drug0"
            }
          4 : 
            {
              1 : "A toxic encephalopathy characterized by depressed level of consciousness , drug1 , and ataxia developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of drug2 and pyrilamine maleate . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1738 : 
        {
          1 : "NN dep NNS nmod VBN acl NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep agents nmod provoked acl occasions nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We describe a patient who developed drug1 on three separate occasions provoked by two different chemotherapeutic agents -- drug2 and mitoxantrone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1739 : 
        {
          1 : "NN compound NNS nmod NN nmod NN nmod NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound beverages nmod ingestion nmod intoxication nmod patient nmod *considered* nsubjpass possibility nmod drug0"
            }
          4 : 
            {
              1 : "The possibility of severe drug1 should be considered in a patient with water intoxication due to massive ingestion of drug2 beverages . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1740 : 
        {
          1 : "NN nmod NN nmod NN advcl VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod association nmod *report* advcl used nsubjpass combinations nmod drug0"
            }
          4 : 
            {
              1 : "Although combinations of drug1 , ergotamine , and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s , this is the first known case report of its association with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1741 : 
        {
          1 : "NN dep NN nmod VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep receptor nmod treated advcl *observed* dobj drug0"
            }
          4 : 
            {
              1 : "OBSERVATIONS : We observed drug1 when treated topically with the toll-like receptor ( TLR ) 7 agonist drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1742 : 
        {
          1 : "NN dobj VB parataxis VB nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause parataxis *cause* nsubj therapy compound drug0"
            }
          4 : 
            {
              1 : "Intravenous drug1 therapy in babies may cause apnea , hypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause drug2 ; quinidine may be related to the death ; children with `` familial seizure disorders '' may in fact have the long QT interval syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1743 : 
        {
          1 : "NN nsubjpass VBN acl:relcl NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass prescribed acl:relcl pregnancies nmod *incidence* nmod drug0"
            }
          4 : 
            {
              1 : "In a single practice during the 21 years 1971-1991 , the incidence of drug1 in pregnancies in which drug2 was prescribed was 32.4 % ( 22 of 69 ) in comparison with 7.1 % in pregnancies in which the women did not take norethisterone ( 137 of 1 , 684 ) ( p < 0.001 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1744 : 
        {
          1 : "NN dobj VBN advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *reported* advcl tolerated nsubjpass drug0"
            }
          4 : 
            {
              1 : "Although drug1 is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : `` the drug2 '' . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1745 : 
        {
          1 : "NN nmod NN nmod NN nmod VBZ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injury nmod pattern nmod *presents* nsubj injury compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 liver injury presents with a cholestatic pattern of injury with drug2 , possibly leading to ductopenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1746 : 
        {
          1 : "NN appos NN nmod VBN acl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos maleate nmod induced acl *papilloedema* conj drug0"
            }
          4 : 
            {
              1 : "Papilloedema and drug1 apparently induced by perhexiline maleate ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1747 : 
        {
          1 : "NN nsubjpass VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass incriminated conj *excluded* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Salicylate drug1 was excluded , and drug2 was finally incriminated . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1748 : 
        {
          1 : "NN compound NN nmod NNS ccomp VBP nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound nephrotoxicity nmod targets ccomp *suggest* nmod drug0"
            }
          4 : 
            {
              1 : "Based upon the observed drug1 , the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria , we suggest that in this case the tubules and/or interstitium are the main targets for drug2 nephrotoxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1749 : 
        {
          1 : "NN nmod NN dep NN nmod VBD nsubj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose dep week nmod *followed* nsubj patient acl presented nmod drug0"
            }
          4 : 
            {
              1 : "A 65-year-old female patient presented with drug1 followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat , 1 week after the fourth dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1750 : 
        {
          1 : "NN nmod NN nmod NN dep NNS nmod VBD acl NN conj NNS nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod initiation dep days nmod demonstrated acl *evidence* conj features nmod degeneration nmod infiltration conj drug0"
            }
          4 : 
            {
              1 : "The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis , and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and drug1 , demonstrated 20 days after the initiation of antithyroid therapy with 20 mg drug2 daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1751 : 
        {
          1 : "NN nmod VBN nsubjpass NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *followed* nsubjpass re-initiation nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "However , re-initiation of drug1 treatment was followed by drug2 again . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1752 : 
        {
          1 : "NN dobj VBG acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl:relcl *patient* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of a patient with drug1 who had been taking drug2 for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1753 : 
        {
          1 : "NN nmod VBN nmod CD nmod NNS acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *contributed* nmod 0 nmod cases acl:relcl taking dobj drug0"
            }
          4 : 
            {
              1 : "In 2 of the 3 cases the patients were also taking drug1 and beta-blockers , both of which could have contributed to the drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1754 : 
        {
          1 : "NN compound NN nmod:npmod RB advmod VBD nsubj VBG nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound h nmod:npmod later advmod *produced* nsubj loading nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "In addition , loading with one low oral dose of drug1 produced drug2 5 h later which lasted 3-6 h . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1755 : 
        {
          1 : "NN compound NN dobj VBG advcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj starting advcl *developing* dobj drug0"
            }
          4 : 
            {
              1 : "A 25-year-old man with a history of mid-borderline ( BB ) Hansen 's disease developing a drug1 after starting drug2 and rifampin therapy is presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1756 : 
        {
          1 : "NN dobj VBD nmod:tmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nmod:tmod week nmod initial-dose nmod drug0"
            }
          4 : 
            {
              1 : "One week after the initial-dose of drug1 ( 160 mg ) , which was initiated due to an acute exacerbation of Crohn 's disease , the patient developed a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1757 : 
        {
          1 : "NN dobj VB advcl NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj render advcl *injury* nmod users compound drug0"
            }
          4 : 
            {
              1 : "Sunburn may sometimes be a major injury in drug1 users because high doses or inappropriate use of the drug may render the drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1758 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod occurred acl:relcl *case* nmod incontinence appos drug0"
            }
          4 : 
            {
              1 : "The authors report a case of urinary incontinence ( drug1 ) that occurred in a woman after administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1759 : 
        {
          1 : "NN nsubj VBD conj VBG advcl VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj developed conj swelling advcl *given* nsubjpass i.v. compound drug0"
            }
          4 : 
            {
              1 : "Phenytoin was discontinued after admission ; however , drug1 1 g i.v. was given for a tonic-clonic seizure two days after admission , after which swelling of the face and legs and drug2 developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1760 : 
        {
          1 : "NN nmod NN dobj VBD acl:relcl NN dep NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episode dobj triggered acl:relcl evening dep *tablet* compound drug0"
            }
          4 : 
            {
              1 : "Even after a strict warning , he took another drug1 tablet that evening , which triggered his fifth episode of severe drug2 , and confirmed the etiology of quinine-induced thrombocytopenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1761 : 
        {
          1 : "NN dobj VB advcl VBZ dobj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj include advcl *extends* dobj spectrum nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "This case extends the spectrum of drug1 pulmonary toxicity to include drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1762 : 
        {
          1 : "NN conj NN nmod NN conj NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj melphalan nmod treatment conj term nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a 59-year-old patient with chronic myeloid leukemia , who developed drug1 after short term and sequential treatment with melphalan and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1763 : 
        {
          1 : "NN dobj VB nmod NN nmod NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *develop* nmod percent nmod patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Up to four percent of patients treated with drug1 may develop drug2 , which usually resolves with discontinuation of the drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1764 : 
        {
          1 : "NN dobj VBD nsubj NNS nmod NN acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *showed* nsubj cases nmod leprosum acl:relcl doses nmod drug0"
            }
          4 : 
            {
              1 : "Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of drug1 , showed drug2 , subungual hyperkeratosis and onycholysis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1765 : 
        {
          1 : "NN nmod NN appos NN nmod NNS appos NN nmod VBN acl NNS nmod NNS nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod derivative appos ifosfamide nmod tumors appos wilms nmod treated acl children nmod *symptoms* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1766 : 
        {
          1 : "NN nmod NNS conj NNS nsubj VBD nmod NN nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cases conj abortions nsubj *were* nmod series nmod cases nmod use nmod drug0"
            }
          4 : 
            {
              1 : "In a series of 104 cases of intentional or inadvertent use of drug1 at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of drug2 occurring among a total of 88 cases where the pregnancy progressed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1767 : 
        {
          1 : "NN appos NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos albuterol nmod doses nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 after normal doses of neubulized albuterol ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1768 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod JJ appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl family nmod antipsychotic appos *drug0*"
            }
          4 : 
            {
              1 : "CASE SUMMARY : We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral drug1 , an antipsychotic from the thioxanthene family , who developed an acute , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1769 : 
        {
          1 : "NN compound NN conj NN nmod VBN acl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound monotherapy conj schizophrenia nmod diagnosed acl man nmod *reported* nsubjpass case nmod drug0"
            }
          4 : 
            {
              1 : "A case of drug1 is reported in a 32-year-old man diagnosed with schizophrenia and on drug2 monotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1770 : 
        {
          1 : "NN nmod NNS nsubjpass VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cases nsubjpass reviewed conj *discussed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 and its serious adverse effects are discussed , and other cases of drug2 with infliximab use are also reviewed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1771 : 
        {
          1 : "NN nmod NN amod NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *solution* amod % dep drug0"
            }
          4 : 
            {
              1 : "drug1 to 50 % solution of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1772 : 
        {
          1 : "NN nsubjpass VBN ccomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass considered ccomp *induced* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 induced drug2 must be considered in all patients who develop unexplained lung disease while receiving fludarabine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1773 : 
        {
          1 : "NN compound NN nmod IN xcomp VBN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod while xcomp *considered* nmod patients compound drug0"
            }
          4 : 
            {
              1 : "Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all drug1 patients while on drug2 therapy , despite the absence of pulmonary symptomatology . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1774 : 
        {
          1 : "NN dobj VBG conj VBD acl:relcl NN nmod VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj ingesting conj suffered acl:relcl man nmod occurring acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "CASE REPORT : We report a case of drug1 occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting drug2 daily for one year . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1775 : 
        {
          1 : "NN nmod JJ advmod JJ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *aware* advmod due nmod use nmod drug0"
            }
          4 : 
            {
              1 : "Due to the increasing use of drug1 in children , clinicians should be aware of this potentially life-threatening , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1776 : 
        {
          1 : "NN conj NN dobj VBG dep VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fatigue dobj having dep *responding* nmod drug0"
            }
          4 : 
            {
              1 : "The first patient is undergoing hemodialysis and , though responding to drug1 , is having significant fatigue and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1777 : 
        {
          1 : "NN nsubj VB acl:relcl NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj become acl:relcl *ratio* nmod changes compound drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : The risk/benefit ratio of drug1 therapy changes in the over 75s , when drug2 become more common . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1778 : 
        {
          1 : "NN conj NN nmod NN nmod VBN nsubjpass NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj stroke nmod cause nmod *implicated* nsubjpass phenylpropanolamine appos drug0"
            }
          4 : 
            {
              1 : "Phenylpropanolamine ( drug1 ) recently has been publicly implicated as a cause of stroke and other drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1779 : 
        {
          1 : "NN conj NN nmod NN dobj VBG advcl VBZ dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj levamisole nmod regimen dobj adding advcl *describes* dobj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This case describes the clinically significant drug1 in an elderly patient after adding a chemotherapy regimen of levamisole and drug2 to a previous regimen of warfarin alone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1780 : 
        {
          1 : "NN compound NN nmod NN nmod NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod course nmod *man* dep drug0"
            }
          4 : 
            {
              1 : "A 55-yr-old man developed drug1 and sicca complex after a course of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1781 : 
        {
          1 : "NN compound NN nmod VB dobj NN nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod *report* dobj case nmod episodes nmod activity compound drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of multiple episodes of drug1 activity in an AIDS patent following drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1782 : 
        {
          1 : "NN appos NN dep NNS nmod VBN acl:relcl NNS nsubj VBD ccomp VBD nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos chloride dep causes nmod associated acl:relcl cases nsubj were ccomp *showed* nsubj study nmod deaths nmod drug0"
            }
          4 : 
            {
              1 : "A retrospective epidemiological study of deaths from drug1 ( HAS ) in the U.S. showed that during 1964 -- 74 there were 168 such cases , of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride , drug2 ' , and inorganic arsenic ) and 4 ( 3.1 % ) of the remaining 131 cases with the use of androgenic-anabolic steroids . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1783 : 
        {
          1 : "NN dobj VB xcomp VBN conj VBN nsubjpass NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp known conj *used* nsubjpass 0-mp conj drug0"
            }
          4 : 
            {
              1 : "Both 6-MP and drug1 are widely used and are known to cause drug2 in a proportion of patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1784 : 
        {
          1 : "NN dep NN nmod NN dobj VBG acl NNS nmod VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep fat nmod infusion dobj receiving acl infants nmod *described* nsubjpass cases nmod drug0"
            }
          4 : 
            {
              1 : "Four cases of drug1 are described in infants receiving prolonged intravenous infusion of fat ( drug2 20 % ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1785 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBD nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod months nmod *developed* nsubj purpura appos drug0"
            }
          4 : 
            {
              1 : "Thrombotic thrombocytopenic purpura ( drug1 ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1/2 months of treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1786 : 
        {
          1 : "NN conj NN nmod NN nmod VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj docetaxel nmod chemotherapy nmod *presenting* nmod drug0"
            }
          4 : 
            {
              1 : "We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with drug1 after chemotherapy with docetaxel and drug2 producing severe respiratory insufficiency , and simulating a progression of the tumor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1787 : 
        {
          1 : "NN dobj VBG acl NN nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl chemotherapy nmod secondary amod *drug0*"
            }
          4 : 
            {
              1 : "In four patients , thrombosis occurred 2-45 days after severe drug1 ( HVOD ) secondary to intensive chemotherapy containing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1788 : 
        {
          1 : "NN nmod VBD acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complained acl:relcl retinitis nmod *treatment* nmod drug0"
            }
          4 : 
            {
              1 : "We present a patient with human immunodeficiency virus infection under treatment with drug1 for CMV retinitis who complained of drug2 and polyuria . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1789 : 
        {
          1 : "NN nmod JJ parataxis VBP ccomp VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod low parataxis *suggest* ccomp cause nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : These results suggest that drug1 may cause TD ; however , the prevalence is low and the severity is relatively mild , with no or mild self-reported drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1790 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN appos NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod *based* nmod onset appos presence nmod drug0"
            }
          4 : 
            {
              1 : "The diagnosis was based on the rapid onset of renal failure , presence of drug1 , skin rash , and characteristic renal biopsy finding , following the administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1791 : 
        {
          1 : "NN nsubjpass VBN advcl VBG acl NNS nmod VB dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass coadministered advcl occurring acl disorders nmod *report* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report 2 cases of drug1 with serious extrapyramidal movement disorders occurring when drug2 was coadministered with sertraline or venlafaxine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1792 : 
        {
          1 : "NN compound NN nmod VBN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound dosage nmod caused acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "The fourth patient showed drug1 that were initially caused by a 20-mg daily drug2 dosage and were later mitigated when olanzapine was reduced and ropinirole was administered . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1793 : 
        {
          1 : "NN dep NN nmod NN nmod VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep enzyme nmod treatment nmod *describe* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We describe the first case of de novo drug1 following treatment with the angiotensin converting enzyme ( ACE ) inhibitor drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1794 : 
        {
          1 : "NN nmod JJ nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod related nmod secondary amod *drug0*"
            }
          4 : 
            {
              1 : "We report a patient with inoperable pancreatic cancer who developed drug1 secondary to radiation-recall related to drug2 and review literature . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1795 : 
        {
          1 : "NN compound NN nmod NN xcomp VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod consequence xcomp *appears* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : drug1 in these cases appears to be a consequence of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1796 : 
        {
          1 : "NN nmod VBN xcomp VBN nsubjpass NNS compound NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod caused xcomp *believed* nsubjpass toxicities compound system compound drug0"
            }
          4 : 
            {
              1 : "drug1 central nervous system ( CNS ) excitatory toxicities are believed to be caused by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1797 : 
        {
          1 : "NN compound NN nmod NN nmod VBN advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod consequence nmod *reported* advcl reported nsubjpass drug0"
            }
          4 : 
            {
              1 : "Although drug1 has been reported in the course of hairy cell leukaemia , it has only rarely been reported as the consequence of drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1798 : 
        {
          1 : "NN dobj VBD conj VBN nsubjpass NN nmod NN dep VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *started* nsubjpass therapy nmod coma dep containing dobj drug0"
            }
          4 : 
            {
              1 : "After therapy for diabetic coma with insulin ( containing the preservative drug1 ) and electrolyte solutions was started , the patient complained of increasing myalgia , developed a drug2 and respiratory and metabolic acidosis and lost consciousness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1799 : 
        {
          1 : "NN dobj VBG acl NN nmod JJ advcl JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj causing acl potential nmod *alert* advcl beneficial nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Although drug1 may be beneficial because of its anti-inflammatory effects , clinicians should be alert to its potential for causing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1800 : 
        {
          1 : "NN nmod NN conj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod form conj dose nmod *occurrence* nmod drug0"
            }
          4 : 
            {
              1 : "Major points illustrated are , ( 1 ) occurrence of drug1 with any dose or form of drug2 ; ( 2 ) misperceptions on the diagnostic criteria ; ( 3 ) correct ( thrombin inhibitors ) and incorrect ( platelet transfusions and warfarin ) management ; ( 4 ) influence of management strategy on clinical outcomes ; ( 5 ) severity of the syndrome ; and ( 6 ) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1801 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN ccomp VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cycle nmod infusion nmod delivered ccomp *developed* dobj drug0"
            }
          4 : 
            {
              1 : "CASE REPORT : We report a patient who developed a drug1 after a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1802 : 
        {
          1 : "NN nsubjpass VBN ccomp VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass reported ccomp *induced* nsubj case nmod drug0"
            }
          4 : 
            {
              1 : "A case of drug1 induced drug2 is reported in a middle aged woman who underwent gastric surgery for morbid obesity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1803 : 
        {
          1 : "NN conj NN nmod NN nmod VBD xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj lamotrigine nmod overdose nmod *became* xcomp drug0"
            }
          4 : 
            {
              1 : "METHODS : A 55-year-old woman became drug1 after overdose with lamotrigine ( LTG ) and drug2 ( VPA ) tablets . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1804 : 
        {
          1 : "NN compound NN nmod VBN conj VBD acl:relcl NN nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound withdrawal nmod resolved conj occurred acl:relcl therapy nmod related amod *drug0*"
            }
          4 : 
            {
              1 : "The authors report five cases of drug1 related to itraconazole therapy , which occurred within 1-12 months of initiating treatment and resolved gradually following drug2 withdrawal . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1805 : 
        {
          1 : "NN nmod NN nmod JJ amod NN amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod secondary amod *hyponatremia* amod drug0"
            }
          4 : 
            {
              1 : "A patient with disseminated herpes zoster developed a drug1 and profound hyponatremia secondary to the administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1806 : 
        {
          1 : "NN compound NN nmod VBZ acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound accumulation nmod occurs acl:relcl *complication* nsubj drug0"
            }
          4 : 
            {
              1 : "Metformin-associated drug1 ( MALA ) is a serious metabolic complication that occurs because of drug2 accumulation in patients who become dehydrated or developed acute renal failure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1807 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound sodium dobj receiving acl patient nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 , disseminated intravascular coagulation , and anuric renal failure requiring dialysis occurred in a patient receiving drug2 sodium for toothache . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1808 : 
        {
          1 : "NN compound NN nmod VBG acl VBG conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound dose nmod resulting acl wheezing conj *urticaria* conj drug0"
            }
          4 : 
            {
              1 : "METHODS : The patient required insulin desensitization for severe urticaria , drug1 , and occasional wheezing resulting from her drug2 dose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1809 : 
        {
          1 : "NN appos NN nmod VBN conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos suppression nmod associated conj *agent* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression , typically drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1810 : 
        {
          1 : "NN nmod VBN dep VB"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod prescribed dep *drug0*"
            }
          4 : 
            {
              1 : "Can drug1 prescribed for pain cause drug2 ? "
            }
          5 : 
            {
              1 : 1
            }
        }
      1811 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod NN nmod NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound monotherapy nmod followed acl lansoprazole nmod therapy nmod weeks dep *drug0*"
            }
          4 : 
            {
              1 : "A 57-year-old man developed drug1 four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by drug2 monotherapy for gastroesophageal reflux disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1812 : 
        {
          1 : "NN conj NNS appos NNS nmod NN nmod NN appos NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj disorders appos fractures nmod incidence nmod increase appos decrease nmod *effects* nmod drug0"
            }
          4 : 
            {
              1 : "There are major side effects of drug1 including decrease in both lumbar spine and total hip bone mineral density , increase in the incidence of all bone fractures ( especially fractures of spine , hip and wrist ) , joint disorders and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1813 : 
        {
          1 : "NN dobj VBG acl NN nmod NN nmod NNP nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl arthritis nmod woman nmod *hepatitis* nmod drug0"
            }
          4 : 
            {
              1 : "Hepatitis with drug1 and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1814 : 
        {
          1 : "NN dobj VB xcomp VBN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj have xcomp *found* nmod infusion compound drug0"
            }
          4 : 
            {
              1 : "After the second drug1 infusion , he was found to have a drug2 ( 0.5 x 10 ( 9 ) / L ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1815 : 
        {
          1 : "NN nmod NN xcomp VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effect xcomp believed acl *drug0*"
            }
          4 : 
            {
              1 : "In summary , we report herein the first case of drug1 believed to be an adverse effect of drug2 , which may therefore needed to be added to the list of drugs which can induce SIADH . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1816 : 
        {
          1 : "NN dobj VBD nmod NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nmod day nmod administration nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "On the fifth day after administration of a high dose of drug1 ( 2 g/m2 intravenously every 12 hours ) , she developed drug2 , sepsis , and death on the 22nd day . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1817 : 
        {
          1 : "NN nmod JJ amod NN dobj VBD xcomp VBN nsubjpass NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod related amod ataxia dobj developed xcomp *added* nsubjpass inhibitors dep drug0"
            }
          4 : 
            {
              1 : "Protease inhibitors ( drug1 and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1818 : 
        {
          1 : "NN compound NN dobj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj *complicates* nsubj drug0"
            }
          4 : 
            {
              1 : "In contrast to chronic or subacute thyroiditis , drug1 rarely complicates drug2 therapy for chronic viral C hepatitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1819 : 
        {
          1 : "NN appos JJ nmod JJ amod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos 0-chloro-0-nitrobenzofurazan nmod due amod *pharmacist* acl suffered nmod drug0"
            }
          4 : 
            {
              1 : "A 30-year-old pharmacist suffered from drug1 due to 4-chloro-7-nitrobenzofurazan ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1820 : 
        {
          1 : "NN dep IN dep VBD nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep that dep *complained* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy , and the latter patient complained twice during drug1 therapy that his drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1821 : 
        {
          1 : "NN dobj VBP"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *drug0*"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This study confirmed that in most patients drug1 drug2 is not aggressive . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1822 : 
        {
          1 : "VB xcomp VBN advcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp led advcl *enhanced* dobj activation nmod drug0"
            }
          4 : 
            {
              1 : "Immobilization , while Paget 's bone disease was present , and perhaps enhanced activation of drug1 by rifampicin , could have led to drug2 into the circulation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1823 : 
        {
          1 : "NN conj VBD conj VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj became conj *began* advcl stopped nsubjpass drug0"
            }
          4 : 
            {
              1 : "The day after drug1 was stopped , while he was still receiving clomipramine 150 mg/d , he began behaving oddly , started sweating profusely , shivering , and became tremulous , agitated , and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1824 : 
        {
          1 : "NN nmod NN nmod NN dep NN nmod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod infusion dep hour nmod *cold* nmod drug0"
            }
          4 : 
            {
              1 : "The patient described feeling cold with drug1 and chills approximately one hour after infusion of the first dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1825 : 
        {
          1 : "NN nmod NN dobj VBD advcl VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose dobj received advcl *developed* dobj edema conj drug0"
            }
          4 : 
            {
              1 : "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and drug1 after she received a single dose of intravenous drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1826 : 
        {
          1 : "NN nmod NN dobj VBD nsubj NN acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episode dobj *reported* nsubj man acl:relcl taking dobj drug0"
            }
          4 : 
            {
              1 : "A 62-year-old Caucasian man with atrial fibrillation who was taking drug1 reported an episode of drug2 ; his international normalized ratio ( INR ) was 1.74 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1827 : 
        {
          1 : "NN dobj VBD nsubj NNS acl VBG dobj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj volunteers acl receiving dobj omeprazole acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole , three of six young female volunteers receiving omeprazole and two young female volunteers receiving drug1 developed drug2 within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1828 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod VBG nmod NNS conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound spray nmod use dep weeks nmod *swelling* nmod lips conj cavity conj drug0"
            }
          4 : 
            {
              1 : "We report a 43-year-old woman who developed sore throat , swelling of the lips and oral cavity and drug1 , 2 weeks after the use of drug2 spray ( Budefat ) for treatment of bronchial asthma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1829 : 
        {
          1 : "NN nmod VBN conj VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated conj *recurred* nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "After a second dose of drug1 , these symptoms recurred and were associated with drug2 , agitation , fever , diaphoresis , tachypnea , tachycardia , and hypertension . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1830 : 
        {
          1 : "NN nmod NN nsubj VBD conj JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nsubj appeared conj *related* nsubj drug0"
            }
          4 : 
            {
              1 : "It was concluded that drug1 is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with drug2 appeared to induce ANCA . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1831 : 
        {
          1 : "NN nsubj VBN conj VBN nsubjpass NNS appos NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj resolved conj *stopped* nsubjpass drugs appos cyclosporin conj drug0"
            }
          4 : 
            {
              1 : "The disease-modifying drugs he was taking , cyclosporin and drug1 , were stopped , and the drug2 resolved spontaneously without the use of chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1832 : 
        {
          1 : "NN xcomp VBD acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp became acl:relcl *min* nmod administration nmod drug0"
            }
          4 : 
            {
              1 : "Approximately 15 min after the first administration of nebulised drug1 the patient became markedly drug2 ( respiratory rate : 4-5 bpm ) , hypotensive ( BP 70/40 mmHg ) , and responded only partially to command . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1833 : 
        {
          1 : "NN nmod NN nsubj VB dep NNS nmod VBD nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod insertion nsubj implant dep days nmod *appeared* nsubj manifestations nmod drug0"
            }
          4 : 
            {
              1 : "We describe a heroin abuser in whom clinical and laboratory manifestations of drug1 appeared a few days after the insertion of a subcutaneous drug2 implant . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1834 : 
        {
          1 : "NN nsubj VBZ nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *alters* nmod addition nmod effect nmod drug0"
            }
          4 : 
            {
              1 : "In addition to its known effect on drug1 , drug2 alters bile acid composition and may thus hasten intrahepatic sludge and stone formation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1835 : 
        {
          1 : "NN nmod NNS dobj VBN nsubj NNS nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod rates dobj *demonstrated* nsubj studies nmod interferon-beta appos drug0"
            }
          4 : 
            {
              1 : "Post marketing studies of Interferon-beta ( drug1 ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1836 : 
        {
          1 : "NN dobj VBG advcl VBD acl:relcl NNS nmod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking advcl occurred acl:relcl *patients* nmod moderate nmod drug0"
            }
          4 : 
            {
              1 : "We describe 3 elderly patients with moderate to severe drug1 that occurred while they were taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1837 : 
        {
          1 : "NN nmod NN dep NN dobj VBD nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod pain dep right dobj *experienced* nmod remission nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Five and one-half years after the diagnosis of myeloma , while in remission on drug1 therapy , the patient experienced severe abdominal right lower quadrant pain due to a large drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1838 : 
        {
          1 : "NN nmod NNS nsubjpass VBN conj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cases nsubjpass reported conj *has* nsubj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 has mild renal toxicity , but cases of gemcitabine-associated drug2 ( HUS ) have been reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1839 : 
        {
          1 : "NN dobj VB xcomp VBN nsubjpass NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp *reported* nsubjpass voriconazole appos drug0"
            }
          4 : 
            {
              1 : "Voriconazole ( drug1 ) has not previously been reported to cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1840 : 
        {
          1 : "NN nmod NN dobj VB xcomp VBZ acl:relcl NN dobj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effect dobj cause xcomp appears acl:relcl agent dobj *channel* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1841 : 
        {
          1 : "NN conj NN dep NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj anaemia dep *occurrence* nmod effects nmod drug0"
            }
          4 : 
            {
              1 : "In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low-dose drug1 : an acute megaloblastic anaemia and a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1842 : 
        {
          1 : "NN xcomp VBD dep VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp thought dep *admitted* nmod drug0"
            }
          4 : 
            {
              1 : "Four months after receiving an orthotopic liver transplant , a 51-year-old man was admitted for drug1 and severe hepatocellular necrosis thought to be due to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1843 : 
        {
          1 : "NN nmod JJ amod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod concomitant amod *symptoms* nmod drug0"
            }
          4 : 
            {
              1 : "DATA SYNTHESIS : A 49-year-old man developed symptoms of drug1 concomitant with drug2 ( 250 mg bid ) treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1844 : 
        {
          1 : "NN conj NN nmod VBZ ccomp VBD conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj reaction nmod results ccomp were conj *taken* dobj drug0"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken drug1 for 6 months , and there were strong positive photopatch test results with immediate erythema reaction , cross-reaction to promethazine , decreased MED to both UVA and UVB , and drug2 over a 3-year follow-up period after discontinuation of the mequitazine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1845 : 
        {
          1 : "NN dobj VBG advcl JJ amod NNS nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj inducing advcl capable amod agents nmod list nmod *added* nsubjpass drug0"
            }
          4 : 
            {
              1 : "It is suggested therefore that drug1 be added to the list of agents capable of inducing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1846 : 
        {
          1 : "NN nmod VBN advcl VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod based advcl *develops* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 develops in most patients after transplantation when immunosuppression is based on drug2 and prednisone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1847 : 
        {
          1 : "NN conj NNS nmod NN dobj VBG conj VBG ccomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj levels nmod increase dobj provoking conj diminishing ccomp *acted* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 acted as a CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1848 : 
        {
          1 : "NN dobj VBG advcl VBD nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking advcl *sought* nmod manifestations nmod drug0"
            }
          4 : 
            {
              1 : "A 25-year-old woman sought medical attention because of iliocaval manifestations of drug1 while she was taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1849 : 
        {
          1 : "NN nsubjpass VBN advcl VBP nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass *considered* advcl develop nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "When vague symptoms develop during drug1 therapy , drug2 must be considered as part of the differential diagnosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1850 : 
        {
          1 : "NN appos NN compound NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos d-penicillamine compound treatment nmod *anemia* conj drug0"
            }
          4 : 
            {
              1 : "A 66-year-old Japanese woman with severe scleroderma developed anemia and drug1 due to D-penicillamine ( drug2 ) treatment , although the leukopenia was not markedly severe . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1851 : 
        {
          1 : "NN nmod NNS dobj VB acl JJ nmod VBN nsubjpass NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects dobj cause acl potential nmod *known* nsubjpass derivatives dep drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : The new quinolone derivatives ( drug1 , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system-related adverse effects , including drug2 , dizziness and insomnia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1852 : 
        {
          1 : "NN nmod VBN advcl VBD dobj NN acl VBG xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated advcl *developed* dobj syndrome acl resembling xcomp drug0"
            }
          4 : 
            {
              1 : "Six patients with rheumatoid arthritis developed a syndrome resembling drug1 while being treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1853 : 
        {
          1 : "NN dobj VBD acl:relcl NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl *salts* compound drug0"
            }
          4 : 
            {
              1 : "We describe a patient with rheumatoid arthritis treated with drug1 salts , who developed drug2 and showed a dramatic response on corticosteroid therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1854 : 
        {
          1 : "NN compound NN nmod NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod abstinence nmod years nmod *drug0*"
            }
          4 : 
            {
              1 : "Case 3 : A 29-year-old female alcoholic complained of general fatigue and a slight drug1 after 1.5 years of abstinence with drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1855 : 
        {
          1 : "NN nmod VBN acl:relcl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod followed acl:relcl *event* compound drug0"
            }
          4 : 
            {
              1 : "We report an HIV-infected woman who developed mild leukopenia as the first sign of a drug1 adverse event , which was followed by drug2 associated with a more severe leukopenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1856 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod chemotherapy nmod cycle nmod developed acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We present a case of drug1 that developed during the 4th cycle of combination chemotherapy with drug2 , 5-fluorouracil and leucovorin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1857 : 
        {
          1 : "NN compound NNS nmod NN dobj VB advcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound levels nmod range dobj explain advcl *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : The observation that drug1 developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of drug2 levels reported in similar cases . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1858 : 
        {
          1 : "NN dobj VBD conj VBD nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj presented conj *developed* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "We describe two women who developed HUS after drug1 therapy and presented drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1859 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod associated acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "PURPOSE : We studied a case of drug1 that was associated with the use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1860 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN nsubjpass VBN conj JJ nsubj NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patients nmod testing nsubjpass considered conj *possible* nsubj reaction nmod pranlukast conj drug0"
            }
          4 : 
            {
              1 : "The case demonstrates that hypersensitivity reaction to pranlukast and resultant drug1 is possible , and that periodic urine testing in patients receiving drug2 should be considered . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1861 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD nsubj NNS amod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod ml nmod injection nmod *developed* nsubj manifestations amod indicative nmod drug0"
            }
          4 : 
            {
              1 : "We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of drug1 , developed following the injection of 0.3 ml of 10 % drug2 into the cervical subarachnoid space at the C4 -- C5 level for the control of severe right arm pain . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1862 : 
        {
          1 : "NN nmod VB acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod lead acl:relcl *accumulation* nmod drug0"
            }
          4 : 
            {
              1 : "Caution is , therefore , needed to prevent undesired accumulation of drug1 that may lead to protracted drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1863 : 
        {
          1 : "NN appos NN nmod NN dep NNS nmod NN acl:relcl VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos spray nmod use dep weeks nmod *woman* acl:relcl developed dobj throat conj drug0"
            }
          4 : 
            {
              1 : "We report a 43-year-old woman who developed sore throat , drug1 and dysphagia , 2 weeks after the use of budesonide spray ( drug2 ) for treatment of bronchial asthma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1864 : 
        {
          1 : "NN nmod NNS nmod VBN conj VBP nsubj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod complicated conj *have* nsubj treatments compound drug0"
            }
          4 : 
            {
              1 : "drug1 treatments have the potential to decrease the burden of disease , but are complicated by side effects , including drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1865 : 
        {
          1 : "NN nmod NNS conj NN nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod reports conj *agent* nsubj methotrexate appos drug0"
            }
          4 : 
            {
              1 : "Methotrexate ( drug1 ) is a commonly used second line agent for RA , and there have been several recent reports of drug2 in MTX-treated RA patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1866 : 
        {
          1 : "NN compound NNS nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound concentrations nmod *result* nsubj drug0"
            }
          4 : 
            {
              1 : "This case suggests that drug1 when given intravenously in doses of 10 mg/kg may result in drug2 concentrations . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1867 : 
        {
          1 : "NN appos NN nmod NN nmod VB xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos carbamazepine nmod association nmod occur xcomp *known* nsubjpass variety nmod drug0"
            }
          4 : 
            {
              1 : "A variety of drug1 are known to occur in association with carbamazepine ( drug2 ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1868 : 
        {
          1 : "NN compound NN dobj VBG acl:relcl NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl:relcl children nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware of the potential for the development of drug1 among children who are receiving long-term drug2 therapy for the treatment of systemic inflammatory illnesses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1869 : 
        {
          1 : "NN dobj VBG advcl VBG nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving advcl *presenting* nsubj drug0"
            }
          4 : 
            {
              1 : "We describe a 15-year-old female patient diagnosed with drug1 presenting with status epilepticus after receiving intrathecal drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1870 : 
        {
          1 : "NN nmod NN nmod JJ nmod NN acl VB dobj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod regard nmod *aware* nmod need acl review dobj indications nmod use compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : All doctors need to be aware of the need to review the indications for drug1 use during periods of acute illness , especially with regard to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1871 : 
        {
          1 : "NN conj NN nsubj VBN conj VBD advcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj eosinophilia nsubj resolved conj *improved* advcl discontinuing dobj drug0"
            }
          4 : 
            {
              1 : "After discontinuing drug1 and starting systemic steroids , her symptomatology rapidly improved , and her eosinophilia and drug2 both resolved . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1872 : 
        {
          1 : "NN nmod NN conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod sarcoma conj *abscess* conj drug0"
            }
          4 : 
            {
              1 : "Listeria brain abscess , drug1 and Kaposi 's sarcoma after drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1873 : 
        {
          1 : "NN conj NNS nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj drugs nmod treatment nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of recurrent drug1 following treatment with pentavalent antimonial drugs and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1874 : 
        {
          1 : "NN nmod VBN acl NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *deposits* compound drug0"
            }
          4 : 
            {
              1 : "drug1 and anterior segment deposits in a patient treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1875 : 
        {
          1 : "NN conj NN nmod VBD nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj weakness nmod *complained* nsubj woman acl taking dobj drug0"
            }
          4 : 
            {
              1 : "A 74-year-old hypercholestrerolaemic woman taking drug1 ( 0.15 mg/day ) for 22 days complained of general muscle weakness and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1876 : 
        {
          1 : "NN appos NN nmod NN nmod VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos olanzapine nmod treatment nmod *produced* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "First , a review of the literature produced 41 anecdotic cases of drug1 or agranulocytosis during treatment with olanzapine ( drug2 ) reported in a total of 24 publications . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1877 : 
        {
          1 : "NN nmod VBG advcl VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod replacing advcl *present* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "AIMS : To present a case of drug1 after replacing fluvoxamine maleate with drug2 , and to analyse this effect based on receptor occupancy theory . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1878 : 
        {
          1 : "NN nmod NN nmod CD dobj VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod g nmod one dobj improved acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Two other patients who did not receive prochlorperazine , developed drug1 which later improved , one after only 15 g of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1879 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBG xcomp VBN acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj starting acl hours nmod developing xcomp aged acl man nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of fulminant drug1 in a man aged 70 developing within 12 hours of starting six-hourly intravenous drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1880 : 
        {
          1 : "NN appos NN nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos interferon-alpha nmod therapy nmod *induced* nsubjpass drug0"
            }
          4 : 
            {
              1 : "These drug1 may be induced or worsened during antiviral therapy with interferon-alpha ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1881 : 
        {
          1 : "NN nmod NN xcomp VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause xcomp *appears* nsubj exposure nmod drug0"
            }
          4 : 
            {
              1 : "Although other nitrites induce methemoglobinemia , exposure to drug1 during phenylpropanolamine production appears to be a new cause of occupational drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1882 : 
        {
          1 : "NN nsubjpass VBN advcl VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass stopped advcl resolved acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Subsequently , he developed drug1 ( fasting blood glucose 138 mg/dL ) that resolved when drug2 was stopped and recurred ( fasting blood glucose 150 mg/dL ) after 2 days of rechallenge with olanzapine 2.5 mg twice daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1883 : 
        {
          1 : "NN compound NN nmod VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *experienced* dobj hemoglobinemia conj drug0"
            }
          4 : 
            {
              1 : "A previous review described data on 15 patients who experienced acute hemoglobinemia or drug1 following drug2 administration for ITP or secondary thrombocytopenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1884 : 
        {
          1 : "NN appos NN root , punct NN root , punct PRP nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos fever root , punct myelosuppression root , punct them nmod *drug0*"
            }
          4 : 
            {
              1 : "Thirty-six patients with AL received , in a three-month period , 51 cycles of combined chemotherapy which included , in all of them , drug1 ( ARA-C ) ; among them , along with myelosuppression , five experienced fever , drug2 , gastrointestinal tract symptoms and severe myalgias . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1885 : 
        {
          1 : "NN nmod NN dobj VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development dobj *accelerated* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 may have accelerated the development of drug2 by several mechanisms , including increased renal calcium excretion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1886 : 
        {
          1 : "NN dobj VBD dep VBN advcl VBN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed dep *resolved* advcl changed nmod acid appos drug0"
            }
          4 : 
            {
              1 : "When SASP was changed to 5-aminosalicylic acid ( drug1 ) , his skin eruptions were resolved , however , he developed drug2 and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1887 : 
        {
          1 : "NN nmod VBG acl NNS nmod VBN conj NN nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presenting acl patients nmod considered conj *complication* nsubj hypersensitivity nmod drug0"
            }
          4 : 
            {
              1 : "Hypersensitivity to drug1 is a rare but real complication of therapy and should be considered in patients presenting with drug2 whilst receiving carboplatin therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1888 : 
        {
          1 : "NN compound NN conj NN acl:relcl VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration conj *male* acl:relcl developed dobj episodes nmod drug0"
            }
          4 : 
            {
              1 : "This paper reports on a 6.9-year-old autistic male who developed repeated episodes of drug1 associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal , as well as during subsequent drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1889 : 
        {
          1 : "NN nmod NN conj NN nmod VBN nsubjpass NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development conj oligohidrosis nmod *monitored* nsubjpass children acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "Children receiving drug1 should be monitored for oligohidrosis and the development of drug2 associated with an elevation of body temperature . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1890 : 
        {
          1 : "NN dep NNS nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep months nmod *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "PURPOSE : To report a case of drug1 and Enterobacter keratitis 34 months after drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1891 : 
        {
          1 : "NN dep NN nmod VB conj VBN nsubjpass NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep form nmod produce conj *reported* nsubjpass form appos drug0"
            }
          4 : 
            {
              1 : "The latter form ( drug1 ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form -- drug2 , acute and chronic pulmonary reactions , peripheral neuropathy , blood dyscrasias and allergic reactions -- and does so just as rapidly and floridly ; one such case is reported here . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1892 : 
        {
          1 : "VB acl:relcl NNS conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 acl:relcl reports conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 has been used in the treatment of several cancers , but there have been several reports that it may drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1893 : 
        {
          1 : "NN conj NN dep NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj valproate dep agents nmod *experienced* dobj drug0"
            }
          4 : 
            {
              1 : "We present findings from three patients who experienced a drug1 apparently due to the antiepileptic agents sodium valproate and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1894 : 
        {
          1 : "NN compound NN nmod NNS nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod effects nmod list nmod *included* nsubjpass drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 in combination with other neurological signs , simulating multiple sclerosis , should be included in the list of adverse effects of recombinant and natural drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1895 : 
        {
          1 : "NN compound NN nmod VBD nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound injection nmod *occurred* nsubj woman appos drug0"
            }
          4 : 
            {
              1 : "In the other patient , a 78-year-old woman , drug1 occurred after a single drug2 injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1896 : 
        {
          1 : "NN nmod NNS nmod VBP dobj NN nmod JJ acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cycles nmod *report* dobj patient nmod recurrent acl complicated nmod drug0"
            }
          4 : 
            {
              1 : "We report a patient with recurrent , increasingly severe episodes of PPE , ultimately complicated by a severe drug1 , following successive cycles of high-dose drug2 for the treatment of acute lymphoblastic leukaemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1897 : 
        {
          1 : "NN nsubjpass VBN acl:relcl NNS nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass considered acl:relcl drugs nmod ingestion nmod result nmod *drug0*"
            }
          4 : 
            {
              1 : "These cases were chosen for study because they were all drug1 as a result of suicidal ingestion of drugs in which drug2 was considered a significant factor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1898 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj serositis nmod manifested acl:relcl *lupus* compound drug0"
            }
          4 : 
            {
              1 : "It is suggested that the patient had drug1 lupus , which manifested with serositis and drug2 in the absence of joint symptoms . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1899 : 
        {
          1 : "NN nmod VBD conj JJ advmod RB nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod led conj *progressive* advmod regardless nmod discontinuation nmod drug0"
            }
          4 : 
            {
              1 : "The changes were progressive regardless of discontinuation of drug1 and led to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1900 : 
        {
          1 : "NN conj NNS nmod VBN acl NNS nmod VBN nsubjpass VB nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj corticosteroids nmod treated acl patients nmod *described* nsubjpass flare nmod drug0"
            }
          4 : 
            {
              1 : "Flare of drug1 ( KS ) is well described in immunosuppressed patients treated with corticosteroids and drug2 , but has not yet been reported during treatment with imatinib . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1901 : 
        {
          1 : "NN nmod NN nmod VB dobj VB nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod range nmod rise dobj *give* nsubj treatment compound drug0"
            }
          4 : 
            {
              1 : "The case history confirms that drug1 treatment , even in the same patient , can give rise to a wide range of drug2 , which in many cases do not break out until long after the drug has been withdrawn . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1902 : 
        {
          1 : "NN dobj VBD conj VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *received* dobj interferon conj drug0"
            }
          4 : 
            {
              1 : "METHOD : The authors followed a patient with chronic HCV who received interferon and drug1 and who developed drug2 ultimately requiring psychiatric hospitalization . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1903 : 
        {
          1 : "NN nmod NN conj VBZ nmod NN nmod NN nmod NN nmod NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod documentation conj *indicates* nmod cause nmod relationship nmod occurrence nmod diarrhea conj administration compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and drug1 administration , lack of concomitant medications , and documentation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1904 : 
        {
          1 : "NN conj VBG dep NN nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj vomiting dep *nausea* nsubj effects acl associated nmod drug0"
            }
          4 : 
            {
              1 : "The most common side effects associated with drug1 are nausea , vomiting , hypotension , hypocalcemia and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1905 : 
        {
          1 : "NN appos NN dep IN amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos factor dep after amod *drug0*"
            }
          4 : 
            {
              1 : "drug1 after granulocyte colony-stimulating factor ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1906 : 
        {
          1 : "NN conj NN nmod JJ amod NN nmod NN nmod NNS nmod:tmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj phenobarbital nmod daily amod mg nmod addition nmod months nmod:tmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and drug2 already being administered . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1907 : 
        {
          1 : "NN compound NN nmod JJ conj VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound exposure nmod susceptible conj *predisposed* nmod drug0"
            }
          4 : 
            {
              1 : "This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to drug1 and thus was more susceptible to ductal closure in response to drug2 exposure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1908 : 
        {
          1 : "NN conj NN dobj VB conj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj sludge dobj hasten conj *alters* nsubj drug0"
            }
          4 : 
            {
              1 : "In addition to its known effect on gallbladder stasis , drug1 alters bile acid composition and may thus hasten intrahepatic sludge and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1909 : 
        {
          1 : "NN compound NN nmod VBD nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod *developed* nsubj hypertrophy conj drug0"
            }
          4 : 
            {
              1 : "STUDY DESIGN : Case reports are presented of three premature infants ( mean gestational age 27 weeks ) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and drug1 developed during drug2 treatment for bronchopulmonary dysplasia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1910 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN nsubjpass VBN conj JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patients nmod testing nsubjpass considered conj *possible* nsubj drug0"
            }
          4 : 
            {
              1 : "The case demonstrates that drug1 to pranlukast and resultant ATIN is possible , and that periodic urine testing in patients receiving drug2 should be considered . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1911 : 
        {
          1 : "NN dobj VBN advcl VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj received advcl detected acl *drug0*"
            }
          4 : 
            {
              1 : "A teenage girl with crescentic glomerulonephritis had drug1 ( ANCA ) detected after she had received drug2 ( PTU ) for hyperthyroidism without cutaneous vasculitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1912 : 
        {
          1 : "NN compound NNS nmod VBN acl NN nmod NNS nmod VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound drops nmod treated acl glaucoma nmod patients nmod *described* nsubjpass reports nmod drug0"
            }
          4 : 
            {
              1 : "Two case reports of drug1 are described in patients with open angle glaucoma treated with drug2 0.6 % eye drops . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1913 : 
        {
          1 : "NN nmod VBN conj VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod played conj *describe* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "Here we describe another case of drug1 occurring after LT , but in which the causative role was played by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1914 : 
        {
          1 : "NN dep NN nmod NN acl:relcl VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep *case* nmod woman acl:relcl developed nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report the case of a young woman with Graves ' disease in whom ototoxicity developed because of drug1 ( PTU ) - induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1915 : 
        {
          1 : "NN nmod VBD acl:relcl NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented acl:relcl *case* nmod woman nmod disorder nmod depakote compound drug0"
            }
          4 : 
            {
              1 : "We report a case of 48-year-old woman with seizure disorder on drug1 ( Depakote ) who presented with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1916 : 
        {
          1 : "NN compound NN nmod NN nmod VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod discontinuation nmod *occurred* nsubj remission nmod drug0"
            }
          4 : 
            {
              1 : "Complete remission of the drug1 occurred after discontinuation of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1917 : 
        {
          1 : "NN nmod NNS dobj VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod signs dobj exhibited acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Six days after starting drug1 she exhibited signs of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1918 : 
        {
          1 : "NN dobj VB dep NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj lead dep *inhibitor* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an angiotensin-converting enzyme inhibitor ( ACE-inhibitor ) and overdose can lead to prolonged hypotension and , less frequently , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1919 : 
        {
          1 : "NN nmod NN advmod RB advmod RB"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *administration* advmod soon advmod drug0"
            }
          4 : 
            {
              1 : "However , one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea , and another four patients developed eruptions , hypotension , and drug1 soon after administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1920 : 
        {
          1 : "NN compound NN dep NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound teratogenicity dep *atresia* conj drug0"
            }
          4 : 
            {
              1 : "Choanal atresia and drug1 : drug2 teratogenicity or a new syndrome ? "
            }
          5 : 
            {
              1 : 1
            }
        }
      1921 : 
        {
          1 : "NN nmod VBN advcl VBP nmod NN acl:relcl VBD dobj NN nmod NN appos NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated advcl *report* nmod patient acl:relcl developed dobj pseudo-obstruction nmod colon appos variant nmod drug0"
            }
          4 : 
            {
              1 : "We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon , a variant of drug1 , while being treated with intravenous drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1922 : 
        {
          1 : "NN nmod JJ acl:relcl NN nmod VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod similar acl:relcl exposure nmod *observed* nmod site nmod drug0"
            }
          4 : 
            {
              1 : "In addition , an immediate erythematous macule was observed on the photopatch test site of drug1 directly after UV exposure which was similar to the drug2 noted in chlorpromazine photoallergy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1923 : 
        {
          1 : "NN dobj VBG dep VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj having dep *responding* nmod drug0"
            }
          4 : 
            {
              1 : "The first patient is undergoing hemodialysis and , though responding to drug1 , is having significant drug2 and hypertension . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1924 : 
        {
          1 : "NN nsubj JJ advcl VB nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *reversible* advcl cause nsubj amiodarone conj drug0"
            }
          4 : 
            {
              1 : "While both amiodarone and drug1 can cause permanent visual changes , the drug2 are often reversible . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1925 : 
        {
          1 : "NN nmod VBD conj VBN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod died conj *placed* nmod adriamycin appos drug0"
            }
          4 : 
            {
              1 : "She was placed on adjuvant Adriamycin ( drug1 ) chemotherapy , but 6 months later died of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1926 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod day nmod infected acl patients nmod *drug0*"
            }
          4 : 
            {
              1 : "We report 2 cases of drug1 and fever in patients infected with human immunodeficiency virus ( HIV ) on the 2nd day of first administration of drug2 , a protease inhibitor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1927 : 
        {
          1 : "NN compound NNS conj NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound regimens conj chemotherapies nmod *reported* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 has been reported after several anticancer chemotherapies and most often after drug2 chemotherapy regimens . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1928 : 
        {
          1 : "NN dobj VBD conj VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *treated* nmod hydration conj drug0"
            }
          4 : 
            {
              1 : "The patient was initially treated with hydration and drug1 but developed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1929 : 
        {
          1 : "NN compound NN nmod NN nmod VBD nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nmod association nmod *occurred* nsubj episodes nmod drug0"
            }
          4 : 
            {
              1 : "We have cared for three children in whom four episodes of dystonia proceeding to drug1 occurred in association with drug2 use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1930 : 
        {
          1 : "NN nmod NN dobj VBD dep NNS nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy dobj began dep weeks nmod *woman* acl presented nmod drug0"
            }
          4 : 
            {
              1 : "OBSERVATIONS : A 48-year-old woman presented with drug1 10 weeks after she began antiviral therapy with drug2 and ribavirin for chronic hepatitis C infection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1931 : 
        {
          1 : "NN nmod VBN acl JJ amod NN nmod NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl recipient amod transplant nmod *cholelithiasis* conj drug0"
            }
          4 : 
            {
              1 : "Cholelithiasis and drug1 in a renal transplant recipient treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1932 : 
        {
          1 : "NN dobj VBG advcl JJ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj using advcl *aware* nmod possibility nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Although a definite association has not been proven , clinicians should be aware of the possibility of drug1 while using drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1933 : 
        {
          1 : "NN dobj VB nsubj NN advmod RB nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *produce* nsubj cyclosporin advmod together nmod drug0"
            }
          4 : 
            {
              1 : "We postulate that cyclosporin , possibly together with drug1 , can produce drug2 with eye movement abnormality in occasional patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1934 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN acl NN dobj VBD nsubj NNS acl:relcl VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod affect nmod development nmod followed acl response dobj *had* nsubj outpatients acl:relcl participated nmod trial nmod drug0"
            }
          4 : 
            {
              1 : "Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of drug1 had an initial good response to the medication followed by development of intolerable affect , including drug2 and depression and periods of crying and insomnia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1935 : 
        {
          1 : "NN nmod NN dobj VBZ acl:relcl NN nmod NNS nmod JJ conj VB nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development dobj favors acl:relcl hypothyroidism nmod patients nmod *aware* conj monitor nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK , GOT and GPT during the treatment of diabetes insipidus with drug1 , especially in patients with associated hypothyroidism , latent or overt , which possibly favors the development of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1936 : 
        {
          1 : "NN conj VBN nsubjpass NN nmod NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *followed* nsubjpass administration nmod spirits appos drug0"
            }
          4 : 
            {
              1 : "The administration of `` sweet spirits of nitre '' ( drug1 ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin drug2 from the consequences of hypoxemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1937 : 
        {
          1 : "NN nmod VBN nsubjpass NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *contraindicated* nsubjpass treatment nmod alpha appos drug0"
            }
          4 : 
            {
              1 : "Treatment of chronic hepatitis C with interferon alpha ( drug1 ) is relatively contraindicated in patients with psychiatric disorders because of possible severe drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1938 : 
        {
          1 : "NN compound NNS nmod VBN acl NN dobj VBD nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound lesions nmod characterized acl syndrome dobj *had* nsubj patient acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "A patient receiving drug1 for a serious staphylococcal infection had a lupus-like syndrome characterized by a drug2 , pain and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1939 : 
        {
          1 : "NN compound NN nmod VBG nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound chemotherapy nmod *occurring* nsubj incidence nmod drug0"
            }
          4 : 
            {
              1 : "The purpose of this study was to examine the incidence and cause of drug1 occurring after drug2 combination chemotherapy in ovarian cancer patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1940 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN csubjpass VBG dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod angina nmod treatment nmod *observed* csubjpass alternating dobj rhythm conj drug0"
            }
          4 : 
            {
              1 : "Alternating sinus rhythm and drug1 was observed in a 57-year-old woman , under treatment for angina with 80 mg drug2 daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1941 : 
        {
          1 : "NN compound NN nmod NN nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nmod *complication* nsubj insipidus appos drug0"
            }
          4 : 
            {
              1 : "Nephrogenic diabetes insipidus ( drug1 ) is a well-documented complication of drug2 use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1942 : 
        {
          1 : "NN appos NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos *antagonist* appos drug0"
            }
          4 : 
            {
              1 : "There is evidence that the angiotensin II receptor antagonist , drug1 , drug2 by reducing reabsorption of urate in the renal proximal tubule . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1943 : 
        {
          1 : "NN conj NN dobj VBD nsubj CD nmod NNS acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hypertension dobj *had* nsubj one nmod subjects acl:relcl using dobj drug0"
            }
          4 : 
            {
              1 : "One of the subjects who was using extemporaneous topical drug1 had hypertension and drug2 and the other died of a myocardial infarction . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1944 : 
        {
          1 : "NN appos NN nmod VBN acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos salazosulfapyridine nmod induced acl *patients* nmod drug0"
            }
          4 : 
            {
              1 : "We report two patients with drug1 induced by salazosulfapyridine ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1945 : 
        {
          1 : "NN conj NN nmod VBN acl:relcl NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj oxaliplatinum nmod treated acl:relcl yrs nmod developed acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 , T-CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age , who was treated with oxaliplatinum and drug2 for unresectable rectum carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1946 : 
        {
          1 : "NN nmod NNS nsubjpass VBN conj VBD parataxis VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod changes nsubjpass observed conj developed parataxis *disappeared* nmod therapy nmod drug0"
            }
          4 : 
            {
              1 : "After therapy with parenteral drug1 ( 2300 mg in 3 days ) and other measures , signs of congestive heart failure disappeared ; subsequently the patient developed jaundice , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of drug2 were observed in hepatic biopsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1947 : 
        {
          1 : "NN nsubj VBN nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *resolved* nmod months nmod withdrawal compound drug0"
            }
          4 : 
            {
              1 : "Within 6 months of drug1 withdrawal , drug2 resolved and urinary sediment and renal function normalized . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1948 : 
        {
          1 : "NN compound NN nmod VBG acl NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound formation nmod leading acl blockage conj *inflammation* compound drug0"
            }
          4 : 
            {
              1 : "drug1 Meibomian duct inflammation and blockage leading to drug2 formation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1949 : 
        {
          1 : "NN nmod NNS nmod VBD dobj NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod courses nmod *developed* dobj impairment acl attributed nmod drug0"
            }
          4 : 
            {
              1 : "A young diamond dealer developed visual impairment attributed to drug1 following only four courses of intermittent drug2 used as part of a five-drug antiemetic regimen for cisplatin-associated nausea . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1950 : 
        {
          1 : "NN nmod NN dobj JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause dobj *likely* nsubj drug0"
            }
          4 : 
            {
              1 : "In this case drug1 was likely the cause of a drug2 exemplifying again the potential role of herbal related liver injury . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1951 : 
        {
          1 : "NN nmod NN nmod JJ amod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod coincident amod patients nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "We describe the development of drug1 in 3 patients coincident with the use of drug2 in low cumulative doses of less than 100 U . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1952 : 
        {
          1 : "NN compound NN nmod NNS nmod VBN acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod symptoms nmod associated acl *enlargement* appos drug0"
            }
          4 : 
            {
              1 : "In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true drug1 ) , mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1953 : 
        {
          1 : "NN compound NNS nmod NNS nmod VB dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusions nmod cases nmod *describe* dobj occurrence nmod drug0"
            }
          4 : 
            {
              1 : "The aim of this study was to describe the occurrence of drug1 in 3 cases of drug2 infusions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1954 : 
        {
          1 : "NN nmod NN nmod VBP dobj NN nmod NN acl VBN nmod NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod chemotherapy nmod *report* dobj patient nmod adenocarcinoma acl complicated nmod syndrome nmod secretion nmod hormone appos drug0"
            }
          4 : 
            {
              1 : "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( drug1 ) following systemic chemotherapy with drug2 ( CDDP ) and vindesine ( VDS ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1955 : 
        {
          1 : "NN compound NN nmod VBZ ccomp VBD conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound reaction nmod results ccomp were conj *taken* dobj drug0"
            }
          4 : 
            {
              1 : "In case no. 2 , the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy , as he had taken drug1 for 6 months , and there were strong positive photopatch test results with immediate drug2 reaction , cross-reaction to promethazine , decreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1956 : 
        {
          1 : "NN nmod NN nmod NN nmod NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod initiation nmod patient nmod *lack* nmod control nmod drug0"
            }
          4 : 
            {
              1 : "Case report : lack of control of drug1 and weight gain in a patient on initiation and rechallenge of therapy with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1957 : 
        {
          1 : "NN compound NN nmod NN nmod VBG nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod site nmod swelling nmod complicated acl *drug0*"
            }
          4 : 
            {
              1 : "Here we describe a patient with Crohn 's disease who developed a drug1 ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1958 : 
        {
          1 : "NN nsubj VB acl:relcl NNS nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj result acl:relcl illnesses nmod patients nmod *use* nmod drug0"
            }
          4 : 
            {
              1 : "We recommend the cautious use of drug1 in patients with underlying illnesses where NSAID-induced drug2 could result in adverse otologic consequences . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1959 : 
        {
          1 : "NN nmod NNS dobj VB conj VBD nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod findings dobj discuss conj *induced* nsubj cases nmod drug0"
            }
          4 : 
            {
              1 : "We report three cases of drug1 induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1960 : 
        {
          1 : "NN nmod NN dobj VBD csubj VB nmod NNS conj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development dobj *documented* csubj replicate nmod weeks conj months nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of drug1 therapy documented the development of new drug2 during this period , while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1961 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj starting acl month nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 68-year-old woman developed a dry , drug1 within one month of starting drug2 therapy for the treatment of essential hypertension . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1962 : 
        {
          1 : "NN compound NN dobj VBG advcl VBP nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj undergoing advcl *report* nmod patients nmod drug0"
            }
          4 : 
            {
              1 : "The authors report on two patients with drug1 while the patients were undergoing oral drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1963 : 
        {
          1 : "NN nmod NN nmod VBG dobj VBN nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episode nmod precipitating dobj *represented* nsubj overdose nmod drug0"
            }
          4 : 
            {
              1 : "The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of drug1 could have represented the precipitating of the episode of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1964 : 
        {
          1 : "NN compound NN nmod NN xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod complication xcomp *considered* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Regardless of a negative history of asthma , therefore , life-threatening drug1 must be considered a possible complication of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1965 : 
        {
          1 : "NN nmod NN nmod NN dobj VBG advcl VBN xcomp VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mg/day nmod dose dobj taking advcl *found* xcomp have dobj drug0"
            }
          4 : 
            {
              1 : "The patient was found to have drug1 with a normal sperm count , while taking a dose of 400 mg/day of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1966 : 
        {
          1 : "NN nmod NN nmod NNS conj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod cases conj *reports* nmod drug0"
            }
          4 : 
            {
              1 : "Several case reports of drug1 with use of acetazolamide , and two cases with use of drug2 , have appeared in the literature . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1967 : 
        {
          1 : "NN nmod NNS nmod VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episodes nmod *correlated* nmod regimen nmod drug0"
            }
          4 : 
            {
              1 : "A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of drug1 as episodes of drug2 and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1968 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod NN nmod VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod start dep months nmod number nmod *increased* nsubj drug0"
            }
          4 : 
            {
              1 : "Although they had only a few nodules at diagnosis , the drug1 increased in number and size 3 to 4 months after the start of drug2 therapy in both patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1969 : 
        {
          1 : "NN root , punct NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct *prophylaxis* compound drug0"
            }
          4 : 
            {
              1 : "k bipolar manic-depressive patient , developed while on drug1 prophylaxis , drug2 at therapeutic serum lithium levels and subsequently bucco-linguo-masticatory dyskinesia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1970 : 
        {
          1 : "NN nmod NN nmod NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod *rash* conj days compound drug0"
            }
          4 : 
            {
              1 : "A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and drug1 4 and 7 days , respectively , following a single dose of 40 mg/m2 drug2 ( MTX ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1971 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod ingestion nmod attributed acl:relcl woman nmod *case* nmod pustulosis appos drug0"
            }
          4 : 
            {
              1 : "We report a case of acute generalized exanthematous pustulosis ( drug1 ) in a 50-year-old woman that was attributed to the ingestion of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1972 : 
        {
          1 : "NN nmod NNS dobj VBP nsubj NNS nmod:poss NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod possibilities dobj *offer* nsubj effects nmod:poss drug0"
            }
          4 : 
            {
              1 : "drug1 's extensive physiologic effects , inconsistent street purity , and multiple routes of administration offer many possibilities for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1973 : 
        {
          1 : "NN nmod NNS nmod VBD conj VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consequences nmod died conj *followed* nsubjpass administration nmod drug0"
            }
          4 : 
            {
              1 : "The administration of `` drug1 '' ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1974 : 
        {
          1 : "NN dobj VBN acl:relcl NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl *patients* nmod retinopathy compound drug0"
            }
          4 : 
            {
              1 : "With the use of optical coherence tomography ( OCT ) , two patients with drug1 retinopathy who had developed drug2 and reduced visual acuity during the clinical course of IFN therapy were observed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1975 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl:relcl therapy compound drug0"
            }
          4 : 
            {
              1 : "A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance drug1 therapy developed a drug2 following high doses of trazodone for treatment of an acute depression . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1976 : 
        {
          1 : "NN nmod NN nmod VBD parataxis VBN xcomp NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod started parataxis *thought* xcomp cause nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Sustained-release verapamil is thought to be the cause of the drug1 in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained-release drug2 and were relieved after its discontinuation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1977 : 
        {
          1 : "NN nmod NN nmod VBP nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *are* nmod literature nmod emergence nmod drug0"
            }
          4 : 
            {
              1 : "There are no previous reports in the literature about the emergence of drug1 during treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1978 : 
        {
          1 : "NN nmod VBD acl:relcl NNS nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod developed acl:relcl *cases* nmod chorioretinitis appos drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( drug1 ) that developed after intravitreal drug2 ( IVTA ) injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1979 : 
        {
          1 : "NN appos NN nmod NN nmod NN nmod VBG dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos methotrexate nmod infusion nmod completion nmod *impending* dobj toxicity conj drug0"
            }
          4 : 
            {
              1 : "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme drug1 and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate ( drug2 ) ( 12 g/m2 ) , and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1980 : 
        {
          1 : "NN conj NN nmod NN dobj VB conj VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj colitis nmod relationship dobj review conj *treated* nmod drug0"
            }
          4 : 
            {
              1 : "We describe the development of ischemic colitis in a woman who was treated with drug1 and review the relationship among ischemic colitis , tegaserod use , and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1981 : 
        {
          1 : "NN nmod NNS nmod NN nmod VBZ acl:relcl NN nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod incidence nmod results acl:relcl efficacy nmod *member* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2/5HT2 binding ratio , which results in a low incidence of extrapyramidal side effects including drug2 ( TD ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1982 : 
        {
          1 : "NN nmod VBN acl NN nmod NNS nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl arthritis nmod patients nmod *event* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Significant drug1 is a potential adverse event in patients with rheumatoid arthritis treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1983 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resolution nmod *resulted* nsubj discontinuation nmod simvastatin conj drug0"
            }
          4 : 
            {
              1 : "Discontinuation of simvastatin and drug1 resulted in resolution of drug2 and normalization of renal function . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1984 : 
        {
          1 : "NN nmod VBG acl NN nmod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod consisting acl chemotherapy nmod cycle nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related drug1 during the second cycle of neoadjuvant chemotherapy consisting of drug2 , bleomycin , and methotrexate . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1985 : 
        {
          1 : "NN nsubj VBD nmod NNS dep NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *developed* nmod days dep injection nmod mg nmod drug0"
            }
          4 : 
            {
              1 : "Four days after the initial injection of 3.6 mg of drug1 , drug2 developed due to worsening pleuritis carcinomatosa , which was considered as a flare-up . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1986 : 
        {
          1 : "NN conj NN dobj VBP nsubj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj suppression dobj *include* nsubj signs nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "Well-known signs of drug1 toxicity include bone marrow suppression and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1987 : 
        {
          1 : "NN dobj VB xcomp JJ nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp *potential* nsubj limitation nmod use nmod drug0"
            }
          4 : 
            {
              1 : "A major limitation in the use of drug1 is its potential to cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1988 : 
        {
          1 : "NN compound NN nmod NN nmod VBP nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod course nmod *occur* nsubj abnormalities nmod drug0"
            }
          4 : 
            {
              1 : "Retinal abnormalities , including drug1 and `` cotton-wool '' spots , often occur within the first 8 weeks in the course of drug2 therapy in patients with chronic hepatitis C . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1989 : 
        {
          1 : "NN conj NN nmod VB acl:relcl NN dobj VB nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fibrosis nmod lead acl:relcl damage dobj *induce* nsubj methotrexate appos drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : Methotrexate ( drug1 ) may induce liver damage , which in some psoriatics will lead to fibrosis or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1990 : 
        {
          1 : "NN compound NN nmod NN nmod VBN conj VBN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod discontinuance nmod relieved conj associated acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Two 65-year-old white men with coronary heart disease , given niacin therapy for dyslipidemia for 5 months , developed drug1 that was associated with increases in dose and that was relieved with discontinuance of drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1991 : 
        {
          1 : "NN nmod VBP dobj NNS nmod NN nmod NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *report* dobj cases nmod elimination nmod patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "The authors report two cases of delayed elimination of methotrexate in patients receiving drug1 , with severe drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1992 : 
        {
          1 : "NN nmod NNS conj DT nmod VBN nsubjpass NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complications conj those nmod *monitored* nsubjpass patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "That review suggested that patients receiving drug1 be monitored for those and other potential complications of drug2 , particularly disseminated intravascular coagulation ( DIC ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1993 : 
        {
          1 : "NN nsubjpass VBN advcl VBN nmod NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass *reported* advcl seen nmod patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Although moderate myelosuppression is not uncommonly seen in patients treated with drug1 , drug2 has not previously been reported to be associated with this agent . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1994 : 
        {
          1 : "NN appos NNS nmod NN nmod VBZ conj JJ ccomp VBZ advcl VBZ nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos symptoms nmod frequency nmod does conj effective ccomp *appears* advcl consists nsubj literature nmod use nmod drug0"
            }
          4 : 
            {
              1 : "Although the literature on the use of drug1 in elderly patients with dementia consists largely of uncontrolled trials , case reports , and chart reviews , it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1995 : 
        {
          1 : "NN dobj VBG advcl VBG acl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving advcl leading acl neuropathy conj *drug0*"
            }
          4 : 
            {
              1 : "We describe a patient with acute leukemia who developed drug1 and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1996 : 
        {
          1 : "NN nmod VBP dobj NN nmod NN nmod VBG conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *describe* dobj management nmod patient nmod swelling conj drug0"
            }
          4 : 
            {
              1 : "INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and drug1 ( ICP ) after severe drug2 ( VPA ) intoxication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1997 : 
        {
          1 : "NN appos NN nmod VBN acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos alpha-0a nmod associated acl *syndrome* appos drug0"
            }
          4 : 
            {
              1 : "We report the first case of fulminant adult respiratory distress syndrome ( drug1 ) associated with pegylated interferon alpha-2a ( drug2 ) and ribavirin use for hepatitis C , complicated by subsequent and ultimately fatal sepsis and multiorgan failure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1998 : 
        {
          1 : "NN nsubj NN ccomp VBN advcl VBN nsubjpass NN nmod NNS appos NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj effect ccomp *recognized* advcl shown nsubjpass introduction nmod wafers appos wafers compound drug0"
            }
          4 : 
            {
              1 : "While the introduction of carmustine wafers ( drug1 wafers ) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma , it is recognized that clinically significant drug2 is a potential adverse effect . "
            }
          5 : 
            {
              1 : 1
            }
        }
      1999 : 
        {
          1 : "NN nmod NN dobj VB xcomp VB xcomp VBP nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod potential dobj enhance xcomp act xcomp *appear* nsubj cytarabine conj drug0"
            }
          4 : 
            {
              1 : "Intravenous cytarabine and drug1 appear to act synergistically to enhance the potential for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2000 : 
        {
          1 : "VB xcomp JJ amod NN nmod VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp secondary amod involvement nmod *describe* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "To our knowledge , we describe the first reported case of drug1 and peripheral neuropathy , without systemic involvement , secondary to drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2001 : 
        {
          1 : "NN nsubj NN advcl VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *effect* advcl sensitize nsubj drug0"
            }
          4 : 
            {
              1 : "Because drug1 sensitize skin to ultraviolet A light , drug2 are the most frequent adverse effect of this treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2002 : 
        {
          1 : "NN nmod JJ amod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod secondary amod patient nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a pediatric patient secondary to drug2 , a recalled medication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2003 : 
        {
          1 : "NN nmod NN nmod VBD conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod dropped conj *drug0*"
            }
          4 : 
            {
              1 : "Since the drug1 immediately after initiation and dropped immediately after discontinuation of drug2 and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count , these two antibiotics were regarded causative . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2004 : 
        {
          1 : "NN nmod VBN acl DT appos NNS nsubj VBP conj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl all appos reports nsubj are conj *increases* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( RFP ) increases hepatic microsomal enzyme activity , and there are case reports of RFP-induced hypothyroidism , all associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2005 : 
        {
          1 : "NN nsubj JJ dep NN nmod VBN conj JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj common dep toxicity nmod limited conj *effective* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( AmB ) is effective , but its use is limited by toxicity : drug2 , anaemia , fever , malaise , and hypokalaemia are common . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2006 : 
        {
          1 : "NN nmod NNS dobj VBN conj JJ nmod VB nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects dobj understood conj unexpected nmod *call* nmod time nmod cessation nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "We wish to call for cautious approach at time of cessation of prolonged drug1 therapy because of possible unexpected and only partially understood hazardous side effects such as drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2007 : 
        {
          1 : "NN nmod NN nmod VBD dobj NNS nmod NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod *manifested* dobj symptoms nmod drug dep drug0"
            }
          4 : 
            {
              1 : "Four patients who manifested symptoms of the antiepileptic drug ( AED ) drug1 during therapy with drug2 are reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2008 : 
        {
          1 : "NN compound NN nmod VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound toxicity nmod *related* nsubj drug0"
            }
          4 : 
            {
              1 : "During the anti-tuberculous therapy , drug1 can be related to drug2 toxicity or the tuberculosis infection itself . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2009 : 
        {
          1 : "NN conj NN nmod NN dobj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj propylthiouracil nmod treatment dobj *followed* nsubj drug0"
            }
          4 : 
            {
              1 : "This is , to the best of our knowledge , the first report of a case in which drug1 followed treatment with both propylthiouracil and drug2 in the same patient . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2010 : 
        {
          1 : "NN dep NNS nmod NN nmod VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep individuals nmod % nmod *occur* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occur in 3 % of individuals administered drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2011 : 
        {
          1 : "NN dobj VBN acl:relcl JJ nmod VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj received acl:relcl newborn nmod treated conj *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Life-threatening drug1 , requiring hydrocortisone supplementation and intensive therapy , was observed and successfully treated in a newborn , whose mother had received high-dose drug2 in late pregnancy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2012 : 
        {
          1 : "NN nmod NN dobj VB nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occurrence dobj *precipitate* nsubj interferon-alpha appos drug0"
            }
          4 : 
            {
              1 : "Interferon-alpha ( drug1 ) may precipitate or exacerbate the occurrence of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2013 : 
        {
          1 : "NN nmod NN dobj VBD nsubj NNS nmod NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod hyperactivity dobj *demonstrated* nsubj studies nmod monitoring nmod levels compound drug0"
            }
          4 : 
            {
              1 : "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma drug1 levels demonstrated marked motor hyperactivity during augmentation , with drug2 , tonic grouped discharges and flexor spasms , associated with painful dysesthesia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2014 : 
        {
          1 : "NN nmod NNS nmod NNS nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod *symptoms* nmod syndrome appos drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : We report a typical symptoms of Charles-Bonnet syndrome ( drug1 ) in patients with severe AMD after intravitreal drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2015 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN nsubjpass NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod completion nmod *seen* nsubjpass dysarthria conj drug0"
            }
          4 : 
            {
              1 : "During the first treatment , dysarthria and drug1 were seen after completion of the patient 's eighth and final dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2016 : 
        {
          1 : "NN nmod NN dep NNS nmod NN xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod exposure dep years nmod % xcomp *estimated* nsubjpass risk nmod drug0"
            }
          4 : 
            {
              1 : "The risk of developing drug1 is estimated to be between 1 % and 5 % , 2-20 years after exposure to drug2 but may also be related to cumulative drug doses , treatment schedules , host factors and co-administration of other antineoplastic agents . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2017 : 
        {
          1 : "NN appos NN dep VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos dizziness dep caused acl:relcl *interaction* nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This is the first report of a possible interaction between drug1 and citalopram , which caused propafenone adverse effects ( eg , dizziness , drug2 ) and mimicked coronary artery disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2018 : 
        {
          1 : "NN nmod VBN acl:relcl NNS dobj VBG acl NNS nmod NN dobj VB xcomp VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod related acl:relcl features dobj exhibiting acl patients nmod interaction dobj suspect xcomp *makes* nsubj use nmod drug0"
            }
          4 : 
            {
              1 : "The wide use of drug1 during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2019 : 
        {
          1 : "NN nmod NN nsubj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *toxicity* nsubj rash nmod sjs compound drug0"
            }
          4 : 
            {
              1 : "Severe rash , including the drug1 ( SJS ) , is the major toxicity of drug2 and is described in the package labeling with a prominent , boxed warning . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2020 : 
        {
          1 : "NN compound NN nmod NN amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound amblyopia nmod *potential* amod drug0"
            }
          4 : 
            {
              1 : "drug1 and visual-evoked potential in drug2 amblyopia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2021 : 
        {
          1 : "NN conj NN dobj VBD acl:relcl NNS nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj 0-fluorouracil dobj received acl:relcl patients nmod developed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Observations in our patient suggest that the drug1 that developed in previously reported patients who received 5-fluorouracil and drug2 may have been caused at least partly by levamisole . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2022 : 
        {
          1 : "NN compound NN nsubj VBN advcl VBN conj VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nsubj occurred advcl considered conj *obtained* nmod patients nmod drug0"
            }
          4 : 
            {
              1 : "In patients with drug1 and pneumonia , a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if drug2 use has occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2023 : 
        {
          1 : "NN dobj VBD dep VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induced dep *contained* nmod drug0"
            }
          4 : 
            {
              1 : "The fluorine contained in drug1 induced a marked drug2 in all 3 cases . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2024 : 
        {
          1 : "NN nmod NN dobj VB acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod tincture dobj compound acl *cases* nmod drug0"
            }
          4 : 
            {
              1 : "Nineteen cases of drug1 to compound tincture of drug2 are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2025 : 
        {
          1 : "NN conj NN nmod NN dobj VBG xcomp VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj insensitivity nmod existence dobj suggesting xcomp *controlled* nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "The induced hyperglycaemia could not be controlled sufficiently , despite a high dose of drug1 ( > 110 units/day ) , suggesting the existence of insulin insensitivity and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2026 : 
        {
          1 : "NN nmod NNS nsubjpass VBN ccomp VBN nsubjpass NNS acl:relcl VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mechanisms nsubjpass reviewed ccomp *described* nsubjpass mechanisms acl:relcl decreases nsubj drug0"
            }
          4 : 
            {
              1 : "Possible mechanisms by which drug1 decreases spasticity are described , probable mechanisms of induced drug2 are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2027 : 
        {
          1 : "NN nmod NN nmod VBD conj VBN nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod led conj *destroyed* nsubj dose nmod drug0"
            }
          4 : 
            {
              1 : "We thus concluded that an excessive dose of drug1 had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2028 : 
        {
          1 : "NN nmod NNS dobj VBP conj VBP ccomp VBD nsubj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cases dobj comprise conj *constitute* ccomp reported nsubj cases nmod hepatotoxicity compound drug0"
            }
          4 : 
            {
              1 : "Our cases constitute the most severe cases of drug1 hepatotoxicity reported so far , and comprise the first cases of drug2 and cirrhosis related to benzarone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2029 : 
        {
          1 : "NN appos JJ conj JJ amod NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos long-acting conj intermediate amod insulins nmod *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was observed with both intermediate ( neutral protamine hagedorn ) and long-acting ( drug2 ) insulins , and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2030 : 
        {
          1 : "NN dep NNS dobj VBG advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep inhibitors dobj taking advcl *observed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 was observed in five female patients after taking proton pump inhibitors drug2 , lansoprazole , or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2031 : 
        {
          1 : "NN nmod VB acl:relcl NN dobj VB nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod lead acl:relcl damage dobj *induce* nsubj methotrexate appos drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : Methotrexate ( drug1 ) may induce liver damage , which in some psoriatics will lead to drug2 or cirrhosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2032 : 
        {
          1 : "NN compound NN nmod VBD nsubj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *appeared* nsubj symptoms compound drug0"
            }
          4 : 
            {
              1 : "In all the patients , drug1 symptoms appeared during drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2033 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl woman nmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed in a 24-year-old black woman who had been treated with drug2 and propranolol for hyperthyroidism . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2034 : 
        {
          1 : "NN nsubjpass VBN advcl VBN nsubjpass NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass *described* advcl reported nsubjpass manifestations nmod cardiotoxicity compound drug0"
            }
          4 : 
            {
              1 : "Although various manifestations of drug1 cardiotoxicity have been reported , to our knowledge , drug2 associated with this agent has not been described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2035 : 
        {
          1 : "NN compound NN nmod VBG acl NN nmod NN conj NN nmod JJ nmod NN nmod NN nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod occurring acl fixation nmod case conj administration nmod *aware* nmod risk nmod aiha nmod patients nmod history nmod drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware of the risk of severe AIHA in CLL patients with a history of drug1 or positivation of the DAT during previous fludarabine administration , or in case of secondary fixation of complement to the red cell membrane occurring during drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2036 : 
        {
          1 : "NN nsubj NN dep NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj event dep *0-fluorouracil* appos drug0"
            }
          4 : 
            {
              1 : "5-fluorouracil ( drug1 ) - associated drug2 is an uncommon event . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2037 : 
        {
          1 : "NN appos NN nmod NN nmod VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos drug nmod treatment nmod *developed* dobj onset nmod drug0"
            }
          4 : 
            {
              1 : "A patient is described who developed a rapid onset of drug1 following treatment with a new non-steroidal anti-inflammatory drug , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2038 : 
        {
          1 : "NN nmod VBD nsubj NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *resulted* nsubj overkill nmod treatment nmod methotrexate nmod rescue compound drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with drug1 rescue , resulted in the drug2 ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2039 : 
        {
          1 : "NN dobj VBG acl NN nmod NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl failure nmod patients nmod experienced acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 experienced by patients with chronic heart failure taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2040 : 
        {
          1 : "NN nmod VBG advcl VBN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulting advcl *treated* nmod ointment compound drug0"
            }
          4 : 
            {
              1 : "We experienced a male patient with psoriasis and hypertension whose conditions were treated with drug1 ointment and thiazide , respectively , resulting in drug2 and hypercalcemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2041 : 
        {
          1 : "NN nmod NN dep NN nmod NN dobj VBD conj VBN dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod onset dep week nmod level dobj had conj *finished* dobj course nmod drug0"
            }
          4 : 
            {
              1 : "She had just finished a 3-week course of intravenous drug1 for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2042 : 
        {
          1 : "NN conj NN nmod NNS dobj VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj lidocaine nmod agents dobj diluting acl *drug0*"
            }
          4 : 
            {
              1 : "Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from ( a ) direct pharmacologic and physical effects of methamphetamine ; ( b ) the drug1 of diluting or `` cutting '' agents such as lidocaine and drug2 ; ( c ) effects related to the route of drug administration ( intravenous , inhalation , smoking ) ; and ( d ) manufacture-related effects of exposure to unintentional caustic contaminants in the final product . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2043 : 
        {
          1 : "NN appos NN nmod NN nmod VBG acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos arabinoside nmod dose nmod resulting acl *necrolysis* appos drug0"
            }
          4 : 
            {
              1 : "We report a fatal case of toxic epidermal necrolysis ( drug1 ) resulting from a high dose of cytosine arabinoside ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2044 : 
        {
          1 : "NN nmod VBN acl CD nmod CD nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod exposed acl 0 nmod 0 nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurred in 5 of 39 ( 12.8 % ) exposed to drug2 ; all were cases of clitoral hypertrophy not requiring surgical treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2045 : 
        {
          1 : "NN dobj VB xcomp VBN advcl JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp reported advcl *responsible* nsubj drug0"
            }
          4 : 
            {
              1 : "The clinical course suggests that drug1 , which is present in oolong tea , was mainly responsible for the rhabdomyolysis as well as the delirium , although severe hyponatremia has been reported to cause drug2 on rare occasions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2046 : 
        {
          1 : "NN nsubj VBD advcl VBN nsubjpass NNS nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj developed advcl *given* nsubjpass chemotherapeutics nmod vincristine nmod case conj drug0"
            }
          4 : 
            {
              1 : "The chemotherapeutics , including vincristine , actinomycin D , and epirubicin in case 1 and drug1 and actinomycin D in case 2 , were given before the drug2 developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2047 : 
        {
          1 : "NN compound NN nsubjpass VBN acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nsubjpass complicated acl:relcl *patient* nmod drug0"
            }
          4 : 
            {
              1 : "We describe a patient with a drug1 due to Entamoeba histolytica , in whom drug2 therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2048 : 
        {
          1 : "NN compound NN nmod VBD advmod RB"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *developed* advmod drug0"
            }
          4 : 
            {
              1 : "We describe two patients with rheumatoid factor-positive , polyarticular-onset juvenile rheumatoid arthritis in whom drug1 developed during drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2049 : 
        {
          1 : "NN dep NN nmod VBD acl:relcl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep chemotherapy nmod developed acl:relcl *ischemia* conj drug0"
            }
          4 : 
            {
              1 : "We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and drug1 that developed after combined chemotherapy ( drug2 and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2050 : 
        {
          1 : "NN appos NN nmod VBN advcl VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos drug nmod started advcl *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed when a diabetic patient , previously treated with glyburide , was started on another oral sulfonylurea drug , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2051 : 
        {
          1 : "NN root , punct RB dep NN dobj VBD dep VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct profusely dep sweating dobj started dep *began* advcl stopped nsubjpass drug0"
            }
          4 : 
            {
              1 : "The day after drug1 was stopped , while he was still receiving clomipramine 150 mg/d , he began behaving oddly , started sweating profusely , drug2 , and became tremulous , agitated , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2052 : 
        {
          1 : "NN nmod NN nmod:tmod VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod day nmod:tmod *developed* dobj failure nmod drug0"
            }
          4 : 
            {
              1 : "A sixty-year-old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with drug1 , the day after 5 g/m2 bolus drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2053 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD dobj NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment dobj receiving advcl *developed* dobj failure conj d compound drug0"
            }
          4 : 
            {
              1 : "However , he developed acute renal failure , hyperkalemia , and drug1 30 d after receiving the drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2054 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod developed acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of reversible drug1 and new-onset DM that developed in a demented patient who was treated with drug2 for 14 days . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2055 : 
        {
          1 : "NN compound NN conj NN dobj VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion conj carboplatin dobj receiving acl *patient* nmod drug0"
            }
          4 : 
            {
              1 : "A 68-year-old female patient with advanced ovarian carcinoma drug1 whilst receiving a carboplatin and drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2056 : 
        {
          1 : "NN conj NN nmod VBN xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj piperacillin nmod related xcomp *thought* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Thus , drug1 in our cases are thought to be related to piperacillin and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2057 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod VBD dobj NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound prescription nmod commencement dep months nmod *developed* dobj syndrome nmod secretion nmod hormone appos drug0"
            }
          4 : 
            {
              1 : "We describe a 74-year-old man with rheumatoid arthritis ( RA ) who developed syndrome of inappropriate secretion of antidiuretic hormone ( drug1 ) 1.5 months after commencement of drug2 prescription when his arthritis was improved . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2058 : 
        {
          1 : "NN nmod NN advcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause advcl *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a child with neuroblastoma while on oral drug2 : what is the cause ? "
            }
          5 : 
            {
              1 : 1
            }
        }
      2059 : 
        {
          1 : "NN nmod NN dobj VBG dep NNS nmod VBD nmod:tmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment dobj initiating dep weeks nmod *developed* nmod:tmod drug0"
            }
          4 : 
            {
              1 : "In both cases , drug1 , skin rash , liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2060 : 
        {
          1 : "NN conj JJ amod NNS nmod NNS dobj VBD conj VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj severe amod days nmod signs dobj developed conj *treated* nmod injection nmod drug0"
            }
          4 : 
            {
              1 : "METHODS : Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of drug1 and developed signs of severe but drug2 2 days later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2061 : 
        {
          1 : "NN nmod NN nmod VBD conj VBD xcomp VB nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episode nmod showed conj *started* xcomp occur nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Multiple syncopal episodes started to occur during drug1 treatment , and a Holter electrocardiogram showed multiple abnormalities , with an episode of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2062 : 
        {
          1 : "JJ amod NNS dobj VB xcomp VBN nsubjpass JJ acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 amod effects dobj have xcomp *recognized* nsubjpass male acl treated nmod drug0"
            }
          4 : 
            {
              1 : "RESULTS : A male and a female patient with spasticity treated with intrathecal drug1 were recognized to have drug2 side effects from treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2063 : 
        {
          1 : "NN nmod VBG acl NN nmod NN nsubjpass VBN parataxis NN advcl VBN nsubjpass NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod leading acl arrhythmia nmod occurrence nsubjpass emphasized parataxis *release* advcl described nsubjpass increases nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Although transient increases in ectopy after drug1 therapy have been described , presumably due to catecholamine release , the occurrence of life-threatening ventricular arrhythmia leading to drug2 has not previously been emphasized . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2064 : 
        {
          1 : "NN dobj VB parataxis NN nsubj NN nmod NNS nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj reverse parataxis *care* nsubj treatment nmod patients nmod reactions compound drug0"
            }
          4 : 
            {
              1 : "The principle treatment for DPD-deficient patients with severe acute drug1 reactions is supportive care ; however , the administration of thymidine potentially may reverse severe 5-FU-induced drug2 such as encephalopathy and coma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2065 : 
        {
          1 : "NN nmod NN nmod NN dep NNS nmod VBD acl NN conj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod initiation dep days nmod demonstrated acl *evidence* conj features nmod drug0"
            }
          4 : 
            {
              1 : "The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis , and biopsy features of drug1 with granulocytic portal infiltration and bile stasis , demonstrated 20 days after the initiation of antithyroid therapy with 20 mg drug2 daily . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2066 : 
        {
          1 : "NN conj NN nmod NN dobj VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj rate nmod loss dobj *developed* nmod course nmod drug0"
            }
          4 : 
            {
              1 : "After a six-week course of low-dose drug1 , she developed a severe but reversible loss of glomerular filtration rate and drug2 despite of low cyclosporine A plasma levels . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2067 : 
        {
          1 : "CD nummod NN nmod JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nummod % nmod *safe* nsubj drug0"
            }
          4 : 
            {
              1 : "Subcutaneous drug1 is safe and well tolerated , with a drug2 % . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2068 : 
        {
          1 : "NN nmod VBN acl NN nmod NN nmod NN conj NN nmod VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented acl arthritis nmod oxaprozin nmod woman conj pain nmod *taking* dobj drug0"
            }
          4 : 
            {
              1 : "RESULTS : A 44-year-old man taking drug1 for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with drug2 and cutaneous fragility on the face and the back of the hands . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2069 : 
        {
          1 : "NN conj NN dobj VB advcl JJ nsubj NN nmod NN conj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj myopathy dobj prevent advcl *important* nsubj caution nmod usage conj recognition nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "Caution in longterm usage and early recognition of drug1 toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2070 : 
        {
          1 : "NN conj NN nmod VBD nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj agitation nmod *arrived* nmod weeks nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "After three weeks of drug1 therapy , the patient arrived at the emergency department ( ED ) with severe agitation and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2071 : 
        {
          1 : "NN dobj VBD parataxis VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed parataxis *disappeared* nmod therapy nmod drug0"
            }
          4 : 
            {
              1 : "After therapy with parenteral drug1 ( 2300 mg in 3 days ) and other measures , signs of congestive heart failure disappeared ; subsequently the patient developed drug2 , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2072 : 
        {
          1 : "NN compound NN nmod NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod institution nmod *weeks* compound drug0"
            }
          4 : 
            {
              1 : "We report a male patient with advanced AIDS who developed drug1 2 weeks after institution of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2073 : 
        {
          1 : "NN nmod JJ amod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod postchemotherapy amod *months* compound drug0"
            }
          4 : 
            {
              1 : "Herein , we describe a patient with AIDS who presented to medical attention with drug1 48 months postchemotherapy with drug2 , prednisone , vincristine , cyclophosphamide , doxorubicin , and rituximab ( R-EPOCH ) for diffuse large B-cell lymphoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2074 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod years nmod *developed* dobj mellitus conj drug0"
            }
          4 : 
            {
              1 : "A 7-year-old girl developed diabetes mellitus and drug1 after 3.5 years of almost continuous treatment with drug2 and/or prednisone for idiopathic auto-immune haemolytic anaemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2075 : 
        {
          1 : "NN dobj VBD dep NNS dep VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* dep months dep initiating dobj therapy compound drug0"
            }
          4 : 
            {
              1 : "Five months after initiating drug1 therapy , she developed drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2076 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl solutions nmod support nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "A 16-year-old white male with acute biphenotypic leukemia developed evidence of the drug1 associated with total parenteral nutritional support with solutions containing drug2 , which were given during his initial induction chemotherapy and also after autologous marrow transplantation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2077 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *diagnosed* nsubjpass course nmod patients nmod drug0"
            }
          4 : 
            {
              1 : "We describe the clinical course of 2 patients with Crohn 's disease ( CD ) in whom drug1 was diagnosed after treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2078 : 
        {
          1 : "NN appos NN nmod NN nmod JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos actinomycin-d nmod administration nmod *related* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 were temporally related to the administration of the antitumor antibiotics actinomycin-D ( drug2 ) and mithramycin ( NSC-24559 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2079 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod VBD dobj NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound cream nmod therapy nmod day nmod *developed* dobj stools conj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 25-year-old postpartum white woman developed multiple watery stools and drug1 on day 6 of therapy with drug2 vaginal cream for bacterial vaginosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2080 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NNS acl:relcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod *predisposed* nsubjpass patients acl:relcl had dobj treatment nmod drug0"
            }
          4 : 
            {
              1 : "Patients with lymphoblastic lymphoma who had treatment with drug1 and steroid are predisposed to the development of drug2 and may have this syndrome in addition to a dural puncture headache . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2081 : 
        {
          1 : "NN dobj VBD nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *provoked* nsubj peginterferon conj drug0"
            }
          4 : 
            {
              1 : "The clinical course suggested that recombinant alpha-2b peginterferon plus drug1 provoked drug2 , therefore , in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2082 : 
        {
          1 : "NN nsubj VBD conj JJ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj occurred conj *low* nsubj dose compound drug0"
            }
          4 : 
            {
              1 : "The drug1 dose was low ( 1 mg/kg ) and drug2 occurred after 56 days therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2083 : 
        {
          1 : "NN dobj VBD nsubj NNS acl VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *experienced* nsubj patients acl undergoing dobj treatment nmod drug0"
            }
          4 : 
            {
              1 : "PATIENTS : Two patients , ages 40 and 51 years , undergoing treatment with drug1 for malignant neoplasms experienced drug2 with disc-related field defects and segmental optic disc edema . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2084 : 
        {
          1 : "NN nmod IN advcl VBD dobj JJ appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod while advcl *developed* dobj transient appos drug0"
            }
          4 : 
            {
              1 : "A patient developed transient , drug1 while on drug2 ( Accutane ) therapy for acne . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2085 : 
        {
          1 : "NN nmod VBG advcl VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod leading advcl *superimposed* nsubjpass vasculitis compound drug0"
            }
          4 : 
            {
              1 : "In one patient the vasculitis resolved after termination of the ciprofloxacin therapy ; in the other patient the drug1 hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to drug2 and a below-knee amputation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2086 : 
        {
          1 : "NN nmod NN dobj VBZ acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation dobj necessitates acl:relcl *risk* nmod neutropenia conj drug0"
            }
          4 : 
            {
              1 : "It carries a well-known risk of neutropenia and drug1 , which necessitates the immediate discontinuation of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2087 : 
        {
          1 : "NN nsubj VBD dep NN nmod NN nmod NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj began dep day nmod ng/ml nmod level nmod *rose* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 , which began to be administered 12 days earlier , rose to a level of 44 ng/mL ( normal range , 10-20 ng/mL ) 1 day before drug2 began . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2088 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj ceasing advcl reversed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients , and this report describes a stable heart-lung transplant recipient who developed a drug1 that reversed after ceasing drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2089 : 
        {
          1 : "NN conj NN dobj VBP acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj tinnitus dobj include acl:relcl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a commonly used nonsteroidal anti-inflammatory drug ( NSAID ) whose side effects include tinnitus and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2090 : 
        {
          1 : "NN nsubjpass VBN advcl NN nsubj NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass *kept* advcl hyperparathyroidism nsubj hazards nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Although major hazards of treatment of hypophosphatemic osteomalacia with drug1 and calcitriol are secondary hyperparathyroidism and vitamin D intoxication , drug2 also should be kept in mind . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2091 : 
        {
          1 : "NN nmod NN appos NNP dobj VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod analogue appos kalimate dobj following acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a rare case of drug1 following Kalimate ( calcium polystryrene sulfonate ) , an analogue of drug2 without sorbitol in a 34-yr-old man . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2092 : 
        {
          1 : "NN nmod VBN acl NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod experienced acl *drug0*"
            }
          4 : 
            {
              1 : "We describe the drug1 experienced by the first two patients in our institution treated with drug2 ( 10 mg/m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2093 : 
        {
          1 : "NN appos NN nmod VBN nsubjpass NNS appos NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos congenita nmod *associated* nsubjpass drugs appos methimazole appos drug0"
            }
          4 : 
            {
              1 : "However , there remain questions concerning whether these drugs , especially methimazole ( drug1 ) , may be associated with aplasia cutis congenita ( drug2 ) and how best to avoid impairment of fetal thyroid function during their use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2094 : 
        {
          1 : "VB xcomp VBZ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp *leads* nsubj treatment compound drug0"
            }
          4 : 
            {
              1 : "High-dose drug1 treatment leads to drug2 in hypophosphatemic osteomalacia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2095 : 
        {
          1 : "NN dobj VBN acl:relcl NN acl VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj prescribed acl:relcl *man* acl found dobj drug0"
            }
          4 : 
            {
              1 : "This article describes the case of a 25-year-old man found drug1 at home who had been prescribed drug2 for schizophrenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2096 : 
        {
          1 : "NN compound NN nmod VBD dobj NNS nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound exposure nmod *developed* dobj symptoms nmod disease appos drug0"
            }
          4 : 
            {
              1 : "RESULTS : Three patients who developed symptoms of inflammatory bowel disease ( drug1 ) during drug2 exposure are described along with pathology findings . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2097 : 
        {
          1 : "NN appos NN dobj VBG dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos trimethoprim dobj receiving dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "A 27-year-old man who had a history of bronchial asthma , eosinophilic enteritis , and eosinophilic pneumonia presented with fever , skin eruptions , cervical lymphadenopathy , hepatosplenomegaly , atypical lymphocytosis , and drug1 two weeks after receiving trimethoprim ( drug2 ) - sulfamethoxazole ( SMX ) treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2098 : 
        {
          1 : "NN conj NN dep NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj presentation dep pattern nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 , the most common offender , has been associated with a dimorphic clinical pattern : a PCT-like presentation and one simulating drug2 in the pediatric population . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2099 : 
        {
          1 : "NN compound NNS nmod NNS dep NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound effects nmod *cases* dep case appos drug0"
            }
          4 : 
            {
              1 : "Since recent studies have reported no negative interactions with concurrent use , we here report three cases ( one case of a prolonged seizure , a drug1 and a focal seizure ) of severe drug2 side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2100 : 
        {
          1 : "NN compound NNS nmod NNS dobj VBP conj VBP dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound injections nmod effects dobj discuss conj *highlight* dobj instances nmod drug0"
            }
          4 : 
            {
              1 : "We highlight two instances of drug1 , and discuss the potential side effects of local drug2 injections in the orthopaedic setting as well as the evidence base for its use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2101 : 
        {
          1 : "NN nmod NN nmod NNS nmod NN nmod NN nmod NN acl VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod days nmod *man* nmod history nmod mellitus acl presented nmod collapse conj drug0"
            }
          4 : 
            {
              1 : "A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and drug1 after 9 days of treatment with drug2 , a recently developed atypical antipsychotic agent available only in Japan . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2102 : 
        {
          1 : "NN appos NNP nmod NN nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos kayexalate nmod administration nmod complication nmod *known* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is known as a rare complication following the administration of Kayexalate ( drug2 ) in sorbitol . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2103 : 
        {
          1 : "NN conj NN nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *nausea* nsubj effects acl associated nmod drug0"
            }
          4 : 
            {
              1 : "The most common side effects associated with drug1 are nausea , drug2 , hypotension , hypocalcemia and allergic reactions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2104 : 
        {
          1 : "JJ conj JJ amod NN conj CD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj teratogenic amod agent conj *one* nsubj use nmod drug0"
            }
          4 : 
            {
              1 : "Currently the use of drug1 is one of the few specific measures available , and as a potentially teratogenic and drug2 agent , any decision for its use requires evaluation of the potential for fetal damage . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2105 : 
        {
          1 : "NN nmod NN nmod NN dobj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mixture nmod administration dobj *followed* nsubj episode nmod drug0"
            }
          4 : 
            {
              1 : "A second episode of drug1 followed the intravaginal administration of a mixture of drug2 and nifuroxime . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2106 : 
        {
          1 : "NN nmod VBN xcomp JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated xcomp *likely* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is more likely to be associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2107 : 
        {
          1 : "NN compound NN nmod NN nmod VBN acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound analog nmod use nmod associated acl condition appos *drug0*"
            }
          4 : 
            {
              1 : "A patient with monocular open-angle glaucoma had drug1 , a condition associated with the use of a drug2 analog . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2108 : 
        {
          1 : "NN dobj VBG acl:relcl NN nmod JJ dep NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl:relcl a nmod adolescent dep virus nmod *occurrence* nmod drug0"
            }
          4 : 
            {
              1 : "We report the occurrence of spontaneous drug1 in an human immunodeficiency virus ( HIV ) - infected adolescent with hemophilia A who was receiving drug2 ( APV ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2109 : 
        {
          1 : "NN compound NN nmod NNS acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound myopathy nmod features acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Muscle biopsy revealed drug1 and few vacuolated fibers which were features of drug2 myopathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2110 : 
        {
          1 : "NN nmod NN nmod VBN acl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod complicated acl *inhaler* compound drug0"
            }
          4 : 
            {
              1 : "The use of drug1 inhaler complicated by the development of an drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2111 : 
        {
          1 : "NN dobj VBD nsubj NN acl VBG dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj woman acl receiving dobj alpha-0a conj drug0"
            }
          4 : 
            {
              1 : "PATIENT AND METHOD : A 34-year-old woman with chronic hepatitis C , genotype 3 , receiving pegylated interferon alpha-2a and drug1 for 6 months , developed drug2 and anemia 6 months after the end of treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2112 : 
        {
          1 : "NN conj NNS nmod NN nmod NN appos NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fractures nmod incidence nmod increase appos decrease nmod *effects* nmod drug0"
            }
          4 : 
            {
              1 : "There are major side effects of drug1 including decrease in both lumbar spine and total hip bone mineral density , increase in the incidence of all bone fractures ( especially fractures of spine , hip and wrist ) , drug2 and increase in the cholesterol level . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2113 : 
        {
          1 : "NN conj NN nmod NN nmod JJ amod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj interferon nmod therapy nmod due amod patients nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in hepatitis C patients due to combination therapy with pegylated interferon and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2114 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod therapy dep hours nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2115 : 
        {
          1 : "NN nmod VBP acl:relcl NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod present acl:relcl *patients* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on drug1 therapy who present with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2116 : 
        {
          1 : "NN conj NN conj NN dobj VBD ccomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj acidosis conj fever dobj developed ccomp *started* nsubjpass therapy nmod drug0"
            }
          4 : 
            {
              1 : "After therapy for diabetic coma with drug1 ( containing the preservative cresol ) and electrolyte solutions was started , the patient complained of increasing myalgia , developed a high fever and respiratory and metabolic acidosis and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2117 : 
        {
          1 : "NN compound NN conj VBD conj VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound cream conj *had* conj developed dobj drug0"
            }
          4 : 
            {
              1 : "A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed drug1 and glycosuria during a period of topical administration of a corticosteroid cream , drug2 cream 0.1 % , under occlusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2118 : 
        {
          1 : "NN nmod NN nmod NN nmod VBN acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod initiation nmod associated acl *ejaculation* appos drug0"
            }
          4 : 
            {
              1 : "We report two patients with anhedonic ejaculation ( drug1 ) associated with initiation of treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2119 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod recurrence nmod *resulted* nsubj weeks nmod rechallenge nmod drug0"
            }
          4 : 
            {
              1 : "Two weeks following rechallenge with drug1 resulted in recurrence of his drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2120 : 
        {
          1 : "NN nmod NN nsubjpass VBN conj VBN xcomp VB nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nsubjpass described conj *known* xcomp occur nmod association nmod carbamazepine appos drug0"
            }
          4 : 
            {
              1 : "A variety of movement disorders are known to occur in association with carbamazepine ( drug1 ) therapy in adults and children , but development of drug2 has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2121 : 
        {
          1 : "NN compound NNS nmod VBN acl NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound irrigations nmod induced acl *encephalopathy* conj drug0"
            }
          4 : 
            {
              1 : "Encephalopathy and drug1 induced by intravesical drug2 irrigations . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2122 : 
        {
          1 : "NN dobj VB xcomp VBN advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj avoid xcomp *paid* advcl prescribed nsubjpass drug0"
            }
          4 : 
            {
              1 : "When drug1 is prescribed in patients with coronary artery disease or renal dysfunction , close attention must be paid to avoid drug2 due to high plasma concentrations of the drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2123 : 
        {
          1 : "NN compound NN nsubjpass VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nsubjpass described acl *drug0*"
            }
          4 : 
            {
              1 : "A patient with acute changes suggesting drug1 after parenteral drug2 administration is described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2124 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment dobj receiving acl patient nmod occurring acl *drug0*"
            }
          4 : 
            {
              1 : "This is the first report of a drug1 occurring in a patient receiving drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2125 : 
        {
          1 : "NN nmod NN conj NN nmod VBN acl NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development conj hyperpyrexia nmod characterized acl *lithium* conj toxicity compound drug0"
            }
          4 : 
            {
              1 : "The authors describe a case of combined lithium and drug1 toxicity characterized by hyperpyrexia , severe rigidity , mutism , and development of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2126 : 
        {
          1 : "NN nmod NNS nmod NNS nmod VBN nsubj NNS nmod NNS acl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod samples nmod *documented* nsubj studies nmod patients acl receiving dobj cream compound drug0"
            }
          4 : 
            {
              1 : "DISCUSSION : No published clinical studies in patients receiving drug1 vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2127 : 
        {
          1 : "NN conj NNS nmod VBN nsubjpass NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hemorrhages nmod *characterized* nsubjpass interferon appos drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : Interferon ( drug1 ) - associated retinopathy is typically characterized by retinal hemorrhages and drug2 at the posterior fundus , but visual function is usually maintained . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2128 : 
        {
          1 : "NN conj NN nmod VBN nsubjpass NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj adenocarcinoma nmod *considered* nsubjpass events acl associated nmod drug0"
            }
          4 : 
            {
              1 : "In deciding if tamoxifen therapy is warranted , all potentially life-threatening adverse events associated with drug1 should be considered , including endometrial adenocarcinoma or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2129 : 
        {
          1 : "NN nmod VBN acl:relcl NN dobj VB nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod characterized acl:relcl syndrome dobj *induce* nsubj c appos drug0"
            }
          4 : 
            {
              1 : "In rare cases mitomycin C ( drug1 ) may induce cancer-associated hemolytic uremic syndrome , which is characterized by drug2 , thrombocytopenia and progressive renal failure . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2130 : 
        {
          1 : "NN nmod JJ nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod rare nmod *cause* nsubj drug0"
            }
          4 : 
            {
              1 : "We conclude that drug1 and actinomycin D were the cause of this rare from of drug2 and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2131 : 
        {
          1 : "NN nmod VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *suffering* nmod drug0"
            }
          4 : 
            {
              1 : "The third patient had been suffering from serious drug1 while on drug2 , and was cured after switching to olanzapine , but thereafter the patient suffered from RLS at nighttime . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2132 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBD nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod course dobj completing advcl *presented* nmod nausea conj drug0"
            }
          4 : 
            {
              1 : "We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea , drug1 , azotemia , and hyperkalemia shortly after completing a course of intravenous drug2 ( IVIG ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2133 : 
        {
          1 : "NN dobj VBG acl NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl decongestant nmod use nmod *cae* nmod drug0"
            }
          4 : 
            {
              1 : "We report a cae of drug1 following use of a decongestant containing drug2 and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2134 : 
        {
          1 : "NN appos NN root IN acl NN dobj VBG advcl VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos immunoglobulin root of acl course dobj completing advcl *presented* nmod drug0"
            }
          4 : 
            {
              1 : "We report the case of an 87-year-old white woman with myasthenia gravis who presented with drug1 , shortness of breath , azotemia , and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2135 : 
        {
          1 : "NN nmod NN nsubj VBD nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod avt nsubj occurred nmod *increase* nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "Two years later , 24 hours following an increase in the dose of drug1 from 300 to 600 mg/day , AVT with drug2 occurred ; isoproterenol abolished the arrhythmia instantly . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2136 : 
        {
          1 : "NN nmod VBD ccomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complained ccomp *started* nsubjpass therapy nmod drug0"
            }
          4 : 
            {
              1 : "After therapy for diabetic coma with drug1 ( containing the preservative cresol ) and electrolyte solutions was started , the patient complained of drug2 , developed a high fever and respiratory and metabolic acidosis and lost consciousness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2137 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod NN nmod NN conj NN nmod VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj bullae nmod presented acl arthritis nmod oxaprozin nmod woman conj pain nmod *taking* dobj drug0"
            }
          4 : 
            {
              1 : "RESULTS : A 44-year-old man taking drug1 for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and drug2 on the face and the back of the hands . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2138 : 
        {
          1 : "NN conj NN nmod VBG advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj accumulation nmod leading advcl *decreased* nsubjpass metabolism nmod drug0"
            }
          4 : 
            {
              1 : "In patients with cirrhosis , the metabolism of drug1 is decreased , leading to accumulation of the parent drug and possible drug2 similar to hepatic encephalopathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2139 : 
        {
          1 : "NN appos NN dobj VBG advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos agent dobj taking advcl *admitted* nmod drug0"
            }
          4 : 
            {
              1 : "A 70-year-old man was admitted to our hospital because of drug1 after taking an antihistaminic agent ( drug2 ) for itching . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2140 : 
        {
          1 : "NN nmod VBD ccomp VBN nsubjpass NN nmod NN dep VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complained ccomp *started* nsubjpass therapy nmod coma dep containing dobj drug0"
            }
          4 : 
            {
              1 : "After therapy for diabetic coma with insulin ( containing the preservative drug1 ) and electrolyte solutions was started , the patient complained of drug2 , developed a high fever and respiratory and metabolic acidosis and lost consciousness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2141 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod association nmod banned acl:relcl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 , also known as metamizole , is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2142 : 
        {
          1 : "NN nmod NN nmod JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod extent nmod *responsible* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : The administration of drug1 was responsible for the large extent of drug2 and should be considered in the differential diagnosis of hemorrhagic choroidal detachment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2143 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj lisinopril nmod treated acl boy nmod *associated* nmod drug0"
            }
          4 : 
            {
              1 : "This report describes a case of acute compromise of renal function associated with drug1 in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2144 : 
        {
          1 : "NN dobj VBG advcl VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj replacing advcl induced acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 induced by replacing drug2 with milnacipran . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2145 : 
        {
          1 : "NN nmod VBG acl NN dobj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod involving acl eruption dobj *caused* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 , used for dysmenorrhea , caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a drug2 on the dorsal hand . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2146 : 
        {
          1 : "NN compound NN dep NNS nmod VBD acl NN dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound initiation dep days nmod occurred acl mm0 dep *episode* nmod drug0"
            }
          4 : 
            {
              1 : "However , a new episode of drug1 , with a WBC count of 2.8 x 10 ( 3 ) / mm3 and ANC of 0.448 x 10 ( 3 ) / mm3 , occurred 11 days after drug2 initiation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2147 : 
        {
          1 : "NN appos NN nmod NN nmod VBD dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos phosphate nmod administration nmod *developed* dobj block appos drug0"
            }
          4 : 
            {
              1 : "A 57-year-old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( drug1 ) following administration of disopyramide phosphate ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2148 : 
        {
          1 : "NN compound NNS conj NN nmod VBN acl NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound regimens conj oxaliplatinum nmod associated acl feature appos *drug0*"
            }
          4 : 
            {
              1 : "It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a drug1 , a feature never previously associated with oxaliplatinum and drug2 regimens . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2149 : 
        {
          1 : "NN conj NN nmod NN nsubjpass VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj g nmod therapy nsubjpass *stopped* nmod drug0"
            }
          4 : 
            {
              1 : "Because of a drug1 , initial therapy with penicillin G and drug2 was stopped and substituted with cefazolin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2150 : 
        {
          1 : " NN compound NNP conj NN"
          2 : 1
          3 : 
            {
              1 : " *drug0* compound methylphenidate conj drug0"
            }
          4 : 
            {
              1 : "Methylphenidate and drug1 drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2151 : 
        {
          1 : "NN nmod NN dep NNS nmod NN conj NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment dep days nmod loss conj pain nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We describe a case of advanced ovarian carcinoma who developed drug1 because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly drug2 ( 80 mg/m ( 2 ) x3 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2152 : 
        {
          1 : "NN compound NN nmod VBN acl NN appos NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod induced acl *myositis* appos fever appos drug0"
            }
          4 : 
            {
              1 : "We describe a case of disseminated muscular cysticercosis followed by myositis ( fever , drug1 , weakness of the lower limbs , and inflammatory reaction around dying cysticerci ) induced by drug2 therapy , an event not described previously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2153 : 
        {
          1 : "NN dep JJ advcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep *aware* advcl facing dobj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Clinicians should be aware of this adverse reaction when facing similar complex drug1 in patients who are receiving the antibiotic treatment described here , especially drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2154 : 
        {
          1 : "NN nmod NN nmod NN dobj VBG advcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod chemotherapy nmod course dobj receiving advcl *demonstrated* dobj relapse nmod drug0"
            }
          4 : 
            {
              1 : "Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the drug1 after receiving a subsequent course of the same chemotherapy with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2155 : 
        {
          1 : "NN dobj VBG acl NN dobj VB nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developing acl risk dobj *increase* nsubj acid appos drug0"
            }
          4 : 
            {
              1 : "Cis-retinoic acid ( drug1 ) may further increase the risk of developing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2156 : 
        {
          1 : "NN nmod NN dobj VB csubj VBG dobj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod risk dobj *carry* csubj combining dobj drugs compound drug0"
            }
          4 : 
            {
              1 : "Combining drug1 and Chinese herbal drugs might carry a risk of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2157 : 
        {
          1 : "NN nmod VBN dobj NNS compound NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *exhibited* dobj reactions compound medium conj drug0"
            }
          4 : 
            {
              1 : "Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and drug1 reactions to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2158 : 
        {
          1 : "NN dobj VBP nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *include* nsubj grade nmod drug0"
            }
          4 : 
            {
              1 : "The more common grade 3 or 4 adverse effects of drug1 include drug2 , fatigue , hand-foot syndrome , elevated lipase and lymphopenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2159 : 
        {
          1 : "NN nmod NNS dobj VBD nsubj NNS acl:relcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod episodes dobj *developed* nsubj patients acl:relcl treated nmod drug0"
            }
          4 : 
            {
              1 : "Seven patients with hematologic malignancies who were treated with drug1 for either suspected or proven fungal infections developed eight episodes of major adverse drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2160 : 
        {
          1 : "NN dep DT advmod VB ccomp TO xcomp VBD acl NN conj VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep a advmod be ccomp to xcomp showed acl decrease conj *developed* nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : We report a patient who developed neutropenia on drug1 , but behind the cell count decrease showed to be a drug2 ( WBC ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2161 : 
        {
          1 : "NN nmod NN dobj VBD acl:relcl NNS nmod NN dobj VBG advcl NN nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod recall dobj developed acl:relcl patients nmod number dobj bringing advcl *manifestation* nsubj case nmod drug0"
            }
          4 : 
            {
              1 : "The authors also determined that their case of drug1 developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall , thereby bringing the number of patients who developed radiation recall to drug2 and were discussed in the current study to 13 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2162 : 
        {
          1 : "NN nmod VBN acl NN nmod NN dobj VBN dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl farmer nmod leishmaniasis dobj reported dep *cases* nmod drug0"
            }
          4 : 
            {
              1 : "CASE PRESENTATION : Three cases of drug1 in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with drug2 for asthma , a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis , and a visceral involvement after cutaneous leishmaniasis in a man receiving CS . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2163 : 
        {
          1 : "NN compound NN nmod NN nmod VBP acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound od nmod complication nmod occur acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Continuous EEG monitoring is helpful in managing drug1 that occur as a complication of drug2 OD , after the course of recovery or worsening , and in providing assistance with prognosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2164 : 
        {
          1 : "NN nmod NN conj NN dep NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod hepatitis conj granulocytopenia dep *complications* nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Multiple complications of drug1 treatment : granulocytopenia , eosinophilia , skin reaction and hepatitis with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2165 : 
        {
          1 : "NN appos CD dep VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos one dep *experienced* dobj reactions nmod drug0"
            }
          4 : 
            {
              1 : "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to drug1 : one , involving intrahepatic artery infusion , manifested drug2 , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2166 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBN dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl patients nmod *received* dobj reports nmod drug0"
            }
          4 : 
            {
              1 : "The NZ Pharmacovigilance Centre has received 7 additional reports of drug1 in patients with RA taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2167 : 
        {
          1 : "NN conj NN nmod NN conj NN appos NN nmod VBD nsubj NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hypocalcaemia nmod hyperphosphataemia conj hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod methotrexate nmod rescue compound drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with drug1 rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and drug2 , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2168 : 
        {
          1 : "NN compound NN nmod VBZ conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod occurs conj *factor* nmod drug0"
            }
          4 : 
            {
              1 : "Hypoxia is a predisposing factor for drug1 and often occurs after maternal drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2169 : 
        {
          1 : "NN appos NN conj DT nmod VBN nsubjpass NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos coagulation conj those nmod *monitored* nsubjpass patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "That review suggested that patients receiving drug1 be monitored for those and other potential complications of hemoglobinemia , particularly disseminated intravascular coagulation ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2170 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod course dobj completing advcl *presented* nmod drug0"
            }
          4 : 
            {
              1 : "We report the case of an 87-year-old white woman with myasthenia gravis who presented with drug1 , shortness of breath , azotemia , and hyperkalemia shortly after completing a course of intravenous drug2 ( IVIG ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2171 : 
        {
          1 : "NN dobj VB nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *include* nsubj effects acl associated nmod drug0"
            }
          4 : 
            {
              1 : "Behavioral side effects associated with drug1 may include drug2 , aggression , hyperactivity , irritability , property destruction , and temper tantrums . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2172 : 
        {
          1 : "NN appos NN compound NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos d-penicillamine compound treatment nmod *drug0*"
            }
          4 : 
            {
              1 : "A 66-year-old Japanese woman with severe scleroderma developed drug1 and thrombocytopenia due to D-penicillamine ( drug2 ) treatment , although the leukopenia was not markedly severe . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2173 : 
        {
          1 : "NN compound NN nmod VB xcomp VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound neurotoxicity nmod result xcomp *seems* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 in this patient seems to result from drug2 neurotoxicity rather than mechanical compression of the intraorbital optic nerve . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2174 : 
        {
          1 : "NN nmod VBZ acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod gravis acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Primary drug1 complicating treatment of myasthenia gravis with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2175 : 
        {
          1 : "NN nmod VBN advcl VBG acl NNS nmod VB dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod coadministered advcl occurring acl disorders nmod *report* dobj cases nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report 2 cases of drug1 with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with drug2 or venlafaxine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2176 : 
        {
          1 : "NN nsubj JJ advcl VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *likely* advcl shown nsubj drug0"
            }
          4 : 
            {
              1 : "Although drug1 has shown significant activity in advanced ovarian cancer , drug2 is likely to become the major dose-limiting toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2177 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl patient nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a patient receiving drug2 therapy for chronic hepatitis C virus infection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2178 : 
        {
          1 : "NN dep NN dobj VBG acl NNS nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep drug dobj receiving acl patients nmod *complication* nsubj drug0"
            }
          4 : 
            {
              1 : "In conclusion , drug1 is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( drug2 or tacrolimus ) , even under monotherapy or with a low steroid dose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2179 : 
        {
          1 : "NN nmod VBZ conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod has conj *cleared* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment , but conversely has prolonged effects in drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2180 : 
        {
          1 : "NN nmod JJ amod NN nmod NN nmod NNS nmod:tmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod daily amod mg nmod addition nmod months nmod:tmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the drug2 and phenytoin already being administered . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2181 : 
        {
          1 : "NN nmod NN xcomp VBN nsubjpass NNS acl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod risk xcomp *known* nsubjpass children acl undergoing dobj chemotherapy compound drug0"
            }
          4 : 
            {
              1 : "Young children undergoing drug1 chemotherapy are known to be at risk for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2182 : 
        {
          1 : "NN compound NN nmod NN nmod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod complication nmod *aware* nmod drug0"
            }
          4 : 
            {
              1 : "Clinicians should be aware of drug1 as an unusual but potentially serious complication of drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2183 : 
        {
          1 : "NN nmod NN nmod VBN advcl VB acl:relcl NN xcomp VBP dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod combination nmod used advcl occur acl:relcl sign xcomp *consider* dobj drug0"
            }
          4 : 
            {
              1 : "We consider drug1 to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as lithium or clozapine are used in combination with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2184 : 
        {
          1 : "NN conj NN compound NN dobj VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj cisplatin compound chemotherapy dobj receiving advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed drug1 shortly after receiving cisplatin and drug2 chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2185 : 
        {
          1 : "NN nsubj VBD conj NN dobj VBD nsubj NN conj VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj disappeared conj response dobj *produced* nsubj administration conj decreasing dobj dose nmod drug0"
            }
          4 : 
            {
              1 : "Administration of steroid and decreasing the dose of drug1 produced a good clinical response and the drug2 disappeared . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2186 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBN nsubjpass NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl infant nmod *detected* nsubjpass infection acl associated nmod drug0"
            }
          4 : 
            {
              1 : "Prenatal cytomegalovirus ( CMV ) infection associated with severe drug1 was detected in an infant whose mother had been treated with drug2 and azathioprine for systemic lupus erythematosus ( SLE ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2187 : 
        {
          1 : "NN nmod NNS nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injections nmod *admitted* nmod drug0"
            }
          4 : 
            {
              1 : "One patient was an 80-year-old woman who was admitted for drug1 after several intraarticular injections of drug2 and corticosteroids . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2188 : 
        {
          1 : "NN compound NNS nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound *reactions* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 are perhaps the most common drug2 reactions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2189 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBD acl NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod years nmod developed acl *woman* nmod disease appos drug0"
            }
          4 : 
            {
              1 : "RESULTS : In a 22-year-old Thai woman with Graves ' disease , drug1 , hearing impairment in the left ear ( with progression to the right ear ) , and vertigo developed after 3 years of therapy with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2190 : 
        {
          1 : "NN nmod VBG advcl VBD acl:relcl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod receiving advcl developed acl:relcl patient conj *drug0*"
            }
          4 : 
            {
              1 : "We report four cases of encephalopathy coincident with drug1 as well as one patient who developed seizures while receiving continuous bladder irrigations with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2191 : 
        {
          1 : "NN nmod NN nsubj JJ ccomp VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod loss nsubj severe ccomp *treated* nmod drug0"
            }
          4 : 
            {
              1 : "However , we recently saw two patients with renal tuberculosis treated with drug1 in whom visual loss from drug2 was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2192 : 
        {
          1 : "NN dobj VBN nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *reported* nsubj company acl producing dobj drug0"
            }
          4 : 
            {
              1 : "The pharmaceutical company producing drug1 has reported 8 drug2 , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2193 : 
        {
          1 : "NN conj NN dep NN nmod VBN acl NN dobj VBD nsubj NN acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj antibody dep thyrotropin nmod accompanied acl thyrotoxicosis dobj *developed* nsubj patient acl:relcl taking dobj drug0"
            }
          4 : 
            {
              1 : "Among 12 thyrotoxic patients , a patient with arrhythmogenic right ventricular dysplasia , who had been taking drug1 for 4 years , developed thyrotoxicosis with subacute onset , accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ) , or drug2 ( TBII ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2194 : 
        {
          1 : "NN compound NNS nmod VBN acl:relcl NN nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound patients nmod considered acl:relcl *entity* nsubj disorder compound drug0"
            }
          4 : 
            {
              1 : "drug1 lung disorder is an extremely rare entity which must be considered in all drug2 patients while on sulfasalazine therapy , despite the absence of pulmonary symptomatology . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2195 : 
        {
          1 : "NN dobj VBZ conj NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj implicates conj *rules* nmod causes nmod drug0"
            }
          4 : 
            {
              1 : "This report rules out other causes of drug1 and implicates drug2 in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2196 : 
        {
          1 : "NN compound NN dobj VBP acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound loss dobj include acl:relcl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a commonly used nonsteroidal anti-inflammatory drug ( NSAID ) whose side effects include drug2 and transient hearing loss . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2197 : 
        {
          1 : "NN nmod NN nmod NNS conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod hours conj *rash* conj drug0"
            }
          4 : 
            {
              1 : "She developed a generalized rash and drug1 , sore throat , and dizziness approximately 4 hours after the first dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2198 : 
        {
          1 : "NN conj NN nmod NN nmod NNS nmod VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj azathioprine nmod treatment nmod years nmod *developed* dobj mellitus conj drug0"
            }
          4 : 
            {
              1 : "A 7-year-old girl developed diabetes mellitus and drug1 after 3.5 years of almost continuous treatment with azathioprine and/or drug2 for idiopathic auto-immune haemolytic anaemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2199 : 
        {
          1 : "NN conj JJ amod NN appos NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj rare amod reaction appos *syndrome* compound drug0"
            }
          4 : 
            {
              1 : "It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called `` 3-week drug1 syndrome '' , a rare , but often drug2 , immunoallergic reaction to sulphasalazine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2200 : 
        {
          1 : "NN dobj VBD conj VB xcomp VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj rise xcomp *began* advcl discontinued nsubjpass drug0"
            }
          4 : 
            {
              1 : "After the drug1 was discontinued , the wbc count began to slowly rise and the patient developed clinical drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2201 : 
        {
          1 : "NN compound NN dobj VBG advcl VBD advmod RB"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj starting advcl *developed* advmod drug0"
            }
          4 : 
            {
              1 : "In addition , a 31-year-old man with obsessive-compulsive disorder developed drug1 soon after starting drug2 therapy , which persisted at PSG study 19 months after fluoxetine discontinuation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2202 : 
        {
          1 : "NN compound NN nmod VBN advcl VBP dobj NN nmod NN amod JJ dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod maintained advcl *report* dobj case nmod priapism amod recurrent dep drug0"
            }
          4 : 
            {
              1 : "We report a rare case of recurrent ( drug1 ) priapism in a patient with protein C deficiency while maintained on drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2203 : 
        {
          1 : "NN compound NN nmod VBN advcl VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod described advcl *developed* nmod drug0"
            }
          4 : 
            {
              1 : "The case of a bipolar patient who developed thyrotoxicosis with drug1 while on drug2 therapy is described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2204 : 
        {
          1 : "NN nmod VBN dep VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod followed dep *induced* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "Administration of excessive drug1 induced hypoglycemia within 4 to 8 hours , followed by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2205 : 
        {
          1 : "NN conj VBD acl:relcl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj showed acl:relcl *toxicity* compound drug0"
            }
          4 : 
            {
              1 : "We present two cases of drug1 pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated drug2 , thought to represent established fibrosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2206 : 
        {
          1 : "NN nmod VB acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod lead acl:relcl *hepatotoxin* nsubj drug0"
            }
          4 : 
            {
              1 : "The three reported cases demonstrate that drug1 is an idiosyncratic hepatotoxin that can lead to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2207 : 
        {
          1 : "NN nmod NN nmod VBG advcl VBZ dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod regimen nmod adding advcl *describes* dobj drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This case describes the clinically significant drug1 in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of drug2 alone . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2208 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBN nsubjpass NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl children nmod *observed* nsubjpass lesions compound drug0"
            }
          4 : 
            {
              1 : "drug1 neutrophilic skin lesions were observed in two children receiving drug2 ( G-CSF ) for treatment of idiopathic neutropenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2209 : 
        {
          1 : "NN compound NN nmod VBG acl NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound intoxication nmod suffering acl *patients* compound drug0"
            }
          4 : 
            {
              1 : "Nine drug1 patients suffering from drug2 intoxication were examined with the Mini-Mental State Exam ( MMS ) to describe the clinical course of the disorder . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2210 : 
        {
          1 : "NN compound NN nmod VBN acl NN dobj VBD conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod developed acl obstruction dobj left conj *drug0*"
            }
          4 : 
            {
              1 : "STUDY DESIGN : Case reports are presented of three premature infants ( mean gestational age 27 weeks ) cared for in the intensive care nursery in whom clinically significant drug1 and left ventricular outflow tract obstruction developed during drug2 treatment for bronchopulmonary dysplasia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2211 : 
        {
          1 : "NN nmod NN nmod NN nmod VBG acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod withdrawal nmod recovery nmod collapsing acl patient nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We describe a case of drug1 in a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) with complete recovery after withdrawal of drug2 ( CSA ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2212 : 
        {
          1 : "NN conj JJ nmod VBG acl NN nmod NN conj NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj severe nmod leading acl vincristine nmod interaction conj *absence* nmod benefit nmod prophylaxis compound drug0"
            }
          4 : 
            {
              1 : "The authors suggest that in the absence of any proven benefit of drug1 prophylaxis , and given the interaction of this drug with vincristine leading to severe and even potentially drug2 , the combination use of these drugs should be avoided . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2213 : 
        {
          1 : "NN appos NN dobj VBD nsubj NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos psoriasis dobj *provoked* nsubj hydrochloride dep drug0"
            }
          4 : 
            {
              1 : "We report a patient in whom the anti-depressant trazodone hydrochloride ( drug1 , Roussel ) , a serotonin antagonist , provoked generalized pustular psoriasis ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2214 : 
        {
          1 : "NN conj NN nmod NNS dobj VB parataxis NN nsubj NN nmod NNS nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj encephalopathy nmod symptoms dobj reverse parataxis *care* nsubj treatment nmod patients nmod reactions compound drug0"
            }
          4 : 
            {
              1 : "The principle treatment for DPD-deficient patients with severe acute drug1 reactions is supportive care ; however , the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2215 : 
        {
          1 : "NN nmod VBN nsubjpass NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *considered* nsubjpass events acl associated nmod drug0"
            }
          4 : 
            {
              1 : "In deciding if tamoxifen therapy is warranted , all potentially life-threatening adverse events associated with drug1 should be considered , including drug2 or uterine sarcoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2216 : 
        {
          1 : "NN compound NN nmod VBD nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *presented* nmod eruption conj drug0"
            }
          4 : 
            {
              1 : "We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and drug1 following drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2217 : 
        {
          1 : "NN nmod NNS nmod VBN conj VBN nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod degrees nmod associated conj *increased* nsubj addition nmod drug0"
            }
          4 : 
            {
              1 : "The addition of intrathecal drug1 to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2218 : 
        {
          1 : "NN nmod NN nmod VBN conj VBN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause nmod overlooked conj *described* nmod complication nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Hyperammonemia has been described as a complication of drug1 therapy but may often be overlooked as a cause of drug2 in the postictal patient who presents to the emergency department . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2219 : 
        {
          1 : "NN nmod NN nmod NN nmod VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod month nmod occurring acl pcp nmod *drug0*"
            }
          4 : 
            {
              1 : "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course : 3 of these patients drug1 of PCP occurring during the first month of treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2220 : 
        {
          1 : "NN nmod VBN acl NN nmod NN nmod NN nmod NN nmod NN conj NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod *nephritis* nmod context nmod rash nmod eosinophilia conj symptoms appos drug0"
            }
          4 : 
            {
              1 : "This case of linezolid-associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( drug1 ) syndrome in a patient treated with drug2 raises concerns about the presumed renal safety of this drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2221 : 
        {
          1 : "NN appos NN nmod NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos factor nmod association dep *drug0*"
            }
          4 : 
            {
              1 : "drug1 in two children with idiopathic neutropenia : association with granulocyte colony-stimulating factor ( drug2 ) therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2222 : 
        {
          1 : "NN dobj VB xcomp VBN nsubjpass NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause xcomp *demonstrated* nsubjpass pan conj drug0"
            }
          4 : 
            {
              1 : "Both PAN and drug1 have been independently demonstrated to cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2223 : 
        {
          1 : "NN nmod NN nsubjpass VBN conj VBN advmod RB advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dosage nsubjpass reduced conj *started* advmod soon advcl diagnosed nsubjpass drug0"
            }
          4 : 
            {
              1 : "The treatment for acidosis and hyperkalaemia should be started as soon as drug1 is diagnosed , and the dosage of drug2 should also be reduced if possible . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2224 : 
        {
          1 : "NN nmod NN nmod NN nmod VBZ acl:relcl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod association nmod has acl:relcl enteropathica nmod *associated* nsubjpass type nmod drug0"
            }
          4 : 
            {
              1 : "One type of drug1 is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2225 : 
        {
          1 : "NN nmod NN nmod VBN ccomp VBP acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod caused ccomp believe acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We present two cases in which both patients suffered with drug1 , which we believe was caused following administration of drug2 , to our knowledge not described in the intensive care patient previously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2226 : 
        {
          1 : "NN nmod NN dep NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod infusion dep weeks nmod *diagnosed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "The second is a 29-year-old man with CD in whom drug1 was diagnosed 3 weeks after infusion with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2227 : 
        {
          1 : "NN nsubj VBD conj JJ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj developed conj *elevated* nmod dosage nmod drug0"
            }
          4 : 
            {
              1 : "Despite the low dosage of drug1 , international normalized ratio ( INR ) was markedly elevated from 1.15 to 11.28 for only 4 days , and drug2 concurrently developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2228 : 
        {
          1 : "NN compound NN dep NN nmod VBG nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dep h nmod *occurring* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 occurring 24 h after drug2 therapy , with full recovery 48 h after cessation of chloroquine , has not been described previously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2229 : 
        {
          1 : "NN conj NN nmod NN appos NN nmod VBD nsubj NN nmod NN nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj acidosis nmod hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod methotrexate nmod rescue compound drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose methotrexate with drug1 rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and drug2 ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2230 : 
        {
          1 : "NN compound NN nmod VBG acl NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod occurring acl bladder nmod carcinoma nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report an unusual case of simultaneous drug1 and distal ureter without transitional cell carcinoma of the bladder occurring after chronic drug2 therapy for nonHodgkin 's lymphoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2231 : 
        {
          1 : "NN compound NN nmod NN dobj VBG advcl VBD nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod trial dobj beginning advcl *occurred* nsubj arrests nmod drug0"
            }
          4 : 
            {
              1 : "In the second case , five cardiac arrests due to drug1 and fibrillation occurred during several hours after beginning a trial of drug2 maintenance therapy for complex ventricular ectopy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2232 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl NN acl VBN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj myoglobin nmod release nmod followed acl *ischemia* acl developed nmod infusion compound drug0"
            }
          4 : 
            {
              1 : "Because there were no other obvious causes of renal failure in either patient , we propose that skeletal muscle ischemia developed during drug1 infusion , followed by release of myoglobin and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2233 : 
        {
          1 : "NN compound NN parataxis VBZ nsubj NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound drug parataxis *has* nsubj number nmod prescriptions compound drug0"
            }
          4 : 
            {
              1 : "RESULTS : The estimated number of drug1 prescriptions for reproductive-aged women has more than doubled in the past 10 years ; it is the most widely used drug2 drug in the United States , with approximately 2.5 per 1 , 000 reproductive-aged women exposed to Accutane in 1999 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2234 : 
        {
          1 : "NN dep NNS nmod NN dobj VB xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep autoantibodies nmod increase dobj produce xcomp *known* nsubjpass treatment nmod drug0"
            }
          4 : 
            {
              1 : "Treatment with drug1 is known to produce an increase of autoantibodies ( drug2 , anti-double-stranded DNA ) , but not clinical disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2235 : 
        {
          1 : "NN compound NNS nmod NNS dobj VBD parataxis NN nmod NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound diagnoses nmod criteria dobj increased parataxis *period* nmod combination nmod patients nmod drug0"
            }
          4 : 
            {
              1 : "RESULTS : After 4 - to 14-month period of therapy with the combination of indapamide ( 2.5 mg/day ) and fosinopril ( 10 mg/day ) in three patients and 6-month period of monotherapy with drug1 ( 2.5 mg/day ) in one patient , glucose levels of all patients increased and achieve criteria of drug2 diagnoses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2236 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *resulted* nsubj hypocalcemia nmod hormone appos drug0"
            }
          4 : 
            {
              1 : "A case is reported in which severe hypocalcemia , with a low plasma parathyroid hormone ( drug1 ) concentration , resulted from the therapeutic use of drug2 for toxemia of pregnancy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2237 : 
        {
          1 : "NN nmod JJ amod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod related amod *hepatitis* conj drug0"
            }
          4 : 
            {
              1 : "Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub ) fulminant hepatitis and drug1 related to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2238 : 
        {
          1 : "NN nmod NN nsubj VBD conj VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod delirium nsubj developed conj *treated* nmod drug0"
            }
          4 : 
            {
              1 : "A patient with coccidioidal meningitis was treated with intrathecally administered drug1 , and an acute toxic delirium with drug2 developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2239 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj methimazole nmod pregnancy nmod treated acl woman nmod *born* nsubjpass girl nmod atresia conj drug0"
            }
          4 : 
            {
              1 : "An infant girl with choanal atresia , drug1 , minor anomalies , and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2240 : 
        {
          1 : "NN dobj VB xcomp VBN csubjpass VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj have xcomp *found* csubjpass noted nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "FINDINGS : Six children with growth retardation noted after treatment with high-dose drug1 were found to have drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2241 : 
        {
          1 : "NN nmod NNS conj NN nmod NNS nmod VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod types conj nephrotoxicity nmod effects nmod associated conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is widely used against methicillin-resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of drug2 - an anaphylactoid reaction known as `` red man syndrome '' and anaphylaxis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2242 : 
        {
          1 : "NN nmod IN dep VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod while dep *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report the case of a 60-year-old woman who developed drug1 and erosions in the axilla and groin while on drug2 for breast cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2243 : 
        {
          1 : "NN dobj VBG acl NN nmod VBP dobj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl woman nmod *describe* dobj case nmod infection nmod drug0"
            }
          4 : 
            {
              1 : "We describe a case of infection with drug1 in a 67-year-old woman receiving drug2 as a component of her therapy for RA . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2244 : 
        {
          1 : "NN nsubj VBN ccomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj improved ccomp *induced* nsubj drug0"
            }
          4 : 
            {
              1 : "Prior to surgery , drug1 induced drug2 had improved ( < or = 50 % ) under treatment with amantadine ( 400 mg/day , po ) in all three patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2245 : 
        {
          1 : "NN compound NN dobj VBG nsubj NN acl VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound mg/d dobj *taking* nsubj female acl followed nmod drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : An 80-year-old white female , followed up at the Memory Clinic for drug1 , had been taking drug2 900 mg/d for > 10 years for paroxysmal atrial fibrillation without adverse effects . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2246 : 
        {
          1 : "NN dobj VBG acl:relcl NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl:relcl patient nmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 developed in a patient with rheumatoid arthritis who had been receiving drug2 for about 1 year . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2247 : 
        {
          1 : "NN nmod CD appos NNS nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod 0 appos *patients* nmod damage nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "We report 3 patients with severe hepatocellular damage due to drug1 therapy , 2 with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2248 : 
        {
          1 : "NN nmod VB nsubj NNS conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *contribute* nsubj factors conj effect nmod drug0"
            }
          4 : 
            {
              1 : "Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin-associated vasodilation in some vascular beds , and the effect of drug1 on the renin-angiotensin system may further contribute to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2249 : 
        {
          1 : "NN nmod CD"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *drug0*"
            }
          4 : 
            {
              1 : "A 23-year-old woman with systemic lupus erythematosus had a drug1 to the drug drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2250 : 
        {
          1 : "NN compound NN nmod VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod *develops* nsubj drug0"
            }
          4 : 
            {
              1 : "When drug1 develops during drug2 treatment , it is important to suspect HITTs and to assay for the associated antibodies , regardless of the actual platelet count . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2251 : 
        {
          1 : "NN appos NN dobj VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos drug dobj given advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "This case describes a 52-year-old white woman who developed a drug1 after given the antiangiogenic drug , drug2 , for metastatic ovarian cancer treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2252 : 
        {
          1 : "NN conj NN nmod NN nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj diaphragm nmod displacement nmod effusion nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and drug2 , resulting in acute myopia and angle-closure glaucoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2253 : 
        {
          1 : "NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *effects* compound drug0"
            }
          4 : 
            {
              1 : "This profile should trigger a `` red flag '' as to the possibility of drug1 behavioral side effects or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2254 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NNS acl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occurrence nmod *warned* nsubjpass patients acl prescribed nsubjpass drug0"
            }
          4 : 
            {
              1 : "Elderly patients for whom drug1 has been prescribed should be warned of the occurrence of drug2 , leading to unconsciousness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2255 : 
        {
          1 : "NN nmod VBN xcomp VBD acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated xcomp thought acl *drug0*"
            }
          4 : 
            {
              1 : "PURPOSE : Symptomatic drug1 thought to be associated with drug2 has been reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2256 : 
        {
          1 : "NN dobj VBD nsubj NNS acl:relcl VBN dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *had* nsubj patients acl:relcl begun dobj therapy compound drug0"
            }
          4 : 
            {
              1 : "RESULTS : Five of 70 patients who had begun drug1 therapy had significant drug2 that could not be linked to other identifiable etiologies . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2257 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod VB xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl children nmod occur xcomp *believed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 ( RS ) is believed to occur infrequently among children receiving long-term drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2258 : 
        {
          1 : "NN nmod VB xcomp VBN acl NNS nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occur xcomp known acl *risks* nsubj neutropenia conj drug0"
            }
          4 : 
            {
              1 : "Neutropenia and drug1 are risks known to occur with drug2 and clozapine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2259 : 
        {
          1 : "NN nmod VBN conj VBN advcl VBP nsubj NN nmod NNS nmod NN nmod:poss NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod implicated conj *discussed* advcl are nsubj number nmod concerns nmod teratogenicity nmod:poss drug0"
            }
          4 : 
            {
              1 : "In this article lithium is not discussed , although there are a number of concerns about drug1 's potential teratogenicity , and it has been implicated in drug2 , a congenital heart defect among infants born to women taking lithium ; as with other medications , however , the data have specific limitations . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2260 : 
        {
          1 : "NN nmod NN nsubjpass VBN advcl VBN acl NN appos NN nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod combination nsubjpass used advcl documented acl effect appos mmf nmod *occur* nsubj drug0"
            }
          4 : 
            {
              1 : "This report suggests that drug1 can occur due to MMF , in particular when it is given with prednisone , a side effect well documented in the transplantation literature when the triple combination of drug2 , cyclosporine and prednisone is used . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2261 : 
        {
          1 : "NN nmod NN dobj VB xcomp VBN nsubjpass NNS conj VB nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mechanism dobj investigate xcomp *undertaken* nsubjpass studies conj rechallenge nmod drug0"
            }
          4 : 
            {
              1 : "Metabolic balance studies and rechallenge with drug1 were undertaken to investigate the mechanism of the thiazide-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2262 : 
        {
          1 : "NN nmod NN nmod VBG dobj NN acl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *developing* dobj failure acl coupled nmod failure nmod drug0"
            }
          4 : 
            {
              1 : "She died within six weeks of developing congestive heart failure coupled with liver failure due to drug1 despite regular use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2263 : 
        {
          1 : "NN appos NN compound NN nmod VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos thiomalate compound injection nmod corresponding advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "The first patient developed drug1 and pain in a band-like distribution , corresponding to T10-T12 dermatomes , shortly after gold sodium thiomalate ( drug2 ) injection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2264 : 
        {
          1 : "NN dep JJ xcomp VBD acl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep severe xcomp caused acl *administration* compound drug0"
            }
          4 : 
            {
              1 : "In a female with acute lymphoblastic leukemia , inadvertent drug1 administration intrathecally caused severe , life-threatening , drug2 with high-pressure hydrocephalus . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2265 : 
        {
          1 : "NN conj NN nmod VBG advcl VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hypercalciuria nmod resulting advcl *treated* nmod ointment conj drug0"
            }
          4 : 
            {
              1 : "We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and drug1 , respectively , resulting in hypercalciuria and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2266 : 
        {
          1 : "NN compound NN nmod NN dep NN nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod completion dep h nmod developed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "A case is described of drug1 which developed 3 h after completion of drug2 infusion for suspected acute myocardial infarction . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2267 : 
        {
          1 : "NN nmod NN nmod VBD nsubj NN nmod NN conj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doubling nmod *resulted* nsubj dose nmod sertraline conj levels compound drug0"
            }
          4 : 
            {
              1 : "In case 1 , a total daily dose of 25 mg sertraline , with nondetectable sertraline and drug1 blood levels , resulted in a doubling of the lamotrigine blood level with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2268 : 
        {
          1 : "NN dep NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep inhibitors nmod observed acl *drug0*"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 though rare is occasionally observed with EGFR inhibitors drug2 or erlotinib . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2269 : 
        {
          1 : "VB xcomp VBG acl NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp switching acl *man* dep drug0"
            }
          4 : 
            {
              1 : "METHODS : A 68-year-old man developed drug1 and cystoid macula edema after switching from latanoprost to drug2 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2270 : 
        {
          1 : "NN nmod NNS nmod NN nmod VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod features nmod resolution nmod *resulted* nsubj discontinuation nmod drug0"
            }
          4 : 
            {
              1 : "Investigation confirmed the diagnosis of rhabdomyolysis , and discontinuation of drug1 resulted in resolution of clinical and biochemical features of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2271 : 
        {
          1 : "NN compound NN nmod NN nmod VBN nsubj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound dosage nmod increase nmod *related* nsubj dyspnea conj drug0"
            }
          4 : 
            {
              1 : "On the second day of hospitalization , it was noted that the patient 's dyspnea and drug1 could be related to a recent increase in his drug2 dosage . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2272 : 
        {
          1 : "NN conj NNS nmod NN nmod NN conj NN nmod NN dobj VBD dep VBN advcl VBN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj legs nmod dysesthesia nmod worsening conj arm nmod weakness dobj developed dep *resolved* advcl changed nmod acid appos drug0"
            }
          4 : 
            {
              1 : "When SASP was changed to 5-aminosalicylic acid ( drug1 ) , his skin eruptions were resolved , however , he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2273 : 
        {
          1 : "NN dobj VB advcl JJ nsubj NN nmod NN conj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj prevent advcl *important* nsubj caution nmod usage conj recognition nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "Caution in longterm usage and early recognition of drug1 toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced drug2 and localized neuropathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2274 : 
        {
          1 : "NN dobj VBZ conj VBN nsubjpass NN acl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj causes conj *reported* nsubjpass reaction acl associated nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "A chronic reaction associated with long-term treatment with drug1 has also been reported and causes irreversible drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2275 : 
        {
          1 : "NN nmod VBN acl NN nmod VBN acl:relcl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl skin nmod followed acl:relcl *event* compound drug0"
            }
          4 : 
            {
              1 : "We report an HIV-infected woman who developed mild leukopenia as the first sign of a drug1 adverse event , which was followed by skin and hepatic toxicity associated with a more severe drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2276 : 
        {
          1 : "NN nmod VBN conj VBN dobj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented conj *prescribed* dobj alendronate appos drug0"
            }
          4 : 
            {
              1 : "This case report describes a patient who was previously prescribed alendronate ( drug1 ) and presented with postoperative drug2 and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2277 : 
        {
          1 : "NN compound NN acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment acl:relcl *man* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of a 64-year-old man with secondary drug1 who has been on a chronic transdermal drug2 treatment because of sciatic pain syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2278 : 
        {
          1 : "NN nmod VBN advcl JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated advcl *severe* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 was no less severe ( degree of hyperglycaemia , need for insulin therapy ) when associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2279 : 
        {
          1 : "NN dobj VBG conj VBG ccomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj provoking conj diminishing ccomp *acted* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 acted as a CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an drug2 and clinical toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2280 : 
        {
          1 : "NN compound NN nmod VBN nsubj NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod *associated* nsubj myoglobinuria conj drug0"
            }
          4 : 
            {
              1 : "Myoglobinuria and drug1 associated with intravenous drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2281 : 
        {
          1 : "NN nmod VBN conj VBD acl:relcl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod followed conj resulted acl:relcl thrombolysis nmod *substituted* nsubjpass treatment nmod drug0"
            }
          4 : 
            {
              1 : "Initial treatment with drug1 was substituted with thrombolysis , which resulted in clinical improvement and dissolution of right heart thrombus but was followed by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2282 : 
        {
          1 : "NN nmod NNS nmod VBN conj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod periods nmod reinitiated conj *persisted* nsubj drug0"
            }
          4 : 
            {
              1 : "In addition , the drug1 persisted and was repeatedly spontaneously reinitiated for prolonged periods after drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2283 : 
        {
          1 : "NN nmod VBN dep VBP dobj NN acl:relcl VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complicated dep *describe* dobj patient acl:relcl developed dobj reaction compound drug0"
            }
          4 : 
            {
              1 : "Here we describe a patient with Crohn 's disease who developed a severe drug1 infusion reaction ( IIR ) , complicated 1 day later by drug2 to the site of infliximab infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2284 : 
        {
          1 : "NN nmod VBN conj VBN dep VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated conj admitted dep *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "A drug1 occurred in a patient with an history of depression with hypomanic rebounds , admitted for a manic episode and treated with drug2 , diazepam and lithium carbonate . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2285 : 
        {
          1 : "NN dobj VBG xcomp VB"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj following xcomp *drug0*"
            }
          4 : 
            {
              1 : "PURPOSE/OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency , which predisposes patients with cancer to potentially drug1 following drug2 ( 5-FU ) - based chemotherapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2286 : 
        {
          1 : "NN nmod NN conj NN dobj VB conj VBG dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment conj prevention dobj achieve conj impairing dep *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVE : To study therapy with drug1 impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention , diagnoses and treatment of drug2 induced by indapamide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2287 : 
        {
          1 : "NN nmod NNS dobj VBP nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod reactions dobj *include* nsubj events nmod drug0"
            }
          4 : 
            {
              1 : "Less common adverse events to drug1 include the idiosyncratic reactions of drug2 and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis-like syndrome , and minor neurological and gastrointestinal complaints . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2288 : 
        {
          1 : " NN amod JJ conj NN"
          2 : 1
          3 : 
            {
              1 : " *drug0* amod vecuronium-induced conj drug0"
            }
          4 : 
            {
              1 : "A noninvasive method in the differential diagnosis of vecuronium-induced and drug1 drug2 in a severely preeclamptic patient . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2289 : 
        {
          1 : "NN nmod VBN acl NNS nmod VB nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod *develop* nsubj complications nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Significant ocular complications such as an drug1 may develop in patients treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2290 : 
        {
          1 : "NN nmod NN nmod VB conj VBN nsubjpass NNS acl:relcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod addition nmod have conj *predisposed* nsubjpass patients acl:relcl had dobj treatment nmod drug0"
            }
          4 : 
            {
              1 : "Patients with lymphoblastic lymphoma who had treatment with drug1 and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2291 : 
        {
          1 : "NN conj NN nmod VBG acl NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj c nmod receiving acl patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "Three cases of drug1 in patients receiving long-term therapy with mitomycin C and drug2 are reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2292 : 
        {
          1 : "NN nmod NN nmod NN dobj IN advcl VB dobj NN acl VBN nmod JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod administration dobj after advcl *avoid* dobj phenomenon acl characterized nmod sudden conj drug0"
            }
          4 : 
            {
              1 : "A small initial dose of prazosin ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and drug1 after the administration of the first dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2293 : 
        {
          1 : "NN nmod NNS nsubjpass VBN advcl VB acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod drugs nsubjpass used advcl occur acl:relcl *sign* nmod drug0"
            }
          4 : 
            {
              1 : "We consider asterixis to be an easily overlooked sign of drug1 , which may occur even at low or moderate dosage levels , if certain drugs as drug2 or clozapine are used in combination with CBZ . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2294 : 
        {
          1 : "NN dobj VBD nsubj NNS acl:relcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patients acl:relcl receiving dobj drug0"
            }
          4 : 
            {
              1 : "Two patients who were receiving drug1 by infusion developed drug2 and subsequent intestinal perforation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2295 : 
        {
          1 : "NN nmod NN conj NN appos NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod hyperphosphataemia conj hyper-uricaemia appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose drug1 with folinic acid rescue , resulted in the ` phosphate shower syndrome ' ( hyper-uricaemia , hyperkalaemia and hyperphosphataemia with drug2 and tetany , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2296 : 
        {
          1 : "NN conj NN nmod VBN advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj isoniazid nmod treated advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A patient developed drug1 while being treated with isoniazid and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2297 : 
        {
          1 : "NN nmod NN nsubj NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *cause* nsubj toxicity nmod salts compound drug0"
            }
          4 : 
            {
              1 : "The pulmonary toxicity of drug1 salts is an uncommon cause of life-threatening drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2298 : 
        {
          1 : "NN dobj VB nsubj NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *mimic* nsubj symptoms nmod effects nmod drug0"
            }
          4 : 
            {
              1 : "Since early symptoms of the toxic effects of drug1 can mimic drug2 , cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2299 : 
        {
          1 : "NN dobj VBD acl:relcl NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj received acl:relcl infants nmod *recognized* nsubjpass drug0"
            }
          4 : 
            {
              1 : "After drug1 was recognized in several infants who received drug2 , we studied the association between the drug and this complication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2300 : 
        {
          1 : "NN nmod VBG acl NN nmod VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod receiving acl patient nmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "The drug1 developed in a patient receiving therapy with drug2 for rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2301 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj beginning acl weeks nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "All developed drug1 within 20 weeks of beginning im drug2 therapy , at a time when RA had improved markedly compared to pretreatment status . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2302 : 
        {
          1 : "NN nmod VBN nsubjpass NN conj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *associated* nsubjpass leukemia conj alpha appos drug0"
            }
          4 : 
            {
              1 : "Chronic myelogenous leukemia ( CML ) , hepatitis C , and interferon alpha ( drug1 ) have all been associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2303 : 
        {
          1 : "NN nmod NN nmod VBD nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injection nmod *suffered* nmod change conj drug0"
            }
          4 : 
            {
              1 : "AIM : To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and drug1 after intravitreal injection of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2304 : 
        {
          1 : "NN dobj VBG acl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj revealing acl *technique* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : During and after drug1 therapy , OCT is a useful examination technique for revealing drug2 in patients who have decreased vision . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2305 : 
        {
          1 : "NN nmod VBD conj VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod died conj *placed* nmod drug0"
            }
          4 : 
            {
              1 : "She was placed on adjuvant drug1 ( doxorubicin ) chemotherapy , but 6 months later died of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2306 : 
        {
          1 : "NN compound NN nmod JJ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod *aware* nmod risk nmod drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware of the risk of severe drug1 in CLL patients with a history of AIHA or positivation of the DAT during previous drug2 administration , or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2307 : 
        {
          1 : "NN conj NN nmod VBN advcl VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj cyclosporine nmod based advcl *develops* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 develops in most patients after transplantation when immunosuppression is based on cyclosporine and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2308 : 
        {
          1 : "NN nmod NNS appos NN nmod VBN acl NNS nmod NNS nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod tumors appos wilms nmod treated acl children nmod *symptoms* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with drug2 , a derivative of cyclophosphamide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2309 : 
        {
          1 : "NN nmod VBN acl NN nmod NNS nmod VBN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl cml nmod cases nmod reported acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "The renal biopsy showed drug1 , which has only been previously reported in two cases of CML treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2310 : 
        {
          1 : "NN nmod VB dep NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod lead dep *inhibitor* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an angiotensin-converting enzyme inhibitor ( ACE-inhibitor ) and overdose can lead to drug2 and , less frequently , transient renal impairment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2311 : 
        {
          1 : "NN nmod VBD conj VBG conj VBN advcl VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod suffered conj *suffering* conj cured advcl switching nmod drug0"
            }
          4 : 
            {
              1 : "The third patient had been suffering from serious akathisia while on risperidone , and was cured after switching to drug1 , but thereafter the patient suffered from drug2 at nighttime . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2312 : 
        {
          1 : "NN nmod VBG conj VBG dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulting conj resulting dep *treatment* nmod drug0"
            }
          4 : 
            {
              1 : "We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. drug1 ( 5.0 microg/kg ) not only resulting in resolution of bradycardia but also resulting in an drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2313 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl patients nmod *effect* nsubj drug0"
            }
          4 : 
            {
              1 : "The dermatology literature heretofore has not noted that drug1 is a side effect of patients taking drug2 to treat pemphigus . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2314 : 
        {
          1 : "NN nmod NNS dobj VBD conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod phases dobj developed conj *prescribed* nsubjpass drug0"
            }
          4 : 
            {
              1 : "We have described three patients with hepatitis C for whom drug1 and ribavirin were prescribed and who developed two successive phases of silent drug2 followed by hyperthryroidism relapse due to Graves ' disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2315 : 
        {
          1 : "NN conj NN conj NN dobj VBD ccomp VBN nsubjpass NN nmod NN dep VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj acidosis conj fever dobj developed ccomp *started* nsubjpass therapy nmod coma dep containing dobj drug0"
            }
          4 : 
            {
              1 : "After therapy for diabetic coma with insulin ( containing the preservative drug1 ) and electrolyte solutions was started , the patient complained of increasing myalgia , developed a high fever and respiratory and metabolic acidosis and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2316 : 
        {
          1 : "NN conj NN dep NNS nmod VBN acl:relcl NNS nsubj VBD ccomp VBD nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj chloride dep causes nmod associated acl:relcl cases nsubj were ccomp *showed* nsubj study nmod deaths nmod drug0"
            }
          4 : 
            {
              1 : "A retrospective epidemiological study of deaths from drug1 ( HAS ) in the U.S. showed that during 1964 -- 74 there were 168 such cases , of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride , ` Thorotrast ' , and drug2 ) and 4 ( 3.1 % ) of the remaining 131 cases with the use of androgenic-anabolic steroids . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2317 : 
        {
          1 : "NN nmod NN nmod JJ advcl VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod interference nmod *cautious* advcl causes nsubj drug0"
            }
          4 : 
            {
              1 : "Therefore , although drug1 reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics , one must be cautious of the interference of other drugs during drug2 in order to prevent TdP . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2318 : 
        {
          1 : "NN nmod VB acl:relcl NN dobj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod lead acl:relcl damage dobj *induce* nsubj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 ( MTX ) may induce liver damage , which in some psoriatics will lead to drug2 or cirrhosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2319 : 
        {
          1 : "NN nmod VBG acl NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod receiving acl patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "Three cases of drug1 in patients receiving long-term therapy with drug2 and 5-fluorouracil are reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2320 : 
        {
          1 : "NN compound NN nmod VBG acl VBG conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound dose nmod resulting acl wheezing conj *drug0*"
            }
          4 : 
            {
              1 : "METHODS : The patient required insulin desensitization for drug1 , angioedema , and occasional wheezing resulting from her drug2 dose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2321 : 
        {
          1 : "NN nmod NN nmod VBG xcomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod leading xcomp *accelerated* nsubj drug0"
            }
          4 : 
            {
              1 : "The possibility can be raised that drug1 accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2322 : 
        {
          1 : " VB nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : " *drug0* nsubj therapy compound drug0"
            }
          4 : 
            {
              1 : "We conclude that low-dose drug1 therapy in patients with thalassemia intermedia may drug2 levels sufficiently to eliminate the need for transfusions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2323 : 
        {
          1 : "NN root , punct VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct *treated* nmod drug0"
            }
          4 : 
            {
              1 : "When the patient was treated again with drug1 nine months later , the drug2 after the second course of treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2324 : 
        {
          1 : "NN appos NN nmod IN advcl VBD dobj JJ appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos isotretinoin nmod while advcl *developed* dobj transient appos drug0"
            }
          4 : 
            {
              1 : "A patient developed transient , drug1 while on isotretinoin ( drug2 ) therapy for acne . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2325 : 
        {
          1 : "NN conj NN nmod NN nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hypoalbuminemia nmod occurrence nmod *effects* nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Ophthalmologists should be aware of the ocular side effects of drug1 therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2326 : 
        {
          1 : "NN nmod NNS nmod VBG advcl VBN advcl VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injections nmod relapsing/remitting advcl treated advcl *developed* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "CASE REPORT : We present a case of a 28-yr-old male who developed a severe case of drug1 while being treated for relapsing/remitting Multiple Sclerosis ( RRMS ) with weekly injections of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2327 : 
        {
          1 : "NN dobj VBP acl:relcl NNS nmod NN dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj contain acl:relcl drugs nmod use dep *cause* nmod drug0"
            }
          4 : 
            {
              1 : "An unusual cause of drug1 : unsupervised use of drugs that contain drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2328 : 
        {
          1 : "NN appos NN nmod NN nmod NN nmod VBG dobj NN amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos methotrexate nmod infusion nmod completion nmod *impending* dobj elevation amod drug0"
            }
          4 : 
            {
              1 : "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending drug1 and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate ( drug2 ) ( 12 g/m2 ) , and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2329 : 
        {
          1 : "NN nmod VBG xcomp JJ nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presenting xcomp *unusual* nsubj reactions nmod drug0"
            }
          4 : 
            {
              1 : "Idiosyncratic pulmonary reactions to drug1 are not unusual , often presenting as drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2330 : 
        {
          1 : "NN xcomp VBN conj VBD dobj NNS amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp become conj *received* dobj drugs amod drug0"
            }
          4 : 
            {
              1 : "Our patient was a 72-year-old man with advanced Parkinson 's disease ( PD ) who received drug1 and anti-cholinergic drugs and whose head had become almost drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2331 : 
        {
          1 : "NN conj NNS nmod NN nmod VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj extremities nmod paralysis nmod *developed* advcl started nsubjpass drug0"
            }
          4 : 
            {
              1 : "Ten days after drug1 was started , he developed paralytic ileus , neurogenic bladder , mild left ptosis , and absence of deep reflexes , with severe paralysis of the lower extremities and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2332 : 
        {
          1 : "NN nmod VBG advcl VBG acl NN nmod NN nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod resulting advcl shallowing acl diaphragm nmod displacement nmod effusion nmod *associated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : drug1 may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing , resulting in drug2 and angle-closure glaucoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2333 : 
        {
          1 : "NN nmod VBN dep NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complicated dep *case* nmod overdose compound drug0"
            }
          4 : 
            {
              1 : "A case of drug1 overdose complicated by drug2 preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2334 : 
        {
          1 : " NN nsubj NNS nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : " *drug0* nsubj hazards nmod treatment nmod phosphate conj drug0"
            }
          4 : 
            {
              1 : "Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and drug1 are drug2 and vitamin D intoxication , potassium loss also should be kept in mind . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2335 : 
        {
          1 : "NN conj NN nmod NN nmod NNS nmod VBD dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj azathioprine nmod treatment nmod years nmod *developed* dobj insufficiency compound drug0"
            }
          4 : 
            {
              1 : "A 7-year-old girl developed drug1 and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or drug2 for idiopathic auto-immune haemolytic anaemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2336 : 
        {
          1 : "NN nmod NN nmod NNS nmod NN nmod NN nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod days nmod *man* nmod history nmod mellitus acl presented nmod drug0"
            }
          4 : 
            {
              1 : "A 32-year-old man with a family history of type 2 diabetes mellitus presented with drug1 and deep coma after 9 days of treatment with drug2 , a recently developed atypical antipsychotic agent available only in Japan . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2337 : 
        {
          1 : "NN nmod NN nmod VBZ nsubj NN nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presentation nmod *results* nsubj presence nmod defect acl combined nmod drug0"
            }
          4 : 
            {
              1 : "We conclude that the presence of this metabolic defect combined with topical drug1 ( a drug demonstrating a narrow therapeutic index ) results in the unusual presentation of drug2 after treatment with a topical drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2338 : 
        {
          1 : "NN dobj VBD acl:relcl NN dobj VBD acl:relcl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj produced acl:relcl nucleus dobj affected acl:relcl *complication* nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "After reviewing the literature we suggest the CPM was a complication of drug1 toxicity which affected the lateral geniculate nucleus which produced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2339 : 
        {
          1 : "NN compound NNS dobj VBN nsubj NNS nmod NNS acl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound samples dobj *documented* nsubj studies nmod patients acl receiving dobj cream compound drug0"
            }
          4 : 
            {
              1 : "DISCUSSION : No published clinical studies in patients receiving drug1 vaginal cream for bacterial vaginosis have documented drug2 samples of patients with diarrhea . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2340 : 
        {
          1 : "NN nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We report 4 patients , 2 on methylphenidate and 2 on drug1 who presented with drug2 , livedo reticularis , or Raynaud phenomenon . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2341 : 
        {
          1 : "NN compound NN nmod NNS nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound thyroiditis nmod patients nmod *develop* nsubj drug0"
            }
          4 : 
            {
              1 : "These in vitro findings and clinical course suggest that drug1 may develop in patients with drug2 destructive thyroiditis , as reported in patients with destructive thyroiditis , such as subacute and silent thyroiditis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2342 : 
        {
          1 : "NN appos NN conj NN nmod NN nmod JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos mithramycin conj actinomycin-d nmod administration nmod *related* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 were temporally related to the administration of the antitumor antibiotics actinomycin-D ( NSC-3053 ) and mithramycin ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2343 : 
        {
          1 : "NN nmod NN dobj VBG dep NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cycle dobj completing dep weeks nmod *drug0*"
            }
          4 : 
            {
              1 : "A 73-year-old woman presented with drug1 and cough 2 weeks after completing the third cycle of drug2 for chronic lymphocytic leukemia ( CLL ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2344 : 
        {
          1 : "NN conj NN dobj VBD nsubj NNS nmod NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hyperactivity dobj *demonstrated* nsubj studies nmod monitoring nmod levels compound drug0"
            }
          4 : 
            {
              1 : "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma drug1 levels demonstrated marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , tonic grouped discharges and drug2 , associated with painful dysesthesia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2345 : 
        {
          1 : "NN dobj VBP nsubj NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *develop* nsubj patients nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Pellagra should be suspected whenever tuberculous patients under treatment with drug1 develop drug2 , even in the absence of typical pellagra dermatitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2346 : 
        {
          1 : "NN dobj VBP acl:relcl NNS nmod NN nmod VBN nsubjpass NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj produce acl:relcl drugs nmod list nmod *added* nsubjpass valproate conj drug0"
            }
          4 : 
            {
              1 : "Sodium valproate and drug1 , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2347 : 
        {
          1 : "NN compound NN nmod NN dobj VB conj VB dobj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use nmod feasibility dobj determine conj *investigate* dobj mechanisms acl involved nmod drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To investigate the mechanisms involved in drug1 to cyclosporine and determine the feasibility of future drug2 use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2348 : 
        {
          1 : "NN conj NN nmod VBN nsubjpass NNS acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj reaction nmod *evaluated* nsubjpass patients acl receiving dobj drug0"
            }
          4 : 
            {
              1 : "Patients receiving drug1 who develop only fever should be evaluated for an adverse drug reaction , as well as for drug2 and fevers of neutropenia , and it may be necessary to discontinue the drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2349 : 
        {
          1 : "NN nmod NN acl:relcl NN nmod NN nmod VBN acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod regimen acl:relcl patient nmod case nmod developed acl honeycombing nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of drug2 for 18 years . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2350 : 
        {
          1 : "NN nmod VBP acl:relcl NNS amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod present acl:relcl *drugs* amod drug0"
            }
          4 : 
            {
              1 : "Physicians should be cognizant of this potential complication in patients receiving drug1 or thalidomide-like drugs who present with drug2 and pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2351 : 
        {
          1 : "NN conj JJ xcomp VBD conj VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj tremulous xcomp became conj *began* advcl stopped nsubjpass drug0"
            }
          4 : 
            {
              1 : "The day after drug1 was stopped , while he was still receiving clomipramine 150 mg/d , he began behaving oddly , started sweating profusely , shivering , and became tremulous , drug2 , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2352 : 
        {
          1 : "NN compound NN nmod VBP acl:relcl NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod have acl:relcl patients nmod *considered* nsubjpass drug0"
            }
          4 : 
            {
              1 : "Drug-induced drug1 should be considered in patients who have unexplained high temperatures during drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2353 : 
        {
          1 : "NN conj NN dep NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj glare dep *report* nmod initiation nmod drug0"
            }
          4 : 
            {
              1 : "CASE REPORT : Soon after initiation of drug1 ( 200 mg/day ) , a 76-year-old man came to us with symptoms of visual `` shining , '' glare , drug2 , and gradually decreased vision . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2354 : 
        {
          1 : "VB conj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj *elicit* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 , a hydrocarbon , may not elicit a normal protective cough reflex and may drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2355 : 
        {
          1 : "NN appos NN nmod NN nmod VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos arabinoside nmod dose nmod resulting acl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a fatal case of drug1 ( TEN ) resulting from a high dose of cytosine arabinoside ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2356 : 
        {
          1 : "NN dobj VBG acl NN dobj VB xcomp VBN acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj inducing acl propensity dobj have xcomp believed acl:relcl *drug* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an atypical antipsychotic drug that is believed to have a low propensity for inducing drug2 , including tardive dyskinesia ( TD ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2357 : 
        {
          1 : "NN compound NN dobj VBG acl:relcl NN nmod VBN acl NNS conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl:relcl man nmod developed acl autoantibodies conj *pneumonitis* conj drug0"
            }
          4 : 
            {
              1 : "Pneumonitis , drug1 , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43-year-old man , who was receiving long-term drug2 therapy for chronic ulcerative colitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2358 : 
        {
          1 : "NN compound NNS nmod NN nmod VBD csubj VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound concentrations nmod decrease nmod *resulted* csubj replacing dobj drug0"
            }
          4 : 
            {
              1 : "RESULTS : Replacing drug1 with lamotrigine resulted in a decrease in drug2 concentrations in all 3 women . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2359 : 
        {
          1 : "NN nsubj VBZ advcl VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj develops advcl *stop* dobj drug0"
            }
          4 : 
            {
              1 : "As these cases revealed , close monitoring of blood chemistry is mandatory after starting spironolactone , and patients should be advised to stop drug1 immediately if drug2 develops . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2360 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod patient nmod bout nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "We present a case of significant drug1 temporally associated with a bout of protracted diarrhea in a patient on drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2361 : 
        {
          1 : "NN compound NN nmod NN nmod VBN nsubjpass NNS conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod complication nmod *reported* nsubjpass cases conj case nmod drug0"
            }
          4 : 
            {
              1 : "No cases of renal acidosis , and only one case of drug1 , has been previously reported as a complication of drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2362 : 
        {
          1 : "NN compound NN nmod NN dep NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *block* dep type appos drug0"
            }
          4 : 
            {
              1 : "Type I second-degree AV block ( Mobitz type I , drug1 ) during drug2 therapy for preterm labor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2363 : 
        {
          1 : "NN nmod NN nmod VBD conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod re-administration nmod subsided conj *relieved* nsubjpass drug0"
            }
          4 : 
            {
              1 : "This drug1 was not relieved by taking etizolam and flunitrazepam again , but subsided rapidly by the re-administration of drug2 30 mg/day , and because of that the depressive symptom also disappeared . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2364 : 
        {
          1 : "NN dep NN root , root IN dep JJ dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep case root , root by dep related dep *drug0*"
            }
          4 : 
            {
              1 : "We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed drug1 and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered drug2 and , in the second by intrathecally administered methotrexate and cranial irradiation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2365 : 
        {
          1 : "NN nmod NN nmod VBD acl:relcl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod association nmod developed acl:relcl *rifampicin* conj drug0"
            }
          4 : 
            {
              1 : "After seven months ' continuous treatment for suspected tuberculosis with rifampicin and drug1 a nine-year-old boy developed polyarthritis , rash and hepatitis in association with drug2 and positive antinuclear factor . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2366 : 
        {
          1 : "NN compound NN conj NN dobj VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy conj c dobj complicating acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 complicating long-term mitomycin C and drug2 therapy for gastric carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2367 : 
        {
          1 : "NN nsubj VBD ccomp VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj developed ccomp *given* nsubjpass i.v. compound drug0"
            }
          4 : 
            {
              1 : "Phenytoin was discontinued after admission ; however , drug1 1 g i.v. was given for a tonic-clonic seizure two days after admission , after which drug2 and pruritus developed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2368 : 
        {
          1 : "NN nmod NN nmod VBZ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause nmod *argues* nmod favor nmod drug0"
            }
          4 : 
            {
              1 : "We believe the temporal association of the abnormal liver enzymes in this patient , in the absence of other offending agents , argues strongly in favor of drug1 as a cause of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2369 : 
        {
          1 : "NN nmod NN nsubjpass VBN advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod termination nsubjpass *recommended* advcl worsened nsubjpass drug0"
            }
          4 : 
            {
              1 : "Because the drug1 may be worsened by continuation of therapy after initial onset of symptoms , prompt termination of drug2 is recommended . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2370 : 
        {
          1 : "NN nmod NN nsubj VBZ conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nsubj makes conj *cause* nmod drug0"
            }
          4 : 
            {
              1 : "We suggest that nicotinic acid was the cause of his drug1 , that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure , and that the probable increased use of drug2 for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2371 : 
        {
          1 : "NN nmod VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *related* nsubj drug0"
            }
          4 : 
            {
              1 : "Intravenous verapamil therapy in babies may cause apnea , hypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; drug1 may be related to the drug2 ; children with `` familial seizure disorders '' may in fact have the long QT interval syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2372 : 
        {
          1 : "NN nmod NNS conj JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod diuretics conj *aware* nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "Clinicians have been aware of drug1 toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced drug2 and nephrogenic diabetes insipidus . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2373 : 
        {
          1 : "NN conj NN dobj VBD nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj enlargement dobj *developed* nsubj women acl treated nmod drug0"
            }
          4 : 
            {
              1 : "CASES : Two postmenopausal women treated with drug1 and progestational agents for breast carcinoma developed uterine enlargement and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2374 : 
        {
          1 : "NN compound NN conj NN nmod NNS nmod VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment conj alpha nmod patients nmod *develop* nsubj drug0"
            }
          4 : 
            {
              1 : "We suggest that drug1 may develop in chronic hepatitis C patients during interferon alpha and/or drug2 treatment , and diagnostic tests for this adverse effect should be performed during the follow-ups . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2375 : 
        {
          1 : "NN nmod VBN acl NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "However , a recent post-marketing survey in Japan revealed that drug1 occurred in 4 among approximately 2 000 Japanese patients treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2376 : 
        {
          1 : "NN nmod NNS dobj VB nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects dobj *cause* nsubj exposure nmod drug0"
            }
          4 : 
            {
              1 : "Exposure of the fetus to drug1 by administration of the drug to the mother may cause many side effects , including drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2377 : 
        {
          1 : "NN compound NN nmod VBG acl NN nmod NN conj NN nmod JJ nmod NN nmod NN nmod NNS nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod occurring acl fixation nmod case conj administration nmod *aware* nmod risk nmod aiha nmod patients nmod history nmod aiha conj drug0"
            }
          4 : 
            {
              1 : "Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or drug1 during previous fludarabine administration , or in case of secondary fixation of complement to the red cell membrane occurring during drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2378 : 
        {
          1 : "NN conj NN nmod NN dobj VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj cisplatin nmod treatment dobj undergoing advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a 46-yr-old woman with ovarian carcinoma who developed drug1 while undergoing treatment with cisplatin and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2379 : 
        {
          1 : "NN compound NNS nmod NNS dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound effects nmod *cases* dep case nmod drug0"
            }
          4 : 
            {
              1 : "Since recent studies have reported no negative interactions with concurrent use , we here report three cases ( one case of a drug1 , a serotonin syndrome and a focal seizure ) of severe drug2 side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2380 : 
        {
          1 : "NN compound NN nmod NNS nmod VBN nsubjpass NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod patients nmod *described* nsubjpass prolongation nmod interval conj drug0"
            }
          4 : 
            {
              1 : "Prolongation of the QT interval and drug1 have been described in patients on drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2381 : 
        {
          1 : "NN nmod NNS conj NN dep NNS dobj VBD nsubj NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod defects conj deficiency dep manifestations dobj *shared* nsubj cases nmod exposure nmod drug0"
            }
          4 : 
            {
              1 : "The reported cases of in utero exposure to drug1 shared the following manifestations with our patient : growth deficiency , developmental delay , craniosynostosis , blepharophimosis , flat nasal bridge , abnormal ears , and distal limb defects including drug2 and oligodactyly . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2382 : 
        {
          1 : "NN nmod VB acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occur acl *potential* nmod drug0"
            }
          4 : 
            {
              1 : "Surgeons and physicians should therefore be aware of the potential for drug1 to occur with drug2 after any organ transplantation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2383 : 
        {
          1 : "NN compound NN nmod NN nmod VBD dep JJ nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod cessation nmod recovered dep *present* nsubj causes nmod drug0"
            }
          4 : 
            {
              1 : "Other potential causes of drug1 were not present in our patient and his renal function gradually recovered with the cessation of drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2384 : 
        {
          1 : " NN nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : " *drug0* nsubj effects acl associated nmod drug0"
            }
          4 : 
            {
              1 : "The most common side effects associated with drug1 are drug2 , vomiting , hypotension , hypocalcemia and allergic reactions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2385 : 
        {
          1 : "NN conj NN nmod VBN acl NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj alfa nmod treated acl patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "We report two new cases of drug1 in two patients with hepatitis C virus infection treated with interferon alfa and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2386 : 
        {
          1 : "NN nmod VBD nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *complained* nsubj woman acl taking dobj drug0"
            }
          4 : 
            {
              1 : "A 74-year-old hypercholestrerolaemic woman taking drug1 ( 0.15 mg/day ) for 22 days complained of general drug2 and muscle pain . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2387 : 
        {
          1 : "NN compound NN nmod NNS ccomp VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound nephrotoxicity nmod targets ccomp *suggest* nsubj drug0"
            }
          4 : 
            {
              1 : "Based upon the observed fall of the filtration fraction , the drug1 and the increase in proteinuria , we suggest that in this case the tubules and/or interstitium are the main targets for drug2 nephrotoxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2388 : 
        {
          1 : "NN dobj VBG acl NN nmod JJ amod NN dep NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl chemotherapy nmod secondary amod disease dep days nmod *occurred* nsubj drug0"
            }
          4 : 
            {
              1 : "In four patients , drug1 occurred 2-45 days after severe hepatic veno-occlusive disease ( HVOD ) secondary to intensive chemotherapy containing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2389 : 
        {
          1 : "NN compound NNS nsubj NN parataxis VBP dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound levels nsubj mcg/ml parataxis *present* dobj patients nmod drug0"
            }
          4 : 
            {
              1 : "We present three patients with paradoxical drug1 ; their serum drug2 levels were 43.5 mcg/mL , 46.5 mcg/mL and 38.3 mcg/mL . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2390 : 
        {
          1 : "NN conj NNS dobj VBP acl:relcl NNS nmod NN nmod JJ conj VBP nmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj symptoms dobj precede acl:relcl abnormalities nmod detection nmod useful conj *correlate* nmod loss nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from drug1 toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2391 : 
        {
          1 : "NN dobj VBD conj VBD advcl VBN advcl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj started conj *began* advcl stopped advcl receiving dobj mg/d compound drug0"
            }
          4 : 
            {
              1 : "The day after clozapine was stopped , while he was still receiving drug1 150 mg/d , he began behaving oddly , started drug2 , shivering , and became tremulous , agitated , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2392 : 
        {
          1 : "NN compound NN conj NN nmod NN dobj VB conj VBN acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound use conj colitis nmod relationship dobj review conj treated acl:relcl woman nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "We describe the development of drug1 in a woman who was treated with tegaserod and review the relationship among ischemic colitis , drug2 use , and irritable bowel syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2393 : 
        {
          1 : "NN appos NN nmod VBG acl NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos pneumonia nmod presenting acl *ingestion* compound drug0"
            }
          4 : 
            {
              1 : "We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic drug1 ingestion presenting as asymptomatic exogenous lipoid pneumonia ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2394 : 
        {
          1 : "NN dobj VBD acl:relcl NNS acl:relcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj experienced acl:relcl *children* acl:relcl associated nsubjpass drug0"
            }
          4 : 
            {
              1 : "A review of the literature found 11 children and 2 adults in whom intranasal drug1 was associated with hyponatremia , all of whom experienced drug2 or altered mental status . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2395 : 
        {
          1 : "NN compound NN nmod NNS nmod VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod years nmod *appear* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 appear after 2-3 years of drug2 treatment , and affect at least 50 % of patients after five years . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2396 : 
        {
          1 : "NN dobj VB conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj facilitate conj *inhibitor* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a potent inhibitor of simvastatin metabolism , and may therefore facilitate simvastatin-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2397 : 
        {
          1 : "NN appos NNS root , punct JJ dep IN dep VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos symptoms root , punct mild dep in dep *resulted* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "Administration of intrathecal drug1 in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild , transient neurological symptoms ( drug2 ) in only one of 30 patients so treated . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2398 : 
        {
          1 : "NN nmod NNS nmod VBN advcl VB nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod reported advcl *develop* nmod patients nmod thyroiditis compound drug0"
            }
          4 : 
            {
              1 : "These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with drug1 destructive thyroiditis , as reported in patients with drug2 , such as subacute and silent thyroiditis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2399 : 
        {
          1 : "NN nmod VBN acl NN nmod VBG acl NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patient nmod occurring acl *leukemia* conj drug0"
            }
          4 : 
            {
              1 : "Acute myeloid leukemia and drug1 occurring in a chronic lymphocytic leukemia patient treated with drug2 and autologous peripheral blood stem-cell transplantation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2400 : 
        {
          1 : "NN compound NN nmod NN nmod NN dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod course nmod dose dep week nmod *drug0*"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 61-year-old woman with no apparent risk factors for liver injury developed drug1 one week after the final dose of a long-term course of pulse drug2 therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk ) for onychomycosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2401 : 
        {
          1 : "NN nsubj JJ advcl VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *possible* advcl exhibits nsubj drug0"
            }
          4 : 
            {
              1 : "However , because drug1 also exhibits type IA sodium channel blockade , drug2 is also possible . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2402 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause nmod *implicated* nsubjpass phenylpropanolamine appos drug0"
            }
          4 : 
            {
              1 : "Phenylpropanolamine ( drug1 ) recently has been publicly implicated as a cause of drug2 and other neurologic events . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2403 : 
        {
          1 : "NN dobj VBD conj VBG conj VBN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *suffering* conj treated nmod cycles nmod drug0"
            }
          4 : 
            {
              1 : "A woman 38-year-old , suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal drug1 , developed a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2404 : 
        {
          1 : "NN compound NNS dobj VBZ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound concentrations dobj *induces* nsubj coadministration compound drug0"
            }
          4 : 
            {
              1 : "The present report suggests that drug1 coadministration induces drug2 concentrations , which may result in carbamazepine toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2405 : 
        {
          1 : "NN dep DT dep IN nmod VBN acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep the dep with nmod associated acl:relcl *agent* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( MMC ) is an alkylating agent that has been recently associated with the drug2 ( HUS ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2406 : 
        {
          1 : "NN dobj VBG acl NNS nmod VBN acl NN nmod VBP dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl herbicides nmod exposed acl patient nmod *report* dobj case nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 associated with muscle and oesophageal involvement in a patient exposed to herbicides containing drug2 , diuron and aminotriazole . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2407 : 
        {
          1 : "NN dobj VB xcomp VBD conj VBN dobj NN acl VBG nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj develop xcomp went conj *manifested* dobj evidence acl impending nmod completion nmod infusion nmod drug0"
            }
          4 : 
            {
              1 : "A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose drug1 ( MTX ) ( 12 g/m2 ) , and went on to develop drug2 with life-threatening hyperkalemia 29 hours later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2408 : 
        {
          1 : "NN dobj VBD nsubj JJ nmod NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj drug0"
            }
          4 : 
            {
              1 : "A 7-year-old with congenital toxoplasmosis who took drug1 and sulfadiazine for reactivated chorioretinitis developed drug2 , severe cutaneous involvement , swelling , abdominal pain and transaminitis , persisting weeks after withholding medicines . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2409 : 
        {
          1 : "NN conj NN nmod NN nmod VBN nsubjpass NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj sulfonate nmod administration nmod *caused* nsubjpass ulcer conj drug0"
            }
          4 : 
            {
              1 : "We concluded that the colonic ulcer and the drug1 had been caused by the administration of calcium polystyrene sulfonate and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2410 : 
        {
          1 : "NN nmod NN nmod JJ conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod production nmod responsible conj *antagonist* nsubj drug0"
            }
          4 : 
            {
              1 : "The currently available clinical and neuropharmacologic data suggest that drug1 may be an antagonist of dopamine and that this property is responsible for the production of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2411 : 
        {
          1 : "NN nmod VB nsubj JJ acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *lead* nsubj prolonged acl used nmod drug0"
            }
          4 : 
            {
              1 : "Prolonged used of drug1 in patients with ET may lead to therapy-associated drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2412 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed acl:relcl leukemia nmod patients conj *drug0*"
            }
          4 : 
            {
              1 : "We report 5 patients ( 3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral drug1 and two patients with chronic myelocytic leukemia ) who developed drug2 at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2413 : 
        {
          1 : "NN nmod VBN xcomp VBD conj VBD ccomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod stopped xcomp had conj *recurred* ccomp used nsubjpass drug0"
            }
          4 : 
            {
              1 : "When the disease recurred conventional drug1 was used again , but had to be stopped because of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2414 : 
        {
          1 : "NN nmod NN nmod NN nmod NN dep NNS nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mg nmod treatment nmod cycle dep weeks nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a 31-year-old women with recurrent Hodgkin 's lymphoma and unrecognized HMSN-1 who developed drug1 3 weeks after the first cycle of treatment including 2 mg of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2415 : 
        {
          1 : "NN nmod NN nmod NN acl VBN nmod NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod initiation nmod *patient* acl treated nmod inhibitor acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed drug1 , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of drug2 , and all symptoms and signs resolved following discontinuation of fentanyl . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2416 : 
        {
          1 : "NN nmod NN nmod VBN acl:relcl NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod performed acl:relcl downgrowth nmod caused acl *drug0*"
            }
          4 : 
            {
              1 : "We report a case of secondary drug1 caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2417 : 
        {
          1 : "NN conj NNS nmod NN conj NN nsubjpass VBN ccomp VBD parataxis VBD nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj levels nmod increase conj jaundice nsubjpass observed ccomp developed parataxis *disappeared* nmod therapy nmod drug0"
            }
          4 : 
            {
              1 : "After therapy with parenteral drug1 ( 2300 mg in 3 days ) and other measures , signs of congestive heart failure disappeared ; subsequently the patient developed jaundice , marked increase in serum transaminase levels and drug2 , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2418 : 
        {
          1 : "NN nmod NN nmod VBN advcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod association nmod *reported* advcl reaction nsubj drug0"
            }
          4 : 
            {
              1 : "Although drug1 is a known adverse reaction of sustained treatment with traditional neuroleptic agents , it was only rarely reported in association with drug2 , a selective D2-receptor antagonist . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2419 : 
        {
          1 : "NN nmod VBD acl:relcl NN dobj VBD nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod progressed acl:relcl lesion dobj *developed* nmod days nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "After 5 days of treatment with drug1 , the patient developed a hemorrhagic lesion that progressed to drug2 , as well as grade 4 pancytopenia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2420 : 
        {
          1 : "NN compound NNS nmod NNS nsubj VBN dep VBP dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound drops nmod *effects* nsubj increased dep lash dobj length conj drug0"
            }
          4 : 
            {
              1 : "Increased lash length , thickness , and drug1 are well-documented side effects of drug2 analog glaucoma drops . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2421 : 
        {
          1 : "NN compound NN nmod JJ amod NN acl:relcl VBD dobj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod secondary amod *boy* acl:relcl had dobj stricture nmod narrowing nmod drug0"
            }
          4 : 
            {
              1 : "We report a 5-year-old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to drug1 , secondary to drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2422 : 
        {
          1 : "NN compound NNS nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound features nmod *changes* compound drug0"
            }
          4 : 
            {
              1 : "drug1 mood changes with drug2 features in adults . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2423 : 
        {
          1 : "NN nmod NN nmod NN nmod VBD nsubj NN acl VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod substitution nmod admission nmod *ended* nsubj reaction acl resulting nmod drug0"
            }
          4 : 
            {
              1 : "In one instance a systemic hypoglycemic reaction resulting in drug1 and confusion ended in an emegency hospital admission following the substitution of drug2 for acetazolamide . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2424 : 
        {
          1 : "NN nmod VBG acl NN nmod VBN nsubjpass NN acl:relcl VBN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod suffering acl unit nmod *admitted* nsubjpass boy acl:relcl treated nmod dose nmod meleate appos drug0"
            }
          4 : 
            {
              1 : "An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate ( drug1 ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2425 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl intent nmod *took* dobj drug0"
            }
          4 : 
            {
              1 : "A 66-year-old mand suffering from severe coronary heart disease took drug1 with suicidal intent an was treated for the ensuing drug2 with digoxin-specific antibody fragments . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2426 : 
        {
          1 : "NN compound NN nmod VBN csubjpass VBN conj NNS acl:relcl VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod treated csubjpass described conj *cases* acl:relcl evolved nmod drug0"
            }
          4 : 
            {
              1 : "In this report , two cases of ET which evolved into drug1 without prior exposure to radiation or alkylating agents , and which were treated with long-term drug2 therapy , are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2427 : 
        {
          1 : "NN conj NN nmod VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj effect nmod *has* nsubj drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : drug1 has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2428 : 
        {
          1 : "NN dobj VBG acl NN nmod NN nmod NNP nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking acl arthritis nmod woman nmod *hepatitis* nmod fibrosis conj drug0"
            }
          4 : 
            {
              1 : "Hepatitis with bridging fibrosis and drug1 in a woman with rheumatoid arthritis taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2429 : 
        {
          1 : "NN nmod NNS dobj VB parataxis NN nsubj NN nmod NNS nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod symptoms dobj reverse parataxis *care* nsubj treatment nmod patients nmod reactions compound drug0"
            }
          4 : 
            {
              1 : "The principle treatment for DPD-deficient patients with severe acute drug1 reactions is supportive care ; however , the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as drug2 and coma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2430 : 
        {
          1 : "NN compound NN nmod NNS nmod VBD nsubj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound initiation nmod days nmod *appeared* nsubj rashes compound drug0"
            }
          4 : 
            {
              1 : "drug1 and maculopapular rashes appeared at 10 days after drug2 initiation , and then the drug was discontinued . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2431 : 
        {
          1 : "NN conj NN dobj VBG acl NNS nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj sertraline dobj receiving acl patients nmod reactions nmod *risk* nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Clinicians should be aware of a risk of drug1 with serious extrapyramidal reactions in patients receiving sertraline or drug2 when metoclopramide is coadministered even in a single , conventional dose . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2432 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBG acl NNS dobj VBD conj VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dosing nmod weeks nmod worsening acl signs dobj showed conj persisted acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "RESULTS : Both cases presented here describe drug1 that persisted and showed signs of worsening during weeks of frequent topical dosing with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2433 : 
        {
          1 : "NN appos NN nmod NN nmod VBG conj VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos inhibitor nmod administration nmod vomiting conj *observed* dobj patients nmod drug0"
            }
          4 : 
            {
              1 : "We observed 3 diabetic patients with drug1 followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2434 : 
        {
          1 : "NN dobj VB xcomp JJ amod NN nmod NNS nmod VB advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj produce xcomp sufficient amod ethambutol nmod elevations nmod *lead* advcl excreted nsubjpass drug0"
            }
          4 : 
            {
              1 : "Since drug1 is actively excreted via the renal system , compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2435 : 
        {
          1 : "NN compound NN nmod NN nmod JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod result nmod *evident* nsubj alteration nmod drug0"
            }
          4 : 
            {
              1 : "In each of the three reported patients , alteration of eyelid appearance with drug1 was evident as the result of topical drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2436 : 
        {
          1 : "NN nmod VB acl:relcl NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod result acl:relcl *concentrations* compound drug0"
            }
          4 : 
            {
              1 : "The present report suggests that clarithromycin coadministration induces increased plasma drug1 concentrations , which may result in drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2437 : 
        {
          1 : "NN dobj VBZ dep NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj has dep *sulindac* appos drug0"
            }
          4 : 
            {
              1 : "Sulindac ( drug1 ) , a nonsteroidal anti-inflammatory agent , has few reported drug2 , all of which have been associated with systemic disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2438 : 
        {
          1 : "NN conj NN nmod VBN acl:relcl NNS nmod VBN nsubj NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj oxaliplatinum nmod treated acl:relcl yrs nmod *developed* nsubj diarrhoea conj drug0"
            }
          4 : 
            {
              1 : "Diarrhoea , drug1 and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age , who was treated with oxaliplatinum and drug2 for unresectable rectum carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2439 : 
        {
          1 : "NN conj NN compound NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj irradiation compound treatment nmod changes nmod *drug0*"
            }
          4 : 
            {
              1 : "In keeping with findings in the literature , the drug1 by secondary changes following irradiation and drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2440 : 
        {
          1 : "NN compound NN nmod VBP dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod *develop* dobj pain conj drug0"
            }
          4 : 
            {
              1 : "The condition should be suspected in patients who develop unexplained abdominal pain or drug1 following drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2441 : 
        {
          1 : "NN compound NN xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound overdose xcomp *considered* nsubjpass cause nmod drug0"
            }
          4 : 
            {
              1 : "In all cases , drugs in addition to quetiapine were detected , but in cases # 1 and # 2 , the cause of drug1 was considered to be a drug2 overdose and the other drugs were not considered to be contributory . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2442 : 
        {
          1 : "NN nmod VBN acl NNS nmod NN dobj VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod cancer dobj resembling acl *drug0*"
            }
          4 : 
            {
              1 : "Increased awareness is needed on the possible occurrence of drug1 resembling gastric cancer in rheumatoid arthritis patients treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2443 : 
        {
          1 : "NN conj NN nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj dilatation nmod *started* nmod drug0"
            }
          4 : 
            {
              1 : "He was started on drug1 , 0.25 mg daily , because of echocardiographically demonstrated left ventricular dilatation and drug2 ; he died of ventricular fibrillation 15 days later . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2444 : 
        {
          1 : "NN compound NN dobj VBD advcl VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound distress dobj *presented* advcl administered nsubjpass drug0"
            }
          4 : 
            {
              1 : "While drug1 was administered , the patient presented drug2 and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2445 : 
        {
          1 : "NN appos NN nmod NN nmod VBD xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos lamotrigine nmod overdose nmod *became* xcomp drug0"
            }
          4 : 
            {
              1 : "METHODS : A 55-year-old woman became drug1 after overdose with lamotrigine ( drug2 ) and valproic acid ( VPA ) tablets . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2446 : 
        {
          1 : "NN nmod NNS dobj VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod agents dobj diluting acl *drug0*"
            }
          4 : 
            {
              1 : "Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from ( a ) direct pharmacologic and physical effects of methamphetamine ; ( b ) the drug1 of diluting or `` cutting '' agents such as drug2 and quinine ; ( c ) effects related to the route of drug administration ( intravenous , inhalation , smoking ) ; and ( d ) manufacture-related effects of exposure to unintentional caustic contaminants in the final product . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2447 : 
        {
          1 : "NN compound NN dobj VBG acl NNS nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound inhaler dobj overusing acl years nmod *presented* nmod drug0"
            }
          4 : 
            {
              1 : "A patient presented with drug1 after many years of overusing an drug2 inhaler . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2448 : 
        {
          1 : "NN nmod VBN acl NNS nmod NNP conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod *arthritis* conj drug0"
            }
          4 : 
            {
              1 : "Arthritis and drug1 in multiple sclerosis patients treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2449 : 
        {
          1 : "NN nmod VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod receiving acl patient nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a patient receiving treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2450 : 
        {
          1 : "NN compound NN nmod VBN acl NNS nmod VB dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound neptazane nmod started acl days nmod *develop* dobj failure conj drug0"
            }
          4 : 
            {
              1 : "A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and drug1 four days after being started on drug2 ( Neptazane ) for an ophthalmologic problem . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2451 : 
        {
          1 : "NN compound NN nmod NN dobj VB nsubj NN nmod NNS conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound formation nmod risk dobj *clarify* nsubj study nmod groups conj combination nmod drug0"
            }
          4 : 
            {
              1 : "A study following large patient groups on theophylline and a combination of drug1 and steroids might clarify the risk of drug2 formation in patients being treated with these medications for asthma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2452 : 
        {
          1 : "NN nmod VBG advcl VBN conj JJ conj VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod switching advcl removed conj able conj *required* nmod result nmod drug0"
            }
          4 : 
            {
              1 : "One patient required nursing home placement and a feeding gastrostomy as a result of the drug1 during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from drug2 to clozapine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2453 : 
        {
          1 : "NN appos NN conj NNS dep NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos *heparin* conj heparins dep fragmin conj drug0"
            }
          4 : 
            {
              1 : "By means of the in vitro heparin-induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and drug1 ( Sanofi Labaz , Munich , FRG ) , as well as the enoxaparine Clexane ( Nattermann , Cologne , FRG ) , all induced drug2 with the patient 's serum . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2454 : 
        {
          1 : "NN conj NNS dobj VB xcomp VBD acl:relcl NNS nmod NN nmod NN nmod VBN nsubjpass NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj infections dobj potentiate xcomp appeared acl:relcl cases nmod basis nmod treatment nmod *contraindicated* nsubjpass use nmod methotrexate appos drug0"
            }
          4 : 
            {
              1 : "The use of methotrexate ( drug1 ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2455 : 
        {
          1 : "NN dobj VBP acl:relcl NNS nmod VBN ccomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj develop acl:relcl patients nmod considered ccomp *induced* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 induced lung toxicity must be considered in all patients who develop unexplained drug2 while receiving fludarabine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2456 : 
        {
          1 : "NN root , punct NN root , punct PRP nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct myelosuppression root , punct them nmod *drug0*"
            }
          4 : 
            {
              1 : "Thirty-six patients with AL received , in a three-month period , 51 cycles of combined chemotherapy which included , in all of them , drug1 ( ARA-C ) ; among them , along with myelosuppression , five experienced drug2 , infectious complications , gastrointestinal tract symptoms and severe myalgias . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2457 : 
        {
          1 : "NN dep NNS nmod NN nmod NN nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep weeks nmod *woman* nmod history nmod thyrotoxicosis acl presented nmod drug0"
            }
          4 : 
            {
              1 : "A 72-year-old woman with a history of thyrotoxicosis presented with drug1 and fever two weeks after starting drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2458 : 
        {
          1 : "NN nmod NN nsubjpass VBN conj VBN nsubjpass NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod diagnosis nsubjpass considered conj *obtained* nsubjpass history nmod use compound drug0"
            }
          4 : 
            {
              1 : "In patients with swallowing dysfunction and pneumonia , a history of drug1 use should be obtained and a diagnosis of drug2 should be considered in the differential diagnoses if mineral oil use has occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2459 : 
        {
          1 : "NN nmod VBG advcl VBN nsubj NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod leading advcl *reported* nsubj company acl producing dobj drug0"
            }
          4 : 
            {
              1 : "The pharmaceutical company producing drug1 has reported 8 cardiac arrests , leading to 6 drug2 , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2460 : 
        {
          1 : "NN nmod NNS dobj VB nsubj NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients dobj *have* nsubj patients nmod allergy compound drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Patients with drug1 allergy may not have complete resolution of their symptoms after standard desensitization , particularly those patients with concomitant drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2461 : 
        {
          1 : "NN nmod NN nmod VBN nsubjpass NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod appearance nmod *suggested* nsubjpass relation nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "The relation between drug1 treatment and staining was suggested by the appearance of drug2 during topical tacrolimus treatment and its clinical disappearance when treatment was stopped . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2462 : 
        {
          1 : "NN conj JJ nmod NN nmod NN nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pentobarbital nmod combination nmod administration nmod *developed* nsubj drug0"
            }
          4 : 
            {
              1 : "A drug1 characterized by depressed level of consciousness , marked irritability , and ataxia developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of pentobarbital and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2463 : 
        {
          1 : "NN conj NN nmod VBD nmod:tmod NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pain nmod *complained* nmod:tmod day nmod administration compound drug0"
            }
          4 : 
            {
              1 : "The day after drug1 administration , the patient complained of severe back pain and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2464 : 
        {
          1 : "NN compound NN nmod NN nmod VBD conj VBN acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod course nmod reduced conj developed acl:relcl *patients* nmod drug0"
            }
          4 : 
            {
              1 : "With the use of optical coherence tomography ( OCT ) , two patients with IFN-associated drug1 who had developed macular edema and reduced visual acuity during the clinical course of drug2 therapy were observed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2465 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod *resulting* nmod drug0"
            }
          4 : 
            {
              1 : "We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from drug1 in a patient who was being treated with drug2 for atrial fibrillation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2466 : 
        {
          1 : "NN root , punct VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 root , punct *improved* nsubj mg/day nmod drug0"
            }
          4 : 
            {
              1 : "While 40 mg/day of drug1 improved hepatic dysfunction dramatically , her drug2 seriously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2467 : 
        {
          1 : "NN compound NN nmod VBN dep VBP"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod developed dep *drug0*"
            }
          4 : 
            {
              1 : "Two of the five patients who drug1 also developed encephalopathy during drug2 treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2468 : 
        {
          1 : "NN nmod NN dobj VBD advcl VBP dobj NN nmod NN nmod NN acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod evidence dobj had advcl *report* dobj case nmod patient nmod syndrome acl treated nmod drug0"
            }
          4 : 
            {
              1 : "We report the case of a patient with the acquired immunodeficiency syndrome treated with drug1 who had a ` normal ' screening test for adrenal insufficiency , yet had clinical evidence of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2469 : 
        {
          1 : "NN compound NN nmod VBN acl NNS dobj VBD conj VBN nsubjpass NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound relapse nmod followed acl phases dobj developed conj *prescribed* nsubjpass ifn-alpha conj drug0"
            }
          4 : 
            {
              1 : "We have described three patients with hepatitis C for whom IFN-alpha and drug1 were prescribed and who developed two successive phases of silent thyroiditis followed by drug2 relapse due to Graves ' disease . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2470 : 
        {
          1 : "NN nmod VBN nsubjpass NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *associated* nsubjpass drugs appos drug0"
            }
          4 : 
            {
              1 : "However , there remain questions concerning whether these drugs , especially drug1 ( MMI ) , may be associated with drug2 ( ACC ) and how best to avoid impairment of fetal thyroid function during their use . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2471 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl angiography nmod demonstrated acl *drug0*"
            }
          4 : 
            {
              1 : "We believe this is the first report of drug1 due to coronary spasm , demonstrated by angiography associated with drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2472 : 
        {
          1 : "NN nmod VBN acl NNS nmod JJ xcomp VBP nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl women nmod common xcomp *seem* nsubj disorders acl characterized nmod drug0"
            }
          4 : 
            {
              1 : "BACKGROUND : Reproductive endocrine disorders characterized by drug1 , polycystic ovaries , and hyperandrogenism seem to be common among women treated with drug2 for epilepsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2473 : 
        {
          1 : "VB xcomp VBG advcl VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp switching advcl *developed* dobj hyperemia conj drug0"
            }
          4 : 
            {
              1 : "METHODS : A 68-year-old man developed intense conjunctival hyperemia and drug1 after switching from latanoprost to drug2 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2474 : 
        {
          1 : "NN compound NN nmod VB nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *occur* nsubj dystonia nmod drug0"
            }
          4 : 
            {
              1 : "From these data , acute generalized dystonia with drug1 may occur in WD patients after an initial drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2475 : 
        {
          1 : "NN nmod NN nmod NN conj NN nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod dysfunction conj numbness nmod combined acl *drug0*"
            }
          4 : 
            {
              1 : "Case 2 , a 29-year-old woman , developed drug1 combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of drug2 for chronic myelogenous leukemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2476 : 
        {
          1 : "NN nsubj JJ parataxis VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj common parataxis *reported* nmod association nmod drug0"
            }
          4 : 
            {
              1 : "A wide variety of adverse central nervous system effects have been reported in association with drug1 ; drug2 is the most common . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2477 : 
        {
          1 : "NN conj NN dobj VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj valproate dobj receiving acl child nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in a child receiving valproate and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2478 : 
        {
          1 : "NN nmod NN dobj VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod solution dobj injected acl *drug0*"
            }
          4 : 
            {
              1 : "A patient presented with a drug1 having injected a solution of drug2 and methylphenidate into his radial artery . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2479 : 
        {
          1 : "NN nmod NN nmod VBN conj JJ advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod discontinuation nmod resolved conj apparent advcl *delayed* nsubjpass diagnosis nmod drug0"
            }
          4 : 
            {
              1 : "The diagnosis of drug1 was delayed until it was apparent for several days but resolved with the discontinuation of drug2 and continuation of clozapine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2480 : 
        {
          1 : "NN dep NN dep NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep b0 dep clofazimine nmod treatment nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 following the treatment of lepromatous leprosy with clofazimine ( B663 ; drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2481 : 
        {
          1 : "NN nmod VBN conj VBN ccomp VBP acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod desensitized conj stopped ccomp point acl:relcl *recurrence* nmod drug0"
            }
          4 : 
            {
              1 : "The patient had recurrence of drug1 and angioedema a year and a half later , at which point the NPH was stopped and she was desensitized to regular drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2482 : 
        {
          1 : "NN nmod NN dobj VBD acl:relcl JJ nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod onset dobj developed acl:relcl as nmod *treated* nmod drug0"
            }
          4 : 
            {
              1 : "We describe 3 AS patients treated with drug1 for active AS who developed new onset of drug2 while AS related symptoms responded well to etanercept . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2483 : 
        {
          1 : "NN nmod VB"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *drug0*"
            }
          4 : 
            {
              1 : "Of the four patients who responded to drug1 with an drug2 , all reported symptomatic improvement and three have not required further transfusions . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2484 : 
        {
          1 : "NN dep NN nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep chemotherapy nmod developed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We describe a 57-year-old man with acral erythrocyanosis progressing to drug1 and gangrene that developed after combined chemotherapy ( drug2 and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2485 : 
        {
          1 : "NN nmod VB xcomp VBN acl NNS nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occur xcomp known acl *risks* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 and agranulocytosis are risks known to occur with drug2 and clozapine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2486 : 
        {
          1 : "NN nmod NNS nmod VBN nsubjpass NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod medications nmod *caused* nsubjpass rashes conj drug0"
            }
          4 : 
            {
              1 : "Cutaneous rashes and drug1 can be caused by many medications , including drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2487 : 
        {
          1 : "NN nmod NN nsubj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *cause* nsubj doses nmod drug0"
            }
          4 : 
            {
              1 : "In our patient , an objective causality scale showed that therapeutic doses of drug1 for FMF were the definite cause of drug2 , even though his renal and hepatic function were normal . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2488 : 
        {
          1 : "NN conj NN nmod VBN conj VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj hypophosphatemia nmod presented conj *prescribed* dobj drug0"
            }
          4 : 
            {
              1 : "This case report describes a patient who was previously prescribed drug1 ( Fosamax ) and presented with postoperative hypophosphatemia and drug2 after bowel preparation with Fleet Phospho-Soda . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2489 : 
        {
          1 : "NN nsubj VBN parataxis VB dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj related parataxis *cause* dobj drug0"
            }
          4 : 
            {
              1 : "Intravenous verapamil therapy in babies may cause drug1 , hypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; drug2 may be related to the death ; children with `` familial seizure disorders '' may in fact have the long QT interval syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2490 : 
        {
          1 : "NN dobj VBG advcl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking advcl *informed* nmod risk nmod drug0"
            }
          4 : 
            {
              1 : "Patients should be informed about the risk of drug1 when taking drug2 as an antiemetic drug . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2491 : 
        {
          1 : "NN appos NN nmod NNS nmod VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos agent nmod patients nmod *reported* nsubjpass effects nmod drug0"
            }
          4 : 
            {
              1 : "Comparable adverse effects , such as drug1 and temporary amnesia , have been reported in patients in the analogous agent , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2492 : 
        {
          1 : "NN dobj VBD conj VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj mimicked conj caused acl:relcl *interaction* nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : This is the first report of a possible interaction between drug1 and citalopram , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2493 : 
        {
          1 : "NN conj NN nmod VBG xcomp VBD advcl VBG dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj pain nmod worsening xcomp *developed* advcl undergoing dobj treatment nmod drug0"
            }
          4 : 
            {
              1 : "While undergoing treatment with drug1 , he developed worsening diarrhea with abdominal pain and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2494 : 
        {
          1 : "NN nmod JJ conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod specific conj *effect* nsubj drug0"
            }
          4 : 
            {
              1 : "It remains to be seen whether the drug1 associated with troglitazone is a drug-class effect or specific to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2495 : 
        {
          1 : "NN nmod VBD dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *ingested* dobj g nmod drug0"
            }
          4 : 
            {
              1 : "We present the case of a 58-year-old woman who ingested more than 35 g of drug1 in a drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2496 : 
        {
          1 : "NN dobj VBG acl NN nmod VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patient nmod responded acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We report a case of drug1 , which responded well to steroid therapy , in a patient receiving drug2 plus IFN-alpha for metastatic renal cell carcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2497 : 
        {
          1 : "NN dobj VB xcomp VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj induce xcomp *appeared* nsubj treatment nmod drug0"
            }
          4 : 
            {
              1 : "It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with drug1 appeared to induce drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2498 : 
        {
          1 : "NN dobj VBD nsubj NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj patient acl:relcl received dobj drug0"
            }
          4 : 
            {
              1 : "A patient that received drug1 for cancer-associated pain developed drug2 as a side effect . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2499 : 
        {
          1 : "NN dep NN root , root IN dep JJ dep NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep case root , root by dep related dep *leukoencephalopathy* conj drug0"
            }
          4 : 
            {
              1 : "We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and drug1 related to central nervous system prophylaxis by , in the first case intrathecally administered drug2 and , in the second by intrathecally administered methotrexate and cranial irradiation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2500 : 
        {
          1 : "NN compound NN dobj VBG acl NN nmod NN nmod NN nmod NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment dobj receiving acl disorder nmod patient nmod *development* nmod defects appos drug0"
            }
          4 : 
            {
              1 : "This case report describes the development of asymptomatic visual field defects ( drug1 ) in a psychiatric patient with bipolar disorder receiving adjunctive drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2501 : 
        {
          1 : "NN nmod NNS nmod VBN acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injections nmod treated acl:relcl epithelioma nmod *development* nmod drug0"
            }
          4 : 
            {
              1 : "We report the development of drug1 within a basal-cell epithelioma that was treated with intralesional injections of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2502 : 
        {
          1 : "NN dobj VBD nsubj NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *provoked* nsubj hydrochloride dep drug0"
            }
          4 : 
            {
              1 : "We report a patient in whom the anti-depressant trazodone hydrochloride ( drug1 , Roussel ) , a serotonin antagonist , provoked drug2 ( GPP ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2503 : 
        {
          1 : "NN conj NNS dobj VB xcomp VBD acl:relcl NNS nmod NN nmod NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj infections dobj potentiate xcomp appeared acl:relcl cases nmod basis nmod treatment nmod *contraindicated* nsubjpass use nmod drug0"
            }
          4 : 
            {
              1 : "The use of drug1 ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2504 : 
        {
          1 : "NN nmod NN nmod NN nmod JJ nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod initiation nmod complication nmod *aware* nmod development nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Healthcare professionals should be aware of the possible development of drug1 as a complication of initiation of drug2 and other phenylpiperidine opioids in patients treated with SSRIs . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2505 : 
        {
          1 : "NN compound NN nmod VBN acl:relcl NNS nmod NN nmod VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod induced acl:relcl dermatoses nmod spectrum nmod *belong* nsubj drug0"
            }
          4 : 
            {
              1 : "We believe that these drug1 belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2506 : 
        {
          1 : "NN compound NNS nmod NNS dobj VBD parataxis NN nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound diagnoses nmod criteria dobj increased parataxis *period* nmod combination nmod indapamide conj drug0"
            }
          4 : 
            {
              1 : "RESULTS : After 4 - to 14-month period of therapy with the combination of indapamide ( 2.5 mg/day ) and drug1 ( 10 mg/day ) in three patients and 6-month period of monotherapy with indapamide ( 2.5 mg/day ) in one patient , glucose levels of all patients increased and achieve criteria of drug2 diagnoses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2507 : 
        {
          1 : "NN conj NN nmod NN nmod VBN acl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj methimazole nmod pregnancy nmod treated acl woman nmod *born* nsubjpass girl nmod drug0"
            }
          4 : 
            {
              1 : "An infant girl with drug1 , athelia , minor anomalies , and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2508 : 
        {
          1 : "NN compound NN nmod NN dobj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod suspension dobj *necessitated* nsubj drug0"
            }
          4 : 
            {
              1 : "Due to discomfort , diplopia and lagophthalmos , the drug1 necessitated suspension of drug2 therapy and a surgical evacuation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2509 : 
        {
          1 : "NN nmod NN nmod VBD dobj NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *produced* dobj cases nmod neutropenia conj drug0"
            }
          4 : 
            {
              1 : "First , a review of the literature produced 41 anecdotic cases of neutropenia or drug1 during treatment with drug2 ( Zyprexa ) reported in a total of 24 publications . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2510 : 
        {
          1 : "NN nmod NN dep NNS nmod VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment dep months nmod occurred acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "This report presents a case of drug1 which occurred 4 months after treatment with intraperitoneal drug2 for stage IB ovarian papillary serous cystadenocarcinoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2511 : 
        {
          1 : "NN nmod NN nmod NN amod JJ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod initiation nmod *patient* amod consistent nmod drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with drug1 , following initiation of drug2 , and all symptoms and signs resolved following discontinuation of fentanyl . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2512 : 
        {
          1 : "NN nmod JJ xcomp VBN acl:relcl NNS nmod VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod neutropenic xcomp found acl:relcl years nmod *receiving* dobj drug0"
            }
          4 : 
            {
              1 : "The second was an 82-year-old man receiving drug1 for 2 years when , during a febrile episode , he was found neutropenic with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2513 : 
        {
          1 : "NN nsubj VBD conj VBN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj occurred conj *improved* nmod infusion compound drug0"
            }
          4 : 
            {
              1 : "Hypoxemia improved during continuous drug1 infusion , but drug2 occurred . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2514 : 
        {
          1 : "NN nmod VBN acl DT appos NNS nsubj VBP conj VBZ nsubj NNP appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl all appos reports nsubj are conj *increases* nsubj rifampin appos drug0"
            }
          4 : 
            {
              1 : "Rifampin ( drug1 ) increases hepatic microsomal enzyme activity , and there are case reports of RFP-induced hypothyroidism , all associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2515 : 
        {
          1 : "NN dobj VB xcomp VB"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj precipitate xcomp *drug0*"
            }
          4 : 
            {
              1 : "Can drug1 precipitate drug2 in patients with Cushing 's syndrome ? "
            }
          5 : 
            {
              1 : 1
            }
        }
      2516 : 
        {
          1 : "NN nmod NN nmod JJ amod NN dobj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod related amod course dobj *showed* nsubj drug0"
            }
          4 : 
            {
              1 : "In this report , two newborns with congenital heart anomalies demonstrated the drug1 , one whose skin findings showed a course related to the dose of systemic drug2 , suggesting a possible association . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2517 : 
        {
          1 : "NN nmod JJ nmod NN dep NNS nmod VBG nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod low-risk nmod surgery dep months nmod *switching* nmod drug0"
            }
          4 : 
            {
              1 : "METHODS : A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from drug1 to bimatoprost 9 months after cataract surgery in an eye at low-risk for this drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2518 : 
        {
          1 : "NN dep RB advmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep later advmod *placed* nmod drug0"
            }
          4 : 
            {
              1 : "She was placed on adjuvant drug1 ( doxorubicin ) chemotherapy , but 6 months later drug2 of Adriamycin toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2519 : 
        {
          1 : "NN appos NN nmod NN nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos temozolomide nmod treatment nmod *woman* nmod t-mds appos drug0"
            }
          4 : 
            {
              1 : "We report a 44-year-old woman with t-MDS ( drug1 ) following treatment of recurrent anaplastic astrocytoma with temozolomide ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2520 : 
        {
          1 : "NN nmod NNS nsubj JJ dep VBG conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *effects* nsubj testicular dep swelling conj drug0"
            }
          4 : 
            {
              1 : "The observations suggest that testicular swelling and drug1 are side effects of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2521 : 
        {
          1 : "NN conj NN nmod NNS nmod VBN nmod NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj spasm nmod complaints nmod *presented* nmod days dep drug0"
            }
          4 : 
            {
              1 : "Four days after intravenous drug1 , the patient presented to emergency room with complaints of carpopedal spasm and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2522 : 
        {
          1 : "NN nmod NN nmod VBZ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod causation nmod *implicates* nmod drug0"
            }
          4 : 
            {
              1 : "The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to drug1 in the causation of the drug2 in this case . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2523 : 
        {
          1 : "NN appos NN nmod NNS nmod NN nmod VBZ acl:relcl NN nmod NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos dyskinesia nmod effects nmod incidence nmod results acl:relcl efficacy nmod *member* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2/5HT2 binding ratio , which results in a low incidence of extrapyramidal side effects including tardive dyskinesia ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2524 : 
        {
          1 : "NN dobj VBD conj VBP dobj NN nmod NN acl:relcl VBD dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *present* dobj case nmod woman acl:relcl received dobj doses nmod drug0"
            }
          4 : 
            {
              1 : "Here we present the case of a woman who received high doses of drug1 ( 1 g iv daily ) for active Graves ' ophthalmopathy , and developed drug2 followed by myocardial infarction on the fifth day of treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2525 : 
        {
          1 : "NN dobj VBG acl NN dobj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj inducing acl potential dobj *has* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 also has a potential for inducing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2526 : 
        {
          1 : "NN nmod NN nmod NNS nmod VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod application nmod years nmod *referred* nmod repair nmod drug0"
            }
          4 : 
            {
              1 : "Nine eyes from 6 patients , 74 years to 90 years of age , referred by ophthalmologists for repair of drug1 after at least 2 years of twice-a-day application of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2527 : 
        {
          1 : "NN nmod NN dobj VBD acl:relcl JJ conj NNS acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effect dobj developed acl:relcl third conj *patients* acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "In the present paper the authors describe 2 female patients who developed drug1 secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2528 : 
        {
          1 : "NN compound NN nmod VBN acl NN nmod VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound overdosage nmod caused acl spasm nmod *resulted* nsubj drug0"
            }
          4 : 
            {
              1 : "It is suggested that the drug1 may have resulted from arterial spasm caused by drug2 overdosage and possibly complicated by thrombosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2529 : 
        {
          1 : "NN appos NN nmod JJ amod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos trimethoprim-sulfamethoxazole nmod secondary amod *necrolysis* compound drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 epidermal necrolysis ( SJS/TEN ) secondary to trimethoprim-sulfamethoxazole ( drug2 ) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus ( CA-MRSA ) infection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2530 : 
        {
          1 : "NN compound NN nmod NN dobj VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound outcome nmod susceptibility dobj *suggests* nsubj occurrence nmod drug0"
            }
          4 : 
            {
              1 : "The authors describe three families in whom the occurrence of drug1 in all the siblings strongly suggests hereditary susceptibility to drug2 adverse outcome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2531 : 
        {
          1 : "NN compound NN nmod VBN acl NN dep NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod induced acl *myositis* dep fever conj drug0"
            }
          4 : 
            {
              1 : "We describe a case of disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , weakness of the lower limbs , and drug1 ) induced by drug2 therapy , an event not described previously . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2532 : 
        {
          1 : "VB xcomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp *led* nsubj drug0"
            }
          4 : 
            {
              1 : "However , drug1 and bone marrow depression led to drug2 withdrawal in seven patients , and neuropathy may not be fully reversible in all patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2533 : 
        {
          1 : "NN compound NN nmod VBG acl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nmod occurring acl pregnancy nmod *patient* nmod drug0"
            }
          4 : 
            {
              1 : "An infertile patient with amenorrhea-galactorrhea syndrome drug1 during a pregnancy occurring after drug2 treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2534 : 
        {
          1 : "NN nmod NNS dobj VBN acl:relcl NNS nmod NNS nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses dobj received acl:relcl patients nmod organs nmod *found* nsubjpass evidence nmod drug0"
            }
          4 : 
            {
              1 : "Autopsy evidence of drug1 was found in visceral organs of four leukemic patients who had received large doses of drug2 ( cytosine arabinoside ; Ara-C ) shortly before their death . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2535 : 
        {
          1 : "NN compound NN nmod IN advmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound regimen nmod while advmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A patient with Wegener 's granulomatosis rapidly developed a drug1 while on a drug2 regimen that had caused resolution of systemic symptoms and pulmonary infiltrates . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2536 : 
        {
          1 : "NN compound NN nmod VBD acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound administration nmod presented acl:relcl male nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following drug2 administration . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2537 : 
        {
          1 : "NN nmod VBN acl NN conj NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl sclerosis conj *seizures* conj drug0"
            }
          4 : 
            {
              1 : "Seizures and drug1 in a patient with Tourette 's syndrome , Asperger 's syndrome , and multiple sclerosis treated with drug2 and clomipramine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2538 : 
        {
          1 : "NN nmod NN nmod NNS nmod NN dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod injection nmod eyes nmod *man* dep drug0"
            }
          4 : 
            {
              1 : "RESULTS : A 34-year-old man acquired drug1 and severe vision loss in both eyes after intravitreal injection of drug2 for diabetic macular edema . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2539 : 
        {
          1 : "NN compound NNS nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound injections nmod *caused* nmod drug0"
            }
          4 : 
            {
              1 : "Visual system side effects caused by drug1 after drug2 injections . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2540 : 
        {
          1 : "NN nmod NN dobj VBN conj VBD acl:relcl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mg dobj given conj presented acl:relcl patients nmod *drug0*"
            }
          4 : 
            {
              1 : "We observed drug1 in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2541 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj using acl patients nmod *anemia* conj drug0"
            }
          4 : 
            {
              1 : "Aplastic anemia and drug1 in patients using drug2 for glaucoma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2542 : 
        {
          1 : "NN conj NN nmod NN nmod VBD dobj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj ifn nmod therapy nmod *developed* dobj lesions compound drug0"
            }
          4 : 
            {
              1 : "We describe two dark-skinned patients who developed drug1 and tongue lesions during combination therapy with IFN and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2543 : 
        {
          1 : "NN compound NN nmod NN root IN dep RB advmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod administration root after dep shortly advmod *demonstrated* nsubjpass drug0"
            }
          4 : 
            {
              1 : "We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation , in which marked drug1 and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2544 : 
        {
          1 : "NN nmod NN conj NN dep NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod occurrence conj report dep *use* compound drug0"
            }
          4 : 
            {
              1 : "drug1 use in pregnancy : a report on 104 cases and the occurrence of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2545 : 
        {
          1 : "NN nmod NN nmod IN dep VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod chemotherapy nmod while dep *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We describe a patient with transitional cell carcinoma of the renal pelvis who developed drug1 and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with drug2 , a methotrexate analog . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2546 : 
        {
          1 : "NN appos NN nmod NN nmod VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos drug nmod cessation nmod *took* nsubj recovery nmod drug0"
            }
          4 : 
            {
              1 : "Recovery of the drug1 took 15 days following cessation of the offending drug , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2547 : 
        {
          1 : "NN nmod NNP nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *fluorouracil* nmod drug0"
            }
          4 : 
            {
              1 : "Fluorouracil for drug1 to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2548 : 
        {
          1 : "NN conj NN nmod VBD ccomp VBD nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fever nmod consisted ccomp *developed* nsubj reaction compound drug0"
            }
          4 : 
            {
              1 : "A child in whom a drug1 hypersensitivity drug reaction developed which consisted of fever , drug2 , alopecia , icterus , protein-losing enteropathy , myositis , and nephritis , is described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2549 : 
        {
          1 : "NN appos NN nmod NN nmod VBD dobj NNS acl VBN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos inhibitor nmod administration nmod *observed* dobj patients acl followed nmod nausea conj drug0"
            }
          4 : 
            {
              1 : "We observed 3 diabetic patients with intolerable dizziness followed by nausea and drug1 immediately after an initial administration of the alpha-glucosidase inhibitor , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2550 : 
        {
          1 : "NN appos NN nmod VBN acl:relcl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos syndrome nmod associated acl:relcl *agent* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 ( MMC ) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2551 : 
        {
          1 : "NN nmod NN nmod VBN advcl JJ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod production nmod *concerned* advcl effective nsubj administration compound drug0"
            }
          4 : 
            {
              1 : "Although drug1 administration may have been effective in killing the parasite in both patients , we are concerned about the production of marked drug2 as a result of treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2552 : 
        {
          1 : "NN compound NNS dobj VBG acl NNS nmod NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound overdoses dobj receiving acl children nmod arrhythmias nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "Hydrocortisone may decrease the incidence of drug1 associated with cardiac arrhythmias in children receiving drug2 overdoses . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2553 : 
        {
          1 : "NN nmod VBN advcl VB dobj NN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated advcl *report* dobj patient dobj drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a patient developing drug1 while being treated with drug2 for pneumonia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2554 : 
        {
          1 : "NN nmod VBN conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated conj *agent* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with drug2 , typically aplastic anemia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2555 : 
        {
          1 : "NN dobj VBG acl NN nmod VB xcomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl solution nmod total xcomp *attributed* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 in a marrow transplant patient attributed to total parenteral nutrition with a solution containing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2556 : 
        {
          1 : "NN compound NN nmod VBD acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod occurred acl:relcl *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of drug1 which occurred during drug2 therapy for chronic hepatitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2557 : 
        {
          1 : "NN dobj VBG acl NNS nmod JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl products nmod related amod *drug0*"
            }
          4 : 
            {
              1 : "The Center for Disease Control has received numerous reports of an drug1 related to products containing drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2558 : 
        {
          1 : "NN nmod NN nmod VBN advcl VBN nsubjpass NN conj NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effect nmod *considered* advcl excluded nsubjpass occurrence conj psychosis nmod sign nmod involvement nmod drug0"
            }
          4 : 
            {
              1 : "Although both the spontaneous occurrence of SLE and the psychosis as a sign of CNS involvement of drug1 can not be excluded , SLE could be considered as an adverse effect of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2559 : 
        {
          1 : "NN dobj VBD advcl VBN nmod NN acl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *experienced* advcl treated nmod factor-alpha acl blocking dobj drug0"
            }
          4 : 
            {
              1 : "We report a patient with type 2 diabetes mellitus who , while treated with the antitumor necrosis factor-alpha blocking agent drug1 for severe plaque psoriasis , experienced drug2 requiring the lowering and eventual elimination of his previous insulin regimen . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2560 : 
        {
          1 : "NN nmod VBN acl NNS nmod NNS nmod NNS nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod metastases nmod patients nmod *considered* nsubjpass possibility nmod drug0"
            }
          4 : 
            {
              1 : "The possibility of drug1 caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST , including patients treated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2561 : 
        {
          1 : "NN nmod VBN xcomp VBN xcomp VBD acl NN nmod VB dobj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated xcomp known xcomp maintained acl patient nmod *report* dobj case nmod necrolysis compound drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report a case of drug1 toxic epidermal necrolysis ( TEN ) in a patient maintained on several other medications more commonly known to be associated with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2562 : 
        {
          1 : "NN dobj VBD conj NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed conj *mg* conj mg nmod drug0"
            }
          4 : 
            {
              1 : "Three patients received respectively 190 mg , 175 mg , and 196 mg of drug1 and developed drug2 without evidence of peripheral blood eosinophilia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2563 : 
        {
          1 : "NN conj NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj gain nmod *discontinued* nsubjpass drug0"
            }
          4 : 
            {
              1 : "The patient was enrolled in a weight-loss clinic , and his diabetes medications were adjusted.Subsequently , drug1 was discontinued because of weight gain and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2564 : 
        {
          1 : "NN nmod NN nmod VBZ nmod NNS acl:relcl VBP dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod emergence nmod *progresses* nmod abstainers acl:relcl take dobj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : In some abstainers who take drug1 for several years , thin septum-like liver fibrosis progresses along with the emergence of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2565 : 
        {
          1 : "NN compound NN nmod NN xcomp VBN nsubjpass NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound development nmod cause xcomp *considered* nsubjpass intoxication compound drug0"
            }
          4 : 
            {
              1 : "drug1 intoxication , along with other factors , was considered to be the cause of drug2 development . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2566 : 
        {
          1 : "NN nmod NN dobj VBG acl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod 0mg dobj receiving acl male nmod *drug0*"
            }
          4 : 
            {
              1 : "drug1 in an Indian male receiving 100mg of drug2 daily , hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2567 : 
        {
          1 : "NN nsubj VB conj VBN advcl VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj occur conj *retarded* advcl used nsubjpass doses nmod drug0"
            }
          4 : 
            {
              1 : "INTERPRETATION : When high doses of drug1 are used , growth may be retarded and drug2 may occur . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2568 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN appos NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod *based* nmod onset appos presence nmod eosinophilia conj drug0"
            }
          4 : 
            {
              1 : "The diagnosis was based on the rapid onset of renal failure , presence of eosinophilia , drug1 , and characteristic renal biopsy finding , following the administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2569 : 
        {
          1 : "NN nmod NNS nsubj JJ ccomp VBZ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nsubj significant ccomp *indicates* nsubj occurrence nmod drug0"
            }
          4 : 
            {
              1 : "Occurrence of withdrawal drug1 indicates that the neuroleptic effects of drug2 may be clinically significant . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2570 : 
        {
          1 : "NN nmod RP advmod NN nmod NN nmod VB dobj NNS acl:relcl VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod off advmod switch nmod part nmod *describe* dobj patients acl:relcl evolved nmod drug0"
            }
          4 : 
            {
              1 : "The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into drug1 after the introduction of oxcarbazepine ( OXC ) , as part of a switch off from drug2 ( CBZ ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2571 : 
        {
          1 : "NN nmod NN dobj VBD ccomp VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod recurrence dobj caused ccomp *led* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : drug1 led to nodular scleritis and rechallenge caused recurrence of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2572 : 
        {
          1 : "NN dobj VBD acl:relcl NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj suffered acl:relcl patient nmod *effects* nmod drug0"
            }
          4 : 
            {
              1 : "We describe the side effects of drug1 in a colon cancer patient who suffered drug2 , desquamating dermatitis , prolonged myelosuppression , and neurologic toxicity that required admission to the intensive care unit . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2573 : 
        {
          1 : "NN appos NN nmod VBN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos sulfate nmod known acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "The occurrence of neuromuscular blockade and the resulting drug1 during magnesium sulfate ( drug2 ) administration is well known . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2574 : 
        {
          1 : "NN nmod VBN nsubjpass NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *anticipated* nsubjpass coadministration nmod agents nmod drug0"
            }
          4 : 
            {
              1 : "Coadministration of antidepressant agents such as drug1 , or any other drug that inhibits the CYP3A4 isoenzyme subfamily , should be anticipated to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2575 : 
        {
          1 : "VB acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 acl *drug0*"
            }
          4 : 
            {
              1 : "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature , and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential drug1 to drug2 a component of the Aquaphor emollient they were using to treat their atopic dermatitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2576 : 
        {
          1 : "NN conj NN nmod VBN acl NN dep VBN conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj syndrome nmod known acl reaction dep associated conj *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is widely used against methicillin-resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as `` red man syndrome '' and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2577 : 
        {
          1 : "NN nmod VBN advcl VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod coadministered advcl occurring acl *drug0*"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report 2 cases of serotonin syndrome with serious drug1 occurring when metoclopramide was coadministered with drug2 or venlafaxine . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2578 : 
        {
          1 : "NN compound NN nmod NNS ccomp VBP nsubj NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound nephrotoxicity nmod targets ccomp *suggest* nsubj rise nmod clearance conj drug0"
            }
          4 : 
            {
              1 : "Based upon the observed fall of the filtration fraction , the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the drug1 , we suggest that in this case the tubules and/or interstitium are the main targets for drug2 nephrotoxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2579 : 
        {
          1 : "NN dobj VBG acl NN nmod JJ xcomp VBZ conj NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj containing acl chemotherapy nmod related xcomp appears conj *event* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing drug2 and to be associated with HVOD . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2580 : 
        {
          1 : "NN nmod NN dobj VBG advcl VBG acl NNS nmod JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use dobj stopping advcl resolving acl symptoms nmod *supportive* nsubj treatment nmod drug0"
            }
          4 : 
            {
              1 : "Treatment of drug1 in children is generally supportive , with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2581 : 
        {
          1 : "NN amod NN dobj VBG xcomp VBN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 amod release dobj causing xcomp *acted* nsubj drug0"
            }
          4 : 
            {
              1 : "This severe illness was likely caused by minocycline , and we speculate that drug1 may have acted as a superantigen , causing drug2 and massive cytokine release . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2582 : 
        {
          1 : "NN appos NN dobj VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos s dobj taking advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a case of a previously healthy , postmenopausal woman who developed drug1 while taking Bellamine S ( drug2 ; ergotamine ; phenobarbital ) for hot flashes . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2583 : 
        {
          1 : "NN appos NN dobj VBG acl NNS nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos pneumonia dobj organising acl obliterans nmod features nmod *use* nmod drug0"
            }
          4 : 
            {
              1 : "The case histories are presented of two patients who developed lung disease associated with the use of drug1 with histological features of bronchiolitis obliterans organising pneumonia ( drug2 ) , a rare but recognised form of drug induced injury . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2584 : 
        {
          1 : "NN compound NN nmod NNS nsubj NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod *effects* nsubj gallstones conj drug0"
            }
          4 : 
            {
              1 : "Gallstones and drug1 are common side effects of drug2 therapy but rarely become symptomatic or require treatment . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2585 : 
        {
          1 : "NN nsubj JJ advcl NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *uncommon* advcl complication nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Although neurotoxicity is a frequent complication of drug1 therapy , drug2 is extremely uncommon , especially in adults . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2586 : 
        {
          1 : "NN dobj VB acl:relcl NNS nmod NN nmod NN xcomp VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause acl:relcl agents nmod list nmod part xcomp *appears* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 appears to also be a part of a long list of agents that can cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2587 : 
        {
          1 : "NN nmod VB advcl VBD nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod result advcl *injured* nsubj toxicity compound drug0"
            }
          4 : 
            {
              1 : "We hypothesize that drug1 toxicity injured the muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2588 : 
        {
          1 : "NN compound NN nsubjpass VBN advcl VBD dobj NNS conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound treatment nsubjpass begun advcl *experienced* dobj hallucinations conj drug0"
            }
          4 : 
            {
              1 : "Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and drug1 after drug2 treatment was begun or its dosage increased . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2589 : 
        {
          1 : "NN appos NN nmod VBD nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos syndrome nmod *resulted* nsubj overkill nmod treatment nmod drug0"
            }
          4 : 
            {
              1 : "Three patients , in whom tumour overkill by cytotoxic treatment , including high dose drug1 with folinic acid rescue , resulted in the ` phosphate shower syndrome ' ( drug2 , hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany , with metabolic acidosis and acute renal impairment ) are described . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2590 : 
        {
          1 : "NN nmod NNS dobj VBD nmod NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod symptoms dobj *presented* nmod administration nmod increase nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "After administration of Oxybutynin concomitantly with an increase in the dose of drug1 , she presented the clinical symptoms and laboratory finding of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2591 : 
        {
          1 : "NN nmod VB nsubj NN advmod RB nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *produce* nsubj cyclosporin advmod together nmod drug0"
            }
          4 : 
            {
              1 : "We postulate that cyclosporin , possibly together with drug1 , can produce transient brain stem or neuromuscular dysfunction with drug2 in occasional patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2592 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod VBG acl:relcl NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj bh-ac nmod composed acl chemotherapy nmod undergoing acl:relcl girl nmod *case* nmod drug0"
            }
          4 : 
            {
              1 : "We report a case of reversible drug1 in a 16-year-old girl with acute myelogenous leukemia ( AML ) , who is undergoing during consolidation chemotherapy composed of BH-AC ( N4-behenoyl-1-beta-D-arabinofuranosyl cytosine ) and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2593 : 
        {
          1 : "NN nmod VBN conj VBN ccomp VBP acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod desensitized conj stopped ccomp point acl:relcl *recurrence* nmod urticaria conj drug0"
            }
          4 : 
            {
              1 : "The patient had recurrence of urticaria and drug1 a year and a half later , at which point the NPH was stopped and she was desensitized to regular drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2594 : 
        {
          1 : "NN compound JJ conj NN nmod NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound repeatable conj pegvisomant nmod treatment nmod patient nmod *drug0*"
            }
          4 : 
            {
              1 : "Drug-induced drug1 in an acromegalic patient during combined treatment with pegvisomant and drug2 long-acting repeatable attributed to the use of pegvisomant . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2595 : 
        {
          1 : "NN compound NN nmod JJ acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound infusion nmod severe acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "With the first cyclosporine dose , the patient complained of drug1 that was most severe during the drug2 infusion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2596 : 
        {
          1 : "NN nmod NN dobj VBG advcl VB advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod risk dobj increasing advcl exacerbate advcl *avoided* nsubjpass use nmod drug0"
            }
          4 : 
            {
              1 : "However , the use of drug1 should be avoided with any patient who is purging , since it may exacerbate the loss of intracellular potassium , thereby increasing the risk of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2597 : 
        {
          1 : "NN conj NN dobj VBD conj VBN nsubjpass NN nmod NN dep VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj fever dobj developed conj *started* nsubjpass therapy nmod coma dep containing dobj drug0"
            }
          4 : 
            {
              1 : "After therapy for diabetic coma with insulin ( containing the preservative drug1 ) and electrolyte solutions was started , the patient complained of increasing myalgia , developed a high fever and drug2 and lost consciousness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2598 : 
        {
          1 : "NN nsubjpass VBN advcl VBN conj VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubjpass withdrawn advcl improved conj *had* dobj function conj drug0"
            }
          4 : 
            {
              1 : "Both had impaired lung function and drug1 , and their condition improved when drug2 was withdrawn and corticosteroid treatment commenced . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2599 : 
        {
          1 : "NN conj NN dobj VBD dep VBN advcl VBN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj weakness dobj developed dep *resolved* advcl changed nmod acid appos drug0"
            }
          4 : 
            {
              1 : "When SASP was changed to 5-aminosalicylic acid ( drug1 ) , his skin eruptions were resolved , however , he developed weakness and drug2 in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2600 : 
        {
          1 : "NN compound NN dobj VBZ nmod NN nmod JJ conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj *complicates* nmod contrast nmod chronic conj drug0"
            }
          4 : 
            {
              1 : "In contrast to chronic or drug1 , Graves ' disease rarely complicates drug2 therapy for chronic viral C hepatitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2601 : 
        {
          1 : "NN nmod NN nmod NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod use nmod *specifics* nmod cases nmod drug0"
            }
          4 : 
            {
              1 : "We report the specifics of 12 cases of drug1 after the intraoperative use of topical drug2 , submucosal epinephrine , or both . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2602 : 
        {
          1 : "NN nmod NN dobj VBG acl NN nmod VBD acl:relcl NN nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod infusion dobj containing acl protocol nmod received acl:relcl girl nmod *reported* nsubjpass episode nmod drug0"
            }
          4 : 
            {
              1 : "An episode of drug1 is reported in a 13-year-old girl who , after standard radiotherapy for a posterior fossa medulloblastoma , received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 drug2 and 12 mg intrathecal methotrexate . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2603 : 
        {
          1 : "NN nmod NN nmod VBZ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod *contributes* nsubj exposure compound drug0"
            }
          4 : 
            {
              1 : "It also highlights a current major etiologic question , that is , whether and to what degree drug1 exposure contributes to the development of drug2 , and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2604 : 
        {
          1 : "NN nmod VBN nsubjpass NN appos JJ acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *referred* nsubjpass patient appos diabetic acl treated nmod drug0"
            }
          4 : 
            {
              1 : "An obese patient , not diabetic , treated with drug1 for some weeks , was referred to us with drug2 , diagnosed with Meckel 's diverticulum . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2605 : 
        {
          1 : "NN dep NN nmod NN acl:relcl VBD nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep *case* nmod woman acl:relcl developed nmod propylthiouracil appos drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report the case of a young woman with Graves ' disease in whom ototoxicity developed because of propylthiouracil ( drug1 ) - induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2606 : 
        {
          1 : "NN conj NN nmod NN nmod RB conj NN nmod NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj alfa nmod combination nmod recently conj alfa nmod *observations* nmod appearance nmod drug0"
            }
          4 : 
            {
              1 : "There have been more than 20 observations of the appearance or aggravation of this drug1 with interferon alfa and more recently with the combination of interferon alfa plus drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2607 : 
        {
          1 : "NN nmod NN dobj VBD conj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod intensity dobj increased conj *remained* nsubj drug0"
            }
          4 : 
            {
              1 : "In two patients , drug1 remained effective in the morning , but increased the intensity of the drug2 in the afternoon . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2608 : 
        {
          1 : "NN compound NN nmod NN dep NNS nmod VBG acl NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound spray nmod use dep weeks nmod swelling acl *woman* acl:relcl developed dobj drug0"
            }
          4 : 
            {
              1 : "We report a 43-year-old woman who developed drug1 , swelling of the lips and oral cavity and dysphagia , 2 weeks after the use of drug2 spray ( Budefat ) for treatment of bronchial asthma . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2609 : 
        {
          1 : "NN nmod NN nmod VB dobj NNS nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod infusion nmod *report* dobj cases nmod epilepticus appos drug0"
            }
          4 : 
            {
              1 : "OBJECTIVE : To report 2 cases of nonconvulsive status epilepticus ( drug1 ) following infusion of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2610 : 
        {
          1 : "NN dobj VBG acl NNS nsubj VBP advcl VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patients nsubj have advcl *considered* nsubjpass possibility nmod drug0"
            }
          4 : 
            {
              1 : "The possibility of phenytoin drug1 should be considered when patients receiving drug2 have unusual symptoms , particularly fever , rash , and lymphadenopathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2611 : 
        {
          1 : "NN nmod NN nmod VBD dobj NN conj NNP appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod *developed* dobj tachycardia conj pointes appos drug0"
            }
          4 : 
            {
              1 : "We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes ( drug1 ) after oral administration of drug2 , a novel quinolone antibiotic agent that differs from the third-generation quinolones , for pneumonia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2612 : 
        {
          1 : "NN nmod VBD acl:relcl NNS nmod VBG dobj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod presented acl:relcl months nmod *taking* dobj sachets compound drug0"
            }
          4 : 
            {
              1 : "After taking drug1 sachets twice daily for two months she presented with drug2 , confusion and drowsiness . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2613 : 
        {
          1 : "NN dobj VBN advcl VB"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taken advcl *drug0*"
            }
          4 : 
            {
              1 : "This progressed to drug1 with stridor after he had taken some drug2 for relief of the neck pain . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2614 : 
        {
          1 : "NN nmod NN nmod VB nsubj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod development nmod *lead* nsubj administration nmod combination nmod drug0"
            }
          4 : 
            {
              1 : "Administration of lamotrigine , especially in combination with drug1 , may lead to the development of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2615 : 
        {
          1 : "NN compound NN dobj VBG acl:relcl NN nmod VBN acl NNS conj NN conj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy dobj receiving acl:relcl man nmod developed acl autoantibodies conj *pneumonitis* conj evidence nmod drug0"
            }
          4 : 
            {
              1 : "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of drug1 , and positive autoantibodies developed in a 43-year-old man , who was receiving long-term drug2 therapy for chronic ulcerative colitis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2616 : 
        {
          1 : "NN nmod VBD nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *presented* nmod drug0"
            }
          4 : 
            {
              1 : "We describe a patient who presented with drug1 after 15 mg drug2 daily for 10 days for osteoarthritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2617 : 
        {
          1 : "NN nmod NN nmod:tmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod day nmod:tmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "A sixty-year-old woman with advanced breast cancer , previously treated with cisplatin , developed an drug1 with anuria , the day after 5 g/m2 bolus drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2618 : 
        {
          1 : "NN nmod VB conj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod accelerate conj *induces* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 induces durable complete remission in Castleman 's disease but may accelerate its transformation to drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2619 : 
        {
          1 : "NN appos NN conj NN nmod NNS dobj VBD nsubj NN acl:relcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos paucity conj cholestasis nmod findings dobj *had* nsubj patient acl:relcl received dobj drug0"
            }
          4 : 
            {
              1 : "One patient who received drug1 had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( drug2 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2620 : 
        {
          1 : "NN compound NN nmod VBN xcomp VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod associated xcomp *appears* nsubj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : Marked drug1 appears to be associated with drug2 therapy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2621 : 
        {
          1 : "NN nmod NN nmod VBD xcomp VB nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treatment nmod *began* xcomp suffer nmod drug0"
            }
          4 : 
            {
              1 : "A 10-year-old asthmatic boy began to suffer from drug1 and moderately severe bronchospasm after 8 weeks ' treatment with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2622 : 
        {
          1 : "NN conj VBN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj prescribed acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "We present a case of a diabetic patient taking drug1 who was prescribed ciprofloxacin and developed drug2 , which persisted for over 24 hours . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2623 : 
        {
          1 : "NN dobj VBG advcl VBD xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj taking advcl *became* xcomp drug0"
            }
          4 : 
            {
              1 : "We describe a patient who became drug1 while taking drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2624 : 
        {
          1 : "NN conj NN dobj VBG acl NN nmod JJ xcomp VBD acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj olanzapine dobj receiving acl patient nmod fatal xcomp proved acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Second , we report a case of drug1 , which proved to be fatal in a schizophrenia patient receiving olanzapine and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2625 : 
        {
          1 : "NN conj NNS nmod NN nmod NN dobj VBD nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj events nmod number nmod increase dobj *revealed* nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "After drug1 treatment , additional sleep studies revealed an increase in the number of apneic events and drug2 suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2626 : 
        {
          1 : "NN nmod VBG dep NNS nmod VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod switching dep months nmod *recurred* nsubj drug0"
            }
          4 : 
            {
              1 : "In this case , unlike those previously reported , drug1 recurred 5 months after switching from drug2 to mirtazapine , which is believed to be a safe antidepressant . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2627 : 
        {
          1 : "NN dobj VBG acl:relcl CD conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl:relcl four conj *noted* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving drug2 , and none of the 16 who were receiving digoxin . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2628 : 
        {
          1 : "NN conj NN nmod NN nsubjpass VBD conj VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj proteinuria nmod association nsubjpass recognized conj *known* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is known to cause acute renal failure and tubulo-interstitial disease , but the recently described association with proteinuria or drug2 is little recognized . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2629 : 
        {
          1 : "NN dobj VBG nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *exacerbating* nsubj drug0"
            }
          4 : 
            {
              1 : "Ten years of behavioral data are presented to support the hypothesis that drug1 was exacerbating drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2630 : 
        {
          1 : "NN compound NN nsubjpass VBN advcl VB nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nsubjpass used advcl *pay* nmod onset nmod drug0"
            }
          4 : 
            {
              1 : "Therefore , clinicians should pay close attention to possible onset of drug1 in patients with multiple risk factors for TD , even when drug2 therapy is used . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2631 : 
        {
          1 : "NN nmod VBN acl NN dobj VB nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod characterized acl deterioration dobj *cause* nsubj reversal nmod drug0"
            }
          4 : 
            {
              1 : "The reversal of heparin by drug1 may cause severe hemodynamic deterioration , characterized by drug2 , pulmonary hypertension , and bronchoconstriction . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2632 : 
        {
          1 : "NN compound NN nmod NN dobj VBD acl:relcl NN nmod VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod link dobj demonstrated acl:relcl pattern nmod *developed* dobj insipidus conj drug0"
            }
          4 : 
            {
              1 : "Our patient developed both nephrogenic diabetes insipidus and drug1 with a temporal pattern that demonstrated a link between drug2 therapy and these abnormalities . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2633 : 
        {
          1 : "NN xcomp VBD conj VBD advcl VBN advcl VBG dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 xcomp became conj *began* advcl stopped advcl receiving dobj mg/d compound drug0"
            }
          4 : 
            {
              1 : "The day after clozapine was stopped , while he was still receiving drug1 150 mg/d , he began behaving oddly , started sweating profusely , shivering , and became drug2 , agitated , and confused . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2634 : 
        {
          1 : "NN nmod NN nmod NN acl:relcl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod complication acl:relcl *drug0*"
            }
          4 : 
            {
              1 : "Sweet 's syndrome is an drug1 that is a known complication of the administration of drug2 , a drug that causes increased neutrophil proliferation and differentiation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2635 : 
        {
          1 : "NN nmod NNS nmod JJ nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod effects nmod *difficult* nsubj diagnosis nmod drug0"
            }
          4 : 
            {
              1 : "Diagnosis of drug1 during treatment can be difficult because of the common side effects of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2636 : 
        {
          1 : "NN compound NN nmod VBG acl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound monotherapy nmod occurring acl *case* nmod dermatitis conj drug0"
            }
          4 : 
            {
              1 : "CASE REPORT : We hereby report a case of radiation recall dermatitis and drug1 occurring on drug2 monotherapy , five months after completing chemoradiation for locally advanced pancreatic cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2637 : 
        {
          1 : "NN nmod NN nmod NN dep NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod dose nmod infusion dep hour nmod *described* dobj drug0"
            }
          4 : 
            {
              1 : "The patient described drug1 with worsening headache and chills approximately one hour after infusion of the first dose of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2638 : 
        {
          1 : "NN dep VBP advcl VBN nsubjpass NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep have advcl *considered* nsubjpass possibility nmod reactions compound drug0"
            }
          4 : 
            {
              1 : "The possibility of drug1 hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms , particularly drug2 , rash , and lymphadenopathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2639 : 
        {
          1 : "NN conj NNS nmod NNS nmod NN dobj VBD nsubj NNS nmod NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj potentials nmod discharges nmod hyperactivity dobj *demonstrated* nsubj studies nmod monitoring nmod levels compound drug0"
            }
          4 : 
            {
              1 : "Videopolysomnographic and pharmacokinetic studies with monitoring of plasma drug1 levels demonstrated marked motor hyperactivity during augmentation , with anarchic discharges of motor unit potentials , drug2 and flexor spasms , associated with painful dysesthesia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2640 : 
        {
          1 : "NN dobj VBP nsubj NN nmod NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *develop* nsubj % nmod patients acl treated nmod drug0"
            }
          4 : 
            {
              1 : "Ten to 15 % of patients treated with drug1 develop an drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2641 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod *case* nmod carcinoma conj drug0"
            }
          4 : 
            {
              1 : "We present the first case of ovarian endometrioid carcinoma and drug1 in a postmenopausal patient who was treated with drug2 for breast cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2642 : 
        {
          1 : "NN dobj VBN acl:relcl NNS nmod VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj found acl:relcl years nmod *receiving* dobj drug0"
            }
          4 : 
            {
              1 : "The second was an 82-year-old man receiving drug1 for 2 years when , during a febrile episode , he was found drug2 with marrow aplasia . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2643 : 
        {
          1 : "NN dobj VBD xcomp VBN nsubjpass NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj developed xcomp *added* nsubjpass inhibitors dep drug0"
            }
          4 : 
            {
              1 : "Protease inhibitors ( drug1 and saquinavir ) were added to the treatment and the patient developed drug2 related to carbamazepine toxicity . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2644 : 
        {
          1 : "NN dobj VBN nsubj NN acl:relcl VBD advcl VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *marked* nsubj patient acl:relcl developed advcl receiving dobj drug0"
            }
          4 : 
            {
              1 : "The second patient , who developed cholestasis after receiving drug1 , had marked drug2 in the liver biopsy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2645 : 
        {
          1 : "NN nmod NNS nmod NNS dep NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod doses nmod *reactions* dep drug0"
            }
          4 : 
            {
              1 : "DATA SYNTHESIS : Genetic deficiencies in DPD , the rate-limiting enzyme responsible for 5-FU catabolism , may occur in 3 % or more of patients with cancer putting them at increased risk for unusually severe adverse reactions ( e.g. , drug1 , stomatitis , mucositis , myelosuppression , neurotoxicity ) to standard doses of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2646 : 
        {
          1 : "NN conj NN nmod VBN acl NN nmod NNS nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj chemotherapy nmod treated acl leukemia nmod patients nmod *reported* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2647 : 
        {
          1 : "NN dobj VBP acl:relcl NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj develop acl:relcl patients nmod *use* nmod drug0"
            }
          4 : 
            {
              1 : "Contrary to previous recommendations , our experience cautions against the further use of high-dose drug1 in patients who develop drug2 , and is a timely reminder of the potential toxicity of this agent , which is now increasingly being used as first-line treatment in the management of haematologic malignancies . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2648 : 
        {
          1 : "NN conj NN nmod NNS nsubjpass VBN advcl VB acl:relcl NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj lithium nmod drugs nsubjpass used advcl occur acl:relcl *sign* nmod drug0"
            }
          4 : 
            {
              1 : "We consider asterixis to be an easily overlooked sign of drug1 , which may occur even at low or moderate dosage levels , if certain drugs as lithium or drug2 are used in combination with CBZ . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2649 : 
        {
          1 : "NN conj NN dobj VBG xcomp VBD nsubj NN acl VBN nmod NN conj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj distress dobj worsening xcomp *developed* nsubj man acl treated nmod prednisone conj mesalamine appos drug0"
            }
          4 : 
            {
              1 : "A 49-year-old man with Crohn 's disease treated with prednisone and mesalamine ( drug1 ) developed worsening respiratory distress and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2650 : 
        {
          1 : "NN nmod VBN acl:relcl NN nmod NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl:relcl patient nmod *changes* acl presented nmod drug0"
            }
          4 : 
            {
              1 : "In this article , we describe another case of subcutaneous changes following repeated glatiramer acetate injection , presented as drug1 in the area around the injection sites , in a 46-year-old female patient who was treated with drug2 for 18 months . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2651 : 
        {
          1 : "NN nmod NN nummod CD compound CD"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *formulation* nummod one compound drug0"
            }
          4 : 
            {
              1 : "Fortunately , a drug1 to one formulation of drug2 does not preclude use of a different formulation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2652 : 
        {
          1 : "NN nmod NN nmod RB advmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod administration nmod prior advmod *kept* nsubjpass risk nmod drug0"
            }
          4 : 
            {
              1 : "The risk of drug1 in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2653 : 
        {
          1 : "NN nmod VBN acl NN nsubj NN appos NN acl VBN xcomp NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod associated acl *drug* nsubj rapamycin/sirolimus appos trade acl named xcomp drug0"
            }
          4 : 
            {
              1 : "Rapamycin/sirolimus ( SR ) , trade named drug1 ( Wyeth-Ayerst , Sydney , Australia ) , is a potent immunosuppressive drug associated with drug2 , hypertension , hyperlipidemia , and infection . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2654 : 
        {
          1 : "NN compound NN nmod NN nmod NN nmod VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound cream nmod therapy nmod day nmod *developed* dobj drug0"
            }
          4 : 
            {
              1 : "CASE SUMMARY : A 25-year-old postpartum white woman developed drug1 and abdominal cramping on day 6 of therapy with drug2 vaginal cream for bacterial vaginosis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2655 : 
        {
          1 : "NN conj NN nmod NNS conj JJ nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj polyuria nmod diuretics conj *aware* nmod toxicity compound drug0"
            }
          4 : 
            {
              1 : "Clinicians have been aware of drug1 toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2656 : 
        {
          1 : "NN advcl VBN dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "He had also developed drug1 while on drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2657 : 
        {
          1 : "NN nmod NN nmod VB"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod cause nmod *drug0*"
            }
          4 : 
            {
              1 : "Hyperammonemia secondary to drug1 as a cause of drug2 in a postictal patient . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2658 : 
        {
          1 : "NN nsubj JJ ccomp VBG xcomp JJ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj responsible ccomp suggesting xcomp *present* nsubj drug0"
            }
          4 : 
            {
              1 : "Beginning drug1 was present in two , suggesting that drug2 might be responsible for the occurrence of prolonged drug-induced cholangiopathy . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2659 : 
        {
          1 : "NN appos NN nmod NN nmod NNS nmod NN nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos gamma nmod therapy nmod months nmod *development* nmod erythematosus appos drug0"
            }
          4 : 
            {
              1 : "The development of systemic lupus erythematosus ( drug1 ) after 38 months of therapy with recombinant human interferon gamma ( drug2 ) was observed in a patient with rheumatoid arthritis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2660 : 
        {
          1 : "NN compound NN nmod JJ xcomp VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod secondary xcomp *suspected* nsubjpass drug0"
            }
          4 : 
            {
              1 : "This case report describes a 38-year-old male in whom drug1 was strongly suspected secondary to drug2 therapy to control a seizure disorder . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2661 : 
        {
          1 : "NN compound NN nmod VBD conj VBP dobj NN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound intoxication nmod raised conj *describe* dobj management nmod patient nmod drug0"
            }
          4 : 
            {
              1 : "INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with drug1 and raised intracranial pressure ( ICP ) after severe drug2 ( VPA ) intoxication . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2662 : 
        {
          1 : "NN nmod NN dobj VB nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod possibility dobj *suggest* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of drug1 should strongly suggest the possibility of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2663 : 
        {
          1 : "NN dobj VBN xcomp VB dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *made* xcomp stop dobj therapy compound drug0"
            }
          4 : 
            {
              1 : "Attempts were made to stop and then restart the drug1 therapy at progressively lower doses ; however , with each attempt , the patient 's drug2 , with serum theophylline levels ranging between 99.9 and 149.9 micromol/L ( 18 and 27 microg/mL ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2664 : 
        {
          1 : "NN nmod VBN advcl VBN conj VBN nmod NN appos NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *favored* advcl done conj associated nmod bleeding appos intensity nmod drug0"
            }
          4 : 
            {
              1 : "Although no coagulation study was done and the Meckel 's diverticulum is normally associated with bleeding , the particular intensity of the following drug1 may have been favored by drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2665 : 
        {
          1 : "NN dobj VB dep VBZ dobj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj cause dep *does* dobj use nmod drug0"
            }
          4 : 
            {
              1 : "Does the use of drug1 in a patient with liver dysfunction increase water retention in the body , i.e. cause insulin drug2 ? "
            }
          5 : 
            {
              1 : 1
            }
        }
      2666 : 
        {
          1 : "NN dobj VB ccomp VBD nsubj VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj resolve ccomp *helped* nsubj discontinuing dobj drug0"
            }
          4 : 
            {
              1 : "In this case , discontinuing drug1 , a nonsteroidal anti-inflammatory drug , and starting a palliative treatment plan helped resolve a patient 's drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2667 : 
        {
          1 : "NN compound NN nmod VBN acl NN nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound therapy nmod associated acl *effect* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 is a rare adverse effect associated with prolonged drug2 therapy , and is potentially serious , especially in end stage renal disease ( ESRD ) patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2668 : 
        {
          1 : "NN dep NNS nmod VBD csubjpass VBN conj VBD nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep weeks nmod developed csubjpass started conj *began* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 began after 2 weeks of treatment , and signs of hepatocellular failure developed 3 weeks after drug2 had been started . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2669 : 
        {
          1 : "NN dobj VBG dep VBN nsubjpass NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj adding dep *triggered* nsubjpass patients nmod drug0"
            }
          4 : 
            {
              1 : "In this report we present four patients treated with a combination of different psychotropic drugs , in whom drug1 was triggered either by adding drug2 ( CBZ ) to a treatment regimen , or by increasing its dosage . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2670 : 
        {
          1 : "NN dobj VBD nsubj JJ nmod NN acl:relcl VBD dobj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *developed* nsubj 0-year-old nmod toxoplasmosis acl:relcl took dobj pyrimethamine conj drug0"
            }
          4 : 
            {
              1 : "A 7-year-old with congenital toxoplasmosis who took pyrimethamine and drug1 for reactivated chorioretinitis developed drug2 , severe cutaneous involvement , swelling , abdominal pain and transaminitis , persisting weeks after withholding medicines . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2671 : 
        {
          1 : "NN nmod VBN acl NN nmod NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl c nmod patients nmod *cases* nmod drug0"
            }
          4 : 
            {
              1 : "Two cases of drug1 in patients with chronic hepatitis C treated with drug2 are reported . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2672 : 
        {
          1 : "NN nmod VBN acl NN nmod JJ acl:relcl NNS dobj VBD nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod induced acl depletion nmod fragile acl:relcl cells dobj *injured* nsubj toxicity compound drug0"
            }
          4 : 
            {
              1 : "We hypothesize that drug1 toxicity injured the muscle cells , which were fragile due to the potassium depletion induced by the drug2 , to result in unusually severe rhabdomyolysis . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2673 : 
        {
          1 : "NN dobj VBD nsubj NNS acl:relcl VBD dep VBN nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *had* nsubj patients acl:relcl developed dep decreased nmod months nmod treatment compound drug0"
            }
          4 : 
            {
              1 : "Two patients who developed decreased visual acuity after several months of drug1 treatment for Mycobacterium avium-intracellulare infection had drug2 that suggested optic chiasm damage . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2674 : 
        {
          1 : "NN nmod VBN acl NNS nmod VBP advcl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod treated acl patients nmod *describe* advcl determined nmod drug0"
            }
          4 : 
            {
              1 : "We describe the clinical response , as determined by drug1 and decreased transfusion needs , in five patients with thalassemia intermedia treated with drug2 alone or in combination with SPB . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2675 : 
        {
          1 : "NN nmod NN nmod JJ nsubj NNS acl VBG dobj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod potential nmod *aware* nsubj clinicians acl treating dobj patients nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Clinicians treating elderly patients with drug1 should be aware of the potential for rapidly developing drug2 and monitor such patients accordingly . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2676 : 
        {
          1 : "NN dep NN dep NNS appos NN dobj VBG advcl VBD dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep ergotamine dep alkaloids appos s dobj taking advcl *developed* dobj drug0"
            }
          4 : 
            {
              1 : "We report a case of a previously healthy , postmenopausal woman who developed drug1 while taking Bellamine S ( belladonna alkaloids ; ergotamine ; drug2 ) for hot flashes . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2677 : 
        {
          1 : "NN conj NN nmod VBD acl:relcl NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj overanticoagulation nmod resulted acl:relcl *interaction* nmod lotion conj drug0"
            }
          4 : 
            {
              1 : "CONCLUSION : This report describes a case of a probable interaction between topical econazole lotion 1 % and drug1 that resulted in overanticoagulation and a life-threatening drug2 in this elderly patient . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2678 : 
        {
          1 : "NN nmod NN nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *cause* nsubj hus compound drug0"
            }
          4 : 
            {
              1 : "Thus , drug1 HUS is a rare cause of drug2 in nephrotic syndrome . "
            }
          5 : 
            {
              1 : 1
            }
        }
      2679 : 
        {
          1 : "NN nmod NN nmod NN nsubj NN nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod action nmod *mechanism* nsubj cicatrization nmod drugs nmod drug0"
            }
          4 : 
            {
              1 : "CONCLUSIONS : Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including drug1 is a possible mechanism of action for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
    }
}